Human U-Species +
embryonic O +
stem O +
cells O +
( O -
hESCs O -
) O +
and O +
neural O +
progenitor O +
( O -
NP O -
) O +
cells O +
are O +
excellent O +
models O +
for O +
recapitulating O +
early O +
neuronal O +
development O +
in O +
vitro O -
, O +
and O +
are O +
key O +
to O +
establishing O +
strategies O +
for O +
the O +
treatment O +
of O +
degenerative O +
disorders O -
. O -

While O +
much O +
effort O +
had O +
been O +
undertaken O +
to O +
analyze O +
transcriptional O +
and O +
epigenetic O +
differences O +
during O +
the O +
transition O +
of O +
hESC O +
to O +
NP O -
, O +
very O +
little O +
work O +
has O +
been O +
performed O +
to O +
understand O +
post O -
- O -
transcriptional O +
changes O +
during O +
neuronal O +
differentiation O -
. O -

Alternative O +
RNA O +
splicing O +
( O -
AS O -
) O -
, O +
a O +
major O +
form O +
of O +
post O -
- O -
transcriptional O +
gene O +
regulation O -
, O +
is O +
important O +
in O +
mammalian O +
development O +
and O +
neuronal O +
function O -
. O -

Human U-Species +
ESC O -
, O +
hESC O -
- O -
derived O +
NP O -
, O +
and O +
human U-Species +
central O +
nervous O +
system O +
stem O +
cells O +
were O +
compared O +
using O +
Affymetrix O +
exon O +
arrays O -
. O -

We O +
introduced O +
an O +
outlier O +
detection O +
approach O -
, O +
REAP O +
( O -
Regression O -
- O -
based O +
Exon O +
Array O +
Protocol O -
) O -
, O +
to O +
identify O +
1,737 O +
internal O +
exons O +
that O +
are O +
predicted O +
to O +
undergo O +
AS O +
in O +
NP O +
compared O +
to O +
hESC O -
. O -

Experimental O +
validation O +
of O +
REAP O -
- O -
predicted O +
AS O +
events O +
indicated O +
a O +
threshold O -
- O -
dependent O +
sensitivity O +
ranging O +
from O +
56 O -
% O +
to O +
69 O -
% O -
, O +
at O +
a O +
specificity O +
of O +
77 O -
% O +
to O +
96 O -
% O -
. O -

REAP O +
predictions O +
significantly O +
overlapped O +
sets O +
of O +
alternative O +
events O +
identified O +
using O +
expressed O +
sequence O +
tags O +
and O +
evolutionarily O +
conserved O +
AS O +
events O -
. O -

Our O +
results O +
also O +
reveal O +
that O +
focusing O +
on O +
differentially O +
expressed O +
genes O +
between O +
hESC O +
and O +
NP O +
will O +
overlook O +
14 O -
% O +
of O +
potential O +
AS O +
genes O -
. O -

In O +
addition O -
, O +
we O +
found O +
that O +
REAP O +
predictions O +
are O +
enriched O +
in O +
genes O +
encoding O +
serine O -
/ O -
threonine O +
kinase O +
and O +
helicase O +
activities O -
. O -

An O +
example O +
is O +
a O +
REAP O -
- O -
predicted O +
alternative O +
exon O +
in O +
the O +
SLK O +
( O -
serine O -
/ O -
threonine O +
kinase O +
2 O -
) O +
gene O +
that O +
is O +
differentially O +
included O +
in O +
hESC O -
, O +
but O +
skipped O +
in O +
NP O +
as O +
well O +
as O +
in O +
other O +
differentiated O +
tissues O -
. O -

Lastly O -
, O +
comparative O +
sequence O +
analysis O +
revealed O +
conserved O +
intronic O +
cis O -
- O -
regulatory O +
elements O +
such O +
as O +
the O +
FOX1 O -
/ O -
2 O +
binding O +
site O +
GCAUG O +
as O +
being O +
proximal O +
to O +
candidate O +
AS O +
exons O -
, O +
suggesting O +
that O +
FOX1 O -
/ O -
2 O +
may O +
participate O +
in O +
the O +
regulation O +
of O +
AS O +
in O +
NP O +
and O +
hESC O -
. O -

In O +
summary O -
, O +
a O +
new O +
methodology O +
for O +
exon O +
array O +
analysis O +
was O +
introduced O -
, O +
leading O +
to O +
new O +
insights O +
into O +
the O +
complexity O +
of O +
AS O +
in O +
human U-Species +
embryonic O +
stem O +
cells O +
and O +
their O +
transition O +
to O +
neural O +
stem O +
cells O -
. O -

Author O +
SummaryDeriving O +
neural O +
progenitors O +
( O -
NP O -
) O +
from O +
human U-Species +
embryonic O +
stem O +
cells O +
( O -
hESC O -
) O +
is O +
the O +
first O +
step O +
in O +
creating O +
homogeneous O +
populations O +
of O +
cells O +
that O +
will O +
differentiate O +
into O +
myriad O +
neuronal O +
subtypes O +
necessary O +
to O +
form O +
a O +
human U-Species +
brain O -
. O -

During O +
alternative O +
RNA O +
splicing O +
( O -
AS O -
) O -
, O +
noncoding O +
sequences O +
( O -
introns O -
) O +
in O +
a O +
pre O -
- O -
mRNA O +
are O +
differentially O +
removed O +
in O +
different O +
cell O +
types O +
and O +
tissues O -
, O +
and O +
the O +
remaining O +
sequences O +
( O -
exons O -
) O +
are O +
joined O +
to O +
form O +
multiple O +
forms O +
of O +
mature O +
RNA O -
, O +
playing O +
an O +
important O +
role O +
in O +
cellular O +
diversity O -
. O -

The O +
authors O +
utilized O +
Affymetrix O +
exon O +
arrays O +
with O +
probes O +
targeting O +
hundreds O +
of O +
thousands O +
of O +
exons O +
to O +
study O +
AS O +
comparing O +
human U-Species +
ES O +
to O +
NP O -
. O -

To O +
accomplish O +
this O -
, O +
a O +
novel O +
computational O +
method O -
, O +
REAP O +
( O -
Regression O -
- O -
based O +
Exon O +
Array O +
Protocol O -
) O -
, O +
is O +
introduced O +
to O +
analyze O +
the O +
exon O +
array O +
data O -
. O -

The O +
authors O +
showed O +
that O +
REAP O +
candidates O +
are O +
consistent O +
with O +
other O +
types O +
of O +
methods O +
for O +
discovering O +
alternative O +
exons O -
. O -

In O +
addition O -
, O +
REAP O +
candidate O +
alternative O +
exons O +
are O +
enriched O +
in O +
genes O +
encoding O +
serine O -
/ O -
theronine O +
kinases O +
and O +
helicase O +
activities O -
. O -

An O +
example O +
is O +
the O +
alternative O +
exon O +
in O +
the O +
SLK O +
( O -
serine O -
/ O -
threonine O +
kinase O +
2 O -
) O +
gene O +
that O +
is O +
included O +
in O +
hESC O -
, O +
but O +
excluded O +
in O +
NP O +
as O +
well O +
as O +
in O +
other O +
differentiated O +
tissues O -
. O -

Finally O -
, O +
by O +
comparing O +
genomic O +
sequences O +
across O +
multiple O +
mammals O -
, O +
the O +
authors O +
identified O +
dozens O +
of O +
conserved O +
candidate O +
binding O +
sites O +
that O +
were O +
enriched O +
proximal O +
to O +
REAP O +
candidate O +
exons O -
. O -

The O +
human U-Species +
central O +
nervous O +
system O +
is O +
composed O +
of O +
thousands O +
of O +
neuronal O +
subtypes O +
originating O +
from O +
neural O +
stem O +
cells O +
( O -
NSCs O -
) O +
that O +
migrate O +
from O +
the O +
developing O +
neural O +
tube O -
. O -

Such O +
neuronal O +
complexity O +
is O +
generated O +
by O +
a O +
vast O +
repertoire O +
of O +
molecular O -
, O +
genetic O -
, O +
and O +
epigenetic O +
mechanisms O -
, O +
such O +
as O +
the O +
active O +
retrotransposition O +
of O +
transposable O +
elements O +
[ O -
1 O -
] O -
, O +
alternative O +
promoter O +
usage O -
, O +
alternative O +
RNA O +
splicing O +
( O -
AS O -
) O -
, O +
alternative O +
polyadenylation O -
, O +
RNA O +
editing O -
, O +
post O -
- O -
translational O +
modifications O -
, O +
and O +
epigenetic O +
modulation O +
[ O -
2 O -
] O -
. O -

Understanding O +
the O +
processes O +
that O +
generate O +
neuronal O +
diversity O +
is O +
key O +
to O +
gaining O +
insights O +
into O +
neuronal O +
development O +
and O +
paving O +
new O +
avenues O +
for O +
biomedical O +
research O -
. O -

Human U-Species +
embryonic O +
stem O +
cells O +
( O -
hESCs O -
) O +
are O +
pluripotent O +
cells O +
that O +
propagate O +
perpetually O +
in O +
culture O +
as O +
undifferentiated O +
cells O +
and O +
can O +
be O +
induced O +
to O +
differentiate O +
into O +
a O +
multitude O +
of O +
cell O +
types O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
[ O -
3 O -
] O -
. O -

As O +
hESCs O +
can O +
theoretically O +
generate O +
all O +
cell O +
types O +
that O +
make O +
up O +
an O +
organism O -
, O +
they O +
serve O +
as O +
an O +
important O +
model O +
for O +
understanding O +
early O +
human U-Species +
embryonic O +
development O -
. O -

In O +
addition O -
, O +
the O +
hESCs O +
are O +
a O +
nearly O +
infinite O +
source O +
for O +
generating O +
specialized O +
cells O +
such O +
as O +
neurons O +
and O +
glia O +
for O +
potential O +
therapeutic O +
purposes O +
[ O -
4,5 O -
] O -
. O -

In O +
recent O +
years O -
, O +
methods O +
have O +
been O +
introduced O +
to O +
induce O +
hESCs O +
to O +
differentiate O +
into O +
neural O +
progenitors O +
( O -
NPs O -
) O +
[ O -
6,7 O -
] O +
and O +
neuronal O +
and O +
glial O +
subtypes O +
[ O -
8–12 O -
] O -
. O -

The O +
therapeutic O +
interest O +
in O +
understanding O +
the O +
molecular O +
basis O +
of O +
pluripotency O +
and O +
differentiation O +
has O +
led O +
to O +
many O +
studies O +
comparing O +
transcriptional O +
profiles O +
in O +
different O +
hESC O +
lines O +
and O +
the O +
study O +
of O +
expression O +
changes O +
during O +
the O +
differentiation O +
of O +
hESCs O +
to O +
various O +
lineages O +
[ O -
13–17 O -
] O -
. O -

NSCs O +
and O +
progenitor O +
cells O +
( O -
NPs O -
) O +
are O +
present O +
throughout O +
development O +
and O +
persist O +
into O +
adulthood O +
[ O -
18–20 O -
] O -
. O -

They O +
are O +
critical O +
for O +
both O +
basic O +
research O +
and O +
developing O +
approaches O +
to O +
treat O +
neurological O +
disorders O -
, O +
such O +
as O +
Parkinson O +
disease O +
and O +
amyotrophic O +
lateral O +
sclerosis O +
( O -
ALS O -
) O -
, O +
and O +
stroke O +
or O +
head O +
injuries O +
[ O -
21,22 O -
] O -
. O -

NSCs O +
and O +
NPCs O +
can O +
be O +
isolated O +
from O +
human U-Species +
fetal O +
brain O +
tissue O +
[ O -
23–26 O -
] O -
, O +
as O +
well O +
as O +
from O +
several O +
regions O +
of O +
the O +
adult O +
human U-Species +
brain O -
, O +
such O +
as O +
the O +
cortex O -
, O +
hippocampus O -
, O +
and O +
the O +
subventricular O +
zone O +
( O -
SVZ O -
) O +
of O +
the O +
lateral O +
ventricles O +
[ O -
26–35 O -
] O -
. O -

Several O +
studies O +
have O +
explored O +
expression O +
patterns O +
of O +
NPCs O -
. O -

For O +
example O -
, O +
Wright O +
et O +
al. O +
identified O +
" O -
expressed O -
" O +
and O +
" O -
not O +
expressed O -
" O +
genes O +
in O +
NPCs O +
isolated O +
from O +
the O +
human U-Species +
embryonic O +
cortex O +
[ O -
24 O -
] O -
; O +
Cai O +
et O +
al. O +
used O +
the O +
massively O +
parallel O +
signature O +
sequencing O +
profiling O +
( O -
MPSS O -
) O +
technique O +
to O +
analyze O +
expression O +
of O +
fetal O +
NPCs O +
in O +
comparison O +
to O +
hESCs O +
and O +
astrocyte O +
precursors O +
[ O -
27 O -
] O -
; O +
Maisel O +
et O +
al. O +
used O +
Affymetrix O +
Gene O +
Chip O +
arrays O +
to O +
compare O +
adult O +
and O +
fetal O +
NPCs O +
propagated O +
in O +
neurospheres O +
[ O -
35 O -
] O -
. O -

However O -
, O +
as O +
with O +
hESCs O -
, O +
the O +
focus O +
thus O +
far O +
has O +
been O +
primarily O +
on O +
transcriptional O +
differences O -
, O +
which O +
ignores O +
differential O +
RNA O +
processing O +
such O +
as O +
AS O -
, O +
polyadenylation O -
, O +
degradation O -
, O +
or O +
promoter O +
usage O -
. O -

AS O +
is O +
frequently O +
used O +
to O +
regulate O +
gene O +
expression O +
and O +
to O +
generate O +
tissue O -
- O -
specific O +
mRNA O +
and O +
protein O +
isoforms O +
[ O -
36–39 O -
] O -
. O -

Recent O +
studies O +
using O +
splicing O -
- O -
sensitive O +
microarrays O +
suggested O +
that O +
up O +
to O +
75 O -
% O +
of O +
human U-Species +
genes O +
undergo O +
AS O -
, O +
where O +
multiple O +
isoforms O +
are O +
derived O +
from O +
the O +
same O +
genetic O +
loci O +
[ O -
40 O -
] O -
. O -

This O +
functional O +
complexity O +
underscores O +
the O +
challenge O +
and O +
importance O +
of O +
elucidating O +
AS O +
regulation O -
. O -

AS O +
appears O +
to O +
play O +
a O +
dominant O +
role O +
in O +
regulating O +
neuronal O +
gene O +
expression O +
and O +
function O +
[ O -
41,42 O -
] O -
. O -

Examples O +
of O +
splicing O +
regulators O +
that O +
are O +
enriched O +
and O +
function O +
specifically O +
in O +
neuronal O +
cells O +
include O +
the O +
brain O -
- O -
specific O +
splicing O +
factor O +
Nova O +
[ O -
43,44 O -
] O +
and O +
neural O -
- O -
specific O +
polypyrimidine O +
tract O +
binding O +
protein O +
( O -
nPTB O -
) O -
, O +
which O +
antagonizes O +
its O +
paralogous O +
PTB O +
to O +
regulate O +
exon O +
exclusion O +
in O +
neuronal O +
cells O +
[ O -
45–47 O -
] O -
. O -

Finally O -
, O +
an O +
early O +
report O +
estimating O +
that O +
15 O -
% O +
of O +
point O +
mutations O +
disrupt O +
splicing O +
underscores O +
the O +
importance O +
of O +
splicing O +
in O +
human U-Species +
disease O +
[ O -
48 O -
] O -
. O -

Indeed O -
, O +
the O +
disruption O +
of O +
specific O +
AS O +
events O +
has O +
been O +
implicated O +
in O +
several O +
human U-Species +
genetic O +
diseases O -
, O +
such O +
as O +
frontotemporal O +
dementia O +
and O +
parkinsonism O -
, O +
Frasier O +
syndrome O -
, O +
and O +
atypical O +
cystic O +
fibrosis O +
[ O -
49 O -
] O -
. O -

While O +
insights O +
into O +
the O +
regulation O +
of O +
AS O +
have O +
come O +
predominantly O +
from O +
the O +
molecular O +
dissection O +
of O +
individual O +
genes O +
[ O -
36,49 O -
] O -
, O +
it O +
is O +
becoming O +
clear O +
that O +
molecular O +
rules O +
can O +
be O +
identified O +
from O +
large O -
- O -
scale O +
studies O +
of O +
both O +
constitutive O +
splicing O +
and O +
AS O +
[ O -
40 O -
] O -
. O -

Most O +
systematic O +
global O +
analyses O +
on O +
AS O +
have O +
focused O +
on O +
comparisons O +
across O +
differentiated O +
human U-Species +
tissues O +
[ O -
50–52 O -
] O -
. O -

Only O +
one O +
study O -
, O +
utilizing O +
expressed O +
sequence O +
tag O +
( O -
EST O -
) O +
collections O +
from O +
stem O +
cells O -
, O +
has O +
attempted O +
to O +
find O +
AS O +
differences O +
between O +
embryonic O +
and O +
hematopoietic O +
stem O +
cells O +
[ O -
53 O -
] O -
. O -

However O -
, O +
utilizing O +
ESTs O +
to O +
identify O +
AS O +
has O +
intrinsic O +
problems O -
, O +
as O +
ESTs O +
tend O +
to O +
be O +
biased O +
for O +
the O +
3′ O +
ends O +
of O +
genes O -
, O +
and O +
full O +
coverage O +
of O +
the O +
genome O +
by O +
ESTs O +
is O +
severely O +
limited O +
by O +
sequencing O +
costs O -
. O -

The O +
commercial O +
availability O +
of O +
Affymetrix O +
exon O +
arrays O +
provides O +
an O +
alternative O +
approach O +
to O +
interrogate O +
the O +
expression O +
of O +
every O +
known O +
and O +
predicted O +
exon O +
in O +
the O +
human U-Species +
genome O -
. O -

The O +
Affymetrix O +
GeneChip O +
Human O +
Exon O +
1.0 O +
ST O +
array O +
contains O +
∼5.4 O +
million O +
features O +
used O +
to O +
interrogate O +
∼1 O +
million O +
exon O +
clusters O +
( O -
collections O +
of O +
overlapping O -
) O +
of O +
known O +
and O +
predicted O +
exons O +
with O +
more O +
than O +
1.4 O +
million O +
probesets O -
, O +
with O +
an O +
average O +
of O +
four O +
probes O +
per O +
exon O -
. O -

Our O +
goal O +
was O +
to O +
identify O +
and O +
characterize O +
AS O +
events O +
that O +
distinguish O +
pluripotent O +
hESCs O +
from O +
multipotent O +
NPs O -
, O +
paving O +
the O +
way O +
for O +
future O +
candidate O +
gene O +
approaches O +
to O +
study O +
the O +
impact O +
of O +
AS O +
in O +
hESCs O +
and O +
NPs O -
. O -

However O -
, O +
as O +
different O +
hESC O +
lines O +
were O +
established O +
under O +
different O +
culture O +
conditions O +
from O +
embryos O +
with O +
unique O +
genetic O +
backgrounds O -
, O +
we O +
expected O +
that O +
hESCs O +
and O +
their O +
derived O +
NPs O +
might O +
have O +
distinct O +
epigenetic O +
and O +
molecular O +
signatures O +
[ O -
54 O -
] O -
. O -

As O +
both O +
common O +
and O +
cell O -
- O -
line O +
specific O +
alternatively O +
spliced O +
exons O +
are O +
likely O +
to O +
be O +
important O +
in O +
regenerative O +
research O -
, O +
in O +
our O +
study O +
two O +
separate O +
hESC O +
lines O +
were O +
used O -
, O +
with O +
independent O +
protocols O +
for O +
differentiating O +
the O +
hESCs O +
into O +
NPs O +
positive O +
for O +
Sox1 O -
, O +
an O +
early O +
neuroectodermal O +
marker O -
. O -

As O +
an O +
endogenously O +
occurring O +
population O +
of O +
NPs O -
, O +
human U-Species +
central O +
nervous O +
system O +
stem O +
cells O +
grown O +
as O +
neurospheres O +
( O -
hCNS O -
- O -
SCns O -
) O +
were O +
utilized O +
as O +
a O +
natural O +
benchmark O +
for O +
derived O +
NPs O -
. O -

We O +
developed O +
an O +
approach O +
called O +
REAP O +
( O -
Regression O -
- O -
based O +
Exon O +
Array O +
Protocol O -
) O -
, O +
which O +
is O +
based O +
on O +
robust O +
regression O +
that O +
analyzed O +
signal O +
estimates O +
from O +
Affymetrix O +
exon O +
array O +
data O +
to O +
identify O +
AS O +
exons O -
. O -

Experimental O +
validation O +
revealed O +
alternative O +
exons O +
that O +
distinguish O +
hESCs O +
from O +
NPs O -
; O +
some O +
of O +
them O +
also O +
distinguish O +
hESCs O +
from O +
a O +
variety O +
of O +
differentiated O +
tissues O -
. O -

A O +
comparison O +
of O +
REAP O -
- O -
predicted O +
alternative O +
events O +
with O +
independent O +
methods O -
, O +
such O +
as O +
using O +
publicly O +
available O +
transcripts O +
( O -
ESTs O +
and O +
mRNAs O -
) O +
and O +
computational O +
predictions O +
based O +
on O +
genomic O +
sequence O +
information O +
alone O +
[ O -
55 O -
] O -
, O +
showed O +
a O +
strong O +
concordance O +
of O +
REAP O -
- O -
identified O +
AS O +
exons O +
with O +
AS O +
events O +
identified O +
from O +
these O +
orthogonal O +
methods O -
. O -

Finally O -
, O +
using O +
analysis O +
of O +
the O +
sequences O +
flanking O +
REAP O -
- O -
identified O +
alternative O +
exons O -
, O +
we O +
were O +
able O +
to O +
discover O +
known O +
and O +
novel O +
cis O -
- O -
regulatory O +
elements O +
that O +
potentially O +
regulate O +
these O +
AS O +
events O -
. O -

Derivation O +
of O +
Neural O +
Progenitors O +
from O +
Embryonic O +
Stem O +
CellsNPs O +
were O +
independently O +
derived O +
from O +
two O +
hESC O +
lines O -
, O +
and O +
RNA O +
extracted O +
from O +
the O +
cell O +
lines O +
was O +
processed O +
and O +
hybridized O +
onto O +
Affymetrix O +
Human U-Species +
1.0 O +
ST O +
exon O +
arrays O -
. O -

Immunohistochemical O +
and O +
reverse O -
- O -
transcriptase O +
polymerase O +
chain O +
reaction O +
( O -
RT O -
- O -
PCR O -
) O +
analyses O +
demonstrated O +
that O +
the O +
hESCs O +
expressed O +
pluripotent O +
marker O +
genes O -
, O +
and O +
the O +
derived O +
NPs O +
expressed O +
multipotent O +
and O +
neurogenic O +
markers O +
similar O +
to O +
hCNS O -
- O -
SCns O -
. O -

Undifferentiated O +
Cythera O +
( O -
Cyt O -
- O -
ES O -
) O +
and O +
HUES6 O +
( O -
HUES6-ES O -
) O +
hESC O +
lines O +
were O +
maintained O +
in O +
culture O +
as O +
previously O +
described O +
[ O -
12,23,56 O -
] O -
. O -

Utilizing O +
specific O +
antibodies O -
, O +
we O +
observed O +
that O +
undifferentiated O +
Cyt O -
- O -
ES O +
and O +
HUES6-ES O +
cells O +
were O +
positive O +
for O +
the O +
pluripotent O +
markers O +
Oct4 O -
, O +
SSEA-4 O -
, O +
and O +
Tra-1–80 O +
( O -
unpublished O +
data O -
) O -
. O -

NPs O +
were O +
derived O +
from O +
the O +
hESC O +
cell O +
lines O +
using O +
protocols O +
optimized O +
for O +
each O +
line O +
( O -
see O +
Materials O +
and O +
Methods O -
) O -
. O -

Greater O +
than O +
90 O -
% O +
of O +
derived O +
NP O +
cells O +
( O -
Cyt O -
- O -
NP O +
from O +
Cyt O -
- O -
ES O +
and O +
HUES6-NP O +
from O +
HUES6-ES O -
) O +
were O +
positive O +
for O +
Sox1 O -
, O +
an O +
early O +
neuroectodermal O +
marker O -
, O +
and O +
Nestin O +
( O -
Figure O +
1A O -
) O -
, O +
and O +
negative O +
for O +
Oct4 O +
( O -
unpublished O +
data O -
) O -
. O -

As O +
a O +
natural O +
benchmark O +
for O +
the O +
derived O +
NPs O -
, O +
we O +
utilized O +
hCNS O -
- O -
SCns O -
, O +
which O +
were O +
previously O +
isolated O +
from O +
fresh O +
human U-Species +
fetal O +
brain O +
tissues O +
using O +
antibodies O +
to O +
cell O -
- O -
surface O +
markers O +
and O +
fluorescence O -
- O -
activated O +
cell O +
sorting O +
[ O -
12,23 O -
] O -
. O -

The O +
hCNS O -
- O -
SCns O +
form O +
neurospheres O +
in O +
culture O +
which O +
are O +
greater O +
than O +
90 O -
% O +
Nestin O +
and O +
Sox1 O +
positive O -
, O +
and O +
differentiate O +
into O +
both O +
neurons O +
and O +
glial O +
cells O +
in O +
vitro O +
[ O -
12,23 O -
] O -
. O -

Immunohistochemical O +
analysis O +
confirmed O +
that O +
hCNS O -
- O -
SCns O +
were O +
negative O +
for O +
Oct4 O +
( O -
unpublished O +
data O -
) O +
and O +
positive O +
for O +
Sox1 O +
and O +
Nestin O +
( O -
Figure O +
1A O -
) O -
.Figure O +
1Molecular O +
Characterization O +
of O +
Human U-Species +
Embryonic O +
Stem O +
Cell O +
Lines O +
and O +
Neuronal O +
Progenitors O -
( O -
A O -
) O +
Immunohistochemical O +
analysis O +
of O +
markers O +
in O +
NPs O +
derived O +
from O +
the O +
hESC O +
lines O +
( O -
Cyt O -
- O -
NP O +
from O +
Cyt O -
- O -
ES O -
; O +
and O +
HUES6-NP O +
from O +
HUES6-ES O -
) O +
and O +
in O +
hCNS O -
- O -
SCns O -
. O -

Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O +
cells O +
were O +
Nestin O +
and O +
Sox1 O +
positive O -
. O -

Nuclei O +
stained O +
positive O +
for O +
Dapi O -
. O -

White O +
horizontal O +
bar O +
indicated O +
15 O +
μm. O -
( O -
B O -
) O +
Gene O -
- O -
level O +
signal O +
estimates O +
of O +
marker O +
genes O +
( O -
GAPDH O -
, O +
Oct4 O -
, O +
Nanog O -
, O +
Nestin O -
, O +
Notch1 O -
, O +
DNER O -
, O +
and O +
Sox1 O -
) O +
from O +
Affymetrix O +
exon O +
array O +
analysis O -
. O -

Vertical O +
bars O +
indicated O +
average O +
log2 O +
normalized O +
signal O +
estimates O -
, O +
and O +
error O +
bars O +
represented O +
standard O +
deviations O +
from O +
three O +
independent O +
replicate O +
experiments O +
per O +
cell O +
type. O -
( O -
C O -
) O +
RT O -
- O -
PCR O +
of O +
marker O +
genes O +
( O -
GAPDH O -
, O +
Oct4 O -
, O +
Nanog O -
, O +
Nestin O -
, O +
Notch1 O -
, O +
DNER O -
, O +
and O +
Sox1 O -
) O -
.Here O -
, O +
known O +
molecular O +
markers O +
were O +
subjected O +
to O +
RT O -
- O -
PCR O +
measurements O -
, O +
which O +
were O +
compared O +
to O +
gene O -
- O -
level O +
signal O +
estimates O +
generated O +
from O +
the O +
exon O +
array O +
data O -
. O -

Total O +
RNA O +
was O +
extracted O -
, O +
and O +
labeled O +
cDNA O +
targets O +
were O +
generated O +
from O +
three O +
independent O +
preparations O +
of O +
each O +
cell O +
type O -
, O +
namely O +
Cyt O -
- O -
ES O -
, O +
HUES6-ES O -
, O +
Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O -
. O -

To O +
facilitate O +
downstream O +
analyses O -
, O +
instead O +
of O +
utilizing O +
the O +
meta O -
- O -
gene O +
sets O +
available O +
from O +
the O +
manufacturers O -
, O +
we O +
generated O +
our O +
own O +
gene O +
models O +
by O +
clustering O +
alignments O +
of O +
ESTs O +
and O +
mRNAs O +
to O +
annotated O +
known O +
genes O +
from O +
the O +
University O +
of O +
California O +
Santa O +
Cruz O +
( O -
UCSC O -
) O +
Genome O +
Browser O +
Database O -
. O -

After O +
hybridization O -
, O +
scanning O -
, O +
and O +
extraction O +
of O +
signal O +
estimates O +
for O +
each O +
probeset O +
on O +
the O +
exon O +
arrays O -
, O +
gene O -
- O -
level O +
estimates O +
were O +
computed O +
based O +
on O +
our O +
gene O +
models O +
using O +
available O +
normalization O +
and O +
signal O +
estimation O +
software O +
from O +
Affymetrix O -
. O -

For O +
every O +
gene O -
, O +
a O +
t O -
- O -
statistic O +
and O +
corresponding O +
p O -
- O -
value O +
were O +
computed O +
representing O +
the O +
relative O +
enrichment O +
of O +
the O +
expression O +
of O +
the O +
gene O +
in O +
hESC O +
versus O +
NP O -
, O +
such O +
as O +
in O +
Cyt O -
- O -
ES O +
versus O +
Cyt O -
- O -
NP O -
. O -

After O +
correcting O +
for O +
multiple O +
hypothesis O +
testing O +
using O +
the O +
Benjamini O -
- O -
Hochberg O +
method O -
, O +
a O +
p O -
- O -
value O +
cutoff O +
of O +
0.01 O +
was O +
used O +
to O +
identify O +
enriched O +
genes O -
. O -

Close O +
inspection O +
of O +
all O +
pairs O +
of O +
hESC O -
- O -
NP O +
comparisons O +
revealed O +
a O +
generally O +
significant O +
overlap O +
from O +
31 O -
% O +
to O +
85 O -
% O +
of O +
the O +
smaller O +
of O +
two O +
compared O +
sets O +
of O +
enriched O +
genes O +
( O -
see O +
Figure O +
S1 O -
) O -
. O -

Thus O +
for O +
the O +
purpose O +
of O +
identifying O +
overall O +
pluripotent O +
and O +
neural O +
lineage O -
- O -
specific O +
genes O -
, O +
the O +
collective O +
set O +
of O +
NPs O +
( O -
Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O -
) O +
was O +
compared O +
to O +
the O +
collective O +
set O +
of O +
hESCs O +
( O -
Cyt O -
- O -
ES O +
and O +
HUES6-ES O -
) O -
.Oct4 O +
and O +
Nanog O -
, O +
which O +
are O +
important O +
in O +
maintaining O +
the O +
pluripotent O +
state O +
of O +
embryonic O +
stem O +
cells O +
( O -
ESCs O -
) O -
, O +
were O +
highly O +
expressed O +
in O +
hESCs O +
but O +
were O +
significantly O +
lower O +
in O +
NPs O +
( O -
Figure O +
1B O -
) O -
. O -

RT O -
- O -
PCR O +
of O +
Oct4 O +
and O +
Nanog O +
mRNA O +
levels O +
accurately O +
reflected O +
the O +
signal O +
estimates O +
from O +
the O +
array O +
( O -
Figure O +
1C O -
) O -
. O -

Interestingly O -
, O +
Nestin O +
was O +
not O +
significantly O +
higher O +
in O +
NPs O +
as O +
compared O +
to O +
the O +
hESC O +
from O +
the O +
gene O -
- O -
level O +
estimates O +
( O -
p O -
- O -
value O +
0.065 O -
) O -
, O +
which O +
was O +
further O +
confirmed O +
by O +
RT O -
- O -
PCR O +
( O -
Figure O +
1C O -
) O -
. O -

Notch O +
was O +
recently O +
identified O +
to O +
be O +
important O +
in O +
promoting O +
the O +
neural O +
lineage O +
entry O +
in O +
mouse U-Species +
ESCs O +
[ O -
57 O -
] O +
and O +
was O +
shown O +
to O +
regulate O +
stem O +
cell O +
proliferation O +
in O +
somatic O +
mouse U-Species +
and O +
hESC O +
[ O -
58 O -
] O -
. O -

Gene O -
- O -
level O +
signal O +
estimates O +
suggested O +
that O +
Notch O +
was O +
significantly O +
higher O +
in O +
hCNS O -
- O -
SCns O +
relative O +
to O +
hESCs O -
, O +
but O +
levels O +
of O +
Notch O +
were O +
not O +
significantly O +
different O +
in O +
the O +
derived O +
NPs O +
compared O +
to O +
hESCs O -
. O -

Delta O -
/ O -
Notch O -
- O -
like O +
EGF O -
- O -
related O +
receptor O +
( O -
DNER O -
) O -
, O +
a O +
neuron O -
- O -
specific O +
transmembrane O +
protein O -
, O +
was O +
recently O +
shown O +
to O +
bind O +
to O +
Notch O +
at O +
cell O -
– O -
cell O +
contacts O +
and O +
activates O +
Notch O +
signaling O +
in O +
vitro O +
[ O -
59 O -
] O -
. O -

RT O -
- O -
PCR O +
validation O +
of O +
DNER O +
confirmed O +
array O -
- O -
derived O +
signal O +
estimates O -
, O +
indicating O +
an O +
enrichment O +
of O +
DNER O +
in O +
NPs O +
relative O +
to O +
hESCs O +
( O -
Figure O +
1C O -
) O -
. O -

Finally O -
, O +
Sox1 O -
, O +
a O +
HMG O -
- O -
box O +
protein O +
related O +
to O +
SRY O -
, O +
was O +
shown O +
to O +
be O +
one O +
of O +
the O +
earliest O +
transcription O +
factors O +
expressed O +
in O +
cells O +
committed O +
to O +
the O +
neural O +
fate O +
[ O -
60 O -
] O -
. O -

Here O +
the O +
gene O -
- O -
level O +
estimates O +
indicated O +
that O +
Sox1 O +
was O +
expressed O +
significantly O +
higher O +
in O +
NPs O +
relative O +
to O +
hESCs O +
( O -
p O -
- O -
value O +
0.00013 O -
, O +
Figure O +
1B O -
) O -
, O +
a O +
finding O +
that O +
was O +
confirmed O +
by O +
RT O -
- O -
PCR O +
( O -
Figure O +
1C O -
) O -
.From O +
these O +
examples O -
, O +
we O +
concluded O +
that O +
RT O -
- O -
PCR O +
validation O +
correlated O +
well O +
with O +
gene O -
- O -
level O +
estimates O +
from O +
the O +
exon O +
array O -
. O -

In O +
addition O -
, O +
the O +
derived O +
NPs O +
had O +
decreased O +
levels O +
of O +
pluripotent O +
markers O +
Oct4 O +
and O +
Nanog O +
but O +
had O +
levels O +
of O +
Sox1 O +
that O +
were O +
comparable O +
to O +
hCNS O -
- O -
SCns O -
. O -

This O +
finding O +
confirmed O +
that O +
the O +
derived O +
NPs O +
were O +
committed O +
to O +
a O +
neural O +
fate O +
and O +
validated O +
the O +
use O +
of O +
hCNS O -
- O -
SCns O +
as O +
a O +
benchmark O +
for O +
NPs O -
. O -

Next O +
we O +
asked O +
whether O +
the O +
highest O +
enriched O +
genes O +
in O +
hESCs O +
relative O +
to O +
NPs O +
reflected O +
our O +
existing O +
knowledge O +
in O +
the O +
literature O -
. O -

Using O +
the O +
above O -
- O -
mentioned O +
groupings O +
of O +
hESCs O +
( O -
Cyt O -
- O -
ES O -
, O +
HUES6-ES O -
) O +
and O +
NPs O +
( O -
Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O -
) O -
, O +
2,945 O +
genes O +
were O +
enriched O +
in O +
hESCs O +
relative O +
to O +
NPs O -
; O +
and O +
552 O +
genes O +
were O +
enriched O +
in O +
the O +
NPs O +
relative O +
to O +
hESCs O -
, O +
at O +
a O +
p O -
- O -
value O +
significance O +
cutoff O +
of O +
0.01 O +
( O -
correcting O +
for O +
multiple O +
hypothesis O +
testing O +
using O +
the O +
Benjamini O -
- O -
Hochberg O +
method O -
) O -
. O -

The O +
15 O +
most O +
enriched O +
genes O +
in O +
hESCs O +
included O +
genes O +
such O +
as O +
teratocarcinoma O -
- O -
derived O +
growth O +
factor O +
1 O +
( O -
TDGF1 O -
/ O -
cripto O -
; O +
p O -
- O -
value O +
< O +
10−12 O -
) O -
, O +
zinc O +
finger O +
protein O +
42 O +
( O -
Zfp42 O -
/ O -
Rex1 O -
; O +
p O -
- O -
value O +
< O +
10−12 O -
) O -
, O +
Oct4 O +
( O -
p O -
- O -
value O +
< O +
10−12 O -
) O -
, O +
Nanog O +
( O -
p O -
- O -
value O +
< O +
10−10 O -
) O -
, O +
lin-28 O +
homolog O +
( O -
p O -
- O -
value O +
< O +
10−10 O -
) O -
, O +
cadherin O +
1 O +
preprotein O +
( O -
p O -
- O -
value O +
< O +
10−10 O -
) O -
, O +
claudin O +
6 O +
( O -
p O -
- O -
value O +
< O +
10−9 O -
) O -
, O +
ephrin O +
receptor O +
EphA1 O +
( O -
p O -
- O -
value O +
< O +
10−9 O -
) O -
, O +
and O +
erbB3 O +
( O -
p O -
- O -
value O +
< O +
10−9 O -
) O -
. O -

TDGF1 O -
/ O -
cripto O +
was O +
first O +
shown O +
to O +
stimulate O +
DNA O +
synthesis O +
and O +
cell O +
proliferation O +
of O +
both O +
undifferentiated O +
and O +
differentiated O +
embryonic O +
carcinoma O +
cells O +
[ O -
61 O -
] O +
and O +
was O +
later O +
shown O +
to O +
be O +
important O +
for O +
cardiomyocyte O +
formation O +
from O +
mouse U-Species +
ESC O +
[ O -
62 O -
] O -
. O -

Oct4 O -
, O +
reviewed O +
in O +
[ O -
63 O -
] O -
, O +
and O +
Nanog O +
[ O -
64 O -
] O +
are O +
crucial O +
for O +
the O +
pluripotency O +
of O +
hESCs O -
. O -

Recently O -
, O +
knockdown O +
of O +
Zfp42 O -
/ O -
Rex-1 O +
in O +
mouse U-Species +
ESC O +
caused O +
the O +
cells O +
to O +
differentiate O +
[ O -
65 O -
] O -
. O -

Our O +
gene O -
- O -
level O +
exon O +
array O +
analysis O +
confirmed O +
that O +
the O +
hESCs O +
and O +
NPs O +
were O +
molecularly O +
distinct O -
. O -

To O +
reveal O +
global O +
functional O +
differences O +
between O +
the O +
enriched O +
genes O +
in O +
hESCs O +
or O +
NPs O -
, O +
the O +
enriched O +
genes O +
were O +
subjected O +
to O +
a O +
Gene O +
Ontology O +
( O -
GO O -
, O +
http://www.geneontology.org O -
) O +
analysis O +
as O +
described O +
previously O +
[ O -
55 O -
] O -
. O -

Enriched O +
genes O +
in O +
hESCs O +
were O +
more O +
likely O +
to O +
be O +
in O +
molecular O +
function O +
categories O -
, O +
such O +
as O +
" O -
RNA O +
binding O -
" O +
( O -
p O -
- O -
value O +
< O +
10−12 O -
) O -
, O +
" O -
structural O +
constituent O +
of O +
ribosome O -
" O +
( O -
p O -
- O -
value O +
< O +
10−51 O -
) O -
, O +
" O -
exonuclease O +
activity O -
" O +
( O -
p O -
- O -
value O +
< O +
10−6 O -
) O -
, O +
" O -
cytochrome O -
- O -
c O +
oxidase O +
activity O -
" O +
( O -
p O -
- O -
value O +
< O +
10−5 O -
) O -
, O +
and O +
" O -
ATP O +
binding O -
" O +
( O -
p O -
- O -
value O +
< O +
10−6 O -
) O -
, O +
and O +
in O +
biological O +
processes O +
involved O +
with O +
" O -
tRNA O +
processing O -
" O +
( O -
p O -
- O -
value O +
< O +
10−6 O -
) O +
and O +
" O -
protein O +
biosynthesis O -
" O +
( O -
p O -
- O -
value O +
< O +
10−48 O -
) O -
, O +
consistent O +
with O +
our O +
knowledge O +
of O +
hESCs O +
as O +
a O +
rapidly O +
proliferating O +
population O +
of O +
cells O +
( O -
Figure O +
2A O -
) O -
. O -

Similar O +
analysis O +
of O +
the O +
enriched O +
genes O +
in O +
NPs O +
revealed O +
an O +
overrepresentation O +
in O +
molecular O +
functional O +
categories O -
, O +
such O +
as O +
" O -
calcium O +
ion O +
binding O -
" O +
( O -
p O -
- O -
value O +
< O +
10−8 O -
) O +
and O +
" O -
structural O +
molecule O +
activity O -
" O +
( O -
p O -
- O -
value O +
< O +
10−5 O -
) O -
, O +
and O +
in O +
biological O +
processes O +
involved O +
with O +
" O -
neurogenesis O -
" O +
( O -
p O -
- O -
value O +
< O +
10−38 O -
) O -
, O +
" O -
cell O +
adhesion O -
" O +
( O -
p O -
- O -
value O +
< O +
10−13 O -
) O -
, O +
" O -
cell O +
motility O -
" O +
( O -
p O -
- O -
value O +
< O +
10−4 O -
) O -
, O +
" O -
development O -
" O +
( O -
p O -
- O -
value O +
< O +
10−6 O -
) O -
, O +
" O -
neuropeptide O +
signaling O +
pathway O -
" O +
( O -
p O -
- O -
value O +
< O +
10−4 O -
) O -
, O +
and O +
" O -
endocytosis O -
" O +
( O -
p O -
- O -
value O +
< O +
10−4 O -
) O +
( O -
Figure O +
2B O -
) O -
. O -

Considering O +
that O +
these O +
were O +
the O +
only O +
categories O +
that O +
were O +
significantly O +
enriched O +
out O +
of O +
more O +
than O +
18,000 O +
GO O +
terms O -
, O +
and O +
that O +
randomly O +
selected O +
sets O +
of O +
similar O +
numbers O +
of O +
genes O +
did O +
not O +
reveal O +
statistical O +
differences O +
in O +
GO O +
categories O -
, O +
our O +
results O +
confirmed O +
that O +
the O +
global O +
molecular O +
profiles O +
derived O +
from O +
exon O +
array O +
analysis O +
were O +
consistent O +
with O +
known O +
differences O +
between O +
hESCs O +
and O +
NPs O -
. O -

Figure O +
2Gene O +
Ontology O +
AnalysisDifferential O +
gene O +
expression O +
of O +
hESCs O +
( O -
Cyt O -
- O -
ES O +
and O +
HUES6-ES O -
) O +
and O +
NPs O +
( O -
Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O -
) O +
was O +
computed O +
from O +
gene O -
- O -
level O +
signal O +
estimates O -
. O -

Statistical O +
significance O +
for O +
differential O +
gene O +
expression O +
was O +
determined O +
by O +
using O +
t O -
- O -
statistics O +
with O +
Benjamini O -
- O -
Hochberg O +
correction O +
for O +
false O +
discovery O +
rate O +
( O -
p O +
< O +
0.01 O -
) O -
. O -

Gene O +
Ontology O +
" O -
molecular O +
function O -
, O -
" O +
" O -
cellular O +
component O -
, O -
" O +
and O +
" O -
biological O +
process O -
" O +
categories O -
, O +
which O +
differed O +
significantly O +
( O -
p O +
< O +
0.05 O -
) O +
in O +
the O +
representation O +
between O +
significantly O +
enriched O +
genes O +
( O -
black O +
bars O -
) O +
and O +
all O +
other O +
genes O +
( O -
white O +
bars O -
) O -
, O +
were O +
shown O -
. O -

Statistical O +
significance O +
for O +
GO O +
analysis O +
was O +
assessed O +
by O +
using O +
χ2 O +
statistics O +
with O +
Bonferroni O +
correction O +
for O +
multiple O +
hypothesis O +
testing O -
. O -

GO O +
categories O +
are O +
ordered O +
from O +
top O +
to O +
bottom O +
in O +
order O +
of O +
decreasingly O +
significant O +
bias O +
toward O +
enriched O +
genes. O -
( O -
A O -
) O +
GO O +
analysis O +
of O +
enriched O +
genes O +
in O +
hESCs. O -
( O -
B O -
) O +
GO O +
analysis O +
of O +
enriched O +
genes O +
in O +
NPs O -
. O -

To O +
summarize O -
, O +
firstly O +
immunohistochemical O +
and O +
RT O -
- O -
PCR O +
evidence O +
validated O +
that O +
the O +
cells O +
exhibited O +
expected O +
characteristics O -
; O +
secondly O -
, O +
stage O -
- O -
specific O +
marker O +
gene O +
differences O +
by O +
RT O -
- O -
PCR O +
were O +
reflected O +
accurately O +
by O +
gene O -
- O -
level O +
estimates O +
from O +
the O +
exon O +
arrays O -
; O +
thirdly O -
, O +
the O +
hESC O -
- O -
enriched O +
genes O +
were O +
coherent O +
with O +
known O +
genes O +
that O +
controlled O +
pluripotency O +
and O +
self O -
- O -
renewal O -
; O +
and O +
lastly O -
, O +
the O +
global O +
functional O +
profiles O +
exemplified O +
expected O +
biological O +
differences O +
between O +
hESC O +
and O +
NP O +
cells O -
. O -

Description O +
of O +
the O +
Regression O -
- O -
Based O +
Exon O +
Array O +
ProtocolConvinced O +
that O +
the O +
signal O +
estimates O +
from O +
the O +
exon O +
arrays O +
reflected O +
expected O +
molecular O +
and O +
biological O +
differences O +
between O +
hESCs O +
and O +
NPs O -
, O +
we O +
sought O +
to O +
identify O +
AS O +
events O -
. O -

We O +
compared O +
Cyt O -
- O -
ES O +
to O +
hCNS O -
- O -
SCns O +
to O +
illustrate O +
our O +
approach O -
. O -

First O +
we O +
normalized O +
the O +
data O +
and O +
generated O +
signal O +
estimates O +
with O +
Robust O +
Multichip O +
Analysis O +
( O -
RMA O -
) O +
and O +
estimated O +
the O +
probability O +
that O +
each O +
probeset O +
was O +
detected O +
above O +
background O +
( O -
DABG O -
) O +
using O +
publicly O +
available O +
Affymetrix O +
Power O +
Tools O +
( O -
APT O -
) O -
. O -

We O +
analyzed O +
probesets O +
that O +
( O -
i O -
) O +
comprised O +
three O +
or O +
more O +
individual O +
probes O -
; O +
( O -
ii O -
) O +
were O +
localized O +
within O +
the O +
exons O +
of O +
our O +
gene O +
models O +
with O +
evidence O +
from O +
at O +
least O +
three O +
sources O +
( O -
mRNA O -
, O +
EST O -
, O +
or O +
full O -
- O -
length O +
cDNA O -
) O -
; O +
and O +
( O -
iii O -
) O +
were O +
detected O +
above O +
background O +
in O +
at O +
least O +
one O +
of O +
the O +
cell O +
lines O -
. O -

In O +
total O -
, O +
17,430 O +
gene O +
models O +
were O +
represented O +
by O +
probesets O +
that O +
satisfied O +
these O +
criteria O -
. O -

Next O +
we O +
asked O +
whether O +
the O +
probeset O +
expression O +
within O +
each O +
gene O +
model O +
was O +
positively O +
correlated O +
for O +
any O +
two O +
cell O +
lines O -
. O -

To O +
do O +
this O +
we O +
calculated O +
the O +
Pearson O +
correlation O +
coefficient O +
between O +
the O +
vectors O +
of O +
median O +
signal O +
estimates O +
across O +
replicates O +
in O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O -
. O -

The O +
vast O +
majority O +
of O +
genes O +
( O -
> O -
80 O -
% O -
) O +
was O +
found O +
to O +
have O +
probeset O -
- O -
level O +
Pearson O +
correlation O +
coefficients O +
of O +
greater O +
than O +
0.8 O +
( O -
Figure O +
3A O -
) O -
. O -

Next O +
we O +
randomly O +
permuted O +
the O +
association O +
between O +
the O +
median O +
signal O +
estimates O +
and O +
the O +
probesets O +
for O +
each O +
gene O +
in O +
hESCs O +
( O -
or O +
hCNS O -
- O -
SCns O -
) O +
and O +
observed O +
that O +
the O +
distribution O +
of O +
Pearson O +
correlation O +
coefficients O +
for O +
the O +
permuted O +
sets O +
was O +
centered O +
at O +
zero O -
, O +
as O +
expected O +
( O -
Figure O +
3A O -
) O -
. O -

This O +
indicated O +
that O +
the O +
signal O +
estimates O +
for O +
probesets O +
between O +
hESCs O +
and O +
hCNS O -
- O -
SCns O +
were O +
highly O +
correlated O +
and O +
suggested O +
that O +
a O +
scatter O +
plot O +
of O +
probeset O +
signal O +
estimates O +
between O +
hESCs O +
and O +
hCNS O -
- O -
SCns O +
would O +
reveal O +
a O +
linear O +
relationship O +
for O +
the O +
majority O +
of O +
genes O -
. O -

We O +
hypothesized O +
that O +
a O +
linear O +
regression O +
to O +
determine O +
if O +
some O +
probesets O +
behaved O +
unexpectedly O +
in O +
one O +
cell O +
type O +
compared O +
to O +
the O +
other O +
might O +
be O +
a O +
reasonable O +
approach O +
to O +
identify O +
AS O +
exons O -
. O -

Figure O +
3Description O +
of O +
the O +
REAP O +
Algorithm O +
Comparing O +
Exon O +
Array O +
Signal O +
Estimates O +
from O +
hCNS O -
- O -
SCns O +
and O +
Cyt O -
- O -
ES O -
( O -
A O -
) O +
Histogram O +
of O +
Pearson O +
correlation O +
coefficients O +
computed O +
from O +
median O +
signal O +
estimates O +
for O +
probesets O +
between O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O +
for O +
genes O +
( O -
blue O +
bars O -
) O -
. O -

Genes O +
were O +
required O +
to O +
have O +
more O +
than O +
five O +
probesets O +
localized O +
within O +
the O +
exons O +
in O +
the O +
gene O -
. O -

Red O +
bars O +
represented O +
Pearson O +
correlation O +
coefficients O +
computed O +
from O +
exons O +
with O +
shuffled O +
signal O +
estimates. O -
( O -
B O -
) O -

Each O +
probeset O +
contained O +
probeset O -
- O -
level O +
estimates O +
from O +
three O +
replicates O +
each O -
, O +
( O -
a O -
, O +
b O -
, O +
c O -
) O +
in O +
Cyt O -
- O -
ES O +
and O +
( O -
d O -
, O +
e O -
, O +
f O -
) O +
in O +
hCNS O -
- O -
SCns O -
. O -

The O +
five O +
points O +
summarizing O +
the O +
log2 O +
probeset O -
- O -
level O +
estimates O +
are O +
indicated O +
by O +
black O +
filled O +
circles. O -
( O -
C O -
) O -

Each O +
probeset O +
was O +
summarized O +
by O +
five O +
points O -
. O -

Scatter O +
plots O +
of O +
signal O +
estimates O +
for O +
probesets O +
that O +
were O +
present O +
in O +
at O +
least O +
one O +
cell O +
type O +
( O -
Cyt O -
- O -
ES O +
or O +
hCNS O -
- O -
SCns O -
) O +
for O +
the O +
EHBP1 O +
gene O -
. O -

Probesets O +
were O +
considered O +
present O +
if O +
the O +
DABG O +
p O -
- O -
value O +
was O +
< O -
0.05 O +
for O +
all O +
three O +
replicates O +
in O +
the O +
cell O +
type O -
. O -

A O +
regression O +
line O +
derived O +
from O +
robust O +
linear O +
regression O +
with O +
MM O +
estimation O +
is O +
indicated O -
. O -

Points O +
above O +
the O +
line O +
represent O +
probesets O +
within O +
exons O +
that O +
were O +
enriched O +
in O +
Cyt O -
- O -
ES O +
and O +
points O +
below O +
represent O +
exons O +
that O +
were O +
enriched O +
in O +
hCNS O -
- O -
SCns O -
. O -

Points O +
close O +
to O +
the O +
regression O +
line O +
are O +
not O +
significantly O +
different O +
in O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O -
. O -

Boxed O +
points O +
represented O +
the O +
five O -
- O -
point O +
summary O +
of O +
a O +
probeset O +
that O +
was O +
significantly O +
enriched O +
in O +
Cyt O -
- O -
ES O +
but O +
was O +
skipped O +
in O +
hCNS O -
- O -
SCns. O -
( O -
D O -
) O +
Histogram O +
of O +
studentized O +
residuals O +
for O +
points O +
from O +
the O +
scatter O +
plot O +
in O +
( O -
C O -
) O +
in O +
EHBP1. O -
( O -
E O -
) O +
The O +
histogram O +
of O +
studentized O +
residuals O +
for O +
all O +
points O +
for O +
all O +
analyzed O +
probesets O +
( O -
100 O +
bins O -
) O -
. O -
( O -
F O -
) O -

The O +
scatter O +
plot O +
of O +
studentized O +
residuals O +
generated O +
from O +
comparing O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O +
and O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O +
of O +
5,000 O +
randomly O +
chosen O +
probesets O -
. O -

Here O -
, O +
a O +
possible O +
representation O +
of O +
the O +
data O +
was O +
explored O -
. O -

If O +
we O +
had O +
N O +
replicates O +
in O +
one O +
condition O +
and O +
M O +
replicates O +
in O +
the O +
other O -
, O +
we O +
could O +
consider O +
N*M O +
points O +
if O +
we O +
analyzed O +
every O +
possible O +
pairing O -
. O -

For O +
instance O -
, O +
three O +
replicate O +
signal O +
estimates O +
for O +
every O +
probeset O +
per O +
cell O +
line O -
, O +
such O +
as O +
signal O +
estimates O +
a O -
, O +
b O -
, O +
and O +
c O +
in O +
hESCs O +
and O +
d O -
, O +
e O -
, O +
and O +
f O +
in O +
hCNS O -
- O -
SCns O -
, O +
would O +
translate O +
to O +
pairing O +
every O +
signal O +
( O -
d O -
, O -
a O -
) O -
, O +
( O -
d O -
, O -
b O -
) O -
, O +
( O -
d O -
, O -
c O -
) O +
… O +
( O -
f O -
, O -
a O -
) O -
, O +
( O -
f O -
, O -
b O -
) O -
, O +
( O -
f O -
, O -
c O -
) O +
for O +
linear O +
regression O +
( O -
Figure O +
3B O -
) O -
. O -

Instead O -
, O +
pairing O +
the O +
signal O +
estimates O +
of O +
all O +
replicates O +
in O +
one O +
condition O +
to O +
the O +
median O +
of O +
the O +
other O +
would O +
only O +
require O +
N O +
+ O +
M O +
− O +
1 O +
points O +
and O +
would O +
capture O +
the O +
variation O +
of O +
the O +
signal O +
estimates O +
of O +
each O +
probeset O -
. O -

For O +
example O -
, O +
we O +
considered O +
( O -
d O -
, O -
b O -
) O -
, O +
( O -
e O -
, O -
a O -
) O -
, O +
( O -
e O -
, O -
b O -
) O -
, O +
( O -
e O -
, O -
c O -
) O -
, O +
and O +
( O -
f O -
, O -
b O -
) O +
points O +
where O +
b O +
and O +
d O +
were O +
the O +
median O +
intensities O +
for O +
the O +
replicates O +
in O +
Cyt O -
- O -
ES O +
and O +
hCNS O -
- O -
SCns O -
, O +
respectively O +
( O -
Figure O +
3B O -
) O -
. O -

A O +
scatter O +
plot O +
of O +
all O +
probesets O +
of O +
the O +
EHBP1 O +
( O -
EH O +
domain O +
binding O +
protein O -
, O +
RefSeq O +
identifier O +
NM_015252 O -
) O +
is O +
shown O +
in O +
Figure O +
3C O +
in O +
the O +
format O +
described O -
. O -

Each O +
probeset O +
was O +
represented O +
by O +
5 O +
points O +
of O +
log O -
- O -
transformed O +
( O -
base O +
2 O -
) O +
values O -
; O +
and O +
each O +
point O +
on O +
the O +
scatter O +
plot O +
reflected O +
the O +
extent O +
of O +
inclusion O +
of O +
an O +
exon O +
in O +
hESCs O +
and O +
in O +
hCNS O -
- O -
SCns O +
( O -
Figure O +
3C O -
) O -
.A O +
classical O +
linear O +
regression O +
model O +
could O +
be O +
proposed O +
to O +
fit O +
the O +
response O +
variable O +
yij O -
, O +
the O +
log2 O +
expression O +
of O +
probeset O +
i O +
in O +
cell O -
- O -
type O +
j O +
( O -
for O +
example O -
, O +
j O +
is O +
Cyt O -
- O -
ESC O -
) O +
to O +
explanatory O +
variables O +
xik O -
, O +
and O +
the O +
log2 O +
expression O +
of O +
probeset O +
i O +
in O +
cell O +
type O +
k O +
( O -
for O +
example O -
, O +
k O +
is O +
hCNS O -
- O -
SCns O -
) O -
. O -

However O -
, O +
classical O +
linear O +
regression O +
by O +
least O -
- O -
squares O +
estimation O +
is O +
biased O +
because O +
the O +
least O +
squares O +
predictions O +
are O +
strongly O +
influenced O +
by O +
the O +
outliers O -
, O +
leading O +
to O +
completely O +
incorrect O +
regression O +
line O +
estimates O -
, O +
masking O +
of O +
the O +
outliers O -
, O +
and O +
incorrect O +
predictions O +
of O +
outliers O -
. O -

Therefore O -
, O +
we O +
applied O +
M O -
- O -
estimation O +
robust O +
regression O +
to O +
estimate O +
the O +
line O -
, O +
which O +
is O +
less O +
sensitive O +
to O +
outliers O -
. O -

Fitting O +
was O +
performed O +
using O +
an O +
iterated O -
, O +
re O -
- O -
weighted O +
least O +
squares O +
analysis O -
. O -

Our O +
assumption O +
was O +
that O +
most O +
of O +
the O +
points O +
were O +
" O -
correct O -
, O -
" O +
i.e. O -
, O +
that O +
most O +
of O +
the O +
exons O +
were O +
constitutively O +
spliced O -
. O -

Thus O -
, O +
robust O +
regression O +
would O +
find O +
the O +
line O +
that O +
was O +
least O +
dependent O +
on O +
outliers O -
, O +
which O +
would O +
be O +
potential O +
AS O +
exons O -
. O -

This O +
assumption O +
was O +
substantiated O +
by O +
our O +
observation O +
that O -
, O +
using O +
publicly O +
available O +
ESTs O +
and O +
mRNAs O -
, O +
a O +
minority O +
of O +
human U-Species +
exons O +
( O -
7 O -
% O -
) O +
have O +
evidence O +
for O +
exon O -
- O -
skipping O -
, O +
the O +
most O +
common O +
form O +
of O +
AS O -
. O -

Using O +
robust O +
regression O -
, O +
the O +
regression O +
line O +
for O +
Cyt O -
- O -
ESC O +
versus O +
hCNS O -
- O -
SCns O +
in O +
the O +
EHBP1 O +
gene O +
is O +
illustrated O +
in O +
Figure O +
3C O -
. O -

The O +
boxed O +
points O +
belonged O +
to O +
a O +
probeset O +
that O +
was O +
enriched O +
in O +
hESCs O +
but O +
depleted O +
in O +
hCNS O -
- O -
SCns O -
, O +
which O +
was O +
suspected O +
to O +
be O +
due O +
to O +
AS O -
. O -

The O +
difference O +
between O +
the O +
actual O +
and O +
regression O -
- O -
based O +
predicted O +
value O -
, O +
normalized O +
by O +
the O +
estimate O +
of O +
its O +
standard O +
deviation O -
, O +
is O +
called O +
the O +
studentized O +
residuals O -
. O -

Studentized O +
residuals O +
were O +
computed O +
for O +
all O +
probeset O +
pairs O +
in O +
EHBP1 O -
, O +
and O +
the O +
histogram O +
depicting O +
their O +
distribution O +
is O +
illustrated O +
in O +
Figure O +
3D O -
. O -

As O +
expected O -
, O +
the O +
mean O +
of O +
the O +
distribution O +
was O +
close O +
to O +
zero O -
, O +
and O +
the O +
distribution O +
was O +
approximated O +
by O +
a O +
t O -
- O -
distribution O +
with O +
n O -
- O -
p-1 O +
degrees O +
of O +
freedom O -
, O +
where O +
n O +
was O +
the O +
number O +
of O +
points O +
on O +
the O +
scatter O +
plot O -
, O +
and O +
the O +
number O +
of O +
parameters O +
p O +
was O +
2 O -
. O -

The O +
boxed O +
points O +
had O +
studentized O +
residuals O +
of O +
1.829 O -
, O +
3.104 O -
, O +
2.634 O -
, O +
3.012 O -
, O +
and O +
2.125 O +
with O +
p O -
- O -
values O +
of O +
0.034 O -
, O +
0.00119 O -
, O +
0.00477 O -
, O +
0.00158 O -
, O +
and O +
0.01780 O -
, O +
respectively O -
, O +
computed O +
based O +
on O +
the O +
t O -
- O -
distribution O +
( O -
Figure O +
3C O -
) O -
. O -

At O +
a O +
stringent O +
p O -
- O -
value O +
cutoff O +
of O +
0.01 O -
, O +
four O +
of O +
the O +
five O +
studentized O +
residuals O +
were O +
designated O +
as O +
significant O +
" O -
outliers O -
, O -
" O +
indicating O +
that O +
the O +
probeset O +
was O +
" O -
unusual O -
. O -
" O +
RT O -
- O -
PCR O +
confirmed O +
that O +
the O +
exon O -
, O +
represented O +
by O +
the O +
probeset O -
, O +
was O +
indeed O +
differentially O +
included O +
in O +
hESCs O +
and O +
skipped O +
in O +
hCNS O -
- O -
SCns O +
( O -
Figure O +
7B O -
) O -
. O -

Applying O +
this O +
approach O +
to O +
all O +
gene O +
models O +
revealed O +
that O -
, O +
as O +
expected O -
, O +
the O +
majority O +
of O +
studentized O +
residuals O +
are O +
centered O +
at O +
zero O +
( O -
Figure O +
3E O -
) O -
. O -

Thus O +
far O +
in O +
the O +
example O -
, O +
our O +
analysis O +
was O +
based O +
on O +
regression O +
of O +
hESCs O +
( O -
y O -
- O -
axis O -
) O +
versus O +
hCNS O -
- O -
SCns O +
( O -
x O -
- O -
axis O -
) O +
( O -
Figure O +
3B–3D O -
) O -
. O -

However O -
, O +
robust O +
regression O +
as O +
described O +
was O +
not O +
symmetrical O -
, O +
i.e. O -
, O +
parameter O +
estimation O +
of O +
y O +
as O +
a O +
function O +
of O +
x O +
was O +
not O +
the O +
same O +
as O +
that O +
of O +
x O +
as O +
a O +
function O +
of O +
y. O +
The O +
negative O +
slope O +
revealed O +
that O +
probesets O +
enriched O +
in O +
hESCs O +
versus O +
hCNS O -
- O -
SCns O +
( O -
positive O +
valued O -
) O -
, O +
were O +
expectedly O +
depleted O +
when O +
hCNS O -
- O -
SCns O +
was O +
compared O +
to O +
hESCs O +
( O -
negative O +
valued O -
; O +
Figure O +
3F O -
) O -
. O -

As O +
our O +
method O +
for O +
predicting O +
candidate O +
alternative O +
exons O +
was O +
based O +
on O +
identification O +
of O +
outliers O +
using O +
robust O +
regression O -
, O +
we O +
named O +
the O +
method O +
REAP O -
. O -

Identification O +
and O +
Removal O +
of O +
False O +
PositivesIn O +
the O +
process O +
of O +
experimentally O +
validating O +
our O +
predictions O -
, O +
we O +
encountered O +
three O +
main O +
sources O +
of O +
false O +
positives O +
( O -
FP O -
) O +
from O +
robust O +
regression O -
. O -

First O -
, O +
we O +
identified O +
genes O +
with O +
probeset O +
signal O +
estimates O +
that O +
were O +
poorly O +
correlated O +
and O +
were O +
not O +
amenable O +
to O +
our O +
method O -
. O -

As O +
an O +
example O -
, O +
the O +
median O +
probeset O +
signal O +
estimates O +
in O +
hESCs O +
and O +
hCNS O -
- O -
SCns O +
of O +
the O +
FIP1L1 O +
gene O +
( O -
gene O +
identifiers O +
BC011543 O -
, O +
AL136910 O -
) O +
had O +
a O +
Pearson O +
correlation O +
coefficient O +
of O +
0.38 O -
, O +
and O +
the O +
distribution O +
of O +
points O +
was O +
not O +
amenable O +
to O +
robust O +
regression O +
( O -
Figure O +
4A O -
) O -
. O -

To O +
avoid O +
inappropriate O +
application O +
of O +
REAP O +
and O +
generating O +
false O +
predictions O -
, O +
we O +
empirically O +
determined O +
that O +
a O +
gene O +
had O +
to O +
have O +
a O +
Pearson O +
correlation O +
coefficient O +
cutoff O +
of O +
0.6 O +
before O +
being O +
amenable O +
to O +
REAP O +
analysis O -
. O -

Next O -
, O +
we O +
managed O +
two O +
additional O +
sources O +
of O +
FPs O -
, O +
namely O +
" O -
high O -
- O -
leverage O -
" O +
and O +
" O -
high O -
- O -
influence O -
" O +
points O -
, O +
which O +
we O +
were O +
able O +
to O +
identify O +
by O +
computing O +
the O +
following O +
metrics O -
. O -

For O +
every O +
point O -
, O +
we O +
computed O +
( O -
i O -
) O +
the O +
studentized O +
residual O +
( O -
as O +
described O +
above O -
) O -
, O +
( O -
ii O -
) O +
the O +
influence O -
, O +
and O +
( O -
iii O -
) O +
the O +
leverage O +
( O -
see O +
Materials O +
and O +
Methods O +
for O +
more O +
details O -
) O -
. O -

Leverage O +
assessed O +
how O +
far O +
away O +
a O +
value O +
of O +
the O +
independent O +
variable O +
was O +
from O +
the O +
mean O +
value O -
; O +
the O +
farther O +
away O +
the O +
observation O +
the O +
more O +
leverage O +
it O +
had O -
. O -

The O +
influence O +
of O +
a O +
point O +
was O +
related O +
to O +
its O +
covariance O +
ratio O -
: O +
a O +
covariance O +
ratio O +
larger O +
( O -
or O +
smaller O -
) O +
than O +
1 O +
implied O +
that O +
the O +
point O +
was O +
closer O +
( O -
or O +
farther O -
) O +
than O +
was O +
typical O +
to O +
the O +
regression O +
line O -
, O +
so O +
removing O +
it O +
would O +
hurt O +
( O -
or O +
help O -
) O +
the O +
accuracy O +
of O +
the O +
line O +
and O +
would O +
increase O +
( O -
or O +
decrease O -
) O +
the O +
error O +
term O +
variance O -
. O -

Influence O +
was O +
computed O +
as O +
the O +
absolute O +
difference O +
between O +
the O +
covariance O +
ratio O +
and O +
unity O -
. O -

To O +
illustrate O +
further O -
, O +
a O +
point O +
was O +
classified O +
as O +
an O +
" O -
outlier O -
" O +
if O +
it O +
had O +
a O +
large O +
studentized O +
residual O +
( O -
p O +
< O +
0.01 O -
) O +
and O +
low O +
leverage O +
( O -
boxed O +
point O +
" O -
a O -
" O -
) O -
; O +
as O +
a O +
" O -
high O -
- O -
leverage O -
" O +
point O +
if O +
it O +
had O +
a O +
low O +
studentized O +
residual O +
and O +
high O +
leverage O +
( O -
boxed O +
point O +
" O -
b O -
" O -
) O -
; O +
and O +
as O +
a O +
" O -
high O -
- O -
influence O -
" O +
point O +
if O +
it O +
had O +
a O +
high O +
studentized O +
residual O -
, O +
high O +
leverage O -
, O +
and O +
high O +
influence O +
( O -
boxed O +
point O +
" O -
c O -
" O -
; O +
Figure O +
4B O -
) O -
. O -

Points O +
that O +
resembled O +
boxed O +
point O +
" O -
a O -
" O +
were O +
designated O +
as O +
potential O +
AS O +
events O -
. O -

For O +
example O -
, O +
four O +
of O +
the O +
five O +
boxed O +
points O +
in O +
Figure O +
3C O +
were O +
" O -
outliers O -
, O -
" O +
and O +
RT O -
- O -
PCR O +
validation O +
indicated O +
that O +
the O +
exon O +
represented O +
by O +
the O +
probeset O +
was O +
indeed O +
skipped O +
in O +
hCNS O -
- O -
SCns O +
( O -
EHBP1 O -
, O +
Figure O +
7B O -
) O -
. O -

Points O +
that O +
were O +
" O -
high O -
- O -
leverage O -
, O -
" O +
such O +
as O +
the O +
five O +
points O +
in O +
the O +
CLCN2 O +
gene O -
, O +
were O +
experimentally O +
verified O +
to O +
be O +
a O +
FP O +
( O -
Figure O +
4C O -
; O +
unpublished O +
data O -
) O -
. O -

Points O +
that O +
were O +
" O -
high O -
- O -
influence O -
, O -
" O +
such O +
as O +
the O +
four O +
of O +
five O +
boxed O +
points O +
in O +
the O +
ABCA3 O +
gene O +
were O +
also O +
experimentally O +
verified O +
to O +
be O +
a O +
FP O +
( O -
Figure O +
4D O -
; O +
unpublished O +
data O -
) O -
. O -

In O +
conclusion O -
, O +
in O +
order O +
to O +
reduce O +
the O +
FP O +
rate O -
, O +
all O +
points O +
were O +
evaluated O +
according O +
to O +
the O +
metrics O +
described O -
, O +
and O +
points O +
that O +
were O +
significant O +
" O -
outliers O -
" O +
were O +
considered O +
putative O +
AS O +
events O -
. O -

Figure O +
4Sources O +
of O +
False O +
Positives O -
( O -
A O -
) O +
Scatter O +
plot O +
of O +
points O +
for O +
the O +
FIP1L1 O +
gene O +
and O +
the O +
line O +
representing O +
the O +
robust O +
regression O +
estimate. O -
( O -
B O -
) O -

Boxed O +
point O +
" O -
a O -
" O +
represents O +
a O +
significant O +
" O -
outlier O -
" O +
( O -
with O +
a O +
significantly O +
different O +
studentized O +
residual O +
and O +
low O +
leverage O -
) O -
. O -

Boxed O +
point O +
" O -
b O -
" O +
represents O +
a O +
" O -
high O +
leverage O -
" O +
point O +
( O -
low O +
studentized O +
residual O +
and O +
a O +
high O +
leverage O -
) O -
. O -

Boxed O +
point O +
" O -
c O -
" O +
represents O +
a O +
" O -
high O +
influence O -
" O +
point O +
( O -
high O +
studentized O +
residual O -
, O +
high O +
leverage O -
, O +
and O +
high O +
influence O -
) O -
. O -
( O -
C O -
) O +
Scatter O +
plot O +
of O +
points O +
for O +
the O +
CLCN2 O +
gene O -
. O -

Boxed O +
points O +
represent O +
" O -
high O +
leverage O -
" O +
points. O -
( O -
D O -
) O +
Scatter O +
plot O +
of O +
points O +
for O +
the O +
ABCA3 O +
gene O -
. O -

Boxed O +
points O +
represent O +
" O -
high O +
influence O -
" O +
points O -
. O -

Global O +
Identification O +
and O +
Characterization O +
of O +
REAP O -
[ O -
+ O -
] O +
ExonsREAP O +
was O +
applied O +
to O +
identify O +
AS O +
events O +
in O +
NPs O +
compared O +
to O +
hESCs O -
: O +
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O -
; O +
HUES6-NP O +
versus O +
HUES6-ES O -
; O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O -
, O +
and O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O -
. O -

After O +
removing O +
potential O +
FPs O -
, O +
11,348 O +
genes O +
containing O +
158,657 O +
probesets O +
were O +
scored O +
by O +
REAP.As O +
described O +
above O -
, O +
for O +
each O +
pair O +
of O +
cell O +
lines O +
compared O -
, O +
each O +
probset O +
was O +
represented O +
by O +
five O +
points O -
, O +
where O +
each O +
point O +
was O +
defined O +
a O +
significant O +
outlier O +
if O +
it O +
had O +
a O +
high O +
residual O +
( O -
p O +
< O +
0.01 O -
) O -
, O +
low O +
influence O -
, O +
and O +
high O +
leverage O -
. O -

Points O +
per O +
probeset O +
should O +
be O +
correlated O -
; O +
in O +
other O +
words O -
, O +
if O +
one O +
point O +
was O +
a O +
significant O +
outlier O -
, O +
the O +
other O +
points O +
were O +
expected O +
to O +
be O +
outliers O +
as O +
well O -
. O -

To O +
ensure O +
that O +
this O +
was O +
the O +
case O -
, O +
we O +
counted O +
the O +
number O +
of O +
probesets O +
with O +
N O +
significant O +
outliers O -
, O +
where O +
N O +
was O +
varied O +
from O +
0 O +
to O +
5 O -
. O -

Next O -
, O +
the O +
identity O +
of O +
the O +
probesets O +
and O +
points O +
derived O +
from O +
them O +
were O +
exchanged O +
with O +
other O +
probesets O -
, O +
keeping O +
constant O +
the O +
total O +
number O +
of O +
points O +
that O +
were O +
considered O +
significant O +
outliers O -
. O -

At O +
N O +
= O +
0 O -
, O +
we O +
observed O +
approximately O +
equal O +
numbers O +
of O +
probesets O +
in O +
the O +
actual O +
versus O +
shuffled O +
controls O -
. O -

In O +
contrast O -
, O +
we O +
observed O +
that O +
there O +
were O +
1.5 O +
times O +
more O +
probesets O +
with O +
N O +
= O +
2 O +
significant O +
outliers O +
relative O +
to O +
shuffled O +
controls O -
; O +
12–31 O +
times O +
more O +
probesets O +
with O +
N O +
= O +
3 O -
; O +
and O +
17–612 O +
times O +
more O +
probesets O +
that O +
had O +
N O +
= O +
4 O +
significant O +
outliers O +
( O -
Figure O +
5A O -
; O +
see O +
Table O +
S1 O -
) O -
. O -

For O +
example O -
, O +
in O +
hCNS O -
- O -
SCns O +
compared O +
to O +
Cyt O -
- O -
ES O -
, O +
approximately O +
0.39 O -
% O +
( O -
490 O +
of O +
124,604 O -
) O +
of O +
probesets O +
had O +
three O +
significant O +
outliers O +
and O +
0.25 O -
% O +
( O -
308 O +
probesets O -
) O +
had O +
four O +
significant O +
outliers O -
, O +
relative O +
to O +
0.02 O -
% O +
and O +
0 O -
% O +
of O +
shuffled O +
controls O -
, O +
respectively O -
. O -

Figure O +
5Correlation O +
between O +
" O -
Outliers" O -
( O -
A O -
) O +
The O +
number O +
of O +
probesets O +
with O +
N O +
significant O +
" O -
outliers O -
" O +
was O +
determined O +
for O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O -
, O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O -
, O +
Cyt O -
- O -
NPs O +
versus O +
Cyt O -
- O -
ES O -
, O +
and O +
HUES6-NPs O +
versus O +
HUES6-ES O +
( O -
N O +
= O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O -
, O +
5 O -
) O -
. O -

For O +
comparison O -
, O +
points O +
to O +
probeset O +
relationships O +
were O +
randomly O +
permuted O -
, O +
retaining O +
the O +
same O +
number O +
of O +
" O -
outliers O -
. O -
" O -

Vertical O +
bars O +
represent O +
the O +
ratio O +
between O +
the O +
number O +
of O +
actual O +
points O +
and O +
the O +
randomly O +
permutated O +
sets. O -
( O -
B O -
) O +
Similar O +
to O +
( O -
A O -
) O -
, O +
except O +
points O +
were O +
counted O +
as O +
" O -
outliers O -
" O +
only O +
if O +
they O +
were O +
" O -
outliers O -
" O +
in O +
both O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O +
and O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O +
( O -
combined O +
hCNS O -
- O -
SCns O +
versus O +
hESC O -
; O +
blue O +
bars O -
) O -
; O +
in O +
both O +
HUES6-NP O +
versus O +
HUES6-ES O +
and O +
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O +
( O -
combined O +
derived O +
NP O +
versus O +
hESC O -
; O +
red O +
bars O -
) O -
; O +
and O +
in O +
all O +
four O +
comparisons O +
( O -
combined O +
NP O +
versus O +
hESC O -
; O +
yellow O +
bar O -
) O -
.Next O +
we O +
asked O +
whether O +
the O +
overlap O +
between O +
related O +
comparisons O +
was O +
higher O +
than O +
expected O -
. O -

Comparing O +
the O +
significant O +
probesets O +
between O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O +
and O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O +
revealed O +
672 O +
significant O +
probesets O +
( O -
N O +
≥ O +
2 O -
) O -
, O +
whereas O +
if O +
we O +
shuffled O +
the O +
associations O +
between O +
probeset O +
identity O +
and O +
significant O +
outliers O -
, O +
only O +
four O +
significant O +
probesets O +
( O -
N O +
≥ O +
2 O -
) O +
were O +
identified O -
— O -
a O +
168-fold O +
enrichment O +
( O -
Figure O +
5B O -
, O +
Table O +
S1 O -
) O -
. O -

A O +
total O +
of O +
236 O +
significant O +
probesets O +
overlapped O +
when O +
we O +
compared O +
the O +
derived O +
NPs O +
to O +
hESCs O +
( O -
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O +
and O +
HUES6-NP O +
versus O +
HUES6-ES O -
) O -
, O +
relative O +
to O +
seven O +
significant O +
probesets O +
( O -
34-fold O +
enrichment O -
) O -
.At O +
a O +
cutoff O +
of O +
two O +
significant O +
outliers O -
, O +
1,737 O +
probesets O +
contained O +
in O +
internal O +
exons O +
were O +
defined O +
as O +
positive O +
REAP O +
predictions O +
( O -
hereafter O +
called O +
REAP O -
[ O -
+ O -
] O -
) O +
exons O -
— O -
candidate O +
AS O +
events O +
that O +
distinguished O +
NP O +
from O +
hESC O -
. O -

Surprisingly O -
, O +
we O +
observed O +
that O +
the O +
majority O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
specific O +
to O +
the O +
pair O +
of O +
hESC O +
and O +
NP O +
that O +
was O +
compared O -
, O +
likely O +
reflecting O +
differences O +
in O +
genetic O +
origins O +
and/or O +
culturing O +
and O +
differentiation O +
conditions O +
of O +
the O +
cell O +
lines O -
: O +
614 O +
REAP O -
[ O -
+ O -
] O +
events O +
were O +
unique O +
to O +
hCNS O -
- O -
SCns O +
versus O +
HUE6-ES O -
; O +
220 O +
were O +
unique O +
to O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O -
; O +
439 O +
were O +
unique O +
to O +
HUES6-NP O +
versus O +
HUES6-ES O -
; O +
and O +
250 O +
were O +
unique O +
to O +
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O -
. O -

The O +
shared O +
events O +
between O +
pairs O +
of O +
comparisons O +
made O +
up O +
a O +
minority O +
of O +
the O +
total O +
number O +
identified O -
: O +
102 O +
REAP O -
[ O -
+ O -
] O +
events O +
were O +
found O +
to O +
be O +
in O +
common O +
between O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O +
and O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O -
; O +
48 O +
between O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O +
and O +
HUES6-NP O +
versus O +
HUES6-ES O -
; O +
and O +
only O +
17 O +
between O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
ES O +
and O +
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O +
( O -
Table O +
S2 O -
) O -
. O -

Comparison O +
of O +
REAP O +
to O +
EST O -
- O -
Based O +
Method O +
and O +
ACEScanTraditionally O -
, O +
AS O +
exons O +
were O +
discovered O +
by O +
using O +
EST O +
alignments O +
to O +
genomic O +
loci O -
, O +
and O +
also O +
more O +
recently O +
by O +
computational O +
algorithms O +
that O +
used O +
sequence O +
information O +
extracted O +
from O +
multiple O +
genomes O -
. O -

Here O -
, O +
we O +
compared O +
REAP O +
predictions O +
to O +
both O +
approaches O -
. O -

In O +
the O +
first O +
comparison O -
, O +
publicly O +
available O +
ESTs O +
and O +
mRNA O +
transcripts O +
were O +
aligned O +
to O +
the O +
human U-Species +
genome O +
sequence O -
. O -

13,934 O +
exons O +
with O +
evidence O +
for O +
exon O -
- O -
skipping O +
and/or O +
inclusion O +
( O -
EST O -
- O -
SE O +
for O +
EST O -
- O -
verified O +
skipped O +
exons O -
) O +
were O +
generated O -
, O +
comprising O +
∼7 O -
% O +
of O +
all O +
internal O +
exons O -
. O -

First O +
we O +
analyzed O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O -
. O -

If O +
we O +
required O +
that O +
none O +
of O +
the O +
points O +
per O +
probeset O +
( O -
exon O -
) O +
was O +
significant O -
, O +
6 O -
% O +
( O -
4,402 O +
of O +
71,731 O -
) O +
of O +
exons O +
( O -
after O +
probeset O +
mapping O -
) O +
had O +
evidence O +
for O +
EST O -
- O -
SE O +
( O -
Figure O +
6A O -
) O -
. O -

Shuffling O +
the O +
mapping O +
between O +
these O +
probesets O +
and O +
exons O +
resulted O +
in O +
8 O -
% O +
( O -
5,777 O +
of O +
71,731 O -
) O +
of O +
exons O +
with O +
evidence O +
for O +
EST O -
- O -
SE O +
( O -
Figure O +
6A O -
) O -
. O -

These O +
percentages O +
were O +
not O +
significantly O +
different O +
from O +
the O +
7 O -
% O +
of O +
exons O +
with O +
EST O +
evidence O +
for O +
AS O +
observed O +
from O +
using O +
all O +
exons O -
. O -

By O +
raising O +
the O +
requirement O +
that O +
probesets O +
had O +
to O +
contain O +
at O +
least O +
one O +
significant O +
point O +
to O +
five O +
significant O +
points O -
, O +
the O +
percentage O +
of O +
EST O -
- O -
SE O +
increased O +
dramatically O +
from O +
11 O -
% O +
( O -
531 O +
of O +
4,898 O +
exons O -
) O +
to O +
26 O -
% O +
( O -
33 O +
of O +
126 O -
) O -
. O -

In O +
comparison O -
, O +
the O +
shuffled O +
probesets O +
at O +
the O +
same O +
requirements O +
remained O +
at O +
∼8 O -
% O -
, O +
rising O +
slightly O +
to O +
11 O -
% O +
at O +
five O +
points O -
, O +
due O +
to O +
small O +
sample O +
sizes O -
. O -

Similar O +
trends O +
were O +
observed O +
with O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O +
and O +
the O +
derived O +
NPs O +
versus O +
hESCs O +
( O -
Figure O +
6A O -
) O -
. O -

Therefore O -
, O +
we O +
concluded O +
that O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
enriched O +
for O +
AS O +
events O +
independently O +
identified O +
by O +
a O +
transcript O -
- O -
based O +
approach O -
. O -

Figure O +
6Comparison O +
of O +
REAP O +
Predictions O +
for O +
hCNS O -
- O -
SCns O +
versus O +
Cyt O -
- O -
hES O -
, O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O -
, O +
Cyt O -
- O -
NP O +
versus O +
Cyt O -
- O -
ES O -
, O +
and O +
HUES6-NPs O +
versus O +
HUES6-ES O +
with O +
Alternative O +
Exons O +
Identified O +
by O +
an O +
EST O -
- O -
Based O +
Method O +
and O +
ACEScan O -
( O -
A O -
) O +
Black O -
- O -
filled O +
squares O +
represented O +
the O +
fraction O +
of O +
exons O +
containing O +
probesets O +
with O +
N O +
significant O +
points O +
that O +
had O +
EST O +
evidence O +
for O +
exon O +
inclusion O +
or O +
exclusion O +
( O -
N O +
= O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O -
, O +
4 O +
and O +
5 O -
) O -
. O -

White O -
- O -
filled O +
triangles O +
represented O +
similarly O +
computed O +
fractions O +
with O +
permuted O +
probeset O +
to O +
exon O +
mappings. O -
( O -
B O -
) O +
Black O -
- O -
filled O +
squares O +
represented O +
the O +
fraction O +
of O +
exons O +
containing O +
probesets O +
with O +
N O +
significant O +
points O +
that O +
had O +
ACEScan O +
positive O +
scores O -
, O +
indicative O +
of O +
evolutionarily O +
conserved O +
alternative O +
exons O -
. O -

White O -
- O -
filled O +
triangles O +
represented O +
similarly O +
computed O +
fractions O +
with O +
permuted O +
probeset O +
to O +
exon O +
mappings O -
. O -

Next O -
, O +
we O +
compared O +
REAP O +
predictions O +
to O +
a O +
computational O +
approach O +
of O +
identifying O +
exons O +
with O +
AS O +
conserved O +
in O +
human U-Species +
and O +
mouse U-Species -
, O +
ACEScan O +
[ O -
55 O -
] O -
. O -

ACEScan O +
receives O +
as O +
input O +
orthologous O +
human U-Species -
– O -
mouse U-Species +
exon O +
pairs O +
and O +
flanking O +
intronic O +
regions O +
and O +
computes O +
sequence O +
features O +
and O +
integrates O +
the O +
features O +
into O +
a O +
machine O -
- O -
learning O +
algorithm O +
to O +
assign O +
a O +
real O -
- O -
valued O +
score O +
to O +
the O +
exon O -
. O -

A O +
positive O +
score O +
indicated O +
a O +
higher O +
likelihood O +
of O +
being O +
AS O +
in O +
both O +
human U-Species +
and O +
mouse U-Species -
. O -

ACEScan O +
was O +
updated O +
in O +
the O +
following O +
ways O -
. O -

Firstly O -
, O +
instead O +
of O +
relying O +
on O +
orthology O +
information O +
by O +
Ensembl O -
, O +
and O +
then O +
aligning O +
flanking O +
introns O +
in O +
" O -
orthologous O -
" O +
exons O -
, O +
conserved O +
exonic O +
and O +
intronic O +
regions O +
in O +
human U-Species +
and O +
mouse U-Species +
from O +
genome O -
- O -
wide O +
multiple O +
alignments O +
were O +
extracted O -
. O -

Secondly O -
, O +
whereas O +
in O +
our O +
previous O +
analysis O +
exons O +
from O +
the O +
longest O +
transcript O +
in O +
Ensembl O +
were O +
utilized O -
, O +
now O +
we O +
collapsed O +
all O +
the O +
transcripts O +
available O +
at O +
the O +
UCSC O +
genome O +
browser O +
and O +
analyzed O +
all O +
exons O +
in O +
the O +
entire O +
gene O +
loci O -
. O -

ACEScan O +
was O +
utilized O +
to O +
assign O +
ACEScan O +
scores O +
to O +
all O +
∼162,000 O +
internal O +
exons O +
in O +
our O +
genes O -
. O -

Exons O +
annotated O +
as O +
first O +
or O +
last O +
exons O +
in O +
Refseq O +
mRNAs O +
were O +
excluded O +
from O +
our O +
analysis O -
, O +
resulting O +
in O +
4,487 O +
positive O -
- O -
scoring O +
exons O -
, O +
2-fold O +
more O +
exons O +
than O +
originally O +
published O -
. O -

Here O +
we O +
repeated O +
our O +
analysis O +
with O +
exons O +
with O +
positive O +
ACEScan O +
scores O +
( O -
ACE O -
[ O -
+ O -
] O -
) O +
instead O +
of O +
EST O -
- O -
SEs O -
. O -

If O +
we O +
required O +
that O +
none O +
of O +
the O +
points O +
per O +
probeset O +
( O -
exon O -
) O +
was O +
significant O -
, O +
2 O -
% O +
( O -
1,645 O +
of O +
71,731 O -
) O +
of O +
exons O +
( O -
after O +
probeset O +
mapping O -
) O +
were O +
ACE O -
[ O -
+ O -
] O +
( O -
Figure O +
6B O -
) O -
. O -

Shuffling O +
the O +
mapping O +
between O +
these O +
probesets O +
and O +
exons O +
resulted O +
in O +
3 O -
% O +
( O -
2,044 O +
of O +
71,731 O -
) O +
of O +
exons O +
being O +
ACE O -
[ O -
+ O -
] O +
( O -
Figure O +
6B O -
) O -
. O -

These O +
percentages O +
were O +
not O +
significantly O +
different O +
from O +
the O +
2.7 O -
% O +
observed O +
from O +
all O +
exons O +
( O -
4,487 O +
of O +
the O +
162,000 O +
exons O +
that O +
were O +
scored O +
by O +
ACEScan O -
) O -
. O -

By O +
raising O +
the O +
requirement O +
that O +
probesets O +
had O +
to O +
contain O +
five O +
significant O +
points O -
, O +
the O +
percentage O +
of O +
ACE O -
[ O -
+ O -
] O +
exons O +
increased O +
from O +
4 O -
% O +
to O +
11 O -
% O -
. O -

However O -
, O +
the O +
sample O +
sizes O +
were O +
small O -
. O -

In O +
comparison O -
, O +
the O +
shuffled O +
probesets O +
at O +
the O +
same O +
requirements O +
remained O +
at O +
∼4 O -
% O -
. O -

Similar O +
overall O +
trends O +
were O +
observed O +
with O +
hCNS O -
- O -
SCns O +
versus O +
HUES6-ES O +
and O +
the O +
derived O +
NPs O +
versus O +
hESCs O +
( O -
Figure O +
6B O -
) O -
. O -

In O +
total O -
, O +
7.5 O -
% O +
( O -
131 O +
of O +
1,737 O -
) O +
of O +
REAP O +
[ O -
+ O -
] O +
exons O +
were O +
designated O +
as O +
ACEScan O -
[ O -
+ O -
] O +
compared O +
to O +
2.4 O -
% O +
( O -
2,328 O +
of O +
97,437 O -
) O +
of O +
REAP O -
[ O -
− O -
] O +
exons O -
. O -

This O +
result O +
suggested O +
that O +
a O +
small O +
but O +
significantly O +
enriched O +
fraction O +
of O +
AS O +
events O +
in O +
hESCs O +
versus O +
NPs O +
was O +
likely O +
to O +
be O +
evolutionarily O +
conserved O +
in O +
human U-Species +
and O +
mouse U-Species -
. O -

In O +
conclusion O -
, O +
our O +
results O +
suggested O +
that O +
REAP O +
predictions O +
were O +
congruent O +
with O +
predictions O +
from O +
two O +
independent O -
, O +
orthogonal O +
methods O -
. O -

Experimental O +
Validation O +
of O +
Alternative O +
ExonsThe O +
sensitivity O +
and O +
specificity O +
of O +
REAP O +
in O +
the O +
identification O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
was O +
tested O +
by O +
RT O -
- O -
PCR O -
. O -

To O +
validate O +
REAP O -
[ O -
+ O -
] O +
alternative O +
exons O -
, O +
RT O -
- O -
PCR O +
primers O +
were O +
designed O +
in O +
the O +
flanking O +
exons O +
to O +
amplify O +
both O +
isoforms O -
. O -

To O +
be O +
a O +
positively O +
validated O +
candidate O -
, O +
the O +
PCR O +
products O +
on O +
a O +
gel O +
had O +
to O +
satisfy O +
all O +
of O +
the O +
following O +
criteria O -
: O +
( O -
i O -
) O +
at O +
least O +
one O +
isoform O +
with O +
the O +
expected O +
size O +
must O +
be O +
visible O +
in O +
each O +
cell O +
type O -
; O +
( O -
ii O -
) O +
the O +
relative O +
abundance O +
of O +
the O +
two O +
isoforms O +
must O +
be O +
altered O +
between O +
two O +
cell O +
types O +
and O +
the O +
direction O +
of O +
change O +
have O +
to O +
be O +
consistent O +
with O +
the O +
REAP O +
studentized O +
residuals O -
: O +
in O +
our O +
study O +
positive O +
residuals O +
implied O +
inclusion O +
in O +
hESCs O +
and O +
skipping O +
in O +
NPs O -
, O +
and O +
negative O +
residuals O +
implied O +
inclusion O +
in O +
NP O +
and O +
skipping O +
in O +
hESCs O -
; O +
and O +
( O -
iii O -
) O +
the O +
results O +
were O +
replicable O +
in O +
at O +
least O +
two O +
experiments O -
. O -

For O +
simplicity O +
of O +
design O -
, O +
we O +
tested O +
candidates O +
predicted O +
from O +
Cyt O -
- O -
ES O +
versus O +
hCNS O -
- O -
SCns O -
. O -

Fifteen O +
REAP O -
[ O -
+ O -
] O +
exons O +
with O +
at O +
least O +
two O +
significant O +
outliers O +
( O -
out O +
of O +
five O -
) O +
were O +
randomly O +
chosen O +
as O +
predicted O +
alternative O +
events O +
and O +
thirty O -
- O -
five O +
exons O +
with O +
less O +
than O +
two O +
significant O +
outliers O +
were O +
randomly O +
chosen O +
as O +
constitutive O +
events O +
( O -
Table O +
S3 O -
) O -
. O -

Nine O +
of O +
the O +
fifteen O +
exons O +
( O -
60 O -
% O -
) O +
were O +
validated O +
as O +
AS O +
events O +
by O +
our O +
criteria O -
. O -

The O +
sensitivity O +
and O +
specificity O +
of O +
the O +
algorithm O +
at O +
the O +
cutoff O +
of O +
two O +
is O +
69 O -
% O +
and O +
77 O -
% O -
. O -

Increasing O +
the O +
cutoff O +
to O +
three O +
increased O +
the O +
specificity O +
to O +
85 O -
% O -
, O +
with O +
a O +
slight O +
decrease O +
in O +
sensitivity O +
to O +
67 O -
% O +
( O -
Figure O +
7A O -
) O -
. O -

The O +
patterns O +
of O +
AS O +
in O +
hESCs O +
were O +
similar O +
in O +
both O +
Cyt O -
- O -
ES O +
and O +
HUES6-ES O +
for O +
all O +
AS O +
events O +
validated O -
, O +
but O +
the O +
NPs O +
( O -
Cyt O -
- O -
NP O -
, O +
HUES6-NP O -
, O +
and O +
hCNS O -
- O -
SCns O -
) O +
had O +
more O +
varied O +
AS O -
. O -

The O +
pattern O +
of O +
AS O +
in O +
the O +
REAP O -
[ O -
+ O -
] O +
exons O +
in O +
the O +
SLK O +
( O -
serine O -
/ O -
threonine O +
kinase O +
2 O -
) O +
and O +
POT1 O +
( O -
protection O +
of O +
telomeres O +
1 O -
) O +
genes O +
showed O +
remarkable O +
agreement O +
within O +
derived O +
NPs O +
and O +
hCNS O -
- O -
SCns O +
( O -
Figure O +
7B O -
) O -
. O -

The O +
AS O +
exon O +
in O +
SLK O +
was O +
observed O +
to O +
be O +
included O +
in O +
hESCs O +
and O +
completely O +
excluded O +
in O +
NPs O -
; O +
the O +
AS O +
exon O +
in O +
the O +
POT1 O +
gene O +
was O +
included O +
more O +
in O +
hESCs O +
and O +
a O +
smaller O +
isoform O +
persisted O +
in O +
NPs O -
. O -

The O +
AS O +
patterns O +
of O +
the O +
other O +
verified O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
consistently O +
similar O +
in O +
hESCs O +
but O +
were O +
more O +
varied O +
in O +
the O +
NP O -
. O -

Interestingly O -
, O +
the O +
patterns O +
of O +
AS O +
in O +
the O +
derived O +
NPs O +
( O -
Cyt O -
- O -
NP O +
and O +
HUES6-NP O -
) O +
were O +
not O +
always O +
identical O +
to O +
those O +
of O +
hCNS O -
- O -
SCns O -
. O -

For O +
example O -
, O +
the O +
AS O +
exon O +
in O +
the O +
EHBP1 O +
( O -
EH O +
domain O +
binding O +
protein O +
1 O -
) O +
gene O +
was O +
included O +
in O +
hESCs O +
but O +
skipped O +
in O +
hCNS O -
- O -
SCns O -
, O +
and O +
both O +
isoforms O +
were O +
present O +
in O +
the O +
derived O +
NPs O +
( O -
Figure O +
7B O -
) O -
. O -

As O +
another O +
example O -
, O +
the O +
AS O +
exon O +
in O +
the O +
SORBS1 O +
( O -
sorbin O +
and O +
SH3 O +
domain O +
containing O +
1 O -
) O +
gene O +
was O +
skipped O +
in O +
hESCs O +
and O +
included O +
in O +
hCNS O -
- O -
SCns O -
, O +
but O +
exhibited O +
an O +
intermediate O +
pattern O +
in O +
the O +
derived O +
NPs O -
. O -

However O -
, O +
in O +
some O +
cases O -
, O +
the O +
AS O +
patterns O +
in O +
the O +
derived O +
NPs O +
were O +
different O +
from O +
both O +
hESCs O +
and O +
hCNS O -
- O -
SCns O +
( O -
such O +
as O +
in O +
the O +
AS O +
exon O +
in O +
UNC84A O -
, O +
SIRT1 O -
, O +
and O +
MLLT10 O -
) O -
.Figure O +
7RT O -
- O -
PCR O +
Validation O +
of O +
REAP O -
- O -
Predicted O +
Alternative O +
Exons O -
( O -
A O -
) O +
Probesets O +
( O -
exons O -
) O +
were O +
considered O +
REAP O -
[ O -
+ O -
] O +
candidates O +
if O +
they O +
contained O +
at O +
least O +
N O +
= O +
2 O +
( O -
white O +
bars O -
) O -
, O +
3 O +
( O -
gray O +
bars O -
) O -
, O +
or O +
4 O +
( O -
black O +
bars O -
) O +
significant O +
outliers O -
. O -

True O +
positive O +
( O -
TP O -
) O -
, O +
true O +
negative O +
( O -
TN O -
) O -
, O +
false O +
positive O +
( O -
FP O -
) O -
, O +
and O +
false O +
negative O +
( O -
FN O -
) O +
rates O +
were O +
calculated O +
from O +
RT O -
- O -
PCR O -
- O -
validated O +
REAP O -
[ O -
+ O -
] O +
exons O +
at O +
the O +
different O +
cutoffs O +
( O -
N O +
= O +
2 O -
, O +
3 O -
, O +
4 O -
) O -
. O -
( O -
B O -
) O +
Nine O +
RT O -
- O -
PCR O +
validated O +
REAP O -
[ O -
+ O -
] O +
AS O +
events O +
in O +
hESCs O +
( O -
Cyt O -
- O -
ES O +
and O +
HUES6-ES O -
) O -
, O +
derived O +
NPs O +
( O -
Cyt O -
- O -
NP O +
and O +
HUES6-NP O -
) O -
, O +
and O +
hCNS O -
- O -
SCns O -
. O -

Arrows O +
indicate O +
the O +
larger O +
( O -
exon O -
- O -
included O -
) O +
isoforms O +
and O +
smaller O +
( O -
exon O -
- O -
skipped O -
) O +
isoforms. O -
( O -
C O -
) O +
RT O -
- O -
PCR O +
of O +
REAP O -
[ O -
+ O -
] O +
alternative O +
exons O +
from O +
EHBP1 O -
, O +
SLK O -
, O +
and O +
RAI14 O +
across O +
a O +
panel O +
of O +
human U-Species +
tissues O -
. O -

Arrows O +
indicate O +
the O +
larger O +
( O -
exon O -
- O -
included O -
) O +
isoforms O +
and O +
smaller O +
( O -
exon O -
- O -
skipped O -
) O +
isoforms O -
. O -

First O -
, O +
given O +
three O +
independent O +
samples O +
each O +
from O +
two O +
conditions O -
, O +
we O +
concluded O +
that O +
REAP O +
was O +
able O +
to O +
identify O +
AS O +
events O +
with O +
high O +
specificity O +
but O +
with O +
moderate O +
sensitivity O -
. O -

Second O -
, O +
AS O +
events O +
in O +
hESCs O +
were O +
more O +
similar O -
, O +
whereas O +
the O +
AS O +
events O +
in O +
derived O +
NPs O +
were O +
consistent O +
with O +
or O +
intermediate O +
to O +
the O +
benchmark O +
hCNS O -
- O -
SCns O -
, O +
likely O +
reflecting O +
differences O +
in O +
the O +
cell O +
lines O +
and/or O +
differentiation O +
protocols O -
. O -

In O +
addition O -
, O +
we O +
tested O +
the O +
AS O +
patterns O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
from O +
EHBP1 O -
, O +
SLK O -
, O +
and O +
RAI14 O +
in O +
a O +
panel O +
of O +
differentiated O +
human U-Species +
tissues O +
( O -
Figure O +
7C O -
) O -
. O -

The O +
REAP O -
[ O -
+ O -
] O +
alternative O +
exon O +
in O +
the O +
RAI14 O +
( O -
retinoic O +
acid O +
induced O +
14 O -
) O +
gene O +
was O +
observed O +
to O +
have O +
the O +
same O +
AS O +
pattern O +
in O +
NPs O +
as O +
in O +
frontal O +
and O +
temporal O +
cortex O +
and O +
in O +
several O +
other O -
, O +
non O -
- O -
brain O +
adult O +
tissues O -
, O +
such O +
as O +
heart O +
and O +
spleen O -
. O -

The O +
AS O +
pattern O +
of O +
the O +
REAP O -
[ O -
+ O -
] O +
exon O +
in O +
the O +
SLK O +
gene O +
in O +
NPs O +
was O +
similar O +
to O +
most O +
differentiated O +
tissues O -
; O +
however O -
, O +
the O +
relatively O +
strong O +
inclusion O +
of O +
the O +
exon O +
in O +
hESCs O +
was O +
unique O -
. O -

Even O +
in O +
esophagus O -
, O +
kidney O -
, O +
liver O -
, O +
and O +
prostate O -
, O +
both O +
isoforms O +
were O +
present O -
. O -

The O +
relative O +
ratio O +
of O +
the O +
exon O -
- O -
included O +
to O +
exon O -
- O -
skipped O +
isoforms O +
in O +
SLK O +
likely O +
represents O +
an O +
ESC O -
- O -
specific O +
AS O +
signature O -
. O -

The O +
alternative O +
exon O +
in O +
the O +
EHBP1 O +
gene O +
was O +
unusual O -
. O -

The O +
exon O +
was O +
included O +
in O +
hESCs O +
but O +
also O +
in O +
frontal O +
cortex O +
and O +
temporal O +
cortex O -
, O +
a O +
finding O +
that O +
was O +
unexpected O +
given O +
the O +
exclusion O +
of O +
the O +
exon O +
in O +
hCNS O -
- O -
SCns O +
( O -
Figure O +
7C O -
) O -
. O -

The O +
AS O +
pattern O +
in O +
hCNS O -
- O -
SCns O +
may O +
represent O +
a O +
transient O -
, O +
early O +
neuronal O +
molecular O +
change O -
. O -

Functional O +
and O +
Expression O +
Characteristics O +
of O +
REAP O -
[ O -
+ O -
] O +
GenesIn O +
total O -
, O +
1,500 O +
genes O +
were O +
identified O +
that O +
contained O +
1,737 O +
REAP O -
[ O -
+ O -
] O +
exons O -
, O +
68 O -
% O +
of O +
which O +
lacked O +
prior O +
transcript O +
( O -
EST O -
/ O -
cDNA O -
) O +
evidence O +
for O +
AS O -
. O -

To O +
determine O +
whether O +
genes O +
that O +
contained O +
REAP O -
[ O -
+ O -
] O +
exons O -
, O +
which O +
we O +
refer O +
to O +
as O +
REAP O -
[ O -
+ O -
] O +
genes O -
, O +
are O +
biased O +
toward O +
particular O +
biological O +
activities O -
, O +
REAP O -
[ O -
+ O -
] O +
genes O +
were O +
compared O +
to O +
a O +
set O +
of O +
REAP O +
analyzed O +
genes O +
not O +
found O +
to O +
have O +
REAP O -
[ O -
+ O -
] O +
exons O +
( O -
REAP O -
[ O -
− O -
] O +
genes O -
) O -
. O -

A O +
Gene O +
Ontology O +
analysis O +
revealed O +
that O +
REAP O -
[ O -
+ O -
] O +
genes O +
are O +
enriched O +
for O +
GO O +
molecular O +
function O +
categories O +
" O -
ATP O +
binding O -
, O -
" O +
" O -
helicase O +
activity O -
, O -
" O +
" O -
protein O +
serine O -
/ O -
theronine O +
kinase O +
activity O -
, O -
" O +
" O -
small O +
GTPase O +
regulatory O -
/ O -
interacting O +
protein O +
activity O -
, O -
" O +
and O +
" O -
thyroid O +
hormone O +
receptor O +
binding O -
" O +
( O -
Table O +
1 O -
) O -
. O -

In O +
terms O +
of O +
GO O +
biological O +
process O +
categories O -
, O +
REAP O -
[ O -
+ O -
] O +
genes O +
were O +
more O +
frequently O +
involved O +
in O +
" O -
ubiquitin O +
cycle O -
. O -
" O -

Similar O +
results O +
were O +
obtained O +
when O +
we O +
compared O +
REAP O -
[ O -
+ O -
] O +
genes O +
to O +
all O +
human U-Species +
genes O +
that O +
did O +
not O +
contain O +
REAP O -
[ O -
+ O -
] O +
exons O +
( O -
Table O +
1 O -
) O +
[ O -
55 O -
] O -
.Table O +
1Significantly O +
Enriched O +
Gene O +
Ontology O +
Terms O +
in O +
REAP O -
[ O -
+ O -
] O +
Genes O +
( O -
Cutoff O +
of O +
Two O +
Significant O +
" O -
Outliers O -
" O +
per O +
Probeset O -
) O -
Next O +
we O +
asked O +
if O +
REAP O -
[ O -
+ O -
] O +
genes O +
are O +
differentially O +
expressed O +
in O +
hESCs O +
compared O +
to O +
NPs O +
and O +
vice O +
versa O -
. O -

For O +
this O +
analysis O -
, O +
the O +
t O -
- O -
statistics O +
computed O +
above O +
measuring O +
the O +
enrichment O +
of O +
a O +
gene O +
in O +
hESCs O +
relative O +
to O +
NPs O +
was O +
utilized O +
for O +
only O +
REAP O -
- O -
analyzed O +
genes O -
. O -

At O +
a O +
defined O +
absolute O -
- O -
valued O +
cutoff O -
, O +
genes O +
were O +
divided O +
into O +
three O +
categories O -
: O +
" O -
enriched O +
in O +
hESCs O -
, O -
" O +
" O -
enriched O +
in O +
NP O -
, O -
" O +
or O +
" O -
unchanged O -
" O +
( O -
Figure O +
8A O -
) O -
. O -

Increasing O +
the O +
t O -
- O -
statistic O +
cutoff O +
from O +
one O +
to O +
five O -
, O +
the O +
fraction O +
of O +
REAP O -
[ O -
+ O -
] O +
genes O +
relative O +
to O +
REAP O -
- O -
analyzed O +
genes O +
remained O +
constant O +
in O +
the O +
" O -
unchanged O -
" O +
categories O +
( O -
Figure O +
8B O -
) O -
. O -

However O -
, O +
the O +
fraction O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
decreased O +
significantly O +
in O +
" O -
enriched O +
in O +
hESCs O -
" O +
and O +
" O -
enriched O +
in O +
NPs O -
" O +
categories O -
. O -

If O +
we O +
increased O +
the O +
cutoffs O +
on O +
genes O +
that O +
were O +
randomly O +
assigned O +
as O +
REAP O -
[ O -
+ O -
] O +
and O +
REAP O -
[ O -
− O -
] O -
, O +
controlling O +
for O +
the O +
same O +
number O +
of O +
genes O +
in O +
each O +
category O -
, O +
we O +
observed O +
that O +
the O +
fraction O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
remained O +
unchanged O +
for O +
all O +
three O +
categories O +
( O -
Figure O +
8C O -
) O -
. O -

To O +
illustrate O -
, O +
at O +
a O +
cutoff O +
of O +
five O -
, O +
10 O -
% O +
( O -
29 O +
of O +
267 O -
) O +
of O +
enriched O +
NP O +
genes O +
were O +
REAP O -
[ O -
+ O -
] O +
genes O +
and O +
8.8 O -
% O +
( O -
102 O +
of O +
1,162 O -
) O +
of O +
enriched O +
hESC O +
genes O +
were O +
REAP O -
[ O -
+ O -
] O -
, O +
significantly O +
different O +
( O -
p O +
< O +
0.000005 O -
) O +
from O +
the O +
random O +
control O +
where O +
∼14 O -
% O +
of O +
enriched O +
NP O +
and O +
enriched O +
hESC O +
genes O +
were O +
REAP O -
[ O -
+ O -
] O -
. O -

At O +
a O +
cutoff O +
of O +
five O -
, O +
14 O -
% O +
( O -
1,368 O +
of O +
9,636 O -
) O +
of O +
genes O +
that O +
were O +
expressed O +
at O +
similar O +
levels O +
between O +
hESCs O +
and O +
NPs O +
were O +
REAP O -
[ O -
+ O -
] O -
. O -

Our O +
results O +
suggested O +
that O +
a O +
strategy O +
of O +
focusing O +
on O +
differentially O +
expressed O +
genes O +
would O +
miss O +
at O +
least O +
14 O -
% O +
of O +
transcriptionally O +
unchanged O +
genes O +
that O +
may O +
nevertheless O +
have O +
functional O +
AS O +
differences O +
between O +
hESCs O +
and O +
NPs O -
. O -

Figure O +
8Analysis O +
of O +
REAP O -
[ O -
+ O -
] O +
Genes O +
Relative O +
to O +
Transcriptional O +
Differences O -
( O -
A O -
) O +
Histogam O +
of O +
t O -
- O -
statistics O +
computed O +
from O +
gene O -
- O -
level O +
signal O +
estimates O +
measuring O +
the O +
enrichment O +
of O +
genes O +
in O +
hESC O +
and O +
in O +
NP O -
. O -

Genes O +
on O +
the O +
right O +
of O +
the O +
vertical O +
line O +
at O +
5 O +
were O +
designated O +
enriched O +
in O +
hESC O +
and O +
genes O +
on O +
the O +
left O +
of O +
the O +
vertical O +
line O +
at O +
−5 O +
were O +
designated O +
enriched O +
in O +
NP O -
; O +
genes O +
in O +
between O +
−5 O +
and O +
5 O +
were O +
designated O +
as O +
" O -
unchanged O -
" O +
or O +
expressed O +
similarly O +
in O +
hESC O +
and O +
NP. O -
( O -
B O -
) O +
Vertical O +
bars O +
representing O +
the O +
percentage O +
of O +
REAP O -
[ O -
+ O -
] O +
genes O +
out O +
of O +
all O +
genes O +
in O +
the O +
different O +
classifications O +
( O -
dashed O +
bar O -
: O +
" O -
enriched O +
in O +
hESC O -
" O -
; O +
black O +
filled O +
bar O -
: O +
" O -
unchanged O -
" O -
; O +
white O +
filled O +
bar O -
: O +
" O -
enriched O +
in O +
NP O -
" O -
) O -
, O +
at O +
different O +
cutoffs O +
of O +
1 O +
to O +
5. O -
( O -
C O -
) O +
Set O +
of O +
genes O +
where O +
REAP O -
[ O -
+ O -
] O +
designation O +
was O +
randomly O +
chosen O -
. O -

Similar O +
representation O +
as O +
in O +
( O -
B O -
) O -
. O -

Conserved O +
Intronic O +
Splicing O +
Regulatory O +
Elements O +
Proximal O +
to O +
REAP O -
[ O -
+ O -
] O +
hESC O +
and O +
NP O +
ExonsMany O -
, O +
if O +
not O +
most O -
, O +
alternative O +
exons O +
undergo O +
cell O +
type O -
– O -
specific O +
regulation O +
by O +
the O +
binding O +
of O +
trans O -
- O -
factors O +
to O +
splicing O +
regulatory O +
cis O -
- O -
elements O +
located O +
proximal O +
to O +
or O +
within O +
the O +
exons O -
. O -

As O +
many O +
tissue O -
- O -
specific O +
splicing O +
cis O -
- O -
regulatory O +
elements O +
were O +
localized O +
in O +
intronic O +
regions O +
of O +
AS O +
exons O -
, O +
we O +
focused O +
on O +
the O +
identification O +
of O +
intronic O +
splicing O +
regulatory O +
elements O +
( O -
ISREs O -
) O +
proximal O +
to O +
REAP O -
[ O -
+ O -
] O +
exons O -
. O -

In O +
addition O -
, O +
we O +
wanted O +
to O +
identify O +
both O +
common O +
and O +
cell O +
type O -
– O -
specific O +
ISREs O -
. O -

Three O +
sets O +
of O +
exons O +
were O +
generated O -
: O +
( O -
i O -
) O +
REAP O -
[ O -
+ O -
] O +
exons O +
that O +
were O +
predicted O +
to O +
be O +
included O +
in O +
NPs O +
and O +
skipped O +
in O +
hESCs O +
( O -
REAP O -
[ O -
+ O -
] O -
NP O -
) O -
; O +
( O -
ii O -
) O +
REAP O -
[ O -
+ O -
] O +
exons O +
that O +
were O +
predicted O +
to O +
be O +
included O +
in O +
hESCs O +
and O +
skipped O +
in O +
NPs O +
( O -
REAP O -
[ O -
+ O -
] O -
hESC O -
) O -
; O +
and O +
( O -
iii O -
) O +
all O +
REAP O -
[ O -
− O -
] O +
exons O -
. O -

Regions O +
of O +
400 O +
base O +
pairs O +
flanking O +
the O +
exons O +
were O +
targeted O +
for O +
search O -
. O -

Initially O -
, O +
5-mers O +
that O +
were O +
significantly O +
enriched O +
between O +
the O +
upstream O +
and O +
downstream O +
intronic O +
regions O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
relative O +
to O +
REAP O -
[ O -
− O -
] O +
exons O +
were O +
enumerated O -
. O -

We O +
were O +
not O +
able O +
to O +
identify O +
5-mers O +
that O +
were O +
statistically O +
significantly O +
different O -
. O -

Next O -
, O +
we O +
focused O +
on O +
splicing O +
signals O +
that O +
were O +
conserved O +
across O +
mammalian O +
genomes O +
as O +
a O +
way O +
of O +
enhancing O +
the O +
signal O +
of O +
detecting O +
functional O +
splicing O +
regulatory O +
sequences O +
[ O -
66 O -
] O -
. O -

Exons O +
that O +
were O +
orthologous O +
across O +
human U-Species -
, O +
dog U-Species -
, O +
rat U-Species -
, O +
and O +
mouse U-Species +
were O +
obtained O +
and O +
the O +
flanking O +
intronic O +
regions O +
were O +
aligned O +
( O -
400 O +
bases O +
upstream O +
and O +
downstream O +
separately O -
; O +
Figure O +
9A O -
) O -
. O -

We O +
enumerated O +
k O -
- O -
mers O +
that O +
were O +
perfectly O +
conserved O +
across O +
all O +
four O +
genomes O +
in O +
the O +
upstream O +
( O -
and O +
downstream O -
) O +
intronic O +
regions O -
. O -

Each O +
conserved O +
k O -
- O -
mer O +
was O +
attributed O +
a O +
χ O +
score O +
representing O +
its O +
enrichment O +
in O +
a O +
set O +
of O +
exons O +
relative O +
to O +
another O +
set O +
of O +
exons O -
. O -

The O +
higher O +
the O +
score O -
, O +
the O +
more O +
frequent O +
the O +
conserved O +
k O -
- O -
mer O +
was O +
in O +
the O +
first O +
set O +
relative O +
to O +
the O +
second O +
set O -
. O -

As O +
a O +
negative O +
control O -
, O +
the O +
associations O +
between O +
REAP O +
scores O +
and O +
exons O +
were O +
shuffled O -
. O -

The O +
enrichment O +
scores O +
for O +
all O +
downstream O +
intronic O +
5-mers O +
for O +
shuffled O +
REAP O -
[ O -
+ O -
] O -
NP O +
versus O +
set O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
x O -
- O -
axis O -
) O -
, O +
and O +
for O +
shuffled O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O +
versus O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
y O -
- O -
axis O -
) O +
were O +
displayed O +
( O -
Figure O +
9B O -
) O -
. O -

At O +
a O +
χ O +
cutoff O +
of O +
three O -
, O +
which O +
corresponded O +
to O +
a O +
p O -
- O -
value O +
of O +
0.0015 O -
, O +
the O +
majority O +
of O +
5-mers O +
were O +
not O +
significantly O +
enriched O +
in O +
either O +
shuffled O +
set O -
. O -

Confident O +
that O +
no O +
association O +
of O +
k O -
- O -
mers O +
with O +
shuffled O +
REAP O +
exons O +
were O +
found O -
; O +
we O +
repeated O +
the O +
analyses O +
for O +
upstream O +
and O +
downstream O +
intronic O +
5-mers O +
for O +
the O +
original O +
unshuffled O +
sets O -
. O -

We O +
identified O +
68 O +
conserved O +
5-mers O +
enriched O +
upstream O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
exons O -
; O +
and O +
34 O +
5-mers O +
enriched O +
upstream O +
of O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O +
( O -
Figure O +
9C O -
; O +
Table O +
S4 O -
) O -
. O -

Of O +
the O +
5-mers O +
that O +
were O +
significantly O +
enriched O +
upstream O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
exons O -
, O +
we O +
identified O +
a O +
U O -
- O -
rich O +
motif O +
( O -
UUUUU O -
) O -
, O +
a O +
GU O -
- O -
rich O +
motif O +
( O -
GUGUG O -
) O -
, O +
and O +
a O +
CU O -
- O -
rich O +
motif O +
( O -
CCUCU O -
, O +
CUCUC O -
, O +
UCUCU O -
, O +
GCUCU O -
) O -
. O -

It O +
is O +
known O +
that O +
the O +
heterogeneous O +
ribonucleoprotein O +
C O +
( O -
hnRNP O +
C O -
) O +
binding O +
site O +
obtained O +
by O +
SELEX O +
is O +
five O +
" O -
U"s O +
[ O -
67 O -
] O -
. O -

GU O -
- O -
rich O +
sequences O +
in O +
flanking O +
intronic O +
regions O +
were O +
shown O +
to O +
bind O +
to O +
splicing O +
factor O +
ETR-3 O +
to O +
regulate O +
AS O +
[ O -
68 O -
] O -
. O -

CU O -
- O -
rich O +
sequences O +
were O +
shown O +
to O +
bind O +
the O +
splicing O +
factor O +
PTB O +
[ O -
69 O -
] O -
. O -

Of O +
the O +
5-mers O +
enriched O +
upstream O +
of O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
, O +
we O +
observed O +
CUAAC O -
, O +
which O +
resembled O +
the O +
splicing O +
branch O -
- O -
signal O -
. O -

Of O +
the O +
six O +
5-mers O +
that O +
were O +
enriched O +
upstream O +
of O +
both O +
REAP O -
[ O -
+ O -
] O -
NP O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
, O +
we O +
identified O +
GCAUG O -
, O +
which O +
was O +
previously O +
shown O +
to O +
be O +
an O +
intronic O +
splicing O +
cis O -
- O -
element O +
for O +
the O +
mammalian O +
fibronectin O +
and O +
calcitonin O -
/ O -
CGRP O +
genes O +
[ O -
70–72 O -
] O -
. O -

More O +
recently O -
, O +
both O +
mammalian O +
Fox1 O +
and O +
2 O +
have O +
been O +
demonstrated O +
to O +
regulate O +
alternatively O +
spliced O +
exons O +
via O +
UGCAUG O +
binding O +
sites O +
in O +
neighboring O +
introns O +
in O +
neuronal O +
cell O +
cultures O +
[ O -
73 O -
] O -
.Figure O +
9Conserved O +
Intronic O +
cis O -
- O -
Elements O +
Enriched O +
Proximal O +
to O +
REAP O -
[ O -
+ O -
] O +
Alternative O +
Exons O -
( O -
A O -
) O +
Schematic O +
describing O +
the O +
enumeration O +
of O +
intronic O +
elements O +
across O +
400 O +
bases O +
of O +
flanking O +
mammalian O +
introns O +
( O -
human U-Species -
, O +
dog U-Species -
, O +
rat U-Species -
, O +
and O +
mouse U-Species -
) O -
. O -

Red O +
and O +
green O +
horizontal O +
bars O +
represent O +
conserved O +
intronic O +
elements O +
and O +
nonconserved O +
elements O -
, O +
respectively O -
. O -

Internal O +
exons O +
were O +
divided O +
into O +
REAP O -
[ O -
+ O -
] O -
NP O -
, O +
REAP O -
[ O -
+ O -
] O -
ES O -
, O +
and O +
REAP O -
[ O -
− O -
] O +
exons O -
. O -

The O +
χ O +
statistic O +
was O +
computed O +
to O +
represent O +
the O +
enrichment O +
of O +
conserved O +
elements O +
in O +
intronic O +
regions O +
flanking O +
REAP O -
[ O -
+ O -
] O -
NP O +
versus O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
x O -
- O -
axis O -
) O -
, O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
versus O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
y O -
- O -
axis O -
) O -
. O -

The O +
sign O +
represented O +
the O +
direction O +
of O +
change O -
, O +
i.e. O -
, O +
positive O +
if O +
enriched O +
in O +
introns O +
flanking O +
REAP O -
[ O -
+ O -
] O +
versus O +
REAP O -
[ O -
− O -
] O +
exon O -
. O -

Each O +
conserved O +
5-mer O +
was O +
associated O +
with O +
two O +
numbers O -
: O +
the O +
enrichment O +
in O +
introns O +
proximal O +
to O +
REAP O -
[ O -
+ O -
] O -
NP O +
versus O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
x O -
- O -
axis O -
) O -
, O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
versus O +
REAP O -
[ O -
− O -
] O +
exons O +
( O -
y O -
- O -
axis O -
) O -
. O -
( O -
B O -
) O +
Downstream O +
intronic O +
regions O -
, O +
where O +
the O +
association O +
between O +
REAP O -
[ O -
+ O -
] O +
designation O +
and O +
the O +
exons O +
was O +
shuffled. O -
( O -
C O -
) O +
Upstream O +
intronic O +
regions O -
. O -

Circled O +
5-mers O +
in O +
the O +
upper O +
right O +
quadrant O +
represent O +
conserved O +
5-mers O +
enriched O +
in O +
the O +
upstream O +
intronic O +
regions O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons. O -
( O -
D O -
) O -

Downstream O +
intronic O +
regions O -
. O -

Circled O +
5-mers O +
in O +
the O +
upper O +
right O +
quadrant O +
represent O +
conserved O +
5-mers O +
enriched O +
in O +
the O +
downstream O +
intronic O +
regions O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
. O -

Eighteen O +
conserved O +
5-mers O +
were O +
significantly O +
enriched O +
in O +
the O +
downstream O +
introns O +
of O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
; O +
and O +
76 O +
5-mers O +
were O +
enriched O +
downstream O +
of O +
REAP O -
[ O -
+ O -
] O -
NP O +
exons O +
( O -
Table O +
S4 O -
, O +
Figure O +
9D O -
) O -
. O -

We O +
identified O +
a O +
motif O +
CUCAU O +
resembling O +
the O +
Nova O +
binding O +
site O +
YCAY O +
[ O -
74 O -
] O -
, O +
and O +
a O +
G O -
- O -
rich O +
motif O +
( O -
AGGGG O -
, O +
GGGGA O -
, O +
GGGGC O -
, O +
GGGGG O -
, O +
GGGGU O -
) O +
enriched O +
in O +
the O +
introns O +
downstream O +
of O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
. O -

G O -
- O -
rich O +
motifs O +
had O +
previously O +
been O +
shown O +
to O +
be O +
part O +
of O +
a O +
bipartite O +
signal O +
that O +
silences O +
AS O +
exons O +
[ O -
75 O -
] O -
. O -

Of O +
the O +
five O +
5-mers O +
that O +
were O +
enriched O +
downstream O +
of O +
both O +
REAP O -
[ O -
+ O -
] O -
NP O +
and O +
REAP O -
[ O -
+ O -
] O -
ES O +
exons O -
, O +
GCAUG O +
and O +
a O +
U O -
- O -
rich O +
motif O +
( O -
UUUUU O -
) O +
were O +
identified O -
. O -

We O +
concluded O +
that O +
potential O +
ISREs O +
were O +
enriched O +
proximal O +
to O +
a O +
subset O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O -
; O +
in O +
particular O -
, O +
the O +
Fox1 O -
/ O -
2 O +
binding O +
site O +
GCUAG O +
may O +
play O +
a O +
regulatory O +
role O +
in O +
controlling O +
AS O +
events O +
in O +
hESCs O +
and O +
NPs O -
. O -

The O +
ability O +
of O +
ESCs O +
to O +
generate O +
all O +
three O +
embryonic O +
germ O +
layers O +
has O +
raised O +
the O +
exciting O +
possibility O +
that O +
hESCs O +
may O +
become O +
an O +
unlimited O +
source O +
of O +
cells O +
for O +
transplantation O +
therapies O +
involving O +
organs O +
or O +
tissues O +
such O +
as O +
the O +
liver O -
, O +
pancreas O -
, O +
blood O -
, O +
and O +
nervous O +
system O -
, O +
and O +
become O +
tools O +
to O +
explore O +
the O +
molecular O +
mechanisms O +
of O +
human U-Species +
development O -
. O -

Despite O +
such O +
interests O -
, O +
relatively O +
little O +
is O +
understood O +
about O +
the O +
molecular O +
mechanisms O +
defining O +
their O +
pluripotency O +
and O +
the O +
molecular O +
changes O +
important O +
for O +
hESCs O +
to O +
differentiate O +
into O +
specific O +
cell O +
types O -
. O -

To O +
understand O +
these O +
events O -
, O +
protocols O +
are O +
still O +
being O +
developed O +
to O +
differentiate O +
ESCs O +
into O +
a O +
variety O +
of O +
lineages O -
. O -

Of O +
particular O +
biomedical O +
interest O +
is O +
in O +
the O +
capacity O +
of O +
hESCs O +
to O +
be O +
differentiated O +
into O +
a O +
self O -
- O -
renewing O +
population O +
of O +
NPs O +
that O +
can O +
be O +
then O +
further O +
coaxed O +
into O +
a O +
variety O +
of O +
neuronal O +
subtypes O -
, O +
such O +
as O +
dopaminergic O +
neurons O +
that O +
are O +
important O +
in O +
the O +
treatment O +
of O +
Parkinson O +
disease O +
or O +
cholinergic O +
neurons O +
for O +
ALS O +
( O -
amyotrophic O +
lateral O +
sclerosis O -
) O -
. O -

While O +
many O +
microarray O +
studies O +
have O +
explored O +
molecular O +
differences O +
between O +
hESCs O +
and O +
derived O +
NPs O -
, O +
most O -
, O +
if O +
not O +
all O -
, O +
have O +
focused O +
on O +
transcriptional O +
changes O -
. O -

These O +
studies O +
have O +
largely O +
ignored O +
intermediate O +
RNA O +
processing O +
events O +
prior O +
to O +
and O +
during O +
translation O -
. O -

In O +
recent O +
years O -
, O +
AS O +
has O +
gained O +
momentum O +
as O +
being O +
important O +
in O +
development O -
, O +
apoptosis O -
, O +
and O +
cancer O -
. O -

REAP O -
, O +
a O +
regression O -
- O -
based O +
method O +
for O +
analyzing O +
exon O +
array O +
data O +
was O +
introduced O -
, O +
and O +
was O +
applied O +
to O +
discover O +
AS O +
events O +
in O +
hESCs O -
, O +
their O +
derived O +
NPs O -
, O +
and O +
in O +
hCNS O -
- O -
SCns O -
. O -

REAP O +
was O +
based O +
on O +
the O +
assumptions O +
that O +
most O +
exons O +
in O +
the O +
gene O +
of O +
interest O +
and O +
in O +
the O +
genome O +
are O +
constitutively O +
spliced O +
and O +
that O +
outliers O +
in O +
a O +
linear O +
pairwise O +
comparison O +
of O +
the O +
signal O +
estimates O +
for O +
probesets O +
in O +
a O +
gene O +
could O +
be O +
detected O +
using O +
a O +
robust O +
regression O -
- O -
based O +
approach O -
. O -

REAP O +
predictions O +
were O +
found O +
to O +
correlate O +
well O +
with O +
transcript O -
- O -
based O +
methods O +
for O +
identifying O +
alternative O +
exons O -
, O +
which O +
interestingly O +
suggested O +
that O +
current O +
databases O +
of O +
transcript O +
information O -
, O +
albeit O +
not O +
specifically O +
enriched O +
for O +
hESC O +
or O +
NPs O -
, O +
in O +
aggregate O +
are O +
nevertheless O +
predictive O +
of O +
AS O +
events O +
in O +
hESC O +
and O +
NP O -
. O -

In O +
addition O -
, O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
also O +
enriched O +
for O +
ACEScan O -
- O -
predicted O +
evolutionarily O +
conserved O +
exons O +
[ O -
55 O -
] O -
. O -

As O +
ACEScan O +
utilized O +
a O +
different O +
set O +
of O +
information O +
from O +
REAP O -
, O +
the O +
agreement O +
between O +
both O +
algorithms O +
served O +
to O +
further O +
validate O +
the O +
predicted O +
alternative O +
exons O -
. O -

Additional O +
studies O +
in O +
mouse U-Species +
ESCs O +
and O +
neural O +
derivatives O +
will O +
be O +
necessary O +
to O +
determine O +
if O +
these O +
AS O +
events O +
are O +
indeed O +
preserved O +
in O +
these O +
analogous O +
and O +
orthologous O +
cell O +
types O -
. O -

Our O +
finding O +
that O +
only O +
a O +
minority O +
of O +
AS O +
events O +
was O +
common O +
between O +
various O +
hESC O +
to O +
NP O +
comparisons O +
is O +
intriguing O -
. O -

A O +
possible O +
explanation O +
is O +
that O +
the O +
cell O +
lines O +
were O +
not O +
only O +
genetically O +
different O -
, O +
but O +
were O +
also O +
exposed O +
to O +
different O +
isolation O +
and O +
culture O +
conditions O -
. O -

In O +
addition O -
, O +
the O +
different O +
differentiation O +
protocols O +
established O +
as O +
optimal O +
for O +
generating O +
Nestin O +
and O +
Sox1 O +
positive O +
neural O +
precursors O +
may O +
lead O +
to O +
vastly O +
different O +
molecular O +
changes O -
. O -

It O +
is O +
likely O +
that O +
post O -
- O -
transcriptional O +
changes O +
such O +
as O +
AS O +
may O +
be O +
more O +
variable O +
despite O +
the O +
cells O +
being O +
at O +
acknowledged O +
" O -
end O -
- O -
points O -
" O +
defined O +
by O +
a O +
limited O +
set O +
of O +
immunohistochemical O +
markers O -
. O -

Our O +
results O +
are O +
consistent O +
with O +
a O +
recent O +
study O +
that O +
showed O +
that O +
while O +
two O +
well O -
- O -
established O +
hESC O +
lines O +
differentiate O +
into O +
functional O +
neurons O -
, O +
the O +
two O +
lines O +
exhibited O +
distinct O +
differentiation O +
potentials O -
, O +
suggesting O +
that O +
some O +
preprogramming O +
had O +
occurred O +
[ O -
76 O -
] O -
. O -

In O +
particular O -
, O +
microRNA O +
profiling O +
revealed O +
significant O +
expression O +
differences O +
between O +
the O +
two O +
hESC O +
lines O -
, O +
suggesting O +
that O +
microRNAs O -
, O +
known O +
post O -
- O -
transcriptional O +
regulators O -
, O +
may O +
sway O +
the O +
differentiation O +
properties O +
of O +
the O +
cell O +
lines O +
[ O -
76 O -
] O -
. O -

We O +
postulated O +
that O +
AS O +
events O +
may O +
serve O +
also O +
to O +
bias O +
the O +
differentiation O +
spectrum O +
of O +
the O +
cells O -
, O +
an O +
important O +
avenue O +
for O +
future O +
work O -
. O -

Experimental O +
validation O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
suggested O +
a O +
high O +
specificity O +
at O +
the O +
expense O +
of O +
relatively O +
moderate O +
sensitivity O -
. O -

We O +
believe O +
that O +
the O +
high O +
FP O +
rates O +
may O +
arise O +
from O +
cross O -
- O -
hybridization O +
effects O +
that O +
remained O +
unaccounted O +
for O -
. O -

However O -
, O +
our O +
specificity O +
of O +
77 O -
% O +
at O +
the O +
cutoff O +
of O +
two O +
significant O +
outliers O +
per O +
probeset O +
allowed O +
us O +
to O +
estimate O +
that O +
at O +
least O +
1,336 O +
of O +
1,737 O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
true O +
AS O +
events O +
that O +
changed O +
during O +
neuronal O +
differentiation O +
of O +
hESC O +
cells O -
, O +
and/or O +
were O +
different O +
between O +
endogeneous O +
NPs O +
and O +
hESC O -
. O -

On O +
average O -
, O +
7 O -
% O +
of O +
all O +
human U-Species +
exons O +
have O +
been O +
estimated O +
by O +
transcript O +
data O +
to O +
undergo O +
AS O -
; O +
thus O +
REAP O -
's O +
validation O +
rate O +
of O +
60 O -
% O +
at O +
the O +
cutoff O +
of O +
two O +
is O +
73-fold O +
( O -
60 O -
/ O -
7 O -
) O +
higher O +
than O +
expected O -
. O -

In O +
addition O -
, O +
we O +
validated O +
nine O +
novel O +
AS O +
events O +
that O +
distinguish O +
hESCs O +
and O +
NPs O -
. O -

Consistent O +
with O +
our O +
computational O +
results O -
, O +
we O +
observed O +
that O +
the O +
AS O +
patterns O +
in O +
hCNS O -
- O -
SCns O +
were O +
not O +
always O +
similar O +
to O +
those O +
of O +
the O +
derived O +
NPs O -
. O -

It O +
was O +
important O +
to O +
point O +
out O +
that O +
while O +
transcriptional O +
expression O +
of O +
these O +
genes O +
did O +
not O +
distinguish O +
these O +
cells O +
from O +
one O +
another O -
, O +
in O +
several O +
instances O +
the O +
REAP O -
- O -
predicted O +
AS O +
event O +
was O +
able O +
to O +
separate O +
derived O +
NPs O +
and O +
hCNS O -
- O -
SCns O -
. O -

A O +
notable O +
exception O +
was O +
the O +
alternative O +
exon O +
in O +
the O +
SLK O +
gene O -
, O +
encoding O +
a O +
serine O -
/ O -
threonine O +
kinase O +
protein O -
, O +
which O +
was O +
commonly O +
included O +
in O +
both O +
hESCs O -
, O +
i.e. O -
, O +
the O +
exon O -
- O -
excluded O +
isoform O +
was O +
not O +
present O +
in O +
hESCs O +
compared O +
to O +
NPs O -
, O +
as O +
well O +
as O +
in O +
a O +
variety O +
of O +
differentiated O +
tissues O -
. O -

Closer O +
inspection O +
of O +
the O +
REAP O -
[ O -
+ O -
] O -
-validated O +
AS O +
exon O +
in O +
the O +
SLK O +
gene O +
revealed O +
strong O +
conservation O +
in O +
the O +
intronic O +
region O +
flanking O +
the O +
exon O -
, O +
a O +
hallmark O +
feature O +
of O +
evolutionarily O +
conserved O +
AS O +
exons O +
[ O -
55,77,78 O -
] O -
. O -

A O +
study O +
analyzing O +
the O +
expression O +
patterns O +
of O +
the O +
SLK O +
gene O +
suggested O +
a O +
potential O +
functional O +
role O +
during O +
embryonic O +
development O +
and O +
in O +
the O +
adult O +
central O +
nervous O +
system O +
[ O -
79 O -
] O -
; O +
however O -
, O +
to O +
our O +
knowledge O -
, O +
our O +
identification O +
of O +
the O +
SLK O +
alternative O +
exon O +
is O +
the O +
first O +
report O +
of O +
a O +
hESC O -
- O -
biased O +
AS O +
pattern O +
during O +
neuronal O +
differentiation O +
and O +
across O +
a O +
myriad O +
of O +
differentiated O +
tissues O -
. O -

In O +
agreement O -
, O +
GO O +
analysis O +
suggested O +
that O +
genes O +
containing O +
REAP O -
[ O -
+ O -
] O +
exons O +
were O +
enriched O +
in O +
serine O -
/ O -
threonine O +
kinase O +
activity O -
, O +
of O +
which O +
SLK O +
is O +
a O +
family O +
member O -
. O -

Future O +
work O +
will O +
be O +
required O +
to O +
study O +
the O +
impact O +
of O +
AS O +
in O +
these O +
genes O +
in O +
hESCs O +
and O +
NPs O -
. O -

We O +
predict O +
it O +
is O +
unlikely O +
that O +
the O +
alternative O +
exon O +
in O +
the O +
SLK O +
gene O +
is O +
the O +
only O +
case O +
common O +
across O +
hESC O +
and O +
different O +
from O +
differentiated O +
tissues O -
, O +
but O +
further O +
studies O +
will O +
be O +
necessary O +
to O +
identify O +
other O +
hESC O -
- O -
specific O +
exons O -
. O -

REAP O -
[ O -
+ O -
] O +
exons O +
were O +
underrepresented O +
in O +
genes O +
that O +
were O +
differentially O +
transcriptionally O +
regulated O +
in O +
hESCs O +
and O +
NPs O -
. O -

Our O +
results O +
act O +
as O +
a O +
reminder O +
that O +
focusing O +
only O +
on O +
genes O +
that O +
are O +
differentially O +
expressed O +
will O +
overlook O +
RNA O +
processing O +
events O +
that O +
may O +
be O +
biologically O +
relevant O +
to O +
the O +
system O +
of O +
interest O -
. O -

Finally O -
, O +
we O +
identified O +
potential O +
cis O -
- O -
regulatory O +
intronic O +
elements O +
conserved O +
and O +
enriched O +
proximal O +
to O +
the O +
REAP O -
[ O -
+ O -
] O +
exons O -
. O -

In O +
particular O -
, O +
the O +
FOX1 O -
/ O -
2 O +
binding O +
site O -
, O +
GCUAG O -
, O +
was O +
conserved O +
and O +
enriched O +
in O +
the O +
flanking O +
introns O +
of O +
a O +
subset O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O -
. O -

Further O +
studies O +
will O +
be O +
required O +
to O +
explore O +
the O +
importance O +
of O +
FOX1 O +
family O +
members O +
in O +
early O +
neuronal O +
differentiation O -
. O -

In O +
conclusion O -
, O +
our O +
introduction O +
of O +
REAP O +
and O +
its O +
application O +
to O +
identifying O +
AS O +
events O +
has O +
revealed O +
new O +
and O +
unanticipated O +
insights O +
into O +
hESC O +
biology O +
and O +
their O +
transition O +
to O +
NP O +
cells O -
. O -

Collectively O -
, O +
these O +
exons O +
represent O +
a O +
set O +
of O +
molecular O +
changes O +
that O +
are O +
likely O +
to O +
be O +
important O +
for O +
studying O +
human U-Species +
neural O +
differentiation O +
with O +
applications O +
in O +
neuronal O +
regenerative O +
medicine O -
. O -

Maintenance O +
and O +
differentiation O +
of O +
hESCs O +
and O +
hCNS O -
- O -
SCns.hESC O +
line O +
Cy203 O +
( O -
Cythera O -
) O +
was O +
cultured O +
as O +
previously O +
described O +
[ O -
12 O -
] O -
. O -

To O +
differentiate O +
into O +
neuroepithelial O +
precursor O +
cells O -
, O +
colonies O +
were O +
manually O +
isolated O +
from O +
mouse U-Species +
embryonic O +
fibroblasts O +
( O -
MEFs O -
) O +
and O +
cut O +
in O +
small O +
pieces O -
. O -

These O +
pieces O +
were O +
transferred O +
to O +
a O +
T75 O +
flask O +
with O +
hESCs O +
differentiation O +
media O +
( O -
same O +
hESC O +
medium O +
but O +
10 O -
% O +
KSR O +
and O +
no O +
FGF-2 O -
) O -
. O -

Medium O +
was O +
changed O +
the O +
next O +
day O +
by O +
transferring O +
the O +
floating O +
hESC O +
aggregates O +
to O +
a O +
new O +
flask O -
. O -

After O +
culturing O +
for O +
a O +
week O -
, O +
the O +
hESC O +
cell O +
aggregates O +
formed O +
mature O +
embroid O +
bodies O +
( O -
EBs O -
; O +
∼10 O +
um O +
round O +
clusters O +
with O +
dark O +
centers O -
) O -
. O -

EBs O +
were O +
plated O +
on O +
a O +
coated O +
10-cm O +
dish O +
in O +
hESC O +
differentiation O +
media O -
. O -

The O +
next O +
day O -
, O +
the O +
medium O +
was O +
changed O +
to O +
DMEM O -
/ O -
F12 O +
supplemented O +
with O +
ITS O +
and O +
fibronectin O -
. O -

Medium O +
was O +
changed O +
every O +
other O +
day O +
for O +
a O +
week O +
or O +
until O +
the O +
cells O +
formed O +
rosette O -
- O -
like O +
columnar O +
structures O +
that O +
were O +
isolated O +
manually O -
. O -

These O +
structures O +
were O +
then O +
transferred O +
to O +
coated O +
dishes O +
in O +
neural O +
induction O +
medium O +
( O -
DMEM O -
/ O -
F12 O +
supplemented O +
with O +
N2 O +
and O +
FGF-2 O -
) O +
for O +
a O +
week O -
. O -

Elongated O +
single O +
cells O +
were O +
separated O +
from O +
leftover O +
aggregates O +
using O +
non O -
- O -
enzymatic O +
dissociation O -
. O -

After O +
one O +
to O +
two O +
passages O -
, O +
the O +
cells O +
formed O +
a O +
monolayer O +
of O +
homogeneous O +
NPs O +
( O -
negative O +
for O +
Sox1 O +
immunostaining O -
) O -
. O -

Upon O +
confluence O -
, O +
cells O +
will O +
form O +
neurospheres O +
that O +
can O +
also O +
be O +
isolated O +
from O +
the O +
neuroepithelial O +
precursor O +
cells O +
( O -
positive O +
for O +
Sox1 O +
immunostaining O -
) O -
. O -

At O +
any O +
of O +
these O +
two O +
stages O -
, O +
pan O -
- O -
neuronal O +
differentiation O +
can O +
be O +
achieved O +
after O +
three O +
to O +
four O +
weeks O -
. O -

hESC O +
line O +
HUES6 O +
was O +
cultured O +
on O +
MEF O +
feeders O +
as O +
previously O +
described O +
( O -
http://www.mcb.harvard.edu/melton/hues/ O -
) O +
or O +
on O +
GFR O +
matrigel O +
coated O +
plates O -
. O -

Cells O +
grown O +
on O +
matrigel O +
were O +
grown O +
in O +
MEF O -
- O -
conditioned O +
medium O +
and O +
FGF-2 O +
was O +
used O +
at O +
20 O +
ng O -
/ O -
mL O +
instead O +
of O +
10 O +
ng O -
/ O -
mL O +
for O +
cells O +
grown O +
on O +
MEFs O -
. O -

To O +
differentiate O +
neuroepithelial O +
precursors O -
, O +
colonies O +
were O +
removed O +
by O +
treatment O +
with O +
collagenase O +
IV O +
( O -
Sigma O -
) O +
and O +
washed O +
three O +
times O +
in O +
growth O +
media O -
. O -

The O +
pieces O +
of O +
colonies O +
were O +
resuspended O +
in O +
HUES O +
growth O +
media O +
without O +
FGF2 O +
in O +
an O +
uncoated O +
bacterial O +
Petri O +
dish O +
to O +
form O +
EBs O -
. O -

After O +
one O +
week O -
, O +
EBs O +
were O +
plated O +
on O +
polyornathine O -
/ O -
laminin O +
coated O +
plates O +
in O +
DMEM O -
/ O -
F12 O +
supplemented O +
with O +
N2 O +
and O +
FGF2 O -
. O -

Rosette O +
structures O +
were O +
manually O +
collected O +
and O +
enzymatically O +
dissociated O +
with O +
TryPLE O +
( O -
Invitrogen O -
) O -
, O +
plated O +
on O +
polyornathine O -
/ O -
laminin O +
coated O +
plates O -
, O +
and O +
grown O +
in O +
DMEM O -
/ O -
F12 O +
supplemented O +
with O +
N2 O +
and O +
B27-RA O +
and O +
20 O +
ng O -
/ O -
mL O +
FGF-2 O -
. O -

Cells O +
could O +
be O +
grown O +
as O +
a O +
monolayer O +
for O +
up O +
to O +
at O +
least O +
ten O +
passages O -
. O -

Cells O +
were O +
Sox1 O +
and O +
nestin O +
positive O +
and O +
readily O +
differentiated O +
into O +
neurons O +
upon O +
withdrawal O +
of O +
FGF-2 O -
. O -

Human U-Species +
central O +
nervous O +
system O +
stem O +
cell O +
line O +
FBR1664 O +
( O -
StemCells O -
) O +
which O +
is O +
referred O +
to O +
as O +
hCNS O -
- O -
SCns O +
in O +
the O +
main O +
text O +
was O +
cultured O +
as O +
previously O +
described O +
[ O -
23 O -
] O -
. O -

The O +
cells O +
were O +
cultured O +
in O +
medium O +
consisting O +
of O +
Ex O +
Vivo O +
15 O +
( O -
BioWhittaker O -
) O +
medium O +
with O +
N2 O +
supplement O +
( O -
GIBCO O -
) O -
, O +
FGF2 O +
( O -
20 O +
ng O -
/ O -
mL O -
) O -
, O +
epidermal O +
growth O +
factor O +
( O -
20 O +
ng O -
/ O -
mL O -
) O -
, O +
lymphocyte O +
inhibitory O +
factor O +
( O -
10 O +
ng O -
/ O -
mL O -
) O -
, O +
0.2 O +
mg O -
/ O -
ml O +
heparin O -
, O +
and O +
60 O +
ug O -
/ O -
mL O +
N O -
- O -
acetylcysteine O -
. O -

Cultures O +
were O +
fed O +
weekly O +
and O +
passaged O +
at O +
∼two O +
to O +
three O +
weeks O +
using O +
collagenases O +
( O -
Roche O -
) O -
. O -

The O +
following O +
antibodies O +
and O +
corresponding O +
dilutions O +
were O +
utilized O +
for O +
the O +
immunohistochemical O +
analysis O +
of O +
marker O +
genes O +
in O +
Cyt O -
- O -
ES O +
and O +
HUES6-ES O -
: O +
Sox2 O +
( O -
Chemicon O -
, O +
1:500 O -
) O -
, O +
Oct4 O +
( O -
Santa O +
Cruz O -
, O +
1:500 O -
) O -
, O +
Sox1 O +
( O -
Chemicon O -
, O +
1:500 O -
) O -
, O +
Nestin O +
( O -
Pharmingen O -
, O +
1:250 O -
) O -
; O +
hCNS O -
- O -
SCns O -
: O +
Sox2 O +
( O -
Chemicon O -
, O +
1:200 O -
) O -
, O +
Nestin O +
( O -
Chemicon O -
, O +
1:200 O -
) O -
. O -

RNA O +
preparation O +
and O +
array O +
hybridization O -
. O -

Total O +
RNA O +
from O +
cells O +
was O +
processed O +
as O +
follows O -
. O -

Cells O +
were O +
lysed O +
in O +
1 O +
mL O +
of O +
RNA O -
- O -
bee O +
( O -
Teltest O -
) O -
. O -

The O +
RNA O +
was O +
isolated O +
by O +
chloroform O +
extraction O +
of O +
the O +
aqueous O +
phase O -
, O +
followed O +
by O +
isopropanol O +
precipitation O +
as O +
per O +
the O +
manufacturer O -
's O +
instructions O -
. O -

The O +
precipitated O +
RNA O +
was O +
washed O +
in O +
75 O -
% O +
ethanol O +
and O +
eluted O +
with O +
DEPC O -
- O -
treated O +
water O -
. O -

Five O +
ug O +
of O +
RNA O +
was O +
treated O +
with O +
RQ1 O +
DNAase O +
( O -
Promega O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O -
. O -

One O +
ug O +
of O +
total O +
RNA O +
for O +
each O +
sample O +
was O +
processed O +
using O +
the O +
Affymetrix O +
GeneChip O +
Whole O +
Transcript O +
Sense O +
Target O +
Labeling O +
Assay O +
( O -
Affymetrix O -
) O -
. O -

Ribosomal O +
RNA O +
was O +
reduced O +
with O +
the O +
RiboMinus O +
Kit O +
( O -
Invitrogen O -
) O -
. O -

Target O +
material O +
was O +
prepared O +
using O +
commercially O +
available O +
Affymetrix O +
GeneChip O +
WT O +
cDNA O +
Synthesis O +
Kit O -
, O +
WT O +
cDNA O +
Amplification O +
Kit O -
, O +
and O +
WT O +
Terminal O +
Labeling O +
Kit O +
( O -
Affymetrix O -
) O +
as O +
per O +
manufacturer O -
's O +
instructions O -
. O -

Hybridization O +
cocktails O +
containing O +
∼5 O +
ug O +
of O +
fragmented O +
and O +
labeled O +
DNA O +
target O +
were O +
prepared O +
and O +
applied O +
to O +
GeneChip O +
Human U-Species +
Exon O +
1.0 O +
ST O +
arrays O -
. O -

Hybridization O +
was O +
performed O +
for O +
16 O +
hours O +
using O +
the O +
Fluidics O +
450 O +
station O -
. O -

Arrays O +
were O +
scanned O +
using O +
the O +
Affymetrix O +
3000 O +
7 O -
G O +
scanner O +
and O +
GeneChip O +
Operating O +
Software O +
version O +
1.4 O +
to O +
produce O +
.CEL O +
intensity O +
files O -
. O -

Detection O +
of O +
AS O +
by O +
RT O -
- O -
PCR.cDNAs O +
were O +
generated O +
from O +
total O +
RNA O +
with O +
Superscript O +
III O +
reverse O +
transcriptase O +
( O -
Invitrogen O -
) O -
. O -

PCR O +
reactions O +
were O +
performed O +
with O +
primer O +
pairs O +
designed O +
for O +
AS O +
targets O +
( O -
annealing O +
at O +
58 O +
° O -
C O +
and O +
amplification O +
for O +
30 O +
or O +
35 O +
cycles O -
) O -
. O -

PCR O +
products O +
were O +
resolved O +
on O +
either O +
1.5 O -
% O +
or O +
3 O -
% O +
agarose O +
gel O +
in O +
TBE O -
. O -

The O +
Ethidium O +
Bromide O -
- O -
stained O +
gels O +
were O +
scanned O +
with O +
Typhoon O +
8600 O +
scanner O +
( O -
Molecular O +
Dynamics O -
) O +
for O +
quantification O -
. O -

The O +
number O +
of O +
true O +
positives O +
( O -
TP O -
; O +
false O +
negatives O -
, O +
FN O -
) O +
was O +
computed O +
as O +
the O +
number O +
of O +
REAP O -
[ O -
+ O -
] O +
( O -
REAP O -
[ O -
− O -
] O -
) O +
exons O +
that O +
were O +
validated O +
by O +
RT O -
- O -
PCR O +
as O +
AS O -
. O -

The O +
number O +
of O +
true O +
negatives O +
( O -
TN O -
; O +
or O +
FPs O -
) O +
was O +
computed O +
as O +
the O +
number O +
of O +
REAP O -
[ O -
− O -
] O +
( O -
REAP O -
[ O -
+ O -
] O -
) O +
exons O +
that O +
were O +
validated O +
by O +
RT O -
- O -
PCR O +
as O +
constitutively O +
spliced O -
. O -

The O +
true O +
( O -
false O -
) O +
positive O +
rate O +
was O +
computed O +
as O +
TP O +
( O -
FP O -
) O +
divided O +
by O +
the O +
total O +
number O +
of O +
REAP O -
[ O -
+ O -
] O +
exons O +
in O +
the O +
experimentally O +
validated O +
set O -
. O -

The O +
true O +
( O -
false O -
) O +
negative O +
rate O +
was O +
computed O +
as O +
the O +
TN O +
( O -
FN O -
) O +
divided O +
by O +
the O +
total O +
number O +
of O +
REAP O -
[ O -
− O -
] O +
exons O +
in O +
the O +
experimentally O +
validated O +
set O -
. O -

Sensitivity O +
was O +
computed O +
as O +
TP O -
/ O -
( O -
TP+FN O -
) O +
and O +
specificity O +
was O +
computed O +
as O +
TN O -
/ O -
( O -
FP+TN O -
) O -
. O -

Sequence O +
databases O -
. O -

Genome O +
sequences O +
of O +
human U-Species +
( O -
hg17 O -
) O -
, O +
dog U-Species +
( O -
canFam1 O -
) O -
, O +
rat U-Species +
( O -
rn3 O -
) O -
, O +
and O +
mouse U-Species +
( O -
mm5 O -
) O +
were O +
obtained O +
from O +
UCSC O -
, O +
as O +
were O +
the O +
whole O -
- O -
genome O +
MULTIZ O +
alignments O +
[ O -
80 O -
] O -
. O -

The O +
lists O +
of O +
known O +
human U-Species +
genes O +
( O -
knownGene O +
containing O +
43,401 O +
entries O -
) O +
and O +
known O +
isoforms O +
( O -
knownIsoforms O +
containing O +
43,286 O +
entries O +
in O +
21,397 O +
unique O +
isoform O +
clusters O -
) O +
with O +
annotated O +
exon O +
alignments O +
to O +
human U-Species +
hg17 O +
genomic O +
sequence O +
were O +
processed O +
as O +
follows O -
. O -

Known O +
genes O +
that O +
were O +
mapped O +
to O +
different O +
isoform O +
clusters O +
were O +
discarded O -
. O -

All O +
mRNAs O +
aligned O +
to O +
hg17 O +
that O +
were O +
greater O +
than O +
300 O +
bases O +
long O +
were O +
clustered O +
together O +
with O +
the O +
known O +
isoforms O -
. O -

Genes O +
containing O +
less O +
than O +
three O +
exons O +
were O +
removed O +
from O +
further O +
consideration O -
. O -

A O +
total O +
of O +
2.7 O +
million O +
spliced O +
ESTs O +
were O +
mapped O +
onto O +
the O +
17,478 O +
high O -
- O -
quality O +
genes O +
to O +
infer O +
AS O -
. O -

Exons O +
with O +
canonical O +
splice O +
signals O +
( O -
GT O -
- O -
AG O -
, O +
AT O -
- O -
AC O -
, O +
GC O -
- O -
AG O -
) O +
were O +
retained O -
, O +
resulting O +
in O +
a O +
total O +
of O +
213,736 O +
exons O -
. O -

Of O +
these O -
, O +
197,262 O +
( O -
92 O -
% O +
of O +
all O +
exons O -
) O +
were O +
constitutive O +
exons O -
, O +
13,934 O +
exons O +
( O -
7 O -
% O -
) O +
had O +
evidence O +
of O +
exon O -
- O -
skipping O -
, O +
1,615 O +
( O -
1 O -
% O -
) O +
exons O +
were O +
mutually O +
exclusive O +
alternative O +
events O -
, O +
5,930 O +
( O -
3 O -
% O -
) O +
exons O +
had O +
alternative O +
3′ O +
splice O +
sites O -
, O +
5,181 O +
( O -
2 O -
% O -
) O +
exons O +
had O +
alternative O +
5′ O +
splice O +
sites O -
, O +
and O +
175 O +
( O -
< O -
1 O -
% O -
) O +
exons O +
overlapped O +
another O +
exon O -
, O +
but O +
did O +
not O +
fall O +
into O +
the O +
above O +
classifications O -
. O -

A O +
total O +
of O +
324,139 O +
probesets O +
from O +
the O +
Affymetrix O +
Human U-Species +
Exon O +
1.0 O +
ST O +
array O +
were O +
mapped O +
to O +
208,422 O +
human U-Species +
exons O -
, O +
representing O +
17,431 O +
genes O -
. O -

These O +
probesets O +
were O +
used O +
to O +
derive O +
gene O +
and O +
exon O -
- O -
level O +
signal O +
estimates O +
from O +
the O +
CEL O +
files O -
. O -

The O +
four O -
- O -
way O +
mammalian O +
( O -
four O -
- O -
mammal O -
) O +
whole O -
- O -
genome O +
alignment O +
( O -
hg17 O -
, O +
canFam1 O -
, O +
mm5 O -
, O +
rn3 O -
) O +
was O +
extracted O +
from O +
the O +
eight O -
- O -
way O +
vertebrate O +
MULTIZ O +
alignments O +
( O -
hg17 O -
, O +
panTrol1 O -
, O +
mm5 O -
, O +
rn3 O -
, O +
canFam1 O -
, O +
galGal2 O -
, O +
fr1 O -
, O +
danRer1 O -
) O +
obtained O +
from O +
the O +
UCSC O +
Genome O +
Browser O -
. O -

Four O -
- O -
way O +
mammal O +
alignments O +
were O +
extracted O +
for O +
all O +
internal O +
exons O -
, O +
and O +
400 O +
bases O +
of O +
flanking O +
intronic O +
sequence O -
, O +
resulting O +
in O +
a O +
total O +
of O +
161,731 O +
conserved O +
internal O +
exons O -
. O -

A O +
total O +
of O +
145,613 O +
( O -
90 O -
% O +
of O +
total O -
) O +
conserved O +
internal O +
exons O +
were O +
constitutive O +
exons O -
, O +
13,653 O +
exons O +
( O -
8 O -
% O -
) O +
had O +
evidence O +
of O +
exon O -
- O -
skipping O -
, O +
1,576 O +
exons O +
were O +
mutually O +
exclusive O +
alternative O +
events O -
, O +
5,818 O +
exons O +
had O +
alternative O +
3′ O +
splice O +
sites O -
, O +
5,046 O +
exons O +
had O +
alternative O +
5′ O +
splice O +
sites O -
, O +
and O +
168 O +
exons O +
overlapped O +
another O +
exon O -
. O -

Exon O +
array O +
analysis O -
. O -

The O +
Affymetrix O +
Power O +
Tools O +
( O -
APT O -
) O +
suite O +
of O +
programs O +
was O +
obtained O +
from O +
http://www.affymetrix.com/support/developer/powertools/index.affx O -
. O -

Exon O +
( O -
probeset O -
) O +
and O +
gene O -
- O -
level O +
signal O +
estimates O +
were O +
derived O +
from O +
the O +
CEL O +
files O +
by O +
RMA O -
– O -
sketch O +
normalization O +
as O +
a O +
method O +
in O +
the O +
apt O -
- O -
probeset O -
- O -
summarize O +
program O -
. O -

To O +
determine O +
if O +
the O +
signal O +
intensity O +
for O +
a O +
given O +
probeset O +
is O +
above O +
the O +
expected O +
level O +
of O +
background O +
noise O -
, O +
we O +
utilized O +
the O +
DABG O +
( O -
detection O +
above O +
background O -
) O +
quantification O +
method O +
available O +
in O +
the O +
apt O -
- O -
probeset O -
- O -
summarize O +
program O +
as O +
part O +
of O +
Affymetrix O +
Power O +
Tools O +
( O -
APT O -
) O -
. O -

Briefly O -
, O +
DABG O +
compared O +
the O +
signal O +
for O +
each O +
probe O +
to O +
a O +
background O +
distribution O +
of O +
signals O +
from O +
anti O -
- O -
genomic O +
probes O +
with O +
the O +
same O +
GC O +
content O -
. O -

The O +
DABG O +
algorithm O +
generated O +
a O +
p O -
- O -
value O +
representing O +
the O +
probability O +
that O +
the O +
signal O +
intensity O +
of O +
a O +
given O +
probe O +
was O +
part O +
of O +
the O +
background O +
distribution O -
. O -

We O +
considered O +
a O +
probeset O +
with O +
a O +
DABG O +
p O -
- O -
value O +
lower O +
than O +
0.05 O +
as O +
detected O +
above O +
background O -
. O -

The O +
statistic O +
thCNS O -
- O -
SCns O -
, O -
ESC O +
= O +
( O -
μhCNS O -
- O -
SCns O +
− O +
μESC O -
) O +
/ O +
sqrt O +
( O -
( O -
( O -
nhCNS O -
- O -
SCns O +
− O +
1 O -
) O -
σ2hCNS O -
- O -
SCns O +
+ O +
( O -
nESC O +
− O +
1 O -
) O -
σ2ESC O -
) O -
( O -
nhCNS O -
- O -
SCns O +
+ O +
nESC O -
) O -
) O +
/ O +
( O -
( O -
nhCNS O -
- O -
SCnsnESC O -
) O +
( O -
nhCNS O -
- O -
SCns O +
+ O +
nESC O +
− O +
2 O -
) O -
) O -
) O -
, O +
where O +
nhCNS O -
- O -
SCns O +
and O +
nESC O +
were O +
the O +
number O +
of O +
replicates O -
, O +
μhCNS O -
- O -
SCns O +
and O +
μESC O +
were O +
the O +
mean O -
, O +
and O +
σ2hCNS O -
- O -
SCns O +
and O +
σ2ESC O +
were O +
the O +
variances O +
of O +
the O +
expression O +
values O +
for O +
the O +
two O +
datasets O +
used O +
to O +
represent O +
the O +
differential O +
enrichment O +
of O +
a O +
gene O +
using O +
gene O -
- O -
level O +
estimates O +
in O +
hCNS O -
- O -
SCns O +
relative O +
to O +
hESCs O -
. O -

Multiple O +
hypothesis O +
testing O +
was O +
corrected O +
by O +
controlling O +
for O +
the O +
false O +
discovery O +
rate O +
( O -
Benjamini O -
- O -
Hochberg O -
) O -
. O -

AS O +
detection O +
by O +
REAP.The O +
log2 O +
signal O +
estimate O +
xij O +
for O +
probeset O +
i O +
in O +
cell O -
- O -
type O +
j O +
had O +
to O +
satisfy O +
two O +
conditions O -
, O +
otherwise O +
the O +
probeset O +
was O +
discarded O -
: O +
( O -
i O -
) O +
2 O +
< O +
xij O +
< O +
10,000 O +
for O +
all O +
conditions O -
/ O -
cell O -
- O -
types O +
j O -
; O +
and O +
( O -
ii O -
) O +
DABG O +
p O -
- O -
value O +
< O +
0.05 O +
for O +
all O +
replicates O +
in O +
at O +
least O +
one O +
condition O -
/ O -
cell O -
- O -
type O +
j. O +
A O +
gene O +
had O +
to O +
have O +
five O +
probesets O +
that O +
satisfied O +
the O +
two O +
conditions O +
above O +
in O +
order O +
to O +
be O +
considered O +
for O +
robust O +
regression O +
analysis O -
. O -

After O +
generating O +
the O +
points O +
( O -
as O +
described O +
in O +
the O +
Results O +
section O -
) O -
, O +
we O +
utilized O +
the O +
robust O +
regression O +
method O +
rlm O +
in O +
R O -
- O -
package O +
" O -
MASS O -
" O +
( O -
version O +
6.1–2 O -
) O +
with O +
M O -
- O -
estimation O +
and O +
a O +
maximum O +
iteration O +
setting O +
of O +
30 O +
to O +
estimate O +
the O +
linear O +
function O +
yi O +
= O +
αxi O +
+ O +
β O -
. O -

For O +
each O +
probeset O -
, O +
we O +
computed O +
the O +
error O +
term O +
ei O -
, O -
, O +
which O +
was O +
the O +
difference O +
between O +
the O +
actual O +
value O +
yi O +
and O +
the O +
estimated O +
value O +
ξi O -
, O +
from O +
the O +
estimated O +
function O +
ξi O +
= O +
Axi O +
+ O +
B O -
, O +
where O +
A O +
and O +
B O +
were O +
estimates O +
of O +
α O +
and O +
β O -
. O -

The O +
error O +
term O +
variance O +
was O +
estimated O +
by O +
se2 O +
= O +
Σei2 O -
/ O -
( O -
n O +
− O +
p O -
) O -
, O +
which O +
was O +
used O +
to O +
estimate O +
the O +
variance O +
of O +
the O +
predicted O +
value O -
, O +
sξi2 O +
= O +
se2 O -
( O -
n−1 O +
+ O +
( O -
xi O +
− O +
μx O -
) O -
2 O +
/ O +
sx2 O -
( O -
n O +
− O +
1 O -
) O -
) O -
. O -

Here O -
, O +
n O +
referred O +
to O +
the O +
number O +
of O +
points O +
( O -
generated O +
for O +
each O +
gene O -
) O -
, O +
and O +
p O +
referred O +
to O +
the O +
number O +
of O +
independent O +
variables O +
( O -
p O +
= O +
2 O +
in O +
our O +
method O -
) O -
; O +
and O +
μx O +
= O +
Σxi2 O -
/ O -
n O -
; O +
sx2 O +
= O +
n−1 O +
Σ O -
( O -
xi O +
− O +
μx O -
) O -
2 O -
. O -

Following O +
Belsley O +
et O +
al. O +
[ O -
81 O -
] O -
, O +
we O +
defined O +
the O +
leverage O +
hi O +
of O +
the O +
ith O +
point O +
as O +
hi O +
= O +
n−1 O +
+ O +
( O -
xi O +
− O +
μx O -
) O -
2 O +
/ O +
sx2 O -
( O -
n O +
− O +
1 O -
) O -
. O -

Here O +
we O +
considered O +
a O +
point O +
to O +
have O +
high O +
leverage O +
if O +
hi O +
> O +
3p O -
/ O -
n O -
. O -

Next O -
, O +
we O +
calculated O +
the O +
covariance O +
ratio O -
, O +
covi O +
= O +
( O -
si2 O -
/ O -
sr2 O -
) O -
p O -
/ O -
( O -
1 O +
− O +
hi O -
) O -
, O +
which O +
is O +
the O +
ratio O +
of O +
the O +
determinant O +
of O +
the O +
covariance O +
matrix O +
after O +
deleting O +
the O +
ith O +
observation O +
to O +
the O +
determinant O +
of O +
the O +
covariance O +
matrix O +
with O +
the O +
entire O +
sample O -
. O -

We O +
considered O +
a O +
point O +
to O +
have O +
high O +
influence O +
if O +
|covi O +
− O +
1| O +
> O +
3p O -
/ O -
n O -
. O -

Lastly O -
, O +
we O +
computed O +
the O +
studentized O +
residuals O -
, O +
rstudenti O +
= O +
ei O +
/ O +
( O -
s O -
( O -
i O -
) O -
2 O +
( O -
1 O +
− O +
hi O -
) O -
0.5 O -
) O -
, O +
where O +
s O -
( O -
i O -
) O -
2 O +
= O +
( O -
n O -
- O -
p O -
) O -
se2 O +
/ O +
( O -
n O -
- O -
p-1 O -
) O +
– O +
ei2 O +
/ O +
( O -
n O -
- O -
p-1 O -
) O -
( O -
1 O +
− O +
hi O -
) O -
, O +
the O +
error O +
term O +
variance O +
after O +
deleting O +
the O +
ith O +
point O -
. O -

As O +
rstudenti O +
was O +
distributed O +
as O +
Student O -
's O +
t O -
- O -
distribution O +
with O +
n O -
- O -
p-1 O +
degrees O +
of O +
freedom O -
, O +
each O +
rstudenti O +
value O +
was O +
associated O +
with O +
a O +
p O -
- O -
value O -
. O -

We O +
considered O +
a O +
point O +
to O +
be O +
an O +
" O -
outlier O -
" O +
if O +
p O +
< O +
0.01 O -
. O -

Identification O +
of O +
motifs O -
. O -

The O +
enrichment O +
score O +
of O +
a O +
sequence O +
element O +
of O +
length O +
k O +
( O -
k O -
- O -
mer O -
) O +
in O +
one O +
set O +
of O +
sequences O +
( O -
set O +
1 O -
) O +
versus O +
another O +
set O +
of O +
sequences O +
( O -
set O +
2 O -
) O +
was O +
represented O +
by O +
the O +
nonparametric O +
χ2 O +
statistic O +
with O +
Yates O +
correction O -
, O +
computed O +
from O +
the O +
two O +
by O +
two O +
contingency O +
table O -
, O +
T O +
( O -
T11 O -
: O +
number O +
of O +
occurrences O +
of O +
the O +
element O +
in O +
set O +
1 O -
; O +
T12 O -
: O +
number O +
of O +
occurrences O +
of O +
all O +
other O +
elements O +
of O +
similar O +
length O +
in O +
set O +
1 O -
; O +
T21 O -
: O +
number O +
of O +
occurrences O +
of O +
element O +
in O +
set O +
2 O -
; O +
T22 O -
: O +
number O +
of O +
occurrences O +
of O +
all O +
other O +
elements O +
of O +
similar O +
length O +
in O +
set O +
2 O -
. O -

All O +
elements O +
had O +
to O +
be O +
greater O +
than O +
5 O -
. O -

To O +
correct O +
for O +
multiple O +
hypothesis O +
testing O -
, O +
p O -
- O -
values O +
were O +
multiplied O +
by O +
the O +
total O +
number O +
of O +
comparisons O -
. O -

Extracts O +
of O +
the O +
creosote B-Species +
bush L-Species +
( O -
Larrea B-Species +
tridentata L-Species -
, O +
family O +
Zygophyllaceae U-Species -
) O +
have O +
long O +
been O +
used O +
as O +
a O +
folk O +
remedy O +
for O +
Type O +
II O +
( O -
non O -
- O -
insulin O -
- O -
dependent O -
) O +
diabetes O +
by O +
native B-Species +
Americans L-Species +
in O +
southwestern O +
North O +
America O -
. O -

In O +
this O +
study O +
we O +
have O +
evaluated O +
the O +
metabolic O +
effects O +
of O +
masoprocol O -
, O +
a O +
pure O +
compound O +
isolated O +
from O +
the O +
creosote B-Species +
bush L-Species -
, O +
in O +
a O +
rat U-Species +
model O +
of O +
Type O +
II O +
diabetes O -
. O -

Animals O +
were O +
fed O +
a O +
20 O -
% O +
fat O +
( O -
by O +
weight O -
) O -
diet O +
for O +
2 O +
weeks O +
prior O +
to O +
intravenous O +
injection O +
with O +
streptozotocin O +
( O -
STZ O -
, O +
0.19 O +
mmol O -
/ O -
kg O -
) O -
. O -

Diabetic O +
animals O +
( O -
glucose O +
16 O -
- O -
33 O +
mmol O -
/ O -
l O -
) O +
were O +
treated O +
with O +
vehicle O -
, O +
metformin O +
( O -
0.83 O +
mmol O -
/ O -
kg O +
body O +
weight O -
) O +
or O +
masoprocol O +
( O -
0.83 O +
mmol O -
/ O -
kg O +
body O +
weight O -
) O +
twice O +
a O +
day O +
for O +
4 O +
days O -
. O -

Masoprocol O +
treatment O +
lowered O +
glucose O +
concentrations O +
an O +
average O +
of O +
35 O -
% O +
compared O +
with O +
vehicle O +
( O -
14.2+ O -
/ O -
-1.1 O +
vs O +
21.7+ O -
/ O -
-1.0 O +
mmol O -
/ O -
l O -
, O +
p O +
< O +
0.001 O -
) O -
, O +
a O +
reduction O +
similar O +
to O +
metformin O +
treatment O +
( O -
12.8+ O -
/ O -
-0.9 O +
mmol O -
/ O -
l O -
) O -
, O +
without O +
any O +
change O +
in O +
insulin O +
concentration O -
. O -

Masoprocol O +
treatment O +
also O +
lowered O +
triglyceride O +
concentrations O +
80 O -
% O +
compared O +
with O +
vehicle O +
( O -
1.0+ O -
/ O -
-0.1 O +
vs O +
4.8+ O -
/ O -
-0.3 O +
mmol O -
/ O -
l O -
, O +
p O +
< O +
0.001 O -
) O -
, O +
a O +
reduction O +
far O +
greater O +
than O +
following O +
metformin O +
treatment O +
( O -
3.6+ O -
/ O -
-0.3 O +
mmol O -
/ O -
l O -
) O -
. O -

Non O -
- O -
esterified O +
fatty O +
acid O +
and O +
glycerol O +
concentration O +
were O +
decreased O +
by O +
approximately O +
65 O -
% O +
by O +
masoprocol O +
compared O +
with O +
vehicle O -
, O +
a O +
reduction O +
approximately O +
twice O +
as O +
great O +
as O +
seen O +
with O +
metformin O +
( O -
p O +
< O +
0.001 O -
) O -
. O -

The O +
effect O +
of O +
masoprocol O +
on O +
in O +
vivo O +
insulin O -
- O -
mediated O +
glucose O +
disposal O +
was O +
evaluated O +
by O +
infusing O +
fat O -
- O -
fed O -
/ O -
STZ O +
rats U-Species +
with O +
glucose O +
( O -
0.22 O +
mmol O +
kg O +
x O +
min O -
( O -
-1 O -
) O -
) O +
and O +
insulin O +
( O -
30 O +
pmol O +
x O +
kg O -
x O +
min O -
( O -
-1 O -
) O -
) O +
for O +
5 O +
h. O +
In O +
response O +
to O +
the O +
infusion O -
, O +
steady O -
- O -
state O +
plasma O +
glucose O +
concentrations O +
were O +
reduced O +
30 O -
% O +
in O +
masoprocol O -
- O -
treated O +
animals O +
compared O +
with O +
vehicle O +
controls O +
( O -
p O +
< O +
0.05 O -
) O +
with O +
no O +
change O +
noted O +
in O +
rats U-Species +
treated O +
with O +
metformin O -
. O -

The O +
effect O +
of O +
masoprocol O +
treatment O +
was O +
also O +
tested O +
in O +
primary O +
adipocytes O +
isolated O +
from O +
normal O +
animals O -
. O -

Adipocytes O +
treated O +
with O +
masoprocol O +
( O -
30 O +
micromol O -
/ O -
l O -
) O +
had O +
higher O +
basal O +
and O +
insulin O -
- O -
stimulated O +
glucose O +
clearance O +
than O +
did O +
adipocytes O +
treated O +
with O +
vehicle O +
( O -
p O +
< O -
0.05 O -
) O -
. O -

These O +
data O +
show O +
that O +
masoprocol O +
decreases O +
both O +
plasma O +
glucose O +
and O +
triglyceride O +
concentrations O +
in O +
fat O -
- O -
fed O -
/ O -
STZ O +
rats U-Species -
, O +
presumably O +
as O +
a O +
result O +
of O +
its O +
ability O +
to O +
both O +
increase O +
glucose O +
disposal O +
and O +
decrease O +
lipolysis O -
. O +

The O +
induction O +
of O +
micronucleated O +
erythrocytes O +
by O +
diisopropylcarbodiimide O +
( O -
DIC O -
) O +
and O +
dicyclohexylcarbodiimide O +
( O -
DCC O -
) O +
was O +
investigated O +
as O +
part O +
of O +
a O +
U.S. O +
National O +
Toxicology O +
Program O +
( O -
NTP O -
) O +
evaluation O +
of O +
the O +
subchronic O +
toxicity O +
of O +
these O +
chemicals O -
. O -

Analysis O +
of O +
peripheral O +
blood O +
smears O +
from O +
male O +
and O +
female O +
B6C3F1 B-Species +
mice L-Species +
exposed O +
to O +
17.5 O -
- O -
140.0 O +
mg O +
DIC O -
/ O -
kg O -
/ O -
day O +
by O +
skin O +
painting O +
for O +
13 O +
weeks O +
revealed O +
dose O -
- O -
related O +
increases O +
in O +
the O +
frequency O +
of O +
micronucleated O +
normochromatic O +
erythrocytes O +
( O -
MN O -
- O -
NCE O -
) O +
in O +
both O +
sexes O -
. O -

Results O +
of O +
a O +
similar O +
13-week O +
peripheral O +
blood O +
micronucleus O +
( O -
MN O -
) O +
test O +
with O +
DCC O +
( O -
1.5 O -
- O -
12.0 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
were O +
also O +
positive O -
, O +
although O +
the O +
increases O +
in O +
MN O -
- O -
NCE O +
were O +
not O +
as O +
great O +
as O +
those O +
observed O +
with O +
DIC O -
. O -

In O +
contrast O +
to O +
the O +
positive O +
results O +
of O +
the O +
subchronic O +
skin O -
- O -
painting O +
studies O +
in O +
mice U-Species -
, O +
acute O +
bone O +
marrow O +
MN O +
studies O +
with O +
DIC O +
and O +
DCC O +
in O +
male O +
F344 B-Species +
rats I-Species -
, L-Species +
using O +
intraperitoneal O +
( O -
i.p O -
. O -
) O +
injection O -
, O +
yielded O +
negative O +
results O -
. O -

Both O +
the O +
acute O +
and O +
the O +
subchronic O +
exposures O +
included O +
doses O +
that O +
produced O +
clinical O +
signs O +
of O +
toxicity O -
. O -

Acute O +
mouse U-Species +
bone O +
marrow O +
MN O +
tests O +
with O +
DIC O +
administered O +
in O +
single O +
or O +
triple O +
i.p O -
. O -

injection O +
protocols O +
were O +
subsequently O +
conducted O +
to O +
determine O +
if O +
the O +
differing O +
responses O +
between O +
mice U-Species +
and O +
rats U-Species +
were O +
due O +
to O +
species O +
or O +
protocol O +
differences O -
. O -

The O -
results O +
of O +
these O +
acute O +
tests O +
were O +
negative O +
or O +
equivocal O -
. O -

Because O +
the O +
subchronic O +
studies O +
produced O +
positive O +
results O -
, O +
it O +
was O +
hypothesized O +
that O +
these O +
carbodiimides O +
required O +
multiple O +
treatments O +
over O +
an O +
extended O +
period O +
of O +
time O +
to O +
produce O +
an O +
increase O +
in O +
MN O -
- O -
erythrocytes O -
. O -

To O +
confirm O +
the O +
original O +
response O -
, O +
a O +
second O +
dermal O +
subchronic O +
study O +
was O +
conducted O +
with O +
DIC O -
; O +
the O +
protocol O +
was O +
modified O +
to O +
include O +
sequential O +
blood O +
samplings O +
to O +
permit O +
monitoring O +
MN O +
frequencies O +
over O +
time O -
. O -

The O +
data O +
demonstrated O +
a O +
small O +
but O +
consistent O +
induction O +
of O +
micronucleated O +
erythrocytes O +
in O +
mice U-Species +
treated O +
with O +
DIC O +
by O +
skin O +
painting O -
. O +

Antibacterial O +
antibiotics O -
, O +
diperamycin O +
( O -
1 O -
) O +
was O +
produced O +
in O +
the O +
culture O +
broth O +
of O +
Streptomyces B-Species +
griseoaurantiacus L-Species +
MK393-AF2 O -
. O -

Various O +
spectroscopic O +
analyses O +
of O +
1 O +
suggested O +
that O +
1 O +
belonged O +
to O +
a O +
member O +
of O +
cyclic O +
hexadepsipeptide O +
antibiotic O -
. O -

Antibiotic O +
1 O +
had O +
potent O +
inhibitory O +
activity O +
against O +
various O +
Gram B-Species -
- I-Species -
positive I-Species +
bacteria L-Species +
including O +
Enterococcus B-Species +
seriolicida L-Species +
and O +
methicillin O -
- O -
resistant O +
Staphylococcus B-Species +
aureus L-Species -
. O +

Subcutaneous O +
tumor O +
induction O +
with O +
three O +
dose O +
levels O +
of O +
3-methylcholanthrene O +
( O -
MCA O -
) O -
, O +
benzo O -
[ O -
a O -
] O -
pyrene O +
( O -
BP O -
) O -
, O +
and O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O +
( O -
DMBA O -
) O +
in O +
two O +
vehicles O +
was O +
studied O +
in O +
C3H O -
/ O -
Anf O +
Cum O -
, O +
C57BL O -
/ O -
6 O +
Cum O -
, O +
DBA O -
/ O -
2J O -
, O +
and O +
( O -
C57BLXC3H O -
/ O -
Anf O -
) O -
F1 O +
( O -
BC3F1 O -
/ O -
Cum O -
) O +
mice U-Species -
. O -

Median O +
tumor O +
dose O +
levels O +
were O +
significantly O +
lower O +
when O +
the O +
three O +
carcinogens O +
were O +
suspended O +
in O +
trioctanoin O -
. O -

When O +
beeswax O -
: O +
trioctanoin O +
( O -
B O -
: O -
T O -
) O -
was O +
used O +
as O +
a O +
vehicle O -
, O +
the O +
three O +
carcinogens O +
differed O +
in O +
their O +
abilities O +
to O +
be O +
absorbed O +
or O +
solubilized O +
from O +
the O +
vehicle O +
by O +
the O +
three O +
strains O +
of O +
mice U-Species +
and O +
the O +
hybrid O -
. O -

In O +
C3H O -
/ O -
Anf O +
mice U-Species -
, O +
BP O +
in O +
B O -
: O -
T O +
failed O +
to O +
produce O +
tumors O -
. O -

In O +
BC3F1 O +
mice U-Species -
, O +
no O +
tumors O +
were O +
produced O +
by O +
MCA O -
, O +
BP O -
, O +
or O +
DMBA O +
in O +
B O -
: O -
T. O +
In O +
C57BL O -
/ O -
6 O +
mice U-Species -
, O +
no O +
tumors O +
were O -
produced O +
with O +
DMBA O +
or O +
MCA O +
in O +
B O -
: O -
T. O +
In O +
DBA O -
/ O -
2 O +
mice U-Species -
, O +
no O +
tumors O +
were O +
produced O +
by O +
BP O +
or O +
MCA O +
in O +
B O -
: O -
T. O +
These O +
results O +
indicated O +
that O +
the O +
interpretation O +
of O +
tumor O +
induction O +
results O +
obtained O +
with O +
B O -
: O -
T O +
vehicle O +
may O +
be O +
related O +
to O +
the O +
conditions O +
of O +
bioassay O +
rather O +
than O +
to O +
the O +
carcinogenic O +
potential O +
of O +
a O +
compound O -
. O +

DNA O -
- O -
dependent O +
protein O +
kinase O +
( O -
DNA O -
- O -
PK O -
) O +
and O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
( O -
PARP O -
) O +
are O -
activated O +
by O +
DNA O +
strand O +
breaks O +
and O +
participate O +
in O +
DNA O +
repair O -
. O -

We O +
investigated O +
the O +
interactive O +
effects O +
of O +
inhibitors O +
of O +
these O +
enzymes O +
[ O -
wortmannin O +
( O -
WM O -
) O -
, O +
which O +
inhibits O +
DNA O -
- O -
PK O -
, O +
and O +
8-hydroxy-2-methylquinazolin-4-one O +
( O -
NU1025 O -
) O -
, O +
a O +
PARP O +
inhibitor O -
] O +
on O +
cell O +
survival O +
and O +
DNA O +
double O -
- O -
strand O +
break O +
( O -
DSB O -
) O +
and O +
single O -
- O -
strand O +
break O +
( O -
SSB O -
) O +
rejoining O +
in O +
Chinese B-Species +
hamster L-Species +
ovary O -
- O -
K1 O +
cells O +
following O +
exposure O +
to O +
ionizing O +
radiation O +
( O -
IR O -
) O +
or O +
temozolomide O -
. O -

WM O +
( O -
20 O +
microM O -
) O +
or O +
NU1025 O +
( O -
300 O +
microM O -
) O +
potentiated O +
the O +
cytotoxicity O +
of O +
IR O +
with O +
dose O +
enhancement O +
factors O +
at O +
10 O -
% O +
survival O -
( O -
DEF10 O -
) O +
values O +
of O +
4.5 O +
+ O -
/- O -

0.6 O +
and O +
1.7 O +
+ O -
/- O -

0.2 O -
, O +
respectively O -
. O -

When O +
used O +
in O +
combination O -
, O +
a O +
DEF10 O +
of O +
7.8 O +
+ O -
/- O -

1.5 O +
was O +
obtained O -
. O -

WM O +
or O +
NU1025 O +
potentiated O +
the O +
cytotoxicity O +
of O +
temozolomide O -
, O +
and O +
an O +
additive O +
effect O +
on O +
the O +
DEF10 O +
value O +
was O +
obtained O +
with O +
the O +
combined O +
inhibitors O -
. O -

Using O +
the O +
same O +
inhibitor O +
concentrations O -
, O +
their O +
single O +
and O +
combined O +
effects O +
on O +
DSB O +
and O +
SSB O +
levels O +
following O +
IR O +
were O +
assessed O +
by O +
neutral O +
and O +
alkaline O +
elution O -
. O -

Cells O +
exposed O +
to O +
IR O +
were O +
post O -
- O -
incubated O +
for O +
30 O +
min O +
to O +
allow O +
repair O +
to O +
occur O -
. O -

WM O +
or O +
NU1025 O +
increased O +
net O +
DSB O +
levels O +
relative O +
to O +
IR O +
alone O +
( O -
DSB O +
levels O +
of O +
1.29 O +
+ O -
/- O -

0.04 O +
and O +
1.20 O +
+ O -
/- O -

0.05 O -
, O +
respectively O -
, O +
compared O +
with O +
1.01 O +
+ O -
/- O -

0.03 O +
for O +
IR O +
alone O -
) O +
and O +
the O +
combination O +
had O +
an O +
additive O +
effect O -
. O -

WM O +
had O +
no O +
effect O +
on O +
SSB O +
levels O -
, O +
either O +
alone O +
or O +
in O +
combination O +
with O +
NU1025 O -
. O -

SSB O +
levels O +
were O +
increased O +
to O +
1.27 O +
+ O -
/- O -

0.05 O +
with O +
NU1025 O +
compared O +
with O +
IR O +
alone O -
, O +
1.02 O +
+ O -
/- O -

0.04 O -
. O -

The O +
dose O -
- O -
dependent O +
effects O +
of O +
the O +
inhibitors O +
on O +
DSB O +
levels O +
showed O +
that O +
they O +
were O +
near O +
maximal O +
by O +
20 O +
microM O +
WM O +
and O +
300 O +
microM O +
NU1025 O -
. O -

DSB O +
repair O +
kinetics O +
were O +
studied O -
. O -

Both O +
inhibitors O +
increased O +
net O +
DSB O +
levels O +
over O +
a O +
3 O +
h O +
time O +
period O -
; O +
when O +
they O +
were O +
combined O -
, O +
net O +
DSB O +
levels O +
at O +
3 O +
h O +
were O +
identical O +
to O +
DSB O +
levels O +
immediately O +
post O -
- O -
IR O -
. O -

The O +
combined O +
use O +
of O +
DNA O +
repair O +
inhibitors O +
may O +
have O +
therapeutic O +
potential O -
. O +

Chemical O +
investigation O +
of O +
the O +
sponge O +
Spongia B-Species +
matamata L-Species +
collected O +
in O +
Yap O -
, O +
Micronesia O -
, O +
has O +
resulted O +
in O +
the O +
isolation O +
of O +
six O +
new O +
spongian O +
diterpenoids O -
, O +
2 O -
- O -
7 O -
, O -
along O +
with O +
the O +
known O +
compound O -
, O +
spongia-13 O -
( O -
16 O -
) O -
, O +
14-dien-19-oic O +
acid O +
( O -
1 O -
) O -
. O -

The O +
structures O +
were O +
determined O +
by O +
spectroscopic O +
methods O -
. O +

Meloxicam O +
[ O -
4-hydroxy-2-methyl O -
- O -
N- O -
( O -
5-methyl-2-thiazolyl O -
) O -
-2H-1,2-benzothiazine O +
-3-carboxamide-1 O -
, O +
1-dioxide O -
] O +
is O +
a O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drug O +
( O -
NSAID O -
) O +
of O -
the O +
oxicam O +
class O +
which O +
shows O +
preferential O +
inhibition O +
of O +
cyclo O -
- O -
oxygenase-2 O -
. O -

Meloxicam O +
has O +
a O +
plasma O +
half O -
- O -
life O +
of O +
approximately O +
20 O +
hours O -
, O +
making O +
it O +
convenient O -
for O +
once O -
- O -
daily O +
administration O -
. O -

Meloxicam O +
is O +
eliminated O +
after O +
biotransformation O +
to O +
4 O +
pharmacologically O +
inactive O +
metabolites O -
, O +
which O +
are O +
excreted O +
in O +
urine O +
and O +
faeces O -
. O -

Meloxicam O +
and O +
its O +
metabolites O +
bind O +
extensively O +
to O +
plasma O +
albumin O -
. O -

Substantial O +
concentrations O +
of O +
meloxicam O +
are O +
attained O +
in O +
synovial O +
fluid O -
, O +
the O +
proposed O +
site O +
of O -
action O +
in O +
chronic O +
inflammatory O +
arthropathies O -
. O -

Neither O +
moderate O +
renal O +
nor O +
hepatic O -
insufficiency O +
significantly O +
alter O +
the O +
pharmacokinetics O +
of O +
meloxicam O -
. O -

Dosage O +
adjustment O +
is O +
not O +
required O +
in O +
the O +
elderly O -
. O -

Drug O -
- O -
drug O +
interaction O +
studies O +
are O +
available O +
for O +
some O +
commonly O +
co O -
- O -
prescribed O +
medications O -
. O -

Concentration O -
- O -
dependent O +
therapeutic O +
and O +
toxicological O +
effects O +
have O +
yet O +
to O +
be O +
extensively O +
elucidated O +
for O +
this O +
NSAID O -
. O +

Recent O +
work O +
within O +
our O +
laboratory O +
has O +
focused O +
on O +
the O +
enzymes O +
we O +
hypothesize O +
are O +
involved O +
in O +
the O +
biosynthesis O +
of O +
bis O -
( O -
monoacylglycerol O -
) O -
phosphate O +
from O +
phosphatidylglycerol O -
. O -

Here O +
we O +
describe O +
a O +
transacylase O -
, O +
active O +
at O +
acidic O +
pH O +
values O -
, O +
isolated O +
from O +
a O +
macrophage O -
- O -
like O +
cell O +
line O -
, O +
RAW O +
264.7 O -
. O -

This O +
enzyme O +
acylates O +
the O +
head O +
group O +
glycerol O +
of O +
sn-3 O -
: O -
sn-1 O -
' O +
lysophosphatidylglycerol O +
to O +
form O +
sn-3 O -
: O -
sn-1 O -
' O +
bis O -
( O -
monoacylglycerol O -
) O -
phosphate O -
. O -

Here O +
we O +
demonstrate O +
that O +
this O +
enzyme O +
uses O +
two O +
lysophosphatidylglycerol O +
molecules O -
, O +
one O +
as O +
an O +
acyl O +
donor O +
and O +
another O +
as O -
an O +
acyl O +
acceptor O -
, O +
and O +
that O +
the O +
acyl O +
contributions O +
from O +
all O +
other O +
lipids O +
tested O +
are O +
comparatively O +
minor O -
. O -

This O +
enzyme O +
prefers O +
saturated O +
acyl O +
chains O +
to O +
monounsaturates O -
, O +
16 O +
and O +
18 O +
carbon O +
fatty O +
acids O +
over O +
14 O +
carbon O +
fatty O +
acids O -
, O +
and O +
saturated O +
acyl O +
chains O +
at O +
the O +
sn-1 O +
position O +
to O +
monounsaturated O +
acyl O +
chains O +
on O +
the O -
sn-2 O +
carbon O +
of O +
lysophosphatidylglycerol O -
. O -

We O +
present O +
data O +
which O +
show O +
the O +
transacylase O +
activity O +
depends O +
on O +
the O +
presence O +
of O +
a O +
lipid O -
- O -
water O +
interface O +
and O +
the O -
lipid O +
polymorphic O +
state O -
. O +

INTRODUCTION O -
We O +
have O +
recently O +
shown O +
that O +
rabbit U-Species +
antibodies O +
to O +
the O +
p O -
- O -
azophenylphosphorylcholine O +
( O -
APPC O -
) O +
determinant O -
, O +
which O +
bears O +
2 O +
charges O +
of O +
opposite O +
sign O -
, O +
have O +
both O +
positively O +
and O +
negatively O +
charged O +
groups O +
in O +
their O +
binding O +
sites O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O -

The O +
positive O +
charge O +
is O +
contributed O +
by O +
the O +
guanidinium O +
group O +
of O +
arginine O +
and O +
the O +
negative O +
charge O +
is O +
contributed O +
by O +
the O +
carboxylate O +
group O +
of O +
either O +
a O +
glutamyl O +
or O +
aspartyl O +
residue O -
. O -

We O +
have O +
also O +
previously O +
shown O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O +
that O +
the O +
phosphorylcholine O -
- O -
binding O +
mouse U-Species +
myeloma O +
protein O -
, O +
HOPC-8 O -
, O +
similarly O +
contains O +
gaunidinium O +
and O +
carboxylate O +
groups O +
in O +
its O +
binding O +
site O -
. O -

In O +
an O +
attempt O +
to O +
gain O +
further O +
insight O +
into O +
the O +
nature O +
of O +
these O +
binding O +
sites O +
we O +
have O +
measured O +
the O +
relative O +
binding O +
constants O +
of O +
several O +
structurally O +
related O +
small O +
molecules O +
with O +
anti O -
- O -
APPC O +
antibodies O +
and O +
with O +
HOPC-8 O -
. O -

The O +
Krel O +
values O +
for O +
hapten O +
binding O +
to O +
the O +
rabbit U-Species +
anti O -
- O -
APPC O +
antibodies O +
and O +
to O +
the O +
myeloma O +
protein O -
, O +
together O +
with O +
our O +
evidence O +
for O +
specific O +
functional O +
groups O +
in O +
the O +
binding O +
sites O -
, O +
have O +
allowed O +
us O +
to O +
draw O +
inferences O +
regarding O +
the O +
topography O +
of O +
the O +
binding O +
sites O +
of O +
anti O -
- O -
APPC O +
antibodies O +
and O +
HOPC-8 O -
. O -

* O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
U.S. O +
Public O +
Health O +
Service O +
Research O +
Grants O +
CA-11656 O +
and O +
AI-03962 O +
from O +
the O +
National O +
Cancer O +
Institute O -
. O -

t O +
A O +
unit O +
of O +
the O +
New O +
York O +
State O +
Department O +
of O +
Health O -
. O -

$ O +
Abbreviations O +
used O -
: O +
APPC O -
, O +
p O -
- O -
azophenylphosphorylcholine O -
; O +
NPPC O -
, O +
p O -
- O -
nitrophenylphosphorylcholine O -
; O +
PC O -
, O +
phosphorylcholine O -
; O +
GPC O -
, O +
L O -
- O -
a O -
- O -
glycerophosphorylcholine O -
; O +
AcC O -
, O +
acetylcholine O -
; O +
I O -
- O -
Ap O -
, O +
p O -
- O -
iodophenyltrimethylammonium O -
; O +
PO3 O -
, O +
phenylphosphate O -
; O +
03 O +
, O +
phenylphosphonate O -
; O +
BBS O -
, O +
borate O +
buffered O +
saline O -
. O -

901 O -
MATERIALS O +
AND O +
METHODS O -
p O -
- O -
Diazonium O +
phenylphosphorylcholine O +
chloride O +
( O -
DPPC O -
) O -
This O +
was O +
prepared O +
according O +
to O +
Chesebro O +
& O +
Metzger O +
( O -
1972 O -
) O +
with O +
the O +
exception O +
that O +
in O +
the O +
diazotization O +
step O +
1.0 O +
N O +
HCl O +
rather O +
than O +
0.1 O +
N O +
HCl O +
was O +
used O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O -
. O -

Haptens O -
Haptens O +
tested O +
were O +
reagent O +
grade O +
commercial O +
products O -
, O +
used O +
without O +
further O +
purification O -
. O -

Goat U-Species +
anti O -
- O -
rabbit U-Species +
IgG O -
This O +
serum O +
was O +
a O +
preparation O +
previously O +
described O +
( O -
Hoffman O +
et O +
al. O -
, O +
1971 O -
) O -
. O -

Rabbit U-Species +
anti O -
- O -
mouse U-Species +
IgA O -
This O +
serum O +
was O +
obtained O +
from O +
Dr. O +
Oliver O +
A. O +
Roholt O +
of O +
our O +
Department O -
. O -

It O +
was O +
prepared O +
by O +
hyperimmunization O +
of O +
rabbits U-Species +
with O +
MOPC-315 O +
myeloma O +
protein O -
. O -

Anti O -
- O -
APPC O +
antibodies O -
The O +
preparation O +
of O +
rabbit U-Species +
antisera O +
to O +
the O +
APPC O +
determinant O +
and O +
the O +
subsequent O +
isolation O +
and O +
purification O +
of O +
the O +
antibodies O +
from O +
individual O +
rabbits U-Species +
by O +
specific O +
immunoadsorption O +
has O +
been O +
described O +
previously O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O -

In O +
the O +
present O +
work O +
preparations O +
from O +
rabbits U-Species +
6055 U-Species +
and O +
6057 U-Species +
were O +
specifically O +
purified O +
anti O -
- O -
APPC O +
antibodies O +
and O +
the O +
preparation O +
from O +
rabbit B-Species +
5920 L-Species +
was O +
a O +
gamma O +
globulin O +
fraction O +
of O +
anti O -
- O -
APPC O +
serum O -
. O -

HOPC-8 O +
myeloma O +
protein O -
This O +
was O +
obtained O +
from O +
the O +
serum O +
of O +
tumor O -
- O -
bearing O +
mice U-Species +
as O +
previously O +
described O +
( O -
Grossberg O +
et O +
al. O -
, O +
1974 O -
) O -
. O -

The O +
myeloma O +
tumor O +
was O +
obtained O +
through O +
the O +
courtesy O +
of O +
Dr. O +
Michael O +
Potter O -
, O +
National O +
Cancer O +
Institute O -
, O +
Bethesda O -
, O +
MD O -
. O -

L. O +
M. O +
KRAUSZ O -
, O +
A. O +
L. O +
GROSSBERG O +
and O +
D. O +
PRESSMAN O -
Rabbit U-Species +
serum O +
albumin O +
( O -
RSA O -
) O -
This O +
was O +
Fraction O +
V O +
obtained O +
from O +
Pentex O -
, O +
Inc. O -
, O +
Kankakee O -
, O +
IL O -
. O -

RSA O -
- O -
APPC O -
This O +
was O +
prepared O +
by O +
reacting O +
160 O +
mg O +
of O +
RSA O +
in O +
about O +
10 O +
ml O +
of O +
pH O +
9.5 O +
borate O +
buffer O +
with O +
90 O +
umoles O +
of O +
DPPC O +
for O +
18 O +
hr O -
. O -

The O +
solution O +
was O +
then O +
dialyzed O +
against O +
pH O +
8 O +
z O +
BBS O -
, O +
stored O +
frozen O +
and O +
used O +
as O +
needed O -
. O -

The O +
entire O +
prep- O +
ae O +
aration O +
was O +
carried O +
out O +
at O +
4 O -
. O -

Radioiodination O +
of O +
RSA O -
- O -
APPC O -
RSA O -
- O -
APPC O +
was O +
trace O +
labeled O +
with O +
' O -
251 O +
by O +
a O +
modification O +
of O +
the O +
method O +
of O +
Greenwood O +
et O +
al. O +
( O -
1963 O -
) O -
. O -

Iodination O +
was O +
carried O +
out O +
in O +
0.45 O +
ml O +
of O +
pH O +
8 O +
BBS O +
containing O +
200 O +
Ug O +
( O -
ca O -
. O -

3 O +
n O -
- O -
mole O -
) O +
RSA O -
- O -
APPC O -
, O +
1 O +
n O -
- O -
mole O +
of O +
KI O -
, O +
0.4 O +
mCi O +
of O +
' O -
ZSI O +
and O +
300 O +
n O -
- O -
mole O +
of O +
chloromine O +
T. O +
The O +
reaction O +
was O +
allowed O +
to O +
proceed O +
for O +
30 O +
min O -
, O +
stopped O +
with O +
300 O +
n O -
- O -
mole O +
of O +
bisulfite O +
and O +
the O +
product O +
dialyzed O +
to O +
remove O +
free O +
" O -
' O -
I O +
and O +
reagents O -
. O -

Measurement O +
of O +
K O -
, O -
e O -
, O -
The O +
method O +
used O +
to O +
obtain O +
the O +
relative O +
binding O +
constants O +
for O +
the O +
various O +
haptens O +
is O +
based O +
on O +
the O +
technique O +
originally O +
developed O +
by O +
Skom O +
& O +
Talmadge O +
( O -
1958 O -
) O +
for O +
precipitating O +
antigen O -
- O -
antibody O +
complexes O +
with O +
antiglobulin O -
. O -

In O +
our O +
assay O +
the O +
primary O +
haptenic O +
determinant O -
, O +
p O -
- O -
azophenylphosphory1choline O -
, O +
was O +
coupled O +
to O +
rabbit U-Species +
serum O +
albumin O +
which O +
was O +
then O +
trace O +
labeled O +
with O +
1251 O -
. O -

Labeled O +
antigen O +
was O +
mixed O +
with O +
varying O +
amounts O +
of O +
antibody O +
and O +
the O +
amount O +
of O +
antigen O +
bound O +
was O +
determined O +
by O +
precipitating O +
all O +
the O +
gamma O +
globulin O +
( O -
i.e. O +
bound O +
and O +
unbound O +
antibody O +
as O +
well O +
as O +
non O -
- O -
specific O +
y O +
globulin O -
) O +
with O +
goat U-Species +
antiglobulin O +
antibody O +
and O +
measuring O +
the O +
radioactivity O +
associated O +
with O +
the O +
precipitate O -
. O -

Relative O +
binding O +
constants O +
( O -
K O -
, O -
e O -
, O -
) O +
for O +
the O +
different O +
haptens O +
were O +
determined O +
by O +
measuring O +
their O +
ability O +
to O +
inhibit O +
the O +
reaction O +
of O +
labeled O +
antigen O +
with O +
antibody O -
. O -

The O +
amount O +
of O +
antibody O +
was O +
chosen O +
so O +
that O +
about O +
60 O -
% O +
of O +
the O +
labeled O +
antigen O +
was O +
bound O +
by O +
antibody O +
in O +
the O +
absence O +
of O +
hapten O -
. O -

In O +
a O +
typical O +
determination O +
the O +
antigen O +
solution O +
was O +
made O +
to O +
contain O +
100 O +
ng O +
per O +
ml O +
of O +
1251-RSA O -
- O -
APPC O +
and O +
1 O +
mg O -
/ O -
ml O +
of O +
RSA O +
in O +
pH O +
8 O +
BBS O -
. O -

The O +
required O +
concentration O +
of O +
antibody O +
was O +
made O +
up O +
in O +
normal O +
rabbit U-Species +
serum O +
diluted O +
1:5 O +
with O +
pH O +
8 O +
BBS O -
. O -

HOPC-8 O +
myeloma O +
protein O +
was O +
made O +
up O +
in O +
normal O +
mouse U-Species +
serum O +
diluted O +
1:5 O -
. O -

To O +
0.1 O +
ml O +
of O +
antibody O +
( O -
or O +
HOPC-8 O -
) O +
solution O +
were O +
added O -
, O +
0.1 O +
ml O +
' O -
251-RSA O -
- O -
APPC O +
solution O +
and O +
0.1 O +
ml O +
hapten O +
solution O +
in O +
pH O +
8 O +
BBS O -
. O -

Hapten O +
concentrations O +
ranged O +
from O +
10 O -
' O +
to O +
10-'M. O +
In O +
one O +
sample O +
( O -
uninhibited O -
) O -
, O +
hapten O +
solution O +
was O +
replaced O +
by O +
buffer O +
to O +
determine O +
the O +
amount O +
of O +
antigen O +
precipitated O +
in O +
the O +
absence O +
of O +
hapten O -
. O -

Another O +
mixture O +
( O -
non O -
- O -
specific O +
control O -
) O +
contained O +
0.1 O +
ml O +
1:5 O +
diluted O +
normal O +
rabbit U-Species +
( O -
or O +
mouse U-Species -
) O +
serum O +
in O +
place O +
of O +
antibody O -
, O +
0.1 O +
ml O +
of O +
antigen O +
and O +
0.1 O +
ml O +
of O +
buffer O -
. O -

All O +
tubes O +
were O +
incubated O +
at O +
37 O +
for O +
30 O +
min O -
. O -

Then O +
0.2 O +
ml O +
of O +
anti O -
- O -
globulin O +
antiserum O +
was O +
added O +
to O +
all O +
tubes O -
. O -

The O +
amount O +
added O +
was O +
that O +
determined O +
to O +
be O +
sufficient O +
to O +
precipitate O +
all O +
the O +
globulin O +
in O +
the O +
mixture O -
. O -

Goat U-Species +
anti O -
- O -
rabbit U-Species +
y O -
- O -
globulin O +
was O +
used O +
to O +
precipitate O +
the O +
rabbit U-Species +
antibodies O +
and O +
rabbit U-Species +
anti O -
- O -
mouse U-Species +
IgA O +
was O +
used O +
to O +
precipitate O +
the O +
HOPC-8 O +
myeloma O +
protein O -
. O -

The O +
reaction O +
mixtures O +
were O +
allowed O +
to O +
stand O +
at O +
room O +
temperature O +
for O +
1 O +
hr O -
, O +
and O +
then O +
stored O +
at O +
5 O +
overnight O -
. O -

The O +
tubes O +
were O +
centrifuged O -
, O +
the O +
supernatants O +
discarded O +
and O +
the O +
precipitates O +
washed O +
twice O +
with O +
saline O -
. O -

Radioactivity O +
in O +
the O +
precipitates O +
was O +
determined O -
. O -

All O +
determinations O +
were O +
done O +
in O +
duplicate O -
. O -

Per O +
cent O +
inhibition O +
is O +
given O +
by O -
: O -
Inhibition O +
= O +
f O +
1 O -
ANTI O -
- O -
APPC O +
# O -
6055 O -
loo O -
50 O -
01 O -
10 O -
- O -
6 O +
10 O -
- O -
5 O -
NPPC O -
GPC O -
, O -
Pc O -
P03 O -
I_AD O -
CHOLINE O -
10 O +
4 O +
10 O -
- O -
3 O +
10-z O +
10 O +
I O -
INHIBITOR O +
CONC O -
. O -

( O -
M O -
) O -
Fig. O +
1 O -
. O -

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O -
of O +
RSA O -
- O -
APPC O +
antigen O +
to O +
anti O -
- O -
APPC O +
antibody O +
from O +
rabbit B-Species -
6055 L-Species -
. O -

Values O +
determined O +
in O +
this O +
manner O +
were O +
reproducible O +
to O +
within O +
% O -
. O -

RESULTS O -
Plots O +
of O +
effect O +
of O +
hapten O +
on O +
antigen O +
binding O +
are O +
given O +
in O +
Fig. O +
1 O +
for O +
anti O -
- O -
APPC O +
from O +
rabbit B-Species +
6055 L-Species +
and O +
in O +
Fig. O +
2 O +
for O +
anti O -
- O -
APPC O +
from O +
rabbit B-Species +
5920 L-Species -
. O -

The O +
plots O +
for O +
anti O -
- O -
APPC O +
from O +
rabbit B-Species +
6057 L-Species -
, O +
were O +
essentially O +
identical O +
to O +
those O +
in O +
Fig. O +
1 O -
. O -

From O +
these O +
data O -
, O +
K O -
, O -
el O +
values O +
were O +
calculated O +
relative O +
to O +
the O +
most O +
inhibitory O +
hapten O -
, O +
NPPC O -
, O +
according O +
to O +
the O +
formula O -
: O -
_ O +
( O -
NPPC O -
) O +
at O +
50 O -
% O +
inhibition O -
K O -
" O -
' O +
( O -
HAPTEN O -
) O +
at O +
50 O -
% O +
inhibition O -
The O +
values O +
of O +
K O -
, O -
e O -
, O +
are O +
given O +
in O +
Table O +
1 O -
. O -

The O +
only O +
effective O +
inhibitors O +
observed O +
are O +
those O +
listed O +
in O +
Table O +
1 O -
, O +
having O +
K O -
, O -
e O -
, O +
values O +
> O +
0.0001 O -
. O -

It O +
is O +
interesting O +
that O +
the O +
p O -
- O -
iodophenyltrimethylammonium O +
ion O +
gave O +
detectable O +
inhibition O +
in O +
2 O +
instances O -
. O -

Twentyfive O +
other O +
haptens O +
were O +
tested O -
. O -

None O +
showed O +
appreciable O +
binding O +
to O +
anti O -
- O -
APPC O +
antibodies O -
. O -

Among O +
those O +
tested O +
were O +
negatively O +
and O +
positively O +
chargen O +
haptens O -
, O +
including O +
other O +
phenyltrimethylammonium O +
ions O +
and O -
ANTI O -
- O -
APPC O +
# O -
5920 O -
loo O -
50 O -
z O -
x O -
NPPC O -
, O -
GPC O +
I O -
- O -
AP O -
PC O -
CHOLINE O -
0 O -
10 O -
- O -
6 O +
10 O -
- O -
5 O +
10 O +
4 O +
10 O -
- O -
3 O +
10-z O -
10-I O -
INHIBITOR O +
CONC. O -
( O -
M O -
) O -
Fig. O +
2 O -
. O -

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O -
of O +
RSA O -
- O -
APPC O +
antigen O +
to O +
anti O -
- O -
APPC O +
antibody O +
from O +
rabbit U-Species -
5920 U-Species -
. O -

inhibited O +
sample O +
counts O -
/ O -
min O -
- O -
non O -
- O -
specific O +
control O +
counts O -
/ O -
min O -
uninhibited O +
sample O +
counts O -
/ O -
min O -
- O -
non O -
- O -
specific O +
control O +
counts O -
/ O -
min O +
x O +
100 O -
. O -

Specificity O +
of O +
Anti O -
- O -
p O -
- O -
Azophenylphosphorylcholine O +
Antibodies O -
Table O +
1 O -
. O -

Relative O +
binding O +
constants O +
of O +
haptens O +
for O +
anti O -
APPC O +
antibodies O -
Hapten O -
NPPC O -
t O -
.- O -
a O -
- O -
glycerophosphorylcholine O -
Phosphorylcholine O -
I O -
- O -
Ap O -
Choline O -
Phenylphosphonate O -
Phenylphosphate O -
Rabbit U-Species +
No. O -
5920 O +
6055 O +
6057 O -
K O -
1.0 O -
0.015 O -
0.0003 O -
0.004 O -
0.0007 O -
0.0001 O -
0.0001 O -
1.0 O -
1.0 O -
0.019 O -
0.016 O -
0.0004 O -
0.0005 O -
0.0001 O +
< O +
0.0001 O -
0.00006 O -
0.00006 O -
0.0002 O +
< O +
0.0001 O -
0.0001 O +
< O +
0.0001 O -
several O +
phenylarsonates O +
and O +
sulfonates O -
. O -

A O +
representative O +
list O +
of O +
some O +
of O +
these O +
non O -
- O -
inhibitory O +
haptens O +
is O +
given O +
in O +
Table O +
2 O -
. O -

The O +
results O +
of O +
inhibition O +
studies O +
with O +
the O +
mouse U-Species +
myeloma O +
protein O +
HOPC-8 O +
are O +
given O +
in O +
Fig. O +
3 O +
where O +
the O +
inhibition O +
curves O +
are O +
drawn O +
only O +
for O +
those O +
haptens O +
showing O +
significant O +
ability O +
to O +
inhibit O -
. O -

K O -
, O -
e O -
, O +
values O +
were O +
calculated O +
as O +
described O +
above O +
and O +
are O +
listed O +
in O +
Table O +
3 O -
. O -

For O +
comparison O -
, O +
Table O +
3 O +
also O +
lists O +
values O +
of O +
K O -
, O -
el O +
calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
( O -
1971 O -
) O +
for O +
TEPC-15 O +
in O +
a O +
system O +
using O +
the O +
C O -
- O -
polysaccharide O +
of O +
pneumococcus U-Species +
as O +
an O +
antigen O -
. O -

There O +
is O +
adequate O +
serological O +
and O +
chemical O +
evidence O +
showing O +
that O +
HOPC-8 O +
and O +
TEPC-15 O +
are O +
nearly O +
identical O +
proteins O +
( O -
Potter O +
& O +
Lieberman O -
, O +
1970 O -
; O +
Hood O +
et O +
al. O -
, O +
1970 O -
) O -
. O -

The O +
values O +
in O +
Table O +
3 O +
show O +
the O +
close O +
correspondence O +
between O +
our O +
values O +
of O +
K O -
, O -
e O -
, O +
for O +
HOPC-8 O +
and O +
those O +
calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
for O +
TECP-15 O -
. O -

The O +
K O -
, O -
e O -
, O +
values O +
for O +
anti O -
- O -
APPC O +
from O +
rabbit U-Species +
6055 U-Species +
are O +
also O +
listed O +
in O +
Table O +
3 O +
to O +
facilitate O +
comparisons O +
with O +
HOPC-8 O -
. O -

In O +
order O +
to O +
assess O +
further O +
the O +
validity O +
of O +
the O +
inhibition O +
method O +
as O +
used O +
here O +
for O +
obtaining O +
Kre O -
, O +
values O -
, O +
we O +
have O +
compared O +
the O +
value O +
of O +
K O -
, O -
e O -
, O +
calculated O +
from O +
the O +
individual O +
binding O +
constants O +
of O +
HOPC-8 O +
for O +
phosphory1choline O +
( O -
PC O -
) O +
and O +
p O -
- O -
nitrophenylphosphorylcholine O +
( O -
NPPC O -
) O +
as O +
determined O +
by O +
equilibrium O +
dialysis O -
, O +
to O +
the O +
Kre O -
, O +
values O +
calculated O +
from O +
the O +
inhibition O +
data O -
. O -

As O +
measured O +
by O +
equilibrium O +
dialysis O +
with O +
HOPC-8 O +
the O +
binding O +
constant O +
for O +
PC O +
( O -
KPc O -
) O +
was O +
found O +
to O +
be O +
1.2 O +
x O +
106 O +
M-1 O +
and O +
for O +
NPPC O +
the O +
KNPPC O +
was O +
0.43 O +
x O +
106 O +
M-1 O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
. O -

The O +
ratio O +
of O +
the O +
two O +
is O -
: O -
1.20 O +
x O +
106 O +
_ O -
KPCIKNPPC O +
- O +
0.43 O +
x O +
106 O +
- O +
2.8 O -
. O -

Table O +
2 O -
. O -

Haptens O +
unable O +
to O +
inhibit O +
binding O +
of O +
RSA O -
- O -
APPC O +
to O +
anti O -
- O -
APPC O +
antibodies O -
" O -
Acetylcholine O +
Phenyltrimethylammonium O +
p O -
- O -
Aminophenyltrimethylammonium O +
chloride O +
Phenylarsonate O +
p O -
- O -
Nitrophenylarsonate O +
p O -
- O -
lodophenylarsonate O +
Hydroxyphenylazo O -
) O -
phenylarsonate O +
p O -
- O -
lodobenzenesulfonate O +
Naphthalene O -
- O -
l O -
- O -
sulfonate O +
5-Nitro-3-iodo-4-hydroxyphenylacetate O +
5-Nitro-4-hydroxyphenylacetate O -
Kre O -
, O +
< O -
0.0001 O -
, O +
relative O +
to O +
NPPC O -
, O +
which O +
is O +
equivalent O +
to O +
< O +
50 O -
% O +
inhibition O +
at O +
0.1 O +
M O +
hapten O +
concentration O -
. O -

903 O -
HOPC-8 O -
100 O -
PC O +
WPC O -
I O -
- O -
Ap O -
GPC O -
AcC O -
m O -
50 O -
z O -
_ O -
< O -
60P O -
Y O -
, O +
OOPO=3 O -
~ O +
OP O -
03 O -
0 O -
ITS O +
I O -
I O -
INHIBITOR O +
CONC O -
. O -

( O -
M O -
) O -
IT O +
2 O +
IT O +
l O -
Fig. O +
3 O -
. O -

Plots O +
of O +
the O +
inhibition O +
by O +
haptens O +
of O +
the O +
binding O -
of O +
RSA O -
- O -
APPC O +
antigen O +
to O +
mouse U-Species +
myeloma O +
protein O -
HOPC-8 O -
. O -

The O +
ratio O +
obtained O +
using O +
K O -
, O -
e O -
, O +
values O +
obtained O +
by O +
hapten O +
inhibition O +
( O -
Table O +
3 O -
) O +
is O +
2.9 O -
, O +
a O +
satisfactory O +
agreement O -
. O -

DISCUSSION O -
The O +
relative O +
binding O +
constants O +
( O -
K O -
, O -
, O -
, O -
) O +
for O +
haptens O +
to O +
anti O -
- O -
APPC O +
antibodies O +
were O +
determined O +
by O +
hapten O +
inhibition O -
. O -

About O +
30 O +
potential O +
ligands O +
were O +
tested O +
and O +
only O +
5 O +
of O +
these O +
were O +
shown O +
to O +
bind O +
significantly O +
( O -
NPPC O -
, O +
glycerophosphorylcholine O -
, O +
I O -
- O -
Ap O -
, O +
choline O +
and O +
phosphorylcholine O -
) O -
. O -

The O +
values O +
of O +
K O -
, O -
, O -
, O +
obtained O +
with O +
the O +
several O +
haptens O +
allow O +
inferences O +
as O +
to O +
the O +
relative O +
importance O +
of O +
the O +
particular O +
structural O +
features O +
of O +
each O +
hapten O +
in O +
contributing O +
to O +
the O +
binding O +
energy O -
. O -

The O +
rabbit U-Species +
anti O -
- O -
APPC O +
antibodies O +
studied O +
here O +
were O +
raised O +
against O +
a O +
hapten O +
having O +
3 O +
distinct O +
structural O +
features O -
- O -
a O +
p O -
- O -
azophenyl O +
group O -
, O +
a O +
negatively O +
charged O +
phosphoryl O +
ester O +
group O -
, O +
and O +
a O +
positively O +
charged O +
quarternary O +
ammonium O +
group O -
. O -

Of O +
these O -
, O +
the O +
one O +
apparently O +
very O +
important O +
for O +
binding O +
is O +
the O +
positively O +
charged O +
group O -
, O +
since O +
haptens O +
which O +
were O +
most O +
effective O +
in O +
inhibiting O +
the O +
binding O +
of O +
the O +
APPC O -
- O -
containing O +
antigen O +
to O +
antibody O +
contained O +
this O +
group O +
( O -
Table O +
1 O -
) O +
and O +
those O +
least O +
effective O +
did O +
not O -
. O -

Thus O -
, O +
removal O +
of O +
the O +
choline O +
group O +
from O +
phenylphosphorylcholine O +
decreases O +
its O +
binding O +
strength O +
by O +
a O +
factor O +
of O +
about O -
Table O +
3 O -
. O -

Comparison O +
of O +
K O -
, O -
e O -
, O +
values O +
for O +
HOPC-8 O -
, O +
TEPC-15 O +
and O +
a O +
rabbit U-Species +
anti O -
- O -
APPC O +
antibody O -
Hapten O -
HOPC-8 O -
2.9 O -
1.0 O -
0.5 O -
0.033 O -
0.015 O -
0.01 O -
" O -
0.001 O -
< O +
0.0001 O -
Rabbit U-Species +
anti O -
APPC O -
- O -
No O -
. O -

6055 O -
K O -
, O +
TEPC-15 O -
Phosphorylcholine O -
NPPC O -
-a O -
- O -
glycerophosphorylchole O -
I O -
- O -
Ap O -
Acetylcholine O -
Choline O -
Phenylphosphate O -
Phenylphosphonate O -
2.9 O -
0.0004 O -
1.0 O -
0.019 O -
0.0001 O -
0.0001 O +
0.008 O -
0.00006 O +
0.005 O -
0.0001 O +
- O -
0.0002 O +
- O -
0.27 O -
Calculated O +
from O +
the O +
data O +
of O +
Leon O +
& O +
Young O +
( O -
1971 O -
) O +
for O +
the O +
inhibition O +
of O +
binding O +
of O +
c O -
- O -
polysaccharide O +
of O +
Pneumococcus U-Species -
. O -

The O +
values O +
were O +
obtained O +
by O +
setting O +
the O +
Kre O -
, O +
value O +
for O +
phosphorylchole O +
at O +
2.9 O +
and O +
calculating O +
the O +
other O +
values O +
relative O +
to O +
this O -
. O -

" O -
Estimated O +
from O +
the O +
value O +
of O +
Kre O -
, O +
for O +
choline O +
with O +
TEPC-15 O -
. O -

904 O -
L. O +
M. O +
KRAUSZ O -
, O +
A. O +
L. O +
GROSSBERG O +
and O +
D. O +
PRESSMAN O -
10,000 O +
since O +
K O -
, O -
e O -
, O +
for O +
phenylphosphate O +
was O +
at O +
least O +
this O +
much O +
smaller O +
than O +
the O +
K O -
, O -
e O -
, O +
for O +
NPPC O +
( O -
Table O +
1 O -
) O -
. O -

Moreover O -
, O +
p O -
- O -
iodophenyltrimethylammonium O +
gave O +
detectable O +
inhibition O +
with O +
one O +
anti O -
- O -
APPC O +
preparation O -
, O +
although O +
its O +
structure O +
is O +
otherwise O +
rather O +
different O +
from O +
the O +
choline O +
inhibitors O -
. O -

The O +
p O -
- O -
nitrophenyl O +
group O +
of O +
NPPC O +
contributes O +
very O +
effectively O +
to O +
the O +
specific O +
interaction O -
, O +
since O +
replacing O +
it O +
by O +
the O +
glycerol O +
group O +
decreases O +
the O +
binding O +
by O +
a O +
factor O +
of O +
50 O +
( O -
Table O +
1 O -
) O -
. O -

Similarly O -
, O +
removing O +
the O +
p O -
- O -
nitrophenyl O +
group O -
, O +
to O +
give O +
phosphorylcholine O -
, O +
decreases O +
the O +
binding O +
by O +
another O +
factor O +
of O +
50 O +
( O -
Table O +
1 O -
) O +
so O +
that O +
phosphorylcholine O +
binds O +
2500 O +
times O +
more O +
weakly O +
than O +
NPPC O -
. O -

The O +
negatively O +
charged O +
phosphoryl O +
group O +
apparently O +
interacts O +
only O +
to O +
a O +
small O +
extent O +
with O +
the O +
antibody O +
site O -
. O -

This O +
is O +
evident O +
from O +
the O +
fact O +
that O +
K O -
, O -
, O -
, O +
for O +
phosphorylcholine O +
is O +
only O +
6 O -
- O -
8 O +
times O +
greater O +
than O +
Kre O -
, O +
for O +
choline O +
for O +
2 O +
antibody O +
preparations O +
studied O +
and O +
is O +
actually O +
smaller O +
than O +
that O +
for O +
choline O +
for O +
the O +
third O +
antibody O +
preparation O +
( O -
Table O +
1 O -
) O -
. O -

In O +
addition O -
, O +
phenylphosphate O +
( O -
Table O +
2 O -
) O +
and O +
phenylphosphonate O +
( O -
Table O +
1 O -
) O +
show O +
only O +
weak O +
binding O +
to O +
the O +
antibodies O -
. O -

Thus O +
the O +
contribution O +
of O +
the O +
negative O +
charge O +
to O +
binding O +
is O +
not O +
great O -
, O +
in O +
spite O +
of O +
the O +
fact O +
that O +
we O +
have O +
previously O +
shown O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O +
that O +
a O +
positively O +
charged O +
arginyl O +
residue O +
is O +
present O +
in O +
the O +
anti O -
- O -
APPC O +
antibody O +
site O -
, O +
providing O +
a O +
basis O +
for O +
electrostatic O +
interaction O +
with O +
the O +
phosphoryl O +
group O -
. O -

When O +
the O +
rabbit U-Species +
anti O -
- O -
APPC O +
antibodies O +
are O +
compared O +
to O +
the O +
mouse U-Species +
myeloma O +
protein O -
, O +
HOPC-8 O -
, O +
some O +
very O +
obvious O +
differences O +
in O +
specificity O +
are O +
apparent O -
. O -

In O +
general O +
HOPC-8 O +
shows O +
broader O +
cross O -
- O -
reactivity O +
than O +
the O +
induced O +
rabbit U-Species +
antibody O -
. O -

The O +
representative O +
comparison O +
of O +
K O -
, O -
e O -
, O +
values O +
( O -
relative O +
to O +
NPPC O -
) O +
given O +
in O +
Table O +
3 O -
, O +
indicates O +
that O +
many O +
more O +
of O +
the O +
compounds O +
listed O +
show O +
appreciable O +
binding O +
( O -
K O -
, O -
e O -
, O +
> O +
0.005 O -
) O +
to O +
HOPC-8 O +
than O +
to O +
rabbit U-Species +
anti O -
- O -
APPC O -
. O -

In O +
addition O -
, O +
the O +
fine O +
specificity O +
of O +
HOPC-8 O +
is O +
quite O +
different O +
from O +
that O +
of O +
the O +
rabbit U-Species +
antibody O -
, O +
since O +
the O +
relative O +
binding O +
constant O +
for O +
phosphorylcholine O +
is O +
10 O -
' O +
greater O +
with O +
HOPC-8 O +
than O +
with O +
rabbit U-Species +
anti O -
- O -
APPC O -
. O -

The O +
binding O +
to O +
the O +
2 O +
proteins O +
differs O +
for O +
glycerophosphorylcholine O +
by O +
a O +
factor O +
of O +
25 O -
, O +
for O +
chohne O +
by O +
a O +
factor O +
of O +
100 O +
and O +
for O +
acetylcholine O +
by O +
a O +
factor O +
greater O +
than O +
100 O -
. O -

The O +
negatively O +
charged O +
phosphoryl O +
group O +
appears O +
to O +
be O +
much O +
more O +
important O +
for O +
binding O +
to O +
HOPC-8 O +
than O +
to O +
the O +
rabbit U-Species +
antibody O -
, O +
since O +
the O +
K- O -
, O +
value O +
for O +
phosphorylcholine O +
is O +
greater O +
than O +
that O +
for O +
choline O +
by O +
a O +
factor O +
of O +
about O +
300 O +
in O +
the O +
case O +
of O +
HOPC-8 O -
. O -

For O +
rabbit U-Species +
antibody O +
this O +
factor O +
is O +
only O +
about O +
10 O +
( O -
Table O +
3 O -
) O -
. O -

Moreover O -
, O +
phenylphosphate O +
binds O +
more O +
than O +
10 O +
times O +
more O +
strongly O +
to O +
HOPC-8 O +
than O +
to O +
anti O -
- O -
APPC O +
antibody O -
. O -

This O +
is O +
in O +
spite O +
of O +
the O +
fact O +
that O +
the O +
addition O +
of O +
the O +
p O -
- O -
nitrophenyl O +
group O +
to O +
phosphorylcholine O +
neither O +
adds O +
to O +
nor O +
subtracts O +
from O +
the O +
binding O +
energy O +
with O +
HOPC-8 O -
, O +
whereas O +
it O +
adds O +
a O +
great O +
deal O +
to O +
the O +
binding O +
energy O +
with O +
anti O -
- O -
APPC O +
antibody O -
. O -

The O +
fact O +
that O +
the O +
HOPC-8 O +
site O +
is O +
large O +
enough O +
to O +
accommodate O +
the O +
p O -
- O -
nitrophenyl O +
group O +
of O +
NPPC O +
with O +
little O +
steric O +
hindrance O +
is O +
of O +
interest O -
, O +
since O +
the O +
site O +
of O +
McPC-603 O +
protein O -
, O +
which O +
also O +
binds O +
phosphorylcholine O +
analogues O +
with O +
similar O +
although O +
not O +
identical O +
specificity O +
( O -
Leon O +
& O +
Young O -
, O +
1971 O -
) O +
also O +
can O +
accommodate O +
a O +
large O +
substituent O +
on O +
phosphorylcholine O -
. O -

Thus O -
, O +
the O +
X O -
- O -
ray O +
crystallographic O +
structure O +
studies O +
of O +
the O +
Fab O -
fragment O +
of O +
McPC-603 O +
as O +
summarized O +
by O +
Segal O +
et O +
al. O +
( O -
1974 O -
) O +
indicate O +
that O +
there O +
is O +
a O +
large O +
region O +
of O +
the O +
cleft O +
in O +
which O +
phosphorylcholine O +
is O +
bound O +
which O +
is O +
available O +
for O +
binding O +
additional O +
structure O -
. O -

Indeed O -
, O +
one O +
of O +
the O +
compounds O +
used O +
in O +
defining O +
the O +
site O +
region O +
was O +
2- O -
( O -
5'-acetoxy O -
- O -
mercury-2'-thiemyl O -
) O -
-ethylphosphory1choline O +
( O -
Padlan O +
et O +
al. O -
, O +
1973 O -
) O -
. O -

Our O +
studies O +
suggest O +
that O +
this O +
large O +
compound O +
might O +
bind O +
equally O +
as O +
well O +
to O +
the O +
HOPC-8 O +
site O +
as O +
to O +
the O +
McPC-603 O +
site O -
. O -

The O +
differences O +
between O +
HOPC-8 O +
sites O +
and O +
rabbit U-Species +
anti O -
- O -
APPC O +
sites O +
are O +
interesting O +
in O +
view O +
of O +
the O +
fact O +
that O +
when O +
APPC O +
conjugated O +
to O +
protein O +
is O +
used O +
as O +
an O +
immunogen O +
in O +
the O +
BALB B-Species -
/ I-Species -
c I-Species +
mouse L-Species -
, O +
the O +
IgM O +
antibodies O +
elicited O +
are O +
largely O +
of O +
the O +
HOPC-8-TEPC-15 O +
idiotype O +
and O +
show O +
the O +
same O +
binding O +
characteristics O +
as O +
the O +
myeloma O +
proteins O +
( O -
Lee O +
it O +
al. O -
, O +
1974 O -
) O -
. O -

Thus O +
it O +
appears O +
that O +
the O +
receptor O +
sites O +
on O +
cells O +
responding O +
to O +
APPC O +
in O +
the O +
rabbits U-Species +
we O +
used O +
are O +
quite O +
different O +
in O +
structure O +
from O +
sites O +
on O +
cells O +
which O +
respond O +
in O +
the O +
mouse U-Species -
. O -

Furthermore O -
, O +
we O +
have O +
previously O +
observed O +
that O +
the O +
rabbit U-Species +
antibodies O +
are O +
rather O +
heterogeneous O -
, O +
as O +
evidenced O +
by O +
their O +
non O -
- O -
linear O +
binding O +
curves O +
( O -
Krausz O +
et O +
al. O -
, O +
1976 O -
) O -
, O +
and O +
their O +
complex O +
isoelectric O +
focusing O +
patterns O +
( O -
Nutt O +
et O +
al. O -
, O +
1976 O -
) O -
. O -

Populations O +
of O +
anti O -
- O -
APPC O +
antibodies O +
produced O +
also O +
differ O +
from O +
rabbit U-Species +
to O +
rabbit U-Species +
as O +
evidenced O +
by O +
the O +
differences O +
in O +
binding O +
strength O +
for O +
p O -
- O -
iodophenyltrimethylammonium O +
and O +
for O +
choline O +
shown O +
by O +
antibodies O +
from O +
rabbits U-Species +
6055 U-Species +
and O +
5920 U-Species +
( O -
Table O +
1 O -
) O -
. O -

On O +
the O +
other O +
hand O -
, O +
the O +
induced O +
mouse U-Species +
antibodies O +
appear O +
to O +
be O +
essentially O +
monoclonal O +
products O +
( O -
Lee O +
et O +
al. O -
, O +
1974 O -
) O -
. O -

There O +
are O -
, O +
of O +
course O -
, O +
some O +
similarities O +
between O +
the O +
rabbit U-Species +
antibodies O +
and O +
HOPC-8 O -
. O -

The O +
major O +
of O +
these O +
is O +
that O +
for O +
both O +
binding O +
sites O +
the O +
positively O +
charged O +
quarternary O +
ammonium O +
group O +
appears O +
to O +
be O +
the O +
immunodominant O +
group O -
, O +
since O +
those O +
haptens O +
not O +
containing O +
this O +
group O +
are O +
bound O +
very O +
poorly O +
in O +
both O +
cases O +
( O -
Table O +
3 O -
) O -
. O -

Thus O +
a O +
negatively O +
charged O +
carboxylate O +
group O +
which O +
would O +
interact O +
with O +
this O +
group O -
, O +
and O +
which O +
we O +
have O +
shown O +
to O +
be O +
present O +
in O +
the O +
combining O +
site O +
of O +
both O +
HOPC-8 O +
and O +
anti O -
- O -
APPC O +
antibodies O -
, O +
is O +
probably O +
the O +
most O +
important O +
common O +
feature O +
of O +
both O +
sites O -
. O -

The O +
above O +
considerations O +
allow O +
us O +
to O +
make O +
the O +
following O +
inferences O +
about O +
the O +
topography O +
of O +
the O +
antiAPPC O +
and O +
HOPC-8 O +
binding O +
sites O -
: O -
( O -
1 O -
) O +
The O +
anti O -
- O -
APPC O +
site O +
contains O +
a O +
region O +
closely O +
complementary O +
to O +
the O +
phenyl O +
group O +
of O +
APPC O -
, O +
so O +
that O +
an O +
appreciable O +
part O +
ofAhe O +
binding O +
interaction O +
occurs O +
in O +
this O +
region O -
. O -

The O +
HOPC-8 O +
site O +
accommodates O +
the O +
phenyl O +
group O +
with O +
little O +
interaction O +
energy O -
. O -

( O -
2 O -
) O +
An O +
arginyl O +
residue O +
in O +
the O +
HOPC-8 O +
site O +
contributes O +
a O +
positive O +
charge O +
which O +
interacts O +
strongly O +
with O +
the O +
negative O +
charge O +
on O +
the O +
phosphoryl O +
group O -
. O -

In O +
the O +
anti O -
- O -
APPC O +
site O -
, O +
which O +
also O +
contains O +
an O +
arginyl O +
residue O -
, O +
the O +
interaction O +
with O +
the O +
phosphoryl O +
group O +
is O +
much O +
weaker O -
, O +
and O +
therefore O +
the O +
2 O +
groups O +
are O +
probably O +
farther O +
apart O +
than O +
in O +
the O +
HOPC-8 O +
site O -
. O -

( O -
3 O -
) O +
Both O +
sites O +
interact O +
strongly O +
with O +
the O +
quaternary O +
ammonium O +
group O +
of O +
choline O +
and O +
thus O +
this O +
group O +
probably O +
closely O +
approaches O +
a O +
carboxylate O +
group O +
present O +
in O +
both O +
sites O -
. O -

Acknowledgements O -
- O -
We O +
thank O +
Messrs. O +
Robert O +
Hewson O -
, O +
Leonard O +
Rendina O +
and O +
Arthur O +
Trott O +
for O +
expert O +
technical O +
assistance O -
. O -

Specificity O +
of O +
Anti O -
- O -
p O -
- O -
Azophenylphosphorylcholine O +
Antibodies O -

Manganous O +
chloride O +
and O +
Congo O +
red O +
incorporated O +
into O +
blotting O +
paper O +
discs O +
have O +
been O +
used O +
to O +
differentiate O +
gonococci U-Species +
from O +
meningococci U-Species -
. O -

The O +
new O +
technique O +
is O +
simple O +
and O +
reliable O -
; O +
the O +
materials O +
for O +
the O +
test O +
are O +
inexpensive O -
. O -

The O +
method O +
will O +
increase O +
the O +
efficiency O +
of O +
distinguishing O +
between O +
the O +
pathogenic O +
Neisseria U-Species +
in O +
any O +
clinical O +
bacteriology O +
laboratory O +
and O +
especially O +
in O +
those O +
in O +
the O +
tropical O +
areas O -
. O +

A O +
methodology O +
to O +
determine O +
the O +
intrinsic O +
capacities O +
of O +
a O +
microflora U-Species +
to O +
degrade O +
gasoline O +
was O +
developed O -
, O +
in O +
particular O +
for O +
assessing O +
the O +
potential O +
of O +
autochtonous O +
populations O +
of O +
polluted O +
and O +
non O +
polluted O +
soils O +
for O +
natural O +
attenuation O +
and O +
engineered O +
bioremediation O -
. O -

A O +
model O +
mixture O +
( O -
GM23 O -
) O +
constituted O +
of O +
the O +
23 O +
most O +
representative O +
hydrocarbons O +
of O +
a O +
commercial O +
gasoline O +
was O +
used O -
. O -

The O +
capacities O +
of O -
the O +
microflorae U-Species +
( O -
kinetics O +
and O +
extent O +
of O +
biodegradation O -
) O +
were O +
assessed O +
by O +
chromatographic O +
analysis O +
of O +
hydrocarbon O +
consumption O +
and O +
of O +
CO2 O +
production O -
. O -

The O +
degradation O +
of O +
the O +
components O +
of O +
GM23 O +
was O +
assayed O +
in O +
separate O +
incubations O +
of O +
each O +
component O +
and O +
in O +
the O +
complete O +
mixture O -
. O -

For O +
the O +
microflora U-Species +
of O +
an O +
unpolluted O +
spruce U-Species +
forest O +
soil O -
, O +
all O +
hydrocarbons O +
of O +
GM23 O +
except O +
cyclohexane O -
, O +
2,2,4- O +
and O +
2,3,4-trimethylpentane O +
isomers O +
were O +
degraded O +
to O +
below O +
detection O +
limit O +
in O +
28 O +
days O -
. O -

This O +
microflora U-Species +
was O +
reinforced O +
with O +
two O +
mixed O +
microbial O +
communities O +
selected O +
from O +
gasoline O -
- O -
polluted O +
sites O +
and O +
shown O +
to O +
degrade O +
cyclohexane O +
and O +
2,2,4-trimethylpentane O -
. O -

With O +
the O +
reinforced O +
microflora U-Species -
, O +
complete O +
degradation O +
of O +
GM23 O +
was O +
observed O -
. O -

The O +
degradation O +
patterns O +
of O +
individual O +
components O +
of O +
GM23 O +
were O +
similar O +
when O +
the O +
compounds O +
were O +
present O +
individually O +
or O +
in O +
the O +
GM23 O +
mixture O -
, O +
as O +
long O +
as O +
the O +
concentrations O +
of O +
2-ethyltoluene O +
and O +
trimethylbenzene O +
isomers O +
were O +
kept O +
sufficiently O +
low O +
( O -
< O +
or O +
= O +
35 O +
mg.l-1 O -
) O +
to O +
remain O +
below O +
their O +
inhibitory O +
level O -
. O +

The O +
first O +
acyclonucleosides O +
based O +
on O +
the O +
benzothiadiazine O +
dioxide O +
system O +
were O +
synthesized O +
following O +
the O +
silylation O +
procedure O -
. O -

Several O +
acyclic O +
moieties O -
, O +
including O +
acetoxyethoxymethyl O -
, O +
benzyloxymethyl O -
, O +
and O +
propargyloxymethyl O +
groups O -
, O +
were O +
introduced O -
. O -

Two O +
synthetic O +
strategies O +
were O +
designed O +
to O +
selectively O +
obtain O +
the O +
N-1 O +
or O +
N-3 O +
derivatives O -
. O -

Lipase O -
- O -
mediated O +
deacylation O +
was O +
used O +
for O +
the O +
deprotection O +
of O +
the O +
acyclonucleosides O -
. O -

Some O +
of O +
the O +
benzothiadiazine O +
dioxide O +
acyclonucleosides O -
, O +
in O +
particular O +
16 O -
, O +
proved O +
active O +
against O +
human O +
cytomegalovirus O +
( O -
CMV O -
) O +
at O +
concentrations O +
slightly O +
higher O +
than O +
that O +
found O +
for O +
ganciclovir O +
[ O -
50 O -
% O +
inhibitory O +
concentration O +
( O -
IC50 O -
) O +
= O +
3 O -
. O +
5 O -
- O -
3.7 O +
micrograms O -
/ O -
mL O -
, O +
cytotoxicity O +
( O -
CC50 O -
) O +
> O -
/= O +
40 O +
micrograms O -
/ O -
mL O -
, O +
MCC O +
= O +
20 O +
micrograms O -
/ O -
mL O -
] O -
. O -

Additionally O -
, O +
compound O +
16 O +
inhibited O +
the O +
replication O +
of O +
human O +
immunodeficiency O +
virus O +
type O +
1 O +
( O -
HIV-1 O -
) O +
and O +
HIV-2 O +
in O +
CEM O +
cells O +
at O +
concentrations O +
that O +
were O +
5-fold O +
lower O +
than O +
its O +
cytotoxic O +
concentration O -
. O +

To O +
examine O +
the O +
stereospecific O +
effects O +
of O +
lipoic O +
compounds O +
on O +
pyruvate O +
metabolism O -
, O +
the O +
effects O +
of O +
R O -
- O -
lipoic O +
acid O +
( O -
R O -
- O -
LA O -
) O -
, O +
S O -
- O -
lipoic O +
acid O +
( O -
S O -
- O -
LA O -
) O +
and O +
1,2-diselenolane-3-pentanoic O +
acid O +
( O -
Se O -
- O -
LA O -
) O +
on O +
the O +
activities O +
of O +
the O +
mammalian U-Species +
pyruvate O +
dehydrogenase O +
complex O +
( O -
PDC O -
) O +
and O +
its O +
catalytic O +
components O +
were O +
investigated O -
. O -

Both O +
S O -
- O -
LA O +
and O +
R O -
- O -
LA O +
markedly O +
inhibited O +
PDC O +
activity O -
; O +
whereas O +
Se O -
- O -
LA O +
displayed O +
inhibition O +
only O +
at O +
higher O +
concentrations O -
. O -

Examination O +
of O +
the O +
effects O +
on O +
the O +
individual O +
catalytic O +
components O +
indicated O +
that O +
Se O -
- O -
LA O +
inhibited O +
the O +
pyruvate O +
dehydrogenase O +
component O -
; O +
whereas O +
R O -
- O -
LA O +
and O +
S O -
- O -
LA O +
inhibited O +
the O +
dihydrolipoamide O +
acetyltransferase O +
component O -
. O -

The O +
three O +
lipoic O +
compounds O +
lowered O +
dihydrolipoamide O -
dehydrogrenase O +
( O -
E3 O -
) O +
activity O +
in O +
the O +
forward O +
reaction O +
by O +
about O +
30 O +
to O +
45 O -
% O -
. O -

The O +
kinetic O +
data O +
of O +
E3 O +
showed O +
that O +
both O +
R O -
- O -
LA O +
and O +
Se O -
- O -
LA O +
are O +
used O +
as O +
substrates O +
by O +
E3 O +
for O +
the O +
reverse O +
reaction O -
. O -

Decarboxylation O +
of O +
[ O -
1 O -
- O -
14C O -
] O -
pyruvate O +
via O +
PDC O +
by O +
cultured O -
HepG2 O +
cells O +
was O +
not O +
affected O +
by O +
R O -
- O -
LA O -
, O +
but O +
moderately O +
decreased O +
with O +
S O -
- O -
LA O +
and O +
Se O -
- O -
LA O -
. O -

These O +
findings O +
indicate O +
that O +
( O -
i O -
) O +
purified O +
PDC O +
and O +
its O +
catalytic O +
components O +
are O +
affected O +
by O +
lipoic O +
compounds O +
based O +
on O +
their O +
stereoselectivity O -
; O +
and O +
( O -
ii O -
) O +
the O +
oxidation O +
of O +
pyruvate O +
by O +
intact O +
HepG2 O +
cells O +
is O +
not O +
inhibited O +
by O +
R O -
- O -
LA O -
. O -

The O +
later O +
finding O +
with O +
the O +
intact O +
cells O +
is O +
in O +
support O +
of O +
therapeutic O +
role O +
of O +
R O -
- O -
LA O +
as O +
an O +
antioxidant O -
. O +

A O +
highly O +
sensitive O +
pre O -
- O -
column O +
HPLC O +
method O +
for O +
simultaneous O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
was O +
developed O -
. O -

The O +
analytes O +
were O +
labelled O +
with O +
4- O -
( O -
5,6-dimethoxy-2-phthalimidinyl O -
) O -
-2-methoxyphenylsulfonyl O +
chloride O +
at O +
70 O +
degrees O +
C O +
for O +
20 O +
min O -
. O -

The O +
derivatives O +
separated O +
on O +
tandem O +
reversed O -
- O -
phase O +
columns O -
by O +
a O +
gradient O +
elution O +
and O +
were O +
monitored O +
with O +
fluorescence O +
detection O +
at O +
318 O +
nm O +
( O -
excitation O -
) O +
and O +
392 O +
nm O +
( O -
emission O -
) O -
. O -

The O +
detection O +
limits O +
for O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
were O +
1 O -
- O -
5 O +
fmol O -
/ O -
injection O +
( O -
S O -
/ O -
N O +
= O +
3 O -
) O -
. O -

Urine O +
samples O +
were O +
treated O +
with O +
o O -
- O -
phthalaldehyde O -
, O +
followed O +
by O +
purification O +
on O +
a O +
Bond O +
Elut O +
C18 O +
column O +
before O +
conducting O +
the O +
labelling O +
reaction O -
. O -

Pro O -
- O -
Hyp O -
, O +
Pro O -
- O -
Gly O +
and O +
Pro O -
- O -
Pro O +
were O +
identified O +
as O +
prolyl O +
dipeptides O +
in O +
urine O -
. O -

The O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
relative O +
standard O +
deviations O +
were O +
1.5 O -
- O -
4.8 O +
and O +
1.7 O -
- O -
5.8 O -
% O -
, O +
respectively O -
. O -

The O +
concentrations O +
of O +
Pro O -
- O -
Hyp O -
, O +
Pro O -
- O -
Gly O -
, O +
Pro O -
- O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
in O +
normal O +
human U-Species +
urine O +
were O +
97.6 O +
+ O -
/- O -

28.2 O -
, O -
2.74 O +
+ O -
/- O -

1.48 O -
, O +
2.08 O +
+ O -
/- O -

1.13 O -
, O +
6.71 O +
+ O -
/- O -

3.34 O +
and O +
2.30 O +
+ O -
/- O -

1.59 O +
nmol O -
/ O -
mg O +
creatinine O -
, O +
respectively O -
. O +

An O +
enzyme O +
with O +
lipase O +
and O +
esterase O +
activity O +
was O +
purified O +
from O +
bovine U-Species +
pancreas O -
. O -

Furthermore O -
, O +
a O +
non O -
- O -
radioactive O +
lipase O +
assay O +
was O +
developed O +
which O +
is O +
100 O +
times O +
more O +
sensitive O +
than O +
the O +
conventional O +
methods O +
and O +
allowed O +
the O +
characterization O +
of O +
the O +
lipase O +
activity O +
of O +
the O +
enzyme O -
. O -

The O +
lipase O +
activity O +
increased O +
42 O +
times O +
in O +
the O +
presence O +
of O +
10 O +
mM O +
sodium O +
taurocholate O -
, O +
which O +
for O +
the O +
first O +
time O +
provides O +
direct O +
evidence O +
that O +
a O +
bile O +
salt O -
- O -
activated O +
lipase O +
( O -
bp O -
- O -
BAL O -
) O +
was O +
isolated O +
from O +
bovine U-Species +
pancreas O -
. O -

This O +
conclusion O +
is O +
further O +
supported O +
by O +
the O +
fact O +
that O +
the O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
of O +
this O +
lipase O -
/ O -
esterase O +
is O +
88 O -
% O +
homologous O +
to O +
human U-Species +
milk O +
BAL O +
and O +
human U-Species +
pancreatic O +
BAL O -
. O -

Staining O +
with O +
various O +
lectins O +
showed O +
that O +
bp O -
- O -
BAL O +
is O +
a O +
glycoprotein O +
which O +
contains O +
fucose O +
residues O -
. O -

Previously O +
from O +
bovine U-Species +
pancreas O +
a O +
lysophospholipase O +
has O +
been O +
purified O +
and O +
a O +
gene O +
was O +
cloned O +
and O +
sequenced O +
encoding O -
an O +
enzyme O +
with O +
cholesterol O +
esterase O -
/ O -
lysophospholipase O +
activity O -
. O -

Comparison O +
of O +
the O +
N O -
- O -
terminal O +
amino O +
acid O +
sequence O +
of O +
bp O -
- O -
BAL O +
with O +
the O +
deduced O +
amino O +
acid O +
sequence O +
of O -
the O +
latter O +
revealed O +
that O +
they O +
are O +
identical O -
. O -

Furthermore O -
, O +
the O +
molecular O +
weight O +
of O +
the O +
purified O +
bp O -
- O -
BAL O +
of O +
63,000 O -
, O +
as O +
estimated O +
by O +
SDS O -
- O -
PAGE O -
, O +
is O +
very O +
similar O +
to O +
that O -
of O +
the O +
purified O +
lysophospholipase O +
( O -
65,000 O -
) O +
and O +
to O +
the O +
theoretical O +
molecular O +
weight O +
of O +
65,147 O +
of O +
the O +
cholesterol O +
esterase O -
/ O -
lysophospholipase O -
. O -

These O +
data O +
suggest O +
that O +
these O +
three O +
enzymes O +
are O +
one O +
and O +
the O +
same O -
. O +

The O +
antioxidant O +
activity O +
of O +
Eriobotrya B-Species +
japonica L-Species +
was O +
determined O +
by O +
measuring O +
the O +
radical O +
scavenging O +
effect O +
on O +
DPPH O +
( O -
1,1-diphenyl-2-picrylhydrazyl O -
) O +
radical O +
and O +
lipid O +
peroxidation O +
produced O +
when O +
mouse U-Species +
liver O +
homogenate O +
was O +
exposed O +
to O +
the O +
air O +
at O +
37 O +
degrees O +
C O -
, O +
using O +
2-thiobarbituric O +
acid O +
( O -
TBA O -
) O -
. O -

The O +
methanol O +
extract O +
and O +
its O +
fractions O +
of O +
Eriobotrya B-Species +
japonica L-Species +
leaves O +
showed O +
strong O +
antioxidant O +
activity O -
. O -

The O +
antioxidant O +
activity O +
of O +
EtOAc O +
and O +
n O -
- O -
BuOH O +
soluble O +
fractions O +
were O +
stronger O +
than O +
the O +
others O -
, O +
and O +
were O +
further O +
purified O +
by O +
repeated O +
silica O +
gel O -
, O +
MCl O +
gel O +
CHP-20P O -
, O +
and O +
Sephadex O +
LH-20 O +
column O +
chromatography O -
. O -

Antioxidant O +
chlorogenic O +
acid O -
, O +
quercetin-3-sambubioside O +
from O +
n O -
- O -
BuOH O +
fraction O -
, O +
and O +
methyl O +
chlorogenate O -
, O +
kaempferol- O +
and O +
quercetin-3-rhamnosides O -
, O +
together O +
with O +
the O +
inactive O +
ursolic O +
acid O -
and O +
2 O +
alpha O -
- O -
hydroxyursolic O +
acid O +
from O +
EtOAc O +
fraction O +
were O +
isolated O -
. O -

Antioxidant O +
flavonoids O +
and O +
chlorogenic O +
acid O +
also O +
showed O +
prominent O +
inhibitory O +
activity O +
against O +
free O +
radical O +
generation O +
in O +
dichlorofluorescein O +
( O -
DCF O -
) O +
method O -
. O +

The O +
synthesis O +
and O +
the O +
antimicrobial O +
properties O +
of O +
a O +
new O +
series O +
of O +
cephalosporinic O +
beta O -
- O -
lactam O +
antibiotics O +
is O +
described O -
. O -

The O +
data O +
reported O +
in O +
the O +
present O +
paper O +
show O +
the O +
potential O +
of O +
this O +
type O +
of O +
substituted O +
cephalosporins O +
as O +
new O +
anti O +
Gram O -
- O -
positive O +
antibiotic O +
drugs O -
. O -

In O +
fact O -
, O +
all O +
compounds O +
tested O +
showed O +
a O +
good O +
in O +
vitro O +
antibacterial O +
activity O +
against O +
the O +
most O +
relevant O +
Gram B-Species -
- I-Species -
positive I-Species +
pathogens L-Species +
including O +
resistant O +
species O +
that O +
currently O +
represent O +
unmet O +
medical O +
need O -
. O -

On O +
the O +
contrary O -
, O +
the O +
new O +
synthesized O +
compounds O +
were O +
found O +
to O +
be O +
completely O +
devoid O +
of O +
any O +
activity O +
on O +
Gram B-Species -
- I-Species -
negative I-Species +
bacteria L-Species +
up O +
to O +
a O +
concentration O +
of O +
the O +
single O +
agent O +
of O +
128 O +
microg O -
/ O -
ml O -
. O +

The O +
hydroxylation O +
at O +
C-2 O +
of O +
testosterone O +
and O +
5alpha O -
- O -
dihydrotestosterone O +
is O +
measured O +
by O +
isolation O +
of O +
HTO O +
after O +
incubating O +
" O -
metabolically O +
labile O -
" O +
tritium O +
labeled O +
steroids O +
with O +
the O +
enzymes O -
. O -

After O +
hydroxylation O +
of O +
testosterone O +
in O +
rat U-Species +
liver O +
2alpha O -
- O -
hydroxytestosterone O +
was O +
isolated O +
and O +
identified O +
by O +
gaschromatography O +
and O +
mass O +
spectra O -
. O +

Oxamniquine O +
( O -
1,2,3,4-tetrahydro-2- O -
[ O -
( O -
isopropylamino O -
) O -
methyl O -
] O -
-7-nitro-6-quinoline O +
methanol O -
) O +
is O +
an O +
antischistosomal O +
agent O +
that O +
is O +
indicated O +
for O +
the O +
treatment O +
of O +
S. B-Species +
mansoni L-Species -
( O -
intestinal O +
schistosomiasis O -
) O +
infection O -
. O -

It O +
has O +
been O +
shown O +
to O +
inhibit O +
DNA O -
, O +
RNA O +
and O +
protein O +
synthesis O +
in O +
schistosomes O -
. O -

The O +
oral O +
bioavailability O +
of O +
oxamniquine O +
is O +
good O -
, O +
effective O +
plasma O +
levels O +
are O +
achieved O +
in O +
1–1.5 O +
h O +
[ O -
1 O -
] O +
. O -

Oxamniquine O +
is O +
the O +
subject O +
of O +
a O +
monograph O +
in O +
the O +
US O +
Pharmacopoeia O +
( O -
USP O +
XXIII O -
) O +
[ O -
2 O -
] O -
whereby O +
a O +
spectrophotometric O +
method O +
is O +
recommended O +
for O +
its O +
determination O -
, O +
whether O +
in O +
its O +
pure O +
form O +
or O +
in O +
capsules O -
. O -

Other O +
reported O +
methods O +
include O +
spectrophotometry O +
[ O -
3,4 O -
] O +
, O +
non O -
- O -
aqueous O +
titration O +
[ O -
5 O -
] O +
, O +
gas O +
chromatography O +
[ O -
6 O -
] O +
, O +
high O -
- O -
performance O +
liquid O +
chromatography O +
[ O -
7–11 O -
] O +
, O +
polarography O +
[ O -
12 O -
] O +
, O +
capillary O +
electrophoresis O +
[ O -
9 O -
] O +
, O +
flow O -
- O -
injection O +
analysis O +
[ O -
13 O -
] O -
and O +
cyclic O +
voltammetry O +
[ O -
14 O -
] O +
. O -

The O +
above O -
- O -
mentioned O +
methods O +
are O +
either O +
not O +
sufficiently O +
sensitive O +
or O +
are O +
tedious O +
and O +
require O +
highly O +
sophisticated O +
instrumentation O -
. O -

Therefore O -
, O +
there O +
is O +
still O +
a O +
need O +
for O +
a O +
much O +
more O +
sensitive O +
and O +
simple O +
method O +
for O +
the O +
determination O +
of O +
oxamniquine O -
, O +
especially O +
in O +
biological O +
fluids O -
. O -

Fluorimetry O -
, O +
by O +
virtue O +
of O +
its O +
high O +
sensitivity O -
, O +
meets O +
this O +
requirement O -
. O -

Reviewing O +
the O +
literature O +
revealed O +
that O +
no O +
fluorimetric O +
methods O +
were O +
reported O +
for O +
oxamniquine O -
. O -

As O +
for O +
2-cyanoacetamide O -
, O +
it O +
has O +
been O +
recently O +
used O +
for O +
the O +
determination O +
of O +
aminoglycosides O +
[ O -
15 O -
] O +
, O +
reducing O +
carbohydrates O +
[ O -
16–18 O -
] O +
, O +
enzymatic O +
degradation O +
products O +
of O +
reducing O +
polysaccharides O +
[ O -
19 O -
] O -
and O +
catecholamines O +
[ O -
20,21 O -
] O +
. O -

The O +
aim O +
of O +
the O +
present O +
work O +
is O +
to O +
study O +
the O +
reaction O +
of O +
the O +
reduced O +
derivative O +
( O -
nitroso O -
) O +
of O +
oxamniquine O +
with O +
2-cyanoacetamide O +
in O +
an O +
attempt O +
to O +
develop O +
a O +
sensitive O +
fluorimetric O +
method O +
to O +
be O +
used O +
for O +
its O +
determination O +
in O +
biological O +
fluids O -
. O -

2 O +
Experimental O +
2.1 O +
Apparatus O +
An O +
Aminco O -
- O -
Bowman O +
Model O +
J4 O +
-9860 O +
spectrofluorometer O +
was O +
used O +
with O +
the O +
excitation O +
and O +
emission O +
slits O +
set O +
at O +
5 O +
mm O -
. O -

A O +
1-cm O +
quartz O +
cell O +
was O +
used O +
for O +
all O +
measurements O -
. O -

2.2 O +
Materials O +
and O +
reagents O +
All O +
the O +
chemicals O +
used O +
were O +
of O +
analytical O +
reagent O +
grade O -
, O +
while O +
the O +
solvents O +
were O +
of O +
the O +
spectroscopic O +
grade O -
. O -

A O +
pure O +
drug O +
sample O +
of O +
oxamniquine O +
was O +
kindly O +
supplied O +
by O +
Pfizer O +
( O -
Sandwich O -
, O +
UK O -
) O +
and O +
was O +
used O +
as O +
received O -
. O -

2-Cyanoacetamide O +
was O +
purchased O +
from O +
Aldrich O +
Chemical O +
Co. O +
Plasma O +
was O +
obtained O +
from O +
Mansoura O +
University O +
Hospital O -
, O +
Mansoura O +
( O -
Egypt O -
) O +
and O +
urine O +
was O +
obtained O +
from O +
healthy O +
volunteers U-Species -
. O -

Freshly O +
prepared O +
10 O -
% O +
aqueous O +
solution O +
of O +
calcium O +
chloride O +
and O +
4 O -
% O +
aqueous O +
solution O +
of O +
2-cyanoacetamide O +
were O +
prepared O +
and O +
used O +
throughout O +
the O +
study O -
. O -

2.2.1 O +
Stock O +
solution O +
Dissolve O +
20 O +
mg O +
of O +
oxamniquine O +
in O +
100 O +
of O +
methanol O -
. O -

Make O +
serial O +
dilutions O +
with O +
water O +
to O +
obtain O +
a O +
final O +
concentration O +
of O +
20 O +
μg O -
/ O -
ml O -
. O -

2.3 O +
Procedure O +
2.3.1 O +
Preparation O +
of O +
the O +
calibration O +
curve O +
Transfer O +
aliquots O +
of O +
oxamniquine O +
final O +
stock O +
solution O +
into O +
a O +
series O +
of O +
25 O +
ml O +
standard O +
flasks O +
so O +
that O +
the O +
final O +
drug O +
concentration O +
is O +
in O +
the O +
range O +
0.08–0.88 O +
μg O -
/ O -
ml O -
. O -

Add O +
to O +
each O +
flask O +
120±5 O +
mg O +
of O +
zinc O +
dust O +
and O +
12 O +
ml O +
of O +
calcium O +
chloride O +
solution O -
. O -

Shake O +
well O +
and O +
leave O +
to O +
stand O +
for O +
20 O +
min O -
. O -

Filter O +
the O +
excess O +
zinc O +
powder O -
. O -

Add O +
1 O +
ml O +
of O +
2-cyanoacetamide O +
solution O +
to O +
the O +
filtrate O -
, O +
then O +
heat O +
on O +
a O +
boiling O +
water O +
bath O +
for O +
1 O +
h. O +
Cool O +
and O +
fill O +
to O +
the O +
mark O +
in O +
25 O +
ml O +
standard O +
flask O +
with O +
water O -
. O -

Measure O +
the O +
fluorescence O +
of O +
the O +
filtrate O +
using O +
370 O +
nm O +
as O +
the O +
excitation O +
wavelength O +
and O +
450 O +
nm O +
as O +
the O +
emission O +
wavelength O -
. O -

A O +
blank O +
reagent O +
is O +
prepared O +
simultaneously O -
. O -

Plot O +
the O +
values O +
of O +
the O +
% O +
relative O +
intensity O +
against O +
the O +
final O +
concentration O +
in O +
μg O -
/ O -
ml O +
to O +
get O +
the O +
calibration O +
graph O -
. O -

Alternatively O -
, O +
the O +
regression O +
equation O +
is O +
derived O -
. O -

2.3.2 O +
Determination O +
of O +
oxamniquine O +
in O +
spiked O +
human U-Species +
plasma O +
and O +
urine O +
A O +
standard O +
calibration O +
curve O +
was O +
prepared O +
daily O +
by O +
spiking O +
blank O +
plasma O +
or O +
urine O +
with O +
varying O +
amounts O +
of O +
oxamniquine O -
. O -

A O +
stock O +
solution O +
containing O +
10 O +
μg O -
/ O -
ml O +
of O +
oxamniquine O +
was O +
freshly O +
prepared O -
. O -

Control O +
samples O +
of O +
plasma O +
or O +
urine O +
were O +
spiked O +
with O +
different O +
quantities O +
of O +
oxamniquine O +
to O +
give O +
a O +
final O +
drug O +
concentration O +
of O +
0.2–0.8 O +
μg O -
/ O -
ml O -
. O -

Add O +
0.8 O +
ml O +
of O +
1 O +
M O +
NaOH O +
with O +
gentle O +
shaking O +
to O +
1.0 O +
ml O +
of O +
the O +
spiked O +
urine O +
or O +
plasma O -
. O -

The O +
solution O +
was O +
then O +
vortexed O +
with O +
3 O -
× O -
5 O +
ml O +
of O +
ether O +
for O +
2 O +
min O +
then O +
centrifuged O +
at O +
2500 O +
rpm O +
for O +
5 O +
min O -
. O -

The O +
resulting O +
supernatant O +
was O +
then O +
evaporated O +
to O +
dryness O +
under O +
nitrogen O +
at O +
ambient O +
temperature O -
. O -

The O +
resulting O +
residue O +
was O +
dissolved O +
in O +
5 O +
ml O +
of O +
methanol O +
and O +
then O +
made O +
up O +
to O +
10 O +
ml O +
with O +
water O +
in O +
a O +
volumetric O +
flask O -
. O -

The O +
procedure O +
described O +
in O +
Section O +
2.3.1 O -
was O +
then O +
applied O -
. O -

A O +
blank O +
experiment O +
using O +
plasma O +
or O +
urine O +
without O +
the O +
drug O +
was O +
carried O +
out O +
simultaneously O -
. O -

The O +
content O +
of O +
oxamniquine O +
was O +
then O +
determined O +
from O +
the O +
previously O +
plotted O +
calibration O +
graphs O -
. O -

3 O +
Results O +
and O +
discussion O +
The O +
nitro O +
group O +
is O +
reported O +
to O +
be O +
reduced O +
into O +
the O +
corresponding O +
nitroso O +
group O +
upon O +
reduction O +
with O +
Zn O -
/ O -
CaCl2 O +
[ O -
22 O -
] O +
. O -

This O +
process O +
was O +
confirmed O +
by O +
testing O +
for O +
the O +
nitroso O +
group O +
using O +
sodium O +
nitroprusside O +
[ O -
23 O -
] O +
. O -

The O +
nitroso O +
compounds O +
were O +
reported O +
to O +
react O +
with O +
active O +
methylene O +
containing O +
compounds O +
with O +
the O +
production O +
of O +
the O +
corresponding O +
imines O +
[ O -
24 O -
] O +
. O -

The O +
latter O +
is O +
proposed O +
to O +
undergo O +
a O +
ring O -
- O -
closing O +
reaction O +
with O +
the O +
elimination O +
of O +
one O +
molecule O +
of O +
ammonia O +
and O +
the O +
production O +
of O +
the O +
3-cyanooxazazepin-2-one O +
derivative O -
, O +
which O +
is O +
the O +
fluorescent O +
product O -
. O -

A O +
proposal O +
of O +
reaction O +
pathway O +
is O +
suggested O +
in O +
Scheme O +
1 O -
. O -

A O +
highly O +
fluorescent O +
product O +
with O +
λmax O -
excitation O +
at O +
370 O +
nm O +
and O +
λmax O -
emission O +
of O +
450 O +
nm O +
was O +
obtained O +
( O -
Fig. O +
1 O -
) O -
. O -

3.1 O +
Study O +
of O +
the O +
experimental O +
conditions O +
The O +
factors O +
affecting O +
the O +
production O +
of O +
nitroso O +
derivative O +
were O +
first O +
studied O -
. O -

All O +
factors O +
were O +
kept O +
constant O +
except O +
one O -
, O +
which O +
was O +
changed O +
in O +
turn O +
to O +
study O +
its O +
effect O -
. O -

Any O +
amount O +
of O +
zinc O +
powder O +
in O +
the O +
range O +
100–300 O +
mg O +
was O +
found O +
to O +
give O +
the O +
same O +
results O -
; O +
therefore O +
120±5 O +
mg O +
were O +
used O +
throughout O +
the O +
work O -
. O -

As O +
for O +
calcium O +
chloride O +
solution O +
12±1 O +
ml O +
of O +
10 O -
% O +
( O -
wt. O -
/ O -
vol O -
. O -
) O -

aqueous O +
solution O +
was O +
found O +
to O +
give O +
maximum O +
fluorescence O -
. O -

Larger O +
volumes O +
caused O +
slight O +
decrease O +
in O +
fluorescence O -
. O -

Increasing O +
the O +
reduction O +
time O +
( O -
at O +
room O +
temperature O -
) O +
was O +
found O +
to O +
increase O +
the O +
fluorescence O +
up O +
to O +
20 O +
min O -
, O +
after O +
which O +
time O +
the O +
fluorescence O +
intensity O +
remained O +
unchanged O -
. O -

3.2 O +
Factors O +
affecting O +
the O +
development O +
of O +
the O +
fluorophore O +
The O +
effect O +
of O +
the O +
concentration O +
of O +
2-cyanoacetamide O +
was O +
studied O +
by O +
using O +
increasing O +
volumes O +
of O +
4 O -
% O +
aqueous O +
solution O -
. O -

It O +
was O +
found O +
that O +
1.0±0.1 O +
ml O +
is O +
appropriate O +
for O +
maximum O +
fluorescence O +
intensity O -
; O +
larger O +
volumes O +
caused O +
no O +
further O +
increase O +
in O +
fluorescence O -
. O -

The O +
temperature O +
and O +
time O +
of O +
heating O +
were O +
also O +
studied O -
. O -

It O +
was O +
concluded O +
that O +
heating O +
in O +
a O +
boiling O +
water O -
- O -
bath O +
for O +
1 O +
h O +
gave O +
the O +
highest O +
fluorescence O +
readings O -
. O -

Longer O +
heating O +
time O +
caused O +
a O +
decrease O +
in O +
fluorescence O +
as O +
shown O +
in O +
Fig. O +
2 O -
. O -

After O +
optimizing O +
the O +
conditions O -
, O +
it O +
was O +
found O +
that O +
the O +
relation O +
between O +
the O +
% O +
relative O +
intensity O +
( O -
% O +
RI O -
) O +
and O +
final O +
concentration O +
of O +
oxamniquine O +
was O +
rectilinear O +
over O +
the O +
range O +
0.08–0.88 O +
μg O -
/ O -
ml O +
with O +
a O +
minimum O +
detectability O +
( O -
S O +
/N O +
= O -
2 O -
) O +
of O +
8 O +
ng O -
/ O -
ml O +
( O -
Fig. O +
3 O -
) O -
. O -

The O +
linear O +
regression O +
analysis O +
of O +
the O +
results O +
gave O +
the O +
following O +
equation:% O +
RI O +
= O -
0.0358 O -
+ O -
107.4C O +
( O -
r=0.9999 O -
) O -
where O +
C O +
= O -
final O +
concentration O +
in O +
μg O -
/ O -
ml O -
, O +
% O +
RI O -
= O -
relative O +
fluorescence O +
intensity O +
and O +
r O +
= O -
correlation O +
coefficient O -
. O -

Statistical O +
analysis O +
of O +
the O +
results O +
of O +
analysis O +
of O +
authentic O +
sample O +
of O +
oxamniquine O +
obtained O +
by O +
both O +
the O +
proposed O +
method O +
and O +
the O +
official O +
method O +
[ O -
2 O -
] O -
revealed O +
no O +
significant O +
difference O +
between O +
the O +
two O +
methods O +
regarding O +
the O +
accuracy O +
and O +
precision O -
, O +
as O +
indicated O +
by O +
the O +
F O +
-test O +
and O +
Student O -
's O +
t O +
-test O -
, O +
respectively O +
[ O -
25 O -
] O +
. O -

Oxamniquine O +
is O +
readily O +
absorbed O +
following O +
oral O +
ingestion O -
, O +
and O +
a O +
peak O +
concentration O +
in O +
plasma O +
occurs O +
within O +
about O +
3 O +
h. O +
The O +
presence O +
of O +
food O +
significantly O +
delays O +
absorption O +
and O +
limits O +
the O +
concentration O +
achieved O +
in O +
plasma O +
during O +
the O +
first O +
several O +
hours O +
after O +
administration O -
. O -

Urinary O +
excretion O +
is O +
the O +
major O +
route O +
of O +
elimination O +
in O +
humans U-Species +
[ O -
26 O -
] O +
. O -

Oxamniquine O +
is O +
given O +
orally O +
in O +
a O +
dose O +
of O +
250 O +
mg O +
three O +
times O +
daily O -
; O +
this O +
leads O +
to O +
a O +
final O +
blood O +
level O +
concentration O +
of O +
about O +
5 O +
μg O -
/ O -
ml O -
, O +
i.e. O +
higher O +
than O +
the O +
upper O +
limit O +
of O +
the O +
working O +
range O +
of O +
the O +
proposed O +
method O -
. O -

Thus O -
, O +
the O +
high O +
sensitivity O +
of O +
the O +
proposed O +
method O +
allowed O +
the O +
determination O +
of O +
oxamniquine O +
in O +
biological O +
fluids O -
. O -

Table O +
1 O -
shows O +
the O +
results O +
for O +
the O +
fluorimetric O +
determination O +
of O +
a O +
pure O +
sample O +
of O +
oxamniquine O -
, O +
while O +
Table O +
2 O -
shows O +
the O +
results O +
of O +
the O +
fluorometric O +
determination O +
of O +
oxamniquine O +
in O +
spiked O +
urine O +
and O +
plasma O +
samples O -
, O +
respectively O -
. O -

The O +
extraction O +
procedure O +
described O +
by O +
Woolhouse O +
and O +
Wood O +
[ O -
6 O -
] O -
was O +
adopted O +
here O -
. O -

The O +
results O +
are O +
satisfactorily O +
accurate O +
and O +
precise O -
. O -

In O +
conclusion O -
, O +
a O +
highly O +
sensitive O +
and O +
accurate O +
method O +
was O +
developed O +
for O +
the O +
determination O +
of O +
oxamniquine O +
in O +
urine O +
and O +
plasma O -
. O -

Although O +
the O +
previously O +
reported O +
methods O +
[ O -
6,7 O -
] O -
for O +
its O +
determination O +
in O +
biological O +
fluids O +
may O +
be O +
less O +
time O -
- O -
consuming O -
, O +
the O +
proposed O +
method O +
is O -
, O +
however O -
, O +
more O +
sensitive O +
and O +
does O +
not O +
need O +
complicated O +
instrumentation O -
. O +

The O +
relationship O +
between O +
taurine O +
and O +
aging O +
of O +
brain O +
neural O +
cells O +
was O +
studied O +
by O +
using O +
primary O +
human U-Species +
fetal O +
brain O +
neural O +
cells O +
cultured O +
in O +
serum O -
- O -
free O +
medium O -
. O -

The O +
results O +
indicated O +
that O +
the O +
activity O +
of O +
superoxide O +
dismutase O +
( O -
SOD O -
) O +
was O +
significantly O +
higher O +
in O +
taurine O +
added O +
group O +
than O +
the O +
control O +
group O +
cultured O +
for O +
6 O -
, O +
9 O +
and O +
15 O +
days O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

With O +
different O +
taurine O +
levels O -
, O +
the O +
SOD O +
activities O +
of O +
50 O +
mg O -
/ O -
L O +
and O +
200 O +
mg O -
/ O -
L O +
taurine O +
groups O +
were O +
significantly O +
higher O +
than O +
the O +
control O +
group O +
cultured O +
for O +
6 O +
days O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

After O +
3-day O +
culture O -
, O +
the O +
activity O +
of O +
glutathione O +
peroxidase O +
( O -
GSH O -
- O -
Px O -
) O +
in O +
the O +
taurine O +
added O +
group O +
was O +
significantly O +
higher O +
than O +
the O +
control O +
group O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

The O +
membrane O +
lipid O +
fluidity O +
of O +
neural O +
cells O +
decreased O +
with O +
time O +
in O +
control O +
group O -
, O +
but O +
was O +
stable O +
in O +
the O +
group O +
treated O +
with O +
taurine O -
. O -

The O +
fluidity O +
was O +
more O +
stable O +
in O +
the O +
groups O +
treated O +
with O +
50 O -
, O +
200 O +
and O +
400 O +
mg O -
/ O -
L O +
groups O +
cultured O +
for O +
6 O +
days O -
, O +
compared O +
with O +
the O +
control O +
group O +
( O -
P O +
< O +
0.05 O +
or O +
0.01 O -
) O -
. O -

The O +
present O +
study O +
showed O +
that O +
taurine O +
is O +
necessary O +
for O +
maintaining O +
membrane O +
lipid O +
fluidity O +
of O +
neural O +
cells O +
in O +
proper O +
levels O -
, O +
and O +
plays O +
an O +
important O -
role O +
in O +
postponing O +
the O +
aging O +
process O +
of O +
brain O +
neural O +
cells O -
. O +

A O +
combination O +
of O +
atovaquone O +
and O +
proguanil O +
has O +
been O +
found O +
to O +
be O +
quite O +
effective O +
in O +
treating O +
malaria O -
, O +
with O +
little O +
evidence O +
of O +
the O +
emergence O +
of O +
resistance O +
when O +
atovaquone O +
was O +
used O +
as O +
a O +
single O +
agent O -
. O -

We O +
have O +
examined O +
possible O +
mechanisms O +
for O +
the O +
synergy O +
between O +
these O +
two O +
drugs O -
. O -

While O +
proguanil O +
by O +
itself O +
had O +
no O +
effect O +
on O +
electron O +
transport O +
or O +
mitochondrial O +
membrane O +
potential O +
( O -
DeltaPsim O -
) O -
, O +
it O +
significantly O +
enhanced O +
the O +
ability O +
of O +
atovaquone O +
to O +
collapse O +
DeltaPsim O +
when O +
used O -
in O +
combination O -
. O -

This O +
enhancement O +
was O +
observed O +
at O +
pharmacologically O +
achievable O +
doses O -
. O -

Proguanil O +
acted O +
as O +
a O +
biguanide O +
rather O +
than O +
as O +
its O +
metabolite O +
cycloguanil O +
( O -
a O +
parasite U-Species +
dihydrofolate O +
reductase O +
[ O -
DHFR O -
] O +
inhibitor O -
) O +
to O +
enhance O +
the O +
atovaquone O +
effect O -
; O +
another O +
DHFR O +
inhibitor O -
, O +
pyrimethamine O -
, O +
also O +
had O +
no O +
enhancing O +
effect O -
. O -

Proguanil O -
- O -
mediated O +
enhancement O +
was O +
specific O +
for O +
atovaquone O -
, O +
since O +
the O +
effects O +
of O -
other O +
mitochondrial O +
electron O +
transport O +
inhibitors O -
, O +
such O +
as O +
myxothiazole O +
and O +
antimycin O -
, O +
were O +
not O +
altered O +
by O +
inclusion O +
of O +
proguanil O -
. O -

Surprisingly O -
, O +
proguanil O +
did O +
not O +
enhance O +
the O +
ability O +
of O +
atovaquone O +
to O +
inhibit O +
mitochondrial O +
electron O +
transport O +
in O +
malaria O +
parasites O -
. O -

These O +
results O +
suggest O +
that O +
proguanil O +
in O +
its O +
prodrug O +
form O +
acts O +
in O +
synergy O +
with O +
atovaquone O +
by O +
lowering O +
the O +
effective O +
concentration O +
at O +
which O +
atovaquone O +
collapses O +
DeltaPsim O +
in O +
malaria O +
parasites O -
. O -

This O -
could O +
explain O +
the O +
paradoxical O +
success O +
of O +
the O +
atovaquone O -
- O -
proguanil O +
combination O +
even O +
in O +
regions O +
where O +
proguanil O +
alone O +
is O +
ineffective O +
due O +
to O +
resistance O -
. O -

The O +
results O +
also O +
suggest O +
that O +
the O +
atovaquone O -
- O -
proguanil O +
combination O +
may O +
act O +
as O +
a O +
site O -
- O -
specific O +
uncoupler O +
of O +
parasite U-Species +
mitochondria O +
in O +
a O +
selective O +
manner O -
. O +

To O +
develop O +
positron O -
- O -
emitting O +
tracers O +
for O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
studies O -
, O +
ex O +
vivo O -
autoradiography O +
( O -
ARG O -
) O +
is O +
a O +
useful O +
technique O +
to O +
demonstrate O +
the O +
distribution O +
of O +
the O +
tracer O +
in O +
the O +
brain O +
as O +
well O +
as O +
in O +
the O +
whole O +
body O -
. O -

A O +
recent O +
advent O +
of O +
radioluminography O +
using O +
phosphor O -
- O -
imaging O +
plates O +
( O -
12 O -
, O +
14 O -
) O -
has O +
enabled O +
the O +
ex O +
vivo O -
ARG O +
to O +
be O +
applied O +
to O +
ultrashort O -
- O -
lived O +
11 O +
C O -
- O -
labeled O +
tracers O -
. O -

Yanai O +
et O +
al. O -
reported O +
a O +
potential O +
of O +
the O +
imaging O +
plates O +
for O +
receptor O +
ARG O +
with O +
11 O +
C O -
- O -
labeled O +
ligands O +
compared O +
with O +
tritiated O +
ligands O +
( O -
25 O -
) O +
. O -

Planas O +
et O +
al. O +
( O -
18 O -
) O -
characterized O +
a O +
cholinesterase O +
inhibitor O +
[ O -
11 O +
C O -
] O -
physostigmine O +
using O +
a O +
similar O +
type O +
storage O +
phosphor O +
plates O -
. O -

We O +
also O +
used O +
imaging O +
plates O +
to O +
characterize O +
newly O +
developed O +
11 O +
C O -
- O -
labeled O +
receptor O +
ligands O +
( O -
3 O -
, O +
10 O -
, O +
16 O -
) O +
. O -

Because O +
the O +
intensity O +
of O +
photo O -
- O -
stimulated O -
- O -
luminescence O +
( O -
PSL O -
) O +
is O +
linearly O +
proportional O +
to O +
the O +
radioactivity O +
in O +
a O +
wide O +
range O -
, O +
ARG O +
images O +
expressed O +
as O +
PSL O +
is O +
considered O +
to O +
reflect O +
the O +
quantitative O +
distribution O +
of O +
radioactivity O -
. O -

Recently O -
, O +
Sihver O +
et O +
al. O +
( O -
21 O -
) O -
have O +
quantitatively O +
evaluated O +
in O +
vitro O -
ARG O +
with O +
storage O +
phosphor O +
plates O +
and O +
11 O +
C O -
- O -
flumazenil O -
. O -

In O +
the O +
present O +
paper O -
, O +
we O +
describe O +
quantitative O +
evaluation O +
of O +
ex O +
vivo O -
and O +
in O +
vitro O -
ARG O +
using O +
an O +
imaging O +
plate O +
and O +
a O +
11 O +
C O -
- O -
labeled O +
dopamine O +
D2 O +
-like O +
receptor O +
ligand O -
, O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
[ O -
11 O +
C O -
] O -
YM-09151 O -
- O -
2 O -
) O +
( O -
5 O -
, O +
6 O -
, O +
8 O -
, O +
9 O -
, O +
11 O -
) O +
. O -

Its O +
tritiated O +
compound O +
has O +
been O +
used O +
widely O +
for O +
pharmacological O +
studies O +
as O +
one O +
of O +
representative O +
dopamine O +
D2 O +
-like O +
receptor O +
ligands O -
. O -

We O +
report O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
for O +
[ O -
11 O +
C O -
] O -
nemonapride O +
in O +
the O +
cortex O +
beside O +
the O +
dopamine O +
D2 O +
-like O +
receptors O +
in O +
the O +
striatum O +
both O +
ex O +
vivo O -
and O +
in O +
vitro O -
. O -

Materials O +
and O +
methods O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
9 O -
) O -
and O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
4 O -
) O -
were O +
synthesized O +
by O +
11 O +
C O -
- O -
methylation O +
of O +
the O +
corresponding O +
desmethyl O +
compound O +
with O +
[ O -
11 O +
C O -
] O -
methyl O +
iodide O +
by O +
the O +
method O +
previously O +
described O -
. O -

The O +
specific O +
activity O +
of O +
the O +
compounds O +
was O +
measured O +
as O +
follows O -
. O -

The O +
radioactivity O +
( O -
MBq O -
) O +
of O +
an O +
appropriate O +
volume O +
of O +
tracer O +
solution O +
was O +
measured O +
by O +
a O +
radioisotope O +
calibrator O +
( O -
type O +
CRC-712 O -
, O +
Capintec O +
Inc. O -
, O +
Ramsey O -
, O +
NJ O -
) O -
, O +
and O +
a O +
part O +
of O +
the O +
solution O +
was O +
applied O +
to O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
to O +
determine O +
the O +
mass O +
( O -
nmol O -
) O +
of O +
the O +
compounds O +
based O +
on O +
the O +
ultraviolet O +
( O -
UV O -
) O +
response O +
to O +
the O +
authentic O +
sample O -
. O -

Male B-Species +
Wistar I-Species +
rats L-Species +
( O -
8–10 O +
weeks O +
old O -
) O +
were O +
obtained O +
from O +
Tokyo O +
Laboratory O +
Animals O +
Company O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O -

The O +
animal U-Species +
studies O +
were O +
approved O +
by O +
the O +
Animal U-Species +
Care O +
and O +
Use O +
Committee O +
of O +
Tokyo O +
Metropolitan O +
Institute O +
of O +
Gerontology O -
. O -

Calibration O +
of O +
PSL O +
Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
filter O +
paper O +
A O +
solution O +
of O +
11 O +
C O -
- O -
tracer O +
was O +
prepared O +
at O +
the O +
concentration O +
of O +
100 O +
MBq O -
/ O -
mL O +
measured O +
with O +
a O +
radioisotope O +
calibrator O +
( O -
t O -
= O +
0 O +
min O -
, O +
26 O +
min O +
after O +
end O +
of O +
bombardment O +
[ O -
EOB O -
] O -
) O -
. O -

The O +
solution O +
was O +
diluted O +
to O +
0.03–10 O +
MBq O -
/ O -
mL O -
, O +
and O +
10 O +
μL O +
of O +
each O +
diluted O +
solution O +
( O -
0.3–100 O +
kBq O -
) O +
was O +
loaded O +
on O +
six O +
pieces O +
of O +
filter O +
paper O +
( O -
5 O +
mm O +
× O +
5 O +
mm O -
, O +
0.23 O +
± O +
0.05 O +
mm O +
thickness O -
, O +
Toyo O +
Roshi O +
Kaisha O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O -

Three O +
pieces O +
of O +
the O +
filter O +
paper O +
were O +
exposed O +
on O +
an O +
imaging O +
plate O +
of O +
type O +
IP O +
BAS O +
SR O +
( O -
FUJIX O +
Fuji O +
Photo O +
Film O +
Co. O -
, O +
Tokyo O -
, O +
Japan O -
) O +
until O +
the O +
decay O -
- O -
out O +
of O +
11 O +
C O +
( O -
t O -
= O +
20 O +
h O -
) O -
. O -

The O +
activity O +
at O +
the O +
start O +
of O +
contact O +
ranged O +
from O +
1.05 O +
to O +
2990 O +
Bq O +
( O -
t O -
= O +
35.5 O +
min O -
) O -
. O -

At O +
the O +
same O +
time O -
, O +
the O +
radioactivity O +
( O -
cpm O -
) O +
of O +
the O +
other O +
three O +
pieces O +
of O +
the O +
filter O +
paper O +
was O +
measured O +
with O +
a O +
well O -
- O -
type O +
auto O -
- O -
gamma O +
counter O +
( O -
type O +
1282 O +
Compugamma O +
CS O -
, O +
Wallac O +
Oy O -
, O +
Turku O -
, O +
Finland O -
) O +
for O +
15 O +
s O -
, O +
and O +
the O +
cpm O -
/ O -
Bq O +
was O +
computed O +
with O +
decay O +
correction O -
. O -

The O +
PSL O +
values O +
over O +
the O +
entire O +
piece O +
of O +
filter O +
paper O +
( O -
25 O +
mm2 O +
) O +
were O +
measured O +
with O +
a O +
bioimaging O +
analyzer O +
of O +
type O +
BAS O +
2500 O +
( O -
FUJIX O +
Fuji O +
Photo O +
Film O +
Co. O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
to O +
compute O +
the O +
PSL O +
per O +
Bq O +
at O +
the O +
start O +
of O +
contact O -
. O -

Reproducibility O +
between O +
imaging O +
plates O +
The O +
filter O +
paper O +
provided O +
with O +
the O +
11 O +
C O -
- O -
radioactivity O +
as O +
described O +
above O +
and O +
the O +
autoradiographic O +
[ O -
14 O +
C O -
] O -
micro O -
- O -
scales O +
( O -
1.11–31.73 O +
kBq O -
/ O -
g O -
) O +
( O -
Amersham O +
International O +
plc O -
. O -
, O +
Buckinghamshire O -
, O +
England O -
) O +
were O +
exposed O +
to O +
five O +
imaging O +
plates O +
of O +
the O +
same O +
type O +
for O +
4 O +
h O +
to O +
examine O +
the O +
reproducibility O +
between O +
imaging O +
plates O -
; O +
the O +
PSL O +
of O +
the O +
micro O -
- O -
scales O +
were O +
measured O +
as O +
PSL O -
/ O -
mm2 O +
. O -

Ex O +
vivo O -
autoradiography O +
Effect O +
of O +
section O +
thickness O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
143 O +
MBq O -
/ O -
4.3 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
a O +
rat O +
( O -
235 O +
g O -
) O +
( O -
t O -
= O +
0 O +
min O -
, O +
29 O +
min O +
after O +
EOB O -
) O -
. O -

Fifteen O +
minutes O +
later O -
, O +
the O +
rat U-Species +
was O +
killed O +
and O +
the O +
brain O +
was O +
removed O -
. O -

The O +
brain O +
at O +
the O +
bregma O +
( O -
17 O -
) O +
was O +
cut O +
into O +
10- O -
, O +
15- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-μm O +
thick O +
coronal O +
sections O +
using O +
a O +
cryotome O +
( O -
Bright O +
Instruments O +
Co. O +
Ltd. O -
, O +
UK O -
) O +
at O +
−15 O -
° O -
C O -
. O -

The O +
brain O +
sections O +
were O +
thaw O -
- O -
mounted O +
on O +
glass O +
plates O +
( O -
20 O +
× O +
32 O +
mm2 O +
) O +
that O +
were O +
precoated O +
with O +
3 O -
% O +
3-aminopropyltriethoxysilane O +
in O +
acetone O -
. O -

The O +
sections O +
were O +
dried O +
on O +
a O +
hot O +
plate O +
at O +
60 O -
° O -
C O +
and O +
apposed O +
placed O +
on O +
an O +
imaging O +
plate O +
( O -
t O -
= O +
110 O +
min O -
) O -
. O -

The O +
tracer O +
uptake O +
was O +
visualized O +
as O +
described O +
above O -
. O -

Regions O +
of O +
interest O +
( O -
ROIs O -
) O +
were O +
placed O +
on O +
the O +
striatum O +
( O -
6–8 O +
mm2 O +
) O +
and O +
on O +
the O +
cerebral O +
cortex O +
( O -
6–8 O +
mm2 O +
) O -
, O +
and O +
the O +
PSL O -
/ O -
mm2 O +
values O +
were O +
measured O -
. O -

From O +
the O +
other O +
rat U-Species +
( O -
230 O +
g O -
) O +
given O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
136 O +
MBq O -
/ O -
4.4 O +
nmol O -
) O -
, O +
the O +
coronal O +
brain O +
sections O +
with O +
10- O -
, O +
15- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-μm O +
thickness O +
were O +
also O +
obtained O +
as O +
described O +
above O -
. O -

The O +
whole O +
section O +
was O +
measured O +
for O +
the O +
radioactivity O +
( O -
cpm O -
) O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
for O +
15 O +
s. O -

The O +
effect O +
of O +
section O +
thickness O +
was O +
evaluated O -
, O +
assuming O +
equal O +
radioactivity O +
concentration O +
between O +
corresponding O +
regions O +
or O +
whole O +
brains O +
in O +
neighboring O +
sections O +
at O +
the O +
bregma O -
. O -

Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
the O +
brain O +
section O +
To O +
obtain O +
coronal O +
brain O +
sections O +
having O +
a O +
wider O +
range O +
of O +
radioactivity O -
, O +
ex O +
vivo O -
ARG O +
was O +
performed O +
with O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O -
, O +
which O +
is O +
more O +
concentrated O +
in O +
the O +
striatum O +
than O +
[ O -
11 O +
C O -
] O -
nemonapride O -
. O -

[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
236 O +
MBq O -
/ O -
11.1 O +
nmol O +
and O +
47 O +
MBq O -
/ O -
2.2 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
two O +
rats U-Species +
( O -
t O -
= O +
0 O +
min O -
, O +
30 O +
min O +
after O +
EOB O -
) O -
. O -

The O +
rats U-Species +
were O +
killed O +
15 O +
min O +
later O -
, O +
and O +
25 O +
pairs O +
of O +
the O +
adjacent O +
coronal O +
brain O +
sections O +
with O +
20-μm O +
thickness O +
were O +
prepared O +
throughout O +
the O +
brain O +
as O +
described O +
above O -
. O -

One O +
set O +
of O +
the O +
brain O +
sections O +
was O +
applied O +
to O +
an O +
imaging O +
plate O +
until O +
decay O -
- O -
out O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
whole O +
section O -
, O +
and O +
the O +
other O +
set O +
was O +
measured O +
for O +
the O +
radioactivity O +
( O -
cpm O -
) O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
( O -
t O -
= O +
102 O +
min O -
) O -
. O -

Then O +
the O +
PSL O -
/ O -
cpm O +
was O +
calculated O +
for O +
each O +
brain O +
section O -
. O -

Regional O +
brain O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
measured O +
by O +
ex O +
vivo O -
ARG O +
and O +
tissue O +
sampling O +
method O +
[ O -
11 O +
C O -
] O -
Nemonapride O +
( O -
82.6–96.7 O +
MBq O -
/ O -
2.1–5.7 O +
nmol O -
) O +
was O +
injected O +
intravenously O +
into O +
four O +
rats U-Species +
( O -
260–290 O +
g O -
) O -
. O -

They O +
were O +
killed O +
30 O +
min O +
later O +
and O +
the O +
brains O +
were O +
removed O -
. O -

From O +
a O +
half O +
brain O +
hemisphere O -
, O +
three O +
pairs O +
of O +
adjacent O +
coronal O +
brain O +
sections O +
with O +
20-μm O +
thickness O +
were O +
cut O +
near O +
bregma O -
. O -

The O +
radioactivity O +
( O -
cpm O -
) O +
of O +
one O +
set O +
of O +
section O +
was O +
measured O +
with O +
an O +
auto O -
- O -
gamma O +
counter O +
and O +
converted O +
to O +
Bq O -
. O -

The O +
other O +
section O +
was O +
exposed O +
to O +
an O +
imaging O +
plate O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
whole O +
section O +
as O +
described O +
above O -
, O +
and O +
the O +
PSL O -
/ O -
Bq O +
was O +
calculated O +
assuming O +
that O +
the O +
pair O +
of O +
adjacent O +
brain O +
sections O +
had O +
the O +
same O +
radioactivity O -
. O -

ROIs O +
were O +
placed O +
on O +
the O +
striatum O +
and O +
on O +
the O +
cortex O +
to O +
measure O +
the O +
PSL O +
for O +
the O +
regional O +
brain O +
section O +
volume O +
( O -
mm2 O -
× O +
0.02 O +
mm O -
) O -
, O +
which O +
was O +
converted O +
to O +
Bq O -
/ O -
mL. O +
Then O -
, O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
the O +
striatum O +
or O +
cortex O +
was O +
assessed O +
as O +
the O +
percent O +
of O +
the O +
injected O +
dose O +
per O +
milliliter O +
of O +
tissue O +
( O -
% O -
ID O -
/ O -
mL O -
) O -
. O -

From O +
the O +
other O +
hemisphere O +
the O +
striatum O +
and O +
cortex O +
were O +
dissected O +
and O +
weighed O -
, O +
and O +
the O +
radioactivity O +
of O +
the O +
tissues O +
was O +
measured O +
with O +
an O +
auto O -
- O -
gamma O +
counter O -
. O -

The O +
uptake O +
was O +
expressed O +
as O +
the O +
percent O +
of O +
the O +
injected O +
dose O +
per O +
gram O +
of O +
tissue O +
( O -
% O -
ID O -
/ O -
g O -
) O -
. O -

Effect O +
of O +
carrier O +
dose O +
To O +
measure O +
the O +
receptor O +
binding O +
capacity O +
quantitatively O +
in O +
ex O +
vivo O -
ARG O -
, O +
the O +
amount O +
of O +
injected O +
carrier O +
ligand O +
must O +
be O +
sufficiently O +
small O +
to O +
avoid O +
saturation O +
effect O -
. O -

To O +
determine O +
if O +
the O +
carrier O +
amount O +
of O +
nemonapride O +
meets O +
this O +
requirement O +
under O +
the O +
specific O +
activity O +
of O +
current O +
experimental O +
condition O -
, O +
the O +
effect O +
of O +
carrier O +
dose O +
on O +
the O +
regional O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
evaluated O +
by O +
tissue O +
sampling O -
. O -

[ O -
11 O +
C O -
] O -
Nemonapride O +
with O +
various O +
amount O +
of O +
carrier O +
( O -
10 O +
MBq O -
/ O -
0.027–500 O +
nmol O -
) O +
was O +
injected O +
into O +
rats U-Species +
( O -
227 O +
± O +
12 O +
g O -
) O -
, O +
and O +
the O +
uptake O +
( O -
% O -
ID O -
/ O -
g O -
) O +
by O +
the O +
striatum O -
, O +
cortex O -
, O +
and O +
cerebellum O +
was O +
measured O +
at O +
30 O +
min O +
after O +
the O +
injection O +
by O +
the O +
tissue O +
sampling O +
method O +
as O +
described O +
above O -
. O -

In O +
vitro O -
autoradiography O +
Effect O +
of O +
section O +
thickness O +
In O +
vitro O -
ARG O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
performed O +
according O +
to O +
the O +
method O +
of O +
Przedborski O +
et O +
al. O +
( O -
19 O -
) O -
with O +
a O +
slight O +
modification O -
. O -

Coronal O +
rat U-Species +
brain O +
sections O +
with O +
10- O -
, O +
20- O -
, O +
30- O -
, O +
75- O -
, O +
100- O -
, O +
and O +
150-μm O +
thickness O +
near O +
the O +
bregma O +
( O -
17 O -
) O -
were O +
prepared O -
. O -

The O +
brain O +
sections O +
were O +
pre O -
- O -
incubated O +
in O +
100 O +
mL O +
50 O +
mM O +
Tris O -
- O -
HCl O -
, O +
pH O +
7.4 O -
, O +
containing O +
120 O +
mM O +
NaCl O +
for O +
30 O +
min O +
at O +
room O +
temperature O -
. O -

Then O -
, O +
the O +
same O +
buffer O +
containing O +
100 O +
kBq O -
/ O -
mL O +
( O -
25 O +
TBq O -
/ O -
mmol O -
) O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
prepared O +
( O -
t O -
= O +
0 O +
min O -
, O +
29 O +
min O +
after O +
EOB O -
) O -
, O +
in O +
which O +
all O +
the O +
sections O +
were O +
incubated O +
for O +
30 O +
min O +
at O +
37 O -
° O -
C O -
. O -

After O +
being O +
washed O +
with O +
ice O -
- O -
cold O +
50 O +
mM O +
Tris O -
- O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
120 O +
mM O +
NaCl O -
, O +
the O +
brain O +
sections O +
were O +
dried O +
on O +
a O +
hot O +
plate O +
at O +
60 O -
° O -
C O -
, O +
and O +
then O +
contacted O +
on O +
an O +
imaging O +
plate O +
( O -
t O -
= O +
58 O +
min O -
) O +
until O +
the O +
activity O +
decayed O +
out O +
( O -
t O -
= O +
20 O +
h O -
) O +
. O -

The O +
binding O +
of O +
11 O +
C O +
was O +
measured O +
as O +
the O +
PSL O -
/ O -
mm2 O -
over O +
the O +
ROIs O +
placed O +
in O +
the O +
same O +
manner O +
as O +
in O +
the O +
ex O +
vivo O -
ARG O -
, O +
and O +
the O +
effect O +
of O +
section O +
thickness O +
was O +
evaluated O -
. O -

The O +
other O +
set O +
of O +
the O +
brain O +
section O +
was O +
also O +
assayed O +
as O +
described O +
above O +
and O +
the O +
radioactivity O +
( O -
cpm O -
) O +
of O +
the O +
whole O +
section O +
was O +
measured O +
with O +
a O +
gamma O +
counter O -
. O -

Saturation O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
binding O +
The O +
buffer O +
containing O +
various O +
concentrations O +
( O -
0.156 O -
, O +
0.313 O -
, O +
0.625 O -
, O +
1.25 O -
, O +
and O +
2.50 O +
nM O -
) O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
( O -
21 O +
TBq O -
/ O -
mmol O -
) O +
was O +
prepared O +
( O -
t O -
= O +
0 O +
min O -
, O +
40 O +
min O +
after O +
EOB O -
) O -
, O +
and O +
six O +
brain O +
sections O +
with O +
20-μm O +
thickness O +
were O +
incubated O +
for O +
30 O +
min O +
at O +
37 O -
° O -
C O +
in O +
each O +
buffer O +
as O +
described O +
above O -
. O -

Nonspecific O +
binding O +
was O +
determined O +
by O +
incubating O +
adjacent O +
six O +
sections O +
in O +
the O +
medium O +
to O +
which O +
haloperidol O +
was O +
added O +
to O +
a O +
final O +
concentration O +
of O +
20 O +
μM. O +
Three O +
brain O +
sections O +
in O +
each O +
assay O +
were O +
exposed O +
on O +
an O +
imaging O +
plate O +
( O -
t O -
= O +
85 O +
min O -
) O +
to O +
measure O +
the O +
PSL O +
values O -
, O +
and O +
the O +
adjacent O +
three O +
sections O +
were O +
measured O +
for O +
radioactivity O +
( O -
cpm O -
) O -
. O -

Then O -
, O +
the O +
PSL O -
/ O -
Bq O +
calculated O +
as O +
described O +
above O +
was O +
converted O +
to O +
concentration O +
of O +
receptor O -
- O -
bound O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
) O +
using O +
the O +
specific O +
activity O +
of O +
the O +
ligand O -
. O -

Scatchard O +
plot O -
, O +
bound O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
) O +
versus O +
bound O +
ligand O -
/ O -
free O +
ligand O +
( O -
nmol O -
/ O -
mL O +
tissue O -
/ O -
nM O -
) O -
, O +
was O +
carried O +
out O -
. O -

Results O +
and O +
discussion O +
Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
filter O +
paper O +
Figure O +
1 O -
shows O +
the O +
PSL O +
values O +
of O +
the O +
standard O +
sample O +
on O +
filter O +
paper O -
. O -

The O +
PSL O +
values O +
were O +
linearly O +
proportional O +
to O +
the O +
11 O +
C O +
radioactivity O +
( O -
Bq O -
) O +
measured O +
with O +
a O +
radioisotope O +
calibrator O +
( O -
Fig. O +
1A O -
) O +
, O +
and O +
the O +
ratio O +
was O +
10.7 O +
PSL O -
/ O -
Bq O +
at O +
the O +
start O +
of O +
contact O -
. O -

Because O +
each O +
sample O +
presented O +
uniform O +
activity O +
distribution O +
within O +
the O +
piece O +
of O +
filter O +
paper O -
, O +
the O +
PSL O +
of O +
the O +
standard O +
sample O +
on O +
the O +
filter O +
paper O +
was O +
expressed O +
as O +
a O +
linear O +
function O +
of O +
radioactivity O +
in O +
the O +
range O +
from O +
0.4 O +
to O +
1110 O +
PSL O -
/ O -
mm2 O -
( O -
0.04–104 O +
Bq O -
/ O -
mm2 O +
) O +
in O +
the O +
present O +
study O -
. O -

The O +
linearity O +
between O +
the O +
radioisotope O +
calibrator O +
and O +
the O +
well O -
- O -
type O +
gamma O +
counter O +
was O +
also O +
confirmed O -
, O +
the O +
ratio O +
being O +
40.1 O +
cpm O -
/ O -
Bq O -
. O -

Reproducibility O +
between O +
imaging O +
plates O +
When O +
the O +
11 O +
C O -
- O -
samples O +
on O +
filter O +
paper O +
and O +
standard O +
[ O -
14 O +
C O -
] O -
micro O -
- O -
scales O +
were O +
exposed O +
to O +
five O +
imaging O +
plates O -
, O +
the O +
coefficient O +
variation O +
( O -
SD O -
/ O -
mean O -
) O +
of O +
the O +
five O +
plates O +
for O +
11 O +
C O -
- O -
sensitivity O +
and O +
14 O +
C O -
- O -
sensitivity O +
was O +
2.4–3.2 O -
% O +
at O +
17.4–164 O +
PSL O -
/ O -
mm2 O -
and O +
2.6–6.9 O -
% O +
at O +
5.2–36.6 O +
PSL O -
/ O -
mm2 O +
, O +
respectively O -
. O -

The O +
variation O +
for O +
11 O +
C O +
was O +
comparable O +
to O +
that O +
for O +
14 O +
C O -
, O +
which O +
confirmed O +
the O +
reliability O +
of O +
our O +
homemade O +
standard O +
source O +
on O +
filter O +
paper O -
. O -

Effect O +
of O +
section O +
thickness O +
Figure O +
2 O -
shows O +
representative O +
autoradiograms O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
ex O +
vivo O -
and O +
in O +
vitro O -
ARG O -
. O -

High O +
11 O +
C O +
density O +
was O +
observed O +
in O +
the O +
caudate O +
putamen O -
, O +
nucleus O +
accumbens O -
, O +
and O +
olfactory O +
tubercle O -
, O +
consistent O +
with O +
the O +
well O -
- O -
known O +
distribution O +
of O +
dopamine O +
D2 O -
receptors O -
. O -

Figure O +
3 O -
illustrates O +
the O +
relationship O +
between O +
brain O +
section O +
thickness O +
and O +
PSL O +
values O +
measured O +
by O +
ex O +
vivo O -
and O +
in O +
vitro O -
ARG O -
. O -

The O +
PSL O -
/ O -
mm2 O -
value O +
for O +
ex O +
vivo O -
ARG O +
was O +
not O +
linearly O +
proportional O +
to O +
the O +
slice O +
thickness O +
( O -
Fig. O +
3A O -
) O +
, O +
suggesting O +
that O +
the O +
absorption O +
of O +
radiation O +
increases O +
as O +
the O +
section O +
thickness O +
increases O -
, O +
because O +
it O +
is O +
reasonably O +
assumed O +
that O +
the O +
radioactivity O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
uniformly O +
distributed O +
throughout O +
the O +
thickness O +
in O +
the O +
striatum O +
and O +
cortex O +
near O +
the O +
bregma O -
. O -

On O +
the O +
other O +
hand O -
, O +
a O +
deviation O +
from O +
the O +
linear O +
function O +
was O +
much O +
larger O +
for O +
the O +
in O +
vitro O -
ARG O +
than O +
for O +
the O +
ex O +
vivo O -
ARG O -
, O +
and O +
the O +
PSL O -
/ O -
mm2 O -
values O +
reached O +
a O +
plateau O +
both O +
in O +
the O +
striatum O +
and O +
cortex O +
for O +
over O +
100-μm O +
thick O +
sections O -
. O -

This O +
finding O +
is O +
probably O +
because O +
diffusion O +
of O +
the O +
11 O +
C O -
- O -
tracer O +
into O +
the O +
brain O +
tissue O +
was O +
not O +
completed O +
in O +
thick O +
brain O +
sections O +
during O +
the O +
incubation O +
period O -
, O +
and O +
the O +
binding O +
did O +
not O +
reach O +
an O +
equilibrium O +
state O -
. O -

The O +
explanation O +
was O +
approved O +
by O +
measurement O +
of O +
radioactivity O +
of O +
the O +
whole O +
brain O +
sections O +
with O +
a O +
gamma O +
counter O +
( O -
Fig. O +
3C O -
) O +
. O -

The O +
radioactivity O +
was O +
linearly O +
proportional O +
to O +
the O +
slice O +
thickness O +
in O +
ex O +
vivo O -
ARG O -
, O +
but O +
not O +
in O +
in O +
vitro O -
ARG O -
. O -

Relationship O +
between O +
PSL O +
and O +
radioactivity O +
on O +
the O +
brain O +
section O +
Figure O +
4 O -
shows O +
relationship O +
between O +
the O +
PSL O +
value O +
and O +
the O +
radioactivity O +
of O +
11 O +
C O +
on O +
the O +
whole O +
section O +
with O +
20-μm O +
thickness O +
and O +
for O +
the O +
entire O +
piece O +
of O +
25-mm2 O -
filter O +
paper O +
with O +
230-μm O +
thickness O -
. O -

The O +
PSL O +
was O +
found O +
to O +
be O +
linearly O +
proportional O +
to O +
the O +
radioactivity O +
within O +
the O +
brain O +
sections O +
or O +
filter O +
paper O -
, O +
although O +
the O +
coefficient O +
was O +
different O +
between O +
the O +
two O +
materials O +
because O +
of O +
different O +
thickness O +
as O +
suggested O +
from O +
Figure O +
2 O +
. O -

Therefore O -
, O +
the O +
PSL O +
value O +
can O +
be O +
converted O +
to O +
the O +
radioactivity O +
expressed O +
as O +
Bq O +
unit O -
, O +
if O +
the O +
radioactivity O +
of O +
the O +
adjacent O +
brain O +
sections O +
with O +
the O +
same O +
thickness O +
is O +
measured O +
with O +
a O +
gamma O -
- O -
counter O -
. O -

Table O +
1 O -
summarizes O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
by O +
the O +
striatum O +
and O +
cortex O +
measured O +
by O +
ex O +
vivo O -
ARG O +
and O +
by O +
the O +
tissue O +
sampling O -
. O -

Comparable O +
values O +
of O +
the O +
striatal O +
and O +
cortical O +
uptake O +
were O +
obtained O +
by O +
the O +
two O +
methods O -
, O +
nevertheless O +
the O +
technical O +
problem O +
that O +
the O +
nonstriatal O +
region O +
might O +
be O +
contaminated O +
with O +
the O +
striatal O +
sample O +
in O +
the O +
tissue O +
sampling O -
, O +
and O +
the O +
fact O +
that O +
the O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
is O +
less O +
homogeneous O +
in O +
the O +
striatum O +
than O +
in O +
the O +
cortex O -
. O -

Therefore O -
, O +
ex O +
vivo O -
ARG O +
may O +
be O +
a O +
suitable O +
method O +
to O +
quantitatively O +
evaluate O +
small O +
regions O +
such O +
as O +
nucleus O +
accumbens O +
and O +
olfactory O +
tubercles O -
. O -

Effect O +
of O +
carrier O +
dose O +
To O +
evaluate O +
the O +
carrier O +
dose O +
on O +
the O +
regional O +
brain O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O -
, O +
the O +
uptake O +
was O +
measured O +
by O +
tissue O +
sampling O +
method O -
. O -

As O +
shown O +
in O +
Figure O +
5 O +
, O -
at O +
the O +
dose O +
of O +
22 O +
nmol O -
/ O -
kg O +
the O +
uptake O +
was O +
slightly O +
decreased O -
, O +
though O +
not O +
statistically O +
significant O -
. O -

In O +
the O +
regional O +
brain O +
distribution O +
study O +
with O +
ex O +
vivo O -
ARG O +
and O +
tissue O +
sampling O +
( O -
Table O +
1 O -
) O +
, O +
the O +
injected O +
doses O +
were O +
320–330 O +
MBq O -
/ O -
kg O +
as O +
radioactivity O +
and O +
8.1–20 O +
nmol O -
/ O -
kg O +
as O +
carrier O +
amounts O -
. O -

Therefore O -
, O +
the O +
injected O +
carrier O +
dose O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
slightly O +
exceeded O +
to O +
the O +
optimum O +
condition O -
. O -

However O -
, O +
because O +
the O +
PSL O -
/ O -
mm2 O -
values O +
measured O +
in O +
the O +
cortex O +
were O +
12–14 O +
at O +
65–70 O +
min O +
after O +
the O +
tracer O +
injection O +
( O -
at O +
35–40 O +
min O +
after O +
the O +
exposing O +
time O -
) O +
in O +
the O +
study O +
described O +
in O +
Table O +
1 O +
, O +
the O +
injected O +
dose O +
for O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
can O +
be O +
reasonably O +
reduced O +
to O +
approximately O +
one O -
- O -
tenth O +
within O +
the O +
linearity O +
range O +
for O +
the O +
PSL O -
/ O -
mm2 O -
( O -
> O -
0.4 O +
in O +
Fig. O +
1 O +
) O -
, O +
although O +
statistical O +
noise O +
is O +
increased O -
. O -

Therefore O -
, O +
the O +
quantitative O +
ex O +
vivo O -
ARG O +
method O +
using O +
imaging O +
plates O +
presented O +
in O +
this O +
study O +
is O +
applicable O +
to O +
quantitative O +
measurement O +
of O +
the O +
receptor O +
binding O +
capacity O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O -
. O -

It O +
can O +
also O +
be O +
applied O +
to O +
other O +
dopamine O +
receptor O +
ligands O +
such O +
as O +
[ O -
11 O +
C O -
] O -
raclopride O -
, O +
[ O -
11 O +
C O -
] O -
N O +
-methylspiperone O -
, O +
and O +
[ O -
11 O +
C O -
] O -
SCH O +
23390 O +
( O -
data O +
not O +
shown O -
) O -
, O +
although O +
the O +
uptake O +
depends O +
in O +
the O +
ligand O -
. O -

Figure O +
5 O -
also O +
showed O +
that O +
a O +
saturable O +
uptake O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
observed O +
in O +
the O +
cortex O +
and O +
cerebellum O +
besides O +
in O +
the O +
striatum O -
, O +
which O +
was O +
preliminarily O +
suggested O +
by O +
a O +
previous O +
report O +
( O -
5 O -
) O +
. O -

In O +
vitro O -
[ O -
11 O +
C O -
] O -
Nemonapride O +
binding O +
to O +
the O +
striatum O +
and O +
cortex O +
In O +
previous O +
studies O +
on O +
in O +
vitro O -
binding O +
of O +
radiolabeled O +
nemonapride O +
( O -
[ O -
3 O +
H O -
] O -
YM-09151 O -
- O -
2 O -
) O +
at O +
room O +
temperature O -
, O +
the O +
tracer O +
binding O +
reached O +
equilibrium O +
after O +
90 O +
min O +
( O -
2 O -
, O +
15 O -
, O +
24 O -
) O +
. O -

In O +
our O +
preliminary O +
experiment O -
, O +
when O +
the O +
incubation O +
was O +
carried O +
out O +
at O +
37 O -
° O -
C O +
to O +
accelerate O +
the O +
equilibration O -
, O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
binding O +
reached O +
a O +
maximal O +
level O +
at O +
30 O +
min O +
( O -
data O +
not O +
shown O -
) O -
, O +
which O +
enabled O +
the O +
use O +
of O +
the O +
short O -
- O -
lived O +
11 O +
C O -
- O -
ligand O -
. O -

The O +
specific O +
activity O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
was O +
reasonably O +
high O +
( O -
25 O +
TBq O -
/ O -
mmol O +
at O +
the O +
start O +
of O +
assay O +
in O +
the O +
present O +
study O -
) O +
compared O +
with O +
conventional O +
in O +
vitro O -
ARG O +
using O +
3 O +
H O -
- O -
labeled O +
compounds O -
. O -

Thus O +
the O +
in O +
vitro O -
ARG O +
with O +
[ O -
11 O +
C O -
] O -
nemonapride O +
is O +
a O +
practicable O +
technique O -
. O -

The O +
period O +
required O +
from O +
the O +
end O +
of O +
radiosynthesis O +
to O +
the O +
exposing O +
the O +
brain O +
slice O +
to O +
imaging O +
plate O +
was O +
approximately O +
90 O +
min O -
. O -

A O +
saturation O +
binding O +
experiment O +
showed O +
a O +
specific O +
binding O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
to O +
the O +
striatum O +
and O +
cortex O +
( O -
Fig. O +
6A O -
) O +
. O -

Scatchard O +
analysis O +
indicated O +
a O +
Kd O -
of O +
730 O +
pM O +
and O +
an O +
apparent O +
Bmax O -
of O +
160 O +
nmol O -
/ O -
mL O +
tissue O +
in O +
the O +
striatum O +
and O +
a O +
Kd O -
of O +
1.5 O +
nM O +
and O +
a O +
Bmax O -
of O +
29 O +
nmol O -
/ O -
mL O +
tissue O +
in O +
the O +
cortex O -
. O -

The O +
Kd O -
value O +
of O +
730 O +
pM O +
for O +
the O +
striatum O +
is O +
in O +
the O +
same O +
order O +
as O +
those O +
obtained O +
with O +
in O +
vitro O +
ARG O +
by O +
Unis O +
et O +
al. O -
( O -
626 O +
pM O -
) O +
( O -
24 O -
) O -
and O +
Yokoyama O +
et O +
al. O -
( O -
315 O +
pM O -
) O +
( O -
26 O -
) O +
, O +
but O +
is O +
larger O +
than O +
those O +
( O -
21–82 O +
pM O -
) O +
measured O +
by O +
the O +
membrane O +
binding O +
assay O +
( O -
1 O -
, O +
13 O -
, O +
15 O -
, O +
23 O -
) O -
or O +
with O +
in O +
vitro O -
ARG O +
( O -
2 O -
) O +
. O -

These O +
differences O +
may O +
be O +
caused O +
by O +
the O +
assay O +
conditions O +
such O +
as O +
incubation O +
time O -
, O +
temperature O -
, O +
blockers O +
used O +
to O +
evaluate O +
the O +
nonspecific O +
binding O -
, O +
other O +
medium O +
components O -
, O +
and O +
slice O +
thickness O +
in O +
ARG O -
. O -

The O +
saturation O +
kinetics O +
may O +
also O +
be O +
different O +
between O +
the O +
membrane O +
homogenate O +
and O +
the O +
brain O +
slice O -
. O -

An O +
in O +
vivo O -
saturation O +
binding O +
experiment O +
in O +
Figure O +
6 O -
revealed O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
for O +
[ O -
11 O +
C O -
] O -
nemonapride O +
in O +
the O +
cortex O +
and O +
striatum O -
. O -

This O +
finding O +
was O +
also O +
revealed O +
by O +
an O +
ex O +
vivo O -
study O +
( O -
Fig. O +
5 O -
) O +
, O +
which O +
also O +
suggested O +
the O +
presence O +
of O +
saturable O +
binding O +
sites O +
in O +
the O +
cerebellum O -
. O -

The O +
specific O +
binding O +
evaluated O +
with O +
a O +
haloperidol O -
- O -
blockade O +
was O +
lower O +
than O +
the O +
nonspecific O +
binding O +
in O +
the O +
cortex O +
( O -
Fig. O +
6A O +
-2 O -
) O -
. O -

Kazawa O +
et O +
al. O +
( O -
13 O -
) O -
demonstrated O +
that O +
[ O -
3 O +
H O -
] O -
nemonapride O +
binding O +
in O +
the O +
cortical O +
membrane O +
was O +
displaced O +
by O +
sulpiride O +
or O +
by O +
haloperidol O -
. O -

They O +
also O +
showed O +
that O +
these O +
binding O +
sites O +
were O +
apparently O +
different O +
from O +
serotonin-2 O +
receptors O -
. O -

The O +
unknown O +
binding O +
sites O +
may O +
be O +
dopamine O +
D4 O -
receptors O -
, O +
because O +
haloperidol O -
, O +
but O +
not O +
raclopride O -
, O +
displaced O +
the O +
uptake O +
( O -
20 O -
) O +
. O -

Sigma O +
receptors O +
may O +
be O +
another O +
candidate O +
for O +
the O +
unknown O +
binding O +
sites O -
. O -

Helmeste O +
et O +
al. O +
( O -
7 O -
) O -
suggested O +
that O +
nemonapride O +
also O +
has O +
an O +
affinity O +
for O +
sigma O +
receptors O -
, O +
which O +
was O +
evaluated O +
by O +
a O +
blocking O +
study O +
with O +
a O +
selective O +
sigma O +
receptor O +
ligand O -
, O +
R O +
( O -
− O -
) O -
-N O +
- O -
( O -
3-phenyl O -
- O -
n O +
-propyl O -
) O -
-1-phenyl-2-aminopropane O +
( O -
PPAP O -
) O -
. O -

Preliminary O +
findings O +
indicated O +
that O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
uptake O +
was O +
reduced O +
by O +
carrier O +
nemonapride O +
or O +
by O +
haloperidol O +
in O +
the O +
striatum O -
, O +
cortex O -
, O +
and O +
cerebellum O +
of O +
the O +
mouse U-Species +
brain O -
, O +
but O +
that O +
other O +
sigma O +
receptor O +
ligands O +
such O +
as O +
PPAP O -
, O +
( O -
+ O -
) O -
-SKF10047 O -
, O +
R O +
( O -
+ O -
) O -
-3- O -
( O -
3-hydroxyphenyl O -
) O -
-N O +
-propylpiperidine O +
hydrochloride O +
( O -
R O +
[ O -
+ O -
] O -
-3-PPP O -
) O +
and O +
NE-100 O +
( O -
22 O -
) O -
did O +
not O +
reduce O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
uptake O +
by O +
the O +
striatum O +
( O -
unpublished O +
data O -
) O -
. O -

The O +
in O +
vivo O -
affinity O +
of O +
the O +
[ O -
11 O +
C O -
] O -
nemonapride O +
for O +
sigma O +
receptors O +
is O +
under O +
investigation O -
. O -

So O +
far O -
, O +
we O +
confirmed O +
in O +
ex O +
vivo O -
and O +
in O +
vitro O -
experiments O +
that O +
the O +
saturable O +
binding O +
sites O +
of O +
[ O -
11 O +
C O -
] O -
nemonapride O +
are O +
present O +
in O +
the O +
cortex O +
( O -
and O +
probably O +
in O +
the O +
cerebellum O -
) O +
although O +
their O +
characteristics O +
remain O +
unknown O -
. O -

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
( O -
B O -
) O +
No. O +
10558115 O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O -
, O +
Japan O -
. O +

Perillyl O +
alcohol O +
is O +
a O +
hydroxylated O +
metabolite O +
of O +
d O +
-limonene O +
[ O -
1–3 O -
] O +
, O +
which O +
is O +
the O +
major O -
, O +
naturally O +
occurring O +
monoterpene O +
present O +
in O +
orange U-Species +
peel O +
oil O -
. O -

Perillyl O +
alcohol O +
is O +
also O +
found O +
in O +
lavender U-Species -
, O +
mints U-Species -
, O +
and O +
celery U-Species +
seeds O -
. O -

It O +
has O +
been O +
shown O +
that O +
d O +
-limonene O +
and O +
metabolites O +
possess O +
chemopreventative O +
and O +
chemotherapeutic O +
activity O +
against O +
human U-Species +
malignancies O +
with O +
low O +
toxicity O +
[ O -
4–8 O -
] O +
. O -

d O +
-Limonene O +
is O +
extensively O +
metabolized O +
( O -
Scheme O +
1 O -
) O -
in O +
animals U-Species +
[ O -
1–5 O -
] O -
and O +
in O +
humans U-Species +
[ O -
9,10 O -
] O -
and O +
perillic O +
acid O +
and O +
dihydroperillic O +
acid O +
were O +
found O +
to O +
be O +
the O +
major O +
circulating O +
metabolites O +
[ O -
1–3,5,6 O -
] O -
and O +
for O +
perillyl O +
alcohol O +
[ O -
11 O -
] O +
. O -

Metabolites O +
of O +
limonene O +
with O +
intermediate O +
polarity O +
such O +
as O +
perillyl O +
alcohol O -
, O +
perillic O +
acid O +
methyl O +
ester O +
and O +
perillaldehyde O +
were O +
found O +
to O +
be O +
more O +
potent O +
inhibitors O +
of O +
isoprenylation O +
of O +
the O +
p21–26 O +
kDa O +
protein O -
, O +
which O +
is O +
involved O +
in O +
cell O +
growth O +
and O +
proliferation O +
[ O -
7 O -
] O +
, O +
than O +
limonene O +
itself O -
. O -

In O +
vivo O -
, O +
perillyl O +
alcohol O +
was O +
also O +
found O +
to O +
be O +
more O +
active O +
than O +
d O +
-limonene O +
[ O -
4–7,12–14 O -
] O +
. O -

Phillips O +
et O +
al. O +
[ O -
11 O -
] O -
conducted O +
a O +
pharmacokinetic O +
study O +
of O +
perillyl O +
alcohol O +
in O +
dogs U-Species +
using O +
a O +
GC O -
– O -
MS O +
method O +
with O +
a O +
sensitivity O +
limit O +
of O +
0.25 O +
μg O -
/ O -
ml O -
, O +
but O +
were O +
unable O +
to O +
detect O +
the O +
parent O +
drug O +
in O +
circulation O -
. O -

In O +
order O +
to O +
understand O +
the O +
pharmacokinetic O +
and O +
disposition O +
characteristics O +
of O +
perillyl O +
alcohol O -
, O +
the O +
development O +
of O +
a O +
more O +
sensitive O +
quantitation O +
assay O +
method O +
is O +
necessary O -
. O -

The O +
present O +
report O +
describes O +
a O +
sensitive O +
GC O -
– O -
MS O +
method O +
for O +
the O +
measurement O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
plasma O +
using O +
the O +
stable O +
isotope O -
- O -
labelled O +
analogs O +
as O +
the O +
internal O +
standards O -
. O -

A O +
derivatization O +
procedure O +
is O +
also O +
used O +
to O +
facilitate O +
the O +
GC O +
separation O +
and O +
mass O +
spectrometric O +
detection O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Chemicals O +
and O +
reagents O +
( O -
S O +
) O -
- O -
( O -
− O -
) O -
-Perillyl O +
alcohol O +
( O -
POH O -
) O +
was O +
purchased O +
from O +
Aldrich O +
( O -
Milwaukee O -
, O +
WI O -
, O +
USA O -
) O -
. O -

Perillic O +
acid O +
( O -
PA O -
) O -
, O +
cis- O +
/trans- O +
dihydroperillic O +
acid O +
( O -
cis- O +
/trans- O +
DHPA O -
, O +
cis- O +
/trans- O +
4 O -
( O -
1′-methylethenyl O -
) O -
cyclohexane-1-carboxylic O +
acid O -
) O -
, O +
perillyl O +
alcohol O -
- O -
d3 O -
( O -
POH O -
- O -
d3 O +
) O +
and O +
perillic O +
acid O -
- O -
d2 O +
-13 O +
C O +
( O -
13 O +
C O -
- O -
PA O -
- O -
d2 O +
) O +
( O -
Fig. O +
1 O -
) O +
were O +
synthesized O +
according O +
to O +
the O +
literature O +
method O +
[ O -
15 O -
] O +
. O -

POH O -
- O -
d3 O -
was O +
used O +
as O +
the O +
internal O +
standard O +
for O +
POH O -
, O +
whereas O +
13 O +
C O -
- O -
PA O -
- O -
d2 O -
was O +
used O +
as O +
the O +
internal O +
standard O +
for O +
PA O +
and O +
cis- O -
/ O -
trans O +
-DHPA O -
. O -

Cis- O -
and O +
trans- O +
1-carboxy-4-methylcyclohexane O +
were O +
purchased O +
from O +
Aldrich O -
. O -

The O +
chemical O +
purity O +
of O +
all O +
these O +
synthetic O +
compounds O +
as O +
well O +
as O +
the O +
isotope O +
purity O +
of O +
labeled O +
compounds O +
was O +
99 O -
% O -
. O -

N O -
,- O -
O O +
-Bis- O -
( O -
trimethylsilyl O -
) O -
silyltrifluoroacetamide O +
( O -
BSTFA O -
) O +
was O +
obtained O +
from O +
Pierce O +
( O -
Rockford O -
, O +
IL O -
, O +
USA O -
) O -
. O -

Acetonitrile O +
( O -
HPLC O +
grade O -
) O +
was O +
purchased O +
from O +
Fisher O +
Scientific O +
( O -
Pittsburgh O -
, O +
PA O -
, O +
USA O -
) O -
. O -

All O +
other O +
organic O +
solvents O +
and O +
reagents O +
purchased O +
from O +
Fisher O +
Scientific O +
were O +
of O +
reagent O +
grade O -
. O -

2.2 O +
Sample O +
extraction O +
To O +
each O +
of O +
a O +
set O +
of O +
16 O -
× O -
125-mm O +
disposable O +
tubes O +
was O +
added O +
appropriate O +
amounts O +
of O +
the O +
internal O +
standards O +
in O +
acetonitrile O +
followed O +
by O +
gentle O +
evaporation O +
of O +
the O +
solvent O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O -

A O +
plasma O +
sample O +
( O -
0.5 O +
ml O +
or O +
less O -
) O +
was O +
then O +
added O +
and O +
the O +
content O +
mixed O -
. O -

The O +
sample O +
volume O +
of O +
less O +
than O +
0.5 O +
ml O +
was O +
made O +
up O +
to O +
0.5 O +
ml O +
by O +
addition O +
of O +
blank O +
mouse U-Species +
or O +
human U-Species +
plasma O -
. O -

Acetonitrile O +
( O -
1.0 O +
ml O -
) O +
was O +
added O +
to O +
precipitate O +
the O +
protein O -
. O -

The O +
mixture O +
was O +
centrifuged O +
at O +
500 O +
g O -
for O +
3 O +
min O -
. O -

The O +
supernatant O +
was O +
transferred O +
to O +
a O +
new O +
set O +
of O +
disposable O +
tubes O +
and O +
was O +
acidified O +
by O +
addition O +
of O +
10 O +
μl O +
of O +
3 O +
M O -
HCl O -
. O -

The O +
extraction O +
was O +
accomplished O +
with O +
3 O -
× O -
2 O +
ml O +
methylene O +
chloride O +
by O +
vigorously O +
mixing O +
on O +
a O +
vortex O -
- O -
mixer O +
for O +
10 O +
s O -
, O +
followed O +
by O +
centrifugation O +
at O +
500 O +
g O -
for O +
3 O +
min O -
. O -

The O +
methylene O +
chloride O +
extracts O +
were O +
combined O +
and O +
evaporated O +
to O +
dryness O +
by O +
a O +
stream O +
of O +
N2 O +
. O -

Forty O +
μl O +
of O +
60 O -
% O +
BSTFA O +
in O +
acetonitrile O +
was O +
then O +
added O -
. O -

The O +
content O +
was O +
allowed O +
to O +
stand O +
at O +
room O +
temperature O +
for O +
5 O +
min O +
before O +
analysis O +
by O +
GC O -
– O -
MS O -
. O -

2.3 O +
GC O -
– O -
MS O +
analysis O +
GC O -
– O -
MS O +
analysis O +
of O +
the O +
analytes O +
was O +
performed O +
on O +
a O +
Finnigan O +
MAT O +
ITS40 O +
( O -
Finnigan O +
MAT O -
, O +
San O +
Jose O -
, O +
CA O -
, O +
USA O -
) O +
coupled O +
to O +
a O +
3300 O -
/ O -
3400 O +
Model O +
Varian O +
gas O +
chromatograph O +
( O -
Walnut O +
Creek O -
, O +
CA O -
, O +
USA O -
) O -
. O -

The O +
gas O +
chromatograph O +
was O +
equipped O +
with O +
a O +
DB-5 O +
fused O -
- O -
silica O +
capillary O +
column O +
( O -
30 O +
m O -
× O -
0.25 O +
mm O -
) O +
wall O -
- O -
coated O +
with O +
0.25 O +
mm O +
of O +
cross O -
- O -
linked O +
95 O -
% O +
methyl- O +
and O +
5 O -
% O +
phenyl O -
- O -
polysiloxane O +
( O -
J&W O +
Scientific O -
, O +
Folsom O -
, O +
CA O -
, O +
USA O -
) O +
and O +
an O +
autosampler O +
( O -
Finnigan O +
MAT O -
) O -
. O -

Ultra O -
- O -
high O +
purity O +
helium O +
was O +
used O +
as O +
the O +
carrier O +
gas O +
with O +
a O +
head O +
pressure O +
of O +
15 O +
psi O +
( O -
ca O -
. O -

105 O -
Pa O -
) O -
. O -

The O +
injection O +
port O +
and O +
the O +
transfer O +
line O +
were O +
set O +
at O +
270 O -
° O -
C O -
. O -

The O +
oven O +
temperature O +
was O +
initiated O +
at O +
100 O -
° O -
C O +
for O +
1 O +
min O -
, O +
and O +
was O +
ramped O +
to O +
250 O -
° O -
C O +
at O +
15 O -
° O -
C O -
/ O -
min O -
, O +
then O +
increased O +
to O +
280 O -
° O -
C O +
at O +
30 O -
° O -
C O -
/ O -
min O -
. O -

The O +
column O +
was O +
held O +
at O +
250 O -
° O -
C O +
for O +
1 O +
min O -
. O -

Analysis O +
was O +
performed O +
using O +
chemical O +
ionization O +
mode O +
and O +
ammonia O +
was O +
used O +
as O +
the O +
reagent O +
gas O -
. O -

Quantitation O +
was O +
performed O +
in O +
the O +
selected O +
ion O +
monitor O +
mode O +
by O +
measuring O +
the O +
base O +
peak O +
of O +
either O +
MH+ O -
or O +
the O +
fragment O +
ions O +
characteristic O +
of O +
the O +
trimethylsilylated O +
derivatives O +
of O +
the O +
analytes O +
and O +
their O +
respective O +
internal O +
standards O -
. O -

The O +
peak O +
area O +
ratio O +
method O +
was O +
used O +
in O +
construction O +
of O +
the O +
calibration O +
curves O -
. O -

2.4 O +
13 O +
C O -
- O -
NMR O +
analysis O +
13 O +
C O -
- O -
NMR O +
spectra O +
were O +
recorded O +
on O +
either O +
a O +
Brucker O +
NR-250 O +
spectrometer O +
at O +
a O +
radio O +
frequency O +
of O +
62.89 O +
MHz O +
or O +
a O +
Brucker O +
AM-500 O +
spectrometer O +
at O +
a O +
radio O +
frequency O +
of O +
125.77 O +
MHz O +
with O +
tetramethylsilane O +
as O +
the O +
internal O +
standard O +
and O +
CDCl3 O -
as O +
the O +
solvent O -
. O -

2.5 O +
Separation O +
of O +
cis- O -
and O +
trans- O +
dihydroperillic O +
acid O +
A O +
mixture O +
of O +
synthetic O +
cis- O -
and O +
trans- O +
dihydroperillic O +
acids O +
was O +
separated O +
by O +
thin O -
- O -
layer O +
chromatography O -
. O -

The O +
mixture O +
( O -
10 O +
mg O -
) O +
was O +
dissolved O +
in O +
a O +
small O +
volume O +
of O +
CH2 O +
Cl2 O -
and O +
the O +
solution O +
was O +
applied O +
onto O +
a O +
precoated O +
silica O +
gel O +
G O +
60 O +
thin O -
- O -
layer O +
plate O +
( O -
EM O +
Merck O -
, O +
thickness O +
0.2 O +
mm O -
, O +
20 O -
× O -
20 O +
cm O -
) O -
. O -

This O +
plate O +
was O +
developed O +
ascendingly O +
with O +
50:1 O +
CH2 O +
Cl2 O +
–MeOH O +
on O +
a O +
lined O +
tank O +
for O +
one O +
full O -
- O -
length O -
. O -

Under O +
UV O +
light O +
visualization O -
, O +
two O +
overlapping O +
spots O +
( O -
ca O -
. O +
50 O -
% O -
) O +
( O -
R O +
f O -
0.55–0.76 O -
) O +
were O +
seen O +
and O +
the O +
upper O +
portion O +
of O +
the O +
faster O -
- O -
running O +
spot O +
( O -
R O +
f O -
0.72–0.76 O -
) O +
was O +
scrapped O +
off O +
and O +
eluted O +
with O +
CH2 O +
Cl2 O +
. O -

The O +
collected O +
compound O +
( O -
ca O -
. O -

2 O +
mg O -
) O +
was O +
found O +
to O +
be O +
the O +
pure O +
component O +
corresponding O +
to O +
a O +
retention O +
time O +
of O +
6.3 O +
min O +
on O +
GC O -
– O -
MS O +
using O +
the O +
condition O +
as O +
described O +
above O -
. O -

The O +
lower O +
portion O +
of O +
the O +
spot O +
was O +
also O +
collected O +
and O +
GC O -
– O -
MS O +
still O +
showed O +
a O +
mixture O +
of O +
cis O -
/ O -
trans O +
-DHPA O +
with O +
retention O +
times O +
of O +
6.3 O +
and O +
6.7 O +
min O -
. O -

Attempts O +
to O +
further O +
resolve O +
these O +
components O +
were O +
unsuccessful O -
. O -

2.6 O +
Assay O +
characterization O +
and O +
validation O +
Detection O +
limit O +
was O +
measured O +
by O +
reducing O +
the O +
amount O +
of O +
each O +
analyte O +
until O +
the O +
signal O -
- O -
to O -
- O -
noise O +
equaled O +
to O +
four O -
, O +
which O +
is O +
defined O +
as O +
the O +
detection O +
limit O -
. O -

The O +
recovery O +
was O +
estimated O +
by O +
comparing O +
the O +
ratio O +
of O +
the O +
extracted O +
analytes O +
to O +
the O +
unextracted O +
internal O +
standard O +
with O +
that O +
of O +
the O +
unextracted O +
pairs O -
. O -

Within O -
- O -
run O +
precision O +
for O +
POH O -
, O +
PA O -
, O +
cis- O -
and O +
trans- O +
DHPA O +
was O +
determined O +
by O +
analyzing O +
six O +
replicates O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
. O -

The O +
concentrations O +
used O +
were O -
: O +
for O +
POH O +
at O +
2 O -
, O +
4 O -
, O +
20 O -
, O +
200 O +
and O +
2000 O +
ng O -
/ O -
ml O -
, O +
for O +
PA O +
at O +
40 O -
, O +
200 O -
, O +
and O +
2000 O +
ng O -
/ O -
ml O -
, O +
and O +
for O +
cis- O -
and O +
trans- O +
DHPA O +
each O +
at O +
20 O -
, O +
100 O -
, O +
and O +
1000 O +
ng O -
/ O -
ml O -
. O -

Between O -
- O -
run O +
precision O +
was O +
evaluated O +
by O +
analyzing O +
the O +
variation O +
of O +
the O +
slopes O +
of O +
six O +
standard O +
curves O +
for O +
each O +
analyte O +
obtained O +
on O +
six O +
different O +
days O -
. O -

2.7 O +
Pilot O +
animal U-Species +
study O +
The O +
femoral O +
and O +
jugular O +
veins O +
of O +
a O +
Sprague B-Species -
- I-Species -
Dawley I-Species +
rat L-Species +
weighing O +
350 O +
g O +
were O +
cannulated O +
under O +
ether O +
anesthesia O -
. O -

Three O +
hours O +
after O +
recovery O -
, O +
the O +
animal U-Species +
was O +
given O +
neat O +
perillyl O +
alcohol O +
( O -
ca O -
. O -

22 O +
μl O -
) O +
at O +
23 O +
mg O -
/ O -
kg O +
i.v O -
. O -

via O +
the O +
femoral O +
cannula O +
over O +
30 O +
s O +
followed O +
by O +
a O +
rinse O +
of O +
0.5 O +
ml O +
normal O +
saline O -
. O -

At O +
the O +
time O +
schedule O +
of O +
0 O -
, O +
3 O -
, O +
5 O -
, O +
10 O -
, O +
30 O -
, O +
60 O -
, O +
120 O -
, O +
180 O -
, O +
240 O -
, O +
300 O -
, O +
360 O -
, O +
480 O -
, O +
720 O -
, O +
960 O -
, O +
1200 O -
, O +
and O +
1440 O +
min O +
following O +
dosing O -
, O +
approximately O +
0.2 O +
ml O +
of O +
heparinized O +
blood O +
each O +
was O +
withdrawn O +
from O +
the O +
jugular O +
vein O +
cannula O -
. O -

Plasma O +
was O +
separated O +
by O +
centrifugation O -
. O -

An O +
aliquot O +
of O +
each O +
plasma O +
sample O +
was O +
appropriately O +
diluted O +
with O +
blank O +
rat U-Species +
plasma O +
to O +
make O +
up O +
to O +
0.5 O +
ml O -
. O -

Under O +
this O +
condition O -
, O +
the O +
measured O +
concentrations O +
were O +
in O +
the O +
range O +
of O +
the O +
calibration O -
- O -
curve O -
. O -

To O +
each O +
plasma O +
sample O +
was O +
added O +
200 O +
ng O +
of O +
the O +
internal O +
standard O +
followed O +
by O +
an O +
addition O +
of O +
1.0 O +
ml O +
acetonitrile O +
to O +
precipitate O +
the O +
protein O -
. O -

The O +
mixture O +
was O +
centrifuged O +
at O +
2000 O +
g O -
for O +
5 O +
m. O +
The O +
supernatant O +
was O +
removed O +
and O +
frozen O +
at O +
−20 O -
° O -
C O +
until O +
analysis O -
. O -

2.8 O +
Preliminary O +
clinical O +
study O +
The O +
clinical O +
study O +
is O +
a O +
part O +
of O +
an O +
ongoing O +
Phase O +
I O +
evaluation O +
of O +
POH O +
as O +
a O +
chemopreventative O +
agent O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
. O -

The O +
Phase O +
I O +
protocol O +
was O +
approved O +
by O +
the O +
Institution O +
Review O +
Board O +
( O -
IRB O -
) O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
. O -

Subjects U-Species +
with O +
a O +
personal O +
history O +
of O +
AJCC O +
Stage O +
I O -
– O -
IIIa O +
breast O +
cancer O +
who O +
have O +
undergone O +
definitive O +
resection O +
with O +
curative O +
intent O +
and O +
who O +
have O +
completed O +
all O +
adjuvant O +
radiation O +
therapy O -
, O +
chemotherapy O -
, O +
and O +
reversible O +
hormone O +
therapy O +
are O +
eligible O +
to O +
enroll O +
in O +
this O +
study O -
. O -

All O +
subjects U-Species +
were O +
in O +
good O +
general O +
health O +
with O +
adequate O +
major O +
organ O +
functions O +
and O +
ECOG O +
Performance O +
Status O +
of O +
0–1 O -
. O -

Patients U-Species +
were O +
treated O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O -
, O +
Cleveland O -
, O +
Ohio O -
. O -

The O +
current O +
study O +
was O +
limited O +
to O +
patients U-Species +
at O +
the O +
first O +
of O +
the O +
five O +
dose O +
levels O -
. O -

Dose O +
at O +
0.5 O +
g O -
/ O -
m2 O -
was O +
given O +
as O +
capsules O -
, O +
which O +
were O +
supplied O +
by O +
the O +
National O +
Cancer O +
Institute O -
. O -

Following O +
dosing O -
, O +
blood O +
samples O +
were O +
drawn O +
at O +
0 O +
( O -
predose O -
) O -
, O +
0.25 O -
, O +
0.5 O -
, O +
0.75 O -
, O +
1.0 O -
, O +
1.5 O -
, O +
2.0 O -
, O +
3.0 O -
, O +
4.0 O -
, O +
6.0 O -
, O +
8.0 O -
, O +
10.0 O -
, O +
and O +
24 O +
h. O +
Plasma O +
was O +
separated O +
from O +
red O +
blood O +
cells O +
by O +
centrifugation O +
and O +
kept O +
frozen O +
at O +
−20 O -
° O -
C O +
until O +
shipment O -
. O -

All O +
frozen O +
specimens O +
were O +
then O +
shipped O +
in O +
a O +
dry O -
- O -
ice O +
container O +
( O -
overnight O -
) O +
to O +
Dr. O +
Chan O -
's O +
Laboratory O +
at O +
the O +
Ohio O +
State O +
University O -
. O -

Plasma O +
samples O +
were O +
analyzed O +
in O +
the O +
same O +
manner O +
as O +
the O +
rat U-Species +
plasma O +
samples O -
. O -

2.9 O +
Quality O +
control O +
and O +
stability O +
Two O +
sets O +
of O +
spiked O +
plasma O +
samples O +
consisting O +
of O +
three O +
concentration O +
levels O -
, O +
20 O -
, O +
50 O -
, O +
and O +
100 O +
ng O -
/ O -
ml O +
of O +
POH O -
, O +
PA O -
, O +
cis- O +
/trans- O +
DHPA O +
were O +
prepared O +
and O +
frozen O +
at O +
−20 O -
° O -
C O -
. O -

One O +
frozen O +
set O +
was O +
sent O +
to O +
the O +
Laboratory O +
at O +
the O +
Cleveland O +
Clinic O +
Foundation O +
by O +
overnight O +
courier O +
service O +
in O +
dry O -
- O -
ice O -
. O -

After O +
storage O +
for O +
approximately O +
one O +
week O +
at O +
−20 O -
° O -
C O -
, O +
the O +
same O +
samples O +
were O +
returned O +
by O +
courier O +
service O +
to O +
the O +
Ohio O +
State O +
University O +
Laboratory O -
. O -

Another O +
set O +
of O +
samples O +
were O +
maintained O +
frozen O +
at O +
the O +
Ohio O +
State O +
University O +
Laboratory O +
for O +
the O +
same O +
duration O +
until O +
analysis O -
. O -

Drug O +
and O +
metabolite O +
levels O +
were O +
analyzed O +
in O +
these O +
two O +
sets O +
of O +
samples O +
at O +
the O +
same O +
time O +
and O +
the O +
results O +
were O +
compared O -
. O -

3 O +
Results O +
3.1 O +
Analysis O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
The O +
GC O -
– O -
MS O +
mass O +
spectra O +
of O +
POH O -
, O +
PA O +
and O +
cis- O +
/trans- O +
DHPA O +
and O +
their O +
internal O +
standards O -
, O +
POH O -
- O -
d3 O -
and O +
13 O +
C O -
- O -
PA O -
- O -
d2 O -
are O +
shown O +
in O +
Fig. O +
1 O +
. O -

As O +
shown O -
, O +
silylated O +
POH O +
and O +
its O +
internal O +
standard O +
each O +
showed O +
the O +
base O +
peak O +
at O +
m O -
/ O -
z O -
135 O +
and O +
138 O +
corresponding O +
to O +
their O +
C O -
– O -
O O +
cleavages O -
. O -

MH+ O -
ions O +
as O +
their O +
TMS O +
derivatives O +
at O +
m O -
/ O -
z O -
239 O +
and O +
m O -
/ O -
z O -
242 O -
, O +
respectively O -
, O +
were O +
detected O +
for O +
PA O +
and O +
13 O +
C O -
- O -
PA O -
- O -
d2 O -
as O +
the O +
base O +
peak O -
, O +
and O +
also O +
for O +
cis- O +
/trans- O +
DHPA O +
at O +
m O -
/ O -
z O -
241 O +
at O +
55 O -
% O +
relative O +
abundance O -
. O -

These O +
ions O +
were O +
used O +
for O +
subsequent O +
quantitation O -
. O -

On O +
this O +
basis O -
, O +
a O +
typical O +
set O +
of O +
GC O +
mass O +
chromatograms O +
of O +
human U-Species +
and O +
rat U-Species +
plasma O +
extracts O +
is O +
shown O +
in O +
Fig. O +
2 O -
. O -

As O +
shown O -
, O +
all O +
analytes O +
were O +
detected O +
as O +
symmetrical O +
peaks O +
and O +
cis- O -
and O +
trans- O +
DHPA O +
were O +
well O +
resolved O -
. O -

The O +
retention O +
times O +
of O +
the O +
analytes O +
were O -
: O +
POH O -
/ O -
POH O -
- O -
d3 O -
at O +
6.2 O +
min O -
, O +
PA O -
/ O -
13 O +
C O -
- O -
PA O -
- O -
d2 O -
at O +
7.3 O +
min O -
, O +
cis- O +
DHPA O +
at O +
6.3 O +
min O -
, O +
and O +
trans- O +
DHPA O +
at O +
6.7 O +
min O -
. O -

The O +
assignments O +
of O +
cis- O -
and O +
trans- O +
DHPA O +
are O +
described O +
below O +
and O +
coincided O +
with O +
those O +
of O +
Phillips O +
et O +
al. O +
[ O -
11 O -
] O +
. O -

No O +
interference O +
peaks O +
at O +
the O +
selected O +
ion O +
regions O +
were O +
found O +
in O +
the O +
human U-Species +
or O +
rat U-Species +
plasma O +
blank O -
, O +
except O +
for O +
low O +
levels O +
of O +
signal O +
contributed O +
by O +
the O +
internal O +
standards O -
. O -

These O +
interference O +
contributions O +
were O +
due O +
to O +
incomplete O +
isotope O +
labeling O +
and O +
were O +
all O +
< O -
2 O -
% O -
. O -

Thus O -
, O +
the O +
ions O +
monitored O +
at O +
m O -
/ O -
z O -
135 O -
, O +
138 O -
, O +
239 O -
, O +
242 O +
and O +
241 O +
were O +
considered O +
to O +
be O +
highly O +
specific O +
and O +
sensitive O +
for O +
detecting O +
POH O +
and O +
its O +
metabolites O -
. O -

3.2 O +
Assignments O +
of O +
cis- O -
and O +
trans- O +
DHPA O +
Phillips O +
et O +
al. O +
[ O -
11 O -
] O -
using O +
GC O -
– O -
MS O +
method O +
with O +
electron O -
- O -
impact O +
ionization O +
partially O +
resolved O +
the O +
underivatized O +
cis- O -
and O +
trans- O +
DHPA O -
. O -

On O +
the O +
basis O +
of O +
the O +
different O +
mass O +
spectral O +
fragmentation O +
patterns O +
of O +
these O +
two O +
isomers O +
augmented O +
by O +
a O +
quantum O +
mechanical O +
calculation O +
to O +
correlate O +
the O +
configuration O +
and O +
mass O +
fragmentation O +
preference O -
, O +
they O +
assigned O +
the O +
smaller O +
component O +
with O +
a O +
shorter O +
retention O +
time O +
as O +
the O +
cis- O +
isomer O +
and O +
the O +
larger O +
slower O -
- O -
eluting O +
component O +
as O +
the O +
trans- O +
isomer O -
. O -

Since O +
we O +
employed O +
derivatization O +
in O +
our O +
GC O -
– O -
MS O +
assay O -
, O +
direct O +
correlation O +
of O +
our O +
system O +
with O +
those O +
of O +
Philips O +
et O +
al. O +
was O +
difficult O -
. O -

Therefore O -
, O +
we O +
resorted O +
to O +
use O +
an O +
alternative O +
method O +
for O +
the O +
assignment O +
of O +
these O +
isomers O -
. O -

Using O +
thin O +
layer O +
chromatographic O +
separation O -
, O +
we O +
were O +
able O +
to O +
partially O +
resolve O +
the O +
two O +
isomers O -
. O -

The O +
faster O +
running O +
spot O +
was O +
enriched O +
and O +
accumulated O -
. O -

The O +
GC O -
– O -
MS O +
showed O +
that O +
the O +
enriched O +
component O +
had O +
a O +
retention O +
time O +
of O +
6.3 O +
min O -
. O -

The O +
H O -
- O -
decoupled O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
synthetic O +
mixture O +
of O +
cis- O -
and O +
trans- O +
DHPA O +
showed O +
sets O +
of O +
doublets O +
at O +
180.97 O +
and O +
181.65 O +
ppm O +
corresponding O +
to O +
the O +
-COOH O +
signals O -
, O +
at O +
149.76 O +
and O +
149.96 O +
ppm O +
corresponding O +
to O +
C-1′ O -
, O +
at O +
108.54 O +
and O +
108.75 O +
ppm O +
corresponding O +
to O +
C-2′ O -
, O +
at O +
44.15 O +
and O +
44.55 O +
ppm O +
corresponding O +
to O +
C-4 O -
, O +
at O +
39.37 O +
and O +
42.98 O +
ppm O +
corresponding O +
to O +
C-1 O -
, O +
and O +
at O +
above O +
40 O +
ppm O +
for O +
the O +
remaining O +
carbons O +
and O +
the O +
side O +
chain O +
methyl O -
. O -

The O +
carbon O +
chemical O +
shift O +
assignments O +
were O +
based O +
on O +
the O +
H O -
- O -
coupling O -
, O +
H O -
- O -
decoupling O +
data O -
, O +
and O +
comparison O +
with O +
known O +
assignments O +
of O +
several O +
monoterpenes O +
and O +
cyclohexane O +
systems O +
[ O -
16–18 O -
] O +
. O -

However O -
, O +
the O +
H O -
- O -
decoupled O +
13 O +
C O -
- O -
NMR O +
spectrum O +
of O +
the O +
above O +
described O +
enriched O +
component O +
failed O +
to O +
show O +
signals O +
with O +
adequate O +
intensity O +
at O +
the O +
downfield O +
region O +
( O -
180 O +
ppm O -
) O +
but O +
signals O +
above O +
120 O +
ppm O +
were O +
clearly O +
discernible O +
with O +
unequal O +
intensity O -
, O +
consistent O +
with O +
the O +
enrichment O -
. O -

Based O +
on O +
the O +
cyclohexanol O +
system O -
, O +
chemical O +
shift O +
of O +
C-1 O +
appears O +
to O +
be O +
most O +
sensitive O +
to O +
cis- O +
/trans- O +
isomerism O +
[ O -
18 O -
] O +
. O -

Thus O -
, O +
13 O +
C O -
- O -
NMR O +
spectra O +
of O +
cis- O -
and O +
trans- O +
1,4-methyl O +
cyclohexanol O +
show O +
C-1 O +
at O +
66.2 O +
and O +
70.0 O +
ppm O -
, O +
respectively O -
, O +
and O +
cis- O -
and O +
trans- O +
1,4-t O -
- O -
butylcyclohexanol O +
show O +
C-1 O +
at O +
65.0 O +
and O +
70.4 O +
ppm O -
, O +
respectively O -
. O -

In O +
both O +
cases O +
C-1s O +
for O +
the O +
cis- O +
isomer O +
are O +
several O +
ppm O +
upfield O +
from O +
the O +
trans- O +
isomer O -
. O -

The O +
enriched O +
DHPA O +
isomer O +
showed O +
only O +
a O +
singlet O +
at O +
39.36 O +
ppm O +
of O +
C-1 O +
with O +
the O +
more O +
downfield O +
signal O +
missing O -
. O -

This O +
suggests O +
that O +
the O +
enriched O +
DHPA O +
isomer O +
may O +
be O +
the O +
cis- O +
isomer O -
. O -

This O +
possibility O +
was O +
further O +
supported O +
by O +
examination O +
of O +
the O +
13 O +
C O -
- O -
NMR O +
spectra O +
of O +
synthetic O +
cis- O -
and O +
trans- O +
1-carboxyl-4-methylcyclohexanes O +
which O +
showed O +
C-1 O +
chemical O +
shifts O +
at O +
31.32 O +
and O +
34.21 O +
ppm O -
, O +
respectively O -
. O -

Again O -
, O +
the O +
C-1 O +
of O +
cis- O +
isomer O +
shows O +
nearly O +
3 O +
ppm O +
upfield O +
from O +
that O +
of O +
the O +
trans- O +
isomer O -
. O -

In O +
order O +
to O +
correlate O +
the O +
GC O -
– O -
MS O +
retention O +
times O +
of O +
the O +
silyl O +
derivatives O +
of O +
these O +
cyclohexane O +
isomers O +
with O +
their O +
stereochemistry O -
, O +
cis- O -
and O +
trans- O +
1-carboxyl-4-methylcyclohexane O +
were O +
silylated O +
with O +
BSTFA O -
. O -

The O +
GC O -
– O -
MS O +
showed O +
that O +
the O +
cis- O +
isomer O +
gave O +
a O +
retention O +
time O +
of O +
4.12 O +
min O +
while O +
the O +
trans- O +
isomer O +
gave O +
a O +
retention O +
time O +
of O +
4.28 O +
min O +
using O +
the O +
similar O +
temperature O +
programming O +
and O +
column O +
as O +
those O +
of O +
DHPA O -
. O -

On O +
this O +
basis O -
, O +
it O +
was O +
concluded O +
that O +
the O +
DHPA O +
isomer O +
with O +
the O +
shorter O +
retention O +
time O +
was O +
the O +
cis- O +
isomer O +
and O +
that O +
with O +
the O +
longer O +
retention O +
time O +
was O +
the O +
isomer O +
with O +
trans- O +
configuration O -
. O -

Interestingly O -
, O +
the O +
assignment O +
appeared O +
to O +
be O +
the O +
same O +
as O +
those O +
of O +
Philips O +
et O +
al. O +
[ O -
11 O -
] O +
, O +
based O +
on O +
the O +
relative O +
retention O +
times O +
of O +
the O +
underivatized O +
compounds O +
and O +
the O +
relative O +
amount O +
of O +
the O +
DHPA O +
found O +
as O +
metabolite O +
in O +
vivo O -
. O -

3.3 O +
Within O -
- O -
run O +
validation O +
When O +
plotting O +
the O +
peak O +
area O +
ratios O +
between O +
the O +
analyte O +
and O +
the O +
internal O +
standard O +
against O +
the O +
added O +
concentrations O +
of O +
the O +
analytes O +
a O +
linear O +
relationship O +
was O +
obtained O +
within O +
the O +
concentration O +
ranges O +
monitored O +
for O +
all O +
analytes O -
. O -

In O +
both O +
human U-Species +
and O +
rat U-Species +
plasma O -
, O +
for O +
POH O +
linearity O +
was O +
demonstrated O +
from O +
2 O +
to O +
2000 O +
ng O -
/ O -
ml O -
, O +
for O +
PA O +
and O +
trans- O +
DHPA O +
from O +
10 O +
to O +
1000 O +
ng O -
/ O -
ml O -
, O +
and O +
for O +
cis- O +
DHPA O +
20 O +
to1000 O +
ng O -
/ O -
ml O -
. O -

The O +
routine O +
sensitivity O +
limit O +
was O +
found O +
to O +
be O +
2 O +
ng O -
/ O -
ml O +
for O +
POH O -
, O +
10 O +
ng O -
/ O -
ml O +
for O +
PA O +
and O +
trans- O +
DHPA O -
, O +
and O +
20 O +
ng O -
/ O -
ml O +
for O +
cis- O +
DHPA O -
. O -

The O +
within O -
- O -
run O +
validation O +
data O +
for O +
POH O +
and O +
metabolites O +
in O +
rat U-Species +
and O +
human U-Species +
plasma O +
are O +
shown O +
in O +
Table O +
1 O -
. O -

Also O +
shown O +
in O +
the O +
same O +
table O +
are O +
the O +
accuracy O +
data O -
. O -

As O +
shown O -
, O +
the O +
% O +
C.V. O +
values O +
ranged O +
from O +
0.5 O +
to O +
8 O -
% O +
with O +
the O +
majority O +
falling O +
below O +
5 O -
% O +
and O +
a O +
mean O +
accuracy O +
value O +
of O +
98.6 O -
% O -
. O -

3.4 O +
Between O -
- O -
run O +
validation O +
The O +
between O -
- O -
run O +
variation O +
for O +
POH O +
in O +
human U-Species +
plasma O +
was O +
5.5 O -
% O +
and O +
6.3 O -
% O +
in O +
rat U-Species +
plasma O +
as O +
measured O +
by O +
the O +
slopes O +
of O +
six O +
calibration O +
curves O +
in O +
each O +
medium O +
at O +
six O +
different O +
occasions O +
( O -
Table O +
2 O -
) O -
. O -

At O +
each O +
case O -
, O +
the O +
mean O +
intercept O +
is O +
less O +
than O +
2 O +
ng O -
/ O -
ml O +
equivalent O -
. O -

The O +
between O -
- O -
run O +
C.V.s O +
for O +
PA O +
by O +
similar O +
measurements O +
were O +
5.5 O -
% O +
in O +
human U-Species +
plasma O +
and O +
3.4 O -
% O +
in O +
rat U-Species +
plasma O -
, O +
all O +
n O +
= O -
6 O -
. O -

The O +
between O -
- O -
run O +
C.V.s O +
for O +
cis- O +
DHPA O +
in O +
human U-Species +
and O +
rat U-Species +
plasma O +
were O +
6.9 O -
% O +
and O +
5.1 O -
% O -
, O +
respectively O +
( O -
n O +
= O -
6 O -
) O -
. O -

The O +
between O -
- O -
run O +
C.V.s O +
for O +
trans- O +
DHPA O +
were O +
5.0 O +
and O +
6.3 O -
% O -
, O +
respectively O +
( O -
n O +
= O -
6 O -
) O +
( O -
Table O +
2 O +
) O -
. O -

In O +
these O +
cases O -
, O +
the O +
mean O +
intercepts O +
for O +
the O +
calibration O +
curves O +
of O +
the O +
metabolites O +
were O +
less O +
than O +
5 O +
ng O -
/ O -
ml O +
analyte O +
equivalent O -
. O -

3.5 O +
Recovery O +
and O +
quality O +
control O +
The O +
recovery O +
values O +
of O +
POH O -
, O +
PA O -
, O +
cis- O -
and O +
trans- O +
DHPA O +
from O +
the O +
entire O +
procedure O +
were O -
: O +
98 O -
% O -
, O +
59 O -
% O -
, O +
64 O -
% O +
and O +
72 O -
% O +
in O +
human U-Species +
plasma O +
and O +
90 O -
% O -
, O +
77 O -
% O -
, O +
69 O -
% O +
and O +
76 O -
% O +
in O +
rat U-Species +
plasma O -
, O +
respectively O -
. O -

There O +
was O +
less O +
than O +
3 O -
% O +
variation O +
for O +
POH O +
and O +
metabolite O +
levels O +
in O +
plasma O +
samples O +
kept O +
at O +
−20 O -
° O -
C O +
over O +
the O +
course O +
of O +
four O +
weeks O +
and O +
there O +
was O +
no O +
appreciable O +
difference O +
in O +
the O +
samples O +
tested O +
through O +
mailing O +
via O +
the O +
courier O +
service O -
. O -

3.6 O +
Preliminary O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
a O +
rat U-Species +
Fig. O +
3 O -
shows O +
a O +
plasma O +
concentration O -
– O -
time O +
profile O +
of O +
POH O +
and O +
metabolites O +
in O +
the O +
rat U-Species +
given O +
POH O +
at O +
23 O +
mg O -
/ O -
kg O +
i.v O -
. O -

As O +
shown O -
, O +
POH O +
was O +
detected O +
in O +
circulation O +
up O +
to O +
360 O +
min O +
with O +
the O +
initial O +
concentration O +
at O +
2089 O +
ng O -
/ O -
ml O -
. O -

The O +
concentrations O +
declined O +
biexponentially O +
with O +
a O +
terminal O +
half O -
- O -
life O +
of O +
approximately O +
135 O +
min O -
. O -

PA O +
appeared O +
in O +
plasma O +
in O +
the O +
first O +
sample O +
at O +
3 O +
min O +
and O +
peaked O +
at O +
10 O +
at O +
8893 O +
ng O -
/ O -
ml O +
and O +
declined O +
approximately O +
monoexponentially O +
to O +
about O +
35 O +
ng O -
/ O -
ml O +
at O +
720 O +
min O -
. O -

Cis O +
- O +
and O +
trans- O +
DHPA O +
appeared O +
in O +
plasma O +
at O +
about O +
10 O +
min O +
and O +
peaked O +
at O +
about O +
60 O +
min O +
and O +
also O +
declined O +
monoexponentially O -
. O -

The O +
plasma O +
levels O +
of O +
the O +
trans- O +
metabolite O +
were O +
significantly O +
higher O +
than O +
those O +
of O +
the O +
cis- O +
isomer O -
. O -

An O +
unknown O +
metabolite O -
, O +
labeled O +
as O +
M2 O -
, O +
was O +
also O +
detected O +
in O +
plasma O +
at O +
high O +
levels O +
and O +
this O +
metabolite O +
has O +
the O +
same O +
m O -
/ O -
z O -
value O +
as O +
PA O +
but O +
with O +
a O +
retention O +
time O +
of O +
8.3 O +
min O -
. O -

M2 O +
appeared O +
in O +
plasma O +
at O +
3 O +
min O +
at O +
2070 O +
ng O -
/ O -
ml O +
PA O +
equivalent O +
and O +
peaked O +
at O +
10 O +
min O +
at O +
levels O +
over O +
6000 O +
ng O -
/ O -
ml O -
. O -

Although O +
the O +
initial O +
levels O +
of O +
this O +
metabolite O +
were O +
slightly O +
lower O +
than O +
those O +
of O +
PA O -
, O +
the O +
levels O +
after O +
2 O +
h O +
exceeded O +
those O +
of O +
PA O +
after O +
and O +
were O +
detectable O +
even O +
at O +
1440 O +
min O -
. O -

The O +
plasma O +
half O -
- O -
life O +
was O +
approximately O +
3 O +
h. O -
3.7 O +
Preliminary O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
a O +
patient U-Species +
The O +
plasma O +
concentration O -
– O -
time O +
profiles O +
of O +
POH O +
and O +
its O +
metabolites O +
were O +
measured O +
in O +
a O +
patient U-Species +
who O +
received O +
a O +
p.o O -
. O -

dose O +
at O +
500 O +
mg O -
/ O -
m2 O -
and O +
the O +
results O +
are O +
shown O +
in O +
Fig. O +
4 O -
. O -

As O +
shown O -
, O +
POH O -
, O +
PA O -
, O +
cis- O -
and O +
trans- O +
DHPA O +
were O +
all O +
detectable O +
in O +
plasma O -
. O -

POH O +
was O +
detectable O +
at O +
3.5 O +
ng O -
/ O -
ml O +
at O +
0.75 O +
h O +
and O +
peaked O +
at O +
5.0 O +
ng O -
/ O -
ml O +
at O +
1.5 O +
h. O +
The O +
levels O +
then O +
declined O +
monoexponentially O +
with O +
a O +
half O -
- O -
life O +
of O +
approximately O +
2.3 O +
h. O +
The O +
AUC O +
value O +
was O +
22 O +
ng O -
/ O -
ml O +
h. O +
The O +
most O +
abundant O +
metabolite O +
in O +
circulation O +
was O +
PA O +
which O +
peaked O +
slowly O +
at O +
11400 O +
ng O -
/ O -
ml O +
at O +
about O +
1.5 O +
h. O +
PA O +
was O +
formed O +
rapidly O +
following O +
the O +
POH O +
administration O -
, O +
and O +
remained O +
at O +
a O +
steady O -
- O -
state O +
for O +
1–2 O +
h O +
before O +
declining O -
. O -

The O +
level O +
then O +
declined O +
monoexponentially O +
to O +
about O +
40 O +
ng O -
/ O -
ml O +
at O +
8 O +
h O +
and O +
became O +
undetectable O +
thereafter O -
. O -

Similar O +
to O +
the O +
case O +
in O +
the O +
rat U-Species -
, O +
cis- O +
DHPA O +
levels O +
were O +
lower O +
than O +
those O +
of O +
trans O -
. O -

Two O +
previously O +
undescribed O +
metabolites O +
were O +
detected O +
in O +
circulation O -
. O -

M1 O +
gave O +
a O +
retention O +
time O +
of O +
7.7 O +
min O +
and O +
M2 O +
gave O +
a O +
retention O +
of O +
8.3 O +
min O -
, O +
which O +
appears O +
identical O +
to O +
the O +
one O +
described O +
in O +
the O +
rat U-Species -
. O -

Both O +
of O +
these O +
metabolites O +
gave O +
the O +
MH+ O -
ion O +
identical O +
to O +
that O +
of O +
PA O -
. O -

Levels O +
of O +
M2 O +
were O +
lower O +
than O +
those O +
of O +
PA O +
but O +
higher O +
than O +
those O +
of O +
M1 O -
. O -

M2 O +
peaked O +
at O +
over O +
1000 O +
ng O -
/ O -
ml O +
at O +
3 O +
h O -
, O +
and O +
M1 O +
peaked O +
at O +
76 O +
ng O -
/ O -
ml O +
at O +
1 O +
h. O -
4 O +
Discussion O +
Previous O +
GC O +
and O +
GC O -
– O -
MS O +
methods O +
failed O +
to O +
detect O +
POH O +
in O +
plasma O +
presumably O +
because O +
of O +
inadequate O +
sensitivity O +
[ O -
11 O -
] O +
. O -

The O +
reason O +
for O +
the O +
low O +
sensitivity O +
may O +
be O +
due O +
to O +
the O +
use O +
of O +
electron O +
impact O +
mass O +
spectrometry O +
for O +
detection O -
. O -

Excess O +
fragmentation O +
under O +
the O +
EI O +
condition O +
significantly O +
reduced O +
the O +
assay O +
sensitivity O -
. O -

Moreover O -
, O +
POH O +
and O +
its O +
metabolites O +
such O +
as O +
PA O +
are O +
still O +
rather O +
polar O -
. O -

Tailing O +
of O +
their O +
GC O +
peaks O +
may O +
also O +
reduce O +
the O +
assay O +
sensitivity O -
. O -

The O +
present O +
method O +
used O +
a O +
soft O +
ammonia O +
chemical O +
ionization O -
, O +
which O +
could O +
reduce O +
fragmentation O +
and O +
increase O +
the O +
relative O +
abundance O +
of O +
the O +
ion O -
. O -

Additionally O -
, O +
we O +
also O +
found O +
that O +
BSTFA O +
derivatization O +
of O +
POH O +
and O +
its O +
metabolites O +
reduced O +
tailing O +
and O +
further O +
reduced O +
fragmentation O +
and O +
enhanced O +
sensitivity O -
. O -

Another O +
improvement O +
of O +
our O +
analytical O +
method O +
was O +
to O +
use O +
the O +
stable O +
isotopically O +
labeled O +
POH O +
and O +
PA O +
as O +
the O +
internal O +
standard O +
that O +
provided O +
the O +
excellent O +
C.V.s O +
obtained O -
. O -

Thus O -
, O +
the O +
current O +
assay O +
provided O +
more O +
than O +
a O +
hundred O -
- O -
fold O +
improvement O +
in O +
sensitivity O +
over O +
the O +
previous O +
GC O -
– O -
MS O +
method O -
, O +
and O +
made O +
it O +
possible O +
to O +
detect O +
circulating O +
POH O +
following O +
POH O +
administration O -
. O -

The O +
use O +
of O +
derivatization O +
and O +
a O +
capillary O +
column O +
in O +
this O +
method O +
also O +
permitted O +
the O +
complete O +
separation O +
of O +
cis- O -
and O +
trans- O +
DHPA O +
( O -
Fig. O +
3 O +
) O -
. O -

The O +
earlier O +
eluting O +
peak O +
( O -
6.3 O +
min O -
) O +
was O +
assigned O +
to O +
be O +
the O +
cis- O +
isomer O -
, O +
based O +
on O +
the O +
NMR O +
method O +
and O +
this O +
assignment O +
is O +
identical O +
to O +
those O +
of O +
Philip O +
et O +
al. O +
[ O -
11 O -
] O -
who O +
assigned O +
their O +
earlier O +
eluting O +
component O +
in O +
the O +
partially O +
resolved O +
pair O +
as O +
the O +
cis- O +
isomer O -
. O -

Both O +
the O +
preliminary O +
rat U-Species +
and O +
human U-Species +
pharmacokinetic O +
data O +
show O +
that O +
POH O +
was O +
detectable O +
in O +
circulation O +
for O +
the O +
first O +
time O +
following O +
POH O +
administration O -
. O -

Metabolites O +
of O +
POH O +
were O +
detected O +
in O +
high O +
levels O +
in O +
both O +
rat U-Species +
and O +
human U-Species +
plasma O -
. O -

PA O +
appeared O +
very O +
rapidly O +
in O +
circulation O +
and O +
rose O +
to O +
high O +
concentrations O -
, O +
suggesting O +
that O +
POH O +
underwent O +
rapid O +
metabolism O -
. O -

Both O +
cis- O -
and O +
trans- O +
DHPA O +
were O +
unequivocally O +
detected O +
in O +
the O +
human U-Species +
and O +
in O +
the O +
rat U-Species +
and O +
their O +
formation O +
as O +
a O +
mixture O +
was O +
previously O +
under O +
debate O +
[ O -
11 O -
] O +
. O -

Two O +
previously O +
undescribed O +
metabolites O +
were O +
detected O +
in O +
significant O +
levels O +
in O +
human U-Species +
plasma O +
and O +
one O +
also O +
in O +
the O +
rat U-Species -
. O -

These O +
two O +
metabolites O +
as O +
their O +
silylated O +
derivatives O +
gave O +
the O +
parent O +
ion O +
( O -
MH+ O +
) O +
at O +
m O -
/ O -
z O -
239 O +
identical O +
to O +
that O +
of O +
silylated O +
PA O +
but O +
with O +
different O +
retention O +
times O -
. O -

Characterization O +
of O +
these O +
metabolites O +
is O +
currently O +
underway O -
. O -

Thus O -
, O +
the O +
current O +
method O +
is O +
useful O +
to O +
support O +
preclinical O +
and O +
clinical O +
investigations O +
of O +
disposition O +
of O +
perillyl O +
alcohol O -
. O -

5 O +
Conclusion O +
A O +
GC O -
– O -
MS O +
stable O +
isotope O -
- O -
dilution O +
method O +
has O +
been O +
developed O +
for O +
the O +
analysis O +
of O +
perillyl O +
alcohol O +
and O +
its O +
metabolites O +
in O +
human U-Species +
and O +
animal U-Species +
plasma O +
and O +
the O +
method O +
has O +
been O +
validated O -
. O -

Unchanged O +
perillyl O +
alcohol O +
in O +
plasma O +
was O +
detected O +
in O +
human U-Species +
and O +
animal U-Species +
circulation O +
for O +
the O +
first O +
time O -
. O -

Isomers O +
of O +
a O +
reduced O +
metabolite O +
DHPA O +
have O +
been O +
total O +
resolved O +
and O +
detected O +
and O +
their O +
previous O +
cis- O -
and O +
trans- O +
assignments O +
verified O +
by O +
alternate O +
techniques O -
. O -

Two O +
new O +
metabolites O +
were O +
also O +
detected O -
. O -

This O +
GC O -
– O -
MS O +
can O +
be O +
applied O +
to O +
investigate O +
preclinical O +
and O +
clinical O +
pharmacokinetics O +
of O +
perillyl O +
alcohol O +
both O +
as O +
a O +
chemopreventative O +
and O +
chemotherapeutical O +
agent O -
. O -

Acknowledgments O +
This O +
study O +
was O +
in O +
part O +
supported O +
by O +
PHS O +
Contract O +
NCI O -
- O -
CN-55083070 O -
, O +
Task O +
22 O -
, O +
awarded O +
to O +
the O +
Cleveland O +
Clinic O +
Foundation O +
subcontracted O +
to O +
the O +
Ohio O +
State O +
University O +
and O +
by O +
P30 O +
CA16058 O +
by O +
the O +
National O +
Cancer O +
Institute O -
. O +

Eosinophils O +
may O +
play O +
important O +
roles O +
in O +
allergic O +
diseases O +
such O +
as O +
asthma O +
and O +
atopic O +
dermatitis O -
) O -
' O +
2 O +
In O +
such O +
diseases O -
, O +
eosinophiis O +
migrate O +
to O +
inflammatory O +
sites O +
and O +
degranulate O +
eytotoxic O +
proteins O +
such O +
as O +
major O +
basic O +
protein O +
and O +
eosinophil O -
- O -
derived O +
neurotoxin O +
( O -
EDN O -
) O -
. O -

The O +
cytotoxic O +
proteins O +
damage O +
tissues O +
and O +
cause O +
physiologic O +
abnormalities O +
in O +
patients U-Species +
with O +
allergic O +
diseases O -
. O -

Therefore O -
, O +
cosinophil O +
degranulation O +
inhibitors O +
may O +
be O +
anti O -
- O -
allergic O +
drugs O -
. O -

Recently O -
, O +
we O +
found O +
that O +
sulochrin O +
( O -
6 O -
) O -
, O +
a O +
metabolite O +
of O +
fungi U-Species -
, O +
was O +
a O +
specific O +
inhibitor O +
of O +
eosinophil O +
degranulation3 O +
and O +
also O +
inhibited O +
eosinophll O +
activation O +
and O +
chemotaxis O -
. O -

* O +
We O +
report O +
here O +
the O +
effects O +
of O +
ortho- O +
substituent O +
groups O +
on O +
inhibitory O +
activity O +
to O +
eosinophil O +
degranulation O -
. O -

Chemistry O +
Sulochrin O +
( O -
6 O -
) O +
was O +
synthesized O +
as O +
shown O +
in O +
scheme O +
1 O -
. O -

Benzoic O +
acid O +
benzyl O +
ester O +
( O -
5 O -
) O +
was O +
obtained O +
by O +
the O +
condensation O +
of O +
2-bromo O +
benzyl O +
alcohol O +
( O -
2 O -
) O +
and O +
benzoic O +
acid O +
( O -
4 O -
) O -
. O -

Anion O +
induced O +
rearrangement O +
of O +
( O -
5 O -
) O +
gave O +
1- O +
benzoyl O +
benzyl O +
alcohol O -
, O +
which O +
was O +
oxidized O +
to O +
benzoyl O +
benzoic O +
acid O +
without O +
isolation.5 O -
' O +
6 O +
Esterification O +
of O +
the O +
benzoyl O +
benzoic O +
acid O +
followed O +
by O +
debenzylatinn O +
afforded O +
sulochrin O +
( O -
6 O -
) O -
.7 O +
All O +
other O +
sulochrin O +
derivatives O +
except O +
for O +
( O -
9 O -
) O +
were O +
obtained O +
through O +
a O +
modified O +
methodology O -
. O -

Compound O +
9 O +
was O +
prepared O +
as O +
shown O +
in O +
scheme O +
2 O -
. O -

Results O +
and O +
Discussion O +
The O +
derivatives O +
of O +
sulochrin O +
( O -
6 O -
) O +
were O +
examined O +
for O +
their O +
inba"oitory O +
activity O +
against O +
eosinophil O +
degranulation O +
as O +
descn'bed O +
previously.3 O +
At O +
first O -
, O +
ester O +
derivatives O +
were O +
synthesized O +
to O +
examine O +
the O +
structure O -
- O -
activity O +
relationship O -
. O -

As O +
shown O +
in O +
Table O +
la O -
, O +
alkyl O +
esters O +
( O -
11 O -
- O -
15 O -
) O +
retained O +
activity O -
, O +
and O +
in O +
particular O -
, O +
n O -
- O -
butyl O +
and O +
see O -
- O -
butyl O +
esters O -
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O -

Pll O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00305 O -
- O -
4 O -
1946 O -
H. O +
Ohashi O +
et O +
al. O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O -

Scheme O +
I O -
OH O -
OBn O +
a O -
, O -
b O -
, O -
c O -
, O -
d O -
Br O -
Me O -
" O -
< O -
~ O -
OH O -
Me O -
" O -
" O -
~ O -
OBn O +
COOMe O -
" O -
~OH O -
e O -
, O -
f O +
1 O -
2 O -
3 O -
4 O -
O O -
OBn O -
7 O -
~ O -
-~ O +
OMe O +
QH13 O -
! O -

r O +
2 O -
+ O -
4 O +
P O -
5~ O +
15 O -
T O +
" O -
Br O +
BnO O -
" O +
- O -
.. O -

: O -
I O +
" O -
Me O -
h O -
, O -
i O -
, O -
j O -
, O -
k O -
, O -
I O -
I O -
" O -
~1 O +
- O +
1 O -
" O +
g O +
OMe O -
MeOOC O -
O O -
OH O +
9 O -
8 O -
5 O -
6 O +
( O -
Sulochrln O -
) O -
( O -
a O -
) O +
BnBr O -
, O +
K O -
~ O -
O~ O -
/ O -
CH3CN O -
/ O -
reflux,33 O -
% O -
; O +
( O -
b O -
) O +
Me O +
zSO4,K O -
~ O -
CO3 O -
/ O -
CHaCN O -
/ O -
reflux,96 O -
% O -
; O +
( O -
c O -
) O +
UAIH4 O -
/ O -
I'HF,96 O -
% O -
; O +
( O -
d O -
) O +
NBS O -
/ O -
CCI4,43 O -
% O -
; O +
( O -
e O -
) O +
BnBr O -
, O +
l O -
~ O -
COa O -
/ O -
DMF O -
/ O -
reflux,74 O -
% O -
; O +
( O -
f O -
) O +
t O -
- O -
BuOWiPr O -
= O -
O O -
/ O -
reflux,93 O -
% O -
; O +
( O -
g O -
) O +
DEAD O -
/ O -
PPh O -
. O -

VrHF,82 O -
% O -
; O +
( O -
h O -
) O +
n O -
- O -
BuLi O -
/ O -
1"HF,-78"C,45 O -
% O -
; O +
( O -
i O -
) O +
PDC O -
/ O -
DMF,54 O -
% O -
; O +
( O -
j O -
) O +
BudNH4 O -
) O -
KMnO,~=yddlne,81 O -
% O -
; O +
( O -
k O -
) O +
Mel O +
K2CO O -
~ O -
JDMF O -
; O +
( O -
I O -
) O +
Pd O -
( O -
OH O -
) O -
rCarbon O -
/ O -
EtOH O -
/ O -
Cyclohexene O -
/ O -
refiux O +
81 O -
% O -
Scheme O +
2 O -
Me O -
~ O -
OMe O +
o~ O -
OMe O +
OH O +
MeO O -
~ O -
OMe O -
~ O -
MeO'~OMe O -
. O -

HO O -
~ O -
Me O -
" O -
COOH O -
m O -
" O -
~ O -
" O -
COCI O -
n O -
, O -
p O +
7 O -
8 O -
O O -
OH O -
( O -
m O -
) O +
SOCle O -
; O +
( O -
n O -
) O +
n O -
- O -
BuLi O -
/ O -
THF O -
, O +
-4YC,15 O -
% O -
; O +
( O -
P O -
) O +
BBrdCH O -
= O -
Cle,64 O -
% O -
( O -
13 O +
and O +
14 O -
) O +
showed O +
more O +
potent O +
activity O +
than O +
sulochrin O +
( O -
6 O -
) O -
. O -

On O +
thc O +
other O +
hand O -
, O +
decarboxyl O +
and O +
flee O +
carboxylic O +
acid O +
derivatives O +
( O -
9 O +
and O +
10 O -
) O +
did O +
not O +
show O +
any O +
activity O +
even O +
at O +
10 O +
pM. O +
These O +
results O +
suggest O +
that O +
the O +
existence O +
of O -
H. O +
Ohashi O +
et O +
al. O -
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O -
1947 O -
Table O +
la O +
Effects O +
of O +
alkylester O +
on O +
eoslnophll O +
degranulation O -
OMe O -
OH O +
R1 O -
O O -
OH O -
Compound O -
R O -
, O -
ICso O +
( O -
mlcroM O -
) O -
Sulochrin O +
( O -
6 O -
) O +
9 O +
10 O +
11 O +
12 O +
13 O +
14 O +
15 O -
COOCHa O +
H O +
COOH O +
COOCH2CHa O +
COOCH O -
= O -
CH O -
= O -
CHa O +
COOCH O -
= O -
CH2CH O -
= O -
CHa O +
COO O -
( O -
CH O -
) O -
CHaCH O -
= O -
CHa O +
COO O -
( O -
CH= O -
) O -
sCH.~ O -
0.1 O +
> O -
10 O +
> O -
10 O +
0.1 O +
0.1 O +
0.04 O +
0.03 O +
0.3 O -
Table O +
lb O +
Effects O +
of O +
phenolic O +
hydroxyl O +
groups O +
on O +
eoslnophil O +
degranulation O -
Sulochdn O +
( O -
6 O -
) O +
HO-,~zFtz O +
12~ O -
16 O +
17 O +
MeOOC O -
O O -
OR O -
, O -
19 O +
2O O -
Compound O -
R2 O -
FL~ O -
P~ O -
ICs0 O +
( O -
microM O -
) O +
H O -
Me O +
H O +
Me O +
H O +
H O +
Me O -
H O +
Me O +
Me O +
Me O +
H O +
( O -
CH2 O -
) O -
2OH O -
H O +
H O +
Me O +
H O +
( O -
CH= O -
) O -
=OH O -
0.1 O +
0.4 O +
0.3 O +
> O -
10 O +
> O -
10 O +
> O -
10 O -
alkyl O +
ester O +
at O +
C-6 O +
position O +
is O +
essential O +
and O +
see O -
- O -
butyl O +
ester O +
is O +
most O +
suitable O +
for O +
activity O -
. O -

Next O -
, O +
we O +
examined O +
the O +
importance O +
of O +
methoxy O +
and O +
hydroxyl O +
groups O +
at O +
C-2 O -
, O +
C-12 O +
and O +
C-16 O +
positions O +
( O -
Table O +
lb O -
) O -
. O -

Compared O +
to O +
sulochrin O +
( O -
6 O -
) O -
, O +
19 O +
showed O +
much O +
less O +
activity O -
. O -

Activity O +
of O +
16 O +
approached O +
that O +
of O +
sulochrin O +
( O -
6 O -
) O +
after O +
methylation O +
of O +
hydroxyl O +
group O +
at O +
C-12 O +
position O +
in O +
19 O -
. O -

Furthermore O -
, O +
compound O +
17 O +
also O +
showed O +
activity O -
. O -

These O +
results O +
indicate O +
that O +
at O +
least O +
one O +
methoxy O +
group O +
at O +
C-2 O +
or O +
( O -
2 O -
- O -
12 O +
position O +
is O +
required O +
for O +
activity O -
. O -

Compound O +
18 O -
, O +
in O +
which O +
two O +
methoxy O +
groups O +
at O +
C-12 O +
and O +
( O -
2 O -
- O -
16 O +
positions O +
on O +
the O +
ring O +
B O +
were O +
introduced O -
, O +
showed O +
much O +
less O +
activity O +
than O +
16 O +
or O +
17 O -
. O -

Furthermore O -
, O +
compound O +
20 O +
also O +
lost O +
activity O -
. O -

These O +
results O +
indicate O +
that O +
at O +
least O +
one O +
free O +
hydroxyl O +
group O +
at O +
ortho O -
- O -
position O +
on O +
the O +
ring O +
B O +
is O +
required O +
for O +
activity O -
, O +
suggesting O +
that O +
hydrogen O +
bond O +
between O +
16-OH O +
and O +
carbunyl O +
at O +
( O -
2 O -
- O -
10 O +
might O +
contn'bute O +
to O +
activity O -
. O -

We O +
have O +
recently O +
shown O +
that O +
substituents O +
at O +
ortho O -
- O -
positions O +
showed O +
effect O +
on O +
the O +
conformation O +
from O +
the O +
analysis O +
of O +
crystal O +
structures O +
of O +
suiochrin O +
derivatives O -
, O -
a O +
The O +
hydrogen O +
bond O +
between O +
16-OH O +
and O +
earbonyl O +
at O +
C-10 O +
may O +
contribute O +
to O +
the O +
conformation O +
where O +
the O +
ring O +
B O +
and O +
the O +
central O +
carbunyl O +
planes O +
are O +
co O -
- O -
planner O +
and O +
cross O +
at O +
a O +
right O +
angle O +
to O +
the O -
1948 O -
1 O -
t O -
. O -

Ohashi O +
et O +
al. O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
1945 O -
- O -
1948 O -
ring O +
A. O +
This O +
conformation O +
would O +
be O +
inaccess O -
~ O -
le O +
to O +
the O +
less O +
active O +
compounds O +
that O +
lack O +
the O +
hydrogen O +
bond O -
, O +
supporting O +
the O +
speculation O -
. O -

Compounds O +
10 O +
and O +
19 O -
, O +
which O +
have O +
more O +
hydrophilic O +
substitution O +
at O +
ortho O -
- O -
positions O -
, O +
lost O +
activity O -
. O -

Therefore O -
, O +
hydrophobicity O +
is O +
also O +
important O +
for O +
activity O -
. O -

In O +
conclusion O -
, O +
we O +
found O +
that O +
i O +
) O +
alkylester O +
at O +
C-6 O +
position O +
is O +
required O -
; O +
ii O +
) O +
see O -
- O -
butyl O +
ester O +
at O +
C-6 O +
position O +
is O +
optimal O +
for O +
activity O -
; O +
ill O +
) O +
optimal O +
hydrophobicity O +
of O +
the O +
ortho O -
- O -
substituents O +
may O +
exist O -
; O +
and O +
iv O -
) O +
the O +
conformation O +
of O +
sulochrin O +
may O +
influence O +
to O +
the O +
inlu'bitory O +
activity O +
against O +
eosinophil O +
degranulation O -
. O -

Acknowledgements O -

We O +
thank O +
to O +
Dr. O +
Masakazu O +
Sakalo'bara O +
for O +
critical O +
reading O +
of O +
this O +
manuscript O -
. O +

An O +
accurate O +
estimation O +
of O +
the O +
onset O +
of O +
oestrus O +
in O +
cows U-Species +
is O +
vital O +
to O +
the O +
cost O -
- O -
efficient O +
application O +
of O +
artificial O +
insemination O +
( O -
AI O -
) O +
procedures O +
( O -
Ball O -
, O +
1982 O +
) O -
. O -

The O +
steroid O +
hormone O +
progesterone O -
, O +
which O +
is O +
secreted O +
by O +
the O +
corpus O +
luteum O -
, O +
functions O +
to O +
prepare O +
the O +
uterus O +
for O +
pregnancy O +
and O +
to O +
maintain O +
pregnancy O +
following O +
conception O -
. O -

Fluctuations O +
in O +
the O +
level O +
of O +
secreted O +
progesterone O +
are O +
reflected O +
throughout O +
the O +
oestrus O +
cycle O +
by O +
the O +
concentration O +
of O +
the O +
hormone O +
present O +
in O +
cows U-Species -
' O +
milk O -
. O -

It O +
follows O +
that O +
by O +
monitoring O +
milk O +
progesterone O +
concentration O +
it O +
has O +
been O +
possible O +
accurately O +
to O +
predict O +
the O +
onset O +
of O +
oestrus O -
; O +
using O +
enzyme O +
immunoassay O +
methodology O +
( O -
Foulkes O +
et O +
al. O -
, O +
1982a O +
) O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
optimum O +
fertility O +
rates O +
can O +
be O +
achieved O +
when O +
AI O +
is O +
performed O +
on O +
the O +
third O +
day O +
of O +
sustained O +
low O +
milk O +
progesterone O +
concentration O +
( O -
Foulkes O +
et O +
al. O -
, O +
1982b O -
; O +
Foulkes O +
and O +
Goodey O -
, O +
1988 O +
) O -
. O -

The O +
search O +
for O +
a O +
rapid O -
, O +
convenient O +
and O +
inexpensive O +
means O +
of O +
frequently O +
monitoring O +
milk O +
progesterone O +
levels O +
in O +
a O +
herd O +
of O +
animals U-Species +
has O +
led O +
into O +
research O +
toward O +
a O +
user O -
- O -
friendly O +
on O -
- O -
the O -
- O -
farm O +
device O -
. O -

One O +
such O +
approach O +
is O +
a O +
disposable O +
screen O -
- O -
printed O +
amperometric O +
biosensor O -
. O -

Previously O -
, O +
we O +
described O +
the O +
development O +
of O +
a O +
prototype O +
progesterone O +
biosensor O +
comprising O +
mAb O +
immobilised O +
on O +
the O +
working O +
surface O +
of O +
a O +
screen O -
- O -
printed O +
carbon O +
electrode O +
( O -
SPCE O -
) O -
. O -

It O +
operated O +
in O +
a O +
competitive O +
immunoassay O +
format O -
, O +
relying O +
upon O +
a O +
reduction O +
in O +
the O +
binding O +
of O +
enzyme O -
- O -
labelled O +
progesterone O +
in O +
the O +
presence O +
of O +
endogenous O +
milk O +
progesterone O -
. O -

Initial O +
proof O -
- O -
of O -
- O -
principle O +
was O +
provided O +
from O +
experiments O +
conducted O +
in O +
aqueous O +
buffer O +
solution O +
using O +
phenyl O +
phosphate O +
as O +
substrate O +
for O +
the O +
enzyme O +
alkaline O +
phosphatase O -
, O +
with O +
a O +
chronoamperometric O +
readout O +
dependent O +
on O +
the O +
oxidation O +
of O +
phenol O +
at O +
a O +
potential O +
of O +
+ O -
700 O +
mV O +
versus O +
SCE O +
( O -
Hart O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

Operating O +
at O +
this O +
relatively O +
high O +
electrode O +
potential O -
, O +
however O -
, O +
it O +
was O +
not O +
possible O +
to O +
obtain O +
a O +
calibration O +
in O +
milk O -
, O +
due O +
to O +
variable O +
adsorption O -
, O +
at O +
the O +
electrode O +
surface O -
, O +
of O +
electroactive O +
species O +
present O +
within O +
this O +
complex O +
matrix O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
; O +
even O +
washing O +
with O +
solvents O +
of O +
varying O +
polarity O +
did O +
not O +
remove O +
the O +
interferent O -
. O -

For O +
this O +
reason O -
, O +
it O +
is O +
desirable O +
to O +
reduce O +
the O +
operating O +
potential O +
to O +
below O +
that O +
required O +
to O +
oxidise O +
the O +
interferent O -
. O -

In O +
order O +
to O +
achieve O +
this O +
objective O -
, O +
two O +
potentially O +
useful O +
enzyme O +
substrates O -
, O +
1-naphthyl O +
phosphate O +
( O -
1-NP O -
) O +
and O +
4-aminophenyl O +
phosphate O +
( O -
4-APP O -
) O -
, O +
may O +
be O +
considered O -
. O -

These O +
are O +
hydrolysed O +
to O +
their O +
corresponding O +
phenols O -
, O +
1-naphthol O +
and O +
4-aminophenol O -
, O +
on O +
reaction O +
with O +
alkaline O +
phosphatase O -
. O -

Both O +
4-APP O +
( O -
Tang O +
et O +
al. O -
, O +
1988 O -
; O +
Pemberton O +
et O +
al. O -
, O +
1998 O -
; O +
Schreiber O +
et O +
al. O -
, O +
1997 O +
) O +
and O +
1-NP O +
( O -
Athey O +
et O +
al. O -
, O +
1993 O -
; O +
Fernandez O -
- O -
Sanchez O +
and O +
Costa O -
- O -
Garcia O -
, O +
1997 O +
) O +
have O +
been O +
investigated O +
previously O +
in O +
immunoassay O +
systems O -
, O +
but O +
no O +
detailed O +
comparative O +
studies O +
of O +
their O +
performance O +
have O +
been O +
reported O +
at O +
SPCEs O -
. O -

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
compare O +
the O +
electrochemical O +
behaviour O +
of O +
1-naphthol O +
and O +
4-aminophenol O +
at O +
bare O +
and O +
antibody O -
- O -
coated O +
SPCEs O +
and O +
to O +
determine O +
which O +
phenol O +
would O +
be O +
the O +
more O +
compatible O +
with O +
biosensor O +
operation O -
. O -

Their O +
phosphorylated O +
derivatives O +
were O +
then O +
evaluated O +
as O +
substrates O +
for O +
use O +
with O +
a O +
milk O +
progesterone O +
immunosensor O -
. O -

This O +
paper O +
describes O +
the O +
results O +
of O +
these O +
studies O -
. O -

2 O +
Experimental O +
2.1 O +
Chemicals O +
and O +
reagents O +
Chemicals O +
used O +
were O +
of O +
AR O -
- O -
grade O +
and O +
were O +
purchased O +
from O +
Merck O +
( O -
Poole O -
, O +
Dorset O -
, O +
UK O -
) O -
. O -

Water O +
for O +
the O +
preparation O +
of O +
buffer O +
solutions O +
was O +
drawn O +
from O +
a O +
Milli O -
- O -
Q O +
Water O +
Purification O +
System O +
( O -
Millipore O +
UK O -
, O +
Watford O -
, O +
UK O -
) O -
. O -

Carbonate O +
coating O +
buffer O +
( O -
CB O -
) O +
comprised O +
0.015 O +
mol O -
/ O -
dm O +
Na2 O +
CO3 O -
and O +
0.035 O +
mol O -
/ O -
dm3 O -
NaHCO3 O -
at O +
a O +
pH O +
of O +
9.6 O -
. O -

Diethanolamine O -
- O -
HCl O +
buffer O +
( O -
DB O -
; O +
0.1 O +
mol O -
/ O -
dm3 O +
) O +
was O +
adjusted O +
to O +
a O +
final O +
pH O +
of O +
7.2 O +
or O +
9.8 O -
. O -

MgCl2 O -
at O +
a O +
concentration O +
of O +
0.01 O +
mol O -
/ O -
dm3 O -
was O +
included O +
in O +
pH9.8 O +
DB O +
as O +
a O +
cofactor O +
for O +
alkaline O +
phosphatase O -
. O -

Before O +
final O +
dilution O +
in O +
DB O -
, O +
4-aminophenol O +
( O -
Sigma O -
- O -
Aldrich O +
Company O -
, O +
Poole O -
, O +
Dorset O -
, O +
UK O -
) O +
was O +
dissolved O +
in O +
0.1 O +
mol O -
/ O -
dm3 O -
NaOH O -
; O +
1-naphthol O +
( O -
Acros O +
Organics O -
, O +
Loughborough O -
, O +
Leics O -
, O +
UK O -
) O +
was O +
dissolved O +
directly O +
in O +
DB O -
. O -

A O +
polyclonal O +
rabbit U-Species +
antibody O +
( O -
IgG O +
fraction O -
) O +
against O +
sheep U-Species +
IgG O +
was O +
purchased O +
from O +
Sigma O -
- O -
Aldrich O +
( O -
rIg O -
) O -
. O -

Sheep U-Species +
monoclonal O +
antibody O +
( O -
mAb O -
) O +
against O +
progesterone O +
( O -
Groves O +
et O +
al. O -
, O +
1990 O +
) O +
was O +
kindly O +
provided O +
by O +
Ridgeway O +
Science O +
Ltd. O +
in O +
the O +
form O +
of O +
culture O +
supernatant O -
. O -

A O +
solution O +
containing O +
alkaline O -
- O -
phosphatase O -
- O -
labelled O +
progesterone O +
( O -
AP O -
- O -
prog O -
) O +
was O +
obtained O +
from O +
the O +
same O +
source O -
. O -

Unlabelled O +
progesterone O +
( O -
f.wt.=314.5 O -
) O +
was O +
purchased O +
from O +
Sigma O -
- O -
Aldrich O -
. O -

4-APP O +
( O -
monosodium O +
salt O -
) O +
and O +
1-NP O +
were O +
purchased O +
from O +
ICN O +
Biomedicals O +
Ltd. O -
, O +
Thame O -
, O +
Oxon O -
, O +
UK O +
and O +
Acros O +
Organics O -
, O +
respectively O -
. O -

Whole O +
milk O +
test O +
samples O +
from O +
six O +
different O +
Fresian B-Species +
Holstein I-Species +
dairy I-Species +
cows L-Species +
at O +
various O +
stages O +
of O +
their O +
oestrus O +
cycles O +
were O +
obtained O +
from O +
Ridgeway O +
Science O +
Ltd. O +
These O +
samples O +
were O +
collected O +
following O +
agitation O +
of O +
the O +
complete O +
milking O +
jar O +
after O +
morning O +
milking O +
of O +
cows U-Species -
. O -

One O +
Lactab O +
MkIII O +
tablet O +
( O -
Thompson O +
and O +
Capper O +
Ltd. O -
, O +
Runcorn O -
, O +
Cheshire O -
, O +
UK O -
) O +
containing O +
30 O +
mg O +
potassium O +
dichromate O +
was O +
added O +
to O +
every O +
25 O +
ml O +
milk O +
as O +
a O +
preservative O -
. O -

Samples O +
were O +
then O +
stored O +
at O +
4 O -
° O -
C O +
where O +
they O +
were O +
stable O +
for O +
up O +
to O +
3 O +
months O -
. O -

In O +
the O +
present O +
study O -
, O +
assays O +
were O +
performed O +
after O +
21 O +
days O +
of O +
storage O -
. O -

Standards O +
containing O +
known O +
concentrations O +
of O +
progesterone O +
were O +
prepared O +
by O +
dissolving O +
progesterone O +
in O +
methanol O +
at O +
1 O +
mg O -
/ O -
ml O -
, O +
aliquoting O +
a O +
known O +
volume O +
into O +
a O +
glass O +
tube O +
and O +
evaporating O +
the O +
methanol O +
under O +
N2 O -
before O +
adding O +
to O +
whole O +
milk O +
( O -
sampled O +
and O +
preserved O +
as O +
above O -
) O +
from O +
an O +
oestrus O +
cow U-Species +
( O -
containing O +
< O -
1 O +
ng O -
/ O -
ml O +
progesterone O -
) O -
. O -

Serial O +
dilutions O +
were O +
then O +
performed O +
in O +
the O +
same O +
milk O +
over O +
the O +
desired O +
concentration O +
range O -
. O -

2.2 O +
Biosensor O +
preparation O +
Carbon O +
electrodes O +
( O -
3 O -
× O -
3 O +
mm O +
working O +
area O -
) O +
were O +
screen O -
- O -
printed O +
using O +
code O +
D14 O +
ink O +
formulation O +
onto O +
PVC O +
backing O +
card O +
at O +
Gwent O +
Electronic O +
Materials O +
Ltd. O +
( O -
Mamhilad O -
, O +
Gwent O -
, O +
UK O -
) O +
as O +
described O +
elsewhere O +
( O -
Sprules O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

Individual O +
screen O -
- O -
printed O +
electrodes O +
( O -
SPCEs O -
) O +
were O +
coated O +
with O +
rIg O +
( O -
to O +
capture O +
and O +
orientate O +
the O +
mAb O -
) O +
and O +
mAb O +
as O +
described O +
previously O +
( O -
Hart O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

For O +
these O +
studies O -
, O +
a O +
1 O -
/ O -
20 O +
dilution O +
of O +
mAb O +
was O +
applied O +
to O +
the O +
electrodes O -
, O +
being O +
chosen O +
empirically O +
as O +
the O +
highest O +
dilution O +
giving O +
an O +
optimum O +
sigmoidal O +
calibration O +
plot O +
for O +
progesterone O +
measured O +
colorimetrically O +
( O -
see O +
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

These O +
are O +
referred O +
to O +
as O +
mAb O -
- O -
SPCEs O -
. O -

2.3 O +
Instrumentation O +
Electrochemical O +
procedures O +
were O +
carried O +
out O +
using O +
an O +
E612 O +
VA O +
Scanner O +
and O +
an O +
E611 O +
VA O +
Detector O +
( O -
Metrohm O -
, O +
Herisau O -
, O +
Switzerland O -
) O +
attached O +
to O +
a O +
Linseis O +
LY18100 O +
x O +
–y O -
plotter O +
( O -
Recorder O +
Laboratory O +
Services O -
, O +
Sutton O -
, O +
Surrey O -
, O +
UK O -
) O -
. O -

A O +
Viglen O +
486 O +
Sx O +
computer O +
was O +
used O +
for O +
simulation O +
of O +
cyclic O +
voltammograms O +
using O +
the O +
simulation O +
program O +
CVSIM O +
( O -
Gosser O -
, O +
1993 O +
) O -
. O -

The O +
simple O +
' O -
E O +
r O +
' O -
, O +
mechanism O +
for O +
a O +
one O -
- O -
electron O +
oxidation O +
of O +
a O +
solution O +
species O +
at O +
the O +
working O +
electrode O +
was O +
used O +
to O +
estimate O +
values O +
for O +
k O +
het O -
from O +
simulations O +
of O +
the O +
oxidation O +
of O +
4-aminophenol O +
at O +
bare O +
and O +
mAb O -
- O -
coated O +
SPCEs O -
. O -

Common O +
electroactive O +
species O +
parameters O +
were O -
: O +
C O +
red O +
= O -
1 O +
mM O -
, O +
C O +
ox O +
= O -
0.0 O +
mM O -
, O +
D O +
= O -
5 O -
× O -
10−6 O -
cm2 O +
/s O -
; O +
and O +
common O +
experimental O +
settings O +
were O -
: O +
number O +
of O +
half O +
cycles=2 O -
, O +
A O +
= O -
0.09 O +
cm2 O +
, O +
E O +
i O -
= O -
−0.3 O +
V O -
, O +
E O +
s O -
= O -
+ O -
1.0 O +
V O -
, O +
E O +
f O -
= O -
−0.3 O +
V O -
, O +
v O +
= O -
0.05 O +
vs−1 O +
. O -

Parameters O +
specific O +
for O +
reaction O +
at O +
a O +
bare O +
SPCE O +
were O -
: O +
E O +
0 O -
/ O +
= O -
−0.050 O +
V O -
, O +
α O +
= O -
0.533 O +
and O +
for O +
reaction O +
at O +
a O +
mAb O -
- O -
coated O +
SPCE O +
were O -
: O +
E O +
0 O -
/ O +
= O -
−0.037 O +
V O -
, O +
α O +
= O -
0.400 O -
. O -

2.4 O +
Cyclic O +
voltammetry O +
and O +
chronoamperometry O +
Cyclic O +
voltammetric O +
studies O +
were O +
conducted O +
using O +
10 O +
ml O +
analyte O +
volumes O +
in O +
a O +
glass O +
voltammetric O +
cell O -
. O -

Individual O +
working O +
SPCEs O +
or O +
mAb O -
- O -
SPCEs O +
were O +
used O +
in O +
a O +
3-electrode O +
configuration O +
in O +
conjunction O +
with O +
a O +
saturated O +
calomel O +
reference O +
and O +
platinum O +
counter O +
electrode O -
. O -

Chronoamperometric O +
measurements O +
were O +
made O +
by O +
using O +
individual O +
working O +
mAb O -
- O -
SPCEs O -
, O +
together O +
with O +
a O +
saturated O +
calomel O +
electrode O +
functioning O +
as O +
a O +
combined O +
counter O -
/ O -
reference O +
electrode O +
in O +
a O +
two O +
electrode O +
configuration O -
. O -

In O +
this O +
way O +
it O +
was O +
possible O +
to O +
perform O +
measurements O +
using O +
a O +
small O +
( O -
0.5 O +
ml O -
) O +
volume O +
of O +
enzyme O +
substrate O +
solution O +
in O +
a O +
conical O +
polypropylene O +
cell O -
. O -

2.5 O +
Electrochemical O +
immunoassay O +
procedure O +
Milk O +
samples O +
were O +
mixed O +
with O +
AP O -
- O -
prog O +
solution O +
in O +
the O +
ratio O +
3:5 O +
( O -
this O +
combination O +
gave O +
a O +
maximum O +
signal O -
: O -
noise O +
ratio O -
) O -
. O -

Eight O +
microlitre O +
volumes O +
of O +
these O +
mixtures O +
were O +
added O +
to O +
the O +
surface O +
of O +
individual O +
mAb O -
- O -
SPCEs O -
. O -

After O +
30 O +
min O +
at O +
room O +
temperature O +
( O -
18–25 O -
° O -
C O -
; O +
RT O -
) O -
, O +
the O +
electrodes O +
were O +
washed O +
three O +
times O +
in O +
DB O -
, O +
pH O +
9.8 O -
, O +
then O +
placed O +
in O +
0.5 O +
ml O +
DB O -
, O +
pH O +
9.8 O +
or O +
the O +
same O +
buffer O +
containing O +
5 O +
mmol O -
/ O -
dm3 O -
4-APP O +
or O +
1-NP O -
. O -

After O +
5 O +
min O +
( O -
a O +
compromise O +
between O +
maximum O +
enzyme O +
activity O +
and O +
speed O +
of O +
assay O +
for O +
multiple O +
samples O -
) O -
, O +
the O +
working O +
electrode O +
potential O +
was O +
stepped O +
from O +
open O +
circuit O +
to O +
+ O -
200 O +
or O +
+ O -
300 O +
mV O +
versus O +
SCE O -
, O +
respectively O +
and O +
the O +
peak O +
current O +
( O -
i O +
p O +
) O +
response O +
was O +
recorded O -
. O -

Calibration O +
graphs O +
were O +
obtained O +
by O +
plotting O +
i O +
p O -
values O +
in O +
the O +
presence O +
of O +
an O +
enzyme O +
substrate O +
minus O +
background O +
i O +
p O -
values O +
in O +
buffer O +
only O +
for O +
each O +
known O +
standard O +
progesterone O +
concentration O +
( O -
y O +
-axis O -
) O +
against O +
progesterone O +
concentration O +
( O -
x O +
-axis O -
) O -
. O -

For O +
each O +
unknown O +
cow U-Species +
sample O -
, O +
a O +
similar O +
subtraction O +
of O +
the O +
buffer O +
blank O +
i O +
p O -
value O +
was O +
performed O +
before O +
using O +
the O +
calibration O +
plot O +
by O +
interpolation O +
to O +
obtain O +
an O +
estimate O +
of O +
progesterone O +
concentration O -
. O -

The O +
relationship O +
between O +
readings O +
obtained O +
by O +
EIA O +
and O +
electrochemical O +
assays O +
was O +
investigated O +
using O +
linear O +
regression O +
analysis O -
. O -

3 O +
Results O +
and O +
discussion O +
3.1 O +
Electrochemistry O +
of O +
4-aminophenol O -
, O +
1-naphthol O +
and O +
corresponding O +
monophosphates O +
The O +
electrochemical O +
behaviour O +
of O +
the O +
enzyme O +
substrates O +
4-APP O +
and O +
1-NP O -
, O +
and O +
their O +
hydrolysis O +
products O -
, O +
4-aminophenol O +
and O +
1-naphthol O -
, O +
was O +
examined O +
by O +
cyclic O +
voltammetry O +
at O +
unmodified O +
SPCEs O +
( O -
Fig. O +
1 O -
) O -
. O -

4-Aminophenol O +
showed O +
well O -
- O -
defined O +
oxidation O +
and O +
reduction O +
peaks O +
and O +
the O +
ΔE O +
p O -
value O +
indicated O +
that O +
the O +
electrode O +
reaction O +
was O +
quasi O -
- O -
reversible O +
( O -
Fig. O +
1 O +
( O -
a O -
) O -
) O -
. O -

The O +
anodic O +
potential O +
( O -
E O +
pa O +
) O +
was O +
well O +
below O +
that O +
required O +
for O +
the O +
oxidation O +
of O +
the O +
corresponding O +
monophosphate O -
, O +
4-APP O +
( O -
Fig. O +
1 O +
( O -
b O -
) O -
) O -
. O -

In O +
contrast O -
, O +
1-naphthol O +
gave O +
only O +
an O +
oxidation O +
peak O +
at O +
+ O -
230 O +
mV O +
( O -
Fig. O +
1 O +
( O -
c O -
) O -
) O -
, O +
which O +
could O +
be O +
due O +
to O +
the O +
electrode O +
reaction O +
itself O +
giving O +
an O +
electro O -
- O -
inactive O +
product O -
, O +
or O +
to O +
the O +
oxidised O +
naphthol O +
product O +
undergoing O +
an O +
irreversible O +
chemical O +
reaction O -
. O -

1-NP O +
( O -
Fig. O +
1 O +
( O -
d O -
) O -
) O +
was O +
not O +
electrochemically O +
active O +
over O +
the O +
potential O +
range O +
studied O -
. O -

At O +
this O +
stage O -
, O +
it O +
appeared O +
that O +
the O +
anodic O +
signals O +
for O +
either O +
4-aminophenol O +
or O +
1-naphthol O +
could O +
be O +
used O +
as O +
the O +
basis O +
for O +
an O +
immunoassay O +
for O +
progesterone O -
. O -

Further O +
studies O +
were O +
therefore O +
performed O +
to O +
gain O +
a O +
better O +
understanding O +
of O +
the O +
voltammetric O +
behaviour O +
of O +
these O +
two O +
phenols O -
. O -

The O +
cyclic O +
voltammetric O +
behaviour O +
of O +
4-aminophenol O +
and O +
1-naphthol O +
was O +
next O +
compared O +
at O +
naked O +
and O +
mAb O -
- O -
SPCEs O +
( O -
Fig. O +
2 O -
) O -
. O -

For O +
both O +
analytes O -
, O +
the O +
presence O +
of O +
the O +
antibodies O +
increased O +
the O +
background O +
oxidation O +
signal O +
at O +
potentials O +
above O +
+ O -
0.5 O +
V O +
( O -
Fig. O +
2 O +
( O -
b O -
, O +
d O -
) O -
) O -
, O +
but O +
the O +
magnitude O +
of O +
the O +
overall O +
peak O +
currents O +
were O +
the O +
same O +
as O +
obtained O +
at O +
naked O +
SPCEs O +
( O -
Fig. O +
2 O +
( O -
a O -
, O +
c O -
) O -
) O -
. O -

However O -
, O +
in O +
the O +
case O +
of O +
4aminophenol O -
, O +
the O +
oxidation O +
peak O +
became O +
broader O +
in O +
the O +
presence O +
of O +
the O +
antibodies O +
and O +
showed O +
a O +
small O +
positive O +
E O +
p O -
shift O +
( O -
∼30 O +
mV O -
, O +
Fig. O +
2 O +
( O -
a O -
, O +
b O -
) O -
) O -
. O -

In O +
the O +
case O +
of O +
1-naphthol O -
, O +
there O +
was O +
also O +
a O +
small O +
positive O +
E O +
p O -
shift O +
( O -
∼10 O +
mV O -
) O +
in O +
the O +
presence O +
of O +
the O +
antibodies O +
( O -
Fig. O +
2 O +
( O -
c O -
, O +
d O -
) O -
) O -
. O -

Further O +
comparison O +
of O +
the O +
electrochemistry O +
of O +
4-aminophenol O +
and O +
1-naphthol O -
, O +
at O +
naked O +
and O +
mAb O -
- O -
coated O +
SPCEs O -
, O +
was O +
obtained O +
by O +
performing O +
cyclic O +
voltammetry O +
at O +
various O +
scan O +
rates O -
. O -

The O +
relationship O +
produced O +
during O +
cyclic O +
voltammetry O +
between O +
peak O +
current O +
( O -
i O +
p O +
) O +
and O +
v O +
1 O -
/ O -
2 O -
is O +
described O +
by O +
the O +
Randles O -
- O -
Sevcik O +
equation O -
, O +
modified O +
for O +
irreversible O +
systems O -
: O -

Cv O +
1 O -
/ O -
2 O -
ip O -
= O -
( O -
2.99 O -
× O -
10 O +
5 O +
) O +
· O -
n O -
( O -
αna O -
) O -
1 O -
/ O -
2 O +
AD1 O -
/ O -
2 O -
( O -
Heineman O +
and O +
Kissinger O -
, O +
1984 O +
) O -
where O +
i O +
p O +
= O -
peak O +
current O +
( O -
μA O -
) O -
, O +
n O +
= O -
number O +
of O +
electrons O -
, O +
αn O +
a O +
= O -
electron O +
transfer O +
coefficient O -
, O +
A O +
= O -
working O +
electrode O +
area O +
( O -
cm2 O +
) O -
, O +
D O +
= O -
diffusion O +
coefficient O +
( O -
cm2 O +
/s O -
) O -
, O +
C= O +
bulk O +
concentration O +
of O +
analyte O +
( O -
mmoles O -
/ O -
ml O -
) O +
and O +
v O +
= O -
scan O +
rate O +
( O -
mV O -
/ O -
s O -
) O -
. O -

Plots O +
of O +
i O +
p O -
versus O +
v O +
1 O -
/ O -
2 O -
for O +
both O +
analytes O +
at O +
naked O +
and O +
mAb O -
- O -
SPCEs O +
are O +
shown O +
in O +
Fig. O +
3 O -
. O -

In O +
the O +
case O +
of O +
4-aminophenol O -
, O +
there O +
is O +
evidence O +
that O +
the O +
presence O +
of O +
the O +
mAb O +
results O +
in O +
lower O +
i O +
p O -
values O +
at O +
all O +
scan O +
rates O +
compared O +
with O +
naked O +
SPCEs O +
( O -
Fig. O +
3 O +
( O -
a O -
) O -
) O -
. O -

These O +
observations O +
suggest O +
that O +
the O +
mAb O +
may O +
slow O +
the O +
diffusion O +
of O +
4-AP O +
towards O +
the O +
electrode O +
surface O -
, O +
and O +
may O +
combine O +
with O +
polyphenols O +
to O +
reduce O +
the O +
working O +
area O +
available O +
for O +
the O +
oxidation O +
of O +
4-AP O -
. O -

In O +
contrast O -
, O +
ip O +
values O +
obtained O +
for O +
1-naphthol O +
at O +
naked O +
and O +
mAb O -
- O -
SPCEs O +
are O +
almost O +
superimposed O +
for O +
scan O +
rates O +
up O +
to O +
200 O +
mVs−1 O -
( O -
Fig. O +
3 O +
( O -
b O -
) O -
) O -
. O -

This O +
suggests O +
that O +
the O +
antibody O +
coating O +
has O +
little O +
effect O +
on O +
the O +
diffusional O +
characteristics O +
of O +
1-naphthol O -
. O -

Electron O +
transfer O +
coefficients O +
( O -
αn O +
a O +
) O +
were O +
calculated O +
for O +
naked O +
and O +
mAb O -
- O -
SPCEs O +
as O +
described O +
previously O +
( O -
Galus O -
, O +
1976 O +
) O -
. O -

For O +
4-aminophenol O -
, O +
these O +
values O +
were O +
0.533 O +
and O +
0.400 O -
, O +
respectively O -
; O +
this O +
decrease O +
indicates O +
that O +
the O +
antibody O +
layer O +
partially O +
inhibits O +
the O +
electron O +
transfer O +
step O -
, O +
possibly O +
due O +
to O +
steric O +
hindrance O -
. O -

A O +
computer O +
simulation O +
program O +
( O -
CVSIM O -
, O +
Gosser O -
, O +
1993 O +
) O +
was O +
used O +
to O +
simulate O +
cyclic O +
voltammograms O +
for O +
4-aminophenol O +
in O +
order O +
to O +
obtain O +
values O +
for O +
the O +
electrochemical O +
rate O +
constant O -
. O -

Using O +
the O +
above O +
αn O +
a O -
values O -
, O +
it O +
was O +
found O +
that O +
the O +
heterogeneous O +
rate O +
constant O +
( O -
k O +
het O +
) O +
for O +
the O +
mAb O -
- O -
SPCEs O +
was O +
3.0 O -
× O -
10−4 O +
/cm O +
s−1 O +
, O +
whereas O +
k O +
het O -
for O +
a O +
naked O +
SPCE O +
was O +
calculated O +
to O +
be O +
6.5 O -
× O -
10−4 O -
cm O +
s−1 O +
. O -

The O +
slower O +
rate O +
constant O +
obtained O +
with O +
the O +
mAb O -
- O -
SPCEs O +
supports O +
the O +
suggestion O +
of O +
partial O +
inhibition O +
discussed O +
above O -
. O -

Finally O -
, O +
the O +
αn O +
a O -
values O +
were O +
calculated O +
for O +
1-naphthol O +
at O +
naked- O +
and O +
mAb O -
- O -
SPCEs O -
, O +
to O +
be O +
0.53 O +
and O +
0.60 O -
, O +
respectively O -
. O -

These O +
values O +
suggest O +
that O +
the O +
antibody O +
coating O +
does O +
not O +
inhibit O +
the O +
rate O +
of O +
electron O +
transfer O +
during O +
the O +
oxidation O +
of O +
this O +
phenol O -
. O -

Fig. O +
4 O -
( O -
a O -
) O +
shows O +
the O +
effect O +
of O +
scan O +
rate O +
on O +
the O +
anodic O +
peak O +
potential O +
for O +
4-aminophenol O -
, O +
at O +
naked O +
and O +
antibody O -
- O -
coated O +
SPCEs O -
. O -

True O +
reversible O +
reactions O +
do O +
not O +
show O +
shifts O +
of O +
E O +
p O -
with O +
scan O +
rate O -
, O +
inferring O +
that O +
the O +
oxidation O +
reactions O +
at O +
both O +
types O +
of O +
SPCE O +
appear O +
to O +
be O +
quasi O -
- O -
reversible O +
over O +
the O +
range O +
studied O -
. O -

In O +
contrast O -
, O +
at O +
scan O +
rates O +
above O +
100 O +
mVs−1 O +
, O +
1-naphthol O +
appears O +
to O +
show O +
more O +
reversible O +
behaviour O +
at O +
both O +
SPCEs O +
than O +
4-aminophenol O -
. O -

This O +
may O +
be O +
explained O +
by O +
a O +
slow O +
chemical O +
follow O -
- O -
up O +
reaction O +
( O -
possibly O +
polymerisation O -
) O +
for O +
1-naphthol O +
after O +
the O +
initial O +
electron O +
transfer O +
step O -
. O -

It O +
should O +
also O +
be O +
noted O +
that O +
the O +
peak O +
potential O +
for O +
the O +
oxidation O +
of O +
1-naphthol O +
obtained O +
at O +
the O +
mAb O -
- O -
SPCE O +
at O +
200 O +
mVs−1 O -
is O +
+ O -
0.38 O +
V O -
; O +
for O +
4-aminophenol O +
at O +
this O +
electrode O +
the O +
E O +
p O -
value O +
was O +
+ O -
0.28 O +
V. O +
All O +
of O +
the O +
above O +
observations O +
using O +
cyclic O +
voltammetry O +
suggested O +
that O +
1-NP O +
would O +
be O +
a O +
suitable O +
candidate O +
for O +
the O +
chronoamperometric O +
immunoassay O -
. O -

Although O +
the O +
magnitude O +
of O +
the O +
anodic O +
response O +
was O +
lower O +
than O +
that O +
seen O +
for O +
4-aminophenol O +
at O +
equivalent O +
concentration O -
, O +
the O +
hydrolysis O +
product O -
, O +
1-naphthol O -
, O +
appeared O +
capable O +
of O +
producing O +
a O +
significant O +
and O +
unimpeded O +
oxidation O +
signal O +
at O +
mAb O -
- O -
SPCEs O -
. O -

3.2 O +
Establishing O +
the O +
operating O +
potential O +
for O +
chronoamperometric O +
detection O +
of O +
l O -
- O -
naphthol O +
Previous O +
cyclic O +
voltammograms O +
with O +
SPCEs O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O +
have O +
demonstrated O +
the O +
presence O -
, O +
in O +
milk O -
, O +
of O +
electroactive O +
species O +
capable O +
of O +
adsorbing O +
onto O +
the O +
electrode O +
surface O +
and O +
being O +
oxidised O +
to O +
produce O +
anodic O +
signals O +
capable O +
of O +
interfering O +
with O +
the O +
operation O +
of O +
the O +
immunosensor O +
by O +
chronoamperometry O -
. O -

Using O +
4-APP O +
as O +
enzyme O +
substrate O +
it O +
was O +
possible O +
to O +
select O +
an O +
operating O +
potential O +
of O +
+ O -
200 O +
mV O -
, O +
well O +
below O +
the O +
potential O +
required O +
to O +
oxidise O +
adsorbed O +
milk O +
species O +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

In O +
order O +
to O +
confirm O +
that O +
1-naphthol O +
could O +
be O +
detected O +
amperometrically O +
and O +
to O +
establish O +
an O +
operating O +
potential O +
for O +
use O +
in O +
the O +
assay O -
, O +
chronoamperometric O +
measurement O +
of O +
a O +
1 O +
mM O +
1-naphthol O +
solution O +
was O +
performed O +
over O +
a O +
range O +
of O +
operating O +
potentials O +
at O +
mAb O -
- O -
SPCEs O +
which O +
had O +
been O +
incubated O +
with O +
enzyme O -
- O -
labelled O +
progesterone O +
either O +
in O +
buffer O +
solution O +
or O +
in O +
milk O -
. O -

Fig. O +
5 O -
shows O +
that O +
in O +
order O +
to O +
avoid O +
signals O +
due O +
to O +
the O +
oxidation O +
of O +
electroactive O +
species O +
within O +
milk O -
, O +
it O +
would O +
be O +
necessary O +
to O +
operate O +
below O +
+ O -
400 O +
mV. O +
It O +
was O +
necessary O +
to O +
operate O +
at O +
+ O -
600 O +
mV O +
to O +
achieve O +
the O +
maximum O +
current O +
signal O +
from O +
chronoamperometry O +
of O +
1-naphthol O -
. O -

However O -
, O +
it O +
was O +
still O +
possible O +
to O +
obtain O +
over O +
50 O -
% O +
of O +
this O +
response O +
at O +
+ O -
300 O +
mV O +
which O +
was O +
therefore O +
chosen O +
as O +
the O +
operating O +
potential O +
for O +
the O +
biosensor O -
. O -

3.3 O +
Analysis O +
of O +
cows U-Species -
' O +
milk O -
- O -
comparison O +
of O +
enzyme O +
substrates O +
4-APP O +
and O +
1-NP O +
In O +
order O +
to O +
compare O +
the O +
performance O +
of O +
the O +
immunosensor O +
using O +
1-NP O +
as O +
an O +
enzyme O +
substrate O +
with O +
its O +
performance O +
using O +
4-APP O -
, O +
milk O +
samples O +
obtained O +
from O +
a O +
number O +
of O +
different O +
cows U-Species +
were O +
analysed O +
for O +
progesterone O +
content O +
using O +
both O +
approaches O -
. O -

The O +
results O +
were O +
then O +
compared O +
with O +
those O +
obtained O +
using O +
a O +
commercial O +
EIA O +
( O -
Ridgeway O +
Science O +
Ltd. O -
; O +
accuracy=±8 O -
% O +
inter O -
- O -
assay O +
C.V. O -
, O +
sensitivity=0.6 O +
ng O -
/ O -
ml O -
) O +
by O +
reference O +
to O +
a O +
standard O +
curve O +
of O +
absorbance O +
reading O +
versus O +
progesterone O +
concentration O +
( O -
Sauer O +
et O +
al. O -
, O +
1986 O +
) O -
. O -

Fig. O +
6 O -
( O -
a O -
) O +
shows O +
the O +
calibration O +
curve O +
obtained O +
using O +
4-APP O +
as O +
substrate O +
to O +
measure O +
progesterone O +
milk O +
standards O +
over O +
the O +
concentration O +
range O -
, O +
0–50 O +
ng O -
/ O -
ml O -
, O +
before O +
and O +
after O +
background O +
subtraction O -
. O -

Precision O +
for O +
triplicate O +
sensors O +
at O +
each O +
concentration O +
ranged O +
from O +
5.3 O +
to O +
18.3 O -
% O -
. O -

The O +
readings O +
obtained O +
for O +
six O +
cows U-Species -
' O +
milk O +
samples O -
, O +
together O +
with O +
those O +
obtained O +
using O +
the O +
standard O +
EIA O +
are O +
shown O +
on O +
a O +
correlation O +
plot O +
for O +
the O +
two O +
sets O +
of O +
values O +
( O -
Fig. O +
6 O +
( O -
b O -
) O -
) O -
. O -

Reasonable O +
agreement O +
( O -
r O +
= O -
0.840 O -
) O +
was O +
obtained O +
between O +
the O +
two O +
methods O -
. O -

One O +
calibration O +
curve O +
obtained O +
using O +
1-NP O +
is O +
shown O +
in O +
Fig. O +
7 O -
( O -
a O -
) O -
, O +
before O +
and O +
after O +
adjustment O +
for O +
background O +
current O -
. O -

Precision O +
for O +
triplicate O +
sensors O +
at O +
each O +
concentration O +
was O +
improved O +
compared O +
with O +
the O +
4-APP O +
assay O +
and O +
ranged O +
from O +
4.1 O +
to O +
12.4 O -
% O -
; O +
this O +
may O +
have O +
been O +
due O +
to O +
the O +
improved O +
solubility O +
of O +
the O +
1-naphthyl O +
phosphate O +
over O +
the O +
4-APP O -
. O -

Readings O +
obtained O +
for O +
the O +
same O +
six O +
cows U-Species -
' O +
milk O +
samples O +
tested O +
above O +
are O +
shown O +
on O +
a O +
correlation O +
plot O +
comparing O +
these O +
values O +
with O +
those O +
obtained O +
by O +
EIA O +
( O -
Fig. O +
7 O +
( O -
b O -
) O -
) O -
. O -

The O +
result O +
was O +
a O +
close O +
agreement O +
between O +
the O +
two O +
sets O +
of O +
readings O +
and O +
an O +
improved O +
correlation O +
( O -
r O +
= O -
0.946 O -
) O +
over O +
the O +
4-APP O +
assay O -
. O -

4 O +
Conclusion O +
In O +
summary O -
, O +
the O +
above O +
results O +
have O +
demonstrated O +
that O +
by O +
using O +
1-naphthyl O +
phosphate O +
( O -
1-NP O -
) O +
as O +
enzyme O +
substrate O -
, O +
it O +
is O +
possible O +
to O +
develop O +
an O +
amperometric O +
screen O -
- O -
printed O +
immunosensor O +
for O +
milk O +
progesterone O +
based O +
on O +
the O +
detection O +
of O +
the O +
product O -
, O +
1-naphthol O +
at O +
an O +
operating O +
potential O +
of O +
+ O -
300 O +
mV. O +
The O +
required O +
detection O +
limit O +
of O +
2–5 O +
ng O -
/ O -
ml O +
( O -
Bulman O -
, O +
1979 O -
; O +
Sauer O +
et O +
al. O -
, O +
1986 O +
) O +
was O +
achieved O +
using O +
this O +
approach O -
. O -

Examination O +
of O +
the O +
electrochemistry O +
of O +
1-naphthol O +
itself O +
indicated O +
that O +
it O +
was O +
readily O +
oxidisable O +
at O +
the O +
surface O +
of O +
an O +
SPCE O +
in O +
the O +
presence O +
or O +
absence O +
of O +
immobilised O +
antibody O -
. O -

This O +
was O +
a O +
potential O +
advantage O +
over O +
4-aminophenol O +
which O +
appeared O +
to O +
suffer O +
from O +
a O +
diffusional O +
barrier O -
, O +
most O +
probably O +
as O +
a O +
result O +
of O +
the O +
formation O +
of O +
polyphenols O +
at O +
the O +
electrode O +
surface O -
. O -

Although O +
the O +
operating O +
potential O +
required O +
for O +
oxidation O +
of O +
1-naphthol O +
was O +
100 O +
mV O +
higher O +
than O +
that O +
used O +
for O +
the O +
detection O +
of O +
4-aminophenol O -
, O +
the O +
1-naphthol O +
assay O +
operated O +
below O +
the O +
oxidation O +
potential O +
of O +
milkborne O +
interferents O +
and O +
did O +
not O +
suffer O +
from O +
a O +
loss O +
of O +
sensitivity O -
. O -

Indeed O -
, O +
a O +
closer O +
agreement O +
than O +
that O +
achieved O +
using O +
4-APP O +
was O +
obtained O +
with O +
an O +
established O +
EIA O +
method O +
for O +
milk O +
samples O +
taken O +
from O +
different O +
cows U-Species +
having O +
varying O +
background O +
responses O -
. O -

Furthermore O -
, O +
this O +
correlation O +
was O +
also O +
better O +
than O +
that O +
obtained O +
using O +
4-APP O +
in O +
a O +
previous O +
study O +
on O +
milk O +
samples O +
taken O +
from O +
a O +
single O +
animal U-Species +
( O -
Pemberton O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

Since O +
1-NP O +
is O +
inexpensive O -
, O +
readily O +
soluble O +
and O +
easy O +
to O +
obtain O -
, O +
the O +
screenprinted O +
immunosensor O +
when O +
used O +
in O +
combination O +
with O +
this O +
substrate O +
may O +
hold O +
promise O +
for O +
future O +
development O +
into O +
a O +
device O +
for O +
large O -
- O -
scale O +
milk O +
monitoring O -
. O -

Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
R. O +
Pittson O +
and O +
his O +
staff O +
at O +
Gwent O +
Electronic O +
Materials O +
Ltd. O -
( O -
GEM O -
) O -
, O +
Mamhilad O -
, O +
Gwent O +
for O +
supplying O +
the O +
SPCEs O -
. O -

Drs O +
D.J. O +
Groves O +
and O +
B.A. O +
Morris O +
from O +
the O +
Heterohybridoma O +
Antibody O +
Group O -
, O +
Department O +
of O +
Biochemistry O -
, O +
University O +
of O +
Surrey O +
are O +
gratefully O +
acknowledged O +
as O +
the O +
originators O +
of O +
the O +
mAb O -
. O -

Financial O +
support O +
for O +
this O +
project O +
was O +
provided O +
by O +
the O +
HEFCE O -
. O +

Ferbam O +
[ O -
iron O -
( O -
III O -
) O +
dimethyldithiocarbamate O -
] O +
is O +
a O +
well O +
known O +
dithiocarbamate O +
effective O +
fungicide O +
widely O +
used O +
against O +
a O +
variety O +
of O +
plant U-Species +
pathogenic O +
fungi U-Species -
. O -

Ferbam O +
is O +
generally O +
determined O +
by O +
the O +
carbon O +
disulphide O +
evolution O +
method O +
based O +
on O +
its O +
decomposition O +
by O +
hot O +
mineral O +
acids O +
to O +
amine O +
and O +
carbon O +
disulfide O +
using O +
different O +
approaches O +
[ O -
1 O -
] O +
. O -

Ferbam O +
is O +
also O +
determined O +
by O +
converting O +
it O +
into O +
moybdenum O +
[ O -
2 O -
] O +
, O +
copper O +
[ O -
3 O -
] O -
and O +
1,10-phenanthroline O +
[ O -
4 O -
] O -
complexes O -
. O -

McLeod O +
and O +
McCulley O +
[ O -
5 O -
] O -
determined O +
dithiocarbamate O +
fungicides O +
by O +
headspace O +
gas O +
chromatography O +
of O +
the O +
carbon O +
disulphide O +
evolved O +
in O +
controlled O +
conditions O +
from O +
foodstuffs O +
and O +
similar O +
methods O +
were O +
also O +
given O +
by O +
the O +
Committee O +
for O +
Analytical O +
Methods O +
[ O -
6 O -
] O +
. O -

However O -
, O +
all O +
these O +
methods O +
suffer O +
from O +
the O +
following O +
disadvantages O -
: O +
( O -
a O -
) O +
Methods O +
other O +
than O +
gas O +
chromatography O +
are O +
indirect O -
, O +
time O +
consuming O +
and O +
sensitivity O +
is O +
low O -
. O -

( O -
b O -
) O +
Gas O +
chromatographic O +
methods O +
are O +
sensitive O +
but O +
suffer O +
from O +
lack O +
of O +
the O +
selectivity O +
since O +
all O +
dithiocarbamate O +
fungicides O +
evolve O +
carbon O +
disulphide O +
on O +
acid O +
hydrolysis O -
. O -

( O -
c O -
) O +
Spectrophotometric O +
methods O +
suffer O +
the O +
interference O +
of O +
various O +
ions O -
. O -

Capillary O +
electrophoresis O +
[ O -
7,8 O -
] O +
, O +
is O +
a O +
microvolume O +
separation O +
technique O +
increasingly O +
achieving O +
recognition O +
for O +
its O +
use O +
in O +
the O +
separation O +
of O +
inorganic O +
and O +
organic O +
compounds O -
. O -

The O +
key O +
features O +
of O +
this O +
technique O +
are O +
its O +
very O +
short O +
analysis O +
time O +
and O +
small O +
sample O +
volumes O +
in O +
the O +
nanoliter O +
and O +
picoliter O +
range O -
. O -

Capillary O +
electrophoresis O +
has O +
been O +
used O +
for O +
the O +
determination O +
of O +
sodium O +
dimethyldithiocarbamate O +
using O +
sulphonic O +
acid O +
polymer O +
coated O +
capillary O +
columns O +
at O +
pH O +
6.5 O +
using O +
sodium O +
phosphate O +
buffer O +
[ O -
9 O -
] O +
. O -

Liang O +
et O +
al. O +
used O +
diode O +
array O +
detection O +
and O +
factor O +
analysis O +
for O +
the O +
determination O +
of O +
dithiocarbamates O +
[ O -
10 O -
] O +
. O -

In O +
another O +
approach O -
, O +
solid O -
- O -
phase O +
extraction O +
was O +
used O +
to O +
separate O +
dithiocarbamates O +
with O +
other O +
pesticides O +
[ O -
11 O -
] O +
. O -

The O +
extensive O +
studies O +
of O +
metal O -
– O -
aminopolycarboxylate O +
complexes O +
are O +
reviewed O +
by O +
Timerbaev O +
[ O -
12 O -
] O +
. O -

This O +
report O +
is O +
concerned O +
with O +
the O +
investigation O +
of O +
the O +
potential O +
of O +
capillary O +
electrophoresis O +
in O +
the O +
determination O +
of O +
Ferbam O -
. O -

As O +
will O +
be O +
demonstrated O +
in O +
this O +
report O -
, O +
capillary O +
electrophoresis O +
with O +
its O +
precision O +
instrumentation O +
and O +
small O +
sample O +
requirements O +
is O +
well O +
suited O +
for O +
the O +
determination O +
of O +
Ferbam O -
. O -

Here O -
, O +
we O +
present O +
a O +
relatively O +
simple O +
and O +
selective O +
capillary O +
electrophoretic O +
method O +
by O +
converting O +
Fe O -
( O -
III O -
) O +
present O +
in O +
Ferbam O +
into O +
Fe O -
( O -
III O -
) O -
–EDTA− O -
complex O -
. O -

The O +
chemical O +
structure O +
of O +
Ferbam O +
is O +
as O +
follows O -
: O +
[ O -
( O -
CH3 O +
) O -
2 O +
–NC O -
( O -
S O -
) O -
2 O +
] O -
3 O +
Fe O -
. O -

2 O +
Experimental O +
2.1 O +
Instrumentation O +
Separations O +
were O +
performed O +
on O +
a O +
Thermo O +
Separation O +
Products O +
100 O +
CE O -
- O -
system O +
equipped O +
with O +
an O +
UV O +
absorbance O +
detector O -
. O -

Fused O +
silica O +
capillaries O +
of O +
75 O +
cm O +
long O +
( O -
45 O +
cm O +
to O +
the O +
detector O -
) O -
× O -
100 O +
μm O +
I.D. O +
were O +
used O -
. O -

The O +
solutes O +
were O +
injected O +
in O +
the O +
hydrodynamic O +
mode O +
by O +
vacuum O +
injection O +
for O +
2 O +
s. O +
TSP O +
1000 O +
software O +
was O +
used O +
for O +
the O +
data O +
acquisition O -
. O -

Detection O +
was O +
performed O +
by O +
direct O +
UV O +
absorbance O +
at O +
254 O +
nm O -
. O -

All O +
experiments O +
were O +
conducted O +
at O +
25±1 O -
° O -
C O -
. O -

2.2 O +
Reagents O +
and O +
solutions O +
All O +
chemicals O +
used O +
were O +
of O +
analytical O -
- O -
reagent O +
grade O +
and O +
doubly O +
distilled O +
water O +
was O +
used O +
for O +
the O +
preparation O +
of O +
solutions O +
and O +
all O +
dilutions O -
. O -

2.2.1 O +
Ferbam O +
solution O +
Ferbam O +
was O +
obtained O +
from O +
Riedel O -
- O -
de O +
Haën O +
( O -
Germany O -
) O +
and O +
used O +
as O +
received O -
. O -

Ferbam O +
solution O +
was O +
prepared O +
by O +
decomposing O +
its O +
20 O +
mg O +
with O +
concentrated O +
nitric O +
acid O +
( O -
5–10 O +
ml O -
) O +
and O +
heated O +
till O +
all O +
the O +
fumes O +
were O +
ceased O +
( O -
almost O +
to O +
dryness O -
) O +
and O +
dissolved O +
the O +
residue O +
in O +
1–2 O +
ml O +
of O +
concentrated O +
HCl O +
and O +
diluted O +
upto O +
30–40 O +
ml O +
and O +
pH O +
adjusted O +
in O +
the O +
range O +
2–3 O +
using O +
dilute O +
NaOH O +
and O +
finally O +
diluted O +
to O +
100 O +
ml O +
in O +
a O +
calibrated O +
flask O -
. O -

The O +
recovery O +
of O +
iron O -
( O -
III O -
) O +
from O +
Ferbam O +
was O +
checked O +
by O +
titrating O +
it O +
using O +
Variamine O +
Blue O +
B O +
as O +
indicator O +
[ O -
13 O -
] O +
. O -

Working O +
solutions O +
of O +
lower O +
concentrations O +
were O +
prepared O +
by O +
appropriate O +
dilutions O +
with O +
distilled O +
water O -
. O -

2.2.2 O +
EDTA O +
solution O +
Stock O +
solution O +
of O +
EDTA O +
( O -
0.5 O +
mM O +
) O +
as O +
disodium O +
salt O +
was O +
prepared O +
in O +
distilled O +
water O -
. O -

2.2.3 O +
Buffer O +
solution O +
Electrophoretic O +
buffer O +
solution O +
was O +
prepared O +
from O +
boric O +
acid O +
50 O +
mM O -
and O +
adjusting O +
the O +
desired O +
pH O +
by O +
adding O +
0.1 O +
M O -
NaOH O +
solution O -
. O -

2.3 O +
Procedures O +
2.3.1 O +
Basic O +
procedure O +
The O +
capillary O +
was O +
rinsed O +
with O +
1 O +
M O -
NaOH O -
, O +
0.1 O +
M O -
NaOH O +
and O +
water O +
for O +
2 O +
min O -
, O +
respectively O -
, O +
then O +
equilibrated O +
with O +
the O +
carrier O +
electrolyte O +
for O +
2 O +
min O -
. O -

Between O +
all O +
electrophoretic O +
separations O +
the O +
capillary O +
was O +
rinsed O +
for O +
2 O +
min O +
with O +
carrier O +
electrolyte O -
. O -

All O +
electrolyte O +
solutions O +
were O +
filtered O +
through O +
a O +
0.45 O +
μm O +
membrane O +
filter O -
. O -

2.3.2 O +
Preparation O +
of O +
standard O +
calibration O +
graph O +
A O +
series O +
of O +
standard O +
solutions O +
of O +
Ferbam O +
were O +
mixed O +
with O +
EDTA O +
( O -
1 O +
ml O -
) O +
and O +
diluted O +
to O +
2 O +
ml O +
with O +
distilled O +
water O +
and O +
injected O +
into O +
the O +
capillary O +
under O +
the O +
optimised O +
conditions O +
to O +
test O +
the O +
linearity O +
of O +
the O +
calibration O +
graph O -
. O -

2.3.3 O +
Determination O +
of O +
Ferbam O +
in O +
grains O +
The O +
method O +
was O +
applied O +
for O +
the O +
determination O +
of O +
Ferbam O +
from O +
wheat U-Species +
grains O -
. O -

A O +
known O +
amount O +
of O +
Ferbam O +
in O +
acetonitrile O +
was O +
crushed O +
with O +
10 O +
g O +
of O +
wheat O +
grains O +
and O +
shaken O +
mechanically O +
with O +
chloroform O +
( O -
100 O +
ml O -
) O +
for O +
1 O +
h. O +
The O +
mixture O +
was O +
filtered O +
and O +
the O +
residue O +
in O +
the O +
funnel O +
was O +
washed O +
with O +
chloroform O +
( O -
3 O -
× O -
10 O +
ml O -
) O -
. O -

The O +
extracts O +
were O +
evaporated O +
to O +
dryness O +
and O +
solution O +
was O +
prepared O +
as O +
discussed O +
above O +
and O +
determined O +
by O +
the O +
general O +
procedure O -
. O -

Untreated O +
samples O +
were O +
taken O +
as O +
reference O +
and O +
the O +
results O +
indicated O +
good O +
recoveries O +
in O +
all O +
cases O -
. O -

The O +
results O +
of O +
the O +
determinations O +
are O +
given O +
in O +
Table O +
1 O -
. O -

3 O +
Results O +
and O +
discussion O +
A O +
typical O +
capillary O +
electropherogram O +
of O +
Ferbam O +
at O +
pH O +
9.0 O +
is O +
shown O +
in O +
Fig. O +
1 O -
. O -

It O +
shows O +
a O +
sharp O +
peak O +
with O +
baseline O +
resolution O -
. O -

In O +
order O +
to O +
determine O +
the O +
best O +
experimental O +
conditions O +
( O -
peak O +
efficiency O -
, O +
analysis O +
time O -
) O +
borate O -
, O +
phosphate O +
and O +
acetate O +
buffer O +
of O +
pH O +
9.0 O -
, O +
7.0 O +
and O +
4.5 O -
, O +
respectively O +
of O +
1.25–50 O +
mM O -
were O +
investigated O +
and O +
compared O -
. O -

It O +
was O +
observed O +
that O +
below O +
pH O +
7.0 O +
in O +
phosphate O +
and O +
acetate O +
buffer O +
good O +
peak O +
were O +
not O +
observed O -
. O -

A O +
well O +
defined O +
peak O +
was O +
obtained O +
in O +
between O +
25 O +
and O +
50 O +
mM O -
borate O +
buffer O +
of O +
pH O +
9.0 O -
. O -

It O +
was O +
observed O +
that O +
the O +
migration O +
time O +
was O +
more O +
at O +
the O +
higher O +
concentrations O +
of O +
the O +
borate O +
buffer O -
. O -

Above O +
25 O +
mM O -
concentration O +
of O +
borate O +
buffer O +
there O +
was O +
a O +
considerable O +
increase O +
in O +
the O +
migration O +
time O +
of O +
the O +
both O +
analytes O -
, O +
resulting O +
in O +
an O +
increase O +
in O +
the O +
analysis O +
time O -
. O -

Therefore O -
, O +
25 O +
mM O -
of O +
borate O +
buffer O +
concentration O +
was O +
preferred O -
. O -

The O +
influence O +
of O +
the O +
applied O +
voltage O +
was O +
also O +
studied O +
by O +
increasing O +
the O +
applied O +
voltage O -
. O -

The O +
retention O +
time O +
decreases O +
with O +
increasing O +
voltage O -
. O -

Therefore O -
, O +
+ O -
30 O +
kV O +
was O +
applied O +
to O +
get O +
the O +
shortest O +
time O -
. O -

A O +
linear O +
relationship O +
between O +
peak O +
height O +
and O +
concentrations O +
were O +
obtained O +
in O +
the O +
range O +
3.5–500 O +
μg O -
/ O -
ml O +
with O +
an O +
correlation O +
coefficient O +
of O +
0.9994 O -
. O -

The O +
linear O +
regression O +
equation O +
for O +
the O +
calibration O +
curve O +
is O +
y O +
= O -
0.0001x O +
+ O -
0.0003 O -
. O -

Aliquots O +
containing O +
50 O +
μg O -
/ O -
ml O +
of O +
give O +
a O +
relative O +
standard O +
deviation O +
of O +
2.9 O -
% O +
in O +
analysis O -
. O -

Ferbam O -
, O +
if O +
present O +
with O +
other O +
water O +
soluble O +
dithiocarbamates O +
such O +
as O +
nabam O -
, O +
metham O -
, O +
sodium O +
diethyldithiocarbamate O -
, O +
etc O -
. O -
, O +
can O +
easily O +
be O +
separated O +
by O +
extraction O +
with O +
chloroform O -
; O +
Nabam O +
and O +
others O +
will O +
remain O +
in O +
the O +
aqueous O +
phase O +
which O +
can O +
then O +
be O +
analysed O +
by O +
the O +
basic O +
procedure O +
[ O -
14 O -
] O +
. O -

Furthermore O -
, O +
our O +
experiments O +
have O +
shown O +
that O +
Ferbam O +
can O +
be O +
determined O +
directly O +
in O +
the O +
presence O +
of O +
metal O +
ions O +
like O +
Co O -
( O -
II O -
) O -
, O +
Zn O -
( O -
II O -
) O -
, O +
Cu O -
( O -
II O -
) O +
and O +
Ni O -
( O -
II O -
) O +
without O +
any O +
interference O -
, O +
whereas O -
, O +
these O +
metal O +
ions O +
strongly O +
interfere O +
in O +
the O +
spectrophotometric O +
methods O +
[ O -
2,3 O -
] O +
. O -

These O +
results O +
are O +
similar O +
to O +
as O +
reported O +
by O +
earlier O +
workers O +
[ O -
12,15 O -
] O +
. O -

4 O +
Conclusions O +
Capillary O +
electrophoresis O +
provides O +
an O +
important O +
tool O +
in O +
the O +
hands O +
of O +
the O +
analytical O +
chemists O +
for O +
the O +
determination O +
of O +
Ferbam O -
. O -

The O +
detection O +
limit O +
( O -
S O +
/N O +
=3 O -
) O +
using O +
this O +
method O +
is O +
0.7 O +
μg O -
/ O -
ml O +
( O -
0.7 O +
mg O -
/ O -
kg O -
) O +
of O +
Ferbam O +
which O +
is O +
better O +
than O +
1 O +
μg O -
/ O -
ml O +
of O +
Nitowski O +
et O +
al. O -
's O +
[ O -
9 O -
] O -
method O +
reported O +
for O +
dimethyldithiocarbamate O +
using O +
sulphonic O +
acid O +
polymer O -
- O -
coated O +
capillary O +
columns O -
. O -

As O +
most O +
of O +
the O +
cations O +
and O +
anions O +
do O +
not O +
interfere O +
in O +
the O +
determination O +
of O +
Ferbam O -
, O +
moreover O -
, O +
the O +
simplicity O +
and O +
small O +
sample O +
volume O +
requirements O +
makes O +
it O +
advantageous O +
to O +
other O +
chromatographic O +
techniques O -
. O -

Thus O -
, O +
the O +
usefulness O +
of O +
capillary O +
electrophoresis O +
as O +
a O +
tool O +
for O +
checking O +
the O +
amount O +
of O +
Ferbam O +
is O +
successfully O +
demonstrated O -
. O -

Acknowledgements O +
One O +
of O +
the O +
authors O +
( O -
A.K.M. O -
) O +
thanks O +
the O +
AvH O +
Foundation O -
, O +
Bonn O -
, O +
Germany O +
for O +
financial O +
assistance O -
. O +

l O +
-cis O -
Diltiazem O -
, O +
the O +
enantiomer O +
of O +
diltiazem O +
( O -
d O +
-cis O -
diltiazem O -
) O -
, O +
has O +
100 O +
times O +
less O +
Ca2 O -
+ O -
channel O +
blocking O +
activity O +
than O +
diltiazem O +
( O -
Ikeda O +
et O +
al. O -
, O +
1991 O -
) O +
. O -

l O +
-cis O -
Diltiazem O +
is O +
not O +
a O +
simple O +
inactive O +
stereoisomer O +
but O +
has O +
been O +
established O +
as O +
a O +
unique O +
pharmacological O +
tool O +
( O -
Caretta O +
et O +
al. O -
, O +
1979 O -
) O +
. O -

For O +
example O -
, O +
l O +
-cis O -
diltiazem O -
, O +
but O +
not O +
diltiazem O -
, O +
inhibits O +
the O +
cGMP O -
- O -
gated O +
cation O +
channel O +
in O +
rod O +
cells O +
( O -
Stern O +
et O +
al. O -
, O +
1986 O -
; O +
Quandt O +
et O +
al. O -
, O +
1991 O -
) O +
. O -

Interestingly O -
, O +
there O +
have O +
been O +
several O +
reports O +
indicating O +
that O +
l O +
-cis O -
diltiazem O +
protects O +
against O +
ischemic O +
cardiac O +
injury O -
. O -

For O +
example O -
, O +
l O +
-cis O -
diltiazem O +
produces O +
a O +
high O +
recovery O +
of O +
cardiac O +
function O +
after O +
ischemia O -
/ O -
reperfusion O +
and O +
inhibits O +
the O +
increase O +
of O +
non O -
- O -
esterified O +
fatty O +
acids O +
during O +
ischemia O +
in O +
isolated O -
, O +
perfused O +
working O +
rat U-Species +
heart O +
( O -
Nasa O +
et O +
al. O -
, O +
1990 O -
; O +
Xiao O +
et O +
al. O -
, O +
1997 O -
) O +
. O -

Recently O -
, O +
our O +
laboratory O +
has O +
reported O +
that O +
treatment O +
with O +
l O +
-cis O -
diltiazem O +
reduced O +
infarct O +
size O +
without O +
affecting O +
any O +
hemodynamic O +
parameter O +
in O +
rabbit U-Species +
heart O +
in O +
vivo O +
( O -
Nishida O +
et O +
al. O -
, O +
1999 O -
) O +
. O -

Since O +
l O +
-cis O -
diltiazem O +
has O +
a O +
much O +
less O +
potent O +
Ca2 O -
+ O -
channel O +
blocking O +
action O +
than O +
diltiazem O -
, O +
it O +
has O +
been O +
suggested O +
that O +
l O +
-cis O -
diltiazem O +
protects O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O +
with O +
a O +
mechanism O +
other O +
than O +
Ca2 O -
+ O -
channel O +
blockade O -
. O -

We O +
have O +
also O +
demonstrated O +
that O +
treatment O +
with O +
l O +
-cis O -
diltiazem O +
before O +
reperfusion O +
also O +
reduced O +
infarct O +
size O +
in O +
ischemic O +
rabbit U-Species +
heart O +
( O -
Nishida O +
et O +
al. O -
, O +
1999 O -
) O +
. O -

Ca2 O -
+ O -
overload O +
at O +
reperfusion O +
after O +
ischemia O +
( O -
Allen O +
and O +
Orchard O -
, O +
1983 O -
) O -
and O +
reoxygenation O +
after O +
hypoxia O +
( O -
Poole O -
- O -
Wilson O +
et O +
al. O -
, O +
1984 O -
) O -
have O +
been O +
considered O +
to O +
be O +
involved O +
in O +
the O +
final O +
stage O +
of O +
ischemia O -
/ O -
reperfusion O +
injury O +
of O +
cardiac O +
myocytes O +
( O -
Nayler O -
, O +
1981 O -
; O +
Farber O -
, O +
1982 O -
; O +
Steenbergen O +
et O +
al. O -
, O +
1990 O -
) O +
. O -

Thus O -
, O +
it O +
is O +
postulated O +
that O +
l O +
-cis O -
diltiazem O +
elicits O +
a O +
cardioprotective O +
action O +
via O +
the O +
attenuation O +
of O +
Ca2 O -
+ O -
overload O +
after O +
reperfusion O -
. O -

In O +
terms O +
of O +
energy O +
metabolism O -
, O +
ischemic O +
insults O +
can O +
be O +
simulated O -
, O +
in O +
part O -
, O +
by O +
controlled O +
metabolic O +
inhibition O -
. O -

Li O +
et O +
al. O +
( O -
1989 O -
) O -
has O +
reported O +
that O +
the O +
myocytes O +
were O +
reversibly O +
ATP O -
- O -
depleted O +
by O +
metabolic O +
inhibitors O -
. O -

Thus O -
, O +
myocardial O +
Ca2 O -
+ O -
overload O +
induced O +
by O +
ischemia O +
and O +
reperfusion O +
is O +
considered O +
to O +
be O +
simply O +
mimicked O -
, O +
in O +
part O -
, O +
by O +
treatment O +
with O +
carbonyl O +
cyanide O +
m O +
-chrolophenylhydrazone O +
( O -
CCCP O -
) O -
, O +
a O +
mitochondrial O +
uncoupler O -
, O +
followed O +
by O +
washout O +
of O +
CCCP O -
. O -

In O +
order O +
to O +
assess O +
the O +
effect O +
of O +
l O +
-cis O -
diltiazem O +
on O +
reperfusion O -
- O -
induced O +
Ca2 O -
+ O -
overload O -
, O +
we O +
used O +
a O +
model O +
for O +
Ca2 O -
+ O -
overload O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
isolated O +
guinea B-Species +
pig L-Species +
cardiomyocytes O -
. O -

We O +
also O +
assessed O +
the O +
effect O +
of O +
other O +
drugs O -
, O +
Ca2 O -
+ O -
channel O +
blockers O +
and O +
Na+ O +
/Ca2 O -
+ O -
exchanger O +
blockers O -
, O +
to O +
clarify O +
the O +
mechanism O +
for O +
Ca2 O -
+ O -
overload O +
in O +
this O +
model O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Preparation O +
of O +
single O +
cells O +
Ventricular O +
myocytes O +
were O +
isolated O +
enzymatically O +
from O +
the O +
hearts O +
of O +
male O +
Hartley B-Species +
guinea I-Species +
pigs L-Species +
( O -
weight O +
250–500 O +
g O -
) O +
according O +
to O +
the O +
method O +
described O +
( O -
Kurokawa O +
et O +
al. O -
, O +
1997 O -
) O +
. O -

The O +
animals O +
were O +
anaesthetized O +
with O +
sodium O +
pentobarbital O +
( O -
50 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O +
and O +
the O +
ascending O +
aorta O +
was O +
cannulated O +
in O +
situ O +
under O +
artificial O +
respiration O -
. O -

The O +
heart O +
was O +
perfused O +
with O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O +
for O +
10 O +
min O -
, O +
followed O +
by O +
the O +
same O +
solution O +
containing O +
collagenase O +
for O +
7–14 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
8–10 O +
ml O -
/ O -
min O +
via O +
a O +
Langendorff O +
apparatus O +
at O +
37 O -
° O -
C O -
. O -

Subsequently O -
, O +
the O +
enzyme O +
solution O +
was O +
washed O +
out O +
with O +
a O +
high O +
K+ O +
, O +
Ca2 O -
+ O +
-free O +
solution O +
( O -
Kraftbrühe O +
( O -
KB O -
) O +
solution O -
, O +
Isenberg O +
and O +
Klöckner O -
, O +
1982 O +
) O -
. O -

The O +
ventricular O +
myocytes O +
were O +
dissociated O +
by O +
gentle O +
stirring O +
of O +
the O +
tissue O +
fragments O +
at O +
37 O -
° O -
C O -
. O -

The O +
dissociated O +
cells O +
were O +
stored O +
in O +
KB O +
solution O +
at O +
4 O -
° O -
C O -
, O +
and O +
were O +
used O +
up O +
to O +
10 O +
h O +
after O +
isolation O -
. O -

Nominally O +
Ca2 O -
+ O +
-free O +
solution O +
had O +
the O +
following O +
composition O +
( O -
mM O -
) O -
: O +
NaCl O +
135 O -
, O +
KCl O +
5.4 O -
, O +
MgCl2 O -
1 O -
, O +
glucose O +
5.8 O -
, O +
HEPES O +
5 O +
( O -
pH O +
7.4 O -
, O +
adjusted O +
with O +
tris O -
) O -
. O -

Normal O +
Tyrode O +
solution O +
was O +
made O +
by O +
adding O +
1.8 O +
mM O +
CaCl2 O -
to O +
nominally O +
Ca2 O -
+ O +
-free O +
solution O -
. O -

The O +
collagenase O +
solutions O +
were O +
prepared O +
by O +
adding O +
collagenase O +
( O -
110 O +
units O -
/ O -
ml O +
Collagenase O +
S-1 O -
, O +
Nitta O +
Gelatin O -
, O +
Osaka O -
, O +
Japan O -
; O +
200–220 O +
units O -
/ O -
ml O +
collagenase O -
, O +
Yakult O -
, O +
Tokyo O -
. O -

Japan O -
) O +
and O +
10.8 O +
nM O +
CaCl2 O -
to O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
, O +
or O +
by O +
combining O +
collagenase O +
( O -
0.145 O +
U O -
/ O -
ml O +
collagenase O +
A O -
, O +
Boehringer O +
Mannheim O -
, O +
Japan O -
) O +
and O +
protease O +
( O -
0.156 O +
units O -
/ O -
ml O +
protease O +
type O +
IX O -
, O +
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O +
to O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
. O -

The O +
KB O +
solution O +
contained O +
( O -
mM O -
) O -
: O +
potassium O +
glutamate O +
70 O -
, O +
KCl O +
20 O -
, O +
oxalic O +
acid O +
10 O -
, O +
KH2 O +
PO4 O -
10 O -
, O +
taurine O +
10 O -
, O +
glucose O +
5.8 O -
, O +
HEPES O +
5 O -
, O +
EGTA O +
0.5 O +
( O -
pH O +
7.4 O -
, O +
adjusted O +
with O +
KOH O -
) O -
. O -

2.2 O +
Measurement O +
of O +
fluorescence O +
ratio O +
of O +
fura-2 O +
in O +
cardiac O +
myocytes O +
For O +
measurement O +
of O +
a O +
change O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O -
of O +
cardiac O +
myocytes O -
, O +
a O +
Ca2 O -
+ O +
-sensitive O +
fluorescent O +
dye O -
, O +
fura-2 O -
/ O -
acetoxymethylester O +
( O -
fura-2 O -
/ O -
AM O -
) O -
, O +
was O +
used O -
. O -

Fura-2 O -
/ O -
AM O +
( O -
1 O +
mM O -
, O +
dissolved O +
in O +
dimethylsulfoxide O -
, O +
DMSO O -
) O +
was O +
prepared O +
in O +
KB O +
solution O +
and O +
applied O +
to O +
isolated O +
myocytes O +
at O +
a O +
final O +
concentration O +
of O +
10 O +
μM. O +
After O +
the O +
cell O +
suspension O +
had O +
been O +
incubated O +
for O +
10 O +
min O +
at O +
37 O -
° O -
C O -
, O +
the O +
cells O +
settled O +
out O +
and O +
became O +
loosely O +
attached O +
to O +
the O +
bottom O +
of O +
the O +
chamber O -
. O -

Then O +
the O +
fura-2-loaded O +
myocytes O +
were O +
washed O +
and O +
superfused O +
( O -
4–5 O +
ml O -
/ O -
min O -
, O +
37 O -
° O -
C O -
) O +
with O +
normal O +
Tyrode O +
solution O +
containing O +
1.8 O +
mM O +
Ca2 O -
+ O -
for O +
30 O +
min O -
. O -

The O +
myocytes O +
were O +
illuminated O +
with O +
a O +
dual O +
wavelength O +
fluorometer O +
( O -
CAM-230 O -
, O +
Japan O +
Spectroscopic O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O -

Video O +
images O +
were O +
digitized O -
, O +
using O +
an O +
Argus-50 O -
/ O -
Ca O +
system O +
( O -
Hamamatsu O +
Photonics O -
) O -
. O -

The O +
fluorescence O +
ratio O +
was O +
calculated O +
from O +
the O +
value O +
of O +
the O +
fluorescence O +
intensity O +
at O +
500 O +
nm O +
with O +
340- O +
and O +
380-nm O +
excitation O -
. O -

The O +
digital O +
images O +
were O +
obtained O +
every O +
5 O +
min O +
from O +
just O +
before O +
treatment O +
with O +
CCCP O +
till O +
the O +
end O +
of O +
the O +
experiment O -
. O -

2.3 O +
Evaluation O +
of O +
morphological O +
changes O +
of O +
cardiac O +
myocytes O +
Cells O +
lightly O +
attached O +
to O +
the O +
perfusion O +
chamber O +
were O +
superfused O +
with O +
normal O +
Tyrode O +
solution O +
at O +
37 O -
° O -
C O -
. O -

After O +
30 O +
min O +
of O +
stabilization O -
, O +
a O +
rod O -
- O -
shaped O +
cell O +
was O +
selected O +
randomly O +
from O +
those O +
within O +
the O +
microscopic O +
field O +
of O +
the O +
chamber O -
. O -

Caffeine O +
( O -
5 O +
mM O -
) O +
was O +
added O +
for O +
1 O +
min O +
to O +
the O +
chamber O +
in O +
order O +
to O +
confirm O +
that O +
the O +
function O +
of O +
the O +
intracellular O +
Ca2 O -
+ O -
store O +
of O +
the O +
myocyte O +
was O +
maintained O -
. O -

After O +
washing O +
out O +
of O +
the O +
caffeine O +
for O +
5 O +
min O -
, O +
the O +
morphology O +
of O +
the O +
myocyte O +
was O +
recorded O +
as O +
a O +
digital O +
image O +
using O +
the O +
Argus-50 O -
/ O -
Ca O +
system O -
. O -

To O +
examine O +
the O +
morphological O +
change O +
of O +
the O +
myocyte O -
, O +
the O +
morphology O +
of O +
the O +
same O +
cell O +
was O +
also O +
recorded O +
at O +
the O +
end O +
of O +
chemical O +
ischemia O +
and O +
also O +
at O +
the O +
end O +
of O +
30-min O +
reperfusion O -
. O -

After O +
Ca2 O -
+ O -
measurement O -
, O +
the O +
morphological O +
change O +
was O +
analyzed O +
by O +
measuring O +
the O +
area O +
of O +
the O +
myocyte O -
. O -

The O +
cell O +
surface O +
area O +
was O +
calculated O +
from O +
the O +
digitized O +
image O +
of O +
the O +
cell O +
and O +
the O +
post O -
- O -
ischemic O +
value O +
was O +
expressed O +
as O +
percentage O +
of O +
the O +
pre O -
- O -
ischemic O +
value O -
. O -

2.4 O +
Experimental O +
protocols O +
In O +
order O +
to O +
determine O +
the O +
optimal O +
condition O +
of O +
the O +
Ca2 O -
+ O -
overload O +
model O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
, O +
we O +
performed O +
some O +
preliminary O +
experiments O -
. O -

We O +
first O +
followed O +
a O +
protocol O +
for O +
metabolic O +
inhibition O -
, O +
using O +
Tyrode O +
solution O +
containing O +
normal O +
Ca2 O -
+ O -
and O +
1 O +
μM O +
of O +
CCCP O -
. O -

However O -
, O +
the O +
myocytes O +
exposed O +
to O +
CCCP O +
for O +
10–15 O +
min O +
showed O +
a O +
rigor O +
contraction O +
with O +
an O +
increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
, O +
but O +
failed O +
to O +
show O +
Ca2 O -
+ O -
overload O +
on O +
washout O +
of O +
CCCP O +
( O -
energy O +
repletion O -
) O +
after O +
the O +
transition O +
to O +
rigor O +
contraction O +
( O -
the O +
sign O +
of O +
ATP O +
depletion O -
) O -
. O -

These O +
cells O +
showed O +
neither O +
further O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
nor O +
morphological O +
changes O +
after O +
energy O +
repletion O -
. O -

To O +
improve O +
the O +
efficacy O +
of O +
the O +
assessment O +
of O +
reperfusion O +
injury O -
, O +
we O +
used O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O +
for O +
metabolic O +
inhibition O -
, O +
since O +
it O +
was O +
reported O +
that O +
cells O +
in O +
the O +
low O +
Ca2 O -
+ O -
solution O +
remain O +
rod O -
- O -
shaped O +
for O +
a O +
longer O +
period O +
against O +
metabolic O +
inhibition O +
( O -
Li O +
et O +
al. O -
, O +
1988 O -
) O +
. O -

We O +
also O +
examined O +
the O +
dose O -
- O -
dependent O +
effects O +
of O +
CCCP O +
( O -
100 O +
nM O -
, O +
1 O +
and O +
3 O +
μM O -
) O -
, O +
and O +
confirmed O +
that O +
1 O +
μM O +
of O +
CCCP O +
was O +
the O +
most O +
stable O +
to O +
induce O +
Ca2 O -
+ O -
overload O +
after O +
energy O +
repletion O -
. O -

Based O +
on O +
these O +
experiments O -
, O +
we O +
established O +
the O +
standard O +
procedure O +
as O +
follows O -
. O -

After O +
confirmation O +
of O +
the O +
integrity O +
of O +
the O +
myocardial O +
store O +
functions O +
described O +
in O +
the O +
previous O +
section O -
, O +
Ca2 O -
+ O +
-free O +
Tyrode O +
containing O +
CCCP O +
( O -
1 O +
μM O -
) O +
was O +
perfused O +
for O +
40 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
2–3 O +
ml O -
/ O -
min O -
. O -

Ca2 O -
+ O -
overload O +
was O +
induced O +
by O +
washout O +
of O +
CCCP O +
with O +
normal O +
Tyrode O +
solution O +
for O +
30 O +
min O +
at O +
a O +
perfusion O +
rate O +
of O +
4–5 O +
ml O -
/ O -
min O -
. O -

In O +
this O +
study O -
, O +
we O +
employed O +
the O +
following O +
two O +
protocols O -
: O +
( O -
A O -
) O +
before O +
metabolic O +
inhibition O -
, O +
in O +
which O +
drugs O +
were O +
included O +
throughout O +
the O +
experiment O -
, O +
and O +
( O -
B O -
) O +
before O +
energy O +
repletion O -
, O +
in O +
which O +
drugs O +
were O +
included O +
from O +
5 O +
min O +
before O +
energy O +
repletion O +
to O +
the O +
end O +
of O +
the O +
experiment O -
. O -

2.5 O +
Calibration O +
for O +
Ca2 O -
+ O -
concentration O +
The O +
maximum O +
ratio O +
( O -
R O +
max O +
) O +
unique O +
to O +
individual O +
cells O +
was O +
obtained O +
at O +
the O +
end O +
of O +
each O +
experiment O +
by O +
applying O +
ionomycin O +
( O -
2 O +
μM O -
) O +
to O +
the O +
normal O +
Tyrode O +
solution O -
. O -

The O +
minimum O +
ratio O +
( O -
R O +
min O +
) O +
was O +
obtained O +
by O +
applying O +
EGTA O +
( O -
10 O +
mM O -
) O +
to O +
the O +
ionomycin O +
containing O +
Tyrode O +
solution O -
. O -

Both O +
R O +
max O -
and O +
R O +
min O -
values O +
were O +
obtained O +
under O +
steady O +
state O +
conditions O -
. O -

[ O -
Ca2 O -
+ O +
] O -
i O -
was O +
calculated O +
from O +
the O +
following O +
formula O -
: O +
[ O -
Ca2 O -
+ O +
] O -
i O -
( O -
nM O -
) O -
= O -
( O -
R O +
−R O +
min O +
) O -
×K O +
d O +
×F O +
min O +
/ O -
( O -
( O -
R O +
max O +
−R O +
) O -
×F O +
max O +
) O -
) O -
, O +
where O +
R O -
is O +
the O +
ratio O +
obtained O +
from O +
the O +
experiment O -
, O +
F O -
means O +
the O +
fluorescence O +
intensity O +
at O +
380-nm O +
excitation O -
, O +
and O +
K O +
d O -
is O +
the O +
dissociation O +
constant O +
defined O +
as O +
224 O +
nM. O -
2.6 O +
Chemicals O +
l O +
-cis O -
Diltiazem O +
and O +
diltiazem O +
were O +
kind O +
gifts O +
from O +
Tanabe O +
Seiyaku O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O -

A O +
specific O +
inhibitor O +
of O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
, O +
2- O -
[ O -
2- O -
[ O -
4- O -
( O -
4-nitrobenzyloxy O -
) O +
phenyl O -
] O +
ethyl O -
] O +
isothiourea O +
methanesulphonate O +
( O -
KB O -
- O -
R7943 O -
) O -
, O +
was O +
a O +
kind O +
gift O +
from O +
Kanebo O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O -

CCCP O +
was O +
purchased O +
from O +
Sigma O -
. O -

2.7 O +
Statistical O +
analysis O +
All O +
data O +
were O +
expressed O +
as O +
means±S.E.M. O +
The O +
time O +
course O +
data O +
( O -
Ca2 O -
+ O -
measurement O -
) O +
were O +
divided O +
into O +
two O +
events O -
, O +
during O +
40 O +
min O +
of O +
metabolic O +
inhibition O +
and O +
during O +
30-min O +
energy O +
repletion O -
, O +
and O +
repeated O +
measures O +
two O -
- O -
way O +
analysis O +
of O +
variance O +
was O +
used O -
. O -

If O +
there O +
was O +
no O +
interaction O +
between O +
the O +
drug O +
factor O +
and O +
the O +
time O +
factor O -
, O +
Bonferroni O -
/ O -
Dunn O +
( O -
Dunn O -
's O +
Procedure O +
for O +
Comparing O +
a O +
Control O +
to O +
All O +
other O +
Means O -
) O +
post O -
- O -
hoc O +
test O +
was O +
done O +
thereafter O -
. O -

One O -
- O -
way O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
followed O +
by O +
the O +
Bonferroni O -
/ O -
Dunn O +
post O -
- O -
hoc O +
test O +
was O +
used O +
for O +
the O +
cell O +
size O +
data O -
. O -

All O +
statistical O +
analyses O +
were O +
performed O +
using O +
Super O +
ANOVA O -
™ O +
( O -
Abacus O +
Concepts O -
, O +
Berkeley O -
, O +
CA O -
) O -
. O -

Differences O +
were O +
considered O +
to O +
be O +
statistically O +
significant O +
when O +
the O +
P O -
value O +
was O +
less O +
than O +
0.05 O -
. O -

3 O +
Results O +
3.1 O +
Cell O +
selection O +
In O +
all O +
the O +
experiments O -
, O +
rod O -
- O -
shaped O +
myocytes O +
as O +
shown O +
in O +
Fig. O +
1A O -
were O +
selected O -
. O -

A O +
single O +
myocyte O +
was O +
further O +
selected O +
for O +
the O +
ischemia O +
experiment O -
, O +
based O +
on O +
the O +
criterion O +
that O +
it O +
showed O +
a O +
transient O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
on O +
treatment O +
with O +
5 O +
mM O +
caffeine O +
( O -
Fig. O +
1B O -
) O +
. O -

The O +
cells O -
, O +
which O +
did O +
not O +
satisfy O +
these O +
criteria O -
, O +
or O +
which O +
changed O +
morphologically O +
after O +
the O +
treatment O +
with O +
caffeine O -
, O +
were O +
excluded O -
. O -

3.2 O +
Changes O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O -
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
Fig. O +
2 O -
represents O +
the O +
change O +
in O +
time O +
course O +
of O +
[ O -
Ca2 O -
+ O +
] O -

i O -
in O +
the O +
absence O +
and O +
the O +
presence O +
of O +
drugs O -
. O -

Before O +
CCCP O +
treatment O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
of O +
all O +
cells O +
used O +
were O +
almost O +
identical O +
in O +
level O +
( O -
about O +
100 O +
nM O -
) O -
. O -

In O +
the O +
control O +
myocytes O -
, O +
[ O -
Ca2 O -
+ O +
] O -
i O -
did O +
not O +
change O +
during O +
40 O +
min O +
of O +
CCCP O +
treatment O -
. O -

After O +
washout O +
of O +
CCCP O -
, O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increased O +
dramatically O +
within O +
5 O +
min O +
and O +
continued O +
to O +
increase O +
until O +
the O +
end O +
of O +
energy O +
repletion O -
. O -

In O +
order O +
to O +
confirm O +
that O +
this O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
was O +
not O +
due O +
to O +
the O +
simple O +
entry O +
of O +
extracellular O +
Ca2 O -
+ O -
when O +
Ca2 O -
+ O +
-free O +
Tyrode O +
was O +
replaced O +
by O +
normal O +
Tyrode O -
, O +
we O +
performed O +
the O +
same O +
perfusion O +
protocol O +
without O +
CCCP O +
treatment O -
. O -

We O +
observed O +
that O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
showed O +
a O +
small O +
( O -
20–30 O +
nM O -
) O -
, O +
but O +
not O +
significant O -
, O +
increase O +
at O +
5 O +
min O +
after O +
energy O +
repletion O -
. O -

Therefore O -
, O +
the O +
Ca2 O -
+ O -
overload O +
observed O +
here O +
is O +
considered O +
to O +
be O +
induced O +
by O +
the O +
injury O +
due O +
to O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O -

Furthermore O -
, O +
Ni2 O -
+ O -
( O -
5 O +
mM O -
) O +
and O +
KB O -
- O -
R7943 O +
( O -
10 O +
μM O -
) O -
, O +
known O +
as O +
inhibitors O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
, O +
completely O +
blocked O +
the O +
initial O +
rise O +
of O +
[ O -
Ca2 O -
+ O +
] O -
i O -
after O +
washout O +
of O +
CCCP O +
( O -
P O +
< O -
0.01 O +
vs. O +
control O -
) O +
and O +
continued O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
during O +
30 O +
min O +
of O +
energy O +
repletion O -
. O -

However O -
, O +
nitrendipine O +
( O -
10 O +
μM O -
) O -
, O +
a O +
dihydropyridine O +
Ca2 O -
+ O -
channel O +
blocker O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
after O +
washout O +
of O +
CCCP O -
. O -

Nicardipine O +
( O -
10 O +
μM O -
) O -
, O +
another O +
dihydropyridine O +
Ca2 O -
+ O -
channel O +
blocker O -
, O +
also O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
( O -
see O +
Table O +
1 O -
) O -
. O -

Thus O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
in O +
this O +
model O +
was O +
suggested O +
to O +
be O +
mediated O -
, O +
not O +
by O +
L O -
- O -
type O +
Ca2 O -
+ O -
channels O +
but O +
by O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
. O -

As O +
for O +
the O +
treatment O +
with O +
drugs O +
before O +
metabolic O +
inhibition O +
( O -
protocol O +
( O -
A O -
) O -
) O -
, O +
diltiazem O +
( O -
3 O +
μM O -
) O +
and O +
l O +
-cis O -
diltiazem O +
( O -
10 O +
μM O -
) O -
, O +
but O +
not O +
l O +
-cis O -
diltiazem O +
( O -
3 O +
μM O -
) O +
significantly O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
during O +
energy O +
repletion O +
( O -
Fig. O +
3A O -
) O -
. O -

As O +
for O +
the O +
treatment O +
with O +
drugs O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O +
( O -
protocol O +
( O -
B O -
) O -
) O -
, O +
3 O +
μM O +
of O +
diltiazem O -
, O +
which O +
was O +
effective O +
in O +
protocol O +
( O -
A O -
) O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O -
. O -

However O -
, O +
a O +
higher O +
concentration O +
of O +
diltiazem O +
( O -
10 O +
μM O -
) O +
could O +
significantly O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
after O +
energy O +
repletion O +
( O -
Fig. O +
3B O -
) O +
. O -

l O +
-cis O -
Diltiazem O +
( O -
10 O +
μM O -
) O +
also O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
( O -
P O +
< O -
0.01 O +
vs. O +
control O -
) O -
. O -

3.3 O +
Morphological O +
change O +
of O +
the O +
cell O +
after O +
energy O +
repletion O +
Cells O -
, O +
which O +
showed O +
a O +
rigor O +
contraction O +
during O +
CCCP O +
treatment O -
, O +
were O +
all O +
excluded O +
from O +
the O +
experiments O -
. O -

Table O +
1 O -
represents O +
the O +
morphological O +
change O +
in O +
cell O +
size O +
caused O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
the O +
absence O +
and O +
the O +
presence O +
of O +
drugs O -
, O +
accompanied O +
by O +
[ O -
Ca2 O -
+ O +
] O -
i O +
. O -

Compared O +
with O +
the O +
control O -
, O +
l O +
-cis O -
diltiazem O +
( O -
10 O +
μM O -
) O -
, O +
diltiazem O +
( O -
10 O +
μM O -
) O -
, O +
Ni2 O -
+ O -
( O -
5 O +
mM O -
) O +
and O +
KB O -
- O -
R7943 O +
( O -
10 O +
μM O -
) O -
, O +
added O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O -
, O +
all O +
reduced O +
the O +
cell O +
shortening O +
( O -
P O +
< O -
0.05 O -
) O -
, O +
and O +
these O +
effects O +
correlated O +
well O +
with O +
the O +
attenuation O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O -
. O -

Treatment O +
with O +
diltiazem O +
( O -
3 O +
μM O -
) O +
failed O +
to O +
reduce O +
the O +
contraction O -
, O +
which O +
correlated O +
with O +
the O +
increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O +
. O -

Neither O +
nitrendipine O +
( O -
10 O +
μM O -
) O +
nor O +
nicardipine O +
( O -
10 O +
μM O -
) O +
attenuated O +
the O +
contraction O +
or O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
after O +
energy O +
repletion O -
. O -

4 O +
Discussion O +
4.1 O +
Increase O +
in O +
[ O -
Ca2 O -
+ O +
] O -
i O -
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
guinea B-Species +
pig L-Species +
isolated O +
myocytes O +
Isolated O +
cardiomyocytes O +
are O +
reversibly O +
made O +
ATP O -
- O -
depleted O +
by O +
CCCP O -
, O +
a O +
reversible O +
inhibitor O +
of O +
mitochondrial O +
oxidative O +
phosphorylation O +
( O -
Li O +
et O +
al. O -
, O +
1989 O -
) O +
. O -

The O +
myocytes O -
, O +
which O +
show O +
a O +
rigor O +
contraction O +
on O +
metabolic O +
inhibition O +
are O +
reported O +
to O +
have O +
depressed O +
Ca2 O -
+ O -
overload O -
, O +
because O +
the O +
activity O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O +
is O +
inhibited O +
by O +
energy O +
depletion O +
( O -
Li O +
et O +
al. O -
, O +
1988 O -
; O +
Collins O +
et O +
al. O -
, O +
1992 O -
) O +
. O -

Li O +
et O +
al. O +
( O -
1988 O -
) O -
have O +
also O +
reported O +
that O +
cells O +
maintaining O +
a O +
low O +
[ O -
Ca2 O -
+ O +
] O -
i O -
level O +
remain O +
rod O -
- O -
shaped O +
for O +
a O +
longer O +
period O +
against O +
metabolic O +
inhibition O -
. O -

Since O +
our O +
aim O +
was O +
to O +
assess O +
the O +
effect O +
of O +
l O +
-cis O -
diltiazem O +
on O +
reperfusion O -
- O -
induced O +
Ca2 O -
+ O -
overload O +
in O +
vitro O -
, O +
we O +
followed O +
a O +
protocol O +
with O +
Ca2 O -
+ O +
-free O +
Tyrode O +
solution O -
, O +
which O +
improves O +
the O +
efficacy O +
of O +
the O +
assessment O +
of O +
reperfusion O +
injury O -
. O -

Using O +
this O +
type O +
of O +
model O -
, O +
we O +
could O +
partially O +
simulate O +
the O +
ischemia O -
/ O -
reperfusion O -
- O -
induced O +
Ca2 O -
+ O -
overload O +
in O +
vitro O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O -

A O +
marked O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
was O +
observed O +
after O +
washout O +
of O +
CCCP O +
with O +
Ca2 O -
+ O +
-containing O +
Tyrode O +
solution O -
. O -

This O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
was O +
suppressed O +
by O +
Ni2 O -
+ O -
or O +
KB O -
- O -
R7943 O -
, O +
a O +
specific O +
inhibitor O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
, O +
but O +
was O +
not O +
suppressed O +
by O +
nitrendipine O +
or O +
nicardipine O +
( O -
Fig. O +
2 O -
) O +
. O -

These O +
results O +
indicate O +
that O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
by O +
energy O +
repletion O +
occurred O +
via O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
, O +
but O +
not O +
through O +
the O +
dihydropyridine O -
- O -
sensitive O +
Ca2 O -
+ O -
channel O +
in O +
this O +
model O -
. O -

4.2 O +
Cardioprotective O +
effect O +
of O +
l O +
-cis O -
diltiazem O +
on O +
Ca2 O -
+ O -
overload O +
in O +
guinea B-Species +
pig L-Species +
myocytes O +
In O +
the O +
present O +
study O -
, O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O +
attenuated O +
both O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
and O +
the O +
cell O +
shortening O +
induced O +
by O +
CCCP O -
. O -

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O -
demonstrated O +
that O +
both O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O +
attenuated O +
veratridine O -
- O -
induced O +
Ca2 O -
+ O -
overload O +
and O +
hypercontracture O +
in O +
isolated O +
rat U-Species +
hearts O -
. O -

However O -
, O +
this O +
is O +
not O +
direct O +
evidence O +
that O +
l O +
-cis O -
diltiazem O +
actually O +
protects O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O +
by O +
inhibiting O +
Ca2 O -
+ O -
overload O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
mimicked O +
the O +
phenomenon O +
of O +
ischemia O -
/ O -
reperfusion O +
injury O +
in O +
the O +
chamber O +
and O +
our O +
data O +
are O +
the O +
first O +
demonstration O +
that O +
both O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O +
protect O +
against O +
the O +
Ca2 O -
+ O -
overload O +
induced O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
the O +
same O +
concentration O +
range O -
. O -

This O +
observation O -
, O +
together O +
with O +
the O +
observation O +
that O +
nitrendipine O +
and O +
nicardipine O +
were O +
without O +
effect O -
, O +
suggests O +
that O +
their O +
effects O +
are O +
independent O +
of O +
L O -
- O -
type O +
Ca2 O -
+ O -
channel O +
blocking O -
. O -

This O +
possibility O +
is O +
also O +
supported O +
by O +
the O +
results O +
of O +
a O +
previous O +
study O +
in O +
our O +
laboratory O +
showing O +
that O +
l O +
-cis O -
diltiazem O +
( O -
10 O +
μM O -
) O +
as O +
well O +
as O +
diltiazem O +
( O -
3 O +
μM O -
) O +
worked O +
to O +
preserve O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
ischemia O -
– O -
reperfusion O +
model O +
of O +
isolated O +
guinea B-Species +
pig L-Species +
hearts O +
( O -
submitted O +
for O +
publication O -
) O -
. O -

In O +
the O +
present O +
study O -
, O +
inclusion O +
of O +
diltiazem O +
( O -
3 O +
μM O -
) O +
throughout O +
the O +
experiment O +
attenuated O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
during O +
reperfusion O +
( O -
Fig. O +
3A O -
) O +
. O -

However O -
, O +
the O +
addition O +
of O +
diltiazem O +
( O -
3 O +
μM O -
) O -
, O +
started O +
5 O +
min O +
before O +
reperfusion O -
, O +
failed O +
to O +
attenuate O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
( O -
Fig. O +
3B O -
) O +
. O -

Thus O -
, O +
we O +
suggest O +
that O +
some O +
events O +
during O +
chemical O +
ischemia O -
, O +
which O +
could O +
be O +
affected O +
by O +
diltiazem O -
, O +
might O +
be O +
involved O +
in O +
the O +
Ca2 O -
+ O -
overload O +
during O +
reperfusion O +
( O -
Watts O +
et O +
al. O -
, O +
1990 O -
; O +
Sakamoto O +
et O +
al. O -
, O +
1997 O -
) O +
. O -

4.3 O +
Cardioprotective O +
mechanism O +
by O +
l O +
-cis O -
diltiazem O +
on O +
Ca2 O -
+ O -
overload O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
In O +
the O +
present O +
model O -
, O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
after O +
energy O +
repletion O +
was O +
inhibited O +
by O +
both O +
Ni2 O -
+ O -
and O +
KB O -
- O -
R7943 O +
( O -
Fig. O +
2 O -
) O +
. O -

Concerning O +
the O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
in O +
this O +
model O -
, O +
the O +
L O -
- O -
type O +
Ca2 O -
+ O -
channel O +
does O +
not O +
seem O +
to O +
be O +
involved O -
. O -

This O +
is O +
because O +
the O +
dihydropyridine O +
Ca2 O -
+ O -
channel O +
blockers O -
, O +
nitrendipine O +
and O +
nicardipine O -
, O +
affected O +
neither O +
[ O -
Ca2 O -
+ O +
] O -
i O -
increase O +
nor O +
cell O +
shortening O +
( O -
Table O +
1 O -
) O +
. O -

The O +
inhibition O +
of O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O +
may O +
afford O +
protection O +
from O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O -
. O -

A O +
previous O +
report O +
has O +
demonstrated O +
that O +
the O +
intracellular O +
Na+ O -
concentration O +
( O -
[ O -
Na+ O +
] O -
i O +
) O +
is O +
increased O +
by O +
metabolic O +
inhibition O +
in O +
guinea B-Species +
pig L-Species +
myocytes O +
( O -
Satoh O +
et O +
al. O -
, O +
1995 O -
) O +
. O -

This O +
indicates O +
that O +
Na+ O -
overload O +
caused O +
during O +
metabolic O +
inhibition O +
is O +
important O +
in O +
this O +
model O -
. O -

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O -
previously O +
reported O +
that O +
l O +
-cis O -
diltiazem O +
inhibited O +
veratridine O -
- O -
induced O +
Na+ O -
overload O +
in O +
rat U-Species +
cardiac O +
myocytes O -
. O -

Haigney O +
et O +
al. O +
( O -
1992 O -
) O -
reported O +
that O +
the O +
[ O -
Na+ O +
] O -
i O -
increase O +
seen O +
during O +
hypoxia O +
is O +
potentiated O +
after O +
rigor O +
contraction O +
in O +
isolated O +
rat O +
myocytes O -
. O -

They O +
also O +
suggested O +
that O +
inactivation O -
- O -
resistant O +
Na+ O -
channels O +
were O +
involved O +
in O +
this O +
[ O -
Na+ O +
] O -
i O -
increase O -
. O -

We O +
demonstrated O +
in O +
the O +
present O +
study O +
that O +
both O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O +
at O +
10 O +
μM O -
, O +
when O +
introduced O +
5 O +
min O +
before O +
washout O +
of O +
CCCP O -
, O +
attenuated O +
cell O +
shortening O +
after O +
energy O +
repletion O +
( O -
Fig. O +
3B O -
) O +
. O -

Thus O -
, O +
it O +
is O +
speculated O +
that O +
both O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O +
attenuate O +
Ca2 O -
+ O -
overload O +
by O +
inhibiting O +
the O +
[ O -
Na+ O +
] O -
i O -
accumulation O +
early O +
after O +
energy O +
repletion O -
. O -

In O +
conclusion O -
, O +
we O +
first O +
demonstrated O +
that O +
l O +
-cis O -
diltiazem O +
attenuated O +
the O +
Ca2 O -
+ O -
overload O +
caused O +
by O +
metabolic O +
inhibition O +
and O +
energy O +
repletion O +
in O +
guinea B-Species +
pig L-Species +
myocytes O -
. O -

The O +
cardioprotective O +
action O +
of O +
l O +
-cis O -
diltiazem O +
evidenced O +
in O +
the O +
present O +
work O +
merits O +
further O +
research O -
, O +
since O +
l O +
-cis O -
diltiazem O +
could O +
become O +
a O +
lead O +
compound O +
for O +
investigating O +
protection O +
against O +
ischemia O -
/ O -
reperfusion O +
injury O -
. O -

Acknowledgements O +
The O +
authors O +
wish O +
to O +
thank O +
Dr. O +
Satomi O +
Adachi O -
- O -
Akahane O +
( O -
University O +
of O +
Tokyo O -
) O +
for O +
the O +
helpful O +
discussions O +
and O +
Mr. O +
Shoichi O +
Kanda O -
, O +
Ms. O +
Maki O +
Urata O -
, O +
and O +
Mr. O +
Taichiro O +
Tomida O +
( O -
University O +
of O +
Tokyo O -
) O +
for O +
the O +
kind O +
assistance O +
with O +
cell O +
preparation O -
. O -

We O +
thank O +
Tanabe O +
Seiyaku O +
for O +
the O +
kind O +
gift O +
of O +
l O +
-cis O -
diltiazem O +
and O +
diltiazem O -
. O -

We O +
thank O +
Kanebo O +
for O +
the O +
kind O +
gift O +
of O +
KB O -
- O -
R O +
7943 O -
. O -

This O +
work O +
was O +
supported O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O -
, O +
Japan O -
. O +

Dopamine O +
( O -
DA O -
) O +
is O +
a O +
neurotransmitter O +
that O +
plays O +
a O +
fundamental O +
role O +
in O +
the O +
control O +
of O +
a O +
variety O +
of O +
physiological O +
functions O +
including O +
locomotor O +
movement O -
, O +
learning O -
, O +
reward O +
behavior O -
, O +
and O +
hormone O +
synthesis O +
and O +
release O +
[ O -
40 O -
] O +
. O -

However O -
, O +
overflow O +
of O +
DA O +
in O +
the O +
brain O +
has O +
been O +
suggested O +
to O +
participate O +
in O +
certain O +
neurodegenerative O +
processes O -
. O -

These O +
include O +
ischemia O +
[ O -
6 O -
] O +
, O +
hypoxia O +
[ O -
2 O -
] O +
, O +
and O +
neurotoxicities O +
induced O +
by O +
excitatory O +
amino O +
acids O +
[ O -
16 O -
] O +
and O +
methamphetamine O +
[ O -
38 O -
] O +
. O -

In O +
all O +
of O +
the O +
above O +
cases O -
, O +
striatal O +
DA O +
availability O +
in O +
the O +
brain O +
is O +
significantly O +
increased O -
. O -

For O +
example O -
, O +
the O +
striatal O +
DA O +
concentration O +
rapidly O +
reaches O +
concentrations O +
as O +
high O +
as O +
0.2 O +
mM O +
after O +
ligation O +
of O +
the O +
cervical O +
artery O +
in O +
the O +
gerbil U-Species +
ischemic O +
model O +
[ O -
45 O -
] O +
. O -

Depletion O +
of O +
endogenous O +
DA O +
by O +
chemical O +
lesion O +
of O +
the O +
nigrostriatal O +
dopaminergic O +
pathway O +
reduces O +
ischemic O +
insult O +
to O +
the O +
striatum O +
[ O -
17 O -
] O +
. O -

Direct O +
intrastriatal O +
injections O +
of O +
DA O +
result O +
in O +
apoptosis O +
and O +
neurodegeneration O +
[ O -
18 O -
, O +
19 O -
] O +
. O -

This O +
DA O +
neurotoxicity O +
is O +
believed O +
to O +
be O +
mediated O +
through O +
a O +
DA O -
- O -
oxidation O -
- O -
associated O +
pathway O -
. O -

DA O +
oxidative O +
stress O +
is O +
also O +
assumed O +
to O +
be O +
a O +
major O +
pathological O +
factor O +
that O +
contributes O +
to O +
dopaminergic O +
neuronal O +
degeneration O +
in O +
Parkinson O -
's O +
disease O +
[ O -
14 O -
] O +
. O -

We O +
have O +
recently O +
demonstrated O +
that O +
DA O +
induces O +
apoptosis O +
involving O +
the O +
oxidation O -
– O -
JNK O -
– O -
c O -
- O -
Jun O +
activation O +
pathway O +
in O +
in O +
vitro O +
cell O +
cultures O +
[ O -
32 O -
] O +
and O +
activation O +
of O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
κB O +
in O +
an O +
in O +
vivo O +
rat U-Species +
model O +
[ O -
29 O -
] O +
. O -

Direct O +
intrastriatal O +
injections O +
of O +
high O +
concentrations O +
of O +
DA O +
in O +
rats U-Species +
also O +
result O +
in O +
activation O +
of O +
astrocytes O +
as O +
indicated O +
by O +
an O +
increase O +
of O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
immunocytochemical O +
staining O +
and O +
astrocyte O +
proliferation O +
determined O +
by O +
[ O -
3 O +
H O -
] O -
R05 O -
- O -
4864 O +
binding O +
to O +
peripheral O +
benzodiazepine O +
receptors O +
on O +
astrocytes O +
[ O -
15 O -
] O +
. O -

Astrocytes O +
are O +
the O +
intimate O +
partners O +
of O +
neurons O +
and O +
play O +
important O +
physiological O +
roles O +
in O +
the O +
maintenance O +
of O +
the O +
microenvironment O +
of O +
neurons O -
, O +
including O +
sequestration O +
and O +
metabolism O +
of O +
various O +
neurotransmitters O -
, O +
and O +
production O +
of O +
proinflammatory O +
and O +
immunomodulatory O +
cytokines O +
and O +
neuropeptides O +
[ O -
50 O -
] O +
. O -

In O +
the O +
rat U-Species +
ischemic O +
model O -
, O +
activated O +
striatal O +
astrocytes O +
appear O +
to O +
play O +
a O +
protective O +
role O +
for O +
DA O -
- O -
innervated O +
neurons O +
[ O -
51 O -
] O +
. O -

In O +
a O +
cell O +
culture O +
system O -
, O +
striatal O +
astrocytes O +
were O +
also O +
shown O +
to O +
have O +
a O +
protective O +
effect O +
against O +
hydrogen O +
peroxide O +
toxicity O +
in O +
dopaminergic O +
neurons O +
[ O -
24 O -
] O +
. O -

Nevertheless O -
, O +
the O +
mechanism O +
by O +
which O +
DA O +
activates O +
astrocytes O +
is O +
unknown O -
. O -

To O +
investigate O +
potential O +
signaling O +
of O +
activation O +
of O +
astrocytes O +
by O +
DA O -
, O +
we O +
have O +
chosen O +
a O +
rat U-Species +
C6 O +
glioma O +
cell O +
line O +
stably O +
expressing O +
DA O +
D2L O +
receptors O +
based O +
on O +
the O +
following O +
reasons O -
. O -

( O -
1 O -
) O +
C6 O +
glioma O +
cells O +
have O +
been O +
widely O +
used O +
as O +
a O +
model O +
of O +
glial O +
phenotype O +
[ O -
5 O -
, O +
39 O -
] O +
. O -

( O -
2 O -
) O +
Recent O +
evidence O +
suggests O +
that O +
D2 O +
receptors O +
are O +
expressed O +
in O +
striatal O +
astrocytes O -
. O -

Physiologically O -
, O +
DA O +
can O +
induce O +
membrane O +
hyperpolarization O +
in O +
the O +
majority O +
of O +
astrocytes O +
from O +
the O +
striatum O -
, O +
which O +
can O +
be O +
inhibited O +
by O +
application O +
of O +
domperidone O -
, O +
a O +
D2 O +
receptor O +
antagonist O +
[ O -
21 O -
] O +
. O -

D2 O +
antagonists O -
, O +
[ O -
3 O +
H O -
] O -
domperidone O +
and O +
[ O -
3 O +
H O -
] O -
spiperone O -
, O +
can O +
specifically O +
label O +
striatal O +
astrocytes O +
[ O -
20 O -
] O +
. O -

D2 O +
receptor O +
mRNA O +
can O +
be O +
detected O +
by O +
either O +
in O +
situ O +
hybridization O +
or O +
polymerase O +
chain O +
reaction O +
from O +
astrocytes O +
in O +
striatum O -
, O +
an O +
area O +
enriched O +
with O +
dopaminergic O +
termini O -
, O +
but O +
not O +
astrocytes O +
in O +
cerebellum O -
, O +
which O +
receives O +
little O +
dopaminergic O +
innervation O +
[ O -
4 O -
] O +
. O -

This O +
region O -
- O -
specific O +
expression O +
of O +
D2 O +
receptors O +
suggests O +
that O +
dopaminergic O +
neurons O +
may O +
physiologically O +
influence O +
astrocyte O +
functions O -
. O -

( O -
3 O -
) O +
C6-D2L O +
cells O +
stably O +
express O +
recombinant O +
D2L O +
DA O +
receptors O +
[ O -
36 O -
] O +
. O -

The O +
expression O +
level O +
of O +
D2 O +
receptors O +
in O +
C6-D2L O +
cells O +
is O +
about O +
188 O +
fmol O -
/ O -
mg O +
protein O -
, O +
which O +
is O +
close O +
to O +
that O +
in O +
striatal O +
membranes O +
( O -
∼400 O +
fmol O -
/ O -
mg O +
protein O -
) O +
[ O -
30 O -
, O +
37 O -
] O +
. O -

( O -
4 O -
) O +
Like O +
native O +
neuronal O +
D2 O +
receptors O -
, O +
the O +
binding O +
of O +
agonist O +
to O +
D2 O +
receptors O +
in O +
the O +
C6-D2L O +
cells O +
is O +
functionally O +
coupled O +
to O +
pertussis O -
- O -
toxin O -
- O -
sensitive O +
G O +
proteins O -
, O +
resulting O +
in O +
inhibition O +
of O +
adenylate O +
cyclase O +
[ O -
49 O -
] O +
and O +
activation O +
of O +
both O +
extracellular O +
signal O -
- O -
regulated O +
kinases O +
( O -
ERKs O -
) O +
and O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
[ O -
30 O -
] O +
. O -

Given O +
the O +
fact O +
of O +
C6 O +
glial O +
phenotype O +
and O +
D2 O +
receptors O +
in O +
striatal O +
astrocytes O -
, O +
the O +
biological O +
functions O +
stimulated O +
by O +
D2 O +
receptors O +
observed O +
in O +
C6-D2L O +
cells O +
may O +
mimic O +
those O +
produced O +
in O +
vivo O -
. O -

Thus O -
, O +
this O +
C6-D2L O +
cell O +
line O +
may O +
serve O +
as O +
a O +
good O +
in O +
vitro O +
cell O +
culture O +
model O +
for O +
studies O +
of O +
DA O +
regulation O +
of O +
glial O +
response O -
. O -

Using O +
this O +
C6-D2L O +
cell O +
line O -
, O +
we O +
have O +
previously O +
reported O +
that O +
nanomolar O +
levels O +
of O +
DA O +
stimulate O +
cell O +
proliferation O +
through O +
activation O +
of O +
both O +
ERKs O +
and O +
JNK O +
[ O -
30 O -
] O +
. O -

In O +
the O +
present O +
study O -
, O +
we O +
have O +
found O +
that O +
high O +
concentrations O +
( O -
micromolar O +
levels O -
) O +
of O +
DA O +
stimulate O +
a O +
delayed O +
mitogenesis O +
compared O +
to O +
that O +
induced O +
by O +
the O +
nanomolar O +
levels O +
of O +
DA O -
. O -

This O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
D2-receptor O -
- O -
mediated O +
intracellular O +
redox O -
– O -
tyrosine O +
kinase O +
cascade O -
, O +
but O +
does O +
not O +
need O +
ERK O +
activation O -
. O -

In O +
addition O -
, O +
micromolar O +
levels O +
of O +
DA O +
also O +
increase O +
GFAP O +
expression O -
, O +
which O +
is O +
linked O +
to O +
a O +
D2-receptor O -
- O -
independent O +
p38 O +
MAPK O +
activation O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Antibodies O +
against O +
phosphorylated O +
tyrosine O +
( O -
PY99 O -
) O +
and O +
ERK2 O +
were O +
purchased O +
from O +
Santa O +
Cruz O +
Biotechnology O +
( O -
Santa O +
Cruz O -
, O +
CA O -
) O -
. O -

Antibodies O +
against O +
phospho O -
- O -
specific O +
ERK O +
and O +
phospho O -
- O -
specific O +
p38 O +
MAPK O +
were O +
from O +
New O +
England O +
Biolabs O +
( O -
Beverly O -
, O +
MA O -
) O -
. O -

DA O -
, O +
( O -
+ O -
) O -
- O +
and O +
( O -
− O -
) O -
-butaclamol O +
hydrochloride O -
, O +
and O +
( O -
− O -
) O -
-quinpirole O +
hydrochloride O +
were O +
from O +
Research O +
Biochemicals O +
International O +
( O -
Natick O -
, O +
MA O -
) O -
. O -

PD098059 O -
, O +
p38 O +
inhibitor O +
SB O +
203580 O -
, O +
diphenyleneiodonium O +
chloride O +
( O -
DPI O -
) O -
, O +
Herbimycin O +
A O -
, O +
Wortmannin O -
, O +
H7 O -
, O +
and O +
staurosporine O +
were O +
from O +
Calbiochem O +
( O -
San O +
Diego O -
, O +
CA O -
) O -
. O -

Pertussis O +
toxin O +
( O -
PTX O -
) O +
and O +
N O +
-acetyl O -
- O -
l O +
-cysteine O +
( O -
NAC O -
) O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
) O -
. O -

[ O -
3 O +
H O -
] O -
Thymidine O +
was O +
purchased O +
form O +
Amersham O +
( O -
Arlington O +
Heights O -
, O +
IL O -
) O -
. O -

Genistein O +
was O +
from O +
Gibco O +
BRL O +
( O -
Gaithersburg O -
, O +
MD O -
) O -
. O -

Hoechst O +
33342 O +
was O +
from O +
Molecular O +
Probes O +
( O -
Eugene O -
, O +
OR O -
) O -
. O -

2.2 O +
Cell O +
culture O +
and O +
treatments O +
Stably O +
transfected O +
C6-D2L O +
cells O +
were O +
prepared O +
as O +
described O +
[ O -
46 O -
] O +
and O +
maintained O +
in O +
Dulbecco O -
's O +
modified O +
Eagle O -
's O +
medium O +
( O -
DMEM O -
) O +
supplemented O +
with O +
5 O -
% O +
fetal O +
bovine U-Species +
serum O +
and O +
5 O -
% O +
donor O +
calf U-Species +
serum O +
with O +
penicillin O -
/ O -
streptomycin O +
and O +
puromycin O +
( O -
2 O +
μg O -
/ O -
ml O -
) O -
. O -

The O +
wild O -
- O -
type O +
C6 O +
cells O +
were O +
maintained O +
in O +
the O +
above O +
medium O +
without O +
puromycin O -
. O -

For O +
tyrosine O +
phosphorylation O +
and O +
GFAP O +
studies O -
, O +
the O +
cells O +
were O +
starved O +
with O +
serum O -
- O -
free O +
medium O +
containing O +
0.025 O -
% O +
ascorbic O +
acid O +
for O +
6–8 O +
h O +
and O +
then O +
stimulated O +
with O +
indicated O +
reagents O -
. O -

All O +
reagents O +
were O +
prepared O +
or O +
diluted O +
with O +
DMEM O +
plus O +
0.025 O -
% O +
ascorbic O +
acid O -
. O -

For O +
inhibitory O +
experiments O -
, O +
all O +
inhibitory O +
reagents O +
except O +
PTX O +
were O +
added O +
0.5 O +
h O +
( O -
PTX O +
for O +
6 O +
h O -
) O +
prior O +
to O +
stimulation O +
with O +
DA O -
. O -

2.3 O +
Lysate O +
preparation O +
After O +
stimulation O -
, O +
the O +
cells O +
were O +
immediately O +
washed O +
twice O +
using O +
cold O +
PBS O +
and O +
then O +
solubilized O +
with O +
ice O -
- O -
cold O +
buffer O +
consisting O +
of O +
25 O +
mM O +
Hepes O -
, O +
pH O +
7.5 O -
, O +
300 O +
mM O +
NaCl O -
, O +
1.5 O +
mM O +
MgCl2 O +
, O +
0.2 O +
mM O +
EDTA O -
, O +
0.1 O -
% O +
Triton O +
X-100 O -
, O +
20 O +
mM O +
β O -
- O -
glycerophosphate O -
, O +
0.1 O +
mM O +
sodium O +
orthovanadate O -
, O +
0.5 O +
mM O +
DTT O -
, O +
100 O +
μg O -
/ O -
ml O +
PMSF O -
, O +
and O +
2 O +
μg O -
/ O -
ml O +
leupeptin O -
. O -

Cellular O +
extracts O +
were O +
cleared O +
by O +
centrifugation O +
for O +
30 O +
min O +
at O +
14,000 O +
rpm O +
at O +
4 O -
° O -
C O -
. O -

The O +
supernatants O +
were O +
saved O +
and O +
the O +
protein O +
concentration O +
was O +
determined O +
using O +
Bio O -
- O -
Rad O +
protein O +
reagent O -
. O -

For O +
determination O +
of O +
GFAP O -
, O +
the O +
cell O +
lysates O +
were O +
prepared O +
as O +
follows O -
. O -

Stimulated O +
cells O +
were O +
scraped O +
and O +
collected O +
by O +
centrifugation O +
for O +
5 O +
min O +
at O +
3000 O +
rpm O -
. O -

The O +
cell O +
pellets O +
were O +
washed O +
once O +
with O +
cold O +
PBS O -
, O +
pH O +
7.4 O -
, O +
solubilized O +
with O +
hot O +
lysis O +
buffer O +
( O -
80–90 O -
° O -
C O -
) O +
containing O +
10 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.6 O -
, O +
150 O +
mM O +
NaCl O -
, O +
0.5 O +
mm O +
EDTA O -
, O +
1 O +
mM O +
EGTA O -
, O +
1 O -
% O +
sodium O +
dodecyl O +
sulfate O +
( O -
SDS O -
) O -
, O +
1 O +
mM O +
sodium B-Species +
orthovanadate L-Species -
, O +
1 O +
mM O +
PMSF O -
, O +
1 O +
μg O -
/ O -
ml O +
pepstatin O +
A O -
, O +
and O +
2 O +
μg O -
/ O -
ml O +
aprotinin O -
, O +
and O +
heated O +
for O +
20 O +
min O +
at O +
90 O -
° O -
C O -
. O -

The O +
protein O +
concentration O +
of O +
the O +
lysates O +
was O +
determined O +
by O +
using O +
Micro O +
BCA O +
( O -
Pierce O -
, O +
Rockford O -
, O +
IL O -
) O -
. O -

All O +
lysates O +
were O +
used O +
immediately O +
or O +
aliquoted O +
and O +
stored O +
at O +
−70 O -
° O -
C O +
for O +
further O +
use O -
. O -

2.4 O +
Immunoblotting O +
Equal O +
amounts O +
of O +
lysate O +
protein O +
( O -
40 O +
μg O -
/ O -
lane O -
) O +
were O +
run O +
on O +
8–16 O -
% O +
SDS O -
- O -
PAGE O +
and O +
electrophoretically O +
transferred O +
to O +
nitrocellulose O -
. O -

The O +
nitrocellulose O +
blot O +
was O +
blocked O +
with O +
10 O -
% O +
non O -
- O -
fat O +
dry O +
milk O +
in O +
TBST O +
buffer O +
( O -
20 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.4 O -
, O +
500 O +
mM O +
NaCl O -
, O +
and O +
0.01 O -
% O +
Tween-20 O -
) O +
and O +
then O +
incubated O +
with O +
primary O +
antibodies O +
( O -
phospho O -
- O -
specific O +
ERK O -
, O +
ERK2 O -
, O +
phospho O -
- O -
specific O +
p38 O +
MAPK O -
, O +
or O +
PY99 O -
, O +
1:1000 O -
) O +
in O +
TBST O +
containing O +
5 O -
% O +
BSA O +
overnight O +
at O +
4 O -
° O -
C O -
. O -

The O +
immunoreactive O +
bands O +
were O +
detected O +
by O +
sequential O +
incubation O +
with O +
horseradish O -
- O -
peroxidase O -
- O -
conjugated O +
secondary O +
antibody O +
( O -
1:5000 O -
, O +
Jackson O +
ImmunoResearch O +
Laboratories O -
, O +
West O +
Grove O -
, O +
PA O -
) O +
and O +
Renaissance O +
substrate O +
( O -
DuPont O -
; O +
Boston O -
, O +
MA O -
) O -
. O -

For O +
control O +
of O +
protein O +
loading O -
, O +
immunoblotting O +
with O +
ERK2 O +
was O +
performed O +
using O +
either O +
a O +
sister O +
gel O +
or O +
a O +
stripped O +
blot O -
. O -

For O +
quantitative O +
studies O -
, O +
the O +
band O +
was O +
quantified O +
with O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O -

The O +
results O +
were O +
normalized O +
to O +
fold O +
of O +
control O +
and O +
presented O +
as O +
means±S.E.M. O -
2.5 O +
Measurement O +
of O +
mitogenesis O +
The O +
procedures O +
were O +
described O +
elsewhere O +
[ O -
31 O -
] O +
. O -

C6-D2L O +
cells O +
( O -
1 O -
× O -
105 O +
/ml O -
, O +
0.2 O +
ml O -
/ O -
well O -
) O +
were O +
plated O +
in O +
a O +
96-well O +
plate O +
and O +
grown O +
for O +
24 O +
h. O +
The O +
cells O +
were O +
rinsed O +
twice O +
with O +
serum O -
- O -
free O +
DMEM O +
and O +
starved O +
for O +
8 O +
h O +
in O +
serum O -
- O -
free O +
medium O +
containing O +
0.025 O -
% O +
ascorbic O +
acid O -
. O -

After O +
that O -
, O +
the O +
cells O +
were O +
incubated O +
with O +
DA O +
for O +
23 O +
h O +
and O +
pulsed O +
with O +
2 O +
μCi O +
[ O -
3 O +
H O -
] O -
thymidine O +
per O +
well O +
for O +
an O +
additional O +
6 O +
h. O +
The O +
cells O +
in O +
each O +
well O +
were O +
fixed O +
with O +
ice O -
- O -
cold O +
5 O -
% O +
trichloroacetic O +
acid O -
, O +
washed O +
three O +
times O +
with O +
cold O +
STE O +
buffer O +
( O -
150 O +
mM O +
NaCl O -
, O +
50 O +
mM O +
Tris O -
– O -
HCl O -
, O +
pH O +
7.2 O -
, O +
1 O +
mM O +
EDTA O -
) O -
, O +
and O +
solubilized O +
with O +
0.1 O +
ml O +
of O +
a O +
mixture O +
of O +
0.1 O -
% O +
SDS O +
and O +
0.01 O +
N O +
NaOH O -
. O -

Incorporated O +
[ O -
3 O +
H O -
] O -
thymidine O +
was O +
counted O +
with O +
a O +
Beckman O +
liquid O +
scintillation O +
counter O +
and O +
expressed O +
as O +
counts O +
per O +
minute O +
per O +
well O +
( O -
cpm O -
/ O -
well O -
) O -
. O -

2.6 O +
Cell O +
cycle O +
analysis O +
by O +
flow O +
cytometry O +
Cell O +
cycle O +
analysis O +
was O +
performed O +
according O +
to O +
the O +
method O +
by O +
Chrest O +
et O +
al. O +
[ O -
9 O -
] O +
. O -

Briefly O -
, O +
C6-D2L O +
cells O +
were O +
plated O +
in O +
35 O +
mm O +
dishes O -
, O +
and O +
seeded O +
overnight O -
. O -

The O +
cells O +
were O +
starved O +
for O +
8 O +
h O +
by O +
replacing O +
the O +
mixture O +
of O +
DMEM O +
plus O +
0.025 O -
% O +
ascorbic O +
acid O +
and O +
stimulated O +
for O +
29 O +
h. O +
The O +
cells O +
were O +
then O +
collected O +
and O +
suspended O +
in O +
complete O +
cell O +
culture O +
medium O -
. O -

The O +
cells O +
( O -
1 O -
× O -
106 O -
cells O -
/ O -
ml O -
) O +
were O +
treated O +
with O +
1 O +
μM O +
Hoechst O +
33342 O +
for O +
30 O +
min O +
at O +
37 O -
° O -
C O -
. O -

Cells O +
were O +
analyzed O +
for O +
DNA O +
content O +
using O +
a O +
FACStarplus O -
flow O +
cytometer O +
( O -
Becton O +
Dickinson O +
Immunocytometry O +
System O -
, O +
San O +
Jose O -
, O +
CA O -
) O +
equipped O +
with O +
argon O +
and O +
krypton O +
lasers O -
. O -

Hoechst O +
33342 O +
stained O +
cells O +
were O +
excited O +
with O +
350–356 O +
nm O +
wavelength O +
UV O +
light O +
from O +
the O +
krypton O +
laser O +
and O +
the O +
fluorescence O +
emission O +
was O +
collected O +
with O +
a O +
424-nm O +
filter O -
. O -

DNA O +
histograms O +
were O +
acquired O +
by O +
collecting O +
a O +
total O +
of O +
10,000 O +
events O -
. O -

Cell O +
compartments O -
, O +
including O +
G1 O +
, O +
S O -
, O +
and O +
G2 O +
/M O +
phases O -
, O +
were O +
determined O +
using O +
the O +
Multicycle O +
software O +
( O -
Phoenix O +
Flow O +
Systems O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O -

3 O +
Results O +
3.1 O +
DA O +
stimulates O +
mitogenesis O +
We O +
have O +
previously O +
reported O +
that O +
nanomolar O +
levels O +
of O +
DA O +
stimulated O +
mitogenesis O +
in O +
C6-D2L O +
cells O +
[ O -
30 O -
] O +
. O -

The O +
maximal O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
DNA O +
occurs O +
at O +
17 O +
h O +
after O +
exposure O +
to O +
100 O +
nM O +
DA O +
concentration O -
. O -

We O +
extended O +
this O +
study O +
by O +
observing O +
the O +
cell O +
response O +
at O +
high O +
DA O +
concentrations O +
and O +
longer O +
exposure O -
. O -

Interestingly O -
, O +
micromolar O +
levels O +
of O +
DA O +
also O +
stimulate O +
DNA O +
synthesis O +
but O +
with O +
a O +
slower O +
time O +
course O +
( O -
about O +
29 O +
h O +
after O +
DA O +
stimulation O -
, O +
data O +
not O +
shown O -
) O -
. O -

Under O +
these O +
conditions O -
, O +
DA O +
stimulated O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
in O +
a O +
concentration O -
- O -
dependent O +
manner O +
( O -
Fig. O +
1 O -
a O -
) O -
. O -

The O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
DNA O +
was O +
linearly O +
increased O +
from O +
0.1 O +
to O +
500 O +
μM O +
DA O -
. O -

The O +
mitogenic O +
activity O +
at O +
500 O +
μM O +
DA O +
was O +
about O +
3.2±0.2 O +
times O +
higher O +
than O +
that O +
of O +
control O +
group O -
. O -

This O +
DA O -
- O -
induced O +
mitogenesis O +
could O +
be O +
completely O +
inhibited O +
in O +
the O +
presence O +
of O +
aphidicoline O +
( O -
20 O +
μg O -
/ O -
ml O -
, O +
data O +
not O +
shown O -
) O -
, O +
a O +
potent O +
DNA O +
polymerase O +
a O +
inhibitor O -
. O -

To O +
confirm O +
the O +
DA O +
mitogenic O +
activation O -
, O +
we O +
also O +
determined O +
the O +
cell O +
cycle O +
distribution O -
. O -

As O +
shown O +
in O +
Table O +
1 O -
, O +
200 O +
μM O +
DA O +
increased O +
the O +
percentage O +
of O +
the O +
cells O +
in O +
S O +
phase O +
and O +
decreased O +
the O +
percentage O +
of O +
cells O +
in O +
G1 O -
phase O -
, O +
suggesting O +
that O +
DA O +
promotes O +
progression O +
through O +
the O +
cell O +
cycle O -
. O -

Next O -
, O +
we O +
tested O +
whether O +
this O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
activation O +
of O +
D2 O +
receptors O -
. O -

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
10 O +
μM O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
potent O +
D2 O +
receptor O +
antagonist O -
, O +
completely O +
inhibited O +
DA O -
- O -
induced O +
DNA O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O -
, O +
while O +
10 O +
μM O +
( O -
− O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
form O +
of O +
( O -
+ O -
) O -
-butaclamol O -
, O +
had O +
no O +
effect O +
on O +
the O +
DA O -
- O -
stimulated O +
mitogenesis O +
( O -
Fig. O +
1 O +
b O -
) O -
. O -

To O +
confirm O +
these O +
results O -
, O +
we O +
determined O +
the O +
effect O +
of O +
quinpirole O -
, O +
a O +
specific O +
D2 O +
receptor O +
agonist O -
, O +
on O +
cell O +
cycling O -
. O -

Like O +
the O +
effect O +
of O +
micromolar O +
levels O +
of O +
DA O -
, O +
micromolar O +
levels O +
of O +
quinpirole O +
promoted O +
cell O +
proliferation O -
. O -

Quinpirole O +
increased O +
the O +
percentage O +
of O +
cells O +
in O +
S O +
phase O +
and O +
decreased O +
the O +
percentage O +
in O +
G1 O -
phase O +
( O -
Table O +
1 O +
) O -
. O -

Furthermore O -
, O +
we O +
did O +
not O +
observe O +
any O +
mitogenic O +
effect O +
within O +
a O +
DA O +
concentration O +
range O +
of O +
0–500 O +
μM O +
in O +
wild O -
- O -
type O +
C6 O +
cells O +
without O +
expression O +
of O +
D2L O +
receptors O +
( O -
Fig. O +
1 O +
a O -
) O -
. O -

Instead O -
, O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
DNA O +
of O +
wild O -
- O -
type O +
C6 O +
cells O +
was O +
decreased O +
about O +
20–26 O -
% O +
at O +
DA O +
concentrations O +
from O +
10 O +
to O +
500 O +
μM O +
( O -
Fig. O +
1 O +
a O -
) O -
. O -

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
100 O +
ng O -
/ O -
ml O +
PTX O -
, O +
a O +
G O +
protein O -
- O -
receptor O +
uncoupler O -
, O +
partially O +
blocked O +
DA O -
- O -
stimulated O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
DNA O +
( O -
Fig. O +
1 O +
b O -
) O -
. O -

Thus O -
, O +
it O +
appears O +
that O +
this O +
DA O -
- O -
stimulated O +
mitogenesis O +
requires O +
DA O +
D2 O +
receptor O +
activation O -
. O -

3.2 O +
Effects O +
of O +
kinase O +
inhibitors O +
on O +
DA O -
- O -
induced O +
mitogenesis O +
In O +
order O +
to O +
examine O +
the O +
signaling O +
that O +
mediates O +
the O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
we O +
first O +
tested O +
the O +
effect O +
of O +
DA O +
on O +
the O +
activity O +
of O +
ERK O -
, O +
a O +
protein O +
serine O +
kinase O +
that O +
is O +
linked O +
to O +
cell O +
proliferation O +
stimulated O +
by O +
growth O +
factors O -
, O +
cytokines O +
and O +
neurotransmitters O +
[ O -
11 O -
, O +
34 O -
] O +
. O -

As O +
shown O +
in O +
the O +
phospho O -
- O -
specific O +
ERK O +
immunoblot O +
of O +
Fig. O +
2 O -
a O -
, O +
DA O +
had O +
little O +
or O +
no O +
effect O +
on O +
ERK O +
phosphorylation O +
at O +
concentrations O +
corresponding O +
to O +
its O +
mitogenic O +
effect O +
( O -
10–500 O +
μM O -
) O -
, O +
although O +
DA O +
at O +
lower O +
concentrations O +
did O +
stimulate O +
ERK O +
phosphorylation O +
and O +
activity O +
[ O -
30 O -
] O +
. O -

The O +
bottom O +
panel O +
in O +
Fig. O +
2 O +
a O +
shows O +
ERK2 O +
immunoblot O +
of O +
a O +
sister O +
gel O -
, O +
indicating O +
that O +
a O +
similar O +
amount O +
of O +
protein O +
was O +
loaded O -
. O -

To O +
confirm O +
that O +
ERK O +
was O +
not O +
involved O +
in O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
we O +
also O +
examined O +
the O +
effect O +
of O +
PD098059 O -
, O +
a O +
selective O +
MEK1 O +
inhibitor O +
[ O -
3 O -
] O +
, O +
on O +
DA O -
- O -
induced O +
mitogenesis O -
. O -

As O +
shown O +
in O +
Fig. O +
2 O +
b O -
, O +
the O +
DA O -
- O -
stimulated O +
DNA O +
synthesis O +
was O +
only O +
partially O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
PD O +
098059 O +
( O -
10–50 O +
μM O -
) O +
( O -
Fig. O +
2 O +
b O -
) O -
. O -

With O +
application O +
of O +
either O +
10 O +
or O +
50 O +
μM O +
PD O +
098059 O -
, O +
bFGF O -
- O -
stimulated O +
ERK O +
activity O -
, O +
as O +
indicated O +
by O +
ERK O +
phosphorylation O -
, O +
was O +
greatly O +
or O +
completely O +
inhibited O -
, O +
respectively O +
( O -
Fig. O +
2 O +
c O -
) O -
, O +
which O +
serves O +
as O +
a O +
positive O +
control O +
of O +
the O +
inhibitory O +
effect O +
of O +
PD098059 O +
on O +
MEK1–ERK O +
pathway O -
. O -

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
the O +
mitogenesis O +
induced O +
by O +
micromolar O +
levels O +
of O +
DA O +
is O +
not O +
mediated O +
by O +
a O +
MEK O -
– O -
ERK O +
activation O +
pathway O -
. O -

We O +
have O +
also O +
tested O +
other O +
kinase O +
inhibitors O +
on O +
DA O -
- O -
stimulated O +
mitogenesis O -
. O -

These O +
inhibitors O +
included O +
Wortmannin O +
for O +
PI3 O +
kinase O -
, O +
rapamycin O +
for O +
S6 O +
kinase O -
, O +
and O +
SB203580 O +
for O +
p38 O +
MAP O +
kinase O -
. O -

Staurosporine O +
and O +
H7 O +
are O +
inhibitors O +
for O +
a O +
broad O +
spectrum O +
of O +
protein O +
kinases O -
, O +
which O +
include O +
protein O +
kinase O +
A O -
, O +
protein O +
kinase O +
C O -
, O +
protein O +
kinase O +
G O -
, O +
CaM O +
kinase O -
, O +
and O +
myosin O +
light O +
chain O +
kinase O -
. O -

The O +
effect O +
of O +
depletion O +
of O +
PKC O +
on O +
DA O -
- O -
stimulated O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O +
into O +
DNA O +
was O +
also O +
examined O +
by O +
prolonged O +
treatment O +
of O +
the O +
cells O +
with O +
PMA O -
. O -

The O +
data O +
are O +
summarized O +
on O +
Table O +
2 O -
. O -

All O +
these O +
treatments O +
had O +
no O +
effect O +
on O +
DA O -
- O -
induced O +
DNA O +
synthesis O -
. O -

3.3 O +
DA O +
stimulates O +
mitogenesis O -
- O -
associated O +
protein O +
tyrosine O +
phosphorylation O +
DA O +
stimulated O +
protein O +
tyrosine O +
phosphorylation O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
manner O +
( O -
Fig. O +
3 O -
a O +
and O +
b O -
) O -
. O -

The O +
phosphorylated O +
tyrosine O -
- O -
containing O +
proteins O +
were O +
easily O +
immunodetected O +
with O +
monoclonal O +
anti O -
- O -
phosphotyrosine O +
IgG O +
( O -
PY99 O -
) O -
. O -

When O +
C6-D2L O +
cells O +
were O +
treated O +
with O +
200 O +
μM O +
DA O -
, O +
protein O +
tyrosine O +
phosphorylation O +
rapidly O +
increased O +
within O +
5 O +
min O -
, O +
reached O +
a O +
maximum O +
between O +
15 O +
and O +
30 O +
min O -
, O +
then O +
decreased O +
by O +
1 O +
h O +
( O -
Fig. O +
3 O +
a O -
) O -
. O -

A O +
majority O +
of O +
tyrosine O -
- O -
phosphorylated O +
proteins O +
were O +
located O +
within O +
the O +
molecular O +
size O +
range O +
of O +
50–200 O +
kDa O -
, O +
some O +
of O +
which O +
are O +
indicated O +
by O +
arrows O +
in O +
Fig. O +
3 O +
a. O +
DA O -
- O -
stimulated O +
tyrosine O +
phosphorylation O +
was O +
evident O +
within O +
DA O +
concentrations O +
ranging O +
from O +
10 O +
to O +
500 O +
μM O +
( O -
Fig. O +
3 O +
b O -
) O -
, O +
which O +
paralleled O +
the O +
DA O +
concentrations O +
for O +
stimulation O +
of O +
mitogenesis O +
( O -
Fig. O +
1 O +
a O -
) O -
. O -

To O +
monitor O +
the O +
amounts O +
of O +
protein O +
loaded O -
, O +
all O +
blots O +
were O +
stripped O +
and O +
then O +
immunoblotted O +
with O +
anti O -
- O -
ERK2 O -
. O -

The O +
lower O +
anti O -
- O -
ERK2 O +
immunoblottings O +
in O +
Fig. O +
3 O +
a O +
and O +
b O +
show O +
that O +
a O +
similar O +
amount O +
of O +
protein O +
was O +
loaded O -
. O -

This O +
protein O +
tyrosine O +
phosphorylation O -
, O +
mostly O +
at O +
molecular O +
sizes O +
between O +
50 O +
and O +
150 O +
kDa O -
, O +
required O +
D2 O +
receptor O +
activation O -
. O -

Preincubation O +
of O +
C6-D2L O +
cells O +
30 O +
min O +
with O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
specific O +
D2 O +
receptor O +
antagonist O -
, O +
could O +
block O +
DA O -
- O -
induced O +
protein O +
tyrosine O +
phosphorylation O +
( O -
Fig. O +
3 O +
c O -
) O -
. O -

This O +
antagonistic O +
effect O +
was O +
concentration O -
- O -
dependent O -
. O -

Increasing O +
( O -
+ O -
) O -
-butaclamol O +
from O +
1 O +
to O +
100 O +
μM O +
resulted O +
in O +
significant O +
inhibition O +
of O +
protein O +
tyrosine O +
phosphorylation O -
. O -

Especially O +
in O +
the O +
presence O +
of O +
100 O +
μM O +
( O -
+ O -
) O -
-butaclamol O -
, O +
the O +
cells O +
failed O +
to O +
respond O +
to O +
200 O +
μM O +
DA O +
stimulation O +
( O -
upper O +
left O +
panel O -
, O +
Fig. O +
3 O +
c O -
) O -
. O -

This O +
blocking O +
effect O +
was O +
specific O +
to O +
D2 O +
receptors O +
since O +
application O +
of O +
the O +
same O +
amount O +
of O +
( O -
− O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
form O +
of O +
( O -
+ O -
) O -
-butaclamol O -
, O +
did O +
not O +
show O +
any O +
effect O +
on O +
DA O -
- O -
stimulated O +
tyrosine O +
phosphorylation O -
. O -

We O +
have O +
also O +
directly O +
tested O +
the O +
effect O +
of O +
quinpirole O -
, O +
a O +
D2 O +
receptor O +
agonist O -
, O +
on O +
protein O +
tyrosine O +
phosphorylation O -
. O -

As O +
shown O +
in O +
the O +
right O +
panel O +
of O +
Fig. O +
3 O +
c O -
, O +
increasing O +
quinpirole O +
from O +
10 O +
to O +
200 O +
μM O +
resulted O +
in O +
a O +
great O +
increase O +
in O +
the O +
amount O +
of O +
tyrosine O -
- O -
phosphorylated O +
proteins O -
. O -

Furthermore O -
, O +
we O +
could O +
not O +
observe O +
significant O +
changes O +
in O +
tyrosine O -
- O -
phosphorylated O +
proteins O +
in O +
wild O -
- O -
type O +
C6 O +
cells O +
treated O +
with O +
DA O +
concentrations O +
from O +
10 O +
to O +
500 O +
μM O +
( O -
data O +
not O +
shown O -
) O -
. O -

Inactivation O +
of O +
cellular O +
PTX O -
- O -
sensitive O +
G O +
proteins O +
by O +
PTX O +
partially O +
blocked O +
DA O -
- O -
induced O +
protein O +
tyrosine O +
phosphorylation O -
. O -

We O +
have O +
quantified O +
tyrosine O -
- O -
phosphorylated O +
proteins O +
between O +
50 O +
and O +
150 O +
kDa O +
by O +
using O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O -

Pretreatment O +
of O +
the O +
cells O +
with O +
500 O +
ng O -
/ O -
ml O +
PTX O +
inhibited O +
DA O +
( O -
200 O +
μM O -
) O -
-stimulated O +
tyrosine O +
phosphorylation O +
by O +
57±15 O -
% O +
( O -
n O +
= O -
3 O -
) O -
. O -

PTX O +
at O +
a O +
concentration O +
of O +
100 O +
ng O -
/ O -
ml O +
also O +
reduced O +
the O +
tyrosine O -
- O -
phosphorylated O +
proteins O +
by O +
24±13 O -
% O +
( O -
n O +
= O -
3 O -
) O -
. O -

Coincidentally O -
, O +
this O +
percentage O +
of O +
reduction O +
of O +
tyrosine O +
phosphorylation O +
by O +
100 O +
ng O -
/ O -
ml O +
PTX O +
is O +
close O +
to O +
its O +
inhibitory O +
ability O +
( O -
32±10 O -
% O -
, O +
n O +
=3 O -
, O +
Fig. O +
1 O +
b O -
) O +
to O +
DA O -
- O -
stimulated O +
mitogenesis O -
. O -

Thus O -
, O +
these O +
results O +
suggest O +
that O +
D2 O +
receptor O +
activation O +
is O +
associated O +
with O +
protein O +
tyrosine O +
kinase O +
activity O -
. O -

In O +
order O +
to O +
test O +
the O +
idea O +
that O +
tyrosine O +
kinase O +
is O +
involved O +
in O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
we O +
examined O +
the O +
effect O +
of O +
genistein O -
, O +
a O +
potent O +
tyrosine O +
kinase O +
inhibitor O -
, O +
on O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O -

As O +
shown O +
in O +
Fig. O +
4 O -
a O -
, O +
preincubation O +
of O +
either O +
genistein O +
or O +
herbimycin O +
( O -
another O +
tyrosine O +
kinase O +
inhibitor O -
) O +
significantly O +
blocked O +
the O +
protein O +
tyrosine O +
phosphorylation O +
stimulated O +
by O +
200 O +
μM O +
DA O -
. O -

Application O +
of O +
10 O +
μM O +
genistein O +
completely O +
inhibited O +
the O +
DNA O +
synthesis O +
induced O +
by O +
DA O +
( O -
Fig. O +
4 O +
b O -
) O -
. O -

These O +
observations O +
indicate O +
that O +
the O +
activation O +
of O +
protein O +
tyrosine O +
kinase O +
is O +
required O +
for O +
the O +
promotion O +
of O +
mitogenesis O +
induced O +
by O +
DA O -
. O -

3.4 O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
involved O +
in O +
an O +
intracellular O +
redox O -
– O -
tyrosine O +
phosphorylation O +
pathway O +
Although O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
are O +
implicated O +
in O +
pathological O +
cellular O +
processes O -
, O +
including O +
oxidative O +
stress O +
damage O +
[ O -
47 O -
] O +
and O +
ischemic O +
neuronal O +
injury O +
[ O -
10 O -
] O +
, O +
recent O +
evidence O +
suggests O +
that O +
ROS O +
are O +
involved O +
in O +
cell O +
signaling O +
that O +
regulates O +
proliferation O +
and O +
DNA O +
synthesis O +
[ O -
22 O -
] O +
. O -

To O +
test O +
the O +
idea O +
that O +
D2 O +
receptors O +
stimulate O +
mitogenesis O +
through O +
regulation O +
of O +
an O +
intracellular O +
redox O -
– O -
tyrosine O +
kinase O +
cascade O -
, O +
we O +
examined O +
the O +
effect O +
of O +
diphenylene O +
iodonium O +
( O -
DPI O -
) O +
and O +
N O +
-acetyl O +
cysteine O +
( O -
NAC O -
) O +
on O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O -

DPI O +
is O +
an O +
inhibitor O +
of O +
flavonoid O -
- O -
containing O +
oxidases O +
that O +
can O +
catalyze O +
the O +
formation O +
of O +
superoxide O +
from O +
oxygen O +
with O +
NADH O -
/ O -
NADPH O +
as O +
an O +
electron O +
donor O +
[ O -
28 O -
, O +
43 O -
] O +
. O -

Some O +
flavonoid O -
- O -
containing O +
oxidases O -
, O +
such O +
as O +
NADPH O -
- O -
dependent O +
oxidase O -
, O +
have O +
been O +
shown O +
to O +
be O +
regulated O +
by O +
a O +
variety O +
of O +
membrane O +
receptors O -
, O +
such O +
as O +
intrinsic O +
tyrosine O -
- O -
kinase O -
- O -
containing O +
receptors O +
and O +
G O -
- O -
protein O -
- O -
coupled O +
receptors O +
[ O -
22 O -
, O +
23 O -
] O +
. O -

NAC O +
is O +
an O +
antioxidant O +
that O +
can O +
scavenge O +
free O +
radicals O -
. O -

Pretreatment O +
of O +
C6-D2L O +
cells O +
with O +
either O +
1 O +
μM O +
DPI O +
or O +
20 O +
mM O +
NAC O +
greatly O +
reduced O +
tyrosine O +
phosphorylation O +
and O +
consequent O +
mitogenesis O +
induced O +
by O +
DA O +
( O -
Fig. O +
5 O -
a O +
and O +
b O -
) O -
. O -

Either O +
DPI O +
or O +
NAC O +
itself O +
has O +
no O +
effect O +
on O +
tyrosine O +
phosphorylation O +
of O +
proteins O +
( O -
Fig. O +
5 O +
) O -
. O -

The O +
anti O -
- O -
ERK2 O +
immunoblotting O +
of O +
same O +
stripped O +
blot O +
shows O +
that O +
a O +
similar O +
amount O +
of O +
protein O +
was O +
loaded O +
in O +
each O +
lane O +
( O -
lower O +
panel O -
, O +
Fig. O +
5 O +
a O -
) O -
. O -

Thus O -
, O +
these O +
results O +
suggest O +
that O +
the O +
protein O +
tyrosine O +
kinase O +
and O +
consequent O +
mitogenesis O +
may O +
be O +
regulated O +
by O +
intracellular O +
ROS O -
, O +
which O +
are O +
assumed O +
to O +
be O +
produced O +
by O +
flavonoid O -
- O -
containing O +
oxidases O -
. O -

Next O -
, O +
we O +
tested O +
the O +
roles O +
of O +
ROS O +
in O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O +
by O +
application O +
of O +
exogenous O +
H2 O +
O2 O +
. O -

We O +
assumed O +
that O +
the O +
protein O +
tyrosine O +
kinase O +
could O +
be O +
activated O +
by O +
DA O -
- O -
stimulated O +
increase O +
of O +
intracellular O +
ROS O -
. O -

If O +
this O +
is O +
the O +
case O -
, O +
exogenous O +
application O +
of O +
low O +
concentrations O +
of O +
H2 O +
O2 O -
may O +
enhance O +
protein O +
kinase O +
activity O +
and O +
subsequent O +
mitogenesis O +
induced O +
by O +
DA O -
. O -

As O +
shown O +
in O +
Fig. O +
6 O -
a O -
, O +
increasing O +
extracellular O +
H2 O +
O2 O -
concentrations O +
did O +
result O +
in O +
increase O +
of O +
DA O -
- O -
induced O +
tyrosine O -
- O -
phosphorylated O +
proteins O -
. O -

The O +
upper O +
panel O +
shows O +
anti O -
- O -
phosphotyrosine O +
immunoblotting O -
, O +
while O +
the O +
lower O +
panel O +
is O +
a O +
quantified O +
data O +
( O -
from O +
50 O +
to O +
150 O +
kDa O -
) O +
of O +
at O +
least O +
three O +
experiments O +
using O +
the O +
NIH O +
Image O +
1.55 O +
Program O -
. O -

The O +
sister O +
gel O +
was O +
run O +
and O +
immunostained O +
with O +
anti O -
- O -
ERK2 O +
to O +
monitor O +
protein O +
loading O -
. O -

The O +
nanomolar O +
levels O +
of O +
H2 O +
O2 O -
enhanced O +
by O +
about O +
2.7-fold O +
amounts O +
of O +
tyrosine O -
- O -
phosphorylated O +
proteins O +
stimulated O +
by O +
10 O +
μM O +
DA O -
, O +
although O +
H2 O +
O2 O -
levels O +
below O +
1 O +
nM O +
show O +
only O +
a O +
small O +
effect O +
( O -
Fig. O +
6 O +
a O -
) O -
. O -

Furthermore O -
, O +
an O +
enhancement O +
effect O +
of O +
H2 O +
O2 O -
on O +
DA O -
- O -
stimulated O +
mitogenesis O +
was O +
also O +
observed O +
( O -
Fig. O +
6 O +
b O -
) O -
. O -

However O -
, O +
the O +
capability O +
of O +
increasing O +
DA O -
- O -
induced O +
mitogenesis O +
at O +
nanomolar O +
levels O +
of O +
H2 O +
O2 O -
was O +
reduced O +
when O +
compared O +
with O +
that O +
at O +
0.1 O +
pM O +
H2 O +
O2 O -
( O -
Fig. O +
6 O +
b O -
) O -
. O -

This O +
may O +
be O +
due O +
to O +
a O +
dual O +
effect O +
of O +
ROS O +
in O +
cell O +
proliferation O -
: O +
a O +
stimulatory O +
effect O +
at O +
low O +
concentrations O +
and O +
a O +
toxic O +
effect O +
at O +
high O +
concentrations O +
[ O -
22 O -
] O +
. O -

With O +
the O +
application O +
of O +
H2 O +
O2 O -
alone O +
without O +
DA O -
, O +
C6-D2L O +
cells O +
did O +
exhibit O +
such O +
a O +
dual O +
mitogenic O +
effect O +
( O -
data O +
not O +
shown O -
) O -
. O -

3.5 O +
DA O +
increases O +
GFAP O +
expression O +
In O +
addition O +
to O +
stimulating O +
DNA O +
synthesis O -
, O +
DA O +
at O +
micromolar O +
levels O +
also O +
significantly O +
increased O +
the O +
expression O +
of O +
GFAP O -
, O +
a O +
sensitive O +
parameter O +
serving O +
as O +
another O +
criterion O +
of O +
reactive O +
astrocytes O +
[ O -
33 O -
] O +
. O -

As O +
shown O +
in O +
Fig. O +
7 O -
a O -
, O +
C6-D2L O +
cells O +
responded O +
to O +
DA O +
( O -
200 O +
μM O -
) O +
treatment O +
with O +
an O +
increase O +
in O +
GFAP O +
expression O +
in O +
a O +
time O -
- O -
dependent O +
manner O -
. O -

Between O +
0 O +
and O +
48 O +
h O +
after O +
stimulation O -
, O +
the O +
amount O +
of O +
GFAP O +
was O +
increased O +
about O +
2.1±0.1-fold O +
( O -
Fig. O +
7 O +
a O -
) O -
. O -

Concentration O +
dependence O +
studies O +
carried O +
out O +
at O +
24 O +
h O +
showed O +
that O +
maximal O +
stimulation O +
of O +
GFAP O +
expression O +
occurred O +
at O +
200 O +
μM O +
DA O +
( O -
Fig. O +
7 O +
b O -
) O -
. O -

Interestingly O -
, O +
GFAP O +
production O +
was O +
decreased O +
when O +
the O +
cells O +
were O +
exposed O +
to O +
500 O +
μM O +
DA O +
for O +
24 O +
h O +
( O -
Fig. O +
7 O +
b O -
) O -
, O +
which O +
differs O +
from O +
the O +
dose O -
– O -
response O +
data O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
1 O +
) O -
. O -

This O +
observation O +
suggests O +
that O +
DA O +
stimulatory O +
GFAP O +
synthesis O +
may O +
be O +
regulated O +
by O +
a O +
different O +
pathway O +
from O +
mitogenesis O -
. O -

Alternatively O -
, O +
this O +
decrease O +
of O +
GFAP O +
expression O +
at O +
500 O +
μM O +
DA O +
may O +
be O +
due O +
to O +
widespread O +
mitogenesis O +
since O +
immature O +
astrocytes O +
have O +
a O +
less O +
amount O +
of O +
GFAP O +
expression O -
. O -

3.6 O +
DA O -
- O -
induced O +
GFAP O +
generation O +
involves O +
activation O +
of O +
p38 O +
MAPK O +
It O +
became O +
important O +
to O +
determine O +
whether O +
DA O -
- O -
stimulated O +
GFAP O +
production O +
might O +
also O +
be O +
required O +
to O +
activate O +
the O +
D2 O +
receptor O -
– O -
tyrosine O +
kinase O +
pathway O -
. O -

To O +
test O +
this O +
idea O -
, O +
we O +
used O +
a O +
paradigm O +
similar O +
to O +
that O +
for O +
DA O -
- O -
stimulated O +
mitogenesis O +
in O +
C6-D2L O +
cells O +
( O -
Fig. O +
1 O +
) O -
. O -

Surprisingly O -
, O +
the O +
GFAP O +
stimulation O +
did O +
not O +
appear O +
to O +
be O +
regulated O +
by O +
D2 O +
receptors O +
since O +
it O +
was O +
not O +
influenced O +
by O +
the O +
D2 O +
receptor O +
antagonist O -
, O +
( O -
+ O -
) O -
-butaclamol O +
( O -
Fig. O +
8 O -
a O -
) O -
. O -

Application O +
of O +
DA O +
to O +
wild O -
- O -
type O +
C6 O +
cells O +
also O +
resulted O +
in O +
a O +
similar O +
increase O +
in O +
GFAP O +
expression O +
as O +
that O +
in O +
C6-D2L O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O -

Moreover O -
, O +
direct O +
application O +
of O +
quinpirole O +
( O -
200 O +
μM O -
) O -
, O +
a O +
D2 O +
receptor O +
agonist O -
, O +
had O +
no O +
effect O +
on O +
GFAP O +
expression O +
( O -
Fig. O +
8 O +
a O -
) O -
. O -

Pretreatment O +
of O +
the O +
C6-D2L O +
cells O +
with O +
PTX O +
for O +
6 O +
h O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
GFAP O +
generation O +
( O -
Fig. O +
8 O +
a O -
) O -
, O +
suggesting O +
that O +
PTX O -
- O -
sensitive O +
G O +
proteins O +
might O +
also O +
not O +
be O +
involved O -
. O -

Pretreatment O +
of O +
the O +
cells O +
with O +
either O +
10 O +
μM O +
genistein O +
or O +
20 O +
mM O +
NAC O +
also O +
had O +
no O +
effect O +
on O +
GFAP O +
expression O +
due O +
to O +
DA O +
( O -
Fig. O +
8 O +
a O -
) O -
, O +
while O +
the O +
identical O +
treatments O +
resulted O +
in O +
the O +
blocking O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
4 O +
b O -
, O +
Fig. O +
5 O +
b O -
) O -
. O -

PD098059 O +
also O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
GFAP O +
expression O +
( O -
Fig. O +
8 O +
a O -
) O -
. O -

Thus O -
, O +
unlike O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
GFAP O +
stimulation O +
does O +
not O +
seem O +
to O +
involve O +
the O +
D2 O +
receptor O -
– O -
tyrosine O +
kinase O +
pathway O -
. O -

However O -
, O +
we O +
have O +
found O +
that O +
GFAP O +
expression O +
stimulated O +
by O +
DA O +
could O +
be O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
SB203580 O -
, O +
a O +
selective O +
p38 O +
MAPK O +
inhibitor O +
[ O -
13 O -
, O +
27 O -
] O +
. O -

As O +
shown O +
in O +
Fig. O +
8 O +
b O -
, O +
application O +
of O +
10 O +
μM O +
SB O +
203580 O +
completely O +
blocked O +
the O +
increases O +
in O +
GFAP O +
generation O +
stimulated O +
by O +
DA O +
at O +
concentrations O +
ranging O +
from O +
10 O +
to O +
200 O +
μM O -
, O +
suggesting O +
that O +
activation O +
of O +
p38 O +
MAPK O +
might O +
be O +
required O +
for O +
the O +
regulation O +
of O +
GFAP O +
generation O -
. O -

By O +
using O +
anti O -
- O -
phospho O -
- O -
specific O +
p38 O +
MAPK O +
immunoblotting O -
, O +
we O +
examined O +
the O +
effect O +
of O +
DA O +
on O +
p38 O +
MAPK O +
phosphorylation O -
, O +
a O +
requirement O +
for O +
p38 O +
MAPK O +
activity O +
[ O -
42 O -
] O +
. O -

With O +
the O +
application O +
of O +
100 O +
μM O +
DA O +
to O +
C6-D2L O +
cells O -
, O +
p38 O +
MAPK O +
was O +
rapidly O +
phosphorylated O +
within O +
5 O +
min O -
, O +
reached O +
a O +
maximum O +
at O +
15 O +
min O -
, O +
then O +
gradually O +
decreased O +
to O +
basal O +
level O +
by O +
about O +
1 O +
h O +
( O -
Fig. O +
9 O -
a O -
) O -
. O -

The O +
p38 O +
MAPK O +
phosphorylation O +
was O +
greatly O +
increased O +
when O +
the O +
cells O +
were O +
exposed O +
to O +
DA O +
concentrations O +
ranging O +
from O +
10 O +
to O +
200 O +
μM O +
for O +
15 O +
min O +
( O -
Fig. O +
9 O +
b O -
) O -
. O -

Pretreatment O +
of O +
the O +
cells O +
with O +
( O -
+ O -
) O -
-butaclamol O +
had O +
no O +
effect O +
on O +
DA O -
- O -
stimulated O +
phosphorylation O +
of O +
p38 O +
MAPK O +
( O -
Fig. O +
9 O +
c O -
) O -
. O -

These O +
data O +
suggest O +
that O +
DA O -
- O -
activated O +
p38 O +
MAPK O +
may O +
not O +
be O +
mediated O +
by O +
D2 O +
receptors O -
. O -

4 O +
Discussion O +
In O +
this O +
paper O -
, O +
we O +
report O +
that O +
micromolar O +
levels O +
of O +
DA O +
stimulate O +
mitogenesis O +
in O +
C6-D2L O +
cells O -
. O -

In O +
contrast O +
with O +
our O +
previous O +
report O +
for O +
earlier O +
mitogenesis O +
( O -
peaking O +
at O +
17 O +
h O -
) O +
induced O +
by O +
nanomolar O +
levels O +
of O +
DA O +
[ O -
30 O -
] O +
, O +
this O +
mitogenesis O +
stimulated O +
by O +
micromolar O +
levels O +
of O +
DA O +
occurs O +
at O +
about O +
29 O +
h. O +
Biochemically O -
, O +
the O +
earlier O +
phase O +
of O +
mitogenesis O +
requires O +
D2 O +
receptor O -
– O -
MAPK O +
signaling O -
, O +
while O +
the O +
later O +
phase O +
requires O +
the O +
D2-receptor O -
– O -
tyrosine O +
kinase O +
pathway O -
. O -

Although O +
relationship O +
of O +
the O +
two O +
phases O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
not O +
clear O -
, O +
the O +
different O +
signaling O +
mechanisms O +
suggest O +
that O +
they O +
are O +
not O +
likely O +
to O +
be O +
dependent O +
on O +
each O +
other O -
. O -

For O +
example O -
, O +
nanomolar O +
levels O +
of O +
DA O +
strongly O +
stimulate O +
MAPK O +
without O +
significant O +
protein O +
tyrosine O +
phosphorylation O +
and O +
the O +
mitogenesis O +
can O +
be O +
inhibited O +
by O +
blockers O +
of O +
MAPK O +
pathway O -
. O -

Micromolar O +
levels O +
of O +
DA O +
strongly O +
stimulate O +
protein O +
tyrosine O +
kinase O +
without O +
effect O +
on O +
MAPK O -
, O +
and O +
the O +
consequent O +
mitogenesis O +
can O +
be O +
blocked O +
by O +
tyrosine O +
kinase O +
inhibitors O +
but O +
not O +
by O +
blockers O +
of O +
the O +
MAPK O +
pathway O -
. O -

Under O +
normal O +
physiological O +
conditions O -
, O +
striatal O +
astrocytes O +
surround O +
dopaminergic O +
neurons O -
. O -

Although O +
the O +
astrocytes O +
do O +
not O +
have O +
synaptic O +
contact O +
with O +
dopaminergic O +
neurons O -
, O +
D2 O +
receptors O +
in O +
astrocytes O +
may O +
sense O +
DA O +
( O -
low O +
concentrations O -
) O +
that O +
might O +
escape O +
from O +
the O +
synapse O +
and O +
play O +
a O +
physiological O +
role O +
via O +
the O +
MAPK O +
pathway O -
. O -

In O +
pathologic O +
conditions O -
, O +
such O +
as O +
ischemia O -
, O +
hypoxia O +
and O +
excitatory O +
amino O +
acid O -
- O -
induced O +
neurotoxicity O -
, O +
the O +
extracellular O +
DA O +
concentration O +
in O +
striata O +
is O +
significantly O +
increased O +
to O +
micromolar O +
levels O +
[ O -
2 O -
, O +
6 O -
, O +
45 O -
] O +
. O -

Although O +
the O +
length O +
of O +
DA O +
exposure O +
in O +
our O +
cell O +
culture O +
was O +
relatively O +
long O -
, O +
the O +
signaling O +
responses O -
, O +
such O +
as O +
protein O +
tyrosine O +
phosphorylation O +
and O +
p38 O +
MAPK O +
phosphorylation O -
, O +
were O +
rapid O -
, O +
within O +
a O +
few O +
minutes O +
( O -
Fig. O +
3 O +
a O -
, O +
Fig. O +
9 O +
a O -
) O -
. O -

Thus O -
, O +
the O +
micromolar O +
level O +
DA O -
- O -
induced O +
activation O +
of O +
astrocytes O +
may O +
be O +
implicated O +
in O +
these O +
pathologic O +
conditions O -
. O -

Our O +
results O +
suggest O +
that O +
micromolar O +
levels O +
of O +
DA O +
activate O +
C6-D2L O +
cells O +
through O +
an O +
interaction O +
with O +
receptors O -
. O -

This O +
is O +
evident O +
since O +
DA O -
- O -
stimulated O +
mitogenesis O +
can O +
be O +
blocked O +
by O +
( O -
+ O -
) O -
-butaclamol O -
, O +
a O +
selective O +
D2 O +
DA O +
receptor O +
antagonist O -
, O +
with O +
no O +
effect O +
of O +
( O -
− O -
) O -
-butaclamol O -
, O +
an O +
inactive O +
isoform O +
of O +
( O -
+ O -
) O -
-butaclamol O -
. O -

Quinpirole O -
, O +
a O +
specific O +
D2 O +
receptor O +
agonist O -
, O +
also O +
promotes O +
cell O +
cycle O +
progression O -
. O -

Furthermore O -
, O +
wild O -
- O -
type O +
C6 O +
cells O -
, O +
lacking O +
the O +
expression O +
of O +
D2 O +
receptors O -
, O +
exhibit O +
no O +
mitogenic O +
response O +
to O +
stimulation O +
by O +
DA O -
. O -

This O +
also O +
ruled O +
out O +
the O +
possibility O +
that O +
the O +
mitogenesis O +
might O +
be O +
mediated O +
by O +
ROS O +
produced O +
by O +
DA O +
autoxidation O -
. O -

However O -
, O +
considering O +
the O +
fact O +
that O +
C6 O +
cells O +
contain O +
other O +
monoamine O +
receptors O -
, O +
such O +
as O +
β O +
adrenergic O +
receptors O +
[ O -
35 O -
] O +
, O +
we O +
can O -
not O +
exclude O +
the O +
possibility O +
that O +
micromolar O +
levels O +
of O +
DA O +
may O +
also O +
non O -
- O -
specifically O +
stimulate O +
these O +
receptors O +
and O +
may O +
cooperate O +
with O +
DA O +
receptors O -
. O -

A O +
receptor O -
- O -
mediated O +
mechanism O +
may O +
also O +
be O +
involved O +
in O +
GFAP O +
upregulation O +
stimulated O +
by O +
DA O +
since O +
GFAP O +
synthesis O +
could O +
not O +
be O +
prevented O +
by O +
preincubation O +
with O +
20 O +
mM O +
NAC O -
, O +
which O +
can O +
scavenge O +
ROS O +
generated O +
either O +
by O +
DA O +
oxidation O +
or O +
through O +
a O +
D2-receptor O -
- O -
mediated O +
redox O +
system O -
. O -

Although O +
the O +
type O +
of O +
receptor O +
involved O +
in O +
DA O -
- O -
stimulated O +
GFAP O +
expression O +
is O +
currently O +
unknown O -
, O +
it O +
would O +
appear O +
not O +
to O +
be O +
D2 O +
receptors O +
since O +
both O +
wild O -
- O -
type O +
C6 O +
and O +
C6-D2L O +
cells O +
gave O +
a O +
similar O +
GFAP O +
regulatory O +
response O +
to O +
DA O +
stimulation O -
. O -

One O +
potential O +
candidate O +
would O +
be O +
β O +
adrenergic O +
receptors O -
, O +
shown O +
to O +
stimulate O +
GFAP O +
expression O +
through O +
cAMP O +
[ O -
44 O -
] O +
. O -

High O -
- O -
concentration O +
DA O -
- O -
stimulated O +
mitogenesis O +
appears O +
to O +
involve O +
the O +
intracellular O +
production O +
of O +
ROS O +
as O +
supported O +
by O +
the O +
following O +
evidence O -
. O -

First O -
, O +
DA O -
- O -
stimulated O +
mitogenesis O +
can O +
be O +
inhibited O +
by O +
DPI O -
. O -

DPI O +
has O +
been O +
demonstrated O +
to O +
be O +
a O +
potent O +
and O +
selective O +
inhibitor O +
for O +
membrane O -
- O -
bound O +
NADPH O -
- O -
dependent O +
oxidase O +
through O +
a O +
binding O +
to O +
the O +
flavoprotein O +
component O +
of O +
the O +
oxidase O +
[ O -
12 O -
, O +
28 O -
, O +
43 O -
] O +
. O -

This O +
intracellular O +
NADPH O -
- O -
dependent O +
oxidase O +
can O +
directly O +
catalyze O +
substrate O +
oxygen O +
conversion O +
to O +
the O +
superoxide O +
anion O -
, O +
which O +
can O +
in O +
turn O +
generate O +
other O +
reactive O +
oxygen O +
intermediates O -
. O -

Secondly O -
, O +
DA O -
- O -
induced O +
mitogenesis O +
is O +
prevented O +
by O +
the O +
membrane O -
- O -
permeable O +
antioxidant O -
, O +
NAC O -
. O -

Finally O -
, O +
application O +
of O +
very O +
low O +
concentrations O +
of O +
H2 O +
O2 O -
can O +
enhance O +
both O +
DA O -
- O -
induced O +
protein O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O -
. O -

These O +
observations O +
suggest O +
that O +
ROS O +
may O +
serve O +
as O +
a O +
second O +
messenger O +
in O +
the O +
signaling O +
of O +
DA O -
- O -
stimulated O +
mitogenesis O -
, O +
adding O +
evidence O +
in O +
support O +
of O +
the O +
recent O +
notion O +
that O +
ROS O +
act O +
as O +
intracellular O +
messengers O +
of O +
cell O +
proliferation O +
[ O -
22 O -
] O +
. O -

Like O +
other O +
astrocyte O +
mitogens O -
, O +
such O +
as O +
endothelin O +
[ O -
7 O -
, O +
26 O -
] O +
, O +
micromolar O +
level O +
DA O -
- O -
induced O +
mitogenesis O +
requires O +
tyrosine O +
phosphorylation O -
. O -

Application O +
of O +
DA O +
to O +
C6-D2L O +
cells O +
rapidly O +
increases O +
protein O +
tyrosine O +
phosphorylation O -
. O -

Concentration O -
- O -
dependent O +
tyrosine O +
phosphorylation O +
studies O +
show O +
a O +
similar O +
profile O +
to O +
that O +
of O +
DA O -
- O -
induced O +
DNA O +
synthesis O -
. O -

Both O +
protein O +
tyrosine O +
phosphorylation O +
and O +
mitogenesis O +
can O +
be O +
effectively O +
blocked O +
by O +
preincubation O +
of O +
the O +
cells O +
with O +
genistein O -
, O +
a O +
potent O +
protein O +
tyrosine O +
kinase O +
inhibitor O +
[ O -
1 O -
] O +
. O -

However O -
, O +
unlike O +
for O +
the O +
mitogen O +
endothelin O -
, O +
DA O -
- O -
stimulated O +
mitogenesis O +
is O +
not O +
linked O +
to O +
the O +
tyrosine O +
kinase O -
– O -
ERK O +
pathway O +
since O +
DA O +
at O +
micromolar O +
levels O +
has O +
no O +
stimulatory O +
effect O +
on O +
ERK O +
activation O -
. O -

Furthermore O -
, O +
PD098095 O -
, O +
the O +
MEK1 O +
inhibitor O -
, O +
has O +
little O -
, O +
if O +
any O -
, O +
effect O +
on O +
high O +
concentration O +
of O +
DA O -
- O -
induced O +
mitogenesis O +
although O +
it O +
does O +
have O +
some O +
inhibitory O +
effects O +
on O +
basal O +
DNA O +
synthesis O -
. O -

DA O -
- O -
stimulated O +
mitogenesis O +
at O +
micromolar O +
levels O +
is O +
partially O +
mediated O +
by O +
PTX O -
- O -
sensitive O +
G O +
proteins O -
. O -

This O +
is O +
supported O +
by O +
the O +
following O +
evidence O -
. O -

( O -
1 O -
) O +
Pretreatment O +
of O +
the O +
cells O +
with O +
100 O +
ng O -
/ O -
ml O +
PTX O +
only O +
inhibits O +
DA O -
- O -
stimulated O +
mitogenesis O +
by O +
about O +
24–50 O -
% O -
, O +
depending O +
on O +
concentrations O +
of O +
DA O +
( O -
Fig. O +
1 O +
b O -
) O -
. O -

( O -
2 O -
) O +
Application O +
of O +
PTX O -
, O +
even O +
in O +
a O +
very O +
high O +
concentration O +
( O -
500 O +
ng O -
/ O -
ml O -
) O -
, O +
only O +
partially O +
blocks O +
DA O -
- O -
induced O +
tyrosine O +
phosphorylation O -
. O -

( O -
3 O -
) O +
The O +
ability O +
of O +
PTX O +
to O +
inhibit O +
protein O +
tyrosine O +
phosphorylation O +
is O +
correlated O +
with O +
that O +
to O +
inhibit O +
DA O -
- O -
induced O +
mitogenesis O +
( O -
Fig. O +
1 O +
b O -
) O -
. O -

These O +
observations O +
raise O +
the O +
possibility O +
that O +
PTX O -
- O -
resistant O +
G O +
proteins O +
may O +
participate O +
in O +
the O +
signaling O +
of O +
high O +
concentration O +
of O +
DA O -
- O -
induced O +
mitogenesis O -
, O +
although O +
further O +
studies O +
are O +
required O -
. O -

Some O +
literature O +
reports O +
suggest O +
that O +
receptors O +
coupled O +
to O +
PTX O -
- O -
insensitive O +
G O +
proteins O +
or O +
the O +
small O +
G O +
protein O +
Ras O +
can O +
regulate O +
cell O +
proliferation O -
. O -

For O +
example O -
, O +
thrombin O -
, O +
an O +
astrocytic O +
mitogen O -
, O +
has O +
been O +
shown O +
to O +
stimulate O +
DNA O +
synthesis O +
in O +
1321N1 O +
astrocytoma O +
cells O +
through O +
coupling O +
with O +
G12 O +
, O +
a O +
Gq O +
subtype O +
of O +
GTP O +
binding O +
proteins O +
[ O -
41 O -
] O +
. O -

Recently O -
, O +
D2 O +
receptors O +
were O +
also O +
reported O +
to O +
stimulate O +
prolactin O +
release O +
via O +
coupling O +
of O +
a O +
PTX O -
- O -
insensitive O +
G O +
protein O +
pathway O +
[ O -
8 O -
] O +
. O -

Whether O +
or O +
not O +
D2 O +
receptors O +
might O +
be O +
coupled O +
to O +
PTX O -
- O -
insensitive O +
G O +
proteins O +
or O +
Ras O +
small O +
G O +
proteins O +
in O +
response O +
to O +
high O +
concentrations O +
of O +
DA O +
needs O +
further O +
study O -
. O -

Our O +
data O +
suggest O +
that O +
activation O +
of O +
p38 O +
MAPK O +
is O +
required O +
for O +
upregulation O +
of O +
GFAP O +
synthesis O +
following O +
high O +
concentrations O +
of O +
DA O +
stimulation O -
. O -

This O +
is O +
based O +
on O +
the O +
following O +
observations O -
. O -

( O -
1 O -
) O +
Micromolar O +
level O +
DA O -
- O -
stimulated O +
GFAP O +
production O +
can O +
be O +
completely O +
inhibited O +
by O +
pretreatment O +
of O +
the O +
cells O +
with O +
SB203580 O -
, O +
a O +
highly O +
selective O +
inhibitor O +
of O +
p38 O +
MAPK O +
[ O -
13 O -
, O +
27 O -
] O +
. O -

Inhibition O +
of O +
a O +
parallel O +
MAPK O +
pathway O +
by O +
PD098059 O +
has O +
no O +
effect O +
on O +
DA O -
- O -
induced O +
GFAP O +
expression O -
, O +
suggesting O +
that O +
a O +
relative O +
specificity O +
of O +
p38 O +
MAPK O +
may O +
play O +
a O +
role O +
in O +
GFAP O +
generation O -
. O -

( O -
2 O -
) O +
DA O +
activates O +
p38 O +
MAPK O +
activity O +
at O +
concentrations O +
similar O +
to O +
those O +
of O +
DA O -
- O -
induced O +
GFAP O +
expression O -
. O -

( O -
3 O -
) O +
Both O +
activation O +
of O +
p38 O +
MAPK O +
and O +
GFAP O +
synthesis O +
are O +
not O +
regulated O +
by O +
D2 O +
receptors O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
regarding O +
the O +
regulation O +
of O +
GFAP O +
by O +
p38 O +
MAPK O -
. O -

In O +
C6 O +
cells O -
, O +
an O +
increase O +
in O +
intracellular O +
cAMP O -
, O +
either O +
by O +
stimulation O +
of O +
β O -
- O -
adrenergic O +
receptors O +
[ O -
44 O -
] O +
or O +
by O +
stimulation O +
of O +
adenylate O +
cyclase O +
by O +
forskolin O +
[ O -
44 O -
] O +
, O +
is O +
capable O +
of O +
stimulating O +
GFAP O -
. O -

The O +
relationship O +
of O +
cAMP O +
to O +
p38 O +
MAPK O +
deserves O +
further O +
investigation O -
. O -

In O +
our O +
cell O +
culture O +
studies O -
, O +
at O +
least O +
two O +
pathways O +
have O +
been O +
demonstrated O +
to O +
activate O +
C6-D2L O +
glioma O +
cells O -
. O -

One O +
is O +
the O +
D2-receptor O -
- O -
required O +
intracellular O +
redox O -
– O -
protein O +
tyrosine O +
kinase O +
pathway O -
, O +
which O +
is O +
involved O +
in O +
stimulation O +
of O +
cell O +
mitogenesis O -
. O -

Another O +
is O +
the O +
D2 O +
receptor O -
- O -
independent O +
p38 O +
MAPK O +
cascade O -
, O +
which O +
is O +
involved O +
in O +
stimulation O +
of O +
GFAP O +
synthesis O -
. O -

Interestingly O -
, O +
in O +
an O +
in O +
vivo O +
rat U-Species +
model O -
, O +
reactive O +
astrocytes O +
in O +
the O +
brain O +
respond O +
differently O +
to O +
brain O +
injury O -
. O -

Some O +
astrocytes O +
undergo O +
proliferation O +
as O +
indicated O +
only O +
by O +
[ O -
3 O +
H O -
] O -
thymidine O +
incorporation O -
; O +
some O +
exhibit O +
hypertrophy O +
labeled O +
only O +
by O +
GFAP O -
; O +
some O +
are O +
labeled O +
by O +
both O +
GFAP O +
and O +
[ O -
3 O +
H O -
] O -
thymidine O +
[ O -
25 O -
, O +
48 O -
] O +
. O -

This O +
observation O +
suggests O +
that O +
these O +
two O +
separate O +
pathways O +
may O +
operate O +
in O +
the O +
in O +
vivo O +
situation O -
. O -

Taken O +
together O -
, O +
the O +
information O +
from O +
our O +
in O +
vitro O +
cell O +
culture O +
studies O +
may O +
provide O +
insight O +
into O +
the O +
mechanisms O +
of O +
in O +
vivo O +
striatal O +
astrocytic O +
response O +
and O +
help O +
to O +
elucidate O +
potential O +
roles O +
of O +
astrocytes O +
in O +
neurodegeneration O -
. O -

Acknowledgements O -

We O +
thank O +
Dr. O +
K.A. O +
Neve O +
for O +
providing O +
C6-D2L O +
cells O -
. O +

Malaria O +
is O +
still O +
the O +
most O +
important O +
parasitic O +
disease O +
in O +
the O +
world O -
, O +
causing O +
2–3 O +
million O +
deaths O +
every O +
year O +
( O -
WHO O -
, O +
1997 O +
) O -
. O -

The O +
rising O +
resistance O +
of O +
Plasmodium B-Species -
spp L-Species -
. O -
, O +
especially O +
Plasmodium B-Species +
falciparum L-Species +
, O +
to O +
known O +
antimalarials O +
such O +
as O +
chloroquine O +
makes O +
the O +
search O +
for O +
new O +
antimalarial O +
drugs O +
increasingly O +
important O -
. O -

Therefore O -
, O +
we O +
investigated O +
several O +
medicinal O +
plants U-Species -
, O +
which O +
are O +
traditionally O +
used O +
as O +
antimalarial O +
or O +
antipyretic O +
remedies O +
by O +
the O +
indigenous O +
population O +
in O +
Latin O +
America O +
( O -
Duke O -
, O +
1975 O -
; O +
Hirschhorn O -
, O +
1981 O -
; O +
Joly O +
et O +
al. O -
, O +
1987 O -
; O +
Gupta O +
et O +
al. O -
, O +
1993 O +
) O -
. O -

During O +
a O +
screening O +
program O -
, O +
we O +
obtained O +
lipophilic O +
and O +
hydrophilic O +
extracts O +
of O +
these O +
plants U-Species +
with O +
antiplasmodial O +
activity O +
and O +
we O +
selected O +
the O +
most O +
active O +
ones O +
for O +
further O +
investigation O +
( O -
Jenett O -
- O -
Siems O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

Andira B-Species +
inermis L-Species -
( O -
W. O +
Wright O -
) O +
H.B.K. O +
( O -
Fabaceae O -
) O +
is O +
a O +
tall O +
tree O +
characterised O +
by O +
a O +
thick O +
trunk O +
and O +
red O -
- O -
purple O +
flowers O -
, O +
native O +
from O +
southern O +
Mexico O +
to O +
northern O +
South O +
America O -
. O -

As O +
a O +
febrifuge O -
, O +
the O +
bark O +
is O +
boiled O +
in O +
milk O -
, O +
sweetened O +
water O +
or O +
performed O +
in O +
pills O -
. O -

It O +
is O +
also O +
used O +
as O +
a O +
purgative O -
, O +
vermifuge O -
, O +
or O +
for O +
dermal O +
irritations O -
. O -

The O +
seeds O +
have O +
similar O +
uses O -
. O -

Large O +
doses O +
of O +
the O +
stem O +
bark O +
or O +
seeds O +
caused O +
vomiting O +
and O +
violent O +
diarrhoea O -
; O +
in O +
some O +
cases O +
they O +
were O +
even O +
fatal O +
( O -
Hirschhorn O -
, O +
1981 O -
; O +
Morton O -
, O +
1981 O +
) O -
. O -

From O +
this O +
species O -
, O +
several O +
isoflavones O +
and O +
related O +
structures O +
have O +
been O +
reported O +
( O -
Cocker O +
et O +
al. O -
, O +
1962 O -
; O +
Lock O +
de O +
Ugaz O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

The O +
lipophilic O +
extracts O +
of O +
stems O +
and O +
leaves O +
showed O +
moderate O +
in O +
vitro O +
activity O +
against O +
P. B-Species +
falciparum L-Species -
in O +
this O +
screening O +
program O +
and O +
were O +
further O +
analysed O +
by O +
bioassay O -
- O -
guided O +
fractionation O +
to O +
isolate O +
the O +
active O +
compounds O -
. O -

2 O +
Material O +
and O +
methods O +
2.1 O +
General O +
For O +
fractionation O -
, O +
silica O +
gel O +
60 O +
( O -
70–230 O +
mesh O -
) O +
was O +
utilised O -
. O -

Preparative O +
high O +
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
was O +
performed O +
on O +
a O +
Knauer O +
Eurochrom O +
2000 O +
equipped O +
with O +
a O +
Nucleosil O +
P O +
300 O +
C-18 O +
( O -
10 O +
μm O -
) O +
column O -
. O -

Mass O +
spectra O +
were O +
determined O +
with O +
a O +
Finnigan O +
MAT O +
CH7A O +
( O -
220 O -
° O -
C O -
, O +
ionisation O +
70 O +
eV O -
) O +
and O +
1 O +
H O -
- O -
NMR O +
spectra O +
were O +
obtained O +
using O +
acetone O -
- O -
D6 O -
as O +
a O +
solvent O +
with O +
a O +
Bruker O +
AVANCE O +
DPX O +
400 O +
( O -
400 O +
MHz O -
, O +
TMS O +
as O +
internal O +
standard O -
) O -
. O -

The O +
erythrocytes O +
were O +
harvested O +
with O +
an O +
Inotech O +
cell O +
harvester O +
and O +
the O +
β O -
- O -
radiation O +
of O +
the O +
incorporated O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
was O +
measured O +
with O +
a O +
Wallac O +
1450 O +
MicroBeta O +
plus O +
liquid O +
scintillation O +
counter O -
. O -

2.2 O +
Plant O +
material O +
Leaves O +
and O +
stems O +
of O +
A. B-Species +
inermis L-Species -
were O +
collected O +
in O +
the O +
area O +
of O +
Panama O +
City O +
( O -
at O +
the O +
road O +
El O +
Llano O -
- O -
Carti O -
) O -
, O +
Panama O -
, O +
during O +
March O +
1997 O -
. O -

Voucher O +
specimens O +
( O -
FLORPAN O +
2758 O -
) O +
were O +
identified O +
by O +
Professor O +
M.D. O +
Correa O +
A. O +
and O +
deposited O +
at O +
the O +
Herbarium O +
of O +
the O +
University O +
of O +
Panama O -
. O -

2.3 O +
Extraction O +
and O +
isolation O +
In O +
the O +
screening O +
program O -
, O +
the O +
air O -
- O -
dried O +
stem O +
bark O +
and O +
leaves O +
( O -
20 O +
g O -
) O +
were O +
extracted O +
three O +
times O +
for O +
2 O +
h O +
with O +
150 O +
ml O +
petroleum O +
ether O -
/ O -
ethyl O +
acetate O +
( O -
1:1 O -
) O +
at O +
room O +
temperature O -
. O -

Then O +
the O +
plant O +
material O +
was O +
air O +
dried O +
again O +
and O +
treated O +
three O +
times O +
with O +
150 O +
ml O +
methanol O -
/ O -
water O +
( O -
8:2 O -
) O +
to O +
yield O +
the O +
hydrophilic O +
extracts O -
. O -

The O +
solvents O +
were O +
evaporated O +
under O +
reduced O +
pressure O +
at O +
40 O -
° O -
C O -
. O -

For O +
further O +
investigations O -
, O +
the O +
crushed O +
stems O +
( O -
600 O +
g O -
) O +
were O +
air O +
dried O +
and O +
extracted O +
three O +
times O +
with O +
2 O +
l O +
of O +
petroleum O +
ether O -
/ O -
ethyl O +
acetate O +
( O -
1:1 O -
) O +
for O +
24 O +
h O +
at O +
room O +
temperature O -
. O -

The O +
solvents O +
were O +
evaporated O +
under O +
reduced O +
pressure O +
at O +
40 O -
° O -
C O -
. O -

The O +
oily O +
residue O +
( O -
3.3 O +
g O -
) O +
was O +
subjected O +
to O +
column O +
chromatography O +
on O +
silica O +
gel O +
60 O +
( O -
45 O +
g O -
) O +
and O +
eluted O +
with O +
cyclohexane O -
, O +
cyclohexane O -
/ O -
ethyl O +
acetate O +
mixtures O -
, O +
and O +
methanol O +
to O +
yield O +
seven O +
fractions O -
, O +
which O +
were O +
tested O +
against O +
P. B-Species +
falciparum L-Species +
. O -

Fraction O +
5 O +
and O +
6 O -
, O +
which O +
were O +
eluted O +
with O +
cyclohexane O -
/ O -
ethyl O +
acetate O +
( O -
8:2 O +
and O +
7:3 O -
, O +
respectively O -
) O -
, O +
proved O +
to O +
be O +
most O +
active O -
. O -

Further O +
separation O +
of O +
fraction O +
5 O +
( O -
150 O +
mg O -
) O +
by O +
HPLC O +
at O +
a O +
5 O +
ml O -
/ O -
min O +
flow O +
rate O +
of O +
methanol O -
/ O -
water O +
( O -
55:45 O -
) O +
yielded O +
the O +
compounds O +
1 O -
( O -
2.4 O +
mg O -
) O -
, O +
2 O -
( O -
6.1 O +
mg O -
) O -
, O +
and O +
3 O -
( O -
6.6 O +
mg O -
) O -
. O -

Fraction O +
6 O +
was O +
separated O +
with O +
methanol O -
/ O -
water O +
( O -
45:55 O -
) O +
to O +
give O +
the O +
compounds O +
4 O -
( O -
8.3 O +
mg O -
) O -
, O +
5 O -
( O -
8.5 O +
mg O -
) O -
, O +
and O +
6 O -
( O -
1.6 O +
mg O -
) O -
. O -

Compound O +
2 O -
( O -
prunetin O -
) O -
: O +
EI O -
- O -
MS O -
: O +
m O +
/z O -
( O -
rel O -
. O -

int. O -
) O -
=284 O +
( O -
M+ O +
, O +
100 O -
) O -
, O +
166 O +
( O -
35 O -
) O -
, O +
138 O +
( O -
22 O -
) O -
, O +
118 O +
( O -
15 O -
) O -
, O +
110 O +
( O -
10 O -
) O -
, O +
95 O +
( O -
13 O -
) O -
; O +
1 O +
H O -
- O -
NMR O +
( O -
400 O +
MHz O -
, O +
acetone O -
- O -
D6 O +
): O +
δ O -
( O -
ppm O -
) O -
=3.93 O +
( O -
3 O +
H O -
, O +
s O -
, O +
CH3 O +
O-7 O -
) O -
, O +
6.36 O +
( O -
1 O +
H O -
, O +
d O -
, O +
J O +
= O -
2.3 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.55 O +
( O -
1 O +
H O -
, O +
d O -
, O +
J O +
= O -
2.4 O +
Hz O -
, O +
H-8 O -
) O -
, O +
6.91 O +
( O -
2 O +
H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-3′,5′ O -
) O -
, O +
7.47 O +
( O -
2 O +
H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-2′,6′ O -
) O -
, O +
8.22 O +
( O -
1 O +
H O -
, O +
s O -
, O +
H-2 O -
) O -
, O +
13.4 O +
( O -
1 O +
H O -
, O +
s O -
, O +
OH-5 O -
) O -
. O -

2.4 O +
Antiplasmodial O +
bioassay O +
In O +
this O +
study O -
, O +
the O +
chloroquine O -
- O -
sensitive O +
strain O +
of O +
P. B-Species +
falciparum I-Species -
poW L-Species +
( O -
IC50 O +
= O -
0.015 O +
μM O -
) O +
and O +
the O +
chloroquine O -
- O -
resistant O +
clone O +
Dd2 U-Species +
( O -
IC50 O +
= O -
0.14 O +
μM O -
) O +
were O +
used O -
. O -

They O +
were O +
maintained O +
in O +
continuous O +
culture O +
in O +
human O +
red O +
blood O +
cells O +
( O -
A+ O +
) O +
diluted O +
to O +
5 O -
% O +
haematocrit O +
in O +
RPMI O +
1640 O +
medium O +
supplemented O +
with O +
25 O +
mM O +
Hepes O -
, O +
30 O +
mM O +
NaHCO3 O +
, O +
and O +
10 O -
% O +
human O +
A+ O -
serum O -
. O -

Crude O +
extracts O +
and O +
isolated O +
compounds O +
were O +
dissolved O +
in O +
DMSO O +
( O -
1 O +
mg O -
/ O -
50 O +
μl O -
) O +
and O +
diluted O +
in O +
RPMI O +
1640 O +
medium O +
( O -
Trager O +
and O +
Jensen O -
, O +
1976 O +
) O -
. O -

The O +
tests O +
were O +
performed O +
in O +
96-well O +
microtiter O +
plates O +
( O -
Desjardins O +
et O +
al. O -
, O +
1979 O +
) O +
which O +
contained O +
150 O +
μl O +
of O +
a O +
parasitized O +
red O +
blood O +
suspension O +
( O -
A+ O +
, O +
2.5 O -
% O +
haematocrit O -
, O +
0.5 O -
% O +
parasitaemia O -
) O -
. O -

The O +
samples O +
were O +
added O +
to O +
give O +
final O +
concentrations O +
between O +
1.56 O +
and O +
100 O +
μg O -
/ O -
ml O -
. O -

After O +
incubation O +
in O +
a O +
candle O +
jar O +
for O +
24 O +
h O -
, O +
0.5 O +
μCi O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
( O -
1 O +
mCi O -
/ O -
ml O -
, O +
ICN O -
) O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
for O +
another O +
18 O +
h. O +
Incorporation O +
of O +
[ O -
3 O +
H O -
] O -
hypoxanthine O +
was O +
measured O +
by O +
liquid O +
scintillation O +
after O +
harvesting O +
the O +
cells O +
on O +
glass O +
fibre O +
filters O +
with O +
the O +
cell O +
harvester O -
. O -

All O +
tests O +
were O +
performed O +
in O +
triplicate O -
. O -

The O +
percentage O +
of O +
growth O +
inhibition O +
was O +
calculated O +
as O +
follows O -
: O +
( O -
1− O -
[ O -
cpm O +
in O +
drug O +
treated O +
cultures O -
/ O -
cpm O +
in O +
untreated O +
cultures O -
] O -
) O -
× O -
100 O -
. O -

The O +
concentration O +
at O +
which O +
growth O +
was O +
inhibited O +
by O +
50 O -
% O +
( O -
IC50 O +
) O +
was O +
estimated O +
by O +
interpolation O -
. O -

Extracts O +
with O +
IC50 O -
values O +
above O +
50 O +
μg O -
/ O -
ml O +
were O +
considered O +
to O +
be O +
inactive O +
( O -
O'Neill O +
et O +
al. O -
, O +
1985 O +
) O -
. O -

3 O +
Results O +
The O +
isolated O +
compounds O +
1–6 O -
( O -
Fig. O +
1 O -
) O +
turned O +
out O +
to O +
be O +
isoflavones O -
. O -

Compound O +
1 O +
, O +
isolated O +
from O +
both O +
stems O +
and O +
leaves O +
was O +
identified O +
as O +
formononetin O +
by O +
comparison O +
with O +
an O +
authentic O +
sample O -
. O -

According O +
to O +
the O +
spectral O +
data O +
( O -
1 O +
H O -
- O -
NMR O -
, O +
EI O -
- O -
MS O -
) O -
, O +
compound O +
2 O -
proved O +
to O +
be O +
prunetin O -
. O -

To O +
the O +
best O +
of O +
our O +
knowledge O -
, O +
no O +
1 O +
H O -
- O -
NMR O +
values O +
for O +
prunetin O +
have O +
been O +
published O +
so O +
far O -
, O +
therefore O +
they O +
are O +
given O +
in O +
Section O +
2.3 O +
. O -

The O +
isoflavones O +
3 O +
, O +
4 O +
, O +
5 O +
, O +
and O +
6 O -
were O +
identified O +
as O +
biochanin O +
A O -
, O +
calycosin O -
, O +
genistein O -
, O +
and O +
pratensein O -
, O +
respectively O -
, O +
by O +
comparison O +
of O +
1 O +
H O -
- O -
NMR O +
and O +
EI O -
- O -
MS O +
with O +
published O +
data O +
( O -
Asres O +
et O +
al. O -
, O +
1985 O -
; O +
Kobayashi O +
et O +
al. O -
, O +
1985 O +
) O -
. O -

Prunetin O +
( O -
2 O -
) O +
, O +
calycosin O +
( O -
4 O -
) O +
, O +
and O +
pratensein O +
( O -
6 O -
) O -
were O +
detected O +
for O +
the O +
first O +
time O +
from O +
the O +
genus O +
Andira U-Species +
. O -

The O +
lipophilic O +
extracts O +
of O +
A. B-Species +
inermis L-Species -
exhibited O +
IC50 O -
values O +
from O +
56.0 O +
μg O -
/ O -
ml O +
( O -
leaves O -
) O +
to O +
108.7 O +
μg O -
/ O -
ml O +
( O -
stems O -
) O +
against O +
P. B-Species +
falciparum L-Species -
in O +
vitro O +
( O -
Table O +
1 O -
) O -
. O -

The O +
hydrophilic O +
extracts O +
proved O +
to O +
be O +
inactive O -
. O -

For O +
all O +
tested O +
substances O +
the O +
antiparasitic O +
activity O +
against O +
the O +
chloroquine O -
- O -
sensitive O +
strain B-Species +
poW L-Species +
was O +
higher O +
( O -
factor O +
two O -
) O +
than O +
against O +
the O +
chloroquine O -
- O -
resistant O +
clone B-Species +
Dd2 L-Species -
. O -

Calycosin O +
( O -
IC50 O -
4.2 O +
μg O -
/ O -
ml O +
for O +
poW O -
; O +
9.8 O +
μg O -
/ O -
ml O +
for O +
Dd2 O -
) O +
and O +
genistein O +
( O -
IC50 O -
2.0 O +
μg O -
/ O -
ml O +
for O +
poW O -
; O +
4.1 O +
μg O -
/ O -
ml O +
for O +
Dd2 O -
) O +
proved O +
to O +
be O +
most O +
active O -
. O -

The O +
other O +
four O +
compounds O +
were O +
considered O +
to O +
be O +
inactive O -
. O -

4 O +
Discussion O +
Although O +
the O +
lipophilic O +
extracts O +
of O +
A. B-Species +
inermis L-Species -
showed O +
only O +
moderate O +
antiplasmodial O +
activity O +
compared O +
to O +
those O +
known O +
for O +
other O +
plant O +
remedies O +
( O -
O'Neill O +
et O +
al. O -
, O +
1985 O -
; O +
Jenett O -
- O -
Siems O +
et O +
al. O -
, O +
1999 O +
) O +
they O +
afforded O +
two O +
active O +
isoflavones O -
. O -

This O +
is O +
the O +
first O +
report O +
on O +
antiplasmodial O +
activity O +
of O +
isoflavones O +
against O +
P. B-Species +
falciparum L-Species +
. O -

The O +
low O +
concentration O +
of O +
calycosin O +
and O +
genistein O +
( O -
< O -
0.01 O -
% O +
w O -
/ O -
w O -
) O +
may O +
be O +
the O +
explanation O +
for O +
the O +
low O +
antiplasmodial O +
activity O +
of O +
the O +
crude O +
extract O -
. O -

It O +
is O +
known O +
that O +
calycosin O +
also O +
proved O +
to O +
be O +
active O +
against O +
Giardia B-Species +
intestinalis L-Species +
, O +
a O +
potent O +
protozoan O +
agent O +
for O +
enteric O +
diseases O +
( O -
ElSohly O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

During O +
the O +
preparation O +
of O +
this O +
paper O +
a O +
patent O +
application O +
was O +
published O +
( O -
Khan O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
which O +
claimed O +
a O +
method O +
of O +
treating O +
giardiasis O +
and/or O +
malaria O +
comprising O +
the O +
use O +
of O +
isoflavones O -
, O +
but O +
mentioning O +
no O +
data O -
, O +
proving O +
their O +
antiplasmodial O +
activity O +
against O +
P. B-Species +
falciparum L-Species +
. O -

In O +
our O +
study O -
, O +
we O +
have O +
focused O +
on O +
the O +
investigation O +
of O +
the O +
lipophilic O +
extract O -
. O -

The O +
indigenous O +
population O -
, O +
e.g. O +
in O +
Brazil O +
( O -
Morton O -
, O +
1981 O +
) O -
, O +
prefer O +
to O +
boil O +
the O +
stem O +
bark O +
with O +
milk O -
. O -

This O +
procedure O +
covers O +
the O +
bitter O +
taste O +
and O +
probably O +
causes O +
the O +
extraction O +
of O +
lipophilic O +
constituents O -
. O -

Interestingly O -
, O +
hydrophilic O +
extracts O +
( O -
methanol O -
/ O -
water O +
8:2 O -
) O +
from O +
A. B-Species +
inermis L-Species -
did O +
not O +
show O +
antiplasmodial O +
activity O +
in O +
our O +
test O +
system O -
. O -

The O +
evaluation O +
of O +
extracts O +
obtained O +
with O +
water O +
or O +
milk O +
is O +
still O +
in O +
progress O +
and O +
might O +
be O +
interesting O +
with O +
regard O +
to O +
the O +
ethnobotanical O +
use O +
of O +
this O +
species O -
. O -

Acknowledgements O +
The O +
authors O +
are O +
indebted O +
to O +
C. O +
Guerra O -
, O +
for O +
his O +
support O +
in O +
collecting O +
the O +
plant O +
material O -
, O +
and O +
to O +
Professor O +
M.D. O +
Correa O +
A. O -
, O +
Herbarium O +
of O +
the O +
University O +
of O +
Panama O -
, O +
Republic O +
of O +
Panama O -
, O +
for O +
her O +
identification O +
of O +
the O +
species O -
. O -

We O +
thank O +
Drs O +
D.S. O +
Kim O +
and O +
B. O +
Kleuser O -
, O +
Institut O +
für O +
Pharmazie O -
, O +
Freie O +
Universität O +
Berlin O -
, O +
Germany O -
, O +
for O +
their O +
advice O +
concerning O +
determination O +
of O +
radioactivity O -
. O -

This O +
study O +
was O +
supported O +
by O +
a O +
grant O +
from O +
the O +
Deutsche O +
Pharmazeutische O +
Gesellschaft O +
to O +
K. O +
Jenett O -
- O -
Siems O +
and O +
by O +
Charité O +
Grant O +
Nr O -
. O -

98 O -
- O -
700 O -
. O -

CIFLORPAN O +
acknowledges O +
the O +
Fundation O +
Natura O +
and O +
the O +
Organization O +
of O +
American O +
States O +
( O -
OAS O -
) O +
for O +
financial O +
support O -
. O +

Yeast U-Species +
mitochondrial O +
dehydrogenases O +
are O +
associated O +
in O +
a O +
supramolecular O +
complex O -
. O -

Separation O +
of O +
yeast U-Species +
mitochondrial O +
complexes O +
by O +
colorless O +
native O +
polyacrylamide O +
gel O +
electrophoresis O +
led O +
to O +
the O +
identification O +
of O +
a O +
supramolecular O +
structure O +
exhibiting O +
NADH O -
- O -
dehydrogenase O +
activity O -
. O -

Components O +
of O +
this O +
complex O +
were O +
identified O +
by O +
N O -
- O -
terminal O +
Edman O +
degradation O +
and O +
matrix O -
- O -
assisted O +
laser O +
desorption O +
ionization O +
mass O +
spectrometry O -
. O -

The O +
complex O +
was O +
found O +
to O +
contain O +
the O +
five O +
known O +
intermembrane O +
space O -
- O -
facing O +
dehydrogenases O -
, O +
namely O +
two O +
external O +
NADH O -
- O -
dehydrogenases O +
Nde1p O +
and O +
Nde2p O -
, O +
glycerol-3-phosphate O +
dehydrogenase O +
Gut2p O -
, O +
D- O +
and O +
L O -
- O -
lactate O -
- O -
dehydrogenases O +
Dld1p O +
and O +
Cyb2p O -
, O +
the O +
matrix O -
- O -
facing O +
NADH O -
- O -
dehydrogenase O +
Ndi1p O -
, O +
two O +
probable O +
flavoproteins O +
YOR356Wp O +
and O +
YPR004Cp O -
, O +
four O +
tricarboxylic O +
acids O +
cycle O +
enzymes O +
( O -
malate O +
dehydrogenase O +
Mdh1p O -
, O +
citrate O +
synthase O +
Cit1p O -
, O +
succinate O +
dehydrogenase O +
Sdh1p O -
, O +
and O +
fumarate O +
hydratase O +
Fum1p O -
) O -
, O +
and O +
the O +
acetaldehyde O +
dehydrogenase O +
Ald4p O -
. O -

The O +
association O +
of O +
these O +
proteins O +
is O +
discussed O +
in O +
terms O +
of O +
NADH O -
- O -
channeling O -
. O -

Characterization O +
of O +
CAX4 O -
, O +
an O +
Arabidopsis U-Species +
H O -
( O -
+ O -
) O -
/ O -
cation O +
antiporter O -
. O -

Ion O +
compartmentalization O +
is O +
essential O +
for O +
plant O +
growth O +
and O +
development O -
. O -

The O +
Arabidopsis U-Species +
open O +
reading O +
frames O +
for O +
CAX1 O -
, O +
CAX2 O -
, O +
and O +
CAX3 O +
( O -
cation O +
exchangers O +
1 O -
, O +
2 O -
, O +
and O +
3 O -
) O +
were O +
previously O +
identified O +
as O +
transporters O +
that O +
may O +
modulate O +
ion O +
fluxes O +
across O +
the O +
vacuolar O +
membrane O -
. O -

To O +
understand O +
the O +
diversity O +
and O +
role O +
of O +
H O -
( O -
+ O -
) O -
/ O -
cation O +
transporters O +
in O +
controlling O +
plant O +
ion O +
levels O -
, O +
another O +
homolog O +
of O +
the O +
CAX O +
genes O -
, O +
CAX4 O -
, O +
was O +
cloned O +
from O +
an O +
Arabidopsis U-Species +
cDNA O +
library O -
. O -

CAX4 O +
is O +
53 O -
% O +
identical O +
to O +
CAX1 O +
at O +
the O +
amino O +
acid O +
level O -
, O +
42 O -
% O +
identical O +
to O +
CAX2 O -
, O +
and O +
54 O -
% O +
identical O +
to O +
CAX3 O -
. O -

CAX4 O +
transcripts O +
appeared O +
to O +
be O +
expressed O +
at O +
low O +
levels O +
in O +
all O +
tissues O +
and O +
levels O +
of O +
CAX4 O +
RNA O +
increased O +
after O +
Mn O -
( O -
2 O -
+ O -
) O -
, O +
Na O -
( O -
+ O -
) O -
, O +
and O +
Ni O -
( O -
2 O -
+ O -
) O +
treatment O -
. O -

An O +
N O -
- O -
terminal O +
CAX4-hemagglutinin O +
fusion O +
appeared O +
to O +
localize O +
to O +
both O +
yeast U-Species +
and O +
plant O +
vacuolar O +
membranes O -
. O -

When O +
expressed O +
in O +
yeast U-Species -
, O +
CAX4 O -
, O +
like O +
CAX3 O -
, O +
failed O +
to O +
suppress O +
the O +
Ca O -
( O -
2 O -
+ O -
) O +
sensitivity O +
of O +
yeast U-Species +
strains O +
deficient O +
in O +
vacuolar O +
Ca O -
( O -
2 O -
+ O -
) O +
transport O -
. O -

Several O +
modifications O +
to O +
CAX4 O +
allowed O +
the O +
protein O +
to O +
transport O +
Ca O -
( O -
2 O -
+ O -
) O -
. O -

Addition O +
of O +
amino O +
acids O +
to O +
the O +
N O +
terminus O +
of O +
CAX4 O +
and O +
CAX3 O +
caused O +
both O +
transporters O +
to O +
suppress O +
the O +
sensitivity O +
of O +
yeast U-Species +
strains O +
deficient O +
in O +
vacuolar O +
Ca O -
( O -
2 O -
+ O -
) O +
transport O -
. O -

These O +
findings O +
suggest O +
that O +
CAX O +
transporters O +
may O +
modulate O +
their O +
ion O +
transport O +
properties O +
through O +
alterations O +
at O +
the O +
N O +
terminus O -
. O -

A O +
new O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O -
-interacting O +
protein O -
, O +
Sab O +
( O -
SH3BP5 O -
) O -
, O +
associates O +
with O +
mitochondria O -
. O -

We O +
have O +
identified O +
a O +
novel O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O -
-interacting O +
protein O -
, O +
Sab O -
, O +
by O +
yeast U-Species +
two O -
- O -
hybrid O +
screening O -
. O -

Sab O +
binds O +
to O +
and O +
serves O +
as O +
a O +
substrate O +
for O +
JNK O +
in O +
vitro O -
, O +
and O +
was O +
previously O +
found O +
to O +
interact O +
with O +
the O +
Src O +
homology O +
3 O +
( O -
SH3 O -
) O +
domain O +
of O +
Bruton O -
's O +
tyrosine O +
kinase O +
( O -
Btk O -
) O -
. O -

Inspection O +
of O +
the O +
sequence O +
of O +
Sab O +
reveals O +
the O +
presence O +
of O +
two O +
putative O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
interaction O +
motifs O +
( O -
KIMs O -
) O +
similar O +
to O +
that O +
found O +
in O +
the O +
JNK O +
docking O +
domain O +
of O +
the O +
c O -
- O -
Jun O +
transcription O +
factor O -
, O +
and O +
four O +
potential O +
serine O -
- O -
proline O +
JNK O +
phosphorylation O +
sites O +
in O +
the O +
C O -
- O -
terminal O +
half O +
of O +
the O +
molecule O -
. O -

Using O +
deletion O +
and O +
site O -
- O -
directed O +
mutagenesis O -
, O +
we O +
demonstrate O +
that O +
the O +
most O +
N O -
- O -
terminal O +
KIM O +
in O +
Sab O +
is O +
essential O +
for O +
JNK O +
binding O -
, O +
and O +
that O -
, O +
as O +
with O +
c O -
- O -
Jun O -
, O +
physical O +
interaction O +
with O +
JNK O +
is O +
necessary O +
for O +
Sab O +
phosphorylation O -
. O -

Interestingly O -
, O +
confocal O +
immunocytochemistry O +
and O +
cell O +
fractionation O +
studies O +
indicate O +
that O +
Sab O +
is O +
associated O +
with O +
mitochondria O -
, O +
where O +
it O +
co O -
- O -
localizes O +
with O +
a O +
fraction O +
of O +
active O +
JNK O -
. O -

These O +
and O +
previously O +
reported O +
properties O +
of O +
Sab O +
suggest O +
a O +
possible O +
role O +
in O +
targeting O +
JNK O +
to O +
this O +
subcellular O +
compartment O +
and/or O +
mediating O +
cross O -
- O -
talk O +
between O +
the O +
Btk O +
and O +
JNK O +
signal O +
transduction O +
pathways O -
. O -

The O +
proteome O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
mitochondria O -
. O -

We O +
performed O +
a O +
comprehensive O +
approach O +
to O +
determine O +
the O +
proteome O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
mitochondria O -
. O -

The O +
proteins O +
of O +
highly O +
pure O +
yeast U-Species +
mitochondria O +
were O +
separated O +
by O +
several O +
independent O +
methods O +
and O +
analyzed O +
by O +
tandem O +
MS O -
. O -

From O +
> O -
20 O +
million O +
MS O +
spectra O -
, O +
750 O +
different O +
proteins O +
were O +
identified O -
, O +
indicating O +
an O +
involvement O +
of O +
mitochondria O +
in O +
numerous O +
cellular O +
processes O -
. O -

All O +
known O +
components O +
of O +
the O +
oxidative O +
phosphorylation O +
machinery O -
, O +
the O +
tricarboxylic O +
acid O +
cycle O -
, O +
and O +
the O +
stable O +
mitochondria O -
- O -
encoded O +
proteins O +
were O +
found O -
. O -

Based O +
on O +
the O +
mitochondrial O +
proteins O +
described O +
in O +
the O +
literature O +
so O +
far O -
, O +
we O +
calculate O +
that O +
the O +
identified O +
proteins O +
represent O +
approximately O +
90 O -
% O +
of O +
all O +
mitochondrial O +
proteins O -
. O -

The O +
function O +
of O +
a O +
quarter O +
of O +
the O +
identified O +
proteins O +
is O +
unknown O -
. O -

The O +
mitochondrial O +
proteome O +
will O +
provide O +
an O +
important O +
database O +
for O +
the O +
analysis O +
of O +
new O +
mitochondrial O +
and O +
mitochondria O -
- O -
associated O +
functions O +
and O +
the O +
characterization O +
of O +
mitochondrial O +
diseases O -
. O -

Expression O +
and O +
localization O +
of O +
ecto O -
- O -
nucleotide O +
pyrophosphatase O -
/ O -
phosphodiesterase O +
I-1 O +
( O -
E O -
- O -
NPP1 O -
/ O -
PC-1 O -
) O +
and O +
-3 O +
( O -
E O -
- O -
NPP3 O -
/ O -
CD203c O -
/ O -
PD O -
- O -
Ibeta O -
/ O -
B10 O -
/ O -
gp130 O -
( O -
RB13 O -
- O -
6 O -
) O -
) O +
in O +
inflammatory O +
and O +
neoplastic O +
bile O +
duct O +
diseases O -
. O -

Ecto O -
- O -
nucleotide O +
pyrophosphatase O -
/ O -
phosphodiesterase O -
- O -
I O +
enzyme O +
( O -
E O -
- O -
NPP O -
) O +
consists O +
of O +
three O +
closely O +
related O +
molecules O -
: O +
E O -
- O -
NPP1 O -
, O +
E O -
- O -
NPP2 O +
and O +
E O -
- O -
NPP3 O -
. O -

We O +
investigated O +
the O +
expression O +
and O +
localization O +
of O +
E O -
- O -
NPP1 O +
and O +
-3 O +
in O +
human U-Species +
inflammatory O +
and O +
neoplastic O +
bile O +
duct O +
diseases O -
. O -

Immunohistochemically O +
E O -
- O -
NPP1 O +
was O +
located O +
on O +
the O +
apical O +
cytoplasmic O +
side O +
of O +
cancer O +
cells O -
, O +
whereas O +
E O -
- O -
NPP3 O +
was O +
located O +
in O +
the O +
apical O +
plasma O +
membrane O -
. O -

Western O +
blot O +
analysis O +
revealed O +
that O +
the O +
expression O +
of O +
E O -
- O -
NPP3 O -
, O +
but O +
not O +
E O -
- O -
NPP1 O -
, O +
was O +
higher O +
in O +
tumor O +
tissues O +
than O +
in O +
surrounding O +
tissues O +
and O +
the O +
specific O +
form O +
of O +
the O +
E O -
- O -
NPP3 O +
protein O +
was O +
readily O +
detected O +
in O +
the O +
sera O +
of O +
bile O +
duct O +
carcinoma O +
( O -
BDC O -
) O +
patients O -
. O -

Furthermore O -
, O +
it O +
was O +
confirmed O +
that O +
E O -
- O -
NPP3 O +
was O +
associated O +
with O +
migration O +
ability O +
by O +
using O +
of O +
NIH3T3 O +
cells O +
that O +
stably O +
transfected O +
with O +
E O -
- O -
NPP3 O +
cDNA O -
. O -

These O +
results O +
suggest O +
that O +
E O -
- O -
NPP3 O +
is O +
involved O +
in O +
the O +
infiltration O +
of O +
neoplastic O +
BDC O +
and O +
is O +
possible O +
to O +
be O +
a O +
tumor O +
marker O -
. O -

NFAM1 O -
, O +
an O +
immunoreceptor O +
tyrosine O -
- O -
based O +
activation O +
motif O -
- O -
bearing O +
molecule O +
that O +
regulates O +
B O +
cell O +
development O +
and O +
signaling O -
. O -

A O +
functional O +
cDNA O +
cloning O +
system O +
was O +
developed O +
by O +
using O +
a O +
retrovirus O +
library O +
encoding O +
CD8-chimeric O +
proteins O +
and O +
a O +
nuclear O +
factor O +
of O +
activated O +
T O +
cells O +
( O -
NFAT O -
) O -
-GFP O +
reporter O +
cell O +
line O +
to O +
identify O +
molecules O +
inducing O +
NFAT O +
activation O -
. O -

By O +
using O +
this O +
strategy O -
, O +
NFAT O +
activating O +
molecule O +
1 O +
( O -
NFAM1 O -
) O +
was O +
cloned O +
as O +
an O +
immunoreceptor O +
tyrosine O -
- O -
based O +
activation O +
motif O +
( O -
ITAM O -
) O -
-bearing O +
cell O +
surface O +
molecule O +
belonging O +
to O +
the O +
Ig O +
superfamily O +
and O +
is O +
predominantly O +
expressed O +
in O +
spleen O +
B O +
and O +
T O +
cells O -
. O -

NFAM1 O +
crosslinking O +
induced O +
ITAM O +
phosphorylation O -
, O +
ZAP-70 O -
/ O -
Syk O +
recruitment O -
, O +
NFAT O +
activation O -
, O +
and O +
cytokine O +
production O -
. O -

In O +
vivo O +
overexpression O +
of O +
NFAM1 O +
in O +
bone O +
marrow O +
chimeras O +
and O +
transgenic O +
mice U-Species +
induced O +
severe O +
impairment O +
of O +
early O +
B O +
cell O +
development O +
in O +
an O +
ITAM O -
- O -
dependent O +
manner O -
. O -

In O +
NFAM1-expressing O +
B O +
cells O -
, O +
B O +
cell O +
antigen O +
receptor O +
stimulation O +
induced O +
NFAM1 O +
translocation O +
to O +
lipid O +
raft O -
, O +
and O +
NFAM1 O +
co O -
- O -
crosslinking O +
augmented O +
B O +
cell O +
antigen O +
receptor O +
signaling O -
. O -

The O +
results O +
suggest O +
that O +
NFAM1 O +
modulates O +
B O +
cell O +
signaling O +
through O +
its O +
ITAM O -
, O +
which O +
regulates O +
B O +
cell O +
development O -
. O -

Vasohibin O +
as O +
an O +
endothelium O -
- O -
derived O +
negative O +
feedback O +
regulator O +
of O +
angiogenesis O -
. O -

Negative O +
feedback O +
is O +
a O +
crucial O +
physiological O +
regulatory O +
mechanism O -
, O +
but O +
no O +
such O +
regulator O +
of O +
angiogenesis O +
has O +
been O +
established O -
. O -

Here O +
we O +
report O +
a O +
novel O +
angiogenesis O +
inhibitor O +
that O +
is O +
induced O +
in O +
endothelial O +
cells O +
( O -
ECs O -
) O +
by O +
angiogenic O +
factors O +
and O +
inhibits O +
angiogenesis O +
in O +
an O +
autocrine O +
manner O -
. O -

We O +
have O +
performed O +
cDNA O +
microarray O +
analysis O +
to O +
survey O +
VEGF O -
- O -
inducible O +
genes O +
in O +
human U-Species +
ECs O -
. O -

We O +
characterized O +
one O +
such O +
gene O -
, O +
KIAA1036 O -
, O +
whose O +
function O +
had O +
been O +
uncharacterized O -
. O -

The O +
recombinant O +
protein O +
inhibited O +
migration O -
, O +
proliferation O -
, O +
and O +
network O +
formation O +
by O +
ECs O +
as O +
well O +
as O +
angiogenesis O +
in O +
vivo O -
. O -

This O +
inhibitory O +
effect O +
was O +
selective O +
to O +
ECs O -
, O +
as O +
the O +
protein O +
did O +
not O +
affect O +
the O +
migration O +
of O +
smooth O +
muscle O +
cells O +
or O +
fibroblasts O -
. O -

Specific O +
elimination O +
of O +
the O +
expression O +
of O +
KIAA1036 O +
in O +
ECs O +
restored O +
their O +
responsiveness O +
to O +
a O +
higher O +
concentration O +
of O +
VEGF O -
. O -

The O +
expression O +
of O +
KIAA1036 O +
was O +
selective O +
to O +
ECs O -
, O +
and O +
hypoxia O +
or O +
TNF O -
- O -
alpha O +
abrogated O +
its O +
inducible O +
expression O -
. O -

As O +
this O +
molecule O +
is O +
preferentially O +
expressed O +
in O +
ECs O -
, O +
we O +
designated O +
it O +
" O -
vasohibin O -
. O -
" O -

Transfection O +
of O +
Lewis O +
lung O +
carcinoma O +
cells O +
with O +
the O +
vasohibin O +
gene O +
did O +
not O +
affect O +
the O +
proliferation O +
of O +
cancer O +
cells O +
in O +
vitro O -
, O +
but O +
did O +
inhibit O +
tumor O +
growth O +
and O +
tumor O +
angiogenesis O +
in O +
vivo O -
. O -

We O +
propose O +
vasohibin O +
to O +
be O +
an O +
endothelium O -
- O -
derived O +
negative O +
feedback O +
regulator O +
of O +
angiogenesis O -
. O -

Yeast U-Species +
homolog O +
of O +
a O +
cancer O -
- O -
testis O +
antigen O +
defines O +
a O +
new O +
transcription O +
complex O -
. O -

We O +
have O +
isolated O +
a O +
new O +
yeast U-Species +
gene O +
( O -
PCC1 O -
) O +
that O +
codes O +
for O +
a O +
factor O +
homologous O +
to O +
human U-Species +
cancer O -
- O -
testis O +
antigens O -
. O -

We O +
provide O +
evidence O +
that O +
Pcc1p O +
is O +
a O +
new O +
transcription O +
factor O +
and O +
that O +
its O +
mutation O +
affects O +
expression O +
of O +
several O +
genes O -
, O +
some O +
of O +
which O +
are O +
involved O +
in O +
cell O +
cycle O +
progression O +
and O +
polarized O +
growth O -
. O -

Mutation O +
of O +
Pcc1p O +
also O +
affects O +
the O +
expression O +
of O +
GAL O +
genes O +
by O +
impairing O +
the O +
recruitment O +
of O +
the O +
SAGA O +
and O +
Mediator O +
co O -
- O -
activators O -
. O -

We O +
characterize O +
a O +
new O +
complex O +
that O +
contains O +
Pcc1p O -
, O +
a O +
kinase O -
, O +
Bud32p O -
, O +
a O +
putative O +
endopeptidase O -
, O +
Kae1p O +
and O +
two O +
additional O +
proteins O +
encoded O +
by O +
ORFs O +
YJL184w O +
and O +
YMLO36w O -
. O -

Genetic O +
and O +
physical O +
interactions O +
among O +
these O +
proteins O +
strongly O +
suggest O +
that O +
this O +
complex O +
is O +
a O +
functional O +
unit O -
. O -

Chromatin O +
immunoprecipitation O +
experiments O +
and O +
multiple O +
genetic O +
interactions O +
of O +
pcc1 O +
mutants O +
with O +
mutants O +
of O +
the O +
transcription O +
apparatus O +
and O +
chromatin O +
modifying O +
enzymes O +
underscore O +
the O +
direct O +
role O +
of O +
the O +
complex O +
in O +
transcription O -
. O -

Functional O +
complementation O +
experiments O +
indicate O +
that O +
the O +
transcriptional O +
function O +
of O +
this O +
set O +
of O +
genes O +
is O +
conserved O +
throughout O +
evolution O -
. O -

Endoplasmic O +
reticulum O +
stress O -
- O -
activated O +
C O -
/ O -
EBP O +
homologous O +
protein O +
enhances O +
nuclear O +
factor O -
- O -
kappaB O +
signals O +
via O +
repression O +
of O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O -
. O -

Endoplasmic O +
reticulum O +
( O -
ER O -
) O +
stress O +
is O +
a O +
causative O +
factor O +
of O +
inflammatory O +
bowel O +
diseases O -
. O -

ER O +
stress O +
mediators O -
, O +
including O +
CCAAT O +
enhancer O -
- O -
binding O +
protein O +
( O -
C O -
/ O -
EBP O -
) O +
homologous O +
protein O +
( O -
CHOP O -
) O -
, O +
are O +
elevated O +
in O +
intestinal O +
epithelia O +
from O +
patients O +
with O +
inflammatory O +
bowel O +
diseases O -
. O -

The O +
present O +
study O +
arose O +
from O +
the O +
question O +
of O +
how O +
chemical O +
ER O +
stress O +
and O +
CHOP O +
protein O +
were O +
associated O +
with O +
nuclear O +
factor O -
- O -
κB O +
( O -
NF O -
- O -
κB O -
) O -
-mediated O +
epithelial O +
inflammatory O +
response O -
. O -

In O +
a O +
human U-Species +
intestinal O +
epithelial O +
cell O +
culture O +
model O -
, O +
chemical O +
ER O +
stresses O +
induced O +
proinflammatory O +
cytokine O +
interleukin-8 O +
( O -
IL-8 O -
) O +
expression O +
and O +
the O +
nuclear O +
translocation O +
of O +
CHOP O +
protein O -
. O -

CHOP O +
was O +
positively O +
involved O +
in O +
ER O -
- O -
activated O +
IL-8 O +
production O +
and O +
was O +
negatively O +
associated O +
with O +
expression O +
of O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
γ O +
( O -
PPARγ O -
) O -
. O -

ER O +
stress O -
- O -
induced O +
IL-8 O +
production O +
was O +
enhanced O +
by O +
NF O -
- O -
κB O +
activation O +
that O +
was O +
negatively O +
regulated O +
by O +
PPARγ O -
. O -

Mechanistically O -
, O +
ER O +
stress O -
- O -
induced O +
CHOP O +
suppressed O +
PPARγ O +
transcription O +
by O +
sequestering O +
C O -
/ O -
EBPβ O +
and O +
limiting O +
availability O +
of O +
C O -
/ O -
EBPβ O +
binding O +
to O +
the O +
PPARγ O +
promoter O -
. O -

Due O +
to O +
the O +
CHOP O -
- O -
mediated O +
regulation O +
of O +
PPARγ O +
action O -
, O +
ER O +
stress O +
can O +
enhance O +
proinflammatory O +
NF O -
- O -
κB O +
activation O +
and O +
maintain O +
an O +
increased O +
level O +
of O +
IL-8 O +
production O +
in O +
human U-Species +
intestinal O +
epithelial O +
cells O -
. O -

In O +
contrast O -
, O +
PPARγ O +
was O +
a O +
counteracting O +
regulator O +
of O +
gut O +
inflammatory O +
response O +
through O +
attenuation O +
of O +
NF O -
- O -
κB O +
activation O -
. O -

The O +
collective O +
results O +
support O +
the O +
view O +
that O +
balances O +
between O +
CHOP O +
and O +
PPARγ O +
are O +
crucial O +
for O +
epithelial O +
homeostasis O -
, O +
and O +
disruption O +
of O +
these O +
balances O +
in O +
mucosal O +
ER O +
stress O +
can O +
etiologically O +
affect O +
the O +
progress O +
of O +
human U-Species +
inflammatory O +
bowel O +
diseases O -
. O -

Differential O +
extraction O +
and O +
protein O +
sequencing O +
reveals O +
major O +
differences O +
in O +
patterns O +
of O +
primary O +
cell O +
wall O +
proteins O +
from O +
plants O -
. O -

The O +
proteins O +
of O +
the O +
primary O +
cell O +
walls O +
of O +
suspension O +
cultured O +
cells O +
of O +
five O +
plant O +
species O -
, O +
Arabidopsis U-Species -
, O +
carrot U-Species -
, O +
French B-Species +
bean L-Species -
, O +
tomato U-Species -
, O +
and O +
tobacco U-Species -
, O +
have O +
been O +
compared O -
. O -

The O +
approach O +
that O +
has O +
been O +
adopted O +
is O +
differential O +
extraction O +
followed O +
by O +
SDS O -
- O -
polyacrylamide O +
gel O +
electrophoresis O +
( O -
PAGE O -
) O -
, O +
rather O +
than O +
two O -
- O -
dimensional O +
gel O +
analysis O -
, O +
to O +
facilitate O +
protein O +
sequencing O -
. O -

Whole O +
cells O +
were O +
washed O +
sequentially O +
with O +
the O +
following O +
aqueous O +
solutions O -
, O +
CaCl2 O -
, O +
CDTA O +
( O -
cyclohexane O +
diaminotetraacetic O +
acid O -
, O +
DTT O +
( O -
dithiothreitol O -
) O -
, O +
NaCl O -
, O +
and O +
borate O -
. O -

SDS O -
- O -
PAGE O +
analysis O +
showed O +
consistent O +
differences O +
between O +
species O -
. O -

From O +
the O +
233 O +
proteins O +
that O +
were O +
selected O +
for O +
sequencing O -
, O +
63 O -
% O +
gave O +
N O -
- O -
terminal O +
data O -
. O -

This O +
analysis O +
shows O +
that O +
( O -
i O -
) O +
patterns O +
of O +
proteins O +
revealed O +
by O +
SDS O -
- O -
PAGE O +
are O +
strikingly O +
different O +
for O +
all O +
five O +
species O -
, O +
( O -
ii O -
) O +
a O +
large O +
number O +
of O +
these O +
proteins O +
can O -
not O +
be O +
identified O +
by O +
data O +
base O +
searches O +
indicating O +
that O +
a O +
significant O +
proportion O +
of O +
wall O +
proteins O +
have O +
not O +
been O +
previously O +
described O -
, O +
( O -
iii O -
) O +
the O +
major O +
proteins O +
that O +
can O +
be O +
identified O +
belong O +
to O +
very O +
different O +
classes O +
of O +
proteins O -
, O +
( O -
iv O -
) O +
the O +
majority O +
of O +
proteins O +
found O +
in O +
the O +
extracellular O +
growth O +
media O +
are O +
absent O +
from O +
their O +
respective O +
cell O +
wall O +
extracts O -
, O +
and O +
( O -
v O -
) O +
the O +
results O +
of O +
the O +
extraction O +
process O +
are O +
indicative O +
of O +
higher O +
order O +
structure O -
. O -

It O +
appears O +
that O +
aspects O +
of O +
speciation O +
reside O +
in O +
the O +
complement O +
of O +
extracellular O +
wall O +
proteins O -
. O -

The O +
data O +
represent O +
a O +
protein O +
resource O +
for O +
cell O +
wall O +
studies O +
complementary O +
to O +
EST O +
( O -
expressed O +
sequence O +
tag O -
) O +
and O +
DNA O +
sequencing O +
strategies O -
. O -

We O +
report O +
here O +
on O +
a O +
patient U-Species +
who O +
was O +
treated O +
for O +
an O +
atypical O +
brain O +
meningioma O +
with O +
multiple O +
surgeries O +
and O +
multiple O +
sessions O +
of O +
stereotactic O +
radiosurgery O +
with O +
good O +
control O +
of O +
his O +
brain O +
disease O -
. O -

Thirteen O +
years O +
after O +
diagnosis O -
, O +
he O +
developed O +
bilateral O +
large O +
sacroiliac O +
and O +
abdominal O +
metastases O -
. O -

Extracranial O +
metastases O +
from O +
brain O +
meningiomas O +
is O +
a O +
rare O -
, O +
but O +
well O -
- O -
documented O +
entity O -
. O -

Metastases O +
occur O +
mostly O +
in O +
the O +
lungs O -
, O +
pleura O +
and O +
liver O -
, O +
but O +
may O +
also O +
affect O +
lymph O +
nodes O +
and O +
bones O -
. O -

Extraneural O +
metastases O +
from O +
cranial O +
meningioma O -
: O +
a O +
case O +
report O -
. O -

Here O +
we O +
expand O +
the O +
role O +
of O +
GRN O +
in O +
FTLD O -
- O -
U O +
and O +
demonstrate O +
that O +
a O +
common O +
genetic O +
variant O +
( O -
rs5848 O -
) O -
, O +
located O +
in O +
the O +
3'-untranslated O +
region O +
( O -
UTR O -
) O +
of O +
GRN O +
in O +
a O +
binding O -
- O -
site O +
for O +
miR-659 O -
, O +
is O +
a O +
major O +
susceptibility O +
factor O +
for O +
FTLD O -
- O -
U. O -

Loss O -
- O -
of O -
- O -
function O +
mutations O +
in O +
progranulin O +
( O -
GRN O -
) O +
cause O +
ubiquitin- O +
and O +
TAR O +
DNA O -
- O -
binding O +
protein O +
43 O +
( O -
TDP-43 O -
) O -
-positive O +
frontotemporal O +
dementia O +
( O -
FTLD O -
- O -
U O -
) O -
, O +
a O +
progressive O +
neurodegenerative O +
disease O +
affecting O +
approximately O +
10 O -
% O +
of O +
early O -
- O -
onset O +
dementia O +
patients U-Species -
. O -

Common O +
variation O +
in O +
the O +
miR-659 O +
binding O -
- O -
site O +
of O +
GRN O +
is O +
a O +
major O +
risk O +
factor O +
for O +
TDP43-positive O +
frontotemporal O +
dementia O -
. O -

In O +
support O +
of O +
these O +
findings O -
, O +
the O +
neuropathology O +
of O +
homozygous O +
rs5848 O +
T O -
- O -
allele O +
carriers O +
frequently O +
resembled O +
the O +
pathological O +
FTLD O -
- O -
U O +
subtype O +
of O +
GRN O +
mutation O +
carriers O -
. O -

A O +
significant O +
reduction O +
in O +
GRN O +
protein O +
was O +
observed O +
in O +
homozygous O +
T O -
- O -
allele O +
carriers O +
in O +
vivo O -
, O +
through O +
biochemical O +
and O +
immunohistochemical O +
methods O -
, O +
mimicking O +
the O +
effect O +
of O +
heterozygous O +
loss O -
- O -
of O -
- O -
function O +
GRN O +
mutations O -
. O -

We O +
further O +
demonstrate O +
that O +
miR-659 O +
can O +
regulate O +
GRN O +
expression O +
in O +
vitro O -
, O +
with O +
miR-659 O +
binding O +
more O +
efficiently O +
to O +
the O +
high O +
risk O +
T O -
- O -
allele O +
of O +
rs5848 O +
resulting O +
in O +
augmented O +
translational O +
inhibition O +
of O +
GRN O -
. O -

In O +
a O +
series O +
of O +
pathologically O +
confirmed O +
FTLD O -
- O -
U O +
patients U-Species +
without O +
GRN O +
mutations O -
, O +
we O +
show O +
that O +
carriers O +
homozygous O +
for O +
the O +
T O -
- O -
allele O +
of O +
rs5848 O +
have O +
a O +
3.2-fold O +
increased O +
risk O +
to O +
develop O +
FTLD O -
- O -
U O +
compared O +
with O +
homozygous O +
C O -
- O -
allele O +
carriers O +
( O -
95 O -
% O +
CI O -
: O +
1.50 O -
- O -
6.73 O -
) O -
. O -

Translational O +
regulation O +
by O +
miRNAs O +
may O +
represent O +
a O +
common O +
mechanism O +
underlying O +
complex O +
neurodegenerative O +
disorders O -
. O -

We O +
suggest O +
that O +
the O +
expression O +
of O +
GRN O +
is O +
regulated O +
by O +
miRNAs O +
and O +
that O +
common O +
genetic O +
variability O +
in O +
a O +
miRNA O +
binding O -
- O -
site O +
can O +
significantly O +
increase O +
the O +
risk O +
for O +
FTLD O -
- O -
U. O -

Here O -
, O +
we O +
discuss O +
recent O +
data O +
that O +
support O +
a O +
view O +
that O +
endolysosomal O +
positioning O +
of O +
RNA O +
might O +
facilitate O +
intercellular O +
transmission O +
of O +
RNA O +
and O +
host O +
defence O +
against O +
viruses O +
and O +
retrotransposons O -
. O -

Positioning O +
of O +
RNA O +
regulatory O +
mechanisms O +
on O +
endolysosomal O +
membranes O +
might O +
permit O +
rapid O +
and O +
localized O +
control O +
of O +
microRNA O +
( O -
miRNA O -
) O +
gene O +
regulatory O +
programs O +
and O +
mRNA O +
translation O +
in O +
response O +
to O +
environmental O +
signals O -
, O +
such O +
as O +
activated O +
plasma O +
membrane O +
receptors O +
transported O +
on O +
endosomes O -
. O -

Finally O -
, O +
we O +
suggest O +
that O +
the O +
pathology O +
of O +
several O +
conditions O -
, O +
including O +
Huntington O -
's O +
disease O -
, O +
might O +
be O +
a O +
consequence O +
of O +
the O +
disruption O +
of O +
the O +
control O +
of O +
RNA O +
via O +
endolysosomal O +
membranes O -
. O -

Control O +
of O +
RNA O +
silencing O +
and O +
localization O +
by O +
endolysosomes O -
. O -

Recent O +
advances O +
in O +
the O +
cell O +
biology O +
of O +
RNA O +
silencing O +
have O +
unraveled O +
an O +
intriguing O +
association O +
of O +
post O -
- O -
transcriptionally O +
regulated O +
RNA O +
with O +
endolysosomal O +
membranes O +
in O +
several O +
circumstances O +
of O +
mRNA O +
localization O -
, O +
microRNA O +
activity O +
and O +
viral O +
RNA O +
transport O +
and O +
packaging O -
. O -

Endolysosomal O +
membranes O +
are O +
a O +
nexus O +
of O +
communication O +
and O +
transport O +
between O +
cells O +
and O +
their O +
exterior O +
environment O +
for O +
signaling O +
receptors O -
, O +
pathogens O +
and O +
nutrients O -
. O -

The O +
method O +
by O +
which O +
MSCs O +
could O +
be O +
applied O +
for O +
future O +
therapies O +
might O +
require O +
trans O -
- O -
disciplinary O +
approaches O +
for O +
personalized O +
treatments O -
. O -

Implantation O +
of O +
adult O +
human U-Species +
mesenchymal O +
stem O +
cells O +
( O -
MSCs O -
) O +
to O +
treat O +
neural O +
disorders O +
shows O +
promise O -
. O -

Depending O +
on O +
their O +
microenvironment O -
, O +
MSCs O +
could O +
potentially O +
be O +
used O +
for O +
the O +
repair O +
and/or O +
replacement O +
of O +
neurons O +
in O +
traumatic O +
brain O +
injury O +
or O +
the O +
treatment O +
of O +
Parkinson O -
's O +
disease O -
. O -

This O +
cross O -
- O -
disciplinary O +
review O +
incorporates O +
aspects O +
of O +
neuroscience O -
, O +
stem O +
cell O +
biology O -
, O +
cancer O +
biology O +
and O +
immunology O +
to O +
discuss O +
interactions O +
between O +
inflammatory O +
mediators O +
and O +
MSCs O -
. O -

We O +
first O +
discuss O +
the O +
role O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
in O +
neurological O +
development O -
. O -

Neurogenesis O -
: O +
role O +
for O +
microRNAs O +
and O +
mesenchymal O +
stem O +
cells O +
in O +
pathological O +
states O -
. O -

Exploring O +
the O +
predisposition O +
of O +
MSCs O +
to O +
oncogenesis O +
is O +
critical O +
for O +
translational O +
science O +
since O +
the O +
implementation O +
of O +
safeguarding O +
measures O +
prior O +
to O +
therapy O +
can O +
lead O +
to O +
the O +
successful O +
delivery O +
of O +
stem O +
cells O +
to O +
patients U-Species -
. O -

The O +
administration O +
of O +
effective O +
and O +
safe O +
MSC O +
therapy O +
must O +
acknowledge O +
immune O +
mediators O +
that O +
may O +
predispose O +
the O +
early O +
differentiating O +
MSCs O +
to O +
oncogenic O +
insults O -
. O -

Secondly O -
, O +
we O +
discuss O +
the O +
ability O +
of O +
MSCs O +
to O +
transdifferentiate O +
into O +
functional O +
neurons O -
, O +
which O +
are O +
regulated O +
by O +
miRNAs O -
, O +
and O +
the O +
implications O +
of O +
these O +
cells O +
for O +
the O +
therapy O +
of O +
neuropathological O +
states O -
. O -

Immune O +
mediators O +
could O +
be O +
central O +
to O +
MSC O +
responses O +
within O +
a O +
region O +
of O +
tissue O +
injury O +
and O +
are O +
also O +
discussed O +
in O +
detail O -
. O -

Thus O -
, O +
we O +
discuss O +
a O +
key O +
gene O -
, O +
RE-1 O +
silencing O +
transcription O +
factor O +
( O -
REST O -
) O -
, O +
based O +
on O +
its O +
dual O +
role O +
in O +
neurogenesis O +
and O +
cancer O +
development O -
. O -

Finally O -
, O +
a O +
phylogenetic O +
analysis O +
shows O +
that O +
ADCK3 O +
belongs O +
to O +
the O +
family O +
of O +
atypical O +
kinases O -
, O +
which O +
includes O +
phosphoinositide O +
and O +
choline O +
kinases O -
, O +
suggesting O +
that O +
ADCK3 O +
plays O +
an O +
indirect O +
regulatory O +
role O +
in O +
ubiquinone O +
biosynthesis O +
possibly O +
as O +
part O +
of O +
a O +
feedback O +
loop O +
that O +
regulates O +
ATP O +
production O -
. O -

ADCK3 O -
, O +
an O +
ancestral O +
kinase O -
, O +
is O +
mutated O +
in O +
a O +
form O +
of O +
recessive O +
ataxia O +
associated O +
with O +
coenzyme O +
Q10 O +
deficiency O -
. O -

Muscle O +
coenzyme O +
Q O -
( O -
10 O -
) O +
( O -
CoQ O -
( O -
10 O -
) O +
or O +
ubiquinone O -
) O +
deficiency O +
has O +
been O +
identified O +
in O +
more O +
than O +
20 O +
patients U-Species +
with O +
presumed O +
autosomal O -
- O -
recessive O +
ataxia O -
. O -

However O -
, O +
mutations O +
in O +
genes O +
required O +
for O +
CoQ O -
( O -
10 O -
) O +
biosynthetic O +
pathway O +
have O +
been O +
identified O +
only O +
in O +
patients U-Species +
with O +
infantile O -
- O -
onset O +
multisystemic O +
diseases O +
or O +
isolated O +
nephropathy O -
. O -

Our O +
SNP O -
- O -
based O +
genome O -
- O -
wide O +
scan O +
in O +
a O +
large O +
consanguineous O +
family O +
revealed O +
a O +
locus O +
for O +
autosomal O -
- O -
recessive O +
ataxia O +
at O +
chromosome O +
1q41 O -
. O -

The O +
causative O +
mutation O +
is O +
a O +
homozygous O +
splice O -
- O -
site O +
mutation O +
in O +
the O +
aarF O -
- O -
domain O -
- O -
containing O +
kinase O +
3 O +
gene O +
( O -
ADCK3 O -
) O -
. O -

Five O +
additional O +
mutations O +
in O +
ADCK3 O +
were O +
found O +
in O +
three O +
patients U-Species +
with O +
sporadic O +
ataxia O -
, O +
including O +
one O +
known O +
to O +
have O +
CoQ O -
( O -
10 O -
) O +
deficiency O +
in O +
muscle O -
. O -

All O +
of O +
the O +
patients U-Species +
have O +
childhood O -
- O -
onset O +
cerebellar O +
ataxia O +
with O +
slow O +
progression O -
, O +
and O +
three O +
of O +
six O +
have O +
mildly O +
elevated O +
lactate O +
levels O -
. O -

ADCK3 O +
is O +
a O +
mitochondrial O +
protein O +
homologous O +
to O +
the O +
yeast O +
COQ8 O +
and O +
the O +
bacterial O +
UbiB O +
proteins O -
, O +
which O +
are O +
required O +
for O +
CoQ O +
biosynthesis O -
. O -

Three O +
out O +
of O +
four O +
patients U-Species +
tested O +
showed O +
a O +
low O +
endogenous O +
pool O +
of O +
CoQ O -
( O -
10 O -
) O +
in O +
their O +
fibroblasts O +
or O +
lymphoblasts O -
, O +
and O +
two O +
out O +
of O +
three O +
patients U-Species +
showed O +
impaired O +
ubiquinone O +
synthesis O -
, O +
strongly O +
suggesting O +
that O +
ADCK3 O +
is O +
also O +
involved O +
in O +
CoQ O -
( O -
10 O -
) O +
biosynthesis O -
. O -

The O +
deleterious O +
nature O +
of O +
the O +
three O +
identified O +
missense O +
changes O +
was O +
confirmed O +
by O +
the O +
introduction O +
of O +
them O +
at O +
the O +
corresponding O +
positions O +
of O +
the O +
yeast O +
COQ8 O +
gene O -
. O -

Interpretation O +
and O +
applicability O +
of O +
microRNA O +
data O +
to O +
the O +
context O +
of O +
Alzheimer O -
's O +
and O +
age O -
- O -
related O +
diseases O -
. O -

Generated O +
by O +
the O +
ribonuclease O +
III O +
Dicer O -
, O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
predicted O +
to O +
regulate O +
up O +
to O +
90 O -
% O +
of O +
the O +
genes O +
in O +
humans U-Species -
, O +
suggesting O +
that O +
they O +
may O +
control O +
every O +
cellular O +
processes O +
in O +
all O +
cells O +
and O +
tissues O +
of O +
the O +
human U-Species +
body O -
! O -

Likely O +
to O +
play O +
a O +
central O +
role O +
in O +
health O +
and O +
disease O -
, O +
a O +
dysfunctional O +
miRNA O -
- O -
based O +
regulation O +
of O +
gene O +
expression O +
may O +
represent O +
the O +
main O +
etiologic O +
factor O +
underlying O +
age O -
- O -
related O +
diseases O +
affecting O +
major O +
organs O -
, O +
such O +
as O +
the O +
brain O -
. O -

Here O -
, O +
we O +
discuss O +
some O +
of O +
the O +
limitations O +
associated O +
to O +
the O +
interpretation O +
and O +
applicability O +
of O +
miRNA O +
data O -
, O +
based O +
on O +
our O +
recent O +
study O +
on O +
the O +
etiology O +
of O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O -

Using O +
transiently O +
transfected O +
murine U-Species +
neuronal O +
N2a O +
cells O +
in O +
culture O -
, O +
in O +
parallel O +
to O +
a O +
mouse U-Species +
model O +
of O +
AD O -
, O +
we O +
were O +
able O +
to O +
demonstrate O +
a O +
role O +
for O +
two O +
miRNAs O +
( O -
miR-298 O +
and O +
miR-328 O -
) O +
in O +
the O +
regulation O +
of O +
beta O -
- O -
amyloid O +
( O -
Abeta O -
) O +
precursor O +
protein O +
( O -
APP O -
) O -
-converting O +
enzyme O +
( O -
BACE O -
) O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
translation O -
, O +
thereby O +
providing O +
key O +
insights O +
into O +
the O +
molecular O +
basis O +
underlying O +
BACE O +
deregulation O +
in O +
AD O -
. O -

However O -
, O +
whether O +
miRNA O +
data O +
can O +
be O +
extrapolated O +
and O +
transposed O +
to O +
the O +
human U-Species +
context O +
of O +
age O -
- O -
related O +
diseases O -
, O +
such O +
as O +
AD O -
, O +
not O +
only O +
requires O +
caution O -
, O +
but O +
also O +
warrants O +
several O +
considerations O -
. O -

Levels O +
of O +
protein O +
expression O +
of O +
endothelial O +
NO O +
synthase O +
( O -
eNOS O -
) O -
, O +
caveolin-1 O -
, O +
and O +
calmodulin O +
were O +
assessed O +
in O +
carotid O +
arteries O +
using O +
Western O +
analysis O -
. O -

Plasma O +
NO O +
levels O +
were O +
doubled O +
by O +
daidzein O +
or O +
17beta O -
- O -
estradiol O -
. O -

NO O +
production O +
and O +
endothelium O -
- O -
dependent O +
contraction O +
in O +
response O +
to O +
the O +
NOS O +
inhibitor O +
NG O -
- O -
nitro O -
- O -
L O -
- O -
arginine O +
( O -
L O -
- O -
NNA O -
; O +
100 O +
microM O -
) O +
was O +
enhanced O +
by O +
50 O +
to O +
100 O -
% O +
in O +
carotid O +
arteries O +
from O +
rats U-Species +
treated O +
with O +
daidzein O +
or O +
17beta O -
- O -
estradiol O -
. O -

Acetylcholine O -
- O -
induced O +
relaxation O +
was O +
selectively O +
enhanced O +
in O +
carotid O +
arteries O +
from O +
rats U-Species +
treated O +
with O +
daidzein O -
. O -

The O +
use O +
of O +
estrogen O +
for O +
protection O +
against O +
vascular O +
dysfunction O +
is O +
limited O +
due O +
to O +
its O +
effects O +
on O +
the O +
reproductive O +
system O -
, O +
particularly O +
in O +
males O -
. O -

We O +
postulated O +
that O +
daidzein O -
, O +
an O +
isoflavone O +
with O +
estrogen O -
- O -
like O +
effects O +
on O +
the O +
systemic O +
vasculature O +
but O +
not O +
the O +
reproductive O +
system O -
, O +
might O +
enhance O +
nitric O +
oxide O +
( O -
NO O -
) O -
-mediated O +
cerebral O +
vasodilatation O -
. O -

Male O +
rats U-Species +
were O +
administered O +
vehicle O -
, O +
17beta O -
- O -
estradiol O +
( O -
0.1 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O -
, O +
or O +
daidzein O +
( O -
0.2 O +
mg O -
/ O -
kg O +
s.c O -
. O -
) O +
daily O +
for O +
7 O +
days O -
. O -

Basal O +
and O +
acetylcholine O -
- O -
stimulated O +
NO O +
release O +
was O +
assessed O +
in O +
vitro O +
via O +
carotid O +
arterial O +
rings O +
or O +
in O +
vivo O +
by O +
measuring O +
changes O +
in O +
basilar O +
artery O +
diameter O -
. O -

Similarly O -
, O +
constrictor O +
responses O +
of O +
the O +
basilar O +
artery O +
to O +
L O -
- O -
NNA O +
in O +
vivo O +
were O +
selectively O +
augmented O +
by O +
approximately O +
100 O -
% O +
by O +
17beta O -
- O -
estradiol O +
treatment O +
and O +
tended O +
to O +
be O +
approximately O +
50 O -
% O +
greater O +
in O +
daidzein O -
- O -
treated O +
rats U-Species -
. O -

Effect O +
of O +
short O -
- O -
term O +
phytoestrogen O +
treatment O +
in O +
male O +
rats U-Species +
on O +
nitric O +
oxide O -
- O -
mediated O +
responses O +
of O +
carotid O +
and O +
cerebral O +
arteries O -
: O +
comparison O +
with O +
17beta O -
- O -
estradiol O -
. O -

These O +
data O +
suggest O +
that O +
short O -
- O -
term O +
administration O +
of O +
daidzein O +
or O +
17beta O -
- O -
estradiol O +
modulates O +
cerebral O +
artery O +
reactivity O +
in O +
males O +
by O +
enhancing O +
synthesis O +
and O +
release O +
of O +
endothelium O -
- O -
derived O +
NO O -
. O +
Isoflavone O +
therapy O +
may O +
therefore O +
be O +
a O +
feasible O +
approach O +
to O +
protect O +
against O +
cerebrovascular O +
disease O +
and O +
stroke O -
. O -

Expression O +
of O +
caveolin-1 O +
was O +
decreased O -
, O +
and O +
calmodulin O +
was O +
increased O -
, O +
in O +
vessels O +
from O +
daidzein- O +
or O +
17beta O -
- O -
estradiol O -
- O -
treated O +
rats U-Species -
. O -

eNOS O +
expression O +
was O +
unaffected O +
by O +
the O +
treatments O -
. O -

However O -
, O +
we O +
report O +
the O +
experience O +
of O +
a O +
patient U-Species +
who O +
inadvertently O +
received O +
live O +
polio O +
vaccine O +
whilst O +
receiving O +
anti O -
- O -
TNF O +
therapy O -
. O -

International O +
guidelines O +
state O +
that O +
live O +
vaccines O +
are O +
contraindicated O +
in O +
patients U-Species +
on O +
anti O -
- O -
TNF O +
therapy O -
. O -

Live O +
polio O +
vaccine O +
exposure O +
while O +
receiving O +
anti O -
- O -
TNF O +
therapy O +
for O +
reactive O +
arthritis O -
. O -

Patients U-Species +
should O +
be O +
counseled O +
regarding O +
the O +
risks O +
of O +
live O +
vaccines O +
prior O +
to O +
treatment O +
with O +
anti O -
- O -
TNF O +
therapy O -
. O -

However O -
, O +
if O +
we O +
consider O +
adult O +
patients U-Species +
with O +
rheumatic O +
diseases O +
to O +
have O +
altered O +
immunocompetence O -
, O +
it O +
is O +
recommended O +
that O +
they O +
receive O +
the O +
usual O +
inactivated O +
vaccines O +
according O +
to O +
standard O +
schedules O -
, O +
and O +
live O +
vaccines O +
should O +
be O +
avoided O +
in O +
those O +
who O +
are O +
treated O +
with O +
more O +
potent O +
forms O +
of O +
immune O +
suppression O -
. O -

No O +
clear O +
guidelines O +
are O +
available O +
for O +
all O +
vaccines O +
in O +
patients U-Species +
with O +
specific O +
rheumatic O +
diseases O -
. O -

Patient U-Species +
did O +
not O +
suffer O +
from O +
any O +
infectious O +
sequel O +
as O +
a O +
result O -
. O -

Autosomal O -
- O -
recessive O +
cerebellar O +
ataxias O +
comprise O +
a O +
clinically O +
and O +
genetically O +
heterogeneous O +
group O +
of O +
neurodegenerative O +
disorders O -
. O -

In O +
contrast O +
to O +
their O +
dominant O +
counterparts O -
, O +
unraveling O +
the O +
molecular O +
background O +
of O +
these O +
ataxias O +
has O +
proven O +
to O +
be O +
more O +
complicated O +
and O +
the O +
currently O +
known O +
mutations O +
provide O +
incomplete O +
coverage O +
for O +
genotyping O +
of O +
patients U-Species -
. O -

By O +
combining O +
SNP O +
array O -
- O -
based O +
linkage O +
analysis O +
and O +
targeted O +
resequencing O +
of O +
relevant O +
sequences O +
in O +
the O +
linkage O +
interval O +
with O +
the O +
use O +
of O +
next O -
- O -
generation O +
sequencing O +
technology O -
, O +
we O +
identified O +
a O +
mutation O +
in O +
a O +
gene O +
and O +
have O +
shown O +
its O +
association O +
with O +
autosomal O -
- O -
recessive O +
cerebellar O +
ataxia O -
. O -

In O +
a O +
Dutch O +
consanguineous O +
family O +
with O +
three O +
affected O +
siblings O +
a O +
homozygous O +
12.5 O +
Mb O +
region O +
on O +
chromosome O +
3 O +
was O +
targeted O +
by O +
array O -
- O -
based O +
sequence O +
capture O -
. O -

Targeted O +
next O -
- O -
generation O +
sequencing O +
of O +
a O +
12.5 O +
Mb O +
homozygous O +
region O +
reveals O +
ANO10 O +
mutations O +
in O +
patients U-Species +
with O +
autosomal O -
- O -
recessive O +
cerebellar O +
ataxia O -
. O -

The O +
analysis O +
of O +
ANO10 O +
by O +
Sanger O +
sequencing O +
revealed O +
three O +
additional O +
mutations O -
: O +
a O +
homozygous O +
mutation O +
( O -
c.1150_1151del O +
[ O -
p O -
. O -
Leu384fs O -
] O -
) O +
in O +
a O +
Serbian O +
family O +
and O +
a O +
compound O -
- O -
heterozygous O +
splice O -
- O -
site O +
mutation O +
( O -
c.1476 O -
+ O -
1G O -
> O -
T O -
) O +
and O +
a O +
frameshift O +
mutation O +
( O -
c.1604del O +
[ O -
p O -
. O -
Leu535X O -
] O -
) O +
in O +
a O +
French O +
family O -
. O -

This O +
illustrates O +
the O +
power O +
of O +
using O +
initial O +
homozygosity O +
mapping O +
with O +
next O -
- O -
generation O +
sequencing O +
technology O +
to O +
identify O +
genes O +
involved O +
in O +
autosomal O -
- O -
recessive O +
diseases O -
. O -

Prioritization O +
of O +
all O +
detected O +
sequence O +
variants O +
led O +
to O +
four O +
candidate O +
genes O -
, O +
one O +
of O +
which O +
contained O +
a O +
variant O +
with O +
a O +
high O +
base O +
pair O +
conservation O +
score O +
( O -
phyloP O +
score O -
: O +
5.26 O -
) O -
. O -

This O +
variant O +
was O +
a O +
leucine O -
- O -
to O -
- O -
arginine O +
substitution O +
in O +
the O +
DUF O +
590 O +
domain O +
of O +
a O +
16 O -
K O +
transmembrane O +
protein O -
, O +
a O +
putative O +
calcium O -
- O -
activated O +
chloride O +
channel O +
encoded O +
by O +
anoctamin O +
10 O +
( O -
ANO10 O -
) O -
. O -

Moreover O -
, O +
identifying O +
a O +
putative O +
calcium O -
- O -
dependent O +
chloride O +
channel O +
involved O +
in O +
cerebellar O +
ataxia O +
adds O +
another O +
pathway O +
to O +
the O +
list O +
of O +
pathophysiological O +
mechanisms O +
that O +
may O +
cause O +
cerebellar O +
ataxia O -
. O -

These O +
findings O +
further O +
support O +
the O +
idea O +
that O +
iron- O +
and O +
aluminum O -
- O -
sulfates O +
induce O +
genotoxicity O +
via O +
a O +
ROS O -
- O -
mediated O +
up O -
- O -
regulation O +
of O +
specific O +
regulatory O +
elements O +
and O +
pathogenic O +
genes O +
that O +
redirect O +
brain O +
cell O +
fate O +
towards O +
progressive O +
dysfunction O +
and O +
apoptotic O +
cell O +
death O -
. O -

Notably O -
, O +
these O +
same O +
miRNAs O +
are O +
up O -
- O -
regulated O +
in O +
AD O +
brain O -
. O -

The O +
main O +
finding O +
was O +
that O +
these O +
ROS O -
- O -
generating O +
neurotoxic O +
metal O +
sulfates O +
also O +
up O -
- O -
regulate O +
a O +
specific O +
set O +
of O +
miRNAs O +
that O +
includes O +
miR-9 O -
, O +
miR-125b O +
and O +
miR-128 O -
. O -

In O +
this O +
study O +
we O +
have O +
extended O +
our O +
investigations O +
to O +
analyze O +
the O +
expression O +
of O +
micro O +
RNA O +
( O -
miRNA O -
) O +
populations O +
in O +
iron- O +
and O +
aluminum O -
- O -
sulfate O +
treated O +
human U-Species +
neural O +
cells O +
in O +
primary O +
culture O -
. O -

Notably O -
, O +
iron- O +
and O +
aluminum O -
- O -
sulfate O +
induce O +
genes O +
in O +
cultured O +
human U-Species +
brain O +
cells O +
that O +
exhibit O +
expression O +
patterns O +
similar O +
to O +
those O +
observed O +
to O +
be O +
up O -
- O -
regulated O +
in O +
moderate- O +
to O +
late O -
- O -
stage O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O -

Previous O +
studies O +
have O +
shown O +
that O +
following O +
ROS O +
induction O -
, O +
a O +
family O +
of O +
pathogenic O +
brain O +
genes O +
that O +
promote O +
inflammatory O +
signalling O -
, O +
cellular O +
apoptosis O +
and O +
brain O +
cell O +
death O +
is O +
significantly O +
over O -
- O -
expressed O -
. O -

Iron- O +
and O +
aluminum O -
- O -
sulfate O +
together O -
, O +
at O +
nanomolar O +
concentrations O -
, O +
trigger O +
the O +
production O +
of O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
in O +
cultures O +
of O +
human U-Species +
brain O +
cells O -
. O -

Induction O +
of O +
specific O +
micro O +
RNA O +
( O -
miRNA O -
) O +
species O +
by O +
ROS O -
- O -
generating O +
metal O +
sulfates O +
in O +
primary O +
human U-Species +
brain O +
cells O -
. O -

The O +
rapid O +
and O +
exciting O +
pace O +
of O +
advances O +
in O +
glioblastoma O +
genetics O +
has O +
prompted O +
this O +
up O -
- O -
to O -
- O -
date O +
review O -
. O -

The O +
likely O +
impact O +
on O +
care O +
delivery O +
in O +
the O +
clinic O +
may O +
only O +
be O +
a O +
few O +
years O +
away O -
. O -

Within O +
the O +
last O +
few O +
years O -
, O +
high O -
- O -
throughput O +
efforts O +
such O +
as O +
The O +
Cancer O +
Genome O +
Atlas O +
and O +
a O +
massive O +
sequencing O +
project O +
have O +
yielded O +
novel O +
insights O +
and O +
classifications O +
of O +
this O +
dreaded O +
cancer O -
. O -

It O +
has O +
been O +
hoped O +
that O +
dissection O +
of O +
the O +
genetics O +
of O +
this O +
cancer O +
would O +
lead O +
to O +
more O +
targeted O +
and O +
effective O +
treatments O -
, O +
and O +
new O +
advances O +
may O +
finally O +
be O +
bringing O +
this O +
closer O +
to O +
fruition O -
. O -

Glioblastoma O +
genetics O -
: O +
in O +
rapid O +
flux O -
. O -

Glioblastoma O +
is O +
the O +
most O +
common O +
and O +
most O +
lethal O +
primary O +
brain O +
tumor O -
. O -

While O +
small O +
progress O +
has O +
been O +
made O +
in O +
treating O +
this O +
cancer O +
in O +
recent O +
years O -
, O +
glioblastoma O +
remains O +
largely O +
resistant O +
to O +
all O +
existing O +
therapies O -
. O -

Novel O +
animal O +
models O +
for O +
studying O +
complex O +
brain O +
disorders O -
: O +
BAC O -
- O -
driven O +
miRNA O -
- O -
mediated O +
in O +
vivo O +
silencing O +
of O +
gene O +
expression O -
. O -

In O +
schizophrenia O -
, O +
glutamic O +
acid O +
decarboxylase O +
1 O +
( O -
GAD1 O -
) O +
disturbances O +
are O +
robust O -
, O +
consistently O +
observed O -
, O +
cell O -
- O -
type O +
specific O +
and O +
represent O +
a O +
core O +
feature O +
of O +
the O +
disease O -
. O -

In O +
addition O -
, O +
neuropeptide O +
Y O +
( O -
NPY O -
) O -
, O +
which O +
is O +
a O +
phenotypic O +
marker O +
of O +
a O +
sub O -
- O -
population O +
of O +
GAD1-containing O +
interneurons O -
, O +
has O +
shown O +
reduced O +
expression O +
in O +
the O +
prefrontal O +
cortex O +
in O +
subjects O +
with O +
schizophrenia O -
, O +
suggesting O +
that O +
dysfunction O +
of O +
the O +
NPY+ O +
cortical O +
interneuronal O +
sub O -
- O -
population O +
might O +
be O +
a O +
core O +
feature O +
of O +
this O +
devastating O +
disorder O -
. O -

However O -
, O +
modeling O +
gene O +
expression O +
disturbances O +
in O +
schizophrenia O +
in O +
a O +
cell O +
type O -
- O -
specific O +
manner O +
has O +
been O +
extremely O +
challenging O -
. O -

To O +
more O +
closely O +
mimic O +
these O +
molecular O +
and O +
cellular O +
human U-Species +
post O -
- O -
mortem O +
findings O -
, O +
we O +
generated O +
a O +
transgenic B-Species +
mouse L-Species +
in O +
which O +
we O +
downregulated O +
GAD1 O +
mRNA O +
expression O +
specifically O +
in O +
NPY+ O +
neurons O -
. O -

This O +
novel O -
, O +
cell O +
type O -
- O -
specific O +
in O +
vivo O +
system O +
for O +
reducing O +
gene O +
expression O +
uses O +
a O +
bacterial O +
artificial O +
chromosome O +
( O -
BAC O -
) O +
containing O +
the O +
NPY O +
promoter O -
- O -
enhancer O +
elements O -
, O +
the O +
reporter O +
molecule O +
( O -
eGFP O -
) O +
and O +
a O +
modified O +
intron O +
containing O +
a O +
synthetic O +
microRNA O +
( O -
miRNA O -
) O +
targeted O +
to O +
GAD1 O -
. O -

The O +
animals O +
of O +
isogenic O +
strains O +
are O +
generated O +
rapidly O -
, O +
providing O +
a O +
new O +
tool O +
for O +
better O +
understanding O +
the O +
molecular O +
disturbances O +
in O +
the O +
GABAergic O +
system O +
observed O +
in O +
complex O +
neuropsychiatric O +
disorders O +
such O +
as O +
schizophrenia O -
. O -

In O +
the O +
future O -
, O +
because O +
of O +
the O +
small O +
size O +
of O +
the O +
silencing O +
miRNAs O +
combined O +
with O +
our O +
BAC O +
strategy O -
, O +
this O +
method O +
may O +
be O +
modified O +
to O +
allow O +
generation O +
of O +
mice U-Species +
with O +
simultaneous O +
silencing O +
of O +
multiple O +
genes O +
in O +
the O +
same O +
cells O +
with O +
a O +
single O +
construct O -
, O +
and O +
production O +
of O +
splice O -
- O -
variant O -
- O -
specific O +
knockdown O +
animals O -
. O -

Biomarkers O +
associated O +
with O +
metastasis O +
of O +
lung O +
cancer O +
to O +
brain O +
predict O +
patient U-Species +
survival O -
. O -

This O +
research O +
involves O +
comprehensive O +
miRNA O +
expression O +
profiling O -
, O +
evaluation O +
of O +
normalisation O +
techniques O +
and O +
combination O +
of O +
miRNA O +
with O +
imaging O +
features O +
FDG O -
- O -
PET O -
/ O -
CT O +
and O +
CT O +
Scan O -
. O -

We O +
combine O +
validated O +
miRNA O +
expression O +
values O +
with O +
imaging O +
features O +
to O +
classify O +
NSCLC O +
brain O +
mets O +
from O +
non O -
- O -
brain O +
mets O +
and O +
identify O +
possible O +
biomarkers O +
of O +
brain O +
mets O -
. O -

Generally O -
, O +
one O +
miRNA O +
is O +
predicted O +
to O +
regulate O +
several O +
hundred O +
genes O -
, O +
and O +
as O +
a O +
result O -
, O +
miRNAs O +
could O +
serve O +
as O +
a O +
better O +
classifier O +
than O +
gene O +
expression O -
. O -

MicroRNAs O +
influence O +
cell O +
physiology O -
; O +
alteration O +
in O +
miRNA O +
regulation O +
can O +
be O +
implicated O +
in O +
carcinogenesis O +
and O +
disease O +
progression O -
. O -

The O +
biomarkers O +
were O +
validated O +
on O +
an O +
independent O +
data O +
set O +
to O +
predict O +
potential O +
brain O +
mets O -
. O -

Through O +
various O +
experimental O +
approaches O -
, O +
we O +
validated O +
computational O +
predictions O +
and O +
demonstrated O +
that O +
miR-298 O +
and O +
miR-328 O +
recognize O +
specific O +
binding O +
sites O +
in O +
the O +
3'-UTR O +
of O +
BACE1 O +
mRNA O +
and O +
exert O +
regulatory O +
effects O +
on O +
BACE1 O +
protein O +
expression O +
in O +
cultured O +
neuronal O +
cells O -
. O -

Here O +
we O +
also O +
observed O +
a O +
loss O +
of O +
correlation O +
between O +
BACE1 O +
mRNA O +
and O +
protein O +
levels O +
in O +
the O +
hippocampus O +
of O +
a O +
mouse U-Species +
model O +
of O +
AD O -
. O +
Consistent O +
with O +
an O +
impairment O +
of O +
miRNA O -
- O -
mediated O +
regulation O +
of O +
BACE1 O +
expression O -
, O +
these O +
findings O +
prompted O +
us O +
to O +
investigate O +
the O +
regulatory O +
role O +
of O +
the O +
BACE1 O +
3'-UTR O +
element O +
and O +
the O +
possible O +
involvement O +
of O +
specific O +
miRNAs O +
in O +
cultured O +
neuronal O +
( O -
N2a O -
) O +
and O +
fibroblastic O +
( O -
NIH O +
3T3 O -
) O +
cells O -
. O -

Our O +
results O +
may O +
provide O +
the O +
molecular O +
basis O +
underlying O +
BACE1 O +
deregulation O +
in O +
AD O +
and O +
offer O +
new O +
perspectives O +
on O +
the O +
etiology O +
of O +
this O +
neurological O +
disorder O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
key O +
regulatory O +
RNAs O +
known O +
to O +
repress O +
mRNA O +
translation O +
through O +
recognition O +
of O +
specific O +
binding O +
sites O +
located O +
mainly O +
in O +
their O +
3'-untranslated O +
region O +
( O -
UTR O -
) O -
. O -

MicroRNA-298 O +
and O +
microRNA-328 O +
regulate O +
expression O +
of O +
mouse U-Species +
beta O -
- O -
amyloid O +
precursor O +
protein O -
- O -
converting O +
enzyme O +
1 O -
. O -

Intriguingly O -
, O +
previous O +
post O -
- O -
mortem O +
analyses O +
showed O +
higher O +
beta O -
- O -
amyloid O +
precursor O +
protein O -
- O -
converting O +
enzyme O +
( O -
BACE O -
) O +
protein O -
, O +
but O +
not O +
mRNA O -
, O +
levels O +
in O +
the O +
brain O +
of O +
patients U-Species +
that O +
suffered O +
from O +
Alzheimer O +
disease O +
( O -
AD O -
) O -
. O -

Loss O +
of O +
specific O +
miRNA O +
control O +
of O +
gene O +
expression O +
is O +
thus O +
expected O +
to O +
underlie O +
serious O +
genetic O +
diseases O -
. O -

These O +
findings O +
reveal O +
a O +
significant O +
additional O +
mechanism O +
by O +
which O +
alpha O -
- O -
synuclein O +
is O +
regulated O +
and O +
point O +
toward O +
new O +
therapeutic O +
regimes O +
for O +
lowering O +
endogenous O +
alpha O -
- O -
synuclein O +
levels O +
in O +
patients U-Species +
with O +
familial O +
or O +
sporadic O +
Parkinson O +
disease O -
. O -

Overexpression O +
of O +
mir-7 O +
and O +
mir-153 O +
significantly O +
reduces O +
endogenous O +
alpha O -
- O -
synuclein O +
levels O -
, O +
whereas O +
inhibition O +
of O +
mir-7 O +
and O +
mir-153 O +
enhances O +
translation O +
of O +
a O +
luciferase O +
construct O +
bearing O +
the O +
alpha O -
- O -
synuclein O +
3'-untranslated O +
region O +
in O +
primary O +
neurons O -
. O -

They O +
are O +
expressed O +
predominantly O +
in O +
the O +
brain O +
with O +
a O +
pattern O +
that O +
mirrors O +
synuclein O +
expression O +
in O +
different O +
tissues O +
as O +
well O +
as O +
during O +
neuronal O +
development O -
, O +
indicating O +
that O +
they O +
play O +
a O +
tuning O +
role O +
in O +
the O +
amount O +
of O +
alpha O -
- O -
synuclein O +
produced O -
. O -

These O +
microRNAs O +
bind O +
specifically O +
to O +
the O +
3'-untranslated O +
region O +
of O +
alpha O -
- O -
synuclein O +
and O +
down O -
- O -
regulate O +
its O +
mRNA O +
and O +
protein O +
levels O -
, O +
with O +
their O +
effect O +
being O +
additive O -
. O -

Here O -
, O +
two O +
microRNAs O -
, O +
namely O +
mir-7 O +
and O +
mir-153 O -
, O +
have O +
been O +
identified O +
to O +
regulate O +
alpha O -
- O -
synuclein O +
levels O +
post O -
- O -
transcriptionally O -
. O -

Genetic O +
and O +
biochemical O +
studies O +
have O +
established O +
a O +
central O +
role O +
for O +
alpha O -
- O -
synuclein O +
accumulation O +
in O +
the O +
pathogenesis O +
of O +
Parkinson O +
disease O -
. O -

Post O -
- O -
transcriptional O +
regulation O +
of O +
alpha O -
- O -
synuclein O +
expression O +
by O +
mir-7 O +
and O +
mir-153 O -
. O -

Learning O -
, O +
retention O +
and O +
generalization O +
of O +
a O +
mirror O +
tracing O +
skill O +
in O +
Alzheimer O -
's O +
disease O -
. O -

The O +
present O +
study O +
examined O +
the O +
ability O +
of O +
12 O +
patients U-Species +
with O +
probable O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
and O +
12 O +
age- O +
and O +
education O -
- O -
matched O +
normal O +
control O +
( O -
NC O -
) O +
subjects O +
to O +
learn O +
and O +
retain O +
the O +
visuomotor O +
skills O +
necessary O +
to O +
efficiently O +
trace O +
a O +
pattern O +
( O -
e.g. O -
, O +
a O +
4- O +
or O +
6-pointed O +
star O -
) O +
seen O +
only O +
in O +
mirror O -
- O -
reversed O +
view O -
. O -

Those O +
AD O +
( O -
N=6 O -
) O +
and O +
NC O +
( O -
N=7 O -
) O +
subjects O +
who O +
were O +
able O +
to O +
initially O +
perform O +
the O +
basic O +
mirror O +
tracing O +
task O +
did O +
not O +
differ O +
significantly O +
in O +
initial O +
level O +
of O +
performance O -
, O +
learning O +
over O +
trials O -
, O +
retention O +
of O +
the O +
skill O +
over O +
a O +
30-min O +
delay O +
interval O -
, O +
and O +
generalization O +
of O +
the O +
skill O +
to O +
a O +
new O +
figure O +
or O +
to O +
the O +
opposite O +
direction O +
of O +
tracing O -
. O -

The O +
AD O +
patients U-Species +
who O +
were O +
unable O +
to O +
initially O +
perform O +
the O +
mirror O +
tracing O +
task O +
were O +
significantly O +
worse O +
than O +
those O +
who O +
could O +
perform O +
the O +
task O +
on O +
several O +
neuropsychological O +
measures O +
sensitive O +
to O +
deficits O +
in O +
problem O +
solving O +
and O +
executive O +
functions O -
, O +
but O +
not O +
on O +
tests O +
of O +
global O +
cognitive O +
decline O -
, O +
memory O -
, O +
language O -
, O +
or O +
visuoperceptual O +
functioning O -
. O -

These O +
results O +
indicate O +
that O +
acquisition O +
and O +
retention O +
of O +
a O +
complex O +
visuomotor O +
skill O +
can O +
proceed O +
normally O +
in O +
the O +
early O +
stages O +
of O +
AD O +
in O +
those O +
individuals O +
who O +
can O +
initially O +
perform O +
the O +
basic O +
task O -
, O +
and O +
that O +
inability O +
to O +
perform O +
the O +
basic O +
task O +
may O +
be O +
related O +
to O +
the O +
frontal O +
lobe O +
dysfunction O +
that O +
is O +
often O +
prominent O +
in O +
the O +
disorder O -
. O -

Thus O -
, O +
miR-206 O +
slows O +
ALS O +
progression O +
by O +
sensing O +
motor O +
neuron O +
injury O +
and O +
promoting O +
the O +
compensatory O +
regeneration O +
of O +
neuromuscular O +
synapses O -
. O -

Here O -
, O +
we O +
show O +
that O +
a O +
key O +
regulator O +
of O +
this O +
signaling O +
is O +
miR-206 O -
, O +
a O +
skeletal O +
muscle O -
- O -
specific O +
microRNA O +
that O +
is O +
dramatically O +
induced O +
in O +
a O +
mouse U-Species +
model O +
of O +
ALS O -
. O -

Mice U-Species +
that O +
are O +
genetically O +
deficient O +
in O +
miR-206 O +
form O +
normal O +
neuromuscular O +
synapses O +
during O +
development O -
, O +
but O +
deficiency O +
of O +
miR-206 O +
in O +
the O +
ALS O +
mouse U-Species +
model O +
accelerates O +
disease O +
progression O -
. O -

miR-206 O +
is O +
required O +
for O +
efficient O +
regeneration O +
of O +
neuromuscular O +
synapses O +
after O +
acute O +
nerve O +
injury O -
, O +
which O +
probably O +
accounts O +
for O +
its O +
salutary O +
effects O +
in O +
ALS O -
. O -

miR-206 O +
mediates O +
these O +
effects O +
at O +
least O +
in O +
part O +
through O +
histone O +
deacetylase O +
4 O +
and O +
fibroblast O +
growth O +
factor O +
signaling O +
pathways O -
. O -

MicroRNA-206 O +
delays O +
ALS O +
progression O +
and O +
promotes O +
regeneration O +
of O +
neuromuscular O +
synapses O +
in O +
mice U-Species -
. O -

Amyotrophic O +
lateral O +
sclerosis O +
( O -
ALS O -
) O +
is O +
a O +
neurodegenerative O +
disease O +
characterized O +
by O +
loss O +
of O +
motor O +
neurons O -
, O +
denervation O +
of O +
target O +
muscles O -
, O +
muscle O +
atrophy O -
, O +
and O +
paralysis O -
. O -

Understanding O +
ALS O +
pathogenesis O +
may O +
require O +
a O +
fuller O +
understanding O +
of O +
the O +
bidirectional O +
signaling O +
between O +
motor O +
neurons O +
and O +
skeletal O +
muscle O +
fibers O +
at O +
neuromuscular O +
synapses O -
. O -

[ O -
A O +
study O +
on O +
miRNA O +
alternation O +
after O +
H2O2-induced O +
PC12 O +
cell O +
apoptosis O +
using O +
microarray O +
technique O -
] O -
. O -

METHODS O -
: O +
PC12 O +
cells O +
were O +
treated O +
with O +
different O +
concentrations O +
of O +
H2O2 O +
for O +
12 O +
hours O -
, O +
and O +
then O +
the O +
cell O +
viabilities O +
were O +
evaluated O +
by O +
MTT O +
assay O +
and O +
cell O +
apoptosis O +
rates O +
were O +
assessed O +
by O +
flow O +
cytometry O +
( O -
FCM O -
) O -
. O -

OBJECTIVE O -
: O +
To O +
screen O +
the O +
differentially O +
expressed O +
microRNAs O -
( O -
miRNA O -
) O +
between O +
H2O2-induced O +
PC12 O +
cell O +
apoptosis O +
and O +
normal O +
PC12 O +
cells O +
with O +
microarray O +
chips O -
. O -

Of O +
the O +
46 O +
miRNAs O +
in O +
the O +
H2O2 O +
treated O +
groups O -
, O +
39 O +
were O +
similar O +
to O +
that O +
of O +
the O +
control O +
group O +
and O +
6 O +
were O +
significantly O +
down O -
- O -
regulated O -
. O -

CONCLUSION O -
: O +
Our O +
preliminary O +
data O +
may O +
provide O +
a O +
new O +
potential O +
foundation O +
for O +
further O +
study O +
of O +
pathogenesis O +
and O +
its O +
treatment O +
of O +
nerve O +
cell O +
apoptosis O +
caused O +
by O +
cerebral O +
ischemia O +
reperfusion O -
. O -

The O +
apoptosis O +
rates O +
for O +
them O +
were O +
2.6 O -
% O -
, O +
5.2 O -
% O -
, O +
7.2 O -
% O -
, O +
10.4 O -
% O -
, O +
16.6 O -
% O -
, O +
and O +
72.2 O -
% O +
accordingly O -
. O -

Expression O +
of O +
68 O +
miRNAs O +
and O +
46 O +
miRNAs O +
were O +
detected O +
in O +
both O +
control O +
group O +
and O +
the O +
H2O2 O +
treated O +
groups O -
. O -

miRNAs O +
were O +
isolated O +
from O +
control O +
( O -
0 O +
nmol O -
/ O -
L O +
H2O2 O -
) O +
and O +
H2O2 O +
treated O +
( O -
at O +
concentrations O +
of O +
50 O -
, O +
100 O -
, O +
200 O -
, O +
and O +
400 O +
nmol O -
/ O -
L O +
H2O2 O -
, O +
respectively O -
) O +
groups O +
of O +
the O +
PC12 O +
cells O -
, O +
respectively O -
, O +
and O +
were O +
then O +
detected O +
and O +
analyzed O +
by O +
microarray O +
chips O -
. O -

RESULTS O -
: O +
The O +
P12 O +
cell O +
viabilities O +
in O +
control O +
and O +
H2O2 O +
treated O +
group O +
were O +
( O -
92 O +
+ O -
/- O +
9.8 O -
) O -
% O -
, O +
( O -
90 O +
+ O -
/- O +
14.70 O -
) O -
% O -
, O +
( O -
80 O +
+ O -
/- O +
13.85 O -
) O -
% O -
, O +
( O -
54 O +
+ O -
/- O +
12.23 O -
) O -
% O -
, O +
and O +
( O -
22 O +
+ O -
/- O +
7.35 O -
) O -
% O -
, O +
respectively O -
. O -

In O +
particular O -
, O +
SNP O +
rs12720208 O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
( O -
3 O -
' O +
UTR O -
) O +
was O +
linked O +
to O +
PD O -
- O -
risk O +
through O +
a O +
mechanism O +
that O +
would O +
implicate O +
a O +
differential O +
binding O +
to O +
microRNA-433 O +
( O -
miR-433 O -
) O -
. O -

The O +
reduction O +
of O +
the O +
affinity O +
of O +
miR-433 O +
to O +
the O +
3 O -
' O +
UTR O +
would O +
result O +
in O +
increased O +
FGF20 O +
expression O +
and O +
upregulation O +
of O +
alpha O -
- O -
synuclein O -
, O +
which O +
could O +
in O +
turn O +
promote O +
dopaminergic O +
neurons O +
degeneration O -
. O -

FGF20 O +
rs12720208 O +
SNP O +
and O +
microRNA-433 O +
variation O -
: O +
no O +
association O +
with O +
Parkinson O -
's O +
disease O +
in O +
Spanish O +
patients U-Species -
. O -

DNA O +
variation O +
at O +
the O +
FGF20 O +
gene O +
has O +
been O +
associated O +
with O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O -

In O +
conclusion O -
, O +
our O +
work O +
did O +
not O +
confirm O +
the O +
association O +
between O +
rs12720208 O +
and O +
PD O -
, O +
or O +
an O +
effect O +
of O +
miR-433 O +
variants O +
on O +
this O +
disease O -
. O -

None O +
of O +
the O +
patients U-Species +
had O +
miR-433 O +
variants O -
. O -

We O +
did O +
not O +
find O +
significant O +
differences O +
in O +
allele O +
and O +
genotype O +
frequencies O +
between O +
patients U-Species +
and O +
controls O -
. O -

We O +
genotyped O +
the O +
rs12720208 O +
SNP O +
in O +
a O +
total O +
of O +
512 O +
PD O +
patients U-Species +
and O +
258 O +
healthy O +
controls O +
from O +
Spain O -
, O +
and O +
searched O +
for O +
miR-433 O +
variants O +
in O +
the O +
patients U-Species -
. O -

The O +
results O +
suggest O +
( O -
a O -
) O +
that O +
unless O +
specifically O +
stabilized O -
, O +
certain O +
brain O -
- O -
enriched O +
miRNAs O +
represent O +
a O +
rapidly O +
executed O +
signaling O +
system O +
employing O +
highly O +
transient O +
effectors O +
of O +
CNS O +
gene O +
expression O -
, O +
and O +
( O -
b O -
) O +
that O +
in O +
AD O +
temporal O +
lobe O +
neocortex O +
specific O +
brain O +
miRNAs O +
are O +
significantly O +
up O -
- O -
regulated O +
in O +
abundance O +
and O +
strongly O +
correlate O +
with O +
the O +
presence O +
of O +
AD O -
- O -
type O +
neuropatholgical O +
change O -
. O -

In O +
short O +
PMI O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
-affected O +
temporal O +
lobe O +
neocortex O -
, O +
miRNA-9 O -
, O +
miRNA-125b O +
and O +
miRNA-146a O +
were O +
found O +
to O +
be O +
significantly O +
up O -
- O -
regulated O -
, O +
an O +
effect O +
that O +
was O +
not O +
seen O +
in O +
several O +
related O +
neurological O +
disorders O -
. O -

In O +
these O +
studies O -
, O +
miRNA O +
array O +
and O +
Northern O +
blot O +
based O +
tracking O +
of O +
specific O +
miRNA O +
abundances O +
and O +
decay O +
kinetics O +
in O +
human U-Species +
neural O +
( O -
HN O -
) O +
cells O +
in O +
primary O +
culture O +
and O +
in O +
short O +
post O -
- O -
mortem O +
interval O +
( O -
PMI O -
, O +
approximately O +
1h O -
) O +
human U-Species +
brain O +
tissues O +
showed O +
a O +
limited O +
stability O +
and O +
relatively O +
short O +
half O -
- O -
life O +
( O +
approximately O +
1 O -
- O -
3.5h O -
) O +
for O +
specific O +
brain O -
- O -
enriched O +
miRNAs O -
. O -

Micro O -
- O -
RNA O +
( O -
miRNA O -
) O +
mediated O +
regulation O +
of O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
complexity O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
is O +
emerging O +
as O +
a O +
critical O +
factor O +
in O +
the O +
control O +
of O +
CNS O -
- O -
specific O +
gene O +
expression O +
during O +
development O -
, O +
plasticity O -
, O +
aging O +
and O +
disease O -
. O -

Micro O -
- O -
RNA O +
abundance O +
and O +
stability O +
in O +
human U-Species +
brain O -
: O +
specific O +
alterations O +
in O +
Alzheimer O -
's O +
disease O +
temporal O +
lobe O +
neocortex O -
. O -

Keystone O +
symposium O -
, O +
Neurodegenerative O +
Diseases O -
: O +
New O +
Molecular O +
Mechanisms O +
17 O -
- O -
22 O +
February O +
2009 O -
. O -

Glioma O +
angiogenesis O -
: O +
Towards O +
novel O +
RNA O +
therapeutics O -
. O -

Brain O +
tumors O +
exhibit O +
marked O +
and O +
aberrant O +
blood O +
vessel O +
formation O +
indicating O +
angiogenic O +
endothelial O +
cells O +
as O +
a O +
potential O +
target O +
for O +
brain O +
tumor O +
treatment O -
. O -

The O +
brain O +
tumor O +
blood O +
vessels O +
are O +
used O +
for O +
nutrient O +
delivery O -
, O +
and O +
possibly O +
for O +
cancer O +
cell O +
migration O -
. O -

The O +
process O +
of O +
angiogenesis O +
is O +
complex O +
and O +
involves O +
multiple O +
players O -
. O -

The O +
current O +
angiogenesis O +
inhibitors O +
used O +
in O +
clinical O +
trials O +
mostly O +
target O +
single O +
angiogenic O +
proteins O +
and O +
so O +
far O +
show O +
limited O +
effects O +
on O +
tumor O +
growth O -
. O -

Besides O +
the O +
conventional O +
angiogenesis O +
inhibitors O -
, O +
RNA O -
- O -
based O +
inhibitors O +
such O +
as O +
small O -
- O -
interfering O +
RNAs O +
( O -
siRNAs O -
) O +
are O +
being O +
analyzed O +
for O +
their O +
capacity O +
to O +
silence O +
the O +
message O +
of O +
proteins O +
involved O +
in O +
neovascularization O -
. O -

More O +
recently O -
, O +
a O +
new O +
family O +
of O +
non O -
- O -
coding O +
RNAs O -
, O +
named O +
angiomirs O +
[ O -
microRNAs O +
( O -
miRNAs O -
) O +
involved O +
in O +
angiogenesis O -
] O +
has O +
emerged O -
. O -

These O +
small O +
RNAs O +
have O +
the O +
advantage O +
over O +
siRNAs O +
in O +
that O +
they O +
have O +
the O +
potential O +
of O +
silencing O +
multiple O +
messages O +
at O +
the O +
same O +
time O +
and O +
therefore O +
they O +
might O +
become O +
therapeutically O +
relevant O +
in O +
a O +
" O -
one O -
- O -
hit O +
multiple O -
- O -
target O -
" O +
context O +
against O +
brain O +
tumor O +
angiogenesis O -
. O -

In O +
this O +
review O +
we O +
will O +
discuss O +
the O +
emerging O +
technologies O +
in O +
anti O -
- O -
angiogenesis O +
emphasizing O +
on O +
RNA O -
- O -
based O +
therapeutics O -
. O -

Diseases O +
potentially O +
mediated O +
by O +
alterations O +
in O +
RNA O +
processes O +
include O +
tauopathies O -
, O +
myotonic O +
dystrophy O -
, O +
Alzheimer O +
disease O -
, O +
brain O +
cancer O -
, O +
and O +
many O +
others O -
. O -

Some O +
noncoding O +
RNAs O +
have O +
been O +
shown O +
to O +
be O +
involved O +
in O +
human U-Species +
brain O +
diseases O -
. O -

Furthermore O -
, O +
there O +
is O +
poor O +
correlation O +
between O +
mRNA O +
levels O +
and O +
protein O +
levels O +
in O +
mammalian O +
cells O -
, O +
due O +
partly O +
to O +
complicated O +
post O -
- O -
transcriptional O +
regulation O +
by O +
hitherto O +
unknown O +
noncoding O +
RNAs O -
. O -

For O +
example O -
, O +
neurologic O +
illnesses O +
may O +
arise O +
because O +
of O +
perturbations O +
in O +
distinct O +
but O +
interrelated O +
tiers O +
of O +
RNA O -
- O -
based O +
genetic O +
regulation O -
: O +
pre O -
- O -
mRNA O +
splicing O -
; O +
nonsplicing O +
RNA O +
modifications O -
; O +
and O +
mRNA O +
translational O +
regulation O -
. O -

A O +
variety O +
of O +
unforeseen O +
complexities O +
have O +
been O +
identified O -
, O +
many O +
with O +
relevance O +
to O +
human U-Species +
brain O +
disease O -
. O -

RNA O +
research O +
has O +
made O +
great O +
progress O +
in O +
recent O +
years O -
. O -

RNA O +
in O +
brain O +
disease O -
: O +
no O +
longer O +
just O +
" O -
the O +
messenger O +
in O +
the O +
middle O -
" O -
. O -

Here O +
we O +
present O +
an O +
overview O +
of O +
new O +
research O +
highlighting O +
functions O +
for O +
RNA O +
that O +
far O +
surpass O +
the O +
" O -
messenger O +
in O +
the O +
middle O -
" O +
role O +
and O +
that O +
identify O +
RNA O +
molecules O +
as O +
important O +
agents O +
in O +
the O +
human U-Species +
brain O +
in O +
health O +
and O +
in O +
disease O +
states O -
. O -

RNA O +
editing O +
by O +
adenosine O +
deamination O +
is O +
a O +
posttranscriptional O +
mechanism O +
for O +
the O +
regulation O +
of O +
gene O +
expression O +
and O +
is O +
particularly O +
widespread O +
in O +
mammals O -
. O -

Gene O +
regulation O +
through O +
RNA O +
editing O -
. O -

Here O -
, O +
I O +
am O +
reviewing O +
main O +
features O +
of O +
this O +
epigenetic O +
phenomenon O -
, O +
its O +
relevance O +
for O +
health O +
and O +
disease O -
, O +
as O +
well O +
as O +
potential O +
prospects O +
for O +
using O +
RNA O +
editing O +
as O +
a O +
therapeutic O +
tool O -
. O -

Widespread O +
A O -
- O -
to O -
- O -
I O +
modification O +
of O +
repeat O +
sequences O +
in O +
the O +
human U-Species +
transcriptome O +
suggests O +
additional O +
roles O +
for O +
RNA O +
editing O +
and O +
links O +
it O +
to O +
other O +
processes O +
of O +
gene O +
regulation O -
, O +
such O +
as O +
RNA O +
splicing O +
as O +
well O +
as O +
siRNA O +
mediated O +
gene O +
silencing O +
and O +
miRNA O +
function O -
. O -

The O +
deficiency O +
or O +
misregulation O +
of O +
editing O +
has O +
been O +
implicated O +
in O +
the O +
etiology O +
of O +
neurological O +
diseases O -
, O +
such O +
as O +
epilepsy O -
, O +
amyotrophic O +
lateral O +
sclerosis O +
( O -
ALS O -
) O -
, O +
depression O +
and O +
tumor O +
progression O -
. O -

Also O -
, O +
it O +
regulates O +
important O +
functional O +
properties O +
of O +
neurotransmitter O +
receptor O +
genes O +
in O +
the O +
central O +
nervous O +
system O +
by O +
changing O +
single O +
codons O +
in O +
pre O -
- O -
mRNA O -
. O -

A O -
- O -
to O -
- O -
I O +
RNA O +
editing O +
generates O +
transcriptome O +
and O +
proteome O +
diversity O +
allowing O +
organisms O +
to O +
produce O +
many O +
more O +
gene O +
products O +
and O +
functions O +
than O +
predicted O +
based O +
on O +
the O +
number O +
of O +
genes O +
within O +
their O +
genome O -
. O -

Gliomas O +
display O +
a O +
microRNA O +
expression O +
profile O +
reminiscent O +
of O +
neural O +
precursor O +
cells O -
. O -

Gliomas O +
express O +
many O +
genes O +
that O +
play O +
a O +
role O +
in O +
neural O +
precursor O +
cells O +
( O -
NPCs O -
) O -
, O +
but O +
no O +
direct O +
comparison O +
between O +
glioma O +
and O +
stem O +
cell O +
( O -
SC O -
) O +
gene O +
expression O +
profiles O +
has O +
been O +
performed O -
. O -

To O +
investigate O +
the O +
similarities O +
and O +
differences O +
between O +
gliomas O +
and O +
SCs O -
, O +
we O +
compared O +
the O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
signatures O +
of O +
glial O +
tumors O -
, O +
embryonic O +
SCs O +
( O -
ESCs O -
) O -
, O +
NPCs O -
, O +
and O +
normal O +
adult O +
brains O +
from O +
both O +
human U-Species +
and O +
mouse U-Species +
tissues O -
. O -

We O +
demonstrated O +
that O +
both O +
human U-Species +
gliomas O +
( O -
regardless O +
of O +
their O +
grade O -
) O +
and O +
methylcholanthrene O -
- O -
induced O +
mouse U-Species +
glioma O +
shared O +
an O +
miRNA O +
expression O +
profile O +
that O +
is O +
reminiscent O +
of O +
NPCs O -
. O -

About O +
half O +
of O +
the O +
miRNAs O +
expressed O +
in O +
the O +
shared O +
profile O +
clustered O +
in O +
seven O +
genomic O +
regions O +
susceptible O +
to O +
genetic O -
/ O -
epigenetic O +
alterations O +
in O +
various O +
cancers O -
. O -

These O +
clusters O +
comprised O +
the O +
miR17 O +
family O -
, O +
mir183 O -
- O -
182 O -
, O +
and O +
the O +
SC O -
- O -
specific O +
clusters O +
mir367 O -
- O -
302 O +
and O +
mir371 O -
- O -
373 O -
, O +
which O +
are O +
upregulated O +
in O +
gliomas O -
, O +
ESCs O -
, O +
and O +
NPCs O -
. O -

The O +
bipartite O +
cluster O +
of O +
7 O +
+ O +
46 O +
miRNAs O +
on O +
chromosome O +
14q32.31 O -
, O -

which O +
might O +
represent O +
the O +
largest O +
tumor O +
suppressor O +
miRNA O +
cluster O -
, O +
was O +
downregulated O +
in O +
the O +
shared O +
expression O +
profile O -
. O -

This O +
study O +
provides O +
the O +
first O +
evidence O +
for O +
association O +
between O +
these O +
clusters O +
and O +
gliomas O -
. O -

Despite O +
the O +
broad O +
similarity O +
in O +
the O +
miRNA O +
expression O +
profiles O -
, O +
15 O +
miRNAs O +
showed O +
disparate O +
expression O +
between O +
SC O +
and O +
gliomas O -
. O -

Ten O +
miRNAs O +
belong O +
to O +
the O +
2 O +
SC O -
- O -
specific O +
clusters O +
and O +
the O +
remaining O +
( O -
mir135b O -
, O +
mir141 O -
, O +
mir205 O -
, O +
mir200C O -
, O +
and O +
mir301a O -
) O +
have O +
been O +
previously O +
shown O +
to O +
associate O +
with O +
malignancies O -
. O -

Our O +
finding O +
showed O +
that O +
all O +
gliomas O +
displayed O +
NPC O -
- O -
like O +
miRNA O +
signatures O -
, O +
which O +
may O +
have O +
implications O +
for O +
studies O +
of O +
glioma O +
origins O -
. O -

Furthermore O -
, O +
careful O +
study O +
of O +
the O +
15 O +
miRNAs O +
that O +
differ O +
in O +
expression O +
between O +
SCs O +
and O +
gliomas O -
, O +
particularly O +
those O +
5 O +
that O +
are O +
not O +
SC O -
- O -
specific O -
, O +
may O +
enhance O +
our O +
understanding O +
of O +
gliomagenesis O -
. O -

New O +
insights O +
into O +
the O +
roles O +
of O +
microRNAs O +
in O +
drug O +
addiction O +
and O +
neuroplasticity O -
. O -

In O +
this O +
review O -
, O +
the O +
aim O +
is O +
to O +
provide O +
an O +
overview O +
of O +
the O +
emerging O +
role O +
of O +
miRNAs O +
in O +
addiction O -
. O -

miRNAs O +
are O +
small O +
non O -
- O -
coding O +
RNAs O -
, O +
particularly O +
abundant O +
in O +
the O +
nervous O +
system O -
, O +
that O +
play O +
key O +
roles O +
as O +
regulatory O +
molecules O +
in O +
processes O +
such O +
as O +
neurogenesis O -
, O +
synapse O +
development O +
and O +
plasticity O +
in O +
the O +
brain O -
. O -

They O +
also O +
act O +
as O +
key O +
spatiotemporal O +
regulators O +
during O +
dendritic O +
morphogenesis O -
, O +
controlling O +
the O +
expression O +
of O +
hundreds O +
of O +
genes O +
involved O +
in O +
neuroplasticity O +
and O +
in O +
the O +
function O +
of O +
synapses O -
. O -

Recent O +
studies O +
have O +
identified O +
changes O +
of O +
several O +
specific O +
miRNA O +
expression O +
profiles O +
and O +
polymorphisms O +
affecting O +
the O +
interactions O +
between O +
miRNAs O +
and O +
their O +
targets O +
in O +
various O +
brain O +
disorders O -
, O +
including O +
addiction O -
: O +
miR-16 O +
causes O +
adaptive O +
changes O +
in O +
production O +
of O +
the O +
serotonin O +
transporter O -
; O +
miR-133b O +
is O +
specifically O +
expressed O +
in O +
midbrain O +
dopaminergic O +
neurons O -
, O +
and O +
regulates O +
the O +
production O +
of O +
tyrosine O +
hydroxylase O +
and O +
the O +
dopamine O +
transporter O -
; O +
miR-212 O +
affects O +
production O +
of O +
striatal O +
brain O -
- O -
derived O +
neurotrophic O +
factor O +
and O +
synaptic O +
plasticity O +
upon O +
cocaine O -
. O -

Clearly O -
, O +
specific O +
miRNAs O +
have O +
emerged O +
as O +
key O +
regulators O +
leading O +
to O +
addiction O -
, O +
and O +
could O +
serve O +
as O +
valuable O +
targets O +
for O +
more O +
efficient O +
therapies O -
. O -

ABSTRACT O +
: O +
Drug O +
addiction O +
is O +
a O +
major O +
public O +
health O +
issue O -
. O -

It O +
is O +
typically O +
a O +
multigenetic O +
brain O +
disorder O -
, O +
implying O +
combined O +
changes O +
of O +
expression O +
of O +
several O +
hundred O +
genes O -
. O -

Psychostimulants O +
( O -
such O +
as O +
cocaine O -
, O +
heroin O +
and O +
amphetamines O -
) O +
induce O +
strong O +
and O +
persistent O +
neuroadaptive O +
changes O +
through O +
a O +
surfeit O +
of O +
gene O +
regulatory O +
mechanisms O +
leading O +
to O +
addiction O -
. O -

Activity O -
- O -
dependent O +
synaptic O +
plasticity O +
of O +
the O +
mesolimbic O +
dopaminergic O +
system O -
, O +
known O +
as O +
the O +
' O -
reward O +
pathway O -
' O -
, O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
development O +
of O +
drug O +
dependence O -
. O -

Morphological O +
and O +
molecular O +
information O +
of O +
a O +
new O +
species O +
of O +
Geleia O +
( O -
Ciliophora O -
, O +
Karyorelictea O -
) O -
, O +
with O +
redescriptions O +
of O +
two O +
Kentrophoros O +
species O +
from O +
China O -
. O +

The O +
morphology O +
and O +
infraciliature O +
of O +
three O +
karyorelictean O +
ciliates O -
, O +
Geleia B-Species +
sinica I-Species +
spec I-Species -
. L-Species -

nov. U-Species +
and O +
two O +
poorly O +
known O +
Kentrophoros O +
species O -
, O +
K. B-Species +
flavus L-Species +
and O +
K. B-Species +
gracilis L-Species -
, O +
isolated O +
from O +
the O +
intertidal O +
zone O +
of O +
a O +
beach O +
at O +
Qingdao O -
, O +
China O -
, O +
were O +
investigated O -
. O -

Geleia B-Species +
sinica I-Species +
spec I-Species -
. L-Species -

nov. U-Species +
is O +
distinguished O +
from O +
its O +
congeners O +
by O +
the O +
following O +
combination O +
of O +
characters O -
: O +
body O +
medium O -
- O -
sized O +
and O +
slender O -
- O -
cylindrical O -
; O +
with O +
a O +
conspicuous O +
prebuccal O +
fossa O -
; O +
28 O -
- O -
34 O +
somatic O +
kineties O -
; O +
about O +
40 O +
short O +
adoral O +
polykineties O -
; O +
intrabuccal O +
kinety O +
composed O +
of O +
25 O -
- O -
34 O +
dikinetids O -
; O +
paroral O +
kineties O +
composed O +
of O +
closely O +
spaced O +
dikinetids O -
. O -

The O +
comparison O +
with O +
similar O +
congeners O +
clearly O +
supports O +
the O +
validity O +
of O +
this O +
new O +
species O +
based O +
on O +
morphological O +
and O +
small O +
subunit O +
( O -
SSU O -
) O +
rRNA O +
gene O +
sequence O +
data O -
. O -

In O +
light O +
of O +
these O +
new O +
data O +
the O +
" O -
well O -
- O -
known O -
" O +
morphotype O -
, O +
Geleia O +
simplex O +
( B-Species -
Faure I-Species -
- I-Species -
Fremiet I-Species -
, I-Species +
1951 I-Species -
) I-Species -
, I-Species +
is I-Species +
redefined L-Species -
. O -

Two O +
Kentrophoros O +
species O +
are O +
redescribed O +
and O +
improved O +
diagnoses O +
are O +
supplied O -
. O -

Kentrophoros O +
flavus B-Species +
Raikov I-Species +
and I-Species +
Kovaleva I-Species -
, I-Species +
1968 I-Species +
is I-Species +
mainly L-Species +
characterized O +
by O +
having O +
about O +
33 O +
macronuclei O +
and O +
12 O +
micronuclei O +
forming O +
a O +
row O +
that O +
extends O +
along O +
the O +
cell O +
meridian O -
, O +
and O +
12 O -
- O -
19 O +
ciliary O +
rows O +
on O +
the O +
right O +
side O +
of O +
the O +
cell O -
. O -

Kentrophoros O +
gracilis B-Species +
Raikov I-Species -
, I-Species +
1963 I-Species +
is I-Species +
characterized L-Species +
by O +
having O +
about O +
14 O +
macronuclei O -
, O +
13 O +
micronuclei O +
and O +
10 O -
- O -
13 O +
kineties O +
on O +
the O +
right O +
side O +
of O +
the O +
cell O -
. O +

Hydraulic O +
constraints O +
limit O +
height O +
growth O +
in O +
trees O +
at O +
high O +
altitude O -
. O -

* O +
Low O +
temperatures O +
limit O +
the O +
fixation O +
of O +
photosynthates O +
and O +
xylogenesis O -
. O -

Here O -
, O +
we O +
hypothesized O +
that O +
reduced O +
longitudinal O +
growth O +
in O +
trees O +
at O +
high O +
altitude O +
is O +
related O +
to O +
the O +
lower O +
hydraulic O +
efficiency O +
of O +
the O +
transport O +
system O -
. O -

* O +
Apical O +
buds O +
of O +
Norway B-Species +
spruce L-Species +
( O -
Picea B-Species +
abies L-Species -
) O +
trees O +
at O +
high O +
and O +
low O +
elevation O +
were O +
heated O +
during O +
2006 O +
and O +
2007 O -
. O -

At O +
the O +
end O +
of O +
the O +
experiment O -
, O +
trees O +
were O +
felled O -
. O -

Longitudinal O +
increments O +
and O +
tracheid O +
lumen O +
areas O +
were O +
measured O +
along O +
the O +
stem O -
. O -

Apical O +
hydraulic O +
conductivity O +
( O -
k O -
) O +
was O +
estimated O +
from O +
anatomical O +
data O -
. O -

* O +
Before O +
heating O -
, O +
high O -
- O -
altitude O +
trees O +
showed O +
fewer O +
( O -
P O +
= O +
0.002 O -
) O +
and O +
smaller O +
( O -
P O +
= O +
0.008 O -
) O +
apical O +
conduits O -
, O +
and O +
therefore O +
reduced O +
k O +
( O -
P O +
= O +
0.016 O -
) O +
and O +
stem O +
elongation O +
( O -
P O +
< O +
0.0001 O -
) O -
, O +
in O +
comparison O +
with O +
trees O +
at O +
low O +
elevation O -
. O -

After O +
2 O +
yr O +
of O +
heating O -
, O +
k O +
increased O +
at O +
both O +
high O +
( O -
P O +
= O +
0.014 O -
) O +
and O +
low O +
( O -
P O +
= O +
0.047 O -
) O +
elevation O -
. O -

Only O +
high O -
- O -
altitude O +
trees O +
showed O +
increased O +
stem O +
elongation O -
, O +
which O +
reached O +
the O +
same O +
magnitude O +
as O +
that O +
of O +
controls O +
at O +
low O +
elevation O +
( O -
P O +
= O +
0.735 O -
) O -
. O -

Heating O +
around O +
the O +
apical O +
shoots O +
did O +
not O +
appear O +
to O +
induce O +
significant O +
changes O +
in O +
conduit O +
dimension O +
along O +
the O +
rest O +
of O +
the O +
stem O -
. O -

* O +
The O +
total O +
number O +
and O +
size O +
of O +
xylem O +
elements O +
at O +
the O +
stem O +
apex O +
are O +
strongly O +
constrained O +
by O +
low O +
temperatures O -
. O -

Trees O +
at O +
high O +
altitude O +
are O +
therefore O +
prevented O +
from O +
building O +
up O +
an O +
efficient O +
transport O +
system O -
, O +
and O +
their O +
reduced O +
longitudinal O +
growth O +
reflects O +
strong O +
hydraulic O +
limitations O -
. O +

Fitness O +
effects O +
of O +
endemic O +
malaria O +
infections O +
in O +
a O +
wild O +
bird O +
population O -
: O +
the O +
importance O +
of O +
ecological O +
structure O -
. O +

1 O -
. O -

Parasites O +
can O +
have O +
important O +
effects O +
on O +
host O +
populations O +
influencing O +
either O +
fecundity O +
or O +
mortality O -
, O +
but O +
understanding O +
the O +
magnitude O +
of O +
these O +
effects O +
in O +
endemic O +
host O -
- O -
parasite O +
systems O +
is O +
challenging O +
and O +
requires O +
an O +
understanding O +
of O +
ecological O +
processes O +
affecting O +
both O +
host O +
and O +
parasite O -
. O -

2 O -
. O -

Avian O +
blood O +
parasites O +
( O -
Haemoproteus O +
and O +
Plasmodium O -
) O +
have O +
been O +
much O +
studied O -
, O +
but O +
the O +
effects O +
of O +
these O +
parasites O +
on O +
hosts O +
in O +
areas O +
where O +
they O +
are O +
endemic O +
remains O +
poorly O +
known O -
. O -

3 O -
. O -

We O +
used O +
a O +
multistate O +
modelling O +
framework O +
to O +
explore O +
the O +
effects O +
of O +
chronic O +
infection O +
with O +
Plasmodium O +
on O +
survival O +
and O +
recapture O +
probability O +
in O +
a O +
large O +
data O +
set O +
of O +
breeding O +
blue B-Species +
tits L-Species -
, O +
involving O +
3424 O +
individuals O +
and O +
3118 O +
infection O +
diagnoses O +
over O +
nine O +
years O -
. O -

4 O -
. O -

We O +
reveal O +
strong O +
associations O +
between O +
chronic O +
malaria O +
infection O +
and O +
both O +
recapture O +
and O +
survival O -
, O +
effects O +
that O +
are O +
dependent O +
on O +
the O +
clade O +
of O +
parasite O -
, O +
on O +
host O +
traits O +
and O +
on O +
the O +
local O +
risk O +
of O +
infection O -
. O -

5 O -
. O -

Infection O +
with O +
Plasmodium B-Species +
relictum L-Species +
was O +
associated O +
with O +
reduced O +
recapture O +
probability O +
and O +
increased O +
survival O -
, O +
compared O +
to O +
P. B-Species +
circumflexum L-Species -
, O +
suggesting O +
that O +
these O +
parasites O +
have O +
differing O +
virulence O +
and O +
cause O +
different O +
types O +
of O +
selection O +
on O +
this O +
host O -
. O -

6 O -
. O -

Our O +
results O +
suggest O +
a O +
large O +
potential O +
survival O +
cost O +
of O +
acute O +
infections O +
revealed O +
by O +
modelling O +
host O +
survival O +
as O +
a O +
function O +
of O +
the O +
local O +
risk O +
of O +
infection O -
. O -

7 O -
. O -

Our O +
analyses O +
suggest O +
not O +
only O +
that O +
endemic O +
avian O +
malaria O +
may O +
have O +
multiple O +
fitness O +
effects O +
on O +
their O +
hosts O +
and O +
that O +
these O +
effects O +
are O +
species O +
dependent O -
, O +
but O +
also O +
that O +
adding O +
ecological O +
structure O +
( O -
in O +
this O +
case O +
parasite O +
species O +
and O +
spatial O +
variation O +
in O +
disease O +
occurrence O -
) O +
to O +
analyses O +
of O +
host O -
- O -
parasite O +
interactions O +
is O +
an O +
important O +
step O +
in O +
understanding O +
the O +
ecology O +
and O +
evolution O +
of O +
these O +
systems O -
. O +

Jiangella B-Species +
muralis I-Species +
sp. I-Species +
nov. L-Species -
, O +
from O +
an O +
indoor O +
environment O -
. O -

A O +
Gram O -
- O -
stain O -
- O -
positive O -
, O +
non O -
- O -
spore O -
- O -
forming O +
actinobacterium O -
, O +
designated O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O -
, O +
was O +
isolated O +
from O +
wall O +
material O +
of O +
an O +
indoor O +
environment O -
. O -

The O +
isolate O +
formed O +
a O +
rudimentary O +
substrate O +
mycelium O +
that O +
fragmented O +
into O +
rod O -
- O -
shaped O +
cells O -
. O -

On O +
the O +
basis O +
of O +
16S O +
rRNA O +
gene O +
sequence O +
analysis O -
, O +
strain O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O +
was O +
shown O +
to O +
belong O +
to O +
the O +
genus O +
Jiangella O +
and O +
was O +
most O +
closely O +
related O +
to O +
Jiangella B-Species +
alba I-Species +
YIM I-Species +
61503 I-Species -
( I-Species -
T L-Species -
) O +
( O -
99.7 O +
% O +
16S O +
rRNA O +
gene O +
sequence O +
similarity O -
) O -
, O +
Jiangella B-Species +
alkaliphila I-Species +
D8 I-Species -
- I-Species -
87 I-Species -
( I-Species -
T L-Species -
) O +
( O -
99.0 O +
% O -
) O +
and O +
Jiangella B-Species +
gansuensis I-Species +
YIM I-Species +
002 I-Species -
( I-Species -
T L-Species -
) O +
( O -
99.0 O +
% O -
) O -
. O -

The O +
predominant O +
menaquinone O +
was O +
MK-9 O -
( O -
H O -
( O -
4 O -
) O -
) O -
. O -

Whole O -
- O -
cell O +
hydrolysates O +
contained O +
ll O -
- O -
diaminopimelic O +
acid O +
as O +
the O +
diagnostic O +
diamino O +
acid O +
in O +
the O +
cell O +
wall O +
and O +
rhamnose O +
and O +
glucose O +
as O +
the O +
main O +
sugars O -
. O -

Mycolic O +
acids O +
were O +
absent O -
. O -

The O +
polar O +
lipid O +
profile O +
consisted O +
of O +
diphosphatidylglycerol O -
, O +
phosphatidylglycerol O -
, O +
phosphatidylinositol O -
, O +
phosphatidylinositol O +
mannoside O +
and O +
seven O +
unknown O +
phospholipids O -
. O -

The O +
fatty O +
acid O +
profile O +
contained O +
major O +
amounts O +
( O -
> O -
5 O +
% O -
) O +
of O +
anteiso O -
- O -
C O -
( O -
15 O +
: O +
0 O -
) O -
, O +
iso O -
- O -
C O -
( O -
16 O +
: O +
0 O -
) O -
, O +
iso O -
- O -
C O -
( O -
15 O +
: O +
0 O -
) O -
, O +
iso O -
- O -
C O -
( O -
17 O +
: O +
0 O -
) O -
, O +
anteiso O -
- O -
C O -
( O -
17 O +
: O +
0 O -
) O +
and O +
C O -
( O -
17 O +
: O +
1 O -
) O -
omega8c O -
, O +
which O +
supported O +
the O +
affiliation O +
of O +
strain O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O +
to O +
the O +
genus O +
Jiangella O -
. O -

DNA O -
- O -
DNA O +
relatedness O +
and O +
physiological O +
and O +
biochemical O +
tests O +
allowed O +
the O +
differentiation O +
of O +
strain O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O +
from O +
the O +
type O +
strains O +
of O +
the O +
three O +
known O +
Jiangella O +
species O -
. O -

Strain O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O +
represents O +
a O +
novel O +
Jiangella O +
species O -
, O +
for O +
which O +
we O +
propose O +
the O +
name O +
Jiangella B-Species +
muralis I-Species +
sp. I-Species +
nov. L-Species -
, O +
with O +
type O +
strain O +
15-Je-017 B-Species -
( I-Species -
T L-Species -
) O +
( O -
= O -
DSM O +
45357 O -
( O -
T O -
) O +
= O -
CCM O +
7680 O -
( O -
T O -
) O -
) O -
. O +

Soil O +
nutrient O +
status O +
determines O +
how O +
elephant U-Species +
utilize O +
trees O +
and O +
shape O +
environments O -
. O +

1 O -
. O -

Elucidation O +
of O +
the O +
mechanism O +
determining O +
the O +
spatial O +
scale O +
of O +
patch O +
selection O +
by O +
herbivores O +
has O +
been O +
complicated O +
by O +
the O +
way O +
in O +
which O +
resource O +
availability O +
at O +
a O +
specific O +
scale O +
is O +
measured O +
and O +
by O +
vigilance O +
behaviour O +
of O +
the O +
herbivores O +
themselves O -
. O -

To O +
reduce O +
these O +
complications O -
, O +
we O +
studied O +
patch O +
selection O +
by O +
an O +
animal O +
with O +
negligible O +
predation O +
risk O -
, O +
the O +
African B-Species +
elephant L-Species -
. O -

2 O -
. O -

We O +
introduce O +
the O +
concept O +
of O +
nutrient O +
load O +
as O +
the O +
product O +
of O +
patch O +
size O -
, O +
number O +
of O +
patches O +
and O +
local O +
patch O +
nutrient O +
concentration O -
. O -

Nutrient O +
load O +
provides O +
a O +
novel O +
spatially O +
explicit O +
expression O +
of O +
the O +
total O +
available O +
nutrients O +
a O +
herbivore O +
can O +
select O +
from O -
. O -

3 O -
. O -

We O +
hypothesized O +
that O +
elephant U-Species +
would O +
select O +
nutrient O -
- O -
rich O +
patches O -
, O +
based O +
on O +
the O +
nutrient O +
load O +
per O +
2500 O +
m O -
( O -
2 O -
) O +
down O +
to O +
the O +
individual O +
plant O +
scale O -
, O +
and O +
that O +
this O +
selection O +
will O +
depend O +
on O +
the O +
nitrogen O +
and O +
phosphorous O +
contents O +
of O +
plants O -
. O -

4 O -
. O -

We O +
predicted O +
that O +
elephant U-Species +
would O +
cause O +
more O +
adverse O +
impact O +
to O +
trees O +
of O +
lower O +
value O +
to O +
them O +
in O +
order O +
to O +
reach O +
plant O +
parts O +
with O +
higher O +
nutrient O +
concentrations O +
such O +
as O +
bark O +
and O +
root O -
. O -

However O -
, O +
elephant U-Species +
should O +
maintain O +
nutrient O -
- O -
rich O +
trees O +
by O +
inducing O +
coppicing O +
of O +
trees O +
through O +
re O -
- O -
utilization O +
of O +
leaves O -
. O -

5 O -
. O -

Elephant U-Species +
patch O +
selection O +
was O +
measured O +
in O +
a O +
homogenous O +
tree O +
species O +
stand O +
by O +
manipulating O +
the O +
spatial O +
distribution O +
of O +
soil O +
nutrients O +
in O +
a O +
large O +
field O +
experiment O +
using O +
NPK O +
fertilizer O -
. O -

6 O -
. O +
Elephant U-Species +
were O +
able O +
to O +
select O +
nutrient O -
- O -
rich O +
patches O +
and O +
utilized O +
Colophospermum B-Species +
mopane L-Species +
trees O +
inside O +
these O +
patches O +
more O +
than O +
outside O -
, O +
at O +
scales O +
ranging O +
from O +
2500 O +
down O +
to O +
100 O +
m O -
( O -
2 O -
) O +
. O -

7 O -
. O -

Although O +
both O +
nitrogen O +
and O +
phosphorus O +
contents O +
of O +
leaves O +
from O +
C. B-Species +
mopane L-Species +
trees O +
were O +
higher O +
in O +
fertilized O +
and O +
selected O +
patches O -
, O +
patch O +
choice O +
correlated O +
most O +
strongly O +
with O +
nitrogen O +
content O -
. O -

As O +
predicted O -
, O +
stripping O +
of O +
leaves O +
occurred O +
more O +
in O +
nutrient O -
- O -
rich O +
patches O -
, O +
while O +
adverse O +
impact O +
such O +
as O +
uprooting O +
of O +
trees O +
occurred O +
more O +
in O +
nutrient O -
- O -
poor O +
areas O -
. O -

8 O -
. O -

Our O +
results O +
emphasize O +
the O +
necessity O +
of O +
including O +
scale O -
- O -
dependent O +
selectivity O +
in O +
foraging O +
studies O +
and O +
how O +
elephant U-Species +
foraging O +
behaviour O +
can O +
be O +
used O +
as O +
indicators O +
of O +
change O +
in O +
the O +
availability O +
of O +
nutrients O -
. O +

Mating O +
differentiation O +
in O +
Cryptococcus B-Species +
neoformans L-Species +
is O +
negatively O +
regulated O +
by O +
the O +
Crk1 O +
protein O +
kinase O -
. O +

Cryptococcus B-Species +
neoformans L-Species +
is O +
a O +
heterothallic O +
basidiomycete O +
that O +
grows O +
vegetatively O +
as O +
yeast U-Species +
and O +
filamentous O +
hyphae O +
are O +
produced O +
in O +
the O +
sexual O +
state O -
. O -

Previous O +
studies O +
have O +
shown O +
that O +
C. B-Species +
neoformans L-Species +
Cwc1 O +
and O +
Cwc2 O +
are O +
two O +
central O +
photoregulators O +
which O +
form O +
a O +
complex O +
to O +
inhibit O +
the O +
production O +
of O +
sexual O +
filaments O +
upon O +
light O +
treatment O -
. O -

To O +
reveal O +
the O +
detailed O +
regulatory O +
mechanisms O -
, O +
a O +
genome O +
wide O +
mutagenesis O +
screen O +
was O +
conducted O +
and O +
components O +
in O +
the O +
Cwc1 O -
/ O -
Cwc2 O +
complex O +
mediated O +
pathway O +
have O +
been O +
identified O -
. O -

In O +
this O +
study O -
, O +
one O +
suppressor O +
mutant O -
, O +
DJ22 O -
, O +
is O +
characterized O +
and O +
T O -
- O -
DNA O +
is O +
found O +
to O +
disrupt O +
the O +
C. B-Species +
neoformans L-Species +
CRK1 O +
gene O -
, O +
a O +
homologue O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
IME2 O +
and O +
Ustilago B-Species +
maydis L-Species +
crk1 O -
. O -

Ime2 O +
is O +
a O +
meiosis O -
- O -
specific O +
gene O +
with O +
the O +
conserved O +
Ser O -
/ O -
Thr O +
kinase O +
domain O +
and O +
TXY O +
dual O +
phosphorylation O +
site O -
. O -

Consistent O +
with O +
the O +
findings O +
of O +
other O +
suppressors O +
in O +
our O +
screen O -
, O +
C. B-Species +
neoformans L-Species +
Crk1 O +
plays O +
a O +
negative O +
role O +
in O +
the O +
mating O +
process O -
. O -

Dikaryotic O +
filaments O -
, O +
basidia O -
, O +
and O +
basidiospores O +
are O +
produced O +
earlier O +
in O +
the O +
crk1 O +
mutant O +
crosses O +
and O +
mating O +
efficiency O +
is O +
also O +
increased O -
. O -

Artificial O +
elevation O +
of O +
the O +
CRK1 O +
mRNA O +
level O +
inhibits O +
mating O -
. O -

Interestingly O -
, O +
monokaryotic O +
fruiting O +
is O +
defective O +
both O +
in O +
the O +
MATalpha O +
crk1 O +
mutant O +
and O +
CRK1 O +
overexpression O +
strains O -
. O -

Our O +
studies O +
demonstrate O +
that O +
C. O +
neoformans O +
CRK1 O +
gene O +
functions O +
as O +
a O +
negative O +
regulator O +
in O +
the O +
mating O +
differentiation O -
. O +

The O +
Rcs O +
signal O +
transduction O +
pathway O +
is O +
triggered O +
by O +
enterobacterial O +
common O +
antigen O +
structure O +
alterations O +
in O +
Serratia B-Species +
marcescens L-Species -
. O +

The O +
enterobacterial O +
common O +
antigen O +
( O -
ECA O -
) O +
is O +
a O +
highly O +
conserved O +
exopolysaccharide O +
in O +
Gram O -
- O -
negative O +
bacteria O +
whose O +
role O +
remains O +
largely O +
uncharacterized O -
. O -

In O +
a O +
previous O +
work O -
, O +
we O +
have O +
demonstrated O +
that O +
disrupting O +
the O +
integrity O +
of O +
the O +
ECA O +
biosynthetic O +
pathway O +
imposed O +
severe O +
deficiencies O +
to O +
the O +
Serratia B-Species +
marcescens L-Species +
motile O +
( O -
swimming O +
and O +
swarming O -
) O +
capacity O -
. O -

In O +
this O +
work O -
, O +
we O +
show O +
that O +
alterations O +
in O +
the O +
ECA O +
structure O +
activate O +
the O +
Rcs O +
phosphorelay O -
, O +
which O +
results O +
in O +
the O +
repression O +
of O +
the O +
flagellar O +
biogenesis O +
regulatory O +
cascade O -
. O -

In O +
addition O -
, O +
a O +
detailed O +
analysis O +
of O +
wec O +
cluster O +
mutant O +
strains O -
, O +
which O +
provoke O +
the O +
disruption O +
of O +
the O +
ECA O +
biosynthesis O +
at O +
different O +
levels O +
of O +
the O +
pathway O -
, O +
suggests O +
that O +
the O +
absence O +
of O +
the O +
periplasmic O +
ECA O +
cyclic O +
structure O +
could O +
constitute O +
a O +
potential O +
signal O +
detected O +
by O +
the O +
RcsF O -
- O -
RcsCDB O +
phosphorelay O -
. O -

We O +
also O +
identify O +
SMA1167 O +
as O +
a O +
member O +
of O +
the O +
S. B-Species +
marcescens L-Species +
Rcs O +
regulon O +
and O +
show O +
that O +
high O +
osmolarity O +
induces O +
Rcs O +
activity O +
in O +
this O +
bacterium O -
. O -

These O +
results O +
provide O +
a O +
new O +
perspective O +
from O +
which O +
to O +
understand O +
the O +
phylogenetic O +
conservation O +
of O +
ECA O +
among O +
enterobacteria O +
and O +
the O +
basis O +
for O +
the O +
virulence O +
attenuation O +
detected O +
in O +
wec O +
mutant O +
strains O +
in O +
other O +
pathogenic O +
bacteria O -
. O +

Pyrethroid O +
resistance O +
in O +
Sitophilus B-Species +
zeamais L-Species +
is O +
associated O +
with O +
a O +
mutation O +
( O -
T929I O -
) O +
in O +
the O +
voltage O -
- O -
gated O +
sodium O +
channel O -
. O +

The O +
maize B-Species +
weevil L-Species -
, O +
Sitophilus B-Species +
zeamais L-Species -
, O +
is O +
the O +
most O +
important O +
pest O +
affecting O +
stored O +
grain O +
in O +
Brazil O +
and O +
its O +
control O +
relies O +
heavily O +
on O +
the O +
use O +
of O +
insecticides O -
. O -

The O +
intensive O +
use O +
of O +
compounds O +
such O +
as O +
the O +
pyrethroids O +
has O +
led O +
to O +
the O +
emergence O +
of O +
resistance O -
, O +
and O +
previous O +
studies O +
have O +
suggested O +
that O +
resistance O +
to O +
both O +
pyrethroids O +
and O +
1,1,1-trichloro-2,2-bis O -
( O -
p O -
- O -
chlorophenyl O -
) O -
ethane O +
( O -
DDT O -
) O +
may O +
result O +
from O +
reduced O +
sensitivity O +
of O +
the O +
insecticide O +
target O -
, O +
the O +
voltage O -
- O -
gated O +
sodium O +
channel O -
. O -

To O +
identify O +
the O +
molecular O +
mechanisms O +
underlying O +
pyrethroid O +
resistance O +
in O +
S. B-Species +
zeamais L-Species -
, O +
the O +
domain O +
II O +
region O +
of O +
the O +
voltage O -
- O -
gated O +
sodium O +
channel O +
( O -
para O -
- O -
orthologue O -
) O +
gene O +
was O +
amplified O +
by O +
PCR O +
and O +
sequenced O +
from O +
susceptible O +
and O +
resistant O +
laboratory O +
S. B-Species +
zeamais L-Species +
strains O +
that O +
were O +
selected O +
with O +
a O +
discriminating O +
dose O +
of O +
DDT O -
. O -

A O +
single O +
point O +
mutation O -
, O +
T929I O -
, O +
was O +
found O +
in O +
the O +
para O +
gene O +
of O +
the O +
resistant O +
S. B-Species +
zeamais L-Species +
populations O +
and O +
its O +
presence O +
in O +
individual O +
weevils O +
was O +
strongly O +
associated O +
with O +
survival O +
after O +
DDT O +
exposure O -
. O -

This O +
is O +
the O +
first O +
identification O +
of O +
a O +
target O -
- O -
site O +
resistance O +
mutation O +
in O +
S. B-Species +
zeamais L-Species +
and O +
unusually O +
it O +
is O +
a O +
super O -
- O -
kdr O +
type O +
mutation O +
occurring O +
in O +
the O +
absence O +
of O +
the O +
more O +
common O +
kdr O +
( O -
L1014F O -
) O +
substitution O -
. O -

A O +
high O -
- O -
throughput O +
assay O +
based O +
on O +
TaqMan O +
single O +
nucleotide O +
polymorphism O +
genotyping O +
was O +
developed O +
for O +
sensitive O +
detection O +
of O +
the O +
mutation O +
and O +
used O +
to O +
screen O +
field O -
- O -
collected O +
strains O +
of O +
S. B-Species +
zeamais L-Species -
. O -

This O +
showed O +
that O +
the O +
mutation O +
is O +
present O +
at O +
low O +
frequency O +
in O +
field O +
populations O +
and O +
is O +
a O +
useful O +
tool O +
for O +
informing O +
control O +
strategies O -
. O +

Mapping O +
interactions O +
between O +
germinants O +
and O +
Clostridium B-Species +
difficile L-Species +
spores O -
. O -

Germination O +
of O +
Clostridium B-Species +
difficile L-Species +
spores O +
is O +
the O +
first O +
required O +
step O +
in O +
establishing O +
C. B-Species +
difficile L-Species -
- O -
associated O +
disease O +
( O -
CDAD O -
) O -
. O -

Taurocholate O +
( O -
a O +
bile O +
salt O -
) O +
and O +
glycine O +
( O -
an O +
amino O +
acid O -
) O +
have O +
been O +
shown O +
to O +
be O +
important O +
germinants O +
of O +
C. B-Species +
difficile L-Species +
spores O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
tested O +
a O +
series O +
of O +
glycine O +
and O +
taurocholate O +
analogs O +
for O +
the O +
ability O +
to O +
induce O +
or O +
inhibit O +
C. B-Species +
difficile L-Species +
spore O +
germination O -
. O -

Testing O +
of O +
glycine O +
analogs O +
revealed O +
that O +
both O +
the O +
carboxy O +
and O +
amino O +
groups O +
are O +
important O +
epitopes O +
for O +
recognition O +
and O +
that O +
the O +
glycine O +
binding O +
site O +
can O +
accommodate O +
compounds O +
with O +
more O +
widely O +
separated O +
termini O -
. O -

The O +
C. B-Species +
difficile L-Species +
germination O +
machinery O +
also O +
recognizes O +
other O +
hydrophobic O +
amino O +
acids O -
. O -

In O +
general O -
, O +
linear O +
alkyl O +
side O +
chains O +
are O +
better O +
activators O +
of O +
spore O +
germination O +
than O +
their O +
branched O +
analogs O -
. O -

However O -
, O +
L O -
- O -
phenylalanine O +
and O +
L O -
- O -
arginine O +
are O +
also O +
good O +
germinants O +
and O +
are O +
probably O +
recognized O +
by O +
distinct O +
binding O +
sites O -
. O -

Testing O +
of O +
taurocholate O +
analogs O +
revealed O +
that O +
the O +
12-hydroxyl O +
group O +
of O +
taurocholate O +
is O +
necessary O -
, O +
but O +
not O +
sufficient O -
, O +
to O +
activate O +
spore O +
germination O -
. O -

In O +
contrast O -
, O +
the O +
6- O +
and O +
7-hydroxyl O +
groups O +
are O +
required O +
for O +
inhibition O +
of O +
C. B-Species +
difficile L-Species +
spore O +
germination O -
. O -

Similarly O -
, O +
C. B-Species +
difficile L-Species +
spores O +
are O +
able O +
to O +
detect O +
taurocholate O +
analogs O +
with O +
shorter O -
, O +
but O +
not O +
longer O -
, O +
alkyl O +
amino O +
sulfonic O +
acid O +
side O +
chains O -
. O -

Furthermore O -
, O +
the O +
sulfonic O +
acid O +
group O +
can O +
be O +
partially O +
substituted O +
with O +
other O +
acidic O +
groups O -
. O -

Finally O -
, O +
a O +
taurocholate O +
analog O +
with O +
an O +
m O -
- O -
aminobenzenesulfonic O +
acid O +
side O +
chain O +
is O +
a O +
strong O +
inhibitor O +
of O +
C. B-Species +
difficile L-Species +
spore O +
germination O -
. O -

In O +
conclusion O -
, O +
C. B-Species +
difficile L-Species +
spores O +
recognize O +
both O +
amino O +
acids O +
and O +
taurocholate O +
through O +
multiple O +
interactions O +
that O +
are O +
required O +
to O +
bind O +
the O +
germinants O +
and/or O +
activate O +
the O +
germination O +
machinery O -
. O +

In O +
vitro O +
studies O +
of O +
peptidoglycan O +
binding O +
and O +
hydrolysis O +
by O +
the O +
Bacillus B-Species +
anthracis L-Species +
germination O -
- O -
specific O +
lytic O +
enzyme O +
SleB. O +
The O +
Bacillus B-Species +
anthracis L-Species +
endospore O +
loses O +
resistance O +
properties O +
during O +
germination O +
when O +
its O +
cortex O +
peptidoglycan O +
is O +
degraded O +
by O +
germination O -
- O -
specific O +
lytic O +
enzymes O +
( O -
GSLEs O -
) O -
. O -

Although O +
this O +
event O +
normally O +
employs O +
several O +
GSLEs O +
for O +
complete O +
cortex O +
removal O -
, O +
the O +
SleB O +
protein O +
alone O +
can O +
facilitate O +
enough O +
cortex O +
hydrolysis O +
to O +
produce O +
vulnerable O +
spores O -
. O -

As O +
a O +
means O +
to O +
better O +
understand O +
its O +
enzymatic O +
function O -
, O +
SleB O +
was O +
overexpressed O -
, O +
purified O -
, O +
and O +
tested O +
in O +
vitro O +
for O +
depolymerization O +
of O +
cortex O +
by O +
measurement O +
of O +
optical O +
density O +
loss O +
and O +
the O +
solubilization O +
of O +
substrate O -
. O -

Its O +
ability O +
to O +
bind O +
peptidoglycan O +
was O +
also O +
investigated O -
. O -

SleB O +
functions O +
independently O +
as O +
a O +
lytic O +
transglycosylase O +
on O +
both O +
intact O +
and O +
fragmented O +
cortex O -
. O -

Most O +
of O +
the O +
muropeptide O +
products O +
that O +
SleB O +
generates O +
are O +
large O +
and O +
are O +
potential O +
substrates O +
for O +
other O +
GSLEs O +
present O +
in O +
the O +
spore O -
. O -

Study O +
of O +
a O +
truncated O +
protein O +
revealed O +
that O +
SleB O +
has O +
two O +
domains O -
. O -

The O +
N O -
- O -
terminal O +
domain O +
is O +
required O +
for O +
stable O +
peptidoglycan O +
binding O -
, O +
while O +
the O +
C O -
- O -
terminal O +
domain O +
is O +
the O +
region O +
of O +
peptidoglycan O +
hydrolytic O +
activity O -
. O -

The O +
C O -
- O -
terminal O +
domain O +
also O +
exhibits O +
dependence O +
on O +
cortex O +
containing O +
muramic O -
- O -
delta O -
- O -
lactam O +
in O +
order O +
to O +
carry O +
out O +
hydrolysis O -
. O -

As O +
the O +
conditions O +
and O +
limitations O +
for O +
SleB O +
activity O +
are O +
further O +
elucidated O -
, O +
they O +
will O +
enable O +
the O +
development O +
of O +
treatments O +
that O +
stimulate O +
premature O +
germination O +
of O +
B. B-Species +
anthracis L-Species +
spores O -
, O +
greatly O +
simplifying O +
decontamination O +
measures O -
. O +

Endogenous O +
regulation O +
of O +
the O +
growth O -
- O -
rate O +
responses O +
of O +
a O +
spring O -
- O -
dwelling O +
strain O +
of O +
the O +
freshwater O +
alga O -
, O +
Chlorella B-Species +
minutissima L-Species -
, O +
to O +
light O +
and O +
temperature O -
. O +

The O +
paper O +
presents O +
a O +
laboratory O +
investigation O +
of O +
the O +
temperature- O +
and O +
light- O +
dependence O +
of O +
autotrophic O +
growth O +
of O +
the O +
alga O +
Chlorella B-Species +
minutissima L-Species -
. O -

It O +
was O +
isolated O +
from O +
the O +
storage O +
basin O +
of O +
a O +
spring O +
in O +
the O +
mountains O +
of O +
the O +
Massif O +
Central O -
, O +
France O -
. O -

The O +
alga O +
was O +
grown O +
at O +
temperatures O +
between O +
( O -
10 O +
and O +
35 O +
^0C O -
) O +
and O +
under O +
irradiances O +
from O +
30 O +
to O +
550 O +
mumol O +
m O -
( O -
-2 O -
) O +
s O -
( O -
-1 O -
) O -
, O +
under O +
a O +
light O -
/ O -
dark O +
cycle O -
. O -

The O +
results O +
were O +
fitted O +
to O +
selected O +
descriptive O +
models O -
, O +
seeking O +
to O +
express O -
, O +
as O +
far O +
as O +
possible O -
, O +
the O +
observed O +
physiological O +
behaviour O +
of O +
the O +
strain O +
and O +
the O +
minimum O +
irradiance O +
required O +
to O +
sustain O +
net O +
growth O -
. O -

At O +
all O +
temperatures O -
, O +
the O +
maximum O +
rates O +
of O +
growth O +
observed O +
are O +
strikingly O +
slower O +
than O +
those O +
of O +
other O +
Chlorella B-Species +
strains L-Species +
and O +
of O +
other O +
small O +
algae O -
, O +
reported O +
in O +
the O +
literature O -
, O +
even O +
when O +
correction O +
is O +
made O +
for O +
continuous O +
light O -
. O -

The O +
Q10 O +
statistic O +
for O +
growth O +
at O +
temperatures>20 O +
^0C O +
rates O +
is O +
also O +
noticeably O +
lower O +
than O +
in O +
other O +
species O -
, O +
while O +
the O +
apparent O +
threshold O +
of O +
any O +
growth O +
is O +
about O +
8 O +
^0C O -
. O -

Growth O +
rates O +
are O +
readily O +
light O -
- O -
saturated O +
at O +
all O +
temperatures O +
but O +
with O +
little O +
evidence O +
of O +
adaptation O +
of O +
photosynthesis O +
to O +
low O +
photon O -
- O -
flux O +
rates O -
. O -

No O +
short O -
- O -
term O +
flexibility O +
in O +
these O +
properties O +
( O -
over O +
a O +
time O -
- O -
scale O +
of O +
days O -
) O +
was O +
demonstrated O +
during O +
the O +
course O +
of O +
our O +
experiments O -
. O -

We O +
deduce O +
that O +
the O +
algal O +
strain O +
had O +
become O +
genetically O +
adapted O +
to O +
the O +
relatively O +
constant O -
, O +
even O -
- O -
temperature O +
and O +
low O -
- O -
light O +
conditions O +
of O +
the O +
spring O -
- O -
water O +
habitat O +
whence O +
it O +
was O +
originally O +
isolated O -
. O +

Systemic O +
virus O -
- O -
induced O +
gene O +
silencing O +
allows O +
functional O +
characterization O +
of O +
maize U-Species +
genes O +
during O +
biotrophic O +
interaction O +
with O +
Ustilago B-Species +
maydis L-Species -
. O +

Infection O +
of O +
maize U-Species +
( O -
Zea B-Species +
mays L-Species -
) O +
plants O +
with O +
the O +
corn U-Species +
smut O +
fungus O +
Ustilago B-Species +
maydis L-Species +
leads O +
to O +
the O +
formation O +
of O +
large O +
tumors O +
on O +
the O +
stem O -
, O +
leaves O +
and O +
inflorescences O -
. O -

In O +
this O +
biotrophic O +
interaction O -
, O +
plant O +
defense O +
responses O +
are O +
actively O +
suppressed O +
by O +
the O +
pathogen O -
, O +
and O +
previous O +
transcriptome O +
analyses O +
of O +
infected O +
maize U-Species +
plants O +
showed O +
massive O +
and O +
stage O -
- O -
specific O +
changes O +
in O +
host O +
gene O +
expression O +
during O +
disease O +
progression O -
. O -

To O +
identify O +
maize U-Species +
genes O +
that O +
are O +
functionally O +
involved O +
in O +
the O +
interaction O +
with O +
U. B-Species +
maydis L-Species -
, O +
we O +
adapted O +
a O +
virus O -
- O -
induced O +
gene O +
silencing O +
( O -
VIGS O -
) O +
system O +
based O +
on O +
the O +
brome O +
mosaic O +
virus O +
( O -
BMV O -
) O +
for O +
maize U-Species -
. O -

Conditions O +
were O +
established O +
that O +
allowed O +
successful O +
U. B-Species +
maydis L-Species +
infection O +
of O +
BMV O -
- O -
preinfected O +
maize O +
plants O -
. O -

This O +
set O -
- O -
up O +
enabled O +
quantification O +
of O +
VIGS O +
and O +
its O +
impact O +
on O +
U. B-Species +
maydis L-Species +
infection O +
using O +
a O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
-based O +
readout O -
. O -

In O +
proof O -
- O -
of O -
- O -
principle O +
experiments O -
, O +
an O +
U. B-Species +
maydis L-Species -
- O -
induced O +
terpene O +
synthase O +
was O +
shown O +
to O +
negatively O +
regulate O +
disease O +
development O +
while O +
a O +
protein O +
involved O +
in O +
cell O +
death O +
inhibition O +
was O +
required O +
for O +
full O +
virulence O +
of O +
U. O +
maydis O -
. O -

The O +
results O +
suggest O +
that O +
this O +
system O +
is O +
a O +
versatile O +
tool O +
for O +
the O +
rapid O +
identification O +
of O +
maize U-Species +
genes O +
that O +
determine O +
compatibility O +
with O +
U. B-Species +
maydis L-Species -
. O +

Hyphal O +
and O +
cytoskeleton O +
polarization O +
in O +
Tuber B-Species +
melanosporum L-Species -
: O +
a O +
genomic O +
and O +
cellular O +
analysis O -
. O +

Filamentous O +
polarized O +
growth O +
involves O +
a O +
series O +
of O +
events O +
including O +
polarization O +
of O +
the O +
cytoskeleton O +
to O +
selected O +
growth O +
sites O -
, O +
and O +
the O +
transport O +
of O +
secretory O +
vesicles O +
containing O +
the O +
components O +
required O +
for O +
growth O -
. O -

The O +
availability O +
of O +
fungal O +
genome O +
sequences O +
has O +
recently O +
led O +
to O +
the O +
identification O +
of O +
a O +
large O +
number O +
of O +
proteins O +
involved O +
in O +
these O +
processes O -
. O -

We O +
have O +
explored O +
the O +
Tuber B-Species +
melanosporum L-Species +
genome O +
sequence O +
by O +
searching O +
for O +
homologs O +
of O +
genes O +
known O +
to O +
play O +
crucial O +
roles O +
in O +
the O +
morphogenesis O +
and O +
cell O +
polarity O +
of O +
yeasts U-Species +
and O +
filamentous O +
fungi O -
. O -

One O +
hundred O +
and O +
forty O -
- O -
nine O +
genes O +
have O +
been O +
identified O +
and O +
functionally O +
grouped O +
according O +
to O +
the O +
deduced O +
amino O +
acid O +
sequences O +
( O -
44 O +
genes O +
involved O +
in O +
cell O +
polarity O -
/ O -
morphogenesis O -
, O +
39 O +
belonging O +
to O +
the O +
actin O +
cytoskeleton O +
and O +
66 O +
involved O +
in O +
membrane O +
dynamics O -
, O +
septation O +
and O +
exocytosis O -
) O -
. O -

A O +
detailed O +
gene O +
annotation O +
has O +
shown O +
that O +
most O +
components O +
of O +
the O +
cell O +
polarity O +
machinery O -
, O +
morphogenesis O +
and O +
cytoskeleton O +
found O +
in O +
yeasts U-Species +
and O +
filamentous O +
fungi O +
are O +
conserved O -
, O +
although O +
the O +
degree O +
of O +
similarity O +
varies O +
from O +
strong O +
to O +
weak O -
. O -

Microscopic O +
analysis O +
of O +
quick O -
- O -
frozen O +
truffle O +
hyphae O +
detected O +
the O +
characteristic O +
subcellular O +
components O +
of O +
the O +
hyphal O +
tip O +
in O +
septate O +
filamentous O +
fungi O -
, O +
while O +
transcript O +
profiles O +
revealed O +
a O +
moderately O +
variable O +
pattern O +
during O +
the O +
biological O +
cycle O -
. O +

The O +
osmosensing O +
signal O +
transduction O +
pathway O +
from O +
Botrytis B-Species +
cinerea L-Species +
regulates O +
cell O +
wall O +
integrity O +
and O +
MAP O +
kinase O +
pathways O +
control O +
melanin O +
biosynthesis O +
with O +
influence O +
of O +
light O -
. O +

Mitogen O +
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
signal O +
transduction O +
pathways O +
are O +
ubiquitous O +
among O +
eukaryotic O +
organisms O +
with O +
evolutionary O +
conserved O +
modules O -
. O -

Although O +
generally O +
classified O +
as O +
osmotic O +
and O +
cell O +
wall O +
integrity O +
pathways O -
, O +
functional O +
divergences O +
have O +
been O +
observed O +
for O +
HOG1- O +
and O +
SLT2-related O +
MAPK O +
pathways O -
. O -

Here O +
we O +
show O +
that O +
the O +
osmotic O +
signal O +
transduction O +
cascade O +
is O +
involved O +
in O +
cell O +
wall O +
integrity O +
in O +
the O +
phytopathogenic O +
ascomycete O +
Botrytis B-Species +
cinerea L-Species -
. O -

The O +
deletion O +
mutants O +
of O +
the O +
upstream O +
histidine O +
kinase O +
Bos1 O +
and O +
of O +
the O +
MAPK O +
Sak1 O +
showed O +
modified O +
tolerance O +
to O +
cell O +
wall O +
degrading O +
enzymes O +
and O +
cell O +
wall O +
interfering O +
agents O -
, O +
as O +
well O +
as O +
increased O +
staining O +
of O +
Beta1 O -
- O -
3 O +
glucan O +
and O +
chitin O +
compared O +
to O +
the O +
wild O -
- O -
type O -
. O -

The O +
Sak1 O +
MAPK O +
was O +
phosphorylated O +
upon O +
cell O +
wall O +
challenging O -
. O -

Sak1 O +
interfered O +
with O +
the O +
phosphorylation O +
status O +
of O +
the O +
SLT2 O +
type O +
MAPK O +
Bmp3 O +
hinting O +
to O +
cross O +
talk O +
between O +
both O +
MAPK O +
pathways O -
. O -

All O +
signal O +
transduction O +
components O +
interfered O +
with O +
the O +
expression O +
of O +
melanin O +
biosynthesis O +
genes O +
in O +
dark O +
and O +
bright O -
, O +
suggesting O +
a O +
coordinated O +
control O +
of O +
melanin O +
biosynthesis O -
. O +

Ecosystem O +
engineering O +
and O +
predation O -
: O +
the O +
multi O -
- O -
trophic O +
impact O +
of O +
two O +
ant O +
species O -
. O +

1 O -
. O -

Ants O +
are O +
ubiquitous O +
ecosystem O +
engineers O +
and O +
generalist O +
predators O +
and O +
are O +
able O +
to O +
affect O +
ecological O +
communities O +
via O +
both O +
pathways O -
. O -

They O +
are O +
likely O +
to O +
influence O +
any O +
other O +
terrestrial O +
arthropod O +
group O +
either O +
directly O +
or O +
indirectly O +
caused O +
by O +
their O +
high O +
abundance O +
and O +
territoriality O -
. O -

2 O -
. O -

We O +
studied O +
the O +
impact O +
of O +
two O +
ant O +
species O +
common O +
in O +
Central O +
Europe O -
, O +
Myrmica B-Species +
rubra L-Species +
and O +
Lasius B-Species +
niger L-Species -
, O +
on O +
an O +
arthropod O +
community O -
. O -

Colony O +
presence O +
and O +
density O +
of O +
these O +
two O +
ant O +
species O +
were O +
manipulated O +
in O +
a O +
field O +
experiment O +
from O +
the O +
start O +
of O +
ant O +
activity O +
in O +
spring O +
to O +
late O +
summer O -
. O -

3 O -
. O -

The O +
experiment O +
revealed O +
a O +
positive O +
influence O +
of O +
the O +
presence O +
of O +
one O +
ant O +
colony O +
on O +
densities O +
of O +
decomposers O -
, O +
herbivores O +
and O +
parasitoids O -
. O -

However O -
, O +
in O +
the O +
case O +
of O +
herbivores O +
and O +
parasitoids O -
, O +
this O +
effect O +
was O +
reversed O +
in O +
the O +
presence O +
of O +
two O +
colonies O -
. O -

4 O -
. O +
Generally O -
, O +
effects O +
of O +
the O +
two O +
ant O +
species O +
were O +
similar O +
with O +
the O +
exception O +
of O +
their O +
effect O +
on O +
Braconidae O +
parasitoid O +
densities O +
that O +
responded O +
positively O +
to O +
one O +
colony O +
of O +
M. B-Species +
rubra L-Species +
but O +
not O +
of O +
L. B-Species +
niger L-Species -
. O -

5 O -
. O -

Spider O +
density O +
was O +
not O +
affected O +
by O +
ant O +
colony O +
manipulation O -
, O +
but O +
species O +
richness O +
of O +
spiders O +
responded O +
positively O +
to O +
ant O +
presence O -
. O -

This O +
effect O +
was O +
independent O +
of O +
ant O +
colony O +
density O -
, O +
but O +
where O +
two O +
colonies O +
were O +
present O -
, O +
spider O +
richness O +
was O +
significantly O +
greater O +
in O +
plots O +
with O +
two O +
M. B-Species +
rubra L-Species +
colonies O +
than O +
in O +
plots O +
with O +
one O +
colony O +
of O +
each O +
ant O +
species O -
. O -

6 O -
. O -

To O +
test O +
whether O +
the O +
positive O +
ecosystem O +
engineering O +
effects O +
were O +
purely O +
caused O +
by O +
modified O +
properties O +
of O +
the O +
soil O -
, O +
we O +
added O +
in O +
an O +
additional O +
experiment O +
( O -
i O -
) O +
the O +
soil O +
from O +
ant O +
nests O +
( O -
without O +
ants O -
) O +
or O +
( O -
ii O -
) O +
unmodified O +
soil O +
or O +
( O -
iii O -
) O +
ant O +
nests O +
( O -
including O +
ants O -
) O +
to O +
experimental O +
plots O -
. O -

Ant O +
nest O +
soil O +
on O +
its O +
own O +
did O +
not O +
have O +
a O +
significant O +
impact O +
on O +
densities O +
of O +
decomposers O -
, O +
herbivores O +
or O +
predators O -
, O +
which O +
were O +
significantly O -
, O +
and O +
positively O -
, O +
affected O +
by O +
the O +
addition O +
of O +
an O +
intact O +
nest O -
. O -

7 O -
. O -

The O +
results O +
suggest O +
an O +
important O +
role O +
of O +
both O +
ant O +
species O +
in O +
the O +
grassland O +
food O +
web O -
, O +
strongly O +
affecting O +
the O +
densities O +
of O +
decomposers O -
, O +
herbivores O +
and O +
higher O +
trophic O +
levels O -
. O -

We O +
discuss O +
how O +
the O +
relative O +
impact O +
via O +
bottom O -
- O -
up O +
and O +
top O -
- O -
down O +
effects O +
of O +
ants O +
depends O +
on O +
nest O +
density O -
, O +
with O +
a O +
relatively O +
greater O +
top O -
- O -
down O +
predatory O +
impact O +
at O +
higher O +
densities O -
. O +

The O +
effects O +
of O +
dsRNA O +
mycoviruses O +
on O +
growth O +
and O +
murine O +
virulence O +
of O +
Aspergillus B-Species +
fumigatus L-Species -
. O +

Some O +
isolates O +
of O +
the O +
opportunistic O +
human U-Species +
pathogenic O +
fungus O +
Aspergillus B-Species +
fumigatus L-Species +
are O +
known O +
to O +
be O +
infected O +
with O +
mycoviruses O -
. O -

The O +
dsRNA O +
genomes O +
of O +
two O +
of O +
these O +
mycoviruses O -
, O +
which O +
include O +
a O +
chrysovirus O +
and O +
a O +
partitivirus O -
, O +
have O +
been O +
completely O +
sequenced O +
and O +
an O +
RT O -
- O -
PCR O +
assay O +
for O +
the O +
viruses O +
has O +
been O +
developed O -
. O -

Through O +
curing O +
virus O -
- O -
infected O +
A. B-Species +
fumigatus L-Species +
isolates O +
by O +
cycloheximide O +
treatment O +
and O +
transfecting O +
virus O -
- O -
free O +
isolates O +
with O +
purified O +
virus O -
, O +
as O +
checked O +
by O +
RT O -
- O -
PCR O -
, O +
isogenic O +
virus O -
- O -
free O +
and O +
virus O -
- O -
infected O +
lines O +
of O +
the O +
fungus O +
were O +
generated O +
whose O +
phenotypes O +
and O +
growth O +
have O +
been O +
directly O +
compared O -
. O -

Mycovirus O +
infection O +
of O +
A. B-Species +
fumigatus L-Species +
with O +
either O +
the O +
chrysovirus O +
or O +
the O +
partitivirus O +
resulted O +
in O +
significant O +
aberrant O +
phenotypic O +
alterations O +
and O +
attenuation O +
of O +
growth O +
of O +
the O +
fungus O +
but O +
had O +
no O +
effect O +
on O +
susceptibility O +
to O +
common O +
antifungals O -
. O -

Chrysovirus O +
infection O +
of O +
A. B-Species +
fumigatus L-Species +
caused O +
no O +
significant O +
alterations O +
to O +
murine O +
pathogenicity O -
. O +

Suitability O +
of O +
different O +
media O +
for O +
in O +
vitro O +
cultivation O +
of O +
the O +
ruminal O +
protozoa O +
species O +
Entodinium B-Species +
caudatum L-Species -
, O +
Eudiplodinium B-Species +
maggii L-Species -
, O +
and O +
Epidinium B-Species +
ecaudatum L-Species -
. O +

Three O +
protozoal O +
cultivation O +
media O +
were O +
tested O +
to O +
determine O +
the O +
medium O +
which O +
best O +
facilitated O +
growth O +
and O +
viability O +
of O +
key O +
B O -
- O -
type O +
ciliates O +
isolated O +
from O +
the O +
sheep O +
rumen O -
. O -

Entodinium B-Species +
caudatum L-Species +
and O +
Eudiplodinium B-Species +
maggii L-Species +
were O +
grown O +
anaerobically O +
in O +
50-ml O +
flasks O +
for O +
32 O +
days O +
in O +
Caudatum O -
- O -
type O +
( O -
C O -
) O -
, O +
Kisidayova O +
( O -
K O -
) O +
or O +
Dehority O +
( O -
M O -
) O +
medium O -
. O -

On O +
day O +
32 O -
, O +
in O +
media O +
K O +
and O +
M O -
, O +
E. B-Species +
caudatum L-Species +
cell O +
counts O +
were O +
high O +
with O +
5.6x10 O -
( O -
3 O -
) O +
and O +
7.8x10 O -
( O -
3 O -
) O +
mL O -
( O -
-1 O -
) O -
, O +
respectively O -
, O +
and O +
the O +
proportion O +
of O +
dead O +
cells O +
was O +
low O +
with O +
0.6 O +
and O +
1.4 O -
% O -
, O +
respectively O -
. O -

E. B-Species +
maggii L-Species +
concentrations O +
when O +
grown O +
in O +
medium O +
M O +
and O +
C O +
were O +
2.7x10 O -
( O -
3 O -
) O +
and O +
2.4x10 O -
( O -
3 O -
) O +
mL O -
( O -
-1 O -
) O -
, O +
respectively O -
, O +
with O +
3.9 O +
and O +
14.1 O -
% O +
dead O +
cells O -
. O -

Medium O +
M O -
, O +
which O +
favoured O +
growth O +
of O +
both O +
protozoa O +
species O -
, O +
was O +
tested O +
again O +
and O +
Epidinium B-Species +
ecaudatum L-Species +
was O +
included O -
. O -

Protozoa O +
were O +
grown O +
for O +
a O +
4-month O +
period O +
and O +
samples O +
were O +
taken O +
in O +
the O +
last O +
two O +
months O +
on O +
days O +
1 O -
, O +
7 O -
, O +
35 O +
and O +
57 O -
. O -

Average O +
cell O +
concentrations O +
were O +
10.0 O -
, O +
0.8 O +
and O +
0.5x10 O -
( O -
3 O -
) O +
mL O -
( O -
-1 O -
) O +
for O +
E. B-Species +
caudatum L-Species -
, O +
E. B-Species +
maggii L-Species -
, O +
and O +
E. B-Species +
ecaudatum L-Species -
, O +
respectively O -
. O -

In O +
conclusion O -
, O +
medium O +
M O +
would O +
appear O +
to O +
be O +
the O +
best O +
choice O +
for O +
cultivating O +
these O +
three O +
species O +
in O +
one O +
medium O -
. O +

Non O -
- O -
structural O +
protein O +
1 O +
( O -
NS1 O -
) O +
antibody O -
- O -
based O +
assays O +
to O +
differentiate O +
West B-Species +
Nile L-Species +
( O -
WN O -
) O +
virus O +
from O +
Japanese O +
encephalitis O +
virus O +
infections O +
in O +
horses O -
: O +
effects O +
of O +
WN B-Species +
virus L-Species +
NS1 O +
antibodies O +
induced O +
by O +
inactivated O +
WN O +
vaccine O -
. O +

Antibodies O +
to O +
non O -
- O -
structural O +
protein O +
1 O +
( O -
NS1 O -
) O +
of O +
West O +
Nile O +
virus O +
( O -
WNV O -
) O +
have O +
been O +
used O +
to O +
differentiate O +
WNV O +
infection O +
from O +
infection O +
by O +
serologically O +
cross O -
- O -
reactive O +
flaviviruses O -
, O +
including O +
Japanese B-Species +
encephalitis I-Species +
virus L-Species +
( O -
JEV O -
) O -
, O +
in O +
horses O -
. O -

However O -
, O +
since O +
the O +
inactivated O +
West O +
Nile O +
( O -
WN U-Species -
) O +
vaccine O +
has O +
been O +
reported O +
to O +
induce O +
NS1 O +
antibodies O -
, O +
there O +
is O +
concern O +
about O +
the O +
reliability O +
of O +
using O +
NS1-based O +
assays O +
for O +
testing O +
vaccinated O +
horses O -
. O -

Therefore O -
, O +
the O +
effect O +
of O +
inactivated O +
WN U-Species +
vaccine O -
- O -
induced O +
antibodies O +
on O +
an O +
epitope O -
- O -
blocking O +
ELISA O +
and O +
complement O -
- O -
dependent O +
cytotoxicity O +
( O -
CDC O -
) O +
assay O +
were O +
investigated O -
. O -

Both O +
assays O +
are O +
based O +
on O +
NS1 O +
antibodies O +
and O +
were O +
established O +
previously O +
to O +
differentiate O +
WNV U-Species +
from O +
JEV O +
infections O +
in O +
horses O -
. O -

Groups O +
of O +
three O +
horses O +
were O +
vaccinated O +
with O +
two O +
or O +
three O +
doses O +
of O +
a O +
commercial O +
inactivated O +
WN O +
vaccine O +
and O +
NS1 O +
antibodies O +
were O +
detected O +
by O +
a O +
conventional O +
ELISA O +
after O +
the O +
second O +
vaccination O -
. O -

Vaccine O -
- O -
induced O +
NS1 O +
antibodies O +
were O +
also O +
detected O +
by O +
blocking O +
ELISA O +
and O +
a O +
CDC O +
assay O +
and O +
affected O +
the O +
ability O +
of O +
these O +
assays O +
to O +
differentiate O +
WNV U-Species +
from O +
JEV U-Species +
infections O -
. O -

However O -
, O +
the O +
effect O +
was O +
less O +
significant O +
in O +
the O +
CDC O +
assay O -
, O +
where O +
use O +
of O +
a O +
low O +
serum O +
concentration O +
ensured O +
effective O +
differentiation O -
. O -

The O +
more O +
efficient O +
detection O +
of O +
infection O -
- O -
induced O +
antibodies O +
over O +
vaccine O -
- O -
induced O +
antibodies O +
by O +
the O +
CDC O +
assay O +
was O +
potentially O +
attributable O +
to O +
the O +
different O +
IgG O +
isotype O +
profiles O +
of O +
these O +
antibodies O -
. O +

Involvement O +
of O +
extracellular O +
oxidative O +
burst O +
in O +
salicylic O +
acid O -
- O -
induced O +
stomatal O +
closure O +
in O +
Arabidopsis U-Species -
. O +

Salicylic O +
acid O +
( O -
SA O -
) O -
, O +
a O +
ubiquitous O +
phenolic O +
phytohormone O -
, O +
is O +
involved O +
in O +
many O +
plant O +
physiological O +
processes O +
including O +
stomatal O +
movement O -
. O -

We O +
analysed O +
SA O -
- O -
induced O +
stomatal O +
closure O -
, O +
production O +
of O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
and O +
nitric O +
oxide O +
( O -
NO O -
) O -
, O +
cytosolic O +
calcium O +
ion O +
( O -
[ O -
Ca^2+ O -
] O -
( O -
cyt O -
) O -
) O +
oscillations O +
and O +
inward O -
- O -
rectifying O +
potassium O +
( O -
K+ O -
( O -
in O -
) O -
) O +
channel O +
activity O +
in O +
Arabidopsis U-Species -
. O -

SA O -
- O -
induced O +
stomatal O +
closure O +
was O +
inhibited O +
by O +
pre O -
- O -
treatment O +
with O +
catalase O +
( O -
CAT O -
) O +
and O +
superoxide O +
dismutase O +
( O -
SOD O -
) O -
, O +
suggesting O +
the O +
involvement O +
of O +
extracellular O +
ROS O -
. O -

A O +
peroxidase O +
inhibitor O -
, O +
SHAM O +
( O -
salicylhydroxamic O +
acid O -
) O +
completely O +
abolished O +
SA O -
- O -
induced O +
stomatal O +
closure O +
whereas O +
neither O +
an O +
inhibitor O +
of O +
NADPH O +
oxidase O +
( O -
DPI O -
) O +
nor O +
atrbohD O +
atrbohF O +
mutation O +
impairs O +
SA O -
- O -
induced O +
stomatal O +
closures O -
. O -

3,3'-Diaminobenzidine O +
( O -
DAB O -
) O +
and O +
nitroblue O +
tetrazolium O +
( O -
NBT O -
) O +
stainings O +
demonstrated O +
that O +
SA O +
induced O +
H2O2 O +
and O +
O2- O +
production O -
. O -

Guard O +
cell O +
ROS O +
accumulation O +
was O +
significantly O +
increased O +
by O +
SA O -
, O +
but O +
that O +
ROS O +
was O +
suppressed O +
by O +
exogenous O +
CAT O -
, O +
SOD O +
and O +
SHAM O -
. O -

NO O +
scavenger O +
2- O -
( O -
4-carboxyphenyl O -
) O -
-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide O +
( O -
cPTIO O -
) O +
suppressed O +
the O +
SA O -
- O -
induced O +
stomatal O +
closure O +
but O +
did O +
not O +
suppress O +
guard O +
cell O +
ROS O +
accumulation O +
whereas O +
SHAM O +
suppressed O +
SA O -
- O -
induced O +
NO O +
production O -
. O -

SA O +
failed O +
to O +
induce O +
[ O -
Ca^2+ O -
] O -
( O -
cyt O -
) O +
oscillations O +
in O +
guard O +
cells O +
whereas O +
K+ O -
( O -
in O -
) O +
channel O +
activity O +
was O +
suppressed O +
by O +
SA O -
. O -

These O +
results O +
indicate O +
that O +
SA O +
induces O +
stomatal O +
closure O +
accompanied O +
with O +
extracellular O +
ROS O +
production O +
mediated O +
by O +
SHAM O -
- O -
sensitive O +
peroxidase O -
, O +
intracellular O +
ROS O +
accumulation O +
and O +
K+ O -
( O -
in O -
) O +
channel O +
inactivation O -
. O +

Influence O +
of O +
Sticky O +
Trap O +
Color O +
and O +
Height O +
Above O +
Ground O +
on O +
Capture O +
of O +
Alate O +
Elatobium B-Species +
abietinum L-Species +
( O -
Hemiptera O -
: O +
Aphididae O -
) O +
in O +
Sitka O +
Spruce O +
Plantations O -
. O +

A O +
series O +
of O +
field O +
trials O +
were O +
used O +
to O +
assess O +
the O +
practicality O +
of O +
using O +
sticky O +
traps O +
to O +
monitor O +
populations O +
of O +
green O +
spruce O +
aphid O -
, O +
Elatobium O +
abietinum O +
( O -
Walker O -
) O -
, O +
in O +
plantations O +
of O +
Sitka B-Species +
spruce L-Species -
. O -

The O +
highest O +
numbers O +
of O +
alate O +
E. B-Species +
abietinum L-Species +
were O +
caught O +
on O +
sticky O +
traps O +
placed O +
in O +
the O +
upper O +
third O +
of O +
the O +
live O +
canopy O +
at O +
9 O -
- O -
17 O +
m O +
above O +
the O +
ground O -
, O +
whereas O +
low O +
numbers O +
of O +
aphids O +
were O +
caught O +
just O +
below O +
the O +
live O +
canopy O +
or O +
at O +
2 O +
m O +
above O +
the O +
ground O -
. O -

Trials O +
in O +
2005 O +
with O +
sticky O +
traps O +
of O +
different O +
colors O +
showed O +
that O +
significantly O +
more O +
alate O +
E. B-Species +
abietinum L-Species +
were O +
caught O +
on O +
yellow O -
, O +
red O -
, O +
and O +
green O +
sticky O +
traps O +
than O +
on O +
white O -
, O +
blue O -
, O +
and O +
black O +
traps O -
. O -

A O +
repeat O +
trial O +
in O +
2007 O +
resulted O +
in O +
significantly O +
more O +
alate O +
aphids O +
being O +
caught O +
on O +
red O +
sticky O +
traps O +
than O +
on O +
traps O +
of O +
any O +
other O +
color O +
except O +
for O +
green O -
. O -

Attraction O +
to O +
red O +
is O +
unusual O +
among O +
aphids O -
, O +
as O +
aphids O +
are O +
thought O +
not O +
to O +
possess O +
a O +
red O -
- O -
sensitive O +
photoreceptor O -
. O -

The O +
attraction O +
of O +
E. B-Species +
abietinum L-Species +
to O +
red O -
- O -
colored O +
sticky O +
traps O +
suggests O +
that O +
conifer O -
- O -
feeding O +
aphids O +
might O +
have O +
a O +
fundamentally O +
different O +
color O +
response O +
compared O +
with O +
aphids O +
that O +
live O +
on O +
cereals O -
, O +
grasses O -
, O +
or O +
herbaceous O +
plants O -
. O -

Alternatively O -
, O +
the O +
attraction O +
to O +
red O +
might O +
be O +
a O +
physiological O +
artifact O +
related O +
to O +
the O +
presence O +
of O +
red O -
- O -
screening O +
pigments O +
in O +
the O +
aphid O -
's O +
compound O +
eye O -
. O +

Host O +
plant O +
effects O +
on O +
alkaline O +
phosphatase O +
activity O +
in O +
the O +
whiteflies O -
, O +
Bemisia B-Species +
tabaci L-Species +
Biotype O +
B O +
and O +
Trialeurodes B-Species +
vaporariorum L-Species -
. O +

Bemisia B-Species +
tabaci L-Species +
( O -
Gennadius O -
) O +
B O -
- O -
biotype O +
and O +
Trialeurodes B-Species +
vaporariorum L-Species +
( O -
Westwood O -
) O +
( O -
Hemiptera O -
: O +
Aleyrodidae O -
) O +
often O +
coexist O +
on O +
greenhouse O -
- O -
grown O +
vegetable O +
crops O +
in O +
northern O +
China O -
. O -

The O +
recent O +
spread O +
of O +
B. B-Species +
tabaci L-Species +
B O -
- O -
biotype O +
has O +
largely O +
replaced O +
T. B-Species +
vaporariorum L-Species -
, O +
and O +
B O -
- O -
biotype O +
now O +
overlaps O +
with O +
T. B-Species +
vaporariorum L-Species +
where O +
common O +
hosts O +
occur O +
in O +
most O +
invaded O +
areas O -
. O -

The O +
impact O +
of O +
the O +
B O -
- O -
biotype O +
on O +
the O +
agro O +
eco O +
system O +
appears O +
to O +
be O +
widespread O -
, O +
and O +
involves O +
the O +
ability O +
to O +
compete O +
with O +
and O +
perhaps O +
replace O +
other O +
phytophages O +
like O +
T. B-Species +
vaporariorum L-Species -
. O -

An O +
emerging O +
hypothesis O +
is O +
that O +
the O +
B O -
- O -
biotype O +
is O +
physiologically O +
superior O +
due O +
at O +
least O +
in O +
part O +
to O +
an O +
improved O +
ability O +
to O +
metabolically O +
utilize O +
the O +
alkaline O +
phosphatase O +
pathway O -
. O -

To O +
test O +
this O +
hypothesis O -
, O +
alkaline O +
phosphatase O +
activity O +
was O +
studied O +
in O +
the O +
B O -
- O -
biotype O +
and O +
T. B-Species +
vaporariorum L-Species +
after O +
feeding O +
on O +
a O +
number O +
of O +
different O +
hosts O +
for O +
a O +
range O +
of O +
durations O -
, O +
with O +
and O +
without O +
host O +
switching O -
. O -

Alkaline O +
phosphatase O +
activity O +
in O +
T. B-Species +
vaporariorum L-Species +
was O +
1.45 O +
to O +
2.53-fold O +
higher O +
than O +
that O +
of O +
the O +
B O -
- O -
biotype O +
when O +
fed O +
on O +
tomato U-Species +
for O +
4 O +
and O +
24 O +
h O -
, O +
or O +
switched O +
from O +
tomato U-Species +
to O +
cotton U-Species +
and O +
cabbage U-Species +
for O +
the O +
same O +
durations O -
. O -

However O -
, O +
alkaline O +
phosphatase O +
activity O +
in O +
the O +
B O -
- O -
biotype O +
was O +
1.40 O +
to O +
3.35-fold O +
higher O +
than O +
that O +
of O +
T. B-Species +
vaporariorum L-Species +
when O +
the O +
host O +
switching O +
time O +
was O +
-72 O +
and O +
-120 O +
h O +
on O +
the O +
same O +
plant O -
. O -

Both O +
short O -
- O -
term O +
( O -
4 O +
h O -
) O +
and O +
long O -
- O -
term O +
( O -
72 O +
h O -
) O +
switching O +
of O +
plant O +
hosts O +
can O +
significantly O +
affect O +
the O +
alkaline O +
phosphatase O +
activity O +
in O +
the O +
two O +
species O -
. O -

After O +
-120 O +
h O -
, O +
feeding O +
on O +
tomato U-Species +
and O +
cotton U-Species +
alkaline O +
phosphatase O +
activity O +
in O +
the O +
B O -
- O -
biotype O +
was O +
significantly O +
higher O +
than O +
that O +
of O +
T. B-Species +
vaporariorum L-Species -
. O -

It O +
was O +
shown O +
that O +
alkaline O +
phosphatase O +
aids O +
the O +
species O +
feeding O +
on O +
different O +
plant O +
species O -
, O +
and O +
that O +
the O +
B O -
- O -
biotype O +
is O +
physiologically O +
superior O +
to O +
T. B-Species +
vaporariorum L-Species +
in O +
utilizing O +
the O +
enzyme O +
compared O +
to O +
T. B-Species +
vaporariorum L-Species +
over O +
longer O +
periods O +
of O +
feeding O -
. O +

T O +
cell O -
- O -
mediated O +
protection O +
against O +
lethal B-Species +
2009 I-Species +
pandemic I-Species +
H1N1 I-Species +
influenza I-Species +
virus L-Species +
infection O +
in O +
a O +
mouse O +
model O -
. O +

Genetic O +
mutation O +
and O +
reassortment O +
of O +
influenza B-Species +
virus L-Species +
gene O +
segments O -
, O +
in O +
particular O +
those O +
of O +
hemagglutinin O +
( O -
HA O -
) O +
and O +
neuraminidase O +
( O -
NA O -
) O -
, O +
that O +
lead O +
to O +
antigenic O +
drift O +
and O +
shift O +
are O +
the O +
major O +
strategies O +
for O +
influenza B-Species +
virus L-Species +
to O +
escape O +
preexisting O +
immunity O -
. O -

The O +
most O +
recent O +
example O +
of O +
such O +
phenomena O +
is O +
the O +
first O +
pandemic O +
of O +
H1N1 B-Species +
influenza L-Species +
of O +
the O +
21st O +
century O -
, O +
which O +
started O +
in O +
2009 O -
. O -

Cross O -
- O -
reactive O +
antibodies O +
raised O +
against O +
H1N1 B-Species +
viruses L-Species +
circulating O +
before O +
1930 O +
show O +
protective O +
activity O +
against O +
the O +
2009 B-Species +
pandemic I-Species +
virus L-Species -
. O -

Cross O -
- O -
reactive O +
T O -
- O -
cell O +
responses O +
can O +
also O +
contribute O +
to O +
protection O -
, O +
but O +
in O +
vivo O +
support O +
of O +
this O +
view O +
is O +
lacking O -
. O -

To O +
explore O +
the O +
protection O +
mechanisms O +
in O +
vivo O -
, O +
we O +
primed O +
mice O +
with O +
H1 U-Species +
and O +
H3 B-Species +
influenza I-Species +
virus L-Species +
isolates O +
and O +
rechallenged O +
them O +
with O +
a O +
virus O +
derived O +
from O +
the O +
2009 B-Species +
H1N1 I-Species +
A I-Species -
/ I-Species -
CA I-Species -
/ I-Species -
04 I-Species -
/ I-Species -
09 I-Species +
virus L-Species -
, O +
named O +
CA O -
/ O -
E3 O -
/ O -
09 O -
. O -

We O +
found O +
that O +
priming O +
with O +
influenza O +
viruses O +
of O +
both O +
H1 U-Species +
and O +
H3 O +
homo- O +
and O +
heterosubtypes O +
protected O +
against O +
lethal O +
CA O -
/ O -
E3 O -
/ O -
09 O +
virus O +
challenge O -
. O -

Convalescent O -
- O -
phase O +
sera O +
from O +
these O +
primed O +
mice O +
conferred O +
no O +
neutralization O +
activity O +
in O +
vitro O +
and O +
no O +
protection O +
in O +
vivo O -
. O -

However O -
, O +
T O -
- O -
cell O +
depletion O +
studies O +
suggested O +
that O +
both O +
CD4 O +
and O +
CD8 O +
T O +
cells O +
contributed O +
to O +
the O +
protection O -
. O -

Taken O +
together O -
, O +
these O +
results O +
indicate O +
that O +
cross O -
- O -
reactive O +
T O +
cells O +
established O +
after O +
initial O +
priming O +
with O +
distally O +
related O +
viruses O +
can O +
be O +
a O +
vital O +
component O +
for O +
prevention O +
of O +
disease O +
and O +
control O +
of O +
pandemic B-Species +
H1N1 I-Species +
influenza I-Species +
virus L-Species +
infection O -
. O -

Our O +
results O +
highlight O +
the O +
importance O +
of O +
establishing O +
cross O -
- O -
reactive O +
T O -
- O -
cell O +
responses O +
for O +
protecting O +
against O +
existing O +
or O +
newly O +
emerging O +
pandemic O +
influenza O +
viruses O -
. O +

Association O +
of O +
TRIM22 O +
with O +
the O +
type O +
1 O +
interferon O +
response O +
and O +
viral O +
control O +
during O +
primary O +
HIV-1 U-Species +
infection O -
. O +

Type O +
1 O +
interferons O +
( O -
IFNs O -
) O +
induce O +
the O +
expression O +
of O +
the O +
tripartite O +
interaction O +
motif O +
( O -
TRIM O -
) O +
family O +
of O +
E3 O +
ligases O -
, O +
but O +
the O +
contribution O +
of O +
these O +
antiviral O +
factors O +
to O +
HIV U-Species +
pathogenesis O +
is O +
not O +
completely O +
understood O -
. O -

We O +
hypothesized O +
that O +
the O +
increased O +
expression O +
of O +
select O +
type O +
1 O +
IFN O +
and O +
TRIM O +
isoforms O +
is O +
associated O +
with O +
a O +
significantly O +
lower O +
likelihood O +
of O +
HIV-1 U-Species +
acquisition O +
and O +
viral O +
control O +
during O +
primary O +
HIV-1 U-Species +
infection O -
. O -

We O +
measured O +
IFN O -
- O -
alpha O -
, O +
IFN O -
- O -
Beta O -
, O +
myxovirus O +
resistance O +
protein O +
A O +
( O -
MxA O -
) O -
, O +
human U-Species +
TRIM5alpha O +
( O -
huTRIM5alpha O -
) O -
, O +
and O +
TRIM22 O +
mRNA O +
levels O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMCs O -
) O +
of O +
high O -
- O -
risk O -
, O +
HIV-1-uninfected U-Species +
participants O +
and O +
HIV-1-positive U-Species +
study O +
participants O -
. O -

Samples O +
were O +
available O +
for O +
32 O +
uninfected O +
subjects O +
and O +
28 O +
infected O +
persons O -
, O +
all O +
within O +
1 O +
year O +
of O +
infection O -
. O -

HIV-1-positive U-Species +
participants O +
had O +
higher O +
levels O +
of O +
IFN O -
- O -
Beta O +
( O -
P O +
= O +
0.0005 O -
) O -
, O +
MxA O +
( O -
P O +
= O +
0.007 O -
) O -
, O +
and O +
TRIM22 O +
( O -
P O +
= O +
0.01 O -
) O +
and O +
lower O +
levels O +
of O +
huTRIM5alpha O +
( O -
P O +
< O +
0.001 O -
) O +
than O +
did O +
HIV-1-negative O +
participants O -
. O -

TRIM22 O +
but O +
not O +
huTRIM5alpha O +
correlated O +
positively O +
with O +
type O +
1 O +
IFN O +
( O -
IFN O -
- O -
alpha O -
, O +
IFN O -
- O -
Beta O -
, O +
and O +
MxA O -
) O +
( O -
all O +
P O +
< O +
0.0001 O -
) O -
. O -

In O +
a O +
multivariate O +
model O -
, O +
increased O +
MxA O +
expression O +
showed O +
a O +
significant O +
positive O +
association O +
with O +
viral O +
load O +
( O -
P O +
= O +
0.0418 O -
) O -
. O -

Furthermore O -
, O +
TRIM22 O +
but O +
not O +
huTRIM5alpha O -
, O +
IFN O -
- O -
alpha O -
, O +
IFN O -
- O -
Beta O -
, O +
or O +
MxA O +
showed O +
a O +
negative O +
correlation O +
with O +
plasma O +
viral O +
load O +
( O -
P O +
= O +
0.0307 O -
) O +
and O +
a O +
positive O +
correlation O +
with O +
CD4 O -
( O -
+ O -
) O +
T O -
- O -
cell O +
counts O +
( O -
P O +
= O +
0.0281 O -
) O -
. O -

In O +
vitro O +
studies O +
revealed O +
that O +
HIV O +
infection O +
induced O +
TRIM22 O +
expression O +
in O +
PBMCs O +
obtained O +
from O +
HIV O -
- O -
negative O +
donors O -
. O -

Stable O +
TRIM22 O +
knockdown O +
resulted O +
in O +
increased O +
HIV-1 O +
particle U-Species +
release O +
and O +
replication O +
in O +
Jurkat O +
reporter O +
cells O -
. O -

Collectively O -
, O +
these O +
data O +
suggest O +
concordance O +
between O +
type O +
1 O +
IFN O +
and O +
TRIM22 O +
but O +
not O +
huTRIM5alpha O +
expression O +
in O +
PBMCs O +
and O +
that O +
TRIM22 O +
likely O +
acts O +
as O +
an O +
antiviral O +
effector O +
in O +
vivo O -
. O +

The O +
B O +
cell O +
response O +
is O +
redundant O +
and O +
highly O +
focused O +
on O +
V1V2 O +
during O +
early O +
subtype O +
C O +
infection O +
in O +
a O +
Zambian O +
seroconverter O -
. O +

High O -
- O -
titer O +
autologous O +
neutralizing O +
antibody O +
responses O +
have O +
been O +
demonstrated O +
during O +
early O +
subtype O +
C O +
human B-Species +
immunodeficiency I-Species +
virus I-Species +
type L-Species +
1 O +
( O -
HIV-1 U-Species -
) O +
infection O -
. O -

However O -
, O +
characterization O +
of O +
this O +
response O +
against O +
autologous O +
virus O +
at O +
the O +
monoclonal O +
antibody O +
( O -
MAb O -
) O +
level O +
has O +
only O +
recently O +
begun O +
to O +
be O +
elucidated O -
. O -

Here O +
we O +
describe O +
five O +
monoclonal O +
antibodies O +
derived O +
from O +
a O +
subtype O +
C O -
- O -
infected O +
seroconverter O +
and O +
their O +
neutralizing O +
activities O +
against O +
pseudoviruses O +
that O +
carry O +
envelope O +
glycoproteins O +
from O +
48 O +
days O +
( O -
0 O +
month O -
) O -
, O +
2 O +
months O -
, O +
and O +
8 O +
months O +
after O +
the O +
estimated O +
time O +
of O +
infection O -
. O -

Sequence O +
analysis O +
indicated O +
that O +
the O +
MAbs O +
arose O +
from O +
three O +
distinct O +
B O +
cell O +
clones O -
, O +
and O +
their O +
pattern O +
of O +
neutralization O +
compared O +
to O +
that O +
in O +
patient O +
plasma O +
suggested O +
that O +
they O +
circulated O +
between O +
2 O +
and O +
8 O +
months O +
after O +
infection O -
. O -

Neutralization O +
by O +
MAbs O +
representative O +
of O +
each O +
B O +
cell O +
clone O +
was O +
mapped O +
to O +
two O +
residues O -
: O +
position O +
134 O +
in O +
V1 O +
and O +
position O +
189 O +
in O +
V2 O -
. O -

Mutational O +
analysis O +
revealed O +
cooperative O +
effects O +
between O +
glycans O +
and O +
residues O +
at O +
these O +
two O +
positions O -
, O +
arguing O +
that O +
they O +
contribute O +
to O +
a O +
single O +
epitope O -
. O -

Analysis O +
of O +
the O +
cognate O +
gp120 O +
sequence O +
through O +
homology O +
modeling O +
places O +
this O +
potential O +
epitope O +
near O +
the O +
interface O +
between O +
the O +
V1 O +
and O +
V2 O +
loops O -
. O -

Additionally O -
, O +
the O +
escape O +
mutation O +
R189S O +
in O +
V2 O -
, O +
which O +
conferred O +
resistance O +
against O +
all O +
three O +
MAbs O -
, O +
had O +
no O +
detrimental O +
effect O +
on O +
virus O +
replication O +
in O +
vitro O -
. O -

Taken O +
together O -
, O +
our O +
data O +
demonstrate O +
that O +
independent O +
B O +
cells O +
repeatedly O +
targeted O +
a O +
single O +
structure O +
in O +
V1V2 O +
during O +
early O +
infection O -
. O -

Despite O +
this O +
assault O -
, O +
a O +
single O +
amino O +
acid O +
change O +
was O +
sufficient O +
to O +
confer O +
complete O +
escape O +
with O +
minimal O +
impact O +
on O +
replication O +
fitness O -
. O +

Translational O +
control O +
of O +
the O +
abundance O +
of O +
cytoplasmic O +
poly O -
( O -
A O -
) O +
binding O +
protein O +
in O +
human B-Species +
cytomegalovirus L-Species -
- O -
infected O +
cells O -
. O +

Irrespective O +
of O +
their O +
effects O +
on O +
ongoing O +
host O +
protein O +
synthesis O -
, O +
productive O +
replication O +
of O +
the O +
representative O +
alphaherpesvirus O +
herpes B-Species +
simplex I-Species +
virus I-Species +
type L-Species +
1 O -
, O +
the O +
representative O +
gammaherpesvirus O +
Kaposi B-Species -
's I-Species +
sarcoma I-Species +
herpesvirus L-Species -
, O +
and O +
the O +
representative O +
betaherpesvirus O +
human B-Species +
cytomegalovirus L-Species +
[ O -
HCMV U-Species -
] O +
stimulates O +
the O +
assembly O +
of O +
the O +
multisubunit O -
, O +
cap O -
- O -
binding O +
translation O +
factor O +
eIF4F O -
. O -

However O -
, O +
only O +
HCMV U-Species +
replication O +
is O +
associated O +
with O +
an O +
increased O +
abundance O +
of O +
eIF4F O +
core O +
components O +
( O -
eIF4E O -
, O +
eIF4 O -
G O -
, O +
eIF4A O -
) O +
and O +
the O +
eIF4F O -
- O -
associated O +
factor O +
poly O -
( O -
A O -
) O +
binding O +
protein O +
( O -
PABP O -
) O -
. O -

Here O -
, O +
we O +
demonstrate O +
that O +
the O +
increase O +
in O +
translation O +
factor O +
concentration O +
was O +
readily O +
detected O +
in O +
an O +
asynchronous O +
population O +
of O +
HCMV U-Species -
- O -
infected O +
primary O +
human U-Species +
fibroblasts O -
, O +
abolished O +
by O +
prior O +
UV O +
inactivation O +
of O +
virus O -
, O +
and O +
genetically O +
dependent O +
upon O +
viral O +
immediate O -
- O -
early O +
genes O -
. O -

Strikingly O -
, O +
while O +
increased O +
mRNA O +
steady O -
- O -
state O +
levels O +
accompanied O +
the O +
rise O +
in O +
eIF4E O +
and O +
eIF4 O -
G O +
protein O +
levels O -
, O +
the O +
overall O +
abundance O +
of O +
PABP O +
mRNA O -
, O +
together O +
with O +
the O +
half O -
- O -
life O +
of O +
the O +
polypeptide O +
it O +
encodes O -
, O +
remained O +
relatively O +
unchanged O +
by O +
HCMV U-Species +
infection O -
. O -

Instead O -
, O +
HCMV U-Species -
- O -
induced O +
PABP O +
accumulation O +
resulted O +
from O +
new O +
protein O +
synthesis O +
and O +
was O +
sensitive O +
to O +
the O +
mTORC1-selective O +
inhibitor O +
rapamycin O -
, O +
which O +
interferes O +
with O +
phosphorylation O +
of O +
the O +
mTORC1 O +
substrate O +
p70 O +
S6 O -
K O +
and O +
the O +
translational O +
repressor O +
4E O -
- O -
BP1 O -
. O -

While O +
virus O -
- O -
induced O +
PABP O +
accumulation O +
did O +
not O +
require O +
p70 O +
S6 O -
K O -
, O +
it O +
was O +
inhibited O +
by O +
the O +
expression O +
of O +
a O +
dominant O -
- O -
acting O +
4E O -
- O -
BP1 O +
variant O +
unable O +
to O +
be O +
inactivated O +
by O +
mTORC1 O -
. O -

Finally O -
, O +
unlike O +
the O +
situation O +
in O +
alpha- O +
or O +
gammaherpesvirus O -
- O -
infected O +
cells O -
, O +
where O +
PABP O +
is O +
redistributed O +
to O +
nuclei O -
, O +
PABP O +
accumulated O +
in O +
the O +
cytoplasm O +
of O +
HCMV U-Species -
- O -
infected O +
cells O -
. O -

Thus O -
, O +
cytoplasmic O +
PABP O +
accumulation O +
is O +
translationally O +
controlled O +
in O +
HCMV U-Species -
- O -
infected O +
cells O +
via O +
a O +
mechanism O +
requiring O +
mTORC1-mediated O +
inhibition O +
of O +
the O +
cellular O +
4E O -
- O -
BP1 O +
translational O +
repressor O -
. O +

Chikungunya B-Species +
virus L-Species +
induces O +
IPS-1-dependent O +
innate O +
immune O +
activation O +
and O +
protein O +
kinase O +
R O -
- O -
independent O +
translational O +
shutoff O -
. O +

Chikungunya B-Species +
virus L-Species +
( O -
CHIKV U-Species -
) O +
is O +
an O +
arthritogenic O +
mosquito O -
- O -
transmitted O +
alphavirus O +
that O +
is O +
undergoing O +
reemergence O +
in O +
areas O +
around O +
the O +
Indian O +
Ocean O -
. O -

Despite O +
the O +
current O +
and O +
potential O +
danger O +
posed O +
by O +
this O +
virus O -
, O +
we O +
know O +
surprisingly O +
little O +
about O +
the O +
induction O +
and O +
evasion O +
of O +
CHIKV U-Species -
- O -
associated O +
antiviral O +
immune O +
responses O -
. O -

With O +
this O +
in O +
mind O +
we O +
investigated O +
innate O +
immune O +
reactions O +
to O +
CHIKV U-Species +
in O +
human U-Species +
fibroblasts O -
, O +
a O +
demonstrable O +
in O +
vivo O +
target O +
of O +
virus O +
replication O +
and O +
spread O -
. O -

We O +
show O +
that O +
CHIKV U-Species +
infection O +
leads O +
to O +
activation O +
of O +
the O +
transcription O +
factor O +
interferon O +
regulatory O +
factor O +
3 O +
( O -
IRF3 O -
) O +
and O +
subsequent O +
transcription O +
of O +
IRF3-dependent O +
antiviral O +
genes O -
, O +
including O +
beta O +
interferon O +
( O -
IFN O -
- O -
Beta O -
) O -
. O -

IRF3 O +
activation O +
occurs O +
by O +
way O +
of O +
a O +
virus O -
- O -
induced O +
innate O +
immune O +
signaling O +
pathway O +
that O +
includes O +
the O +
adaptor O +
molecule O +
interferon O +
promoter O +
stimulator O +
1 O +
( O -
IPS-1 O -
) O -
. O -

Despite O +
strong O +
transcriptional O +
upregulation O +
of O +
these O +
genes O -
, O +
however O -
, O +
translation O +
of O +
the O +
corresponding O +
proteins O +
is O +
not O +
observed O -
. O -

We O +
further O +
demonstrate O +
that O +
translation O +
of O +
cellular O +
( O -
but O +
not O +
viral O -
) O +
genes O +
is O +
blocked O +
during O +
infection O +
and O +
that O +
although O +
CHIKV U-Species +
is O +
found O +
to O +
trigger O +
inactivation O +
of O +
the O +
translational O +
molecule O +
eukaryotic O +
initiation O +
factor O +
subunit O +
2alpha O +
by O +
way O +
of O +
the O +
double O -
- O -
stranded O +
RNA O +
sensor O +
protein O +
kinase O +
R O -
, O +
this O +
response O +
is O +
not O +
required O +
for O +
the O +
block O +
to O +
protein O +
synthesis O -
. O -

Furthermore O -
, O +
overall O +
diminution O +
of O +
cellular O +
RNA O +
synthesis O +
is O +
also O +
observed O +
in O +
the O +
presence O +
of O +
CHIKV U-Species +
and O +
transcription O +
of O +
IRF3-dependent O +
antiviral O +
genes O +
appears O +
specifically O +
blocked O +
late O +
in O +
infection O -
. O -

We O +
hypothesize O +
that O +
the O +
observed O +
absence O +
of O +
IFN O -
- O -
Beta O +
and O +
antiviral O +
proteins O +
during O +
infection O +
results O +
from O +
an O +
evasion O +
mechanism O +
exhibited O +
by O +
CHIKV U-Species +
that O +
is O +
dependent O +
on O +
widespread O +
shutoff O +
of O +
cellular O +
protein O +
synthesis O +
and O +
a O +
targeted O +
block O +
to O +
late O +
synthesis O +
of O +
antiviral O +
mRNA O +
transcripts O -
. O +

Domain O +
structure O +
of O +
Lassa B-Species +
virus L-Species +
L O +
protein O -
. O -

The O +
200-kDa O +
L O +
protein O +
of O +
arenaviruses O +
plays O +
a O +
central O +
role O +
in O +
viral O +
genome O +
replication O +
and O +
transcription O -
. O -

This O +
study O +
aimed O +
at O +
providing O +
evidence O +
for O +
the O +
domain O +
structure O +
of O +
L O +
protein O +
by O +
combining O +
bioinformatics O +
with O +
a O +
stepwise O +
mutagenesis O +
approach O +
using O +
the O +
Lassa B-Species +
virus L-Species +
minireplicon O +
system O -
. O -

Potential O +
interdomain O +
linkers O +
were O +
predicted O +
using O +
various O +
algorithms O -
. O -

The O +
prediction O +
was O +
challenged O +
by O +
insertion O +
of O +
flexible O +
sequences O +
into O +
the O +
predicted O +
linkers O -
. O -

Insertion O +
of O +
5 O +
or O +
10 O +
amino O +
acid O +
residues O +
was O +
tolerated O +
at O +
seven O +
sites O +
( O -
S407 O -
, O +
G446 O -
, O +
G467 O -
, O +
G774 O -
, O +
G939 O -
, O +
S1952 O -
, O +
and O +
V2074 O +
in O +
Lassa B-Species +
virus I-Species +
AV L-Species -
) O -
. O -

At O +
two O +
of O +
these O +
sites O -
, O +
G467 O +
and O +
G939 O -
, O +
L O +
protein O +
could O +
be O +
split O +
into O +
an O +
N O -
- O -
terminal O +
and O +
a O +
C O -
- O -
terminal O +
part O -
, O +
which O +
were O +
able O +
to O +
trans O -
- O -
complement O +
each O +
other O +
and O +
reconstitute O +
a O +
functional O +
complex O +
upon O +
coexpression O -
. O -

Coimmunoprecipitation O +
studies O +
revealed O +
physical O +
interaction O +
between O +
the O +
N- O +
and O +
C O -
- O -
terminal O +
domains O -
, O +
irrespective O +
of O +
whether O +
L O +
protein O +
was O +
split O +
at O +
G467 O +
or O +
G939 O -
. O -

In O +
confocal O +
immunofluorescence O +
microscopy O -
, O +
the O +
N O -
- O -
terminal O +
domains O +
showed O +
a O +
dot O -
- O -
like O -
, O +
sometimes O +
perinuclear O -
, O +
cytoplasmic O +
distribution O +
similar O +
to O +
that O +
of O +
full O -
- O -
length O +
L O +
protein O -
, O +
while O +
the O +
C O -
- O -
terminal O +
domains O +
were O +
homogenously O +
distributed O +
in O +
cytoplasm O -
. O -

The O +
latter O +
were O +
redistributed O +
into O +
the O +
dot O -
- O -
like O +
structures O +
upon O +
coexpression O +
with O +
the O +
corresponding O +
N O -
- O -
terminal O +
domain O -
. O -

In O +
conclusion O -
, O +
this O +
study O +
demonstrates O +
two O +
interdomain O +
linkers O +
in O +
Lassa B-Species +
virus L-Species +
L O +
protein O -
, O +
at O +
G467 O +
and O +
G939 O -
, O +
suggesting O +
that O +
L O +
protein O +
is O +
composed O +
of O +
at O +
least O +
three O +
structural O +
domains O +
spanning O +
residues O +
1 O +
to O +
467 O -
, O +
467 O +
to O +
939 O -
, O +
and O +
939 O +
to O +
2220 O -
. O -

The O +
first O +
domain O +
seems O +
to O +
mediate O +
accumulation O +
of O +
L O +
protein O +
into O +
cytoplasmic O +
dot O -
- O -
like O +
structures O -
. O +

Antiviral O +
effects O +
of O +
a O +
transgenic O +
RNA O -
- O -
dependent O +
RNA O +
polymerase O -
. O -

Transgenic O +
expression O +
of O +
the O +
RNA O -
- O -
dependent O +
RNA O +
polymerase O +
3D O -
( O -
pol O -
) O +
inhibited O +
infection O +
of O +
Theiler B-Species -
's I-Species +
murine I-Species +
encephalitis I-Species +
virus L-Species +
( O -
TMEV U-Species -
) O -
, O +
a O +
picornavirus O +
from O +
which O +
it O +
was O +
derived O -
. O -

Here O -
, O +
we O +
infected O +
3D O -
( O -
pol O -
) O +
transgenic O +
mice U-Species +
with O +
another O +
picornavirus O -
, O +
as O +
well O +
as O +
an O +
alphaherpesvirus O +
and O +
a O +
rhabdovirus O -
. O -

3D O -
( O -
pol O -
) O +
transgenic O +
FVB O +
mice U-Species +
had O +
significantly O +
lower O +
viral O +
loads O +
and O +
survived O +
longer O +
after O +
infection O +
with O +
all O +
three O +
types O +
of O +
viruses O +
than O +
nontransgenic O +
FVB O +
mice U-Species -
. O -

Viral O +
inhibition O +
among O +
three O +
different O +
types O +
of O +
virus O +
by O +
transgenic O +
3D O -
( O -
pol O -
) O +
suggests O +
that O +
the O +
mechanism O +
of O +
action O +
is O +
not O +
the O +
direct O +
interference O +
with O +
picornaviral O +
3D O -
( O -
pol O -
) O +
but O +
instead O +
may O +
be O +
the O +
changing O +
of O +
host O +
cells O +
to O +
an O +
antiviral O +
state O +
before O +
or O +
after O +
viral O +
infection O +
occurs O -
, O +
as O +
basal O +
interferon O +
levels O +
were O +
higher O +
in O +
3D O -
( O -
pol O -
) O +
transgenic O +
mice U-Species +
before O +
infection O -
. O -

Further O +
study O +
of O +
this O +
mechanism O +
may O +
open O +
new O +
possibilities O +
for O +
future O +
antiviral O +
therapy O -
. O +

The O +
absence O +
of O +
sex O -
- O -
biased O +
dispersal O +
in O +
the O +
cooperatively O +
breeding O +
grey B-Species -
- I-Species -
crowned I-Species +
babbler L-Species -
. O +

1 O -
. O -

Cooperatively O +
breeding O +
birds O +
are O +
thought O +
to O +
be O +
especially O +
vulnerable O +
to O +
habitat O +
fragmentation O -
, O +
in O +
part O +
because O +
dispersal O +
is O +
typically O +
restricted O +
for O +
one O +
sex O -
, O +
increasing O +
the O +
likelihood O +
of O +
inbreeding O -
. O -

Knowledge O +
of O +
dispersal O +
is O +
essential O +
to O +
conservation O +
efforts O -
, O +
but O +
is O +
often O +
hampered O +
by O +
our O +
inability O +
to O +
measure O +
its O +
frequency O +
and O +
distance O +
when O +
dispersal O +
is O +
infrequent O +
and O +
difficult O +
to O +
observe O -
. O -

2 O -
. O -

Disrupted O +
dispersal O +
is O +
a O +
purported O +
cause O +
of O +
decline O +
in O +
the O +
Australian O +
grey B-Species -
- I-Species -
crowned I-Species +
babbler L-Species +
( O -
Pomatostomus B-Species +
temporalis L-Species -
) O -
. O -

Both O +
sexes O +
of O +
offspring O +
delay O +
dispersal O +
for O +
up O +
to O +
several O +
years O +
to O +
help O +
parents O +
raise O +
subsequent O +
broods O -
, O +
yet O +
little O +
else O +
is O +
known O +
about O +
the O +
dispersal O +
of O +
this O +
cooperatively O +
breeding O +
woodland O +
bird O -
. O -

3 O -
. O -

As O +
both O +
sexes O +
appear O +
to O +
help O -
, O +
but O +
only O +
male O +
helpers O +
boost O +
fledgling O +
production O -
, O +
we O +
hypothesized O +
that O +
males O +
would O +
be O +
the O +
more O +
philopatric O +
sex O +
in O +
this O +
species O -
, O +
and O +
that O +
female O +
grey B-Species -
- I-Species -
crowned I-Species +
babblers L-Species +
would O +
disperse O +
over O +
greater O +
distances O -
. O -

4 O -
. O +
To O +
ensure O +
reliable O +
determination O +
of O +
sex O +
and O +
minimize O +
bias O +
towards O +
detecting O +
short O -
- O -
distance O +
dispersal O +
events O -
, O +
we O +
combined O +
molecular O -
- O -
based O +
sexing O +
and O +
analyses O +
of O +
population O +
genetic O +
structure O +
using O +
polymorphic O +
microsatellite O +
loci O +
with O +
observational O +
data O +
obtained O +
over O +
multiple O +
field O +
seasons O -
. O -

5 O -
. O +
Observations O +
of O +
banded O +
birds O +
showed O +
only O +
infrequent O +
fission O +
of O +
groups O +
or O +
short O -
- O -
distance O +
dispersal O +
( O -
mean=854 O +
m O -
) O -
, O +
but O +
no O +
apparent O +
sex O -
- O -
bias O +
in O +
these O +
patterns O -
. O -

6 O -
. O -

There O +
was O +
significant O +
genetic O +
differentiation O +
between O +
social O +
groups O -
, O +
but O +
not O +
between O +
the O +
sexes O -
. O -

Spatial O +
genetic O +
autocorrelation O +
analysis O +
of O +
breeders O +
revealed O +
a O +
random O +
distribution O +
of O +
genotypes O +
across O +
the O +
study O +
area O +
for O +
both O +
sexes O -
. O -

Thus O -
, O +
contrary O +
to O +
expectations O -
, O +
we O +
found O +
no O +
genetic O +
evidence O +
for O +
restricted O +
dispersal O +
or O +
for O +
sex O -
- O -
biased O +
dispersal O +
over O +
the O +
85-km O +
scale O +
of O +
this O +
study O -
, O +
indicating O +
that O +
effective O +
dispersal O +
occurs O +
over O +
greater O +
distances O +
and O +
more O +
frequently O +
than O +
recoveries O +
of O +
banded O +
birds O +
indicated O -
. O -

7 O -
. O -

We O +
conclude O +
that O +
while O +
constraints O +
on O +
independent O +
breeding O +
encourage O +
high O +
rates O +
of O +
philopatry O -
, O +
incest O +
avoidance O +
nonetheless O +
drives O +
high O +
rates O +
of O +
dispersal O +
by O +
both O +
sexes O -
. O -

In O +
fragmented O +
habitat O -
, O +
the O +
dispersal O +
dynamics O +
of O +
this O +
cooperatively O +
breeding O +
species O +
are O +
unlikely O +
to O +
render O +
them O +
particularly O +
vulnerable O +
to O +
genetic O +
consequences O +
such O +
as O +
inbreeding O -
, O +
but O +
may O +
lead O +
to O +
increased O +
group O +
dissolution O -
. O +

Acclimation O +
to O +
high O +
CO2 O +
in O +
maize U-Species +
is O +
related O +
to O +
water O +
status O +
and O +
dependent O +
on O +
leaf O +
rank O -
. O +

The O +
responses O +
of O +
C O -
( O -
3 O -
) O +
plants O +
to O +
rising O +
atmospheric O +
CO O -
( O -
2 O -
) O +
levels O +
are O +
considered O +
to O +
be O +
largely O +
dependent O +
on O +
effects O +
exerted O +
through O +
altered O +
photosynthesis O -
. O -

In O +
contrast O -
, O +
the O +
nature O +
of O +
the O +
responses O +
of O +
C O -
( O -
4 O -
) O +
plants O +
to O +
high O +
CO O -
( O -
2 O -
) O +
remains O +
controversial O +
because O +
of O +
the O +
absence O +
of O +
CO O -
( O -
2 O -
) O +
-dependent O +
effects O +
on O +
photosynthesis O -
. O -

In O +
this O +
study O -
, O +
the O +
effects O +
of O +
atmospheric O +
CO O -
( O -
2 O -
) O +
availability O +
on O +
the O +
transcriptome O -
, O +
proteome O +
and O +
metabolome O +
profiles O +
of O +
two O +
ranks O +
of O +
source O +
leaves O +
in O +
maize U-Species +
( O -
Zea B-Species +
mays L-Species +
L. O -
) O +
were O +
studied O +
in O +
plants O +
grown O +
under O +
ambient O +
CO O -
( O -
2 O -
) O +
conditions O +
( O -
350 O +
+ O -
/- O -

20 O +
muL O +
L O -
( O -
-1 O -
) O +
CO O -
( O -
2 O -
) O +
) O +
or O +
with O +
CO O -
( O -
2 O -
) O +
enrichment O +
( O -
700 O +
+ O -
/- O -

20 O +
muL O +
L O -
( O -
-1 O -
) O +
CO O -
( O -
2 O -
) O +
) O -
. O -

Growth O +
at O +
high O +
CO O -
( O -
2 O -
) O +
had O +
no O +
effect O +
on O +
photosynthesis O -
, O +
photorespiration O -
, O +
leaf O +
C O -
/ O -
N O +
ratios O +
or O +
anthocyanin O +
contents O -
. O -

However O -
, O +
leaf O +
transpiration O +
rates O -
, O +
carbohydrate O +
metabolism O +
and O +
protein O +
carbonyl O +
accumulation O +
were O +
altered O +
at O +
high O +
CO O -
( O -
2 O -
) O +
in O +
a O +
leaf O -
- O -
rank O +
specific O +
manner O -
. O -

Although O +
no O +
significant O +
CO O -
( O -
2 O -
) O +
-dependent O +
changes O +
in O +
the O +
leaf O +
transcriptome O +
were O +
observed O -
, O +
qPCR O +
analysis O +
revealed O +
that O +
the O +
abundance O +
of O +
transcripts O +
encoding O +
a O +
Bowman O -
- O -
Birk O +
protease O +
inhibitor O +
and O +
a O +
serpin O +
were O +
changed O +
by O +
the O +
growth O +
CO O -
( O -
2 O -
) O +
level O +
in O +
a O +
leaf O +
rank O +
specific O +
manner O -
. O -

Moreover O -
, O +
CO O -
( O -
2 O -
) O +
-dependent O +
changes O +
in O +
the O +
leaf O +
proteome O +
were O +
most O +
evident O +
in O +
the O +
oldest O +
source O +
leaves O -
. O -

Small O +
changes O +
in O +
water O +
status O +
may O +
be O +
responsible O +
for O +
the O +
observed O +
responses O +
to O +
high O +
CO O -
( O -
2 O -
, O -
) O +
particularly O +
in O +
the O +
older O +
leaf O +
ranks O -
. O +

Agrobacterium B-Species +
tumefasciens L-Species -
- O -
mediated O +
transformation O +
of O +
the O +
aquatic O +
fungus O +
Blastocladiella B-Species +
emersonii L-Species -
. O +

Agrobacterium B-Species +
tumefaciens L-Species +
is O +
widely O +
used O +
for O +
plant O +
DNA O +
transformation O +
and O +
more O +
recently O -
, O +
has O +
also O +
been O +
used O +
to O +
transform O +
yeast U-Species -
, O +
filamentous O +
fungi O +
and O +
even O +
human U-Species +
cells O -
. O -

Using O +
this O +
technique O -
, O +
we O +
developed O +
the O +
first O +
transformation O +
protocol O +
for O +
the O +
saprobic O +
aquatic O +
fungus O +
Blastocladiella B-Species +
emersonii L-Species -
, O +
a O +
Blastocladiomycete O +
localized O +
at O +
the O +
base O +
of O +
fungal O +
phylogenetic O +
tree O -
, O +
which O +
has O +
been O +
shown O +
as O +
a O +
promising O +
and O +
interesting O +
model O +
of O +
study O +
of O +
cellular O +
function O +
and O +
differentiation O -
. O -

We O +
constructed O +
binary O +
T O -
- O -
DNA O +
vectors O +
containing O +
hygromycin O +
phosphotransferase O +
( O -
hph O -
) O +
or O +
enhanced O +
green O +
fluorescent O +
protein O +
( O -
egfp O -
) O +
genes O -
, O +
under O +
the O +
control O +
of O +
Aspergillus B-Species +
nidulans L-Species +
trpC O +
promoter O +
and O +
terminator O +
sequences O -
. O -

24 O +
h O +
of O +
co O -
- O -
cultivation O +
in O +
induction O +
medium O +
( O -
IM O -
) O +
agar O +
plates O -
, O +
followed O +
by O +
transfer O +
to O +
PYG O -
- O -
agar O +
plates O +
containing O +
cefotaxim O +
to O +
kill O +
Agrobacterium B-Species +
tumefsciens L-Species +
and O +
hygromycin O +
to O +
select O +
transformants O -
, O +
resulted O +
in O +
growth O +
and O +
sporulation O +
of O +
resistant O +
transformants O -
. O -

Genomic O +
DNA O +
from O +
the O +
pool O +
o O +
resistant O +
zoospores O +
were O +
shown O +
to O +
contain O +
T O -
- O -
DNA O +
insertion O +
as O +
evidenced O +
by O +
PCR O +
amplification O +
of O +
hph O +
gene O -
. O -

Using O +
a O +
similar O +
protocol O +
we O +
could O +
also O +
evidence O +
the O +
expression O +
of O +
enhanced O +
green O +
fluorescent O +
protein O +
( O -
EGFP O -
) O +
in O +
zoospores O +
derived O +
from O +
transformed O +
cells O -
. O -

This O +
protocol O +
can O +
also O +
open O +
new O +
perspectives O +
for O +
other O +
non O -
- O -
transformable O +
closely O +
related O +
fungi O -
, O +
like O +
the O +
Chytridiomycete O +
class O -
. O +

Characterization O +
of O +
the O +
oxysterol O -
- O -
binding O +
protein O +
gene O +
family O +
in O +
the O +
yellow B-Species +
fever I-Species +
mosquito L-Species -
, O +
Aedes B-Species +
aegypti L-Species -
. O +

The O +
oxysterol O -
- O -
binding O +
protein O +
( O -
OSBP O -
) O +
and O +
OSBP O -
- O -
related O +
proteins O +
( O -
ORPs O -
) O +
are O +
sterol O -
- O -
binding O +
proteins O +
that O +
may O +
be O +
involved O +
in O +
cellular O +
sterol O +
transportation O -
, O +
sterol O +
metabolism O +
and O +
signal O +
transduction O +
pathways O -
. O -

Four O +
ORP O +
genes O +
were O +
cloned O +
from O +
Aedes B-Species +
aegypti L-Species -
. O -

Based O +
on O +
amino O +
acid O +
sequence O +
homology O +
to O +
human U-Species +
proteins O -
, O +
they O +
are O +
AeOSBP O -
, O +
AeORP1 O -
, O +
AeORP8 O +
and O +
AeORP9 O -
. O -

Splicing O +
variants O +
of O +
AeOSBP O +
and O +
AeORP8 O +
were O +
identified O -
. O -

The O +
temporal O +
and O +
spatial O +
transcription O +
patterns O +
of O +
members O +
of O +
the O +
AeOSBP O +
gene O +
family O +
through O +
developmental O +
stages O +
and O +
the O +
gonotrophic O +
cycle O +
were O +
profiled O -
. O -

AeORP1 O +
transcription O +
seemed O +
to O +
be O +
head O +
tissue O -
- O -
specific O -
, O +
whereas O +
AeOSBP O +
and O +
AeORP9 O +
expression O +
was O +
induced O +
by O +
a O +
bloodmeal O -
. O -

Furthermore O -
, O +
over O -
- O -
expression O +
of O +
AeORPs O +
facilitated O +
[ O -
( O -
3 O -
) O -
H O -
] O -
-cholesterol O +
uptake O +
in O +
Ae B-Species -
. L-Species -

aegypti U-Species +
cultured O +
Aag O +
-2 O +
cells O -
. O +

The O +
minor O +
pilin O +
subunit O +
Sgp2 O +
is O +
necessary O +
for O +
assembly O +
of O +
the O +
pilus O +
encoded O +
by O +
the O +
srtG O +
cluster O +
of O +
Streptococcus B-Species +
suis L-Species -
. O +

Gram O -
- O -
positive O +
pili O +
are O +
composed O +
of O +
covalently O +
bound O +
pilin O +
subunits O +
whose O +
assembly O +
is O +
mediated O +
via O +
a O +
pilus O -
- O -
specific O +
sortase O -
( O -
s O -
) O -
. O -

Major O +
subunits O +
constitute O +
the O +
pilus O +
backbone O +
and O +
are O +
therefore O +
essential O +
for O +
pilus O +
formation O -
. O -

Minor O +
subunits O +
are O +
also O +
incorporated O +
into O +
the O +
pilus O -
, O +
but O +
they O +
are O +
considered O +
to O +
be O +
dispensable O +
for O +
backbone O +
formation O -
. O -

The O +
srtG O +
cluster O +
is O +
one O +
of O +
the O +
putative O +
pilus O +
gene O +
clusters O +
identified O +
in O +
the O +
major O +
swine U-Species +
pathogen O +
Streptococcus B-Species +
suis L-Species -
. O -

It O +
consists O +
of O +
one O +
sortase O +
gene O +
( O -
srtG O -
) O +
and O +
two O +
putative O +
pilin O +
subunit O +
genes O +
( O -
sgp1 O +
and O +
sgp2 O -
) O -
. O -

In O +
this O +
study O -
, O +
by O +
constructing O +
mutants O +
for O +
each O +
of O +
the O +
genes O +
in O +
the O +
cluster O +
and O +
by O +
both O +
immunoblotting O +
and O +
immunogold O +
electron O +
microscopic O +
analysis O +
with O +
antibodies O +
against O +
Sgp1 O +
and O +
Sgp2 O -
, O +
we O +
found O +
that O +
the O +
srtG O +
cluster O +
mediates O +
the O +
expression O +
of O +
pilus O -
- O -
like O +
structures O +
in O +
S. B-Species +
suis I-Species +
strain I-Species +
89 I-Species -
/ I-Species -
1591 L-Species -
. O -

In O +
this O +
pilus O -
, O +
Sgp1 O +
forms O +
the O +
backbone O -
, O +
whereas O +
Sgp2 O +
is O +
incorporated O +
as O +
the O +
minor O +
subunit O -
. O -

In O +
accordance O +
with O +
the O +
current O +
model O +
of O +
pilus O +
assembly O +
by O +
Gram O -
- O -
positive O +
organisms O -
, O +
the O +
major O +
subunit O +
Sgp1 O +
was O +
indispensable O +
for O +
backbone O +
formation O +
and O +
the O +
cognate O +
sortase O +
SrtG O +
mediated O +
the O +
polymerization O +
of O +
both O +
subunits O -
. O -

However O -
, O +
unlike O +
other O +
well O -
- O -
characterized O +
Gram O -
- O -
positive O +
bacterial O +
pili O -
, O +
the O +
minor O +
subunit O +
Sgp2 O +
was O +
required O +
for O +
polymerization O +
of O +
the O +
major O +
subunit O +
Sgp1 O -
. O -

Because O +
Sgp2 O +
homologues O +
are O +
encoded O +
in O +
several O +
other O +
Gram O -
- O -
positive O +
bacterial O +
pilus O +
gene O +
clusters O -
, O +
in O +
some O +
types O +
of O +
pili O -
, O +
minor O +
pilin O +
subunits O +
may O +
contribute O +
to O +
backbone O +
formation O +
by O +
a O +
novel O +
mechanism O -
. O +

Spatial O +
regulation O +
of O +
histidine O +
kinases O +
governing O +
biofilm O +
formation O +
in O +
Bacillus B-Species +
subtilis L-Species -
. O +

Bacillus B-Species +
subtilis L-Species +
is O +
able O +
to O +
form O +
architecturally O +
complex O +
biofilms O +
on O +
solid O +
medium O +
due O +
to O +
the O +
production O +
of O +
an O +
extracellular O +
matrix O -
. O -

A O +
master O +
regulator O +
that O +
controls O +
the O +
expression O +
of O +
the O +
genes O +
involved O +
in O +
matrix O +
synthesis O +
is O +
Spo0A O -
, O +
which O +
is O +
activated O +
by O +
phosphorylation O +
via O +
a O +
phosphorelay O +
involving O +
multiple O +
histidine O +
kinases O -
. O -

Here O +
we O +
report O +
that O +
four O +
kinases O -
, O +
KinA O -
, O +
KinB O -
, O +
KinC O -
, O +
and O +
KinD O -
, O +
help O +
govern O +
biofilm O +
formation O +
but O +
that O +
their O +
contributions O +
are O +
partially O +
masked O +
by O +
redundancy O -
. O -

We O +
show O +
that O +
the O +
kinases O +
fall O +
into O +
two O +
categories O +
and O +
that O +
the O +
members O +
of O +
each O +
pair O +
( O -
one O +
pair O +
comprising O +
KinA O +
and O +
KinB O +
and O +
the O +
other O +
comprising O +
KinC O +
and O +
KinD O -
) O +
are O +
partially O +
redundant O +
with O +
each O +
other O -
. O -

We O +
also O +
show O +
that O +
the O +
kinases O +
are O +
spatially O +
regulated O -
: O +
KinA O +
and O +
KinB O +
are O +
active O +
principally O +
in O +
the O +
older O -
, O +
inner O +
regions O +
of O +
the O +
colony O -
, O +
and O +
KinC O +
and O +
KinD O +
function O +
chiefly O +
in O +
the O +
younger O -
, O +
outer O +
regions O -
. O -

These O +
conclusions O +
are O +
based O +
on O +
the O +
morphology O +
of O +
kinase O +
mutants O -
, O +
real O -
- O -
time O +
measurements O +
of O +
gene O +
expression O +
using O +
luciferase O +
as O +
a O +
reporter O -
, O +
and O +
confocal O +
microscopy O +
using O +
a O +
fluorescent O +
protein O +
as O +
a O +
reporter O -
. O -

Our O +
findings O +
suggest O +
that O +
multiple O +
signals O +
from O +
the O +
older O +
and O +
younger O +
regions O +
of O +
the O +
colony O +
are O +
integrated O +
by O +
the O +
kinases O +
to O +
determine O +
the O +
overall O +
architecture O +
of O +
the O +
biofilm O +
community O -
. O +

Genome O +
copy O +
numbers O +
and O +
gene O +
conversion O +
in O +
methanogenic B-Species +
archaea L-Species -
. O -

Previous O +
studies O +
revealed O +
that O +
one O +
species O +
of O +
methanogenic B-Species +
archaea L-Species -
, O +
Methanocaldococcus B-Species +
jannaschii L-Species -
, O +
is O +
polyploid O -
, O +
while O +
a O +
second O +
species O -
, O +
Methanothermobacter B-Species +
thermoautotrophicus L-Species -
, O +
is O +
diploid O -
. O -

To O +
further O +
investigate O +
the O +
distribution O +
of O +
ploidy O +
in O +
methanogenic B-Species +
archaea L-Species -
, O +
species O +
of O +
two O +
additional O +
genera O -
- O -
Methanosarcina B-Species +
acetivorans L-Species +
and O +
Methanococcus B-Species +
maripaludis L-Species -
- O -
were O +
investigated O -
. O -

M. B-Species +
acetivorans L-Species +
was O +
found O +
to O +
be O +
polyploid O +
during O +
fast O +
growth O +
( O -
t O -
( O -
D O -
) O +
= O +
6 O +
h O -
; O +
17 O +
genome O +
copies O -
) O +
and O +
oligoploid O +
during O +
slow O +
growth O +
( O -
doubling O +
time O +
= O +
49 O +
h O -
; O +
3 O +
genome O +
copies O -
) O -
. O -

M. B-Species +
maripaludis L-Species +
has O +
the O +
highest O +
ploidy O +
level O +
found O +
for O +
any O +
archaeal O +
species O -
, O +
with O +
up O +
to O +
55 O +
genome O +
copies O +
in O +
exponential O +
phase O +
and O +
ca O -
. O -

30 O +
in O +
stationary O +
phase O -
. O -

A O +
compilation O +
of O +
archaeal O +
species O +
with O +
quantified O +
ploidy O +
levels O +
reveals O +
a O +
clear O +
dichotomy O +
between O +
Euryarchaeota O +
and O +
Crenarchaeota O -
: O +
none O +
of O +
seven O +
euryarchaeal O +
species O +
of O +
six O +
genera O +
is O +
monoploid O +
( O -
haploid O -
) O -
, O +
while O -
, O +
in O +
contrast O -
, O +
all O +
six O +
crenarchaeal O +
species O +
of O +
four O +
genera O +
are O +
monoploid O -
, O +
indicating O +
significant O +
genetic O +
differences O +
between O +
these O +
two O +
kingdoms O -
. O -

Polyploidy O +
in O +
asexual O +
species O +
should O +
lead O +
to O +
accumulation O +
of O +
inactivating O +
mutations O +
until O +
the O +
number O +
of O +
intact O +
chromosomes O +
per O +
cell O +
drops O +
to O +
zero O +
( O -
called O +
" O -
Muller O -
's O +
ratchet O -
" O -
) O -
. O -

A O +
mechanism O +
to O +
equalize O +
the O +
genome O +
copies O -
, O +
such O +
as O +
gene O +
conversion O -
, O +
would O +
counteract O +
this O +
phenomenon O -
. O -

Making O +
use O +
of O +
a O +
previously O +
constructed O +
heterozygous O +
mutant O +
strain O +
of O +
the O +
polyploid O +
M. O +
maripaludis O +
we B-Species +
could L-Species +
show O +
that O +
in O +
the O +
absence O +
of O +
selection O +
very O +
fast O +
equalization O +
of O +
genomes O +
in O +
M. O +
maripaludis O +
took B-Species +
place L-Species +
probably O +
via O +
a O +
gene O +
conversion O +
mechanism O -
. O -

In O +
addition O -
, O +
it O +
was O +
shown O +
that O +
the O +
velocity O +
of O +
this O +
phenomenon O +
is O +
inversely O +
correlated O +
to O +
the O +
strength O +
of O +
selection O -
. O +

The O +
peptidoglycan O -
- O -
binding O +
protein O +
FimV O +
promotes O +
assembly O +
of O +
the O +
Pseudomonas B-Species +
aeruginosa L-Species +
type O +
IV O +
pilus O +
secretin O -
. O +

The O +
Pseudomonas B-Species +
aeruginosa L-Species +
inner O +
membrane O +
protein O +
FimV O +
is O +
among O +
several O +
proteins O +
of O +
unknown O +
function O +
required O +
for O +
type O +
IV O +
pilus O -
- O -
mediated O +
twitching O +
motility O -
, O +
arising O +
from O +
extension O +
and O +
retraction O +
of O +
pili O +
from O +
their O +
site O +
of O +
assembly O +
in O +
the O +
inner O +
membrane O -
. O -

The O +
pili O +
transit O +
the O +
periplasm O +
and O +
peptidoglycan O +
( O -
PG O -
) O +
layer O -
, O +
ultimately O +
exiting O +
the O +
cell O +
through O +
the O +
PilQ O +
secretin O -
. O -

Although O +
fimV O +
mutants O +
are O +
nonmotile O -
, O +
they O +
are O +
susceptible O +
to O +
killing O +
by O +
pilus O -
- O -
specific O +
bacteriophage U-Species -
, O +
a O +
hallmark O +
of O +
retractable O +
surface O +
pili O -
. O -

Here O +
we O +
show O +
that O +
levels O +
of O +
recoverable O +
surface O +
pili O +
were O +
markedly O +
decreased O +
in O +
fimV O +
pilT O +
retraction O -
- O -
deficient O +
mutants O +
compared O +
with O +
levels O +
in O +
the O +
pilT O +
control O -
, O +
demonstrating O +
that O +
FimV O +
acts O +
at O +
the O +
level O +
of O +
pilus O +
assembly O -
. O -

Levels O +
of O +
inner O +
membrane O +
assembly O +
subcomplex O +
proteins O +
PilM O -
/ O -
N O -
/ O -
O O -
/ O -
P O +
were O +
decreased O +
in O +
fimV O +
mutants O -
, O +
but O +
supplementation O +
of O +
these O +
components O +
in O +
trans O +
did O +
not O +
restore O +
pilus O +
assembly O +
or O +
motility O -
. O -

Loss O +
of O +
FimV O +
dramatically O +
reduced O +
the O +
levels O +
of O +
the O +
PilQ O +
secretin O +
multimer O +
through O +
which O +
pili O +
exit O +
the O +
cell O -
, O +
in O +
part O +
due O +
to O +
decreased O +
levels O +
of O +
PilQ O +
monomers O -
, O +
while O +
PilF O +
pilotin O +
levels O +
were O +
unchanged O -
. O -

Expression O +
of O +
pilQ O +
in O +
trans O +
in O +
the O +
wild O +
type O +
or O +
fimV O +
mutants O +
increased O +
total O +
PilQ O +
monomer O +
levels O +
but O +
did O +
not O +
alter O +
secretin O +
multimer O +
levels O +
or O +
motility O -
. O -

PG O +
pulldown O +
assays O +
showed O +
that O +
the O +
N O +
terminus O +
of O +
FimV O +
bound O +
PG O +
in O +
a O +
LysM O +
motif O -
- O -
dependent O +
manner O -
, O +
and O +
a O +
mutant O +
with O +
an O +
in O -
- O -
frame O +
chromosomal O +
deletion O +
of O +
the O +
LysM O +
motif O +
had O +
reduced O +
motility O -
, O +
secretin O +
levels O -
, O +
and O +
surface O +
piliation O -
. O -

Together O -
, O +
our O +
data O +
show O +
that O +
FimV O -
's O +
role O +
in O +
pilus O +
assembly O +
is O +
to O +
promote O +
secretin O +
formation O +
and O +
that O +
this O +
function O +
depends O +
upon O +
its O +
PG O -
- O -
binding O +
domain O -
. O +

Activation O +
of O +
the O +
heat O +
shock O +
transcription O +
factor O +
Hsf1 O +
is O +
essential O +
for O +
the O +
full O +
virulence O +
of O +
the O +
fungal O +
pathogen O +
Candida B-Species +
albicans L-Species -
. O +

The O +
evolutionarily O +
conserved O +
heat O +
shock O +
transcription O +
factor O +
Hsf1 O +
plays O +
a O +
central O +
role O +
in O +
thermal O +
adaptation O +
in O +
the O +
major O +
fungal O +
pathogen O +
of O +
humans U-Species -
, O +
Candida B-Species +
albicans L-Species -
. O -

Hsf1 O +
becomes O +
hyperphosphorylated O +
in O +
response O +
to O +
heat O +
shock O +
and O +
activates O +
the O +
transcription O +
of O +
genes O +
with O +
heat O +
shock O +
elements O +
( O -
HSEs O -
) O +
in O +
their O +
promoters O -
, O +
these O +
genes O +
contributing O +
to O +
thermal O +
adaptation O -
. O -

However O -
, O +
the O +
relevance O +
of O +
Hsf1 O +
activation O +
to O +
C. B-Species +
albicans L-Species +
virulence O +
is O +
not O +
clear O +
as O +
this O +
pathogen O +
is O +
thought O +
to O +
be O +
obligately O +
associated O +
with O +
warm O +
blooded O +
animals O -
, O +
and O +
this O +
issue O +
has O +
not O +
been O +
tested O +
because O +
HSF1 O +
is O +
essential O +
for O +
viability O +
in O +
C. B-Species +
albicans L-Species -
. O -

In O +
this O +
study O -
, O +
we O +
demonstrate O +
that O +
the O +
HSE O +
regulon O +
is O +
active O +
in O +
C. B-Species +
albicans L-Species +
cells O +
infecting O +
the O +
kidney O -
. O -

We O +
also O +
show O +
the O +
CE2 O +
region O +
of O +
Hsf1 O +
is O +
required O +
for O +
activation O +
and O +
that O +
the O +
phosphorylation O +
of O +
specific O +
residues O +
in O +
this O +
domain O +
contributes O +
to O +
Hsf1 O +
activation O -
. O -

C. B-Species +
albicans L-Species +
HSF1 O +
mutants O +
that O +
lack O +
this O +
CE2 O +
region O +
are O +
viable O -
. O -

However O -
, O +
they O +
are O +
unable O +
to O +
activate O +
HSE O -
- O -
containing O +
genes O +
in O +
response O +
to O +
heat O +
shock O -
, O +
and O +
they O +
are O +
thermosensitive O -
. O -

Using O +
this O +
HSF1 O +
CE2 O +
deletion O +
mutant O +
we O +
demonstrate O +
that O +
Hsf1 O +
activation O -
, O +
and O +
hence O +
thermal O +
adaptation O -
, O +
contributes O +
significantly O +
to O +
the O +
virulence O +
of O +
C. B-Species +
albicans L-Species -
. O +

Characterization O +
of O +
the O +
developmental O +
regulator O +
FlbE O +
in O +
Aspergillus B-Species +
fumigatus L-Species +
and O +
Aspergillus B-Species +
nidulans L-Species -
. O +

Several O +
upstream O +
developmental O +
activators O +
control O +
asexual O +
development O +
( O -
conidiation O -
) O +
in O +
Aspergillus O -
. O -

In O +
this O +
study O -
, O +
we O +
characterize O +
one O +
of O +
such O +
activators O +
called O +
flbE O +
in O +
Aspergillus B-Species +
fumigatus L-Species +
and O +
Aspergillus B-Species +
nidulans L-Species -
. O -

The O +
predicted O +
FlbE O +
protein O +
is O +
composed O +
of O +
222 O +
and O +
201 O +
aa O +
in O +
A. B-Species +
fumigatus L-Species +
and O +
A. B-Species +
nidulans L-Species -
, O +
respectively O -
. O -

While O +
flbE O +
is O +
transiently O +
expressed O +
during O +
early O +
phase O +
of O +
growth O +
in O +
A. B-Species +
nidulans L-Species -
, O +
it O +
is O +
somewhat O +
constitutively O +
expressed O +
during O +
the O +
lifecycle O +
of O +
A. B-Species +
fumigatus L-Species -
. O -

The O +
deletion O +
of O +
flbE O +
causes O +
reduced O +
conidiation O +
and O +
delayed O +
expression O +
of O +
brlA O +
and O +
vosA O +
in O +
both O +
species O -
. O -

Moreover O -
, O +
FlbE O +
is O +
necessary O +
for O +
salt O -
- O -
induced O +
development O +
in O +
liquid O +
submerged O +
culture O +
in O +
A. B-Species +
fumigatus L-Species -
. O -

The O +
A. B-Species +
nidulans L-Species +
flbE O +
null O +
mutation O +
is O +
fully O +
complemented O +
by O +
A. B-Species +
fumigatus L-Species +
flbE O -
, O +
indicating O +
a O +
functional O +
conservancy O +
of O +
FlbE O +
in O +
Aspergillus O -
. O -

Both O +
the O +
deletion O +
and O +
overexpression O +
of O +
flbE O +
in O +
A. B-Species +
nidulans L-Species +
result O +
in O +
developmental O +
defects O -
, O +
enhanced O +
autolysis O -
, O +
precocious O +
cell O +
death O -
, O +
and O +
delayed O +
expression O +
of O +
brlA O -
/ O -
vosA O -
, O +
suggesting O +
that O +
balanced O +
activity O +
of O +
FlbE O +
is O +
crucial O +
for O +
proper O +
growth O +
and O +
development O -
. O -

Importantly O -
, O +
the O +
N O -
- O -
terminal O +
portion O +
of O +
FlbE O +
exhibits O +
the O +
trans O -
- O -
activation O +
ability O +
in O +
yeast U-Species -
, O +
whereas O +
the O +
C O -
- O -
terminal O +
half O +
negatively O +
affects O +
its O +
activity O -
. O -

Site O -
- O -
directed O +
mutagenesis O +
of O +
certain O +
conserved O +
N O -
- O -
terminal O +
amino O +
acids O +
abolishes O +
the O +
ability O +
of O +
trans O -
- O -
activation O -
, O +
overexpression O -
- O -
induced O +
autolysis O -
, O +
and O +
complementing O +
the O +
null O +
mutation O -
. O -

Finally O -
, O +
overexpression O +
of O +
flbD O -
, O +
but O +
not O +
flbB O +
or O +
flbC O -
, O +
restores O +
conidiation O +
in O +
A. B-Species +
nidulans L-Species +
DeltaflbE O -
, O +
generally O +
supporting O +
the O +
current O +
genetic O +
model O +
for O +
developmental O +
regulation O -
. O +

Universal O +
primers O +
for O +
rapid O +
detection O +
of O +
hytrosaviruses O -
. O -

Hytrosaviridae O +
is O +
a O +
proposed O +
virus O +
family O +
encompassing O +
viruses O +
that O +
cause O +
salivary O +
gland O +
hypertrophy O +
( O -
SGH O -
) O +
syndrome O +
in O +
infected O +
insects O +
and O +
reduce O +
the O +
fertility O +
in O +
their O +
dipteran O +
insect O +
hosts O -
. O -

They O +
contain O +
a O +
large O -
, O +
double O +
stranded O +
DNA O +
genome O +
of O +
120 O -
- O -
190 O +
kbp O -
. O -

To O +
date O -
, O +
these O +
viruses O +
have O +
been O +
detected O +
only O +
in O +
adult O +
Diptera O -
. O -

These O +
include O +
hytrosaviruses O +
detected O +
in O +
various O +
tsetse O +
fly O +
species O +
( O -
Glossina O +
spp O -
. O -
) O -
, O +
the O +
narcissus B-Species +
bulb I-Species +
fly L-Species +
Merodon B-Species +
equestris L-Species +
and O +
the O +
house B-Species +
fly L-Species +
Musca B-Species +
domestica L-Species -
. O -

The O +
limited O +
number O +
of O +
hytrosaviruses O +
reported O +
to O +
date O +
may O +
be O +
a O +
reflection O +
of O +
the O +
frequent O +
absence O +
of O +
external O +
symptoms O +
in O +
infected O +
adult O +
flies O +
and O +
the O +
fact O +
that O +
the O +
virus O +
does O +
not O +
cause O +
rapid O +
mortality O -
. O -

Based O +
on O +
the O +
complete O +
genome O +
sequence O +
of O +
Glossinia B-Species +
pallidipes L-Species +
( O -
GpSGHV O -
) O +
and O +
Musca B-Species +
domestica L-Species +
( O -
MdSGHV O -
) O +
salivary O +
gland O +
hypertrophy O +
viruses O -
, O +
a O +
PCR O +
based O +
methodology O +
was O +
developed O +
to O +
detect O +
the O +
viruses O +
in O +
these O +
species O -
. O -

To O +
be O +
able O +
to O +
detect O +
hytrosaviruses O +
in O +
other O +
Diptera O -
, O +
five O +
degenerate O +
primer O +
pairs O +
were O +
designed O +
and O +
tested O +
on O +
GpSGHV O +
and O +
MdSGHV O +
DNA O +
using O +
gradient O +
PCR O +
with O +
annealing O +
temperatures O +
from O +
37 O +
to O +
61 O -
^ O -
0C O -
. O -

Two O +
pairs O +
of O +
primers O +
were O +
selected O +
from O +
p74 O -
, O +
two O +
pairs O +
from O +
PIF-1 O +
and O +
one O +
pair O +
from O +
ODV O -
- O -
e66 O +
homologous O +
proteins O -
. O -

Four O +
primer O +
pairs O +
generated O +
a O +
virus O +
specific O +
PCR O +
product O +
on O +
both O +
MdSGHV O +
and O +
GpSGHV O +
at O +
all O +
tested O +
annealing O +
temperatures O -
, O +
while O +
the O +
ODV O -
- O -
e66 O +
based O +
primers O +
did O +
not O +
generate O +
a O +
virus O +
specific O +
product O +
with O +
annealing O +
temperatures O +
higher O +
that O +
47 O -
^ O -
0C O -
. O -

No O +
non O -
- O -
specific O +
PCR O +
product O +
was O +
found O +
when O +
using O +
genomic O +
DNA O +
of O +
infected O +
flies O +
as O +
template O +
DNA O -
. O -

These O +
results O +
offer O +
new O +
sets O +
of O +
primers O +
that O +
could O +
be O +
used O +
to O +
detect O +
hytrosaviruses O +
in O +
other O +
insects O -
. O +

Candidate O +
chemosensory O +
ionotropic O +
receptors O +
in O +
a O +
Lepidoptera O -
. O -

A O +
new O +
family O +
of O +
candidate O +
chemosensory O +
ionotropic O +
receptors O +
( O -
IRs O -
) O +
related O +
to O +
ionotropic O +
glutamate O +
receptors O +
( O -
iGluRs O -
) O +
was O +
recently O +
discovered O +
in O +
Drosophila B-Species +
melanogaster L-Species -
. O -

Through O +
Blast O +
analyses O +
of O +
an O +
expressed O +
sequenced O +
tag O +
library O +
prepared O +
from O +
male O +
antennae O +
of O +
the O +
noctuid O +
moth O +
Spodoptera B-Species +
littoralis L-Species -
, O +
we O +
identified O +
12 O +
unigenes O +
encoding O +
proteins O +
related O +
to O +
D. B-Species +
melanogaster L-Species +
and O +
Bombyx B-Species +
mori L-Species +
IRs O -
. O -

Their O +
full O +
length O +
sequences O +
were O +
obtained O +
and O +
the O +
analyses O +
of O +
their O +
expression O +
patterns O +
suggest O +
that O +
they O +
were O +
exclusively O +
expressed O +
or O +
clearly O +
enriched O +
in O +
chemosensory O +
organs O -
. O -

The O +
deduced O +
protein O +
sequences O +
were O +
more O +
similar O +
to O +
B. B-Species +
mori L-Species +
and O +
D. B-Species +
melanogaster L-Species +
IRs O +
than O +
to O +
iGluRs O +
and O +
showed O +
considerable O +
variations O +
in O +
the O +
predicted O +
ligand O -
- O -
binding O +
domains O -
; O +
none O +
have O +
the O +
three O +
glutamate O -
- O -
interacting O +
residues O +
found O +
in O +
iGluRs O -
, O +
suggesting O +
different O +
binding O +
specificities O -
. O -

Our O +
data O +
suggest O +
that O +
we O +
identified O +
members O +
of O +
the O +
insect O +
IR O +
chemosensory O +
receptor O +
family O +
in O +
S. B-Species +
littoralis L-Species +
and O +
we O +
report O +
here O +
the O +
first O +
demonstration O +
of O +
IR O +
expression O +
in O +
Lepidoptera O -
. O +

The O +
RNA O -
- O -
Seq O +
approach O +
to O +
studying O +
the O +
expression O +
of O +
mosquito O +
mitochondrial O +
genes O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
extensive O +
expressed O +
sequence O +
tag O +
evidence O +
obtained O +
through O +
454 O +
and O +
Solexa O +
next O -
- O -
generation O +
sequencing O +
to O +
explore O +
mtDNA O +
transcription O +
in O +
male O +
and O +
female O +
first O +
instar O +
larvae O +
of O +
Aedes B-Species +
aegypti L-Species +
and O +
adults O +
of O +
Aedes B-Species +
aegypti L-Species -
, O +
Anopheles B-Species +
gambiae L-Species -
, O +
and O +
Anopheles B-Species +
quadrimaculatus L-Species -
. O -

Relative O +
abundances O +
of O +
individual O +
transcripts O +
differed O +
considerably O +
within O +
each O +
sample O -
, O +
consistent O +
with O +
the O +
differential O +
stability O +
of O +
messenger O +
RNA O +
species O -
. O -

Large O +
differences O +
were O +
also O +
observed O +
between O +
species O +
and O +
between O +
larval O +
and O +
adult O +
stages O -
; O +
however O -
, O +
the O +
male O +
and O +
female O +
larval O +
samples O +
were O +
remarkably O +
similar O -
. O -

Quantitative O +
PCR O +
analysis O +
of O +
selected O +
genes O -
, O +
cox1 O -
, O +
l O -
- O -
rRNA O +
and O +
nd5 O -
, O +
in O +
larvae O +
and O +
adults O +
of O +
Ae B-Species -
. L-Species -

aegypti U-Species +
and O +
in O +
An B-Species -
. L-Species -

gambiae U-Species +
adults O +
was O +
consistent O +
with O +
the O +
RNA O -
- O -
Seq O -
- O -
based O +
quantification O +
of O +
expression O -
. O -

Finally O -
, O +
the O +
absence O +
of O +
a O +
conserved O +
mtDNA O +
region O +
involved O +
in O +
transcriptional O +
control O +
in O +
other O +
dipterans O +
suggests O +
that O +
mosquitoes O +
have O +
evolved O +
a O +
distinct O +
mechanism O +
of O +
regulation O +
of O +
gene O +
expression O +
in O +
the O +
mitochondrion O -
. O +

Differential O +
PbP27 O +
expression O +
in O +
the O +
yeast O +
and O +
mycelial O +
forms O +
of O +
the O +
Paracoccidioides B-Species +
brasiliensis L-Species +
species O +
complex O -
. O +

p27 O +
is O +
an O +
antigenic O +
protein O +
produced O +
by O +
Paracoccidioides B-Species +
brasiliensis L-Species -
, O +
the O +
etiologic O +
agent O +
of O +
paracoccidioidomycosis O +
( O -
PCM O -
) O -
. O -

Despite O +
its O +
unknown O +
function O -
, O +
it O +
has O +
been O +
suggested O +
as O +
a O +
putative O +
virulence O +
factor O -
, O +
proposed O +
as O +
a O +
suitable O +
target O +
for O +
the O +
design O +
of O +
diagnostic O +
tools O +
and O +
vaccines O -
, O +
and O +
considered O +
as O +
an O +
enhancer O +
in O +
antifungal O +
treatment O +
of O +
PCM O -
. O -

We O +
evaluated O +
sequence O +
polymorphisms O +
of O +
PbP27 O +
gene O +
sequence O +
among O +
isolates O -
, O +
finding O +
some O +
polymorphisms O +
associated O +
with O +
the O +
isolates O -
' O +
phylogenetic O +
origin O -
. O -

In O +
order O +
to O +
determine O +
if O +
there O +
was O +
a O +
differential O +
expression O +
pattern O +
between O +
morphological O +
states O +
and O +
among O +
isolates O -
, O +
we O +
also O +
evaluated O +
PbP27 O +
expression O -
, O +
at O +
transcriptional O +
and O +
translational O +
levels O -
, O +
in O +
mycelia O +
and O +
yeast O +
cultures O +
in O +
14 O +
isolates O +
belonging O +
to O +
the O +
P. B-Species +
brasiliensis I-Species +
species I-Species +
complex L-Species +
( O -
S1 O -
, O +
PS2 O -
, O +
PS3 O -
, O +
and O +
" O -
Pb01-like O -
" O -
, O +
proposed O +
to O +
be O +
named O +
Paracoccidioides B-Species +
lutzii L-Species -
) O +
by O +
two O +
techniques O -
, O +
real O +
time O +
RT O -
- O -
PCR O +
( O -
RT O -
- O -
qPCR O -
) O +
and O +
protein O +
dot O +
blot O -
. O -

For O +
the O +
latter O -
, O +
four O +
protein O +
extracts O +
from O +
different O +
cell O +
localizations O +
( O -
SDS O +
or O +
Beta O -
- O -
mercaptoethanol O -
, O +
cytoplasmic O +
and O +
extracellular O +
proteins O -
) O +
were O +
analyzed O +
for O +
each O +
isolate O -
. O -

p27 O +
was O +
present O +
in O +
the O +
four O +
extracts O +
evaluated O -
, O +
mainly O +
in O +
the O +
SDS O +
extract O -
, O +
corresponding O +
to O +
an O +
extract O +
containing O +
proteins O +
loosely O +
attached O +
to O +
the O +
cell O +
wall O -
. O -

This O +
information O +
correlates O +
with O +
immunohistochemical O +
analysis O -
, O +
where O +
positive O +
staining O +
of O +
the O +
yeasts O -
' O +
cell O +
wall O +
was O +
observed O -
. O -

We O +
found O +
that O +
p27 O +
was O +
present O +
in O +
all O +
isolates O -
, O +
mainly O +
in O +
the O +
yeast O +
form O -
. O -

This O +
pattern O +
was O +
corroborated O +
by O +
RT O -
- O -
qPCR O +
results O -
, O +
with O +
higher O +
expression O +
levels O +
found O +
in O +
the O +
yeast O +
form O +
for O +
most O +
of O +
the O +
isolates O -
. O -

The O +
results O +
provide O +
new O +
insights O +
into O +
the O +
expression O +
patterns O +
of O +
this O +
protein O -
, O +
and O +
further O +
characterize O +
it O +
in O +
view O +
of O +
potential O +
uses O +
as O +
a O +
diagnostic O +
and/or O +
therapeutic O +
tool O -
. O +

Role O +
of O +
lupeol O +
synthase O +
in O +
Lotus B-Species +
japonicus L-Species +
nodule O +
formation O -
. O -

* O +
Triterpenes O +
are O +
plant O +
secondary O +
metabolites O -
, O +
derived O +
from O +
the O +
cyclization O +
of O +
2,3-oxidosqualene O +
by O +
oxidosqualene O +
cyclases O +
( O -
OSCs O -
) O -
. O -

Here O -
, O +
we O +
investigated O +
the O +
role O +
of O +
lupeol O +
synthase O -
, O +
encoded O +
by O +
OSC3 O -
, O +
and O +
its O +
product O -
, O +
lupeol O -
, O +
in O +
developing O +
roots O +
and O +
nodules O +
of O +
the O +
model O +
legume O +
Lotus B-Species +
japonicus L-Species -
. O -

* O +
The O +
expression O +
patterns O +
of O +
OSC3 O +
in O +
different O +
developmental O +
stages O +
of O +
uninfected O +
roots O +
and O +
in O +
roots O +
infected O +
with O +
Mesorhizobium B-Species +
loti L-Species +
were O +
determined O -
. O -

The O +
tissue O +
specificity O +
of O +
OSC3 O +
expression O +
was O +
analysed O +
by O +
in O +
situ O +
hybridization O -
. O -

Functional O +
analysis O -
, O +
in O +
which O +
transgenic O +
L. B-Species +
japonicus L-Species +
roots O +
silenced O +
for O +
OSC3 O +
were O +
generated O -
, O +
was O +
performed O -
. O -

The O +
absence O +
of O +
lupeol O +
in O +
the O +
silenced O +
plant O +
lines O +
was O +
determined O +
by O +
GC O -
- O -
MS O -
. O -

* O +
The O +
expression O +
of O +
ENOD40 O -
, O +
a O +
marker O +
gene O +
for O +
nodule O +
primordia O +
initiation O -
, O +
was O +
increased O +
significantly O +
in O +
the O +
OSC3-silenced O +
plant O +
lines O -
, O +
suggesting O +
that O +
lupeol O +
influences O +
nodule O +
formation O -
. O -

Silenced O +
plants O +
also O +
showed O +
a O +
more O +
rapid O +
nodulation O +
phenotype O -
, O +
consistent O +
with O +
this O -
. O -

Exogenous O +
application O +
of O +
lupeol O +
to O +
M. B-Species +
loti L-Species -
- O -
infected O +
wild O -
- O -
type O +
plants O +
provided O +
further O +
evidence O +
for O +
a O +
negative O +
regulatory O +
effect O +
of O +
lupeol O +
on O +
the O +
expression O +
of O +
ENOD40 O -
. O -

* O +
The O +
synthesis O +
of O +
lupeol O +
in O +
L. B-Species +
japonicus L-Species +
roots O +
and O +
nodules O +
can O +
be O +
solely O +
attributed O +
to O +
OSC3 O -
. O -

Taken O +
together O -
, O +
our O +
data O +
suggest O +
a O +
role O +
for O +
lupeol O +
biosynthesis O +
in O +
nodule O +
formation O +
through O +
the O +
regulation O +
of O +
ENOD40 O +
gene O +
expression O -
. O +

Overexpression O +
of O +
the O +
trichodiene O +
synthase O +
gene O +
tri5 O +
increases O +
trichodermin O +
production O +
and O +
antimicrobial O +
activity O +
in O +
Trichoderma B-Species +
brevicompactum L-Species -
. O +

Trichoderma B-Species +
brevicompactum L-Species +
produces O +
trichodermin O -
, O +
a O +
simple O +
trichothecene O -
- O -
type O +
toxin O +
that O +
shares O +
the O +
first O +
steps O +
of O +
the O +
sesquiterpene O +
biosynthetic O +
pathway O +
with O +
other O +
phytotoxic O +
trichothecenes O +
from O +
Fusarium B-Species +
spp L-Species -
. O -

Trichodiene O +
synthase O +
catalyses O +
the O +
conversion O +
of O +
farnesyl O +
pyrophosphate O +
to O +
trichodiene O +
and O +
it O +
is O +
encoded O +
by O +
the O +
tri5 O +
gene O +
that O +
was O +
cloned O +
and O +
analysed O +
functionally O +
by O +
homologous O +
overexpression O +
in O +
T. B-Species +
brevicompactum L-Species -
. O -

tri5 O +
expression O +
was O +
up O -
- O -
regulated O +
in O +
media O +
with O +
glucose O -
, O +
H O -
( O -
2 O -
) O -
O O -
( O -
2 O -
) O +
or O +
glycerol O -
. O -

tri5 O +
repression O +
was O +
observed O +
in O +
cultures O +
supplemented O +
with O +
the O +
antioxidants O +
ferulic O +
acid O +
and O +
tyrosol O -
. O -

Acetone O +
extracts O +
of O +
tri5-overexpressing O +
transformants O +
displayed O +
higher O +
antifungal O +
activity O +
than O +
those O +
from O +
the O +
wild O -
- O -
type O -
. O -

Chromatographic O +
and O +
spectroscopic O +
analyses O +
revealed O +
that O +
tri5 O +
overexpression O +
led O +
to O +
an O +
increased O +
production O +
of O +
trichodermin O +
and O +
tyrosol O -
. O -

Agar O +
diffusion O +
assays O +
with O +
these O +
two O +
purified O +
metabolites O +
from O +
the O +
tri5-overexpressing O +
transformant O +
T. B-Species +
brevicompactum L-Species +
Tb41tri5 O +
showed O +
that O +
only O +
trichodermin O +
had O +
antifungal O +
activity O +
against O +
Saccharomyces B-Species +
cerevisiae L-Species -
, O +
Kluyveromyces B-Species +
marxianus L-Species -
, O +
Candida B-Species +
albicans L-Species -
, O +
Candida B-Species +
glabrata L-Species -
, O +
Candida B-Species +
tropicalis L-Species +
and O +
Aspergillus B-Species +
fumigatus L-Species -
, O +
in O +
most O +
cases O +
such O +
activity O +
being O +
higher O +
than O +
that O +
observed O +
for O +
amphotericin O +
B O +
and O +
hygromycin O -
. O -

Our O +
results O +
point O +
to O +
the O +
significant O +
role O +
of O +
tri5 O +
in O +
the O +
production O +
of O +
trichodermin O +
and O +
in O +
the O +
antifungal O +
activity O +
of O +
T. B-Species +
brevicompactum L-Species -
. O +

Limitation O +
of O +
Sludge O +
Biotic O +
Index O +
application O +
for O +
control O +
of O +
a O +
wastewater O +
treatment O +
plant O +
working O +
with O +
shock O +
organic O +
and O +
ammonium O +
loadings O -
. O +

This O +
study O +
aimed O +
to O +
determine O +
the O +
relationship O +
between O +
activated O +
sludge O +
microfauna O -
, O +
the O +
sludge O +
biotic O +
index O +
( O -
SBI O -
) O +
and O +
the O +
effluent O +
quality O +
of O +
a O +
full O -
- O -
scale O +
municipal O +
wastewater O +
treatment O +
plant O +
( O -
WWTP O -
) O +
working O +
with O +
shock O +
organic O +
and O +
ammonium O +
loadings O +
caused O +
by O +
periodic O +
wastewater O +
delivery O +
from O +
septic O +
tanks O -
. O -

Irrespective O +
of O +
high O -
/ O -
low O +
effluent O +
quality O +
in O +
terms O +
of O +
COD O -
, O +
BOD O -
( O -
5 O -
) O -
, O +
ammonium O +
and O +
suspended O +
solids O -
, O +
high O +
SBI O +
values O +
( O -
8 O -
- O -
10 O -
) O -
, O +
which O +
correspond O +
to O +
the O +
first O +
quality O +
class O +
of O +
sludge O -
, O +
were O +
observed O -
. O -

High O +
SBI O +
values O +
were O +
connected O +
with O +
abundant O +
taxonomic O +
composition O +
and O +
the O +
domination O +
of O +
crawling O +
ciliates O +
with O +
shelled O +
amoebae O +
and O +
attached O +
ciliates O -
. O -

High O +
SBI O +
values O -
, O +
even O +
at O +
a O +
low O +
effluent O +
quality O -
, O +
limit O +
the O +
usefulness O +
of O +
the O +
index O +
for O +
monitoring O +
the O +
status O +
of O +
an O +
activated O +
sludge O +
system O +
and O +
the O +
effluent O +
quality O +
in O +
municipal O +
WWTP O -
- O -
treated O +
wastewater O +
from O +
septic O +
tanks O -
. O -

It O +
was O +
shown O +
that O +
a O +
more O +
sensitive O +
indicator O +
of O +
effluent O +
quality O +
was O +
a O +
change O +
in O +
the O +
abundance O +
of O +
attached O +
ciliates O +
with O +
a O +
narrow O +
peristome O +
( O -
Vorticella B-Species +
infusionum L-Species +
and O +
Opercularia O +
coarctata O -
) O -
, O +
small O +
flagellates O +
and O +
crawling O +
ciliates O +
( O -
Acineria O +
uncinata O -
) O +
feeding O +
on O +
flagellates O -
. O +

A O +
small O +
protein O +
required O +
for O +
the O +
switch O +
from O +
{ O -
sigma O -
} O -
F O +
to O +
{ O -
sigma O -
} O -
G O +
during O +
sporulation O +
in O +
Bacillus B-Species +
subtilis L-Species -
. O +

A O +
cascade O +
of O +
alternative O +
sigma O +
factors O +
governs O +
the O +
program O +
of O +
developmental O +
gene O +
expression O +
during O +
sporulation O +
in O +
Bacillus B-Species +
subtilis L-Species -
. O -

Little O +
is O +
known O -
, O +
however O -
, O +
about O +
how O +
the O +
early O -
- O -
acting O +
sigma O +
factors O +
are O +
inactivated O +
and O +
replaced O +
by O +
the O +
later O -
- O -
acting O +
factors O -
. O -

Here O +
we O +
identify O +
a O +
small O +
protein O -
, O +
Fin O +
( O -
formerly O +
known O +
as O +
YabK O -
) O -
, O +
that O +
is O +
required O +
for O +
efficient O +
switching O +
from O +
sigma O -
( O -
F O -
) O -
- O +
to O +
sigma O -
( O -
G O -
) O -
-directed O +
gene O +
expression O +
in O +
the O +
forespore O +
compartment O +
of O +
the O +
developing O +
sporangium O -
. O -

The O +
fin O +
gene O -
, O +
which O +
is O +
conserved O +
among O +
Bacillus O +
species O +
and O +
species O +
of O +
related O +
genera O -
, O +
is O +
transcribed O +
in O +
the O +
forespore O +
under O +
the O +
control O +
of O +
both O +
sigma O -
( O -
F O -
) O +
and O +
sigma O -
( O -
G O -
) O -
. O -

Cells O +
mutant O +
for O +
fin O +
are O +
unable O +
to O +
fully O +
deactivate O +
sigma O -
( O -
F O -
) O +
and O -
, O +
conversely O -
, O +
are O +
unable O +
to O +
fully O +
activate O +
sigma O -
( O -
G O -
) O -
. O -

Consistent O +
with O +
their O +
deficiency O +
in O +
sigma O -
( O -
G O -
) O -
-directed O +
gene O +
expression O -
, O +
fin O +
cells O +
are O +
arrested O +
in O +
large O +
numbers O +
following O +
the O +
engulfment O +
stage O +
of O +
sporulation O -
, O +
ultimately O +
forming O +
50-fold O +
fewer O +
heat O -
- O -
resistant O +
spores O +
than O +
the O +
wild O +
type O -
. O -

Based O +
in O +
part O +
on O +
the O +
similarity O +
of O +
Fin O +
to O +
the O +
anti O -
- O -
sigma O -
( O -
G O -
) O +
factor O +
CsfB O +
( O -
also O +
called O +
Gin O -
) O -
, O +
we O +
speculate O +
that O +
Fin O +
is O +
an O +
anti O -
- O -
sigma O -
( O -
F O -
) O +
factor O +
which O -
, O +
by O +
disabling O +
sigma O -
( O -
F O -
) O -
, O +
promotes O +
the O +
switch O +
to O +
late O +
developmental O +
gene O +
expression O +
in O +
the O +
forespore O -
. O +

X O -
- O -
ray O +
structure O +
and O +
site O -
- O -
directed O +
mutagenesis O +
analysis O +
of O +
the O +
Escherichia B-Species +
coli L-Species +
colicin O +
M O +
immunity O +
protein O -
. O +

Colicin O +
M O +
( O -
ColM O -
) O -
, O +
which O +
is O +
produced O +
by O +
some O +
Escherichia B-Species +
coli L-Species +
strains O +
to O +
kill O +
competitor O +
strains O +
from O +
the O +
same O +
or O +
related O +
species O -
, O +
was O +
recently O +
shown O +
to O +
inhibit O +
cell O +
wall O +
peptidoglycan O +
biosynthesis O +
through O +
enzymatic O +
degradation O +
of O +
its O +
lipid O +
II O +
precursor O -
. O -

ColM O -
- O -
producing O +
strains O +
are O +
protected O +
from O +
the O +
toxin O +
that O +
they O +
produce O +
by O +
coexpression O +
of O +
a O +
specific O +
immunity O +
protein O -
, O +
named O +
Cmi O -
, O +
whose O +
mode O +
of O +
action O +
still O +
remains O +
to O +
be O +
identified O -
. O -

We O +
report O +
here O +
the O +
resolution O +
of O +
the O +
crystal O +
structure O +
of O +
Cmi O -
, O +
which O +
is O +
composed O +
of O +
four O +
Beta O +
strands O +
and O +
four O +
alpha O +
helices O -
. O -

This O +
rather O +
compact O +
structure O +
revealed O +
a O +
disulfide O +
bond O +
between O +
residues O +
Cys31 O +
and O +
Cys107 O -
. O -

Interestingly O -
, O +
these O +
two O +
cysteines O +
and O +
several O +
other O +
residues O +
appeared O +
to O +
be O +
conserved O +
in O +
the O +
sequences O +
of O +
several O +
proteins O +
of O +
unknown O +
function O +
belonging O +
to O +
the O +
YebF O +
family O +
which O +
exhibit O +
25 O +
to O +
35 O -
% O +
overall O +
sequence O +
similarity O +
with O +
Cmi O -
. O -

Site O -
- O -
directed O +
mutagenesis O +
was O +
performed O +
to O +
assess O +
the O +
role O +
of O +
these O +
residues O +
in O +
the O +
ColM O +
immunity O -
- O -
conferring O +
activity O +
of O +
Cmi O -
, O +
which O +
showed O +
that O +
the O +
disulfide O +
bond O +
and O +
residues O +
from O +
the O +
C O -
- O -
terminal O +
extremity O +
of O +
the O +
protein O +
were O +
functionally O +
essential O -
. O -

The O +
involvement O +
of O +
DsbA O +
oxidase O +
in O +
the O +
formation O +
of O +
the O +
Cmi O +
disulfide O +
bond O +
is O +
also O +
demonstrated O -
. O +

Cannibalism O +
and O +
intraguild O +
predation O +
of O +
eggs O +
within O +
a O +
diverse O +
predator O +
assemblage O -
. O +

Greater O +
biodiversity O +
among O +
aphid O +
predators O +
sometimes O +
leads O +
to O +
greater O +
predator O +
reproductive O +
success O -
. O -

This O +
could O +
occur O +
if O +
cannibalism O +
of O +
predator O +
eggs O +
is O +
consistently O +
stronger O +
than O +
intraguild O +
predation O -
, O +
such O +
that O +
diversity O +
dilutes O +
cannibalism O +
risk O +
when O +
total O +
predator O +
densities O +
remain O +
constant O +
across O +
diversity O +
levels O -
. O -

We O +
compared O +
the O +
frequency O +
of O +
cannibalism O +
versus O +
intraguild O +
predation O +
by O +
adult O +
predators O +
of O +
four O +
species O +
[ O -
the O +
lady O +
beetles O +
Coccinella B-Species +
septempunctata I-Species +
L. L-Species +
and O +
Hippodamia B-Species +
convergens I-Species +
Guerin I-Species -
- I-Species -
Meneville L-Species -
, O +
and O +
the O +
predatory O +
bugs O +
Geocoris B-Species +
bullatus I-Species +
( I-Species -
Say L-Species -
) O +
and O +
Nabis O +
alternatus O +
Parshley O -
] O +
on O +
the O +
eggs O +
of O +
three O +
predator O +
species O +
( O -
all O +
of O +
these O +
predators O +
but O +
Nabis O -
) O -
. O -

For O +
both O +
coccinellid O +
species O -
, O +
egg O +
predation O +
averaged O +
across O +
all O +
intraguild O +
predators O +
was O +
less O +
frequent O +
than O +
cannibalism O -
. O -

In O +
contrast O -
, O +
Geocoris U-Species +
eggs O +
were O +
generally O +
more O +
likely O +
to O +
be O +
consumed O +
by O +
intraguild O +
predators O +
than O +
by O +
conspecifics O -
. O -

Closer O +
inspection O +
of O +
the O +
data O +
revealed O +
that O +
Geocoris U-Species +
consistently O +
consumed O +
fewer O +
eggs O +
than O +
the O +
other O +
species O -
, O +
regardless O +
of O +
egg O +
species O -
. O -

Indeed O -
, O +
for O +
lady O +
beetle O +
eggs O +
it O +
was O +
relatively O +
infrequent O +
egg O +
predation O +
by O +
Geocoris U-Species +
that O +
brought O +
down O +
the O +
average O +
across O +
all O +
heterospecific O +
predators O -
, O +
masking O +
the O +
fact O +
that O +
adults O +
of O +
the O +
two O +
lady O +
beetles O +
were O +
no O +
more O +
likely O +
to O +
act O +
as O +
egg O +
cannibals O +
than O +
as O +
intraguild O +
predators O -
. O -

Nabis O +
ate O +
eggs O +
of O +
the O +
two O +
beetles O +
at O +
approximately O +
equal O +
rates O -
, O +
but O +
rarely O +
ate O +
Geocoris U-Species +
eggs O -
. O -

Female O +
predators O +
generally O +
consumed O +
more O +
eggs O +
than O +
did O +
males O -
, O +
but O +
this O +
did O +
not O +
alter O +
any O +
of O +
the O +
patterns O +
described O +
above O -
. O -

Altogether O -
, O +
our O +
results O +
suggest O +
that O +
species O -
- O -
specific O +
differences O +
in O +
egg O +
predation O +
rates O +
determined O +
the O +
relative O +
intensity O +
of O +
egg O +
intraguild O -
- O -
predation O +
versus O +
cannibalism O -
, O +
rather O +
than O +
any O +
more O +
general O +
trend O +
for O +
egg O +
cannibalism O +
to O +
always O +
exceed O +
intraguild O +
predation O -
. O +

Reproductive O +
health O -
, O +
and O +
child O +
health O +
and O +
nutrition O +
in O +
India O -
: O +
meeting O +
the O +
challenge O -
. O +

India O -
, O +
with O +
a O +
population O +
of O +
more O +
than O +
1 O +
billion O +
people O -
, O +
has O +
many O +
challenges O +
in O +
improving O +
the O +
health O +
and O +
nutrition O +
of O +
its O +
citizens O -
. O -

Steady O +
declines O +
have O +
been O +
noted O +
in O +
fertility O -
, O +
maternal O -
, O +
infant O +
and O +
child O +
mortalities O -
, O +
and O +
the O +
prevalence O +
of O +
severe O +
manifestations O +
of O +
nutritional O +
deficiencies O -
, O +
but O +
the O +
pace O +
has O +
been O +
slow O +
and O +
falls O +
short O +
of O +
national O +
and O +
Millennium O +
Development O +
Goal O +
targets O -
. O -

The O +
likely O +
explanations O +
include O +
social O +
inequities O -
, O +
disparities O +
in O +
health O +
systems O +
between O +
and O +
within O +
states O -
, O +
and O +
consequences O +
of O +
urbanisation O +
and O +
demographic O +
transition O -
. O -

In O +
2005 O -
, O +
India O +
embarked O +
on O +
the O +
National O +
Rural O +
Health O +
Mission O -
, O +
an O +
extraordinary O +
effort O +
to O +
strengthen O +
the O +
health O +
systems O -
. O -

However O -
, O +
coverage O +
of O +
priority O +
interventions O +
remains O +
insufficient O -
, O +
and O +
the O +
content O +
and O +
quality O +
of O +
existing O +
interventions O +
are O +
suboptimum O -
. O -

Substantial O +
unmet O +
need O +
for O +
contraception O +
remains O -
, O +
adolescent O +
pregnancies O +
are O +
common O -
, O +
and O +
access O +
to O +
safe O +
abortion O +
is O +
inadequate O -
. O -

Increases O +
in O +
the O +
numbers O +
of O +
deliveries O +
in O +
institutions O +
have O +
not O +
been O +
matched O +
by O +
improvements O +
in O +
the O +
quality O +
of O +
intrapartum O +
and O +
neonatal O +
care O -
. O -

Infants O +
and O +
young O +
children O +
do O +
not O +
get O +
the O +
health O +
care O +
they O +
need O -
; O +
access O +
to O +
effective O +
treatment O +
for O +
neonatal O +
illness O -
, O +
diarrhoea O -
, O +
and O +
pneumonia O +
shows O +
little O +
improvement O -
; O +
and O +
the O +
coverage O +
of O +
nutrition O +
programmes O +
is O +
inadequate O -
. O -

Absence O +
of O +
well O +
functioning O +
health O +
systems O +
is O +
indicated O +
by O +
the O +
inadequacies O +
related O +
to O +
planning O -
, O +
financing O -
, O +
human U-Species +
resources O -
, O +
infrastructure O -
, O +
supply O +
systems O -
, O +
governance O -
, O +
information O -
, O +
and O +
monitoring O -
. O -

We O +
provide O +
a O +
case O +
for O +
transformation O +
of O +
health O +
systems O +
through O +
effective O +
stewardship O -
, O +
decentralised O +
planning O +
in O +
districts O -
, O +
a O +
reasoned O +
approach O +
to O +
financing O +
that O +
affects O +
demand O +
for O +
health O +
care O -
, O +
a O +
campaign O +
to O +
create O +
awareness O +
and O +
change O +
health O +
and O +
nutrition O +
behaviour O -
, O +
and O +
revision O +
of O +
programmes O +
for O +
child O +
nutrition O +
on O +
the O +
basis O +
of O +
evidence O -
. O -

This O +
agenda O +
needs O +
political O +
commitment O +
of O +
the O +
highest O +
order O +
and O +
the O +
development O +
of O +
a O +
people O -
's O +
movement O -
. O +

FAD O +
binding O +
by O +
ApbE O +
protein O +
from O +
Salmonella B-Species +
enterica L-Species -
: O +
a O +
new O +
class O +
of O +
FAD O -
- O -
binding O +
proteins O -
. O +

The O +
periplasmic O +
protein O +
ApbE O +
was O +
identified O +
through O +
the O +
analysis O +
of O +
several O +
mutants O +
defective O +
in O +
thiamine O +
biosynthesis O +
and O +
was O +
implicated O +
as O +
having O +
a O +
role O +
in O +
iron O -
- O -
sulfur O +
cluster O +
biosynthesis O +
or O +
repair O -
. O -

While O +
mutations O +
in O +
apbE O +
cause O +
decreased O +
activity O +
of O +
several O +
iron O -
- O -
sulfur O +
enzymes O +
in O +
vivo O -
, O +
the O +
specific O +
role O +
of O +
ApbE O +
remains O +
unknown O -
. O -

Members O +
of O +
the O +
AbpE O +
family O +
include O +
NosX O +
and O +
RnfF O -
, O +
which O +
have O +
been O +
implicated O +
in O +
oxidation O -
- O -
reduction O +
associated O +
with O +
nitrous O +
oxide O +
and O +
nitrogen O +
metabolism O -
, O +
respectively O -
. O -

In O +
this O +
work O -
, O +
we O +
show O +
that O +
ApbE O +
binds O +
one O +
FAD O +
molecule O +
per O +
monomeric O +
unit O -
. O -

The O +
structure O +
of O +
ApbE O +
in O +
the O +
presence O +
of O +
bound O +
FAD O +
reveals O +
a O +
new O +
FAD O -
- O -
binding O +
motif O -
. O -

Protein O +
variants O +
that O +
are O +
nonfunctional O +
in O +
vivo O +
were O +
generated O +
by O +
random O +
and O +
targeted O +
mutagenesis O -
. O -

Each O +
variant O +
was O +
substituted O +
in O +
the O +
environment O +
of O +
the O +
FAD O +
and O +
analyzed O +
for O +
FAD O +
binding O +
after O +
reconstitution O -
. O -

The O +
variant O +
that O +
altered O +
a O +
key O +
tyrosine O +
residue O +
involved O +
in O +
FAD O +
binding O +
prevented O +
reconstitution O +
of O +
the O +
protein O -
. O +

Expanding O +
character O +
sampling O +
for O +
ciliate O +
phylogenetic O +
inference O +
using O +
mitochondrial O +
SSU O -
- O -
rDNA O +
as O +
a O +
molecular O +
marker O -
. O +

Molecular O +
systematics O +
of O +
ciliates O -
, O +
particularly O +
at O +
deep O +
nodes O -
, O +
has O +
largely O +
focused O +
on O +
increasing O +
taxon O +
sampling O +
using O +
the O +
nuclear O +
small O +
subunit O +
rDNA O +
( O -
nSSU O -
- O -
rDNA O -
) O +
locus O -
. O -

These O +
previous O +
analyses O +
have O +
generally O +
been O +
congruent O +
with O +
morphologically O -
- O -
based O +
classifications O -
, O +
although O +
there O +
is O +
extensive O +
non O -
- O -
monophyly O +
at O +
many O +
levels O -
. O -

However O -
, O +
caution O +
is O +
needed O +
in O +
interpreting O +
these O +
results O +
as O +
nSSU O -
- O -
rDNA O +
is O +
just O +
a O +
single O +
molecular O +
marker O -
. O -

Here O +
the O +
mitochondrial O +
small O +
subunit O +
rDNA O +
( O -
mtSSU O -
- O -
rDNA O -
) O +
is O +
evaluated O +
for O +
deep O +
ciliate O +
nodes O +
using O +
the O +
Colpodea O +
as O +
an O +
example O -
. O -

Overall O -
, O +
well O -
- O -
supported O +
nodes O +
in O +
the O +
mtSSU O -
- O -
rDNA O +
and O +
concatenated O +
topologies O +
are O +
well O +
supported O +
in O +
the O +
nSSU O -
- O -
rDNA O +
topology O -
; O +
e.g. O -
, O +
the O +
non O -
- O -
monophyly O +
of O +
the O +
Cyrtolophosidida O -
. O -

The O +
two O +
moderately- O +
to O +
well O -
- O -
supported O +
incongruences O +
between O +
the O +
loci O +
are O +
the O +
placement O +
of O +
the O +
Sorogenida O +
and O +
Colpoda B-Species +
aspera L-Species -
. O -

Our O +
analyses O +
of O +
mtSSU O -
- O -
rDNA O +
support O +
the O +
conclusion O -
, O +
originally O +
derived O +
from O +
nSSU O -
- O -
rDNA O -
, O +
that O +
the O +
morphological O +
characters O +
used O +
in O +
taxonomic O +
circumscriptions O +
of O +
the O +
Colpodea O +
represent O +
a O +
mixture O +
of O +
ancestral O +
and O +
derived O +
states O -
. O -

This O +
demonstration O +
of O +
the O +
efficacy O +
of O +
the O +
mtSSU O -
- O -
rDNA O +
will O +
enable O +
phylogenetic O +
reconstructions O +
of O +
deep O +
nodes O +
in O +
the O +
ciliate O +
tree O +
of O +
life O +
to O +
move O +
from O +
a O +
single O -
- O -
locus O +
to O +
a O +
multi O -
- O -
locus O +
approach O -
. O +

Isolation O +
and O +
characterization O +
of O +
P1 O +
adhesin O -
, O +
a O +
leg O +
protein O +
of O +
the O +
gliding O +
bacterium O +
Mycoplasma B-Species +
pneumoniae L-Species -
. O +

Mycoplasma B-Species +
pneumoniae L-Species -
, O +
a O +
pathogen O +
causing O +
human U-Species +
pneumonia O -
, O +
binds O +
to O +
solid O +
surfaces O +
at O +
its O +
membrane O +
protrusion O +
and O +
glides O +
by O +
a O +
unique O +
mechanism O -
. O -

In O +
this O +
study O -
, O +
P1 O +
adhesin O -
, O +
which O +
functions O +
as O +
a O +
" O -
leg O -
" O +
in O +
gliding O -
, O +
was O +
isolated O +
from O +
mycoplasma O +
culture U-Species +
and O +
characterized O -
. O -

Using O +
gel O +
filtration O -
, O +
blue O -
- O -
native O +
polyacrylamide O +
gel O +
electrophoresis O +
( O -
BN O -
- O -
PAGE O -
) O -
, O +
and O +
chemical O +
cross O -
- O -
linking O -
, O +
the O +
isolated O +
P1 O +
adhesin O +
was O +
shown O +
to O +
form O +
a O +
complex O +
with O +
an O +
accessory O +
protein O +
named O +
P90 O -
. O -

The O +
complex O +
included O +
two O +
molecules O +
each O +
of O +
P1 O +
adhesin O +
and O +
P90 O +
( O -
protein O +
B O -
) O -
, O +
had O +
a O +
molecular O +
mass O +
of O +
about O +
480 O +
kDa O -
, O +
and O +
was O +
observed O +
by O +
electron O +
microscopy O +
to O +
form O +
20-nm O -
- O -
diameter O +
spheres O -
. O -

Partial O +
digestion O +
of O +
isolated O +
P1 O +
adhesin O +
by O +
trypsin O +
showed O +
that O +
the O +
P1 O +
adhesin O +
molecule O +
can O +
be O +
divided O +
into O +
three O +
domains O -
, O +
consistent O +
with O +
the O +
results O +
from O +
trypsin O +
treatment O +
of O +
the O +
cell O +
surface O -
. O -

Sequence O +
analysis O +
of O +
P1 O +
adhesin O +
and O +
its O +
orthologs O +
showed O +
that O +
domain O +
I O +
is O +
well O +
conserved O +
and O +
that O +
a O +
transmembrane O +
segment O +
exists O +
near O +
the O +
link O +
between O +
domains O +
II O +
and O +
III O -
. O +

Anoxybacillus B-Species +
tengchongensis L-Species +
sp. O +
nov. O +
and O +
Anoxybacillus B-Species +
eryuanensis L-Species +
sp. O +
nov. O -
, O +
facultatively O +
anaerobic O -
, O +
alkalitolerant O +
bacteria O +
from O +
hot O +
springs O -
. O +

Two O +
novel O +
thermophilic O -
, O +
spore O -
- O -
forming O +
bacterial O +
strains O -
, O +
T-11 U-Species -
( O -
T O -
) O +
and O +
E-112 U-Species -
( O -
T O -
) O -
, O +
were O +
isolated O +
from O +
hot O +
springs O +
in O +
Tengchong O +
and O +
Eryuan O +
counties O +
of O +
Yunnan O +
province O +
in O +
south O -
- O -
west O +
China O -
. O -

The O +
strains O +
were O +
Gram O -
- O -
stain O -
- O -
positive O +
rods O -
, O +
occurring O +
singly O +
or O +
in O +
chains O -
. O -

Growth O +
of O +
strain O +
T-11 U-Species -
( O -
T O -
) O +
was O +
observed O +
between O +
30 O +
and O +
75 O +
^0C O +
( O -
optimum O +
50 O +
^0C O -
) O +
and O +
at O +
pH O +
7 O -
- O -
11 O +
( O -
optimum O +
pH O +
8.5 O -
) O -
, O +
while O +
the O +
temperature O +
range O +
for O +
strain O +
E-112 U-Species -
( O -
T O -
) O +
was O +
35 O -
- O -
70 O +
^0C O +
( O -
optimum O +
55 O +
^0C O -
) O +
and O +
the O +
pH O +
range O +
was O +
7.0 O -
- O -
11.0 O +
( O -
optimum O +
pH O +
8.0 O -
) O -
. O -

The O +
DNA O +
G+C O +
contents O +
of O +
strains O +
T-11 U-Species -
( O -
T O -
) O +
and O +
E-112 U-Species -
( O -
T O -
) O +
were O +
41.1 O +
and O +
42.6 O +
mol% O -
, O +
respectively O -
. O -

On O +
the O +
basis O +
of O +
16S O +
rRNA O +
gene O +
sequence O +
similarity O -
, O +
the O +
two O +
strains O +
were O +
shown O +
to O +
be O +
related O +
most O +
closely O +
to O +
Anoxybacillus O +
species O -
. O -

The O +
chemotaxonomic O +
characteristics O +
[ O -
predominant O +
isoprenoid O +
quinone O +
menaquinone O +
7 O +
( O -
MK-7 O -
) O -
; O +
major O +
fatty O +
acids O +
iso O -
- O -
C O -
( O -
15 O +
: O +
0 O -
) O +
and O +
iso O -
- O -
C O -
( O -
17 O +
: O +
0 O -
) O -
] O +
also O +
supported O +
the O +
affiliation O +
of O +
strains O +
T-11 U-Species -
( O -
T O -
) O +
and O +
E-112 U-Species -
( O -
T O -
) O +
to O +
the O +
genus O +
Anoxybacillus O -
. O -

The O +
results O +
of O +
DNA O -
- O -
DNA O +
hybridization O +
and O +
physiological O +
and O +
biochemical O +
tests O +
allowed O +
genotypic O +
and O +
phenotypic O +
differentiation O +
of O +
strains O +
T-11 U-Species -
( O -
T O -
) O +
and O +
E-112 U-Species -
( O -
T O -
) O +
from O +
Anoxybacillus O +
species O +
with O +
validly O +
published O +
names O -
. O -

Strains O +
T-11 U-Species -
( O -
T O -
) O +
and O +
E-112 U-Species -
( O -
T O -
) O +
therefore O +
represent O +
two O +
novel O +
species O -
, O +
for O +
which O +
the O +
names O +
Anoxybacillus B-Species +
tengchongensis L-Species +
sp. O +
nov. O +
( O -
type O +
strain O +
T-11 U-Species -
( O -
T O -
) O +
= O -
CCTCC O +
AB209237 O -
( O -
T O -
) O +
= O -
KCTC O +
13721 O -
( O -
T O -
) O -
) O +
and O +
Anoxybacillus B-Species +
eryuanensis L-Species +
sp. O +
nov. O +
( O -
type O +
strain O +
E-112 U-Species -
( O -
T O -
) O +
= O -
CCTCC O +
AB209236 O -
( O -
T O -
) O +
= O -
KCTC O +
13720 O -
( O -
T O -
) O -
) O +
are O +
proposed O -
. O +

Complete O +
genome O +
sequence O +
of O +
Burkholderia B-Species +
rhizoxinica L-Species -
, O +
an O +
Endosymbiont O +
of O +
Rhizopus B-Species +
microsporus L-Species -
. O +

Burkholderia B-Species +
rhizoxinica L-Species +
is O +
an O +
intracellular O +
symbiont O +
of O +
the O +
phytopathogenic O +
fungus O +
Rhizopus B-Species +
microsporus L-Species -
. O -

The O +
vertically O +
transmitted O +
endosymbiont O +
not O +
only O +
delivers O +
the O +
antimitotic O +
macrolide O +
rhizoxin O +
to O +
its O +
host O +
but O +
is O +
also O +
essential O +
for O +
vegetative O +
spore O +
formation O +
of O +
the O +
fungus O -
. O -

To O +
shed O +
light O +
on O +
the O +
genetic O +
equipment O +
of O +
this O +
model O +
organism O -
, O +
we O +
sequenced O +
the O +
whole O +
genome O +
of O +
B. B-Species +
rhizoxinica I-Species +
HKI I-Species +
0454 L-Species -
, O +
thus O +
providing O +
the O +
first O +
genomic O +
insight O +
into O +
an O +
intracellular O +
mutualist O +
of O +
a O +
fungal O +
species O -
. O -

The O +
3.75-Mb O +
genome O +
consists O +
of O +
a O +
chromosome O +
and O +
two O +
strain O -
- O -
specific O +
plasmids O -
. O -

The O +
primary O +
metabolism O +
appears O +
to O +
be O +
specialized O +
for O +
the O +
uptake O +
of O +
fungal O +
metabolites O -
. O -

Besides O +
the O +
rhizoxin O +
biosynthesis O +
gene O +
cluster O -
, O +
there O +
are O +
14 O +
loci O +
coding O +
for O +
nonribosomal O +
peptide O +
synthetase O +
( O -
NRPS O -
) O +
assembly O +
lines O -
, O +
which O +
represent O +
novel O +
targets O +
for O +
genomic O +
mining O +
of O +
cryptic O +
natural O +
products O -
. O -

Furthermore O -
, O +
the O +
endosymbionts O +
are O +
equipped O +
with O +
a O +
repertoire O +
of O +
virulence O -
- O -
related O +
factors O -
, O +
which O +
can O +
now O +
be O +
studied O +
to O +
elucidate O +
molecular O +
mechanisms O +
underlying O +
bacterial O -
- O -
fungal O +
interaction O -
. O +

R5 O +
HIV U-Species +
env O +
and O +
vesicular B-Species +
stomatitis I-Species +
virus L-Species +
G O +
protein O +
cooperate O +
to O +
mediate O +
fusion O +
to O +
naive O +
CD4 O -
+ O +
T O +
Cells O -
. O +

Naive O +
CD4 O -
( O -
4 O -
) O +
T O +
cells O +
are O +
resistant O +
to O +
both O +
HIV U-Species +
R5 O +
env O +
and O +
vesicular B-Species +
stomatitis I-Species +
virus L-Species +
G O +
protein O +
( O -
VSV U-Species -
- O -
G O -
) O -
-mediated O +
fusion O -
. O -

However O -
, O +
viral U-Species +
particles O +
carrying O +
both O +
HIV U-Species +
R5 O +
env O +
and O +
VSV U-Species -
- O -
G O +
infect O +
naive O +
cells O +
by O +
an O +
unexplained O +
mechanism O -
. O -

We O +
show O +
that O +
VSV U-Species -
- O -
G O -
- O -
pseudotyped O +
virus U-Species +
can O -
not O +
fuse O +
to O +
unstimulated O +
cells O +
because O +
the O +
viral U-Species +
particles O +
can O -
not O +
be O +
endocytosed O -
. O -

However O -
, O +
virions O +
carrying O +
both O +
HIV U-Species +
R5 O +
env O +
and O +
VSV U-Species -
- O -
G O +
can O +
fuse O +
because O +
CD4 O +
binding O +
allows O +
viral U-Species +
uptake O -
. O -

Our O +
findings O +
reveal O +
a O +
unique O +
mechanism O +
by O +
which O +
R5 O +
HIV U-Species +
env O +
and O +
VSV U-Species -
- O -
G O +
cooperate O +
to O +
allow O +
entry O +
to O +
naive O +
CD4 O -
( O -
+ O -
) O +
T O +
cells O -
, O +
providing O +
a O +
tool O +
to O +
target O +
naive O +
CD4 O -
( O -
+ O -
) O +
T O +
cells O +
with O +
R5 O +
HIV U-Species +
to O +
study O +
HIV U-Species +
coreceptor O +
signaling O +
and O +
latency O -
. O +

The O +
alphaherpesvirus O +
US3 O -
/ O -
ORF66 O +
protein O +
kinases O +
direct O +
phosphorylation O +
of O +
the O +
nuclear O +
matrix O +
protein O +
matrin O +
3 O -
. O +

The O +
protein O +
kinase O +
found O +
in O +
the O +
short O +
region O +
of O +
alphaherpesviruses O -
, O +
termed O +
US3 O +
in O +
herpes B-Species +
simplex I-Species +
virus I-Species +
type L-Species +
1 O +
( O -
HSV-1 U-Species -
) O +
and O +
pseudorabies B-Species +
virus L-Species +
( O -
PRV U-Species -
) O +
and O +
ORF66 O +
in O +
varicella B-Species -
- I-Species -
zoster I-Species +
virus L-Species +
( O -
VZV U-Species -
) O -
, O +
affects O +
several O +
viral O +
and O +
host O +
cell O +
processes O -
, O +
and O +
its O +
specific O +
targets O +
remain O +
an O +
area O +
of O +
active O +
investigation O -
. O -

Reports O +
suggesting O +
that O +
HSV-1 U-Species +
US3 O +
substrates O +
overlap O +
with O +
those O +
of O +
cellular O +
protein O +
kinase O +
A O +
( O -
PKA O -
) O +
prompted O +
the O +
use O +
of O +
an O +
antibody O +
specific O +
for O +
phosphorylated O +
PKA O +
substrates O +
to O +
identify O +
US3 O -
/ O -
ORF66 O +
targets O -
. O -

HSV-1 U-Species -
, O +
VZV U-Species -
, O +
and O +
PRV U-Species +
induced O +
very O +
different O +
substrate O +
profiles O +
that O +
were O +
US3 O -
/ O -
ORF66 O +
kinase O +
dependent O -
. O -

The O +
predominant O +
VZV U-Species -
- O -
phosphorylated O +
125-kDa O +
species O +
was O +
identified O +
as O +
matrin O +
3 O -
, O +
one O +
of O +
the O +
major O +
nuclear O +
matrix O +
proteins O -
. O -

Matrin O +
3 O +
was O +
also O +
phosphorylated O +
by O +
HSV-1 U-Species +
and O +
PRV U-Species +
in O +
a O +
US3 O +
kinase O -
- O -
dependent O +
manner O +
and O +
by O +
VZV U-Species +
ORF66 O +
kinase O +
at O +
a O +
novel O +
residue O +
( O -
KRRRT150EE O -
) O -
. O -

Since O +
VZV U-Species -
- O -
directed O +
T150 O +
phosphorylation O +
was O +
not O +
blocked O +
by O +
PKA O +
inhibitors O +
and O +
was O +
not O +
induced O +
by O +
PKA O +
activation O -
, O +
and O +
since O +
PKA O +
predominantly O +
targeted O +
matrin O +
3 O +
S188 O -
, O +
it O +
was O +
concluded O +
that O +
phosphorylation O +
by O +
VZV U-Species +
was O +
PKA O +
independent O -
. O -

However O -
, O +
purified O +
VZV U-Species +
ORF66 O +
kinase O +
did O +
not O +
phosphorylate O +
matrin O +
3 O +
in O +
vitro O -
, O +
suggesting O +
that O +
additional O +
cellular O +
factors O +
were O +
required O -
. O -

In O +
VZV U-Species -
- O -
infected O +
cells O +
in O +
the O +
absence O +
of O +
the O +
ORF66 O +
kinase O -
, O +
matrin O +
3 O +
displayed O +
intranuclear O +
changes O -
, O +
while O +
matrin O +
3 O +
showed O +
a O +
pronounced O +
cytoplasmic O +
distribution O +
in O +
late O -
- O -
stage O +
cells O +
infected O +
with O +
US3-negative O +
HSV-1 U-Species +
or O +
PRV U-Species -
. O -

This O +
work O +
identifies O +
phosphorylation O +
of O +
the O +
nuclear O +
matrix O +
protein O +
matrin O +
3 O +
as O +
a O +
new O +
conserved O +
target O +
of O +
this O +
kinase O +
group O -
. O +

Persistent O +
Friend B-Species +
virus L-Species +
replication O +
and O +
disease O +
in O +
Apobec3-deficient O +
mice U-Species +
expressing O +
functional O +
B O -
- O -
cell O -
- O -
activating O +
factor O +
receptor O -
. O +

Rfv3 O +
is O +
an O +
autosomal O +
dominant O +
gene O +
that O +
influences O +
the O +
recovery O +
of O +
resistant O +
mice U-Species +
from O +
Friend B-Species +
retrovirus L-Species +
( O -
FV U-Species -
) O +
infection O +
by O +
limiting O +
viremia O +
and O +
promoting O +
a O +
more O +
potent O +
neutralizing O +
antibody O +
response O -
. O -

We O +
previously O +
reported O +
that O +
Rfv3 O +
is O +
encoded O +
by O +
Apobec3 O -
, O +
an O +
innate O +
retrovirus O +
restriction O +
factor O -
. O -

However O -
, O +
it O +
was O +
recently O +
suggested O +
that O +
the O +
Rfv3 O +
susceptible O +
phenotype O +
of O +
high O +
viremia O +
at O +
28 O +
days O +
postinfection O +
( O -
dpi O -
) O +
was O +
more O +
dominantly O +
controlled O +
by O +
the O +
B O -
- O -
cell O -
- O -
activating O +
factor O +
receptor O +
( O -
BAFF O -
- O -
R O -
) O -
, O +
a O +
gene O +
that O +
is O +
linked O +
to O +
but O +
located O +
outside O +
the O +
genetically O +
mapped O +
region O +
containing O +
Rfv3 O -
. O -

Although O +
one O +
prototypical O +
Rfv3 O +
susceptible O +
mouse U-Species +
strain O -
, O +
A O -
/ O -
WySn O -
, O +
indeed O +
contains O +
a O +
dysfunctional O +
BAFF O -
- O -
R O -
, O +
two O +
other O +
Rfv3 O +
susceptible O +
strains O -
, O +
BALB O -
/ O -
c O +
and O +
A.BY O -
, O +
express O +
functional O +
BAFF O -
- O -
R O +
genes O -
, O +
determined O +
on O +
the O +
basis O +
of O +
genotyping O +
and O +
B O -
- O -
cell O +
immunophenotyping O -
. O -

Furthermore O -
, O +
transcomplementation O +
studies O +
in O +
( O -
C57BL O -
/ O -
6 O +
[ O -
B6 O -
] O +
x O +
BALB O -
/ O -
c O -
) O -
F O -
( O -
1 O -
) O +
and O +
( O -
B6 O +
x O +
A.BY O -
) O -
F O -
( O -
1 O -
) O +
mice U-Species +
revealed O +
that O +
the O +
B6 O +
Apobec3 O +
gene O +
significantly O +
influences O +
recovery O +
from O +
FV U-Species +
viremia O -
, O +
cellular O +
infection O -
, O +
and O +
disease O +
at O +
28 O +
dpi O -
. O -

Finally O -
, O +
the O +
Rfv3 O +
phenotypes O +
of O +
prototypic O +
B6 O -
, O +
A.BY O -
, O +
A O -
/ O -
WySn O -
, O +
and O +
BALB O -
/ O -
c O +
mouse U-Species +
strains O +
correlate O +
with O +
reported O +
Apobec3 O +
mRNA O +
expression O +
levels O -
. O -

Overall O -
, O +
these O +
findings O +
argue O +
against O +
the O +
generality O +
of O +
BAFF O -
- O -
R O +
polymorphisms O +
as O +
a O +
dominant O +
mechanism O +
to O +
explain O +
the O +
Rfv3 O +
recovery O +
phenotype O +
and O +
further O +
strengthen O +
the O +
evidence O +
that O +
Apobec3 O +
encodes O +
Rfv3 O -
. O +

Pterin O -
- O -
based O +
ornamental O +
coloration O +
predicts O +
yolk O +
antioxidant O +
levels O +
in O +
female O +
striped B-Species +
plateau I-Species +
lizards L-Species +
( O -
Sceloporus B-Species +
virgatus L-Species -
) O -
. O +

1 O -
. O -

Maternal O +
investment O +
in O +
egg O +
quality O +
can O +
have O +
important O +
consequences O +
for O +
offspring O +
fitness O -
. O -

For O +
example O -
, O +
yolk O +
antioxidants O +
can O +
affect O +
embryonic O +
development O +
as O +
well O +
as O +
juvenile O +
and O +
adult O +
phenotype O -
. O -

Thus O -
, O +
females O +
may O +
be O +
selected O +
to O +
advertise O +
their O +
yolk O +
antioxidant O +
deposition O +
to O +
discriminatory O +
males O +
via O +
ornamental O +
signals O -
, O +
perhaps O +
depending O +
on O +
the O +
reproductive O +
costs O +
associated O +
with O +
signal O +
production O -
. O -

2 O -
. O -

Female O +
striped B-Species +
plateau I-Species +
lizards L-Species +
( O -
Sceloporus B-Species +
virgatus L-Species -
) O +
develop O +
pterin O -
- O -
based O +
orange O +
colour O +
patches O +
during O +
the O +
reproductive O +
season O +
that O +
influence O +
male O +
behaviour O +
and O +
that O +
are O +
positively O +
associated O +
with O +
the O +
phenotypic O +
quality O +
of O +
the O +
female O +
and O +
her O +
offspring O -
. O -

Here O -
, O +
we O +
assessed O +
one O +
potential O +
developmental O +
mechanism O +
underlying O +
the O +
relationship O +
between O +
offspring O +
quality O +
and O +
female O +
ornamentation O +
in O +
S. B-Species +
virgatus L-Species -
, O +
by O +
examining O +
the O +
relationship O +
between O +
ornament O +
expression O +
and O +
yolk O +
antioxidant O +
levels O -
. O -

3 O -
. O -

As O +
expected O -
, O +
concentrations O +
of O +
the O +
yolk O +
antioxidants O +
vitamin O +
A O -
, O +
vitamin O +
E O +
and O +
carotenoids O +
( O -
lutein O +
and O +
zeaxanthin O -
) O +
were O +
strongly O +
positively O +
intercorrelated O -
. O -

Eggs O +
from O +
larger O +
clutches O +
had O +
fewer O +
antioxidants O +
than O +
eggs O +
from O +
smaller O +
clutches O -
, O +
suggesting O +
that O +
females O +
may O +
be O +
limited O +
in O +
antioxidant O +
availability O +
or O +
use O -
. O -

Fertilized O +
and O +
unfertilized O +
eggs O +
did O +
not O +
differ O +
in O +
yolk O +
antioxidant O +
levels O -
. O -

4 O -
. O -

The O +
size O +
of O +
a O +
female O -
's O +
ornament O +
was O +
positively O +
related O +
to O +
both O +
the O +
concentration O +
and O +
total O +
amount O +
of O +
yolk O +
antioxidants O -
, O +
and O +
ornament O +
colour O +
was O +
positively O +
related O +
to O +
yolk O +
antioxidant O +
concentration O -
. O -

Thus O -
, O +
in O +
S. B-Species +
virgatus L-Species -
, O +
female O +
ornaments O +
may O +
advertise O +
egg O +
quality O -
. O -

In O +
addition O -
, O +
these O +
data O +
suggest O +
that O +
more O +
ornamented O +
females O +
may O +
produce O +
higher O -
- O -
quality O +
offspring O -
, O +
in O +
part O +
because O +
their O +
eggs O +
contain O +
more O +
antioxidants O -
. O -

As O +
the O +
colour O +
ornament O +
of O +
interest O +
is O +
derived O +
from O +
pterins O -
, O +
not O +
carotenoids O -
, O +
direct O +
resource O +
trade O -
- O -
offs O +
between O +
ornaments O +
and O +
eggs O +
may O +
be O +
eliminated O -
, O +
reducing O +
reproductive O +
costs O +
associated O +
with O +
signalling O -
. O -

5 O -
. O -

This O +
is O +
the O +
first O +
example O +
of O +
a O +
positive O +
relationship O +
between O +
female O +
ornamentation O +
and O +
yolk O +
antioxidants O +
in O +
reptiles O +
and O +
may O +
indicate O +
the O +
general O +
importance O +
of O +
these O +
patterns O +
in O +
oviparous O +
vertebrates O -
. O +

The O +
contribution O +
of O +
the O +
S O -
- O -
phase O +
checkpoint O +
genes O +
MEC1 O +
and O +
SGS1 O +
to O +
genome O +
stability O +
maintenance O +
in O +
Candida B-Species +
albicans L-Species -
. O +

Genome O +
rearrangements O -
, O +
a O +
common O +
feature O +
of O +
Candida B-Species +
albicans L-Species +
isolates O -
, O +
are O +
often O +
associated O +
with O +
the O +
acquisition O +
of O +
antifungal O +
drug O +
resistance O -
. O -

In O +
Saccharomyces B-Species +
cerevisiae L-Species -
, O +
perturbations O +
in O +
the O +
S O -
- O -
phase O +
checkpoints O +
result O +
in O +
the O +
same O +
sort O +
of O +
Gross O +
Chromosomal O +
Rearrangements O +
( O -
GCRs O -
) O +
observed O +
in O +
C. B-Species +
albicans L-Species -
. O -

Several O +
proteins O +
are O +
involved O +
in O +
the O +
S. B-Species +
cerevisiae L-Species +
cell O +
cycle O +
checkpoints O -
, O +
including O +
Mec1p O -
, O +
a O +
protein O +
kinase O +
of O +
the O +
PIKK O +
( O -
phosphatidyl O +
inositol O +
3-kinase O -
- O -
like O +
kinase O -
) O +
family O +
and O +
the O +
central O +
player O +
in O +
the O +
DNA O +
damage O +
checkpoint O -
. O -

Sgs1p O -
, O +
the O +
ortholog O +
of O +
BLM O -
, O +
the O +
Bloom O -
's O +
syndrome O +
gene O -
, O +
is O +
a O +
RecQ O -
- O -
related O +
DNA O +
helicase O -
; O +
cells O +
from O +
BLM O +
patients O +
are O +
characterized O +
by O +
an O +
increase O +
in O +
genome O +
instability O -
. O -

Yeast U-Species +
strains O +
bearing O +
deletions O +
in O +
MEC1 O +
or O +
SGS1 O +
are O +
viable O +
( O -
in O +
contrast O +
to O +
the O +
inviability O +
seen O +
with O +
loss O +
of O +
MEC1 O +
in O +
S. B-Species +
cerevisiae L-Species -
) O +
but O +
the O +
different O +
deletion O +
mutants O +
have O +
significantly O +
different O +
phenotypes O -
. O -

The O +
mec1Delta O -
/ O -
Delta O +
colonies O +
have O +
a O +
wild O -
- O -
type O +
colony O +
morphology O -
, O +
while O +
the O +
sgs1Delta O -
/ O -
Delta O +
mutants O +
are O +
slow O -
- O -
growing O -
, O +
producing O +
wrinkled O +
colonies O +
with O +
pseudohyphal O -
- O -
like O +
cells O -
. O -

The O +
mec1Delta O -
/ O -
Delta O +
mutants O +
are O +
only O +
sensitive O +
to O +
ethylmethane O +
sulfonate O +
( O -
EMS O -
) O -
, O +
methylmethane O +
sulfonate O +
( O -
MMS O -
) O -
, O +
and O +
hydroxyurea O +
( O -
HU O -
) O +
but O +
the O +
sgs1Delta O -
/ O -
Delta O +
mutants O +
exhibit O +
a O +
high O +
sensitivity O +
to O +
all O +
DNA O -
- O -
damaging O +
agents O +
tested O -
. O -

In O +
an O +
assay O +
for O +
chromosome O +
1 O +
integrity O -
, O +
the O +
mec1Delta O -
/ O -
Delta O +
mutants O +
exhibit O +
an O +
increase O +
in O +
genome O +
instability O -
; O +
no O +
change O +
was O +
observed O +
in O +
the O +
sgs1Delta O -
/ O -
Delta O +
mutants O -
. O -

Finally O -
, O +
loss O +
of O +
MEC1 O +
does O +
not O +
affect O +
sensitivity O +
to O +
the O +
antifungal O +
drug O +
fluconazole O -
, O +
while O +
loss O +
of O +
SGS1 O +
leads O +
to O +
an O +
increased O +
susceptibility O +
to O +
fluconazole O -
. O -

Neither O +
deletion O +
elevated O +
the O +
level O +
of O +
antifungal O +
drug O +
resistance O +
acquisition O -
. O +

